2021-01-17 13:31:16 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': True, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': './checkpoint_en_underscore/checkpoint_last.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out/en_underscore_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_underscore', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='./checkpoint_en_underscore/checkpoint_last.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out/en_underscore_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-17 13:31:17 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-17 13:31:17 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-17 13:31:17 | INFO | fairseq_cli.generate | loading model(s) from ./checkpoint_en_underscore/checkpoint_last.pt
2021-01-17 13:32:38 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.src
2021-01-17 13:32:38 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.label
2021-01-17 13:32:38 | INFO | fairseq.tasks.translation | ./postprocessed/en_underscore test src-label 2024 examples
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.2986859977245331	▁Clinic al
D-228	-0.2986859977245331	Clinical
P-228	-0.4759 -0.0629 -0.6221 -0.0339
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.6579330563545227	
D-664	-0.6579330563545227	
P-664	-1.2185 -0.0974
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.7619192600250244	▁EH
D-1528	-0.7619192600250244	EH
P-1528	-2.0396 -0.1148 -0.1314
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.41622766852378845	▁case - control _ design
D-1451	-0.41622766852378845	case-control_design
P-1451	-0.4001 -0.3118 -0.0353 -1.0593 -0.7390 -0.2685 -0.0996
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.29156047105789185	
D-133	-0.29156047105789185	
P-133	-0.5653 -0.0178
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.1692476272583008	
D-1685	-1.1692476272583008	
P-1685	-2.1040 -0.2345
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse_events
H-1916	-0.4697929918766022	▁advers e ▁events
D-1916	-0.4697929918766022	adverse events
P-1916	-0.5817 -0.1076 -1.4213 -0.1229 -0.1155
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.27319303154945374	▁tertia ry ▁refer ral ▁centre
D-1497	-0.27319303154945374	tertiary referral centre
P-1497	-0.6003 -0.0851 -0.4552 -0.0225 -0.6151 -0.0739 -0.0603
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-1.0650051832199097	▁NO ▁production _ of ▁EC
D-256	-1.0650051832199097	NO production_of EC
P-256	-4.0003 -0.8212 -1.8065 -0.2643 -0.3609 -0.0521 -0.1498
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.8606664538383484	
D-307	-0.8606664538383484	
P-307	-1.6595 -0.0619
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.26857954263687134	▁molecular ▁mechanism
D-1607	-0.26857954263687134	molecular mechanism
P-1607	-0.0340 -0.8107 -0.0987 -0.1309
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.8483198881149292	▁d XA
D-1496	-0.8483198881149292	dXA
P-1496	-0.9179 -0.1647 -1.9138 -0.3969
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.640849232673645	▁FM
D-18	-0.640849232673645	FM
P-18	-1.7740 -0.1128 -0.0357
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise cardiovascular health
H-1897	-0.599925696849823	▁exercise ▁cardiovascular _ health
D-1897	-0.599925696849823	exercise cardiovascular_health
P-1897	-0.5826 -0.5008 -1.0140 -1.2962 -0.0931 -0.1128
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf pna
H-1699	-0.887784481048584	▁ HF
D-1699	-0.887784481048584	HF
P-1699	-1.2277 -0.2200 -1.9289 -0.1745
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart_failure
H-1066	-0.9774491190910339	▁devices ▁heart _ ▁failure
D-1066	-0.9774491190910339	devices heart_ failure
P-1066	-2.6111 -1.5166 -0.7897 -0.8224 -0.0438 -0.0811
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver_disease
H-233	-0.6892740726470947	▁Live r _ ▁disease
D-233	-0.6892740726470947	Liver_ disease
P-233	-0.6623 -0.1258 -1.0907 -1.5410 -0.4768 -0.2391
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal_artery_stenosis
H-1592	-0.3129429519176483	▁Ren al ▁arter y ▁sten osis
D-1592	-0.3129429519176483	Renal artery stenosis
P-1592	-0.0195 -0.0059 -1.3865 -0.0401 -0.7951 -0.0239 -0.1019 -0.1306
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary_end_point inhospital mortality
H-190	-0.5246351957321167	▁in hospital _ ▁mortal ity
D-190	-0.5246351957321167	inhospital_ mortality
P-190	-2.8956 -0.0118 -0.1823 -0.2797 -0.0107 -0.0785 -0.2140
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective_cohort_study
H-1712	-0.32694023847579956	▁Retro spec tive ▁co hor t ▁study
D-1712	-0.32694023847579956	Retrospective cohort study
P-1712	-1.0650 -0.0060 -0.0110 -0.4043 -0.0095 -0.1717 -1.0926 -0.0669 -0.1155
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute_care_surgery heart_transplant
H-1279	-0.8396924734115601	▁surgery ▁heart ▁transplant ▁recipient s
D-1279	-0.8396924734115601	surgery heart transplant recipients
P-1279	-4.9834 -0.1667 -0.3294 -0.2850 -0.0395 -0.0425 -0.0315
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart_failure latin_america
H-1788	-0.891530454158783	▁heart _ ▁failure ▁Latin ▁America
D-1788	-0.891530454158783	heart_ failure Latin America
P-1788	-3.2603 -0.2707 -1.8512 -0.4335 -0.1451 -0.0615 -0.2185
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational_cohort_study
H-811	-0.6284408569335938	▁Observa tional _ co hor t
D-811	-0.6284408569335938	Observational_cohort
P-811	-3.2405 -0.0218 -0.2712 -0.0801 -0.0052 -0.1701 -1.0737 -0.1648
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic_breathing heart_beat
H-1345	-1.0130906105041504	▁period _ ▁breath ing ▁heart ▁beat
D-1345	-1.0130906105041504	period_ breathing heart beat
P-1345	-2.6984 -2.8490 -1.1769 -0.0613 -1.0204 -0.2077 -0.0394 -0.0516
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective_cohort
H-211	-0.2269303947687149	▁Retro spec tive ▁co hor t
D-211	-0.2269303947687149	Retrospective cohort
P-211	-0.6417 -0.0077 -0.0110 -0.7475 -0.0079 -0.1837 -0.0702 -0.1456
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate_models
H-241	-0.6112003326416016	
D-241	-0.6112003326416016	
P-241	-1.1299 -0.0925
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.501236081123352	▁ HF
D-346	-0.501236081123352	HF
P-346	-1.4365 -0.1141 -0.2641 -0.1903
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.4063034951686859	▁90- day ▁mortal ity
D-589	-0.4063034951686859	90-day mortality
P-589	-1.1036 -0.2303 -0.8512 -0.0046 -0.1165 -0.1316
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.8215556144714355	
D-796	-0.8215556144714355	
P-796	-1.5497 -0.0935
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.28214317560195923	
D-1944	-0.28214317560195923	
P-1944	-0.5516 -0.0127
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-1.0104396343231201	▁trial
D-1982	-1.0104396343231201	trial
P-1982	-2.6414 -0.1315 -0.2584
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.6285739541053772	
D-44	-0.6285739541053772	
P-44	-1.1368 -0.1204
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.7974449396133423	
D-1846	-0.7974449396133423	
P-1846	-1.4372 -0.1577
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.26132577657699585	▁doctor s
D-1686	-0.26132577657699585	doctors
P-1686	-0.3232 -0.1837 -0.4506 -0.0879
S-422	Heart rate was minimally altered.<unk>
T-422	heart_rate
H-422	-0.2652275562286377	▁Heart ▁rate
D-422	-0.2652275562286377	Heart rate
P-422	-0.1574 -0.6385 -0.1186 -0.1463
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart_failure
H-1356	-0.9856283664703369	▁nutrition ▁heart ▁failure
D-1356	-0.9856283664703369	nutrition heart failure
P-1356	-1.8209 -1.5748 -1.3328 -0.0767 -0.1229
S-1620	SETTING: Northwest United States.<unk>
T-1620	united_states
H-1620	-0.42852967977523804	▁North west _ United ▁States
D-1620	-0.42852967977523804	Northwest_United States
P-1620	-0.8953 -0.0220 -0.6479 -0.9593 -0.3546 -0.0399 -0.0807
S-1683	She is going into heart failure.<unk>
T-1683	heart_failure
H-1683	-0.9223905205726624	▁heart ▁failure
D-1683	-0.9223905205726624	heart failure
P-1683	-2.1585 -1.2571 -0.0564 -0.2175
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.49034246802330017	▁surgery
D-363	-0.49034246802330017	surgery
P-363	-1.2627 -0.0962 -0.1122
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.38880589604377747	▁cross - sec tional
D-795	-0.38880589604377747	cross-sectional
P-795	-1.4075 -0.3384 -0.0322 -0.0425 -0.1847 -0.3277
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.4824451804161072	▁INTER ven tions
D-798	-0.4824451804161072	INTERventions
P-798	-0.3044 -1.7058 -0.2219 -0.0896 -0.0905
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.27776122093200684	▁unilateral
D-1595	-0.27776122093200684	unilateral
P-1595	-0.4437 -0.1926 -0.1970
S-979	Heart failure in the young.<unk>
T-979	heart_failure
H-979	-0.43569043278694153	▁Heart ▁failure
D-979	-0.43569043278694153	Heart failure
P-979	-0.1179 -1.0074 -0.3874 -0.2301
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.20744796097278595	
D-1249	-0.20744796097278595	
P-1249	-0.3512 -0.0637
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.34627312421798706	
D-1687	-0.34627312421798706	
P-1687	-0.6746 -0.0179
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.47997838258743286	▁c lin
D-1246	-0.47997838258743286	clin
P-1246	-1.4552 -0.0802 -0.2659 -0.1186
S-1247	Trans.<unk>
T-1247	
H-1247	-0.5120311975479126	▁trans
D-1247	-0.5120311975479126	trans
P-1247	-0.2669 -1.0303 -0.2389
S-1248	Sci.<unk>
T-1248	
H-1248	-0.45160916447639465	▁Sci
D-1248	-0.45160916447639465	Sci
P-1248	-0.7741 -0.3043 -0.2764
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end_point
H-1763	-0.7388021349906921	▁seconda ry
D-1763	-0.7388021349906921	secondary
P-1763	-0.3235 -0.0673 -2.5010 -0.0634
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.4158119559288025	▁Inter media te _ ▁fra il ty
D-1005	-0.4158119559288025	Intermediate_ frailty
P-1005	-0.8214 -0.0225 -0.5122 -0.4386 -1.0951 -0.3756 -0.2743 -0.0881 -0.1146
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.787872314453125	▁random ised ▁studies
D-1963	-0.787872314453125	randomised studies
P-1963	-1.5205 -0.6272 -1.6572 -0.0554 -0.0791
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.49909424781799316	▁CHF
D-222	-0.49909424781799316	CHF
P-222	-0.1982 -1.2599 -0.0392
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.3638977110385895	▁do d son
D-205	-0.3638977110385895	dodson
P-205	-0.7385 -0.0400 -0.0308 -0.8851 -0.1251
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.5675572156906128	
D-392	-0.5675572156906128	
P-392	-1.0189 -0.1163
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.38502055406570435	▁exercise _ ▁modal ity
D-575	-0.38502055406570435	exercise_ modality
P-575	-0.5201 -0.8174 -0.4722 -0.0291 -0.3863 -0.0851
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.7458245158195496	
D-126	-0.7458245158195496	
P-126	-1.3358 -0.1559
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf mi
H-1101	-1.193274974822998	▁temporal _ trend s
D-1101	-1.193274974822998	temporal_trends
P-1101	-0.8214 -0.7053 -0.2129 -0.0069 -5.0922 -0.3209
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.9654747247695923	▁rates ▁risk ▁factors ▁CHF
D-673	-0.9654747247695923	rates risk factors CHF
P-673	-2.6696 -0.8531 -1.4078 -0.5224 -0.1079 -0.2321
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart_failure
H-1886	-1.41134512424469	▁Heart _ ▁failure
D-1886	-1.41134512424469	Heart_ failure
P-1886	-0.7379 -0.6129 -3.6629 -1.6156 -0.4274
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients followed_up
H-825	-0.4048205018043518	▁Patient s
D-825	-0.4048205018043518	Patients
P-825	-1.2024 -0.2348 -0.1158 -0.0663
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air heart_failure
H-1805	-0.47270166873931885	▁air ▁pollution ▁heart _ ▁failure
D-1805	-0.47270166873931885	air pollution heart_ failure
P-1805	-0.0105 -0.9561 -0.5192 -0.8322 -0.7429 -0.0500 -0.1980
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal_support
H-1296	-0.2554194927215576	▁extra corp o real
D-1296	-0.2554194927215576	extracorporeal
P-1296	-0.3788 -0.0036 -0.0465 -0.0536 -0.9493 -0.1007
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients cardiovascular_disease
H-247	-1.1686502695083618	▁cardiovascular _ ▁disease
D-247	-1.1686502695083618	cardiovascular_ disease
P-247	-2.0185 -1.0993 -2.4680 -0.0847 -0.1728
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart_failure disease therapeutics
H-1073	-0.9577321410179138	▁Heart _ ▁failure
D-1073	-0.9577321410179138	Heart_ failure
P-1073	-0.3367 -1.0140 -0.7922 -2.4698 -0.1760
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary_outcomes hemostasis
H-1116	-1.1009910106658936	▁ha tas is
D-1116	-1.1009910106658936	hatasis
P-1116	-3.4264 -0.8360 -0.9152 -0.1776 -0.1497
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote_ischemic_conditioning patients heart_failure
H-53	-1.040907382965088	▁ ische mic _ ▁condition ing ▁heart _ ▁failure
D-53	-1.040907382965088	ischemic_ conditioning heart_ failure
P-53	-2.6780 -1.1427 -0.6260 -0.9496 -0.6999 -0.3856 -3.2576 -0.5235 -1.0193 -0.0632 -0.1044
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart_rate_variability risk_stratification cardiac patients
H-1584	-0.8522329330444336	▁Heart ▁rate _ ▁variabil ity ▁risk _ ▁strat ification ▁cardiac _ ▁patients
D-1584	-0.8522329330444336	Heart rate_ variability risk_ stratification cardiac_ patients
P-1584	-0.1538 -0.8382 -1.8654 -2.1274 -0.0188 -2.0765 -0.7205 -0.5872 -0.2963 -0.0684 -1.7722 -1.1413 -0.0672 -0.1980
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective_matched_cohort_study
H-1619	-0.5947831869125366	▁Retro spec tive ▁match ed _ co hor t
D-1619	-0.5947831869125366	Retrospective matched_cohort
P-1619	-3.8628 -0.0220 -0.0429 -0.3745 -0.0749 -0.7362 -0.1247 -0.0306 -0.1901 -1.0177 -0.0662
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-1.0011941194534302	
D-1754	-1.0011941194534302	
P-1754	-1.8348 -0.1676
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.0730931758880615	
D-749	-1.0730931758880615	
P-749	-2.1130 -0.0332
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.5250473022460938	▁policy
D-312	-0.5250473022460938	policy
P-312	-0.0348 -1.4115 -0.1289
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.27982762455940247	
D-311	-0.27982762455940247	
P-311	-0.5269 -0.0328
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.5414657592773438	
D-885	-0.5414657592773438	
P-885	-1.0165 -0.0665
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.5215785503387451	▁Sham - opera ted _ animal ▁control ▁group
D-1339	-0.5215785503387451	Sham-operated_animal control group
P-1339	-0.7170 -0.2334 -0.0020 -0.2536 -0.6530 -0.6676 -0.1425 -1.9970 -0.1024 -0.4474
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.4195679724216461	▁retro spec tive ▁de script ive _ design
D-1399	-0.4195679724216461	retrospective descriptive_design
P-1399	-1.5756 -0.0220 -0.0108 -0.1772 -0.0074 -0.0114 -0.4190 -1.5393 -0.3397 -0.0933
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-0.37443700432777405	▁tax ono my
D-1125	-0.37443700432777405	taxonomy
P-1125	-0.6865 -0.5275 -0.4290 -0.1190 -0.1101
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient hf
H-364	-0.8605394959449768	▁ HF
D-364	-0.8605394959449768	HF
P-364	-2.6854 -0.2944 -0.2265 -0.2359
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise cardiovascular
H-1900	-0.6342381834983826	▁exercise ▁cardiovascular ▁system
D-1900	-0.6342381834983826	exercise cardiovascular system
P-1900	-0.4183 -0.2455 -2.3781 -0.0432 -0.0861
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting cell anand
H-1037	-0.27105528116226196	▁report ing ▁Cell ▁Anand
D-1037	-0.27105528116226196	reporting Cell Anand
P-1037	-0.2130 -0.0445 -0.9129 -0.1641 -0.1778 -0.1139
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse_events
H-1988	-0.7990902066230774	▁study - related ▁advers e ▁events
D-1988	-0.7990902066230774	study-related adverse events
P-1988	-0.7785 -0.3115 -0.2707 -3.7107 -0.0667 -1.1183 -0.0585 -0.0779
S-949	No major complications occurred during follow-up.<unk>
T-949	complications follow-up
H-949	-0.48496395349502563	
D-949	-0.48496395349502563	
P-949	-0.9357 -0.0343
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin injected
H-957	-0.39416995644569397	▁do xor ubi cin
D-957	-0.39416995644569397	doxorubicin
P-957	-0.7317 -0.0421 -0.2084 -0.3752 -0.8180 -0.1897
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors blood_transfusions
H-1684	-1.1055927276611328	▁doctor s ▁trans fusion s
D-1684	-1.1055927276611328	doctors transfusions
P-1684	-1.2323 -1.3768 -4.1435 -0.0164 -0.5310 -0.1801 -0.2590
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart_failure patients bisphosphonates
H-1534	-0.7179248332977295	▁Heart _ ▁failure ▁bis phos phon ates
D-1534	-0.7179248332977295	Heart_ failure bisphosphonates
P-1534	-0.2938 -1.6022 -0.6095 -1.9202 -0.0116 -1.0829 -0.4488 -0.3434 -0.1490
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic heart_failure outcomes
H-1198	-0.6727831363677979	▁di ure tic ▁heart _ ▁failure ▁outcome s
D-1198	-0.6727831363677979	diuretic heart_ failure outcomes
P-1198	-0.3018 -0.0105 -0.5159 -3.1060 -0.7828 -0.7397 -1.0287 -0.0401 -0.0803 -0.1221
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 gene_expression heart_failure
H-169	-1.1301876306533813	▁Cas pas e _ ▁gene ▁expression ▁heart _ ▁failure
D-169	-1.1301876306533813	Caspase_ gene expression heart_ failure
P-169	-0.9370 -0.2587 -0.3301 -2.0959 -2.8737 -3.5991 -0.2884 -0.5496 -1.2358 -0.0738 -0.1900
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox_proportional_hazards_models
H-712	-0.4912791848182678	▁co x ▁proportion al _ ▁hazard s
D-712	-0.4912791848182678	cox proportional_ hazards
P-712	-0.2621 -0.0288 -0.2182 -0.0202 -0.0700 -2.3781 -0.4736 -0.6742 -0.2964
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute_right_heart_failure pulmonary_hypertension
H-1090	-0.5110602378845215	▁right _ heart _ ▁failure ▁pulmonar y ▁hyper tension
D-1090	-0.5110602378845215	right_heart_ failure pulmonary hypertension
P-1090	-1.0636 -0.6730 -1.6090 -0.5409 -0.3894 -0.0006 -0.0035 -1.2238 -0.0015 -0.0594 -0.0570
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american hf
H-1843	-1.3402451276779175	▁european ▁ HF
D-1843	-1.3402451276779175	european HF
P-1843	-4.3513 -1.3004 -0.1494 -0.7807 -0.1194
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients hypertension
H-1889	-1.3929709196090698	▁hyper tension
D-1889	-1.3929709196090698	hypertension
P-1889	-5.2408 -0.0721 -0.0768 -0.1822
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.6075144410133362	▁gene s
D-1616	-0.6075144410133362	genes
P-1616	-1.5486 -0.1954 -0.6277 -0.0584
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.36333954334259033	▁Literatur e
D-32	-0.36333954334259033	Literature
P-32	-0.9178 -0.1700 -0.2515 -0.1141
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.7808375358581543	▁internal _ ▁reli ability ▁cro n bach
D-786	-0.7808375358581543	internal_ reliability cronbach
P-786	-2.3191 -1.3947 -0.8868 -0.0686 -0.7312 -0.2828 -0.0212 -1.0230 -0.3001
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.48138436675071716	▁trial s
D-804	-0.48138436675071716	trials
P-804	-0.8238 -0.9826 -0.0401 -0.0790
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient conditions
H-0	-0.959829568862915	▁patient _ ▁safety
D-0	-0.959829568862915	patient_ safety
P-0	-1.8639 -0.6267 -1.1861 -0.7991 -0.3234
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.8608583807945251	
D-1759	-0.8608583807945251	
P-1759	-1.6153 -0.1064
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.7314258813858032	▁implant ed ▁monitoring _ ▁devices
D-156	-0.7314258813858032	implanted monitoring_ devices
P-156	-1.5126 -0.0738 -1.3684 -1.1047 -0.8089 -0.1617 -0.0899
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.3013097643852234	▁fe w ▁treatment s ▁clinic al ▁trial s
D-1469	-0.3013097643852234	few treatments clinical trials
P-1469	-0.7918 -0.0066 -1.0112 -0.2016 -0.1519 -0.0254 -0.7628 -0.0253 -0.0158 -0.0207
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea afterload
H-518	-1.4024277925491333	▁HR ▁after load _ ▁burde n
D-518	-1.4024277925491333	HR afterload_ burden
P-518	-3.4583 -5.4918 -0.0008 -1.0837 -0.3212 -0.1441 -0.1713 -0.5481
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths strokes
H-778	-0.49621468782424927	▁per i pro ced ural ▁stroke s
D-778	-0.49621468782424927	periprocedural strokes
P-778	-0.0893 -1.0302 -0.0168 -0.0088 -0.0019 -3.2162 -0.0443 -0.0316 -0.0269
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras atherosclerosis
H-1594	-1.3571746349334717	▁ RAS ▁at hero sc ler osis
D-1594	-1.3571746349334717	RAS atherosclerosis
P-1594	-2.8773 -0.4671 -3.2885 -0.7895 -1.4688 -2.7263 -0.0325 -0.1917 -0.3730
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty heart_failure
H-1000	-0.5638455748558044	▁fra il ty ▁heart _ ▁failure ▁community
D-1000	-0.5638455748558044	frailty heart_ failure community
P-1000	-2.6762 -0.5380 -0.1239 -0.3563 -0.3489 -0.3381 -0.2827 -0.3078 -0.1027
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss exercise training outcomes
H-1932	-0.9046719670295715	▁PS SS ▁exercise _ training
D-1932	-0.9046719670295715	PSSS exercise_training
P-1932	-1.4277 -0.1823 -0.1561 -1.5828 -0.5609 -2.1143 -0.3085
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas heart_failure disease
H-1479	-0.6411455869674683	▁Micro RNA s ▁heart _ ▁failure ▁disease
D-1479	-0.6411455869674683	MicroRNAs heart_ failure disease
P-1479	-1.7901 -0.0086 -0.0604 -0.1833 -0.3377 -1.4044 -0.3724 -1.5010 -0.1124
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise quality_of_life heart_failure
H-612	-1.735364556312561	▁exercise ▁heart _ ▁failure
D-612	-1.735364556312561	exercise heart_ failure
P-612	-3.8070 -4.3125 -0.5365 -1.4291 -0.1460 -0.1810
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard_ratios cox_regression_analysis
H-1770	-0.6278674006462097	▁co x ▁re gression
D-1770	-0.6278674006462097	cox regression
P-1770	-1.1509 -0.0729 -0.5786 -0.1132 -1.4225 -0.4291
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology bromodomain halts heart_failure
H-1033	-0.6375696659088135	▁Card i ology ▁bro modo main ▁inhibi tion _ ▁halt s ▁heart _ ▁failure
D-1033	-0.6375696659088135	Cardiology bromodomain inhibition_ halts heart_ failure
P-1033	-1.5362 -1.0078 -0.0294 -2.4821 -0.0066 -0.7063 -0.7860 -0.0879 -1.2381 -0.9761 -0.0911 -0.1431 -0.3863 -0.6313 -0.0588 -0.0341
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart_failure_with_preserved_ejection_fraction
H-1885	-0.5351810455322266	▁management ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-1885	-0.5351810455322266	management heart_ failure preserved ejection_fraction
P-1885	-1.1990 -2.2540 -0.2975 -1.1151 -0.5437 -0.1171 -0.0854 -0.4905 -0.0362 -0.0360 -1.0707 -0.0052 -0.0859 -0.1562
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.7277382016181946	▁media n _ âge
D-677	-0.7277382016181946	median_âge
P-677	-0.3203 -0.1369 -0.7246 -1.2266 -1.7597 -0.1983
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient medical conditions
H-1688	-0.8629928231239319	▁in patient ▁medical ▁conditions
D-1688	-0.8629928231239319	inpatient medical conditions
P-1688	-2.8151 -0.1120 -1.8688 -0.2434 -0.0292 -0.1094
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness anemia
H-1679	-0.9432241916656494	▁Jehovah _ s ▁Wit ness ▁severe ▁an emia
D-1679	-0.9432241916656494	Jehovah_s Witness severe anemia
P-1679	-0.1869 -1.8580 -4.1639 -0.5432 -0.2964 -1.7748 -0.2475 -0.0080 -0.1753 -0.1781
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology hospital
H-812	-0.5963910818099976	▁department _ of _ card i ology ▁university _ hospital
D-812	-0.5963910818099976	department_of_cardiology university_hospital
P-812	-2.9272 -0.9283 -0.0471 -0.0440 -1.2896 -0.7696 -0.0029 -0.0305 -0.9437 -0.0618 -0.0692 -0.0428
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.4496215581893921	▁ HF p EF
D-1078	-0.4496215581893921	HFpEF
P-1078	-1.0673 -0.3846 -0.0468 -0.9850 -0.1727 -0.0413
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf hf
H-1309	-0.7876691222190857	▁ HF
D-1309	-0.7876691222190857	HF
P-1309	-1.4344 -0.3893 -1.0998 -0.2271
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic_balance
H-1375	-0.3702945113182068	▁autonomi c ▁balance
D-1375	-0.3702945113182068	autonomic balance
P-1375	-1.0867 -0.3788 -0.1609 -0.0598 -0.1652
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty hf
H-624	-0.5913742184638977	▁impact _ of _ fra il ty ▁ HF
D-624	-0.5913742184638977	impact_of_frailty HF
P-624	-1.7613 -1.1866 -0.3395 -0.0446 -1.2175 -0.1571 -0.1848 -0.3171 -0.0073 -1.0228 -0.2667
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient hospital heart_failure
H-1960	-1.359942078590393	
D-1960	-1.359942078590393	
P-1960	-2.4247 -0.2952
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 functional_capacity
H-702	-1.267351746559143	
D-702	-1.267351746559143	
P-702	-2.4384 -0.0963
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart_failure mortality
H-204	-0.37259528040885925	▁Heart _ ▁failure ▁cognitive _ ▁im pair ment ▁mortal ity
D-204	-0.37259528040885925	Heart_ failure cognitive_ impairment mortality
P-204	-0.2320 -0.7350 -0.4093 -0.6831 -0.3549 -0.1699 -0.0008 -0.0657 -1.5469 -0.0029 -0.0515 -0.2191
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv_fibrosis
H-280	-0.6953752636909485	▁LV _ ▁fibro sis ▁ ANS
D-280	-0.6953752636909485	LV_ fibrosis ANS
P-280	-0.3050 -0.7876 -0.0466 -0.3820 -0.7347 -0.0365 -3.1169 -0.1537
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up_duration
H-495	-0.249970480799675	▁media n ▁follow - up _ ▁du ration
D-495	-0.249970480799675	median follow-up_ duration
P-495	-0.0194 -0.3054 -0.3608 -0.0764 -0.0238 -0.6846 -0.6122 -0.0136 -0.2994 -0.1040
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral_growth
H-511	-0.7453245520591736	▁competitive ▁col lateral
D-511	-0.7453245520591736	competitive collateral
P-511	-0.4302 -0.7288 -0.0009 -2.4348 -0.1319
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated mixed_linear_models
H-325	-0.6273056864738464	▁Indi ces ▁CO ▁mix ed ▁linear ▁models
D-325	-0.6273056864738464	Indices CO mixed linear models
P-325	-1.4576 -0.0031 -1.4247 -0.3060 -0.0029 -0.9960 -1.1565 -0.0886 -0.2103
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart_failure hospitalization cardiovascular_death
H-410	-0.7839847803115845	▁heart ▁failure _ hospital ization ▁cardiovascular _ ▁death
D-410	-0.7839847803115845	heart failure_hospitalization cardiovascular_ death
P-410	-0.9361 -2.6468 -1.3753 -0.0242 -0.2447 -0.0162 -0.8588 -1.6603 -0.0287 -0.0488
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary_outcomes quality_of_life
H-1654	-0.7864480018615723	▁cognitive _ function ▁quality
D-1654	-0.7864480018615723	cognitive_function quality
P-1654	-0.2642 -1.1504 -0.4411 -0.7231 -1.9131 -0.2268
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin congestive_heart_failure
H-633	-0.2884322702884674	▁vaso press in ▁con ges tive _ heart _ ▁failure
D-633	-0.2884322702884674	vasopressin congestive_heart_ failure
P-633	-0.0679 -0.3171 -0.4460 -0.0123 -0.0291 -0.1031 -0.2263 -1.0076 -0.5705 -0.5422 -0.0682 -0.0711
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended_criteria_cardiac_transplantation
H-707	-0.9390795826911926	▁cardiac _ ▁transplant ation
D-707	-0.9390795826911926	cardiac_ transplantation
P-707	-3.7944 -1.0497 -0.5124 -0.0938 -0.1188 -0.0652
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral_stenosis medical_treatment heart_failure
H-332	-1.045360803604126	▁Mit ral _ ▁sten osis ▁rever sed ▁medical _ ▁treatment ▁heart _ ▁failure
D-332	-1.045360803604126	Mitral_ stenosis reversed medical_ treatment heart_ failure
P-332	-2.4192 -0.0081 -0.2332 -2.4192 -0.1125 -3.6796 -0.6782 -0.3392 -1.2784 -1.7788 -0.0827 -0.5776 -1.8859 -0.0723 -0.1154
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 hf
H-1211	-0.3272620737552643	▁p de 2 ▁ HF
D-1211	-0.3272620737552643	pde2 HF
P-1211	-1.4933 -0.4779 -0.0400 -0.1464 -0.0073 -0.0370 -0.0889
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-1.1188790798187256	
D-958	-1.1188790798187256	
P-958	-2.1858 -0.0519
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.42130938172340393	▁pro pens ity ▁score - match ed
D-1837	-0.42130938172340393	propensity score-matched
P-1837	-0.0200 -0.0251 -0.0197 -1.6162 -0.6257 -0.0551 -0.1035 -1.2288 -0.0976
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.7728337049484253	
D-1998	-0.7728337049484253	
P-1998	-1.4608 -0.0849
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-1.2054898738861084	▁black
D-1634	-1.2054898738861084	black
P-1634	-1.4369 -1.9373 -0.2423
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.4827916622161865	
D-1261	-0.4827916622161865	
P-1261	-0.9015 -0.0641
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.6545443534851074	▁ metric _ ▁choice ▁read mission _ ▁metri cs
D-134	-0.6545443534851074	metric_ choice readmission_ metrics
P-134	-1.1027 -0.0008 -0.6015 -2.6275 -1.6137 -0.4274 -0.0829 -0.5408 -0.0121 -0.0901 -0.1005
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.9540420174598694	▁ET ▁ex ert s ▁beneficia l _ effect ▁CHF
D-261	-0.9540420174598694	ET exerts beneficial_effect CHF
P-261	-5.8255 -0.4281 -0.0417 -0.0523 -1.1138 -0.2432 -1.2831 -0.6637 -0.5639 -0.0791 -0.1999
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.5946487188339233	▁read mission _ metric
D-145	-0.5946487188339233	readmission_metric
P-145	-1.1076 -0.2520 -0.8340 -0.0106 -1.2809 -0.0828
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician hospital physician
H-1726	-1.275316834449768	▁physician _ ▁volume
D-1726	-1.275316834449768	physician_ volume
P-1726	-0.4449 -1.2496 -0.1368 -3.9884 -0.5568
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.4487687647342682	▁res idu al ▁con found ing ▁short ▁follow - up
D-1839	-0.4487687647342682	residual confounding short follow-up
P-1839	-3.6061 -0.2771 -0.0121 -0.6985 -0.1509 -0.0305 -0.0347 -0.3684 -0.0722 -0.0101 -0.0386 -0.0861
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.2731345593929291	▁media n ▁follow - up
D-1758	-0.2731345593929291	median follow-up
P-1758	-0.3898 -0.1633 -0.8309 -0.1149 -0.0092 -0.3173 -0.0864
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs expenditures
H-1238	-0.9872426390647888	▁ar rhythm ia - related ▁costs
D-1238	-0.9872426390647888	arrhythmia-related costs
P-1238	-1.1993 -0.3103 -1.5678 -1.3920 -0.0818 -0.8783 -2.3104 -0.1580
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication sst2
H-403	-0.45095789432525635	▁Medica tion ▁s ST 2 ▁values
D-403	-0.45095789432525635	Medication sST2 values
P-403	-0.2368 -0.1305 -0.4634 -0.8692 -0.0538 -1.4758 -0.0964 -0.2817
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable_hf
H-481	-1.1808795928955078	
D-481	-1.1808795928955078	
P-481	-2.2741 -0.0876
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality sts
H-159	-0.7826281785964966	▁s ts _ HM
D-159	-0.7826281785964966	sts_HM
P-159	-2.7817 -0.2818 -0.9733 -0.2263 -0.0897 -0.3429
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-0.4725463092327118	▁system a tic _ review ▁network ▁meta - analys is
D-150	-0.4725463092327118	systematic_review network meta-analysis
P-150	-1.8639 -1.2775 -0.0510 -0.3063 -0.1584 -0.0425 -1.5706 -0.0809 -0.0213 -0.1462 -0.0455 -0.1065
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical hypothermic_circulatory_arrest
H-598	-0.508752167224884	▁sur g ical _ ▁tac tics ▁hypothe r mic _ ▁circula tory ▁arrest
D-598	-0.508752167224884	surgical_ tactics hypothermic_ circulatory arrest
P-598	-2.9979 -0.3112 -0.1705 -0.3628 -0.0762 -0.5869 -0.6690 -0.0961 -0.4150 -0.5782 -0.4289 -0.0069 -0.7303 -0.0716 -0.1298
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary_outcomes functional_capacity quality_of_life
H-616	-0.9143847823143005	▁functional _ capaci ty ▁quality
D-616	-0.9143847823143005	functional_capacity quality
P-616	-2.0726 -1.1478 -0.5309 -0.5140 -0.1964 -1.8305 -0.1084
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed mortality random-effects_models
H-64	-0.62225741147995	▁mortal ity ▁random - effect s ▁models
D-64	-0.62225741147995	mortality random-effects models
P-64	-3.2200 -0.0742 -0.0999 -0.1558 -0.0046 -0.0567 -1.8096 -0.0510 -0.1285
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection_fraction bnp
H-194	-0.5703277587890625	▁e je ction _ fraction ▁b NP
D-194	-0.5703277587890625	ejection_fraction bNP
P-194	-1.7649 -0.0814 -0.0049 -0.8627 -0.0405 -1.8652 -0.2198 -0.0496 -0.2441
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up patients
H-1009	-0.6661150455474854	
D-1009	-0.6661150455474854	
P-1009	-1.2861 -0.0462
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic_hf death
H-1796	-0.21350029110908508	▁Chro nic _ HF
D-1796	-0.21350029110908508	Chronic_HF
P-1796	-0.0231 -0.0057 -0.2288 -0.1552 -0.6331 -0.2351
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology diagnosed
H-352	-0.8012903928756714	▁et i ology ▁MR
D-352	-0.8012903928756714	etiology MR
P-352	-1.1432 -0.5267 -0.0030 -0.1575 -2.7985 -0.1788
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients hfpef
H-787	-0.8224208354949951	▁ HF p EF
D-787	-0.8224208354949951	HFpEF
P-787	-2.4199 -1.1418 -0.2103 -0.8765 -0.0768 -0.2093
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac_amyloidosis
H-997	-0.5891799926757812	▁Card iac _ a my lo idos is
D-997	-0.5891799926757812	Cardiac_amyloidosis
P-997	-0.4578 -0.1376 -0.7935 -0.4409 -0.0537 -0.5045 -0.1913 -2.6809 -0.6148 -0.0168
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic medication death
H-507	-0.8041495680809021	▁Pig s ▁anti ar rhythm ic _ ▁medication ▁sud den ▁death
D-507	-0.8041495680809021	Pigs antiarrhythmic_ medication sudden death
P-507	-2.5052 -0.5613 -0.1210 -0.2122 -0.4004 -0.3654 -1.8801 -0.6939 -0.0719 -0.0139 -3.0821 -0.0772 -0.4695
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training heart_failure patients
H-1911	-0.8637798428535461	▁robot - assist ed _ training ▁heart _ ▁failure
D-1911	-0.8637798428535461	robot-assisted_training heart_ failure
P-1911	-1.9397 -0.2256 -0.0005 -0.0446 -0.5999 -1.2406 -0.9021 -0.4250 -2.0782 -1.7415 -0.3039
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients functional_capacity symptoms
H-550	-1.2399407625198364	
D-550	-1.2399407625198364	
P-550	-2.3783 -0.1016
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf patients intubated
H-219	-0.8675673604011536	▁CHF
D-219	-0.8675673604011536	CHF
P-219	-0.0266 -2.4100 -0.1661
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end_point
H-266	-0.9557620286941528	
D-266	-0.9557620286941528	
P-266	-1.8447 -0.0668
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart_rate arterial_pressure
H-424	-0.32212892174720764	▁Heart ▁rate ▁arterial _ ▁pressure
D-424	-0.32212892174720764	Heart rate arterial_ pressure
P-424	-0.2230 -0.8519 -0.0986 -0.4071 -0.5322 -0.0618 -0.0802
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients therapy beta_blockade
H-1736	-1.3685098886489868	▁ therapy ▁beta _ block ade
D-1736	-1.3685098886489868	therapy beta_blockade
P-1736	-6.5822 -1.3328 -0.5080 -1.2347 -0.9159 -0.1154 -0.1229 -0.1362
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb correlated baseline hrqol
H-840	-0.28422924876213074	▁h gb ▁base line _ HR Qo L
D-840	-0.28422924876213074	hgb baseline_HRQoL
P-840	-0.9290 -0.0113 -0.3249 -0.0034 -0.4263 -0.7189 -0.0243 -0.1549 -0.1782 -0.0711
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients cardiac inflammatory biomarkers
H-1914	-0.5732421875	▁cardiac ▁infla mma tory _ bio mark ers
D-1914	-0.5732421875	cardiac inflammatory_biomarkers
P-1914	-0.1968 -3.5055 -0.4948 -0.0547 -0.2958 -0.8602 -0.0197 -0.0275 -0.0991 -0.1784
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected patients systolic_dysfunction
H-1069	-1.1434351205825806	▁sy sto lic _ ▁dys function
D-1069	-1.1434351205825806	systolic_ dysfunction
P-1069	-2.0116 -3.8984 -1.1130 -0.4634 -0.9915 -0.4121 -0.1249 -0.1326
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved_ejection_fraction outcomes
H-1464	-0.46016818284988403	▁pres er ved ▁e je ction ▁ fraction ▁outcome s ▁trial
D-1464	-0.46016818284988403	preserved ejection fraction outcomes trial
P-1464	-0.0486 -0.4082 -0.2053 -1.0176 -0.2029 -0.0320 -0.9874 -0.0001 -1.8984 -0.0202 -0.9404 -0.0331 -0.1879
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated_hf cardiovascular hospitalization
H-1797	-1.2440855503082275	▁cardiovascular _ hospital ization
D-1797	-1.2440855503082275	cardiovascular_hospitalization
P-1797	-6.4647 -0.5305 -0.0264 -0.2767 -0.0693 -0.0969
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic biomarkers chronic_heart_failure
H-1471	-0.5535969734191895	▁bio mark ers ▁chronic _ heart _ ▁failure
D-1471	-0.5535969734191895	biomarkers chronic_heart_ failure
P-1471	-2.1787 -0.0107 -0.0474 -0.0792 -0.1695 -1.2083 -0.3643 -1.3514 -0.0606 -0.0658
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes patients heart_failure emergency_department
H-461	-1.4356098175048828	▁heart _ ▁failure ▁emergency _ ▁department ▁volume
D-461	-1.4356098175048828	heart_ failure emergency_ department volume
P-461	-4.8286 -0.5865 -3.6341 -0.1914 -0.8094 -0.7409 -1.8970 -0.0804 -0.1522
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max significance
H-1255	-0.4595174789428711	▁VO 2 max ▁statistic al
D-1255	-0.4595174789428711	VO2max statistical
P-1255	-0.8602 -0.0215 -0.0056 -0.7361 -0.1477 -1.2905 -0.1550
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart_failure
H-1204	-1.644195556640625	
D-1204	-1.644195556640625	
P-1204	-3.1557 -0.1327
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome tug_test
H-799	-1.4698612689971924	
D-799	-1.4698612689971924	
P-799	-2.8233 -0.1164
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated hf
H-608	-0.6088243126869202	▁HR ▁ HF
D-608	-0.6088243126869202	HR HF
P-608	-0.2692 -2.3771 -0.0227 -0.1567 -0.2184
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.5848495960235596	▁research ▁bio mark ers
D-70	-0.5848495960235596	research biomarkers
P-70	-2.2188 -1.1664 -0.0092 -0.0116 -0.0426 -0.0604
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients esrd
H-394	-1.5475947856903076	
D-394	-1.5475947856903076	
P-394	-2.7949 -0.3003
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.7499600648880005	▁prognos tic _ factor
D-591	-0.7499600648880005	prognostic_factor
P-591	-1.0328 -0.7953 -0.8126 -0.7110 -1.0332 -0.1149
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.1939889192581177	
D-603	-1.1939889192581177	
P-603	-2.3457 -0.0423
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.48698222637176514	▁clinic al ▁trial s
D-1028	-0.48698222637176514	clinical trials
P-1028	-0.4378 -0.0243 -2.2466 -0.0751 -0.0931 -0.0452
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug japan
H-1197	-0.9015406966209412	
D-1197	-0.9015406966209412	
P-1197	-1.7061 -0.0970
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.6113114356994629	▁ab normal _ ▁cardiac _ T 2
D-746	-0.6113114356994629	abnormal_ cardiac_T2
P-746	-0.4750 -0.0020 -0.4980 -1.4265 -0.1006 -0.8173 -0.0153 -2.0836 -0.0834
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.4812714755535126	▁trial s
D-800	-0.4812714755535126	trials
P-800	-0.9078 -0.1662 -0.7557 -0.0953
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.63294517993927	
D-1923	-0.63294517993927	
P-1923	-1.1895 -0.0764
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.446255624294281	▁intervention s
D-1854	-0.446255624294281	interventions
P-1854	-0.8336 -0.2226 -0.6138 -0.1150
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.6346197724342346	▁risk
D-1206	-0.6346197724342346	risk
P-1206	-0.2970 -1.4954 -0.1115
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart_failure_with_preserved_left_ventricular_ejection_fraction
H-1299	-0.6560925245285034	▁Heart _ ▁failure ▁left _ ▁vent ri cular _ e je ction _ fraction
D-1299	-0.6560925245285034	Heart_ failure left_ ventricular_ejection_fraction
P-1299	-0.1245 -0.6538 -0.6477 -1.9284 -0.3225 -2.6412 -0.3865 -0.1781 -0.4186 -1.0402 -0.1008 -0.1638 -1.6477 -0.0079 -0.0959 -0.1397
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality_of_life
H-1919	-0.9343844056129456	▁quality _ of _ life
D-1919	-0.9343844056129456	quality_of_life
P-1919	-1.8976 -0.8129 -0.1577 -0.0463 -0.8633 -2.4465 -0.3164
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate_adjustment cox_proportional_hazards_models
H-785	-0.49270114302635193	▁co x ▁proportion al _ ▁hazard s
D-785	-0.49270114302635193	cox proportional_ hazards
P-785	-0.2060 -0.3896 -0.0626 -0.0225 -0.0878 -1.8947 -0.5137 -1.1391 -0.1183
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan vasopressin_type_2_receptor_antagonist
H-1195	-0.2462266981601715	▁Tol va p tan ▁vaso press in ▁receptor ▁anta gon ist
D-1195	-0.2462266981601715	Tolvaptan vasopressin receptor antagonist
P-1195	-0.0213 -0.2502 -0.0735 -0.0713 -0.0089 -0.0904 -0.6828 -0.1237 -1.3519 -0.0286 -0.2447 -0.1477 -0.1059
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology chronic_heart_failure bisoprolol
H-645	-0.4498297870159149	▁Epidemi ology ▁chronic _ heart _ ▁failure ▁bis o pro lol
D-645	-0.4498297870159149	Epidemiology chronic_heart_ failure bisoprolol
P-645	-1.5248 -0.0034 -0.9173 -0.2447 -1.2432 -0.4196 -0.8693 -0.2924 -0.0549 -0.0141 -0.0137 -0.1408 -0.1094
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone systolic_heart_failure
H-437	-0.32336440682411194	▁spi rono lac tone ▁sy sto lic _ heart _ ▁failure
D-437	-0.32336440682411194	spironolactone systolic_heart_ failure
P-437	-1.2479 -0.0128 -0.0503 -0.0283 -0.0126 -0.0538 -0.1078 -0.2479 -0.6206 -0.8592 -0.7925 -0.0673 -0.1026
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart_failure hf leading mortality society
H-1034	-0.802449107170105	▁Heart _ ▁failure _ HF
D-1034	-0.802449107170105	Heart_ failure_HF
P-1034	-0.3393 -0.1730 -1.5065 -0.8905 -0.3355 -2.0702 -0.3022
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional_ms reported patients degenerative_mr
H-339	-0.315664678812027	▁Fun ction al _ ▁MS ▁de genera tive ▁MR
D-339	-0.315664678812027	Functional_ MS degenerative MR
P-339	-1.0692 -0.0067 -0.0652 -0.5020 -0.1759 -0.6201 -0.0005 -0.0254 -0.8069 -0.0741 -0.1265
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular_scaffolds heart pathology
H-989	-0.5986267924308777	▁e RK 1/2 ▁molecular _ ▁sc af fold s ▁heart _ path ology
D-989	-0.5986267924308777	eRK1/2 molecular_ scaffolds heart_pathology
P-989	-2.5320 -0.0111 -3.7507 -0.3001 -0.1733 -0.4857 -0.6466 -0.6769 -0.0140 -0.0535 -0.1659 -0.0220 -0.0060 -0.0405 -0.1011
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart_failure hf therapy
H-1067	-1.3443033695220947	▁corner stone _ of _ heart _ ▁failure HF _ therapy
D-1067	-1.3443033695220947	cornerstone_of_heart_ failureHF_therapy
P-1067	-6.3723 -0.6061 -1.3958 -0.1437 -0.1878 -0.5807 -0.1325 -3.8543 -1.2007 -1.6166 -0.9511 -0.1732 -0.2611
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet aortic_pressure
H-581	-1.0958080291748047	▁l VET ▁a or tic _ ▁pressure _ ▁cur ve
D-581	-1.0958080291748047	lVET aortic_ pressure_ curve
P-581	-6.1806 -0.1666 -1.3508 -0.3987 -0.1262 -0.0479 -3.7960 -0.4316 -0.2581 -0.0246 -0.0638 -0.3048
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac symptoms congenital lesions
H-983	-0.7997090220451355	▁Card iac ▁con geni tal _ les ions
D-983	-0.7997090220451355	Cardiac congenital_lesions
P-983	-1.6855 -1.2232 -2.7573 -0.0041 -0.3159 -0.3817 -1.0904 -0.3171 -0.0940 -0.1278
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital coprimary_outcome
H-1651	-1.193044900894165	▁night s ▁hospital
D-1651	-1.193044900894165	nights hospital
P-1651	-2.0503 -0.1093 -2.6268 -0.9017 -0.2772
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity patients breast_cancer
H-669	-0.5439316034317017	▁Tras tuz um ab - related ▁cardio toxic ity ▁breast _ cancer
D-669	-0.5439316034317017	Trastuzumab-related cardiotoxicity breast_cancer
P-669	-0.3334 -0.0178 -0.0288 -0.0425 -0.3521 -0.2199 -1.5251 -2.4600 -0.1468 -0.5528 -1.6217 -0.1136 -0.1108 -0.0900
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart_failure public health
H-1606	-0.8794466853141785	▁public _ health _ problem
D-1606	-0.8794466853141785	public_health_problem
P-1606	-2.2435 -0.1891 -1.3311 -0.7698 -1.0580 -0.4746 -0.0900
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician outcomes discharge
H-1414	-0.838559627532959	▁physician ▁continu ity ▁dis charge
D-1414	-0.838559627532959	physician continuity discharge
P-1414	-0.0842 -1.3333 -0.0048 -4.1181 -0.0223 -0.1178 -0.1894
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative albumin
H-539	-0.6201615333557129	▁post operativ e _ normal ization ▁album in ▁level
D-539	-0.6201615333557129	postoperative_normalization albumin level
P-539	-0.2022 -0.0040 -0.7554 -1.9202 -0.4171 -0.2510 -0.1358 -0.1370 -2.2294 -0.6072 -0.1625
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis pathophysiological
H-1276	-0.6699466109275818	▁prognos is ▁pat ho phy si ological
D-1276	-0.6699466109275818	prognosis pathophysiological
P-1276	-0.7599 -1.3774 -0.2835 -0.1638 -0.1493 -1.0738 -0.1658 -2.0004 -0.0555
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients lvad implantation
H-545	-1.493670105934143	
D-545	-1.493670105934143	
P-545	-2.9138 -0.0735
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients heart_failure
H-1821	-1.4258843660354614	▁patients ▁heart _ ▁failure
D-1821	-1.4258843660354614	patients heart_ failure
P-1821	-3.5974 -2.3635 -0.5435 -1.5601 -0.4054 -0.0854
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income expenditure health
H-1792	-2.021272897720337	▁gross ▁income ▁health ▁per ▁capita
D-1792	-2.021272897720337	gross income health per capita
P-1792	-5.0706 -0.8931 -6.5358 -0.8030 -0.0112 -0.3735 -0.4616
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha esc
H-1908	-1.164225459098816	▁ AHA ▁ESC ▁advocate ▁pre - parti cip ation _ ▁screening
D-1908	-1.164225459098816	AHA ESC advocate pre-participation_ screening
P-1908	-1.6738 -0.0422 -2.7688 -4.9197 -1.0737 -0.0577 -0.0201 -0.0032 -0.1932 -1.2807 -0.2769 -2.3287 -0.4962
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity outcomes
H-709	-0.9395062327384949	▁data ▁exam ining ▁long - term ▁outcome s
D-709	-0.9395062327384949	data examining long-term outcomes
P-709	-1.2390 -5.5040 -0.2926 -0.1566 -0.0497 -0.0115 -1.7816 -0.0150 -0.2179 -0.1271
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician hf
H-1732	-0.6669765114784241	▁clinic ian _ expert ▁ HF
D-1732	-0.6669765114784241	clinician_expert HF
P-1732	-0.2577 -1.4574 -1.0692 -0.4952 -0.5890 -0.0169 -1.4107 -0.0396
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic hf
H-1072	-1.0966720581054688	▁diagnostic _ ▁devices ▁ HF
D-1072	-1.0966720581054688	diagnostic_ devices HF
P-1072	-5.4639 -0.9129 -0.9990 -0.1990 -0.0151 -0.0345 -0.0523
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.8226231336593628	▁intervention ▁ad her ence ▁c PG s
D-1848	-0.8226231336593628	intervention adherence cPGs
P-1848	-2.4619 -0.3305 -2.0497 -0.0083 -1.9067 -0.0117 -0.1738 -0.0621 -0.3989
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north_america
H-75	-0.5661500692367554	▁en roll ment
D-75	-0.5661500692367554	enrollment
P-75	-0.4081 -0.0005 -0.0353 -2.2355 -0.1513
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient circulation
H-1824	-1.1238890886306763	
D-1824	-1.1238890886306763	
P-1824	-2.0828 -0.1650
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.5162510275840759	
D-1965	-0.5162510275840759	
P-1965	-1.0032 -0.0293
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-1.322746992111206	
D-1576	-1.322746992111206	
P-1576	-2.3984 -0.2471
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.5401362180709839	
D-1881	-0.5401362180709839	
P-1881	-1.0417 -0.0385
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.4018940031528473	▁insigni fica nt ▁MS
D-372	-0.4018940031528473	insignificant MS
P-372	-0.6795 -0.0746 -0.1991 -0.1925 -1.1980 -0.0678
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive_statistics cox_proportional_hazards_models
H-675	-0.6496128439903259	▁co x ▁proportion al _ ▁hazard s
D-675	-0.6496128439903259	cox proportional_ hazards
P-675	-0.6976 -0.0187 -0.3726 -0.0155 -0.0866 -2.7189 -0.6059 -1.1606 -0.1703
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis patients implantation
H-913	-0.6387502551078796	▁di al ysis ▁device ▁implant ation
D-913	-0.6387502551078796	dialysis device implantation
P-913	-0.1958 -0.0209 -0.0542 -3.5812 -0.9810 -0.0739 -0.0924 -0.1106
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric self-care_of_heart_failure_index_version_6.2
H-1503	-0.5648401379585266	▁self - Car e _ of _ heart _ fail ure _ index
D-1503	-0.5648401379585266	self-Care_of_heart_failure_index
P-1503	-2.4064 -0.0509 -1.0779 -0.0714 -0.7770 -0.0435 -0.5478 -0.9519 -0.0535 -0.5665 -0.1149 -0.5402 -0.1251 -0.8736 -0.2720
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart_failure cox_proportional_hazard_analyses
H-1537	-0.5241159796714783	▁risk _ of _ heart _ ▁failure ▁co x ▁proportion al _ ▁hazard
D-1537	-0.5241159796714783	risk_of_heart_ failure cox proportional_ hazard
P-1537	-0.5578 -1.0985 -0.2971 -0.0772 -0.4622 -0.1556 -2.0129 -0.1213 -0.0253 -0.1903 -0.0048 -0.1021 -1.1255 -1.3314 -0.2997
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial_function flow-mediated_dilatation
H-253	-0.1800524890422821	▁en dot heli al ▁flow - media ted ▁di la tation
D-253	-0.1800524890422821	endothelial flow-mediated dilatation
P-253	-0.1941 -0.2827 -0.0692 -0.0061 -0.4333 -0.0540 -0.0255 -0.4460 -0.4551 -0.1606 -0.0026 -0.0977 -0.1139
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients acute_kidney_injury postoperatively
H-975	-0.8673702478408813	▁a cute ▁ki dne y _ ▁injury
D-975	-0.8673702478408813	acute kidney_ injury
P-975	-1.2908 -0.0068 -0.6516 -0.6571 -0.0297 -1.3470 -1.2262 -2.4060 -0.1911
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological acute_heart_failure
H-1465	-0.6788395643234253	▁Pharma c ology ▁a cute _ heart _ ▁failure
D-1465	-0.6788395643234253	Pharmacology acute_heart_ failure
P-1465	-1.6656 -0.0254 -1.1464 -0.5589 -0.0046 -0.1492 -1.1734 -0.4050 -1.3503 -0.8864 -0.1020
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient postoperatively multiorgan_failure sepsis
H-551	-0.5874758958816528	▁post operativ ely ▁multi organ ▁failure ▁se psis
D-551	-0.5874758958816528	postoperatively multiorgan failure sepsis
P-551	-1.9620 -0.0990 -0.8854 -0.9237 -0.0493 -1.7797 -0.0207 -0.0001 -0.0465 -0.1084
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized walking patients severe_heart_failure
H-567	-2.5301339626312256	▁Nordic _ ▁walking
D-567	-2.5301339626312256	Nordic_ walking
P-567	-0.8783 -2.2463 -5.6880 -3.4979 -0.3401
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping baseline heart_failure
H-1059	-0.898105263710022	▁base line ▁heart _ ▁failure
D-1059	-0.898105263710022	baseline heart_ failure
P-1059	-0.2461 -0.0070 -0.3514 -0.3955 -3.8405 -1.3271 -0.1192
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle_heart_failure_model
H-2011	-0.5971364974975586	▁sur vi val _ project ions ▁Seattle ▁Heart _ ▁Fail ure _ model
D-2011	-0.5971364974975586	survival_projections Seattle Heart_ Failure_model
P-2011	-2.9785 -0.0230 -0.0778 -1.2360 -0.0128 -0.2743 -0.4032 -0.8874 -0.4005 -0.7439 -0.0530 -1.0623 -0.6840 -0.0353 -0.0849
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic_phenotype fontan
H-223	-0.3484598398208618	▁Hem o dynamic _ ▁ph eno type ▁fail ing _ ▁Font an ▁adult _ ▁population
D-223	-0.3484598398208618	Hemodynamic_ phenotype failing_ Fontan adult_ population
P-223	-0.1948 -0.0464 -0.0016 -0.4094 -2.0568 -0.0493 -0.0096 -0.0991 -0.0222 -0.2620 -0.5696 -0.1225 -0.6474 -0.9242 -0.3780 -0.0629 -0.0679
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient surgery echocardiography
H-358	-0.6790207624435425	▁MS ▁e cho card i ography
D-358	-0.6790207624435425	MS echocardiography
P-358	-0.4823 -2.4296 -0.1112 -1.5760 -0.6075 -0.0930 -0.0789 -0.0537
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary_angiography lesions
H-349	-0.7109241485595703	▁Corona ry _ ▁ang i ography
D-349	-0.7109241485595703	Coronary_ angiography
P-349	-0.0364 -0.1902 -0.4219 -1.5414 -2.6992 -0.1215 -0.6273 -0.0495
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate_analyses
H-826	-1.3439948558807373	
D-826	-1.3439948558807373	
P-826	-2.6129 -0.0751
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise life_expectancy
H-1902	-0.9816710948944092	
D-1902	-0.9816710948944092	
P-1902	-1.8764 -0.0869
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal heartmate_ii
H-772	-0.471558541059494	▁off - pump ▁ster nal _ ▁spar ing _ ▁approach ▁Heart Mate _ II ▁exchange
D-772	-0.471558541059494	off-pump sternal_ sparing_ approach HeartMate_II exchange
P-772	-0.1354 -0.0215 -0.0078 -2.7520 -0.0770 -0.5525 -0.0156 -0.0458 -0.7226 -0.9109 -0.0827 -0.1278 -1.0056 -1.3524 -0.0768 -0.0256 -0.1046
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse_events
H-1263	-0.8339735865592957	▁advers e ▁events
D-1263	-0.8339735865592957	adverse events
P-1263	-0.7762 -0.0233 -2.5816 -0.7526 -0.0361
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs_duration
H-888	-0.6522229909896851	▁QR s ▁du ration
D-888	-0.6522229909896851	QRs duration
P-888	-0.2097 -2.5707 -0.3441 -0.0135 -0.5848 -0.1906
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise training outcomes
H-1640	-0.6484740376472473	▁race ▁exercise
D-1640	-0.6484740376472473	race exercise
P-1640	-0.3805 -0.5837 -1.4762 -0.1535
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing nursing
H-1397	-0.7269312143325806	▁nur sing _ ▁terminologi es
D-1397	-0.7269312143325806	nursing_ terminologies
P-1397	-2.7731 -0.1558 -0.6557 -0.4796 -0.0289 -0.7974 -0.1979
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients surgical
H-547	-1.8032180070877075	
D-547	-1.8032180070877075	
P-547	-3.4427 -0.1637
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.3451874554157257	▁media n ▁follow - up
D-1165	-0.3451874554157257	median follow-up
P-1165	-0.1209 -0.0524 -1.4267 -0.0789 -0.0087 -0.7015 -0.0272
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients hospitals
H-3	-0.8598700165748596	
D-3	-0.8598700165748596	
P-3	-1.6545 -0.0652
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit_index
H-1006	-0.6501100063323975	▁deficit s
D-1006	-0.6501100063323975	deficits
P-1006	-0.0353 -1.8822 -0.4471 -0.2358
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-1.4601941108703613	
D-1696	-1.4601941108703613	
P-1696	-2.7835 -0.1369
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-1.1559635400772095	▁g LS
D-810	-1.1559635400772095	gLS
P-810	-0.9712 -0.9450 -2.4534 -0.2543
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-1.112663745880127	
D-370	-1.112663745880127	
P-370	-2.0704 -0.1550
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.7563557028770447	
D-1855	-0.7563557028770447	
P-1855	-1.4279 -0.0848
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic anaerobic_threshold heart_failure
H-1752	-0.821244478225708	▁ana ero bic _ ▁thre s hold ▁heart _ ▁failure
D-1752	-0.821244478225708	anaerobic_ threshold heart_ failure
P-1752	-3.0178 -0.7082 -1.2148 -0.2471 -0.8991 -0.3590 -0.6182 -0.1019 -0.5373 -2.0629 -0.0282 -0.0603
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone_system_inhibitors heart_failure
H-1486	-0.5438023805618286	▁re nin - angi oten sin - al do ster one _ system ▁inhibi tors ▁heart _ ▁failure
D-1486	-0.5438023805618286	renin-angiotensin-aldosterone_system inhibitors heart_ failure
P-1486	-0.1446 -0.0749 -0.0510 -0.0112 -0.2741 -0.6031 -0.1825 -0.0864 -2.7042 -1.0443 -0.2999 -1.3634 -0.2249 -1.3760 -0.0159 -0.0648 -0.3999 -1.7832 -0.0777 -0.0942
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf unilateral_renal_dnx cardiac autonomic_balance
H-1372	-0.48442497849464417	▁CHF ▁unilateral ▁renal _ ▁DN x ▁cardiac _ ▁autonomi c ▁balance
D-1372	-0.48442497849464417	CHF unilateral renal_ DNx cardiac_ autonomic balance
P-1372	-0.2298 -0.2887 -0.2297 -0.4191 -0.7182 -0.0639 -0.0614 -0.6263 -0.7391 -1.9828 -0.7037 -0.0800 -0.1548
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal_muscle exercise_capacity fontan_circulation
H-1491	-0.4455668330192566	▁s kelet al _ ▁muscle _ ▁ab normal ities ▁exercise _ capaci ty ▁Font an ▁circulation
D-1491	-0.4455668330192566	skeletal_ muscle_ abnormalities exercise_capacity Fontan circulation
P-1491	-1.0643 -0.0004 -0.0092 -0.2187 -1.4171 -0.8529 -0.6205 -0.0158 -0.0122 -0.7387 -0.7430 -0.2654 -1.1621 -0.0689 -0.0095 -0.5810 -0.1357 -0.1047
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute_heart_failure
H-1014	-1.2299245595932007	▁a cute _ heart _ ▁failure _ ▁trial s
D-1014	-1.2299245595932007	acute_heart_ failure_ trials
P-1014	-1.9959 -0.0269 -0.2253 -4.6459 -0.2592 -4.8108 -1.2490 -0.0879 -0.0274 -0.0716 -0.1294
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients chronic_kidney_disease ckd
H-898	-0.8492648601531982	▁chronic _ ▁ki dne y _ ▁disease CK D
D-898	-0.8492648601531982	chronic_ kidney_ diseaseCKD
P-898	-1.9462 -0.3998 -0.9965 -0.3164 -0.0839 -0.6664 -2.8230 -1.2859 -0.5911 -0.1367 -0.0958
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral_regurgitation hf symptoms surgery
H-362	-0.4264766275882721	▁mit ral _ re gur gi tation ▁ HF
D-362	-0.4264766275882721	mitral_regurgitation HF
P-362	-2.3630 -0.0675 -0.4139 -0.3653 -0.0347 -0.2605 -0.0853 -0.0815 -0.0119 -0.6679 -0.3397
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease lead hypertension kidney_failure
H-1598	-0.7578655481338501	▁progressive ▁hyper tension ▁ki dne y _ ▁failure
D-1598	-0.7578655481338501	progressive hypertension kidney_ failure
P-1598	-0.3526 -5.4768 -0.0255 -0.2247 -0.0441 -0.0080 -1.1508 -0.0773 -0.0809 -0.1381
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end_stage_heart_failure
H-1669	-1.4658727645874023	▁treatment ▁end ▁stage _ heart _ ▁failure
D-1669	-1.4658727645874023	treatment end stage_heart_ failure
P-1669	-7.4721 -1.4066 -1.0070 -0.2279 -1.0806 -0.4019 -1.4852 -0.0614 -0.0501
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission hospital heart_failure discharge
H-147	-1.1096391677856445	▁hospital ▁heart _ ▁failure ▁dis charge
D-147	-1.1096391677856445	hospital heart_ failure discharge
P-147	-3.4333 -2.1660 -0.2546 -1.7556 -1.0932 -0.0178 -0.0780 -0.0786
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence systolic_hf
H-1798	-0.41878101229667664	▁sy sto lic _ HF
D-1798	-0.41878101229667664	systolic_HF
P-1798	-0.2870 -1.4501 -0.0544 -0.5676 -0.2348 -0.1994 -0.1383
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations hospital longitudinal change
H-143	-0.8468057513237	
D-143	-0.8468057513237	
P-143	-1.6421 -0.0515
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome all-cause_readmissions
H-1580	-0.9713677763938904	▁o UTC _ me as ures ▁read missions
D-1580	-0.9713677763938904	oUTC_measures readmissions
P-1580	-4.0796 -0.0160 -3.2136 -0.0594 -0.3138 -0.6734 -1.3009 -0.0129 -0.0164 -0.0277
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr_variability cardiac_death
H-1589	-0.732891857624054	▁ab normal _ HR _ ▁variabil ity ▁sud den ▁non - sud den ▁cardiac _ ▁death
D-1589	-0.732891857624054	abnormal_HR_ variability sudden non-sudden cardiac_ death
P-1589	-0.4638 -0.0042 -1.0378 -1.4979 -1.8176 -0.0949 -0.0131 -0.6045 -0.0058 -4.2976 -0.0176 -0.0053 -0.0029 -0.7106 -0.4101 -1.9818 -0.0590 -0.1674
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic_blood_pressure
H-1048	-0.742865800857544	▁ toxic ity ▁system ic _ ▁blood ▁pressure
D-1048	-0.742865800857544	toxicity systemic_ blood pressure
P-1048	-0.3518 -0.0584 -0.2941 -0.2593 -0.1694 -0.2903 -3.2546 -2.5992 -0.0634 -0.0881
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication resting_hemodynamics
H-828	-0.4581405818462372	▁medication ▁rest ing _ hem o dynamic s
D-828	-0.4581405818462372	medication resting_hemodynamics
P-828	-1.4498 -1.4335 -0.0534 -0.1047 -1.0799 -0.2205 -0.0013 -0.0999 -0.1000 -0.0384
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician outcomes patients heart_failure
H-1720	-1.3883906602859497	▁Physic ian _ ▁volume
D-1720	-1.3883906602859497	Physician_ volume
P-1720	-0.9318 -0.8214 -1.4549 -0.1762 -4.3907 -0.5554
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation postsystolic_function
H-331	-1.3230619430541992	▁post y sto lic _ function
D-331	-1.3230619430541992	postystolic_function
P-331	-6.0118 -0.6901 -1.5911 -0.3530 -0.9297 -0.7861 -0.1467 -0.0759
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac cardiac_hypertrophy
H-1782	-1.152567744255066	▁Mi ce ▁a ac ▁progressive _ develop ment ▁cardiac _ ▁hyper trop hy
D-1782	-1.152567744255066	Mice aac progressive_development cardiac_ hypertrophy
P-1782	-5.0602 -0.0046 -2.4775 -1.2502 -0.9671 -0.7399 -2.6373 -0.4064 -0.0703 -0.2946 -1.5563 -0.0119 -1.5337 -0.0660 -0.2125
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary_outcome patient post
H-617	-1.4061912298202515	▁patient _ ▁satisfaction ▁sustain ability ▁intervention
D-617	-1.4061912298202515	patient_ satisfaction sustainability intervention
P-617	-2.1827 -1.0068 -1.8342 -2.8436 -0.0041 -0.2821 -3.0063 -0.0898
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic accounting cost
H-1582	-0.8097758889198303	▁economic _ ▁sav ings ▁cost
D-1582	-0.8097758889198303	economic_ savings cost
P-1582	-0.6671 -1.1767 -0.7239 -0.0176 -2.0616 -0.8292 -0.1924
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu mortality
H-582	-0.3989839553833008	▁ ICU _ ▁mortal ity
D-582	-0.3989839553833008	ICU_ mortality
P-582	-0.3014 -0.0158 -1.0105 -0.7761 -0.0067 -0.5953 -0.0871
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses patients disease
H-2020	-0.9161859750747681	▁Nur ses
D-2020	-0.9161859750747681	Nurses
P-2020	-1.4432 -0.0102 -2.1119 -0.0995
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt patients
H-905	-1.1868245601654053	▁c RT ▁di al ysis - dependent
D-905	-1.1868245601654053	cRT dialysis-dependent
P-905	-3.7883 -2.7934 -0.3469 -0.0511 -0.1328 -0.3201 -0.0953 -3.0009 -0.1527
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf patients
H-217	-0.6440262794494629	▁CHF
D-217	-0.6440262794494629	CHF
P-217	-0.3455 -1.5034 -0.0832
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.3126401901245117	
D-163	-1.3126401901245117	
P-163	-2.4884 -0.1368
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-1.047659993171692	▁ HF
D-556	-1.047659993171692	HF
P-556	-3.0676 -0.8842 -0.2071 -0.0318
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia prognostic patients heart_failure
H-529	-0.7354851961135864	▁Hypo album in emia
D-529	-0.7354851961135864	Hypoalbuminemia
P-529	-0.2372 -0.8987 -0.2071 -0.0059 -2.7376 -0.3265
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin_receptor_neprilysin_inhibitor heart_failure
H-1461	-0.45329055190086365	▁ang io ten sin _ ▁receptor ▁nepri ly sin _ ▁inhibi tor ▁heart _ ▁failure
D-1461	-0.45329055190086365	angiotensin_ receptor neprilysin_ inhibitor heart_ failure
P-1461	-0.0629 -1.3319 -0.5558 -0.1786 -1.7657 -0.0111 -0.0251 -0.4092 -0.7777 -0.2602 -0.0319 -0.0321 -0.0441 -0.4204 -1.6895 -0.0486 -0.0614
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded_protein_response cardiac_sodium systolic heart_failure
H-1079	-0.8693304061889648	▁cardiac _ so dium _ ▁current ▁sy sto lic _ heart _ ▁failure
D-1079	-0.8693304061889648	cardiac_sodium_ current systolic_heart_ failure
P-1079	-4.7448 -0.6309 -0.5714 -0.0207 -0.4043 -2.8691 -0.0315 -0.0076 -0.0854 -0.3299 -1.4341 -0.6936 -0.9603 -0.0908 -0.1657
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic_dysfunction patients peripheral_artery_disease
H-1566	-0.41810745000839233	▁dia sto lic _ ▁dys function ▁per i pher al _ ▁arter y ▁disease
D-1566	-0.41810745000839233	diastolic_ dysfunction peripheral_ artery disease
P-1566	-0.0546 -0.4486 -0.4212 -0.5170 -0.9988 -0.0496 -0.0252 -0.1748 -0.0002 -0.0085 -0.4102 -0.6725 -0.1469 -2.6126 -0.0778 -0.0713
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western_blot immunohistochemistry electron_microscopy
H-1252	-0.52630215883255	▁Western ▁blot _ analyse ▁immun oh isto che mist ry ▁electro n _ micro s copy
D-1252	-0.52630215883255	Western blot_analyse immunohistochemistry electron_microscopy
P-1252	-1.5994 -1.3270 -0.8787 -3.1791 -0.0661 -0.0492 -0.5378 -0.3100 -0.2531 -0.2016 -0.0002 -0.0045 -0.2828 -0.1112 -0.4555 -0.0916 -0.0459 -0.0798
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence idiopathic_dilated_cardiomyopathy
H-1741	-0.27755600214004517	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1741	-0.27755600214004517	idiopathic dilated_ cardiomyopathy
P-1741	-0.8448 -0.0126 -0.0509 -0.3812 -0.5130 -0.2221 -0.1097 -0.1135 -0.9769 -0.2287 -0.0376 -0.0757 -0.0415
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic_cardiomyopathy mortality
H-67	-0.46100470423698425	▁i sche mic _ ▁cardio my o pathy ▁male _ ▁sex
D-67	-0.46100470423698425	ischemic_ cardiomyopathy male_ sex
P-67	-0.7553 -0.0001 -0.0579 -0.4307 -0.0912 -0.5724 -0.2591 -0.0385 -0.2821 -0.7672 -0.5570 -2.0029 -0.1787
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient diagnosed hypertensive_lv_dysfunction
H-350	-0.33516886830329895	▁hyper tensi ve _ ▁LV ▁dys function ▁mild ▁MR ▁MS
D-350	-0.33516886830329895	hypertensive_ LV dysfunction mild MR MS
P-350	-0.1272 -0.6688 -0.0462 -0.8523 -0.2755 -1.2021 -0.0212 -0.0603 -0.0880 -0.5567 -0.0212 -0.1025
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf chromatin_hyperacetylation
H-1036	-0.6833317875862122	▁ HF ▁chr omat in _ ▁hyper ace ty lation
D-1036	-0.6833317875862122	HF chromatin_ hyperacetylation
P-1036	-1.4907 -0.0306 -0.7644 -0.0299 -0.8319 -1.0322 -0.6712 -1.3955 -1.7258 -0.0103 -0.1251 -0.0924
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians patients hf
H-1724	-0.8318475484848022	▁physician s ▁ HF
D-1724	-0.8318475484848022	physicians HF
P-1724	-1.8721 -0.4357 -2.4617 -0.0356 -0.1008 -0.0852
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone severe_heart_failure
H-1701	-0.9547601938247681	▁race ▁spi rono lac tone ▁severe _ heart _ ▁failure
D-1701	-0.9547601938247681	race spironolactone severe_heart_ failure
P-1701	-2.3502 -4.5291 -0.0321 -0.2316 -0.0979 -0.7402 -0.7513 -0.3373 -0.9362 -1.0565 -0.1367 -0.2580
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus_rhythm adverse_outcomes
H-1644	-0.9032148718833923	▁sinus _ rhythm ▁AF
D-1644	-0.9032148718833923	sinus_rhythm AF
P-1644	-1.6943 -1.0621 -0.0309 -2.4811 -0.0525 -0.0984
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity_pathway_analysis
H-875	-0.34469109773635864	▁ingen u ity _ path way
D-875	-0.34469109773635864	ingenuity_pathway
P-875	-0.8422 -0.3251 -0.2065 -0.3177 -0.0314 -0.2756 -0.6353 -0.1237
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients heart_failure cardiac_rehabilitation
H-568	-0.9619373083114624	▁heart _ ▁failure ▁cardiac _ rehabilit tion
D-568	-0.9619373083114624	heart_ failure cardiac_rehabilittion
P-568	-3.0020 -0.4389 -2.4542 -0.5898 -0.3408 -0.5637 -1.1441 -0.0630 -0.0611
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis hf etiologies
H-1795	-0.8090053200721741	▁c d ▁ HF ▁et i ologie s
D-1795	-0.8090053200721741	cd HF etiologies
P-1795	-2.4559 -1.6114 -1.2257 -0.0160 -0.9755 -0.4410 -0.9621 -0.2644 -0.0417 -0.0964
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial_infarction
H-1137	-0.6055372953414917	▁My o card ial _ in far ction ▁adult ▁male ▁Wi star ▁rat s
D-1137	-0.6055372953414917	Myocardial_infarction adult male Wistar rats
P-1137	-0.2312 -0.0432 -0.4717 -0.0561 -0.5443 -0.4569 -0.0113 -0.0185 -3.2593 -2.5901 -0.0095 -1.4948 -0.3132 -0.0210 -0.0478 -0.1198
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal diagnostic filling_pressures
H-490	-1.69698965549469	
D-490	-1.69698965549469	
P-490	-3.2087 -0.1853
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia patients heart_disease
H-39	-1.362381935119629	▁an emia
D-39	-1.362381935119629	anemia
P-39	-0.2015 -0.0350 -4.9053 -0.3077
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute_heart_failure
H-468	-0.8726273775100708	▁a cute _ heart _ ▁failure
D-468	-0.8726273775100708	acute_heart_ failure
P-468	-0.6749 -0.0126 -0.1816 -2.6944 -0.4668 -2.1956 -0.5401 -0.2150
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public_reporting patients hospitals
H-1689	-1.0264737606048584	▁report ing
D-1689	-1.0264737606048584	reporting
P-1689	-0.4283 -0.1211 -3.4383 -0.1183
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth longitudinal medicare
H-1617	-0.547354519367218	▁care _ management ▁tele health ▁medica re
D-1617	-0.547354519367218	care_management telehealth medicare
P-1617	-1.9133 -1.5946 -0.0569 -0.0561 -0.1980 -0.0254 -0.0130 -1.0061 -0.0629
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative operative outcomes
H-299	-0.2662382423877716	▁pre operativ e _ ▁demo graphic s ▁operativ e ▁outcome s ▁survival
D-299	-0.2662382423877716	preoperative_ demographics operative outcomes survival
P-299	-0.3652 -0.0019 -0.0865 -0.5438 -0.7231 -0.0218 -0.0431 -0.0354 -0.0264 -1.3911 -0.0486 -0.3772 -0.0158 -0.0475
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad_ai
H-543	-1.0348124504089355	▁post - L VAD _ AI
D-543	-1.0348124504089355	post-LVAD_AI
P-543	-3.6094 -0.0328 -1.9253 -0.0953 -1.4833 -0.8783 -0.0983 -0.1558
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort_study
H-1829	-1.4241752624511719	
D-1829	-1.4241752624511719	
P-1829	-2.7449 -0.1034
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control outcomes
H-1232	-0.7859198451042175	▁ Rhythm - ▁rate - control
D-1232	-0.7859198451042175	Rhythm- rate-control
P-1232	-0.9622 -0.0477 -0.1415 -1.1195 -0.0855 -0.0041 -3.4229 -0.5039
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.8200145363807678	▁re hospital ization
D-1711	-0.8200145363807678	rehospitalization
P-1711	-3.5565 -0.0671 -0.2886 -0.0923 -0.0957
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins tac
H-872	-1.0855579376220703	▁protein s ▁ TAC
D-872	-1.0855579376220703	proteins TAC
P-872	-4.1644 -0.1531 -0.4261 -0.0219 -1.5416 -0.2062
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery mva
H-361	-0.9608457088470459	▁MS
D-361	-0.9608457088470459	MS
P-361	-1.1015 -1.6924 -0.0887
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-1.0234594345092773	
D-1769	-1.0234594345092773	
P-1769	-2.0158 -0.0312
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.6244533061981201	▁Mediterrane an ▁DAS h _ die t _ ▁score s ▁food - fre que ncy
D-688	-0.6244533061981201	Mediterranean DASh_diet_ scores food-frequency
P-688	-0.9180 -0.0050 -0.2107 -0.9276 -0.7852 -2.9131 -0.7654 -0.9516 -1.1074 -0.0835 -0.1468 -0.0622 -0.0011 -0.5791 -0.0569 -0.9951 -0.1069
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise exercise
H-1931	-1.384967565536499	▁social _ support ▁exercise
D-1931	-1.384967565536499	social_support exercise
P-1931	-0.4028 -1.2353 -1.0592 -4.2969 -1.1939 -0.1217
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients diabetes eo-cfus functional_capacity
H-132	-0.672552764415741	▁diabetes ▁ EO - C FU s
D-132	-0.672552764415741	diabetes EO-CFUs
P-132	-0.2718 -2.7942 -0.0115 -0.0710 -1.1060 -0.1004 -0.7052 -0.7687 -0.2241
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk_stratification death all-cause_hospitalization heart_failure clinic outpatients
H-377	-1.333434820175171	▁risk _ strate gy ▁hospital ization ▁heart ▁failure _ ▁clinic ▁out patient s
D-377	-1.333434820175171	risk_strategy hospitalization heart failure_ clinic outpatients
P-377	-1.0422 -2.5712 -2.9059 -1.3367 -5.0599 -0.2358 -0.1503 -4.6380 -0.5503 -0.8720 -0.3704 -0.0024 -0.0263 -0.0742 -0.1661
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization_therapy heart_failure narrow_qrs_complex
H-844	-0.6932944059371948	▁Card iac - re syn chron ization _ therapy ▁heart _ ▁failure
D-844	-0.6932944059371948	Cardiac-resynchronization_therapy heart_ failure
P-844	-0.8983 -1.9714 -0.5834 -0.0450 -0.0451 -0.0012 -0.3513 -1.1131 -0.4854 -0.2920 -0.4231 -2.7290 -0.6678 -0.1000
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home hospital readmission congestive_heart_failure
H-1573	-0.6315760016441345	▁hospital ▁read mission _ re duction _ program ▁con ges tive _ heart _ ▁failure
D-1573	-0.6315760016441345	hospital readmission_reduction_program congestive_heart_ failure
P-1573	-0.1941 -2.9915 -0.1417 -0.2698 -0.7607 -0.0005 -0.8306 -0.9128 -0.0238 -0.0807 -0.2779 -0.1742 -1.0865 -0.6835 -1.9953 -0.1241 -0.1892
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute_walk_distance peak_vo2 baseline
H-1636	-0.9649632573127747	▁Black s ▁lower ▁pe ak ▁VO 2 ▁base line
D-1636	-0.9649632573127747	Blacks lower peak VO2 baseline
P-1636	-1.7975 -0.3603 -4.1722 -0.7485 -0.0564 -2.8455 -0.1268 -0.0365 -0.0025 -0.0750 -0.3934
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate_models odds_ratios accounting hospital
H-191	-0.7801552414894104	▁odds _ rati os ▁hospital ▁cluster ing
D-191	-0.7801552414894104	odds_ratios hospital clustering
P-191	-3.2311 -0.8629 -0.2441 -1.0870 -0.1256 -1.0474 -0.2186 -0.0666 -0.1382
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref hfpef patients regression_line
H-497	-0.6654080748558044	▁H Fr EF ▁ HF p EF
D-497	-0.6654080748558044	HFrEF HFpEF
P-497	-2.1137 -0.1707 -0.4322 -0.0920 -0.0088 -0.0830 -0.4544 -2.2071 -0.4269
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl hno acute heart_failure
H-412	-0.9551966190338135	▁ni tro x yl ▁a cute _ of _ heart _ ▁failure
D-412	-0.9551966190338135	nitroxyl acute_of_heart_ failure
P-412	-1.0733 -0.0480 -0.2591 -0.3649 -3.3678 -0.1142 -0.4330 -4.1669 -0.0821 -0.4219 -0.4839 -2.3010 -0.1056 -0.1510
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician death readmission discharge patients heart_failure
H-1412	-1.0277127027511597	▁physician _ ▁continu ity ▁urgent _ ▁read mission ▁dis charge ▁patients ▁heart _ ▁failure
D-1412	-1.0277127027511597	physician_ continuity urgent_ readmission discharge patients heart_ failure
P-1412	-0.5445 -2.1003 -0.3944 -0.0006 -5.6286 -0.1117 -1.2322 -0.0127 -1.2398 -0.0153 -1.8181 -0.3606 -0.5226 -2.1170 -0.1541 -0.1908
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart_block pulmonary_artery bivp
H-322	-0.6771313548088074	▁Heart _ ▁block ▁pulmonar y _ ▁arter y _ ▁snar ed ▁bi VP
D-322	-0.6771313548088074	Heart_ block pulmonary_ artery_ snared biVP
P-322	-2.0047 -1.8187 -0.8283 -0.0078 -0.0225 -0.8142 -0.2684 -0.4376 -2.2804 -0.5673 -0.0195 -0.8821 -0.0030 -0.0701 -0.1323
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance attrition
H-1319	-0.3377068042755127	▁recruit ment ▁intervention ▁compliance ▁att ri tion
D-1319	-0.3377068042755127	recruitment intervention compliance attrition
P-1319	-1.5320 -0.0363 -0.4881 -0.5235 -0.1161 -0.0229 -0.2101 -0.0804 -0.0299
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin inflammation metabolism heart_disease
H-940	-0.6758922338485718	▁resist in ▁ inflammation ▁metabolism ▁heart _ مرض
D-940	-0.6758922338485718	resistin inflammation metabolism heart_مرض
P-940	-0.0355 -0.1709 -1.1064 -0.0046 -1.0439 -1.0770 -1.0215 -1.9860 -0.1262 -0.1870
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up cardiovascular_events deaths
H-974	-0.7114447355270386	▁cardiovascular _ event s
D-974	-0.7114447355270386	cardiovascular_events
P-974	-1.3407 -0.6318 -1.5847 -0.1539 -0.5160 -0.0416
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change lvet admission follow-up outcome
H-588	-0.3959595263004303	▁L VET ▁ad mission ▁follow - up ▁measure ment ▁outcome
D-588	-0.3959595263004303	LVET admission follow-up measurement outcome
P-588	-3.1170 -0.0163 -0.1316 -0.0175 -0.0180 -0.0302 -0.0114 -1.0166 -0.0376 -0.1016 -0.0422 -0.2115
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray genes heart_failure
H-1605	-1.2601314783096313	▁Bio informati c ▁micro arra y _ data
D-1605	-1.2601314783096313	Bioinformatic microarray_data
P-1605	-1.1212 -0.6417 -0.5244 -3.8223 -0.1275 -0.0200 -1.7860 -0.8285 -3.5181 -0.2118
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad systolic_hf prognostic
H-1183	-0.7841720581054688	▁CAD ▁sy sto lic _ HF
D-1183	-0.7841720581054688	CAD systolic_HF
P-1183	-2.7078 -0.6813 -0.7187 -0.0763 -0.4772 -0.0586 -1.4348 -0.1187
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic outcomes hf
H-1202	-0.5881997346878052	▁di ure tic _ ▁use ▁ HF
D-1202	-0.5881997346878052	diuretic_ use HF
P-1202	-0.7413 -0.3160 -0.4032 -1.2904 -1.2115 -1.1895 -0.0081 -0.0580 -0.0759
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical patients functional_ms
H-373	-1.3260252475738525	
D-373	-1.3260252475738525	
P-373	-2.5841 -0.0680
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients patients echocardiographic
H-813	-1.1398533582687378	▁af ▁patients ▁e cho car dio graphic _ ▁examina tion
D-813	-1.1398533582687378	af patients echocardiographic_ examination
P-813	-2.2163 -4.3340 -0.1157 -0.0476 -0.9263 -2.4760 -1.8593 -1.4592 -0.1254 -0.0370 -0.0486 -0.0328
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life patients
H-161	-1.1734250783920288	
D-161	-1.1734250783920288	
P-161	-2.1802 -0.1666
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital heart lesions
H-985	-0.635668158531189	▁con geni tal _ heart _ Les ions
D-985	-0.635668158531189	congenital_heart_Lesions
P-985	-0.3657 -0.0051 -0.0755 -0.1762 -2.6778 -0.2242 -2.3277 -0.3533 -0.0788 -0.0724
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf pb
H-1349	-0.8457297682762146	▁PV F ▁ PB
D-1349	-0.8457297682762146	PVF PB
P-1349	-0.1471 -0.9424 -1.0525 -0.0637 -2.6700 -0.1987
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 therapy
H-401	-0.9252583980560303	▁s ST 2 _ ▁concentration s ▁BB _ therapy
D-401	-0.9252583980560303	sST2_ concentrations BB_therapy
P-401	-0.0351 -3.8596 -0.0822 -3.0101 -0.2471 -0.1814 -1.2357 -1.2213 -0.1414 -0.0568 -0.1073
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac_function catheter
H-1143	-0.710547924041748	▁Card iac ▁pressure - volu me _ ▁conduct ance _ ▁cat heter _ system
D-1143	-0.710547924041748	Cardiac pressure-volume_ conductance_ catheter_system
P-1143	-0.6314 -0.8574 -1.2865 -0.1390 -0.1012 -0.0439 -0.8420 -1.5970 -0.0283 -0.6331 -2.8445 -0.0036 -2.1398 -0.0469 -0.1187 -0.0553
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf surgical
H-353	-0.8392925262451172	▁MS
D-353	-0.8392925262451172	MS
P-353	-0.9751 -1.3822 -0.1606
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.18313197791576385	▁beta - block ers ▁ad her ence
D-865	-0.18313197791576385	beta-blockers adherence
P-865	-0.6757 -0.0516 -0.1448 -0.0403 -0.0404 -0.3652 -0.0074 -0.1774 -0.1454
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end_point neurological cardiovascular_events
H-1872	-1.1781599521636963	▁safety _ ▁end _ point ▁procedure ▁advers e ▁neurologi cal ▁cardiovascular ▁events
D-1872	-1.1781599521636963	safety_ end_point procedure adverse neurological cardiovascular events
P-1872	-0.7712 -1.3390 -1.6533 -1.7202 -0.5443 -3.9297 -2.0784 -0.0248 -0.2232 -0.0888 -1.4874 -2.4573 -0.0776 -0.0991
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade holosystolic_murmur third_heart_sound apex
H-342	-0.5343176126480103	▁holo sy sto lic _ ▁mur mur ▁third ▁heart _ sound
D-342	-0.5343176126480103	holosystolic_ murmur third heart_sound
P-342	-0.0277 -0.5796 -1.2003 -0.1992 -0.3944 -0.6011 -0.0067 -0.5271 -1.9220 -0.6719 -0.3333 -0.3932 -0.0897
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart_transplantation left_ventricular_assist_device
H-306	-0.9833943843841553	▁heart _ ▁transplant ation ▁left ▁vent ri cular _ assist ance
D-306	-0.9833943843841553	heart_ transplantation left ventricular_assistance
P-306	-1.5105 -1.1199 -0.7718 -0.0585 -0.1109 -3.8985 -0.7500 -0.2481 -0.1744 -0.0223 -2.2594 -1.7822 -0.0776
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right_ventricular_function prognosis heart_failure
H-1157	-0.9710635542869568	▁right ▁vent ri cular _ function ▁body _ ▁composition
D-1157	-0.9710635542869568	right ventricular_function body_ composition
P-1157	-0.3882 -3.2582 -0.5499 -0.0910 -0.8586 -0.8060 -0.1961 -0.9342 -0.4508 -2.9350 -0.2137
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling hf haemodynamic neuronal_stressors
H-1039	-0.34759780764579773	▁ha emo dynamic ▁neuron al ▁stress ors
D-1039	-0.34759780764579773	haemodynamic neuronal stressors
P-1039	-0.4699 -1.4969 -0.0122 -0.1559 -0.0054 -0.7696 -0.0166 -0.0660 -0.1358
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical atherosclerosis linear_models
H-1557	-0.6755235195159912	▁sub clin ical _ at hero sc ler osis ▁general _ model s
D-1557	-0.6755235195159912	subclinical_atherosclerosis general_models
P-1557	-1.4039 -0.0255 -0.0084 -0.1908 -0.1395 -1.2953 -1.4032 -2.5800 -0.2365 -0.0060 -0.4574 -1.1476 -1.0611 -0.0716 -0.1062
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise_intolerance chronic_heart_failure prognosis
H-1273	-0.7389457821846008	▁exercise _ in tolerance ▁chronic _ heart _ ▁failure
D-1273	-0.7389457821846008	exercise_intolerance chronic_heart_ failure
P-1273	-0.6569 -0.6453 -0.3815 -0.0021 -0.4182 -0.1290 -1.2643 -0.5190 -2.3496 -1.6237 -0.1388
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative hypoalbuminemia prognosis lvad surgery
H-538	-0.4976961612701416	▁pre operativ e ▁hypo album in emia ▁l VAD
D-538	-0.4976961612701416	preoperative hypoalbuminemia lVAD
P-538	-0.0082 -0.0046 -0.0884 -0.8162 -0.9096 -0.0842 -0.0363 -2.1927 -0.0678 -1.1271 -0.1395
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary_disease leading heart_failure
H-981	-0.6449076533317566	▁corona ry _ ▁заболевания ▁heart _ ▁failure
D-981	-0.6449076533317566	coronary_ заболевания heart_ failure
P-981	-0.0667 -0.1460 -0.3568 -2.7530 -1.4617 -0.1155 -0.7710 -0.0607 -0.0729
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical connected elevated resistin heart_failure
H-929	-0.8668114542961121	▁clinic al _ studie s ▁eleva ted _ ▁resist in _ ▁levels ▁sever ity ▁heart _ ▁failure
D-929	-0.8668114542961121	clinical_studies elevated_ resistin_ levels severity heart_ failure
P-929	-3.1180 -0.1904 -1.6520 -2.6606 -0.1187 -0.9017 -0.0303 -1.2266 -0.1563 -0.3614 -1.4690 -0.3585 -0.4722 -0.0095 -1.1731 -0.3558 -2.0893 -0.0431 -0.0828
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit_index biological_phenotype mortality
H-1012	-0.2577371597290039	▁deficit _ index ▁bi ological _ ▁ph eno type ▁mortal ity
D-1012	-0.2577371597290039	deficit_index biological_ phenotype mortality
P-1012	-0.3277 -0.6386 -0.2160 -0.0388 -0.0682 -0.1498 -0.7881 -0.0233 -0.0052 -0.8754 -0.0094 -0.0503 -0.1598
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial_fibrillation patients heart_failure
H-1231	-0.46522772312164307	▁at rial _ fi bril lation _ AF ▁heart _ ▁failure
D-1231	-0.46522772312164307	atrial_fibrillation_AF heart_ failure
P-1231	-1.4558 -0.0199 -0.2712 -0.5372 -0.0264 -0.0030 -1.2454 -0.1476 -0.8375 -0.4947 -0.9225 -0.0512 -0.0355
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia right_ventricle heart_failure
H-1457	-0.8137664198875427	▁cache xia ▁right _ ▁vent ric le ▁heart _ ▁failure
D-1457	-0.8137664198875427	cachexia right_ ventricle heart_ failure
P-1457	-1.6831 -0.1946 -2.5233 -0.6048 -0.3493 -0.7980 -0.1486 -0.1189 -0.2819 -0.6517 -2.0918 -0.3192
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling_pathways cardiac_remodelling
H-992	-0.21111200749874115	▁signal ling _ path ways ▁mal adapt ive ▁cardiac _ ▁remodel ling
D-992	-0.21111200749874115	signalling_pathways maladaptive cardiac_ remodelling
P-992	-0.1087 -0.1942 -0.4976 -0.0919 -0.0356 -0.3569 -0.0178 -0.0011 -0.9691 -0.1983 -0.3418 -0.0177 -0.0598 -0.0651
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ecgs electrocardiographers
H-884	-0.5819382071495056	▁base line ▁electro car dio graph ers
D-884	-0.5819382071495056	baseline electrocardiographers
P-884	-0.0038 -0.0046 -1.4235 -0.3599 -1.8557 -1.4091 -0.0601 -0.0788 -0.0420
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd vvd free_wall_rs
H-328	-0.8592609763145447	▁AV d ▁VVD ▁free _ wall _ RS
D-328	-0.8592609763145447	AVd VVD free_wall_RS
P-328	-0.3673 -1.0082 -3.5673 -0.3389 -0.4460 -0.2459 -1.3905 -1.1017 -0.0528 -0.0740
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart_rate
H-1446	-1.413340449333191	▁heart _ rati o
D-1446	-1.413340449333191	heart_ratio
P-1446	-4.5326 -1.4418 -1.0789 -0.4735 -0.8566 -0.0966
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence esrd outpatients hf
H-388	-0.33884063363075256	▁incide nce ▁ES RD ▁out patient s ▁ HF
D-388	-0.33884063363075256	incidence ESRD outpatients HF
P-388	-0.0838 -0.7952 -0.9421 -0.2504 -0.1889 -0.0048 -0.0148 -1.1750 -0.0004 -0.0834 -0.1886
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left_bundle_branch_block
H-1153	-0.4698098599910736	▁bran ch _ ▁block ▁electric al _ activa tion _ se que nce
D-1153	-0.4698098599910736	branch_ block electrical_activation_sequence
P-1153	-1.5626 -0.0094 -0.2842 -1.2929 -0.2074 -0.0064 -0.1542 -0.7068 -0.0512 -0.6269 -0.2287 -0.2309 -1.4020 -0.2216 -0.0620
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4_inhibitors drugs
H-1834	-0.6236869096755981	▁h HF ▁d PP -4 ▁inhibi tors
D-1834	-0.6236869096755981	hHF dPP-4 inhibitors
P-1834	-0.1649 -0.6151 -0.9070 -0.9463 -0.4205 -0.2497 -0.0141 -2.1663 -0.1295
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct heart_failure therapy patients
H-718	-1.112074851989746	▁EC CT ▁advanced _ heart _ ▁failure _ therapy
D-718	-1.112074851989746	ECCT advanced_heart_ failure_therapy
P-718	-1.3840 -0.8174 -0.4800 -0.2692 -1.9206 -0.2431 -5.7958 -0.5202 -0.3084 -0.4192 -0.0749
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death stroke hospitalisation heart_failure
H-815	-0.480886310338974	▁CV ▁death ▁non - fa tal _ ▁stroke ▁hospital isation ▁heart _ ▁failure
D-815	-0.480886310338974	CV death non-fatal_ stroke hospitalisation heart_ failure
P-815	-0.2592 -3.1981 -0.8097 -0.0298 -0.0036 -0.0091 -0.1471 -1.0117 -0.3503 -0.0052 -0.1897 -0.4546 -0.5450 -0.0575 -0.1427
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise training endothelial_function
H-248	-0.4559946358203888	▁exercise _ training ▁en dot heli al _ function
D-248	-0.4559946358203888	exercise_training endothelial_function
P-248	-0.7162 -1.1501 -0.6523 -0.8173 -0.3748 -0.0110 -0.0019 -0.5956 -0.5281 -0.0551 -0.1134
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients heart_transplant ecct
H-714	-1.151155948638916	▁heart _ ▁transplant ▁EC CT
D-714	-1.151155948638916	heart_ transplant ECCT
P-714	-4.9864 -1.0314 -0.5065 -1.3149 -0.0551 -0.0520 -0.1118
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ffm stable
H-20	-1.264543056488037	▁f f f f f f _ of _ the ory ▁body _ weight ▁CC
D-20	-1.264543056488037	ffffff_of_theory body_weight CC
P-20	-1.1443 -1.2244 -0.8582 -0.8961 -1.3840 -1.9417 -2.6942 -4.0871 -0.1516 -3.1237 -0.5922 -1.1024 -1.9331 -0.0290 -0.2537 -0.0275 -0.0540
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications dialysis patients
H-908	-0.5280196070671082	▁per i pro ced ural ▁di al ysis
D-908	-0.5280196070671082	periprocedural dialysis
P-908	-0.3306 -0.8103 -0.0132 -0.0068 -0.0035 -2.2078 -0.1626 -0.6688 -0.9849 -0.0917
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical hfpef
H-943	-0.43374037742614746	▁precipit ating _ factor ▁clinic al _ ▁deteriora tion ▁H FP EF
D-943	-0.43374037742614746	precipitating_factor clinical_ deterioration HFPEF
P-943	-3.0645 -0.0488 -0.1907 -0.0235 -0.6755 -0.0230 -0.2531 -0.7453 -0.1020 -0.7147 -0.0309 -0.0999 -0.0378 -0.0626
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart_failure nurse
H-84	-1.2451726198196411	▁multi hospital _ ▁study ▁heart ▁failure _ ▁guidelines ▁nurse ▁leaders
D-84	-1.2451726198196411	multihospital_ study heart failure_ guidelines nurse leaders
P-84	-2.8447 -0.0128 -2.6331 -0.1420 -1.4474 -4.0751 -1.1528 -0.7149 -0.1185 -1.5401 -0.0469 -0.2136
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota hf
H-1003	-0.6887568235397339	▁South e a stern ▁Minnesota ▁ HF
D-1003	-0.6887568235397339	Southeastern Minnesota HF
P-1003	-2.7797 -0.1959 -0.0336 -0.0077 -1.6371 -1.0541 -0.0368 -0.2400 -0.2139
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac_cachexia
H-9	-0.5729811191558838	▁Card iac _ ▁cache xia ▁body
D-9	-0.5729811191558838	Cardiac_ cachexia body
P-9	-0.8572 -0.0327 -0.2948 -0.3009 -0.1272 -2.0696 -0.8532 -0.0483
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty hf
H-632	-0.3960488736629486	▁Fra il ty ▁risk _ of _ HF
D-632	-0.3960488736629486	Frailty risk_of_HF
P-632	-0.9525 -0.2105 -0.1412 -0.1391 -1.4525 -0.1439 -0.4926 -0.0303 -0.3196 -0.0782
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome hdl
H-254	-0.5459463000297546	▁prote ome ▁HD L _ parti cles ▁shot gun ▁ LC - MS
D-254	-0.5459463000297546	proteome HDL_particles shotgun LC-MS
P-254	-1.4540 -0.3719 -1.9887 -1.3017 -0.6972 -0.4308 -0.0107 -0.1242 -0.0476 -1.1449 -0.0090 -0.0351 -0.0106 -0.3562 -0.2064
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes hospitalization
H-566	-0.9335131049156189	▁Fa tal ▁non fa tal _ ▁outcome s
D-566	-0.9335131049156189	Fatal nonfatal_ outcomes
P-566	-1.7578 -0.0169 -2.4875 -0.0264 -0.0864 -1.9105 -0.5484 -0.0289 -2.2437 -0.2287
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative clinical mortality
H-532	-0.5301689505577087	▁pre operativ e _ ▁clinic al _ ▁character istic s ▁laborator y _ ▁variable ▁mortal ity
D-532	-0.5301689505577087	preoperative_ clinical_ characteristics laboratory_ variable mortality
P-532	-0.3873 -0.0006 -0.2758 -0.8146 -1.0340 -0.0460 -0.3032 -4.2631 -0.5004 -0.0165 -0.0311 -0.0191 -0.2592 -0.3231 -1.1180 -0.0193 -0.0374 -0.0944
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas cardiac pathogenesis
H-1484	-0.9131188988685608	▁cardiac _ path ogen es
D-1484	-0.9131188988685608	cardiac_pathogenes
P-1484	-3.5639 -0.3177 -0.0243 -0.7255 -0.2966 -1.4194 -0.0443
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis mortality patients
H-61	-1.098046898841858	▁mortal ity ▁i CD - HF
D-61	-1.098046898841858	mortality iCD-HF
P-61	-5.0784 -0.0625 -1.1640 -0.1344 -0.0564 -0.0101 -1.9206 -0.3580
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients extubated blood transfusion
H-777	-0.5502039790153503	▁ex tuba ted ▁blood ▁loss ▁trans fusion
D-777	-0.5502039790153503	extubated blood loss transfusion
P-777	-0.8603 -0.0052 -0.1194 -0.6383 -1.6049 -0.0386 -0.0441 -1.4434 -0.1977
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions septal surgical
H-984	-0.5400181412696838	▁sept al ▁defect s ▁sur g ical
D-984	-0.5400181412696838	septal defects surgical
P-984	-0.4857 -0.0339 -3.2119 -0.0219 -0.1397 -0.0597 -0.0367 -0.7781 -0.0925
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients discharge follow-up medication
H-730	-0.2891470491886139	▁dis charge ▁follow - up ▁medication
D-730	-0.2891470491886139	discharge follow-up medication
P-730	-0.5170 -0.1722 -0.5614 -0.0399 -0.0145 -0.5627 -0.3970 -0.0485
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart_failure readmission outcome
H-1030	-0.846986711025238	▁heart _ ▁failure _ care
D-1030	-0.846986711025238	heart_ failure_care
P-1030	-0.4157 -0.4550 -2.4306 -0.2485 -0.2477 -1.9834 -0.1479
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain_proteins
H-1042	-1.3724710941314697	▁bro modo main ▁protein s
D-1042	-1.3724710941314697	bromodomain proteins
P-1042	-6.9070 -0.3165 -0.0673 -2.1720 -0.0322 -0.0368 -0.0756
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient mortality therapeutic
H-1667	-1.441823959350586	▁mortal ity _ rate
D-1667	-1.441823959350586	mortality_rate
P-1667	-4.1135 -0.0108 -2.2808 -0.9768 -1.1832 -0.0859
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt dt implantation
H-315	-0.6704758405685425	▁b TT ▁ DT
D-315	-0.6704758405685425	bTT DT
P-315	-0.9854 -1.0389 -0.3548 -0.0196 -1.5567 -0.0674
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse_event hypotension
H-1970	-0.9394775629043579	▁hypo tension
D-1970	-0.9394775629043579	hypotension
P-1970	-3.0176 -0.1839 -0.4639 -0.0925
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.4427127540111542	▁ pharma ce ut ically
D-948	-0.4427127540111542	pharmaceutically
P-948	-0.3975 -0.0437 -0.0700 -0.4878 -0.1937 -1.8083 -0.0981
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up hf
H-288	-1.3079012632369995	
D-288	-1.3079012632369995	
P-288	-2.5750 -0.0408
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers hf
H-1475	-0.24538764357566833	▁bio mark ers ▁ HF
D-1475	-0.24538764357566833	biomarkers HF
P-1475	-0.3541 -0.0117 -0.0270 -1.0533 -0.0213 -0.1546 -0.0957
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak_vo2
H-1498	-0.4493590295314789	▁Peak _ vo 2
D-1498	-0.4493590295314789	Peak_vo2
P-1498	-0.0739 -0.3634 -0.1825 -0.1595 -1.6917 -0.2253
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 patients plasma
H-699	-0.7629945874214172	▁ST 2 ▁ evalua ble ▁plasma
D-699	-0.7629945874214172	ST2 evaluable plasma
P-699	-1.3484 -0.0914 -1.9764 -0.1031 -0.0486 -1.2902 -1.1417 -0.1041
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients condition economic
H-1575	-1.2873749732971191	
D-1575	-1.2873749732971191	
P-1575	-2.4351 -0.1397
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals outcome
H-1690	-1.4965604543685913	▁quality _ me chan ism
D-1690	-1.4965604543685913	quality_mechanism
P-1690	-1.8497 -2.3367 -1.0117 -2.3378 -0.1791 -2.6487 -0.1123
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf patients
H-671	-0.6358169913291931	▁tras tuz um ab - related _ ▁CHF
D-671	-0.6358169913291931	trastuzumab-related_ CHF
P-671	-1.3119 -0.0590 -0.5949 -0.4475 -0.5125 -0.9378 -1.0500 -0.7127 -0.4627 -0.2693
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients transplants
H-2000	-0.7003186345100403	▁patients ▁transplant s
D-2000	-0.7003186345100403	patients transplants
P-2000	-1.9661 -1.0135 -0.0995 -0.3907 -0.0318
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy engage exercise
H-1903	-0.9924030900001526	▁aero bic _ ▁exercise
D-1903	-0.9924030900001526	aerobic_ exercise
P-1903	-2.1064 -0.4183 -1.6342 -1.5226 -0.1240 -0.1490
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.712375283241272	▁rank ed ▁hospital s
D-1694	-0.712375283241272	ranked hospitals
P-1694	-1.5541 -0.0486 -1.0715 -0.1044 -1.4278 -0.0679
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.0249302387237549	
D-1955	-1.0249302387237549	
P-1955	-2.0064 -0.0434
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-1.5247197151184082	
D-1	-1.5247197151184082	
P-1	-2.9834 -0.0661
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality hf hospital admissions transplant ventricular_assist_device
H-125	-0.45101240277290344	▁ HF ▁hospital ▁ad missions ▁transplant ▁vent ri cular _ assist ▁device
D-125	-0.45101240277290344	HF hospital admissions transplant ventricular_assist device
P-125	-2.0021 -0.0835 -1.1435 -0.1567 -0.0121 -0.2881 -0.2671 -0.3677 -0.0970 -0.1558 -0.0093 -1.5048 -0.0913 -0.1351
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary_artery_disease cad systolic_heart_failure hf
H-1182	-0.7203949689865112	▁Corona ry _ ▁arter y _ ▁disease _ CAD ▁sy sto lic _ heart _ ▁failure HF
D-1182	-0.7203949689865112	Coronary_ artery_ disease_CAD systolic_heart_ failureHF
P-1182	-0.2926 -0.0954 -0.4997 -0.7203 -0.0175 -0.3261 -4.1556 -3.2573 -0.0619 -0.2513 -0.0101 -0.1482 -0.0597 -0.3953 -0.2058 -1.5184 -1.4621 -0.1466 -0.0636
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart_failure patients rheumatoid_arthritis tnf_antagonist
H-600	-0.6585612297058105	▁Heart _ ▁failure ▁rhe um ato id _ ar thri tis ▁T NF _ ▁anta gon ist
D-600	-0.6585612297058105	Heart_ failure rheumatoid_arthritis TNF_ antagonist
P-600	-0.2087 -1.2031 -2.1339 -2.4063 -0.0128 -1.0975 -2.0490 -0.0811 -0.3091 -0.3535 -0.2278 -0.6271 -0.0026 -0.8848 -0.1966 -0.1135 -0.1378 -0.3288 -0.1389
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal_artery_stenosis ras peripheral_arterial_disease
H-1593	-0.4671911299228668	▁Ren al _ ▁arter y _ ▁sten osis ▁ RAS ▁per i pher al _ ▁arterial _ مرض
D-1593	-0.4671911299228668	Renal_ artery_ stenosis RAS peripheral_ arterial_مرض
P-1593	-0.0828 -0.0029 -0.5229 -1.4604 -0.0507 -0.2122 -0.5524 -0.0145 -2.3204 -0.0026 -0.0593 -0.1028 -0.0006 -0.0047 -0.0848 -0.9828 -0.4095 -2.0805 -0.1892 -0.2077
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon_matched-pairs_signed-rank_tests
H-923	-0.3616381585597992	▁Wil co xon ▁signed - rank _ test ▁pre - post _ ▁comparison s
D-923	-0.3616381585597992	Wilcoxon signed-rank_test pre-post_ comparisons
P-923	-0.3131 -0.0009 -0.4443 -0.8462 -0.0312 -0.0064 -0.6870 -0.5146 -0.8480 -0.0105 -0.0270 -0.8624 -0.8562 -0.1436 -0.0702 -0.1244
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left_ventricular_assist_device right_ventricular_support
H-293	-0.5537527203559875	▁left ▁vent ri cular _ assist ▁device ▁right ▁vent ri cular _ support
D-293	-0.5537527203559875	left ventricular_assist device right ventricular_support
P-293	-2.0949 -0.4045 -0.0674 -0.0448 -0.3761 -0.0096 -2.0126 -0.1277 -1.8624 -0.0755 -0.0137 -0.6135 -0.4865 -0.0606 -0.0567
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis atherosclerosis cardiovascular_events rotterdam_study
H-1554	-0.5116045475006104	▁p sori asis ▁at hero sc ler osis ▁incident _ ▁cardiovascular _ ▁events ▁Rotterdam
D-1554	-0.5116045475006104	psoriasis atherosclerosis incident_ cardiovascular_ events Rotterdam
P-1554	-2.1715 -0.2387 -0.1503 -0.3792 -0.0987 -0.3288 -1.2835 -0.0232 -0.0536 -0.2162 -1.3544 -0.3946 -0.6948 -0.1258 -0.6183 -0.0543
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.9115878939628601	
D-1713	-0.9115878939628601	
P-1713	-1.7894 -0.0338
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-1.0102816820144653	▁data
D-154	-1.0102816820144653	data
P-154	-1.2581 -1.7271 -0.0457
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone primary_composite_endpoint
H-1227	-0.2718311846256256	▁e pler en one ▁primary ▁com posit e _ ▁end point
D-1227	-0.2718311846256256	eplerenone primary composite_ endpoint
P-1227	-0.7856 -0.0002 -0.2918 -0.0407 -0.2270 -0.5414 -0.0019 -0.0129 -0.5946 -0.5097 -0.1102 -0.3273 -0.0906
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic_heart_transplantation oht end-stage_heart_failure
H-1280	-0.3123380243778229	▁Ort ho topic _ heart _ ▁transplant ation ▁o HT ▁end - s tage _ heart _ ▁failure
D-1280	-0.3123380243778229	Orthotopic_heart_ transplantation oHT end-stage_heart_ failure
P-1280	-0.1137 -0.0261 -0.2030 -0.1610 -0.8504 -0.4227 -0.4791 -0.0566 -0.0722 -0.3729 -0.6308 -0.0322 -0.0467 -0.0011 -0.2644 -0.4230 -0.3377 -1.6289 -0.0581 -0.0663
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right_atrial_myxoma pulmonary_embolism right_heart_failure
H-592	-0.5077320337295532	▁right _ at rial _ my xo ma ▁pulmonar y _ ▁e mbol ism ▁right _ heart _ ▁failure
D-592	-0.5077320337295532	right_atrial_myxoma pulmonary_ embolism right_heart_ failure
P-592	-0.8928 -1.0797 -0.4128 -0.0102 -0.3329 -2.0608 -0.1236 -0.3990 -0.0009 -0.0053 -0.8295 -0.6539 -0.0002 -0.0103 -0.0041 -0.2198 -0.7878 -0.4681 -2.2502 -0.0698 -0.0507
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral_renal_denervation autonomic_balance chronic_heart_failure
H-1369	-0.681998610496521	▁Uni lateral ▁renal _ ▁den er va tion ▁autonomi c _ ▁balance ▁ conscious ▁rabbi ts ▁chronic _ heart _ ▁failure
D-1369	-0.681998610496521	Unilateral renal_ denervation autonomic_ balance conscious rabbits chronic_heart_ failure
P-1369	-1.1485 -0.0007 -1.2786 -0.2761 -0.5738 -0.7080 -1.6513 -0.0249 -0.0463 -0.2696 -0.9210 -0.1372 -0.5898 -0.0245 -0.1209 -0.0011 -0.4201 -0.1769 -2.0870 -0.6102 -4.4032 -0.0590 -0.1574
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas right_atrium embolize pulmonary_arterial_vasculature
H-594	-0.42827072739601135	▁My xo mas ▁pulmonar y _ ▁arterial _ vas cula ture
D-594	-0.42827072739601135	Myxomas pulmonary_ arterial_vasculature
P-594	-0.7607 -0.0102 -0.0644 -0.0221 -0.0116 -0.6732 -1.5947 -0.2801 -0.4237 -1.2843 -0.1925 -0.0907 -0.1592
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient heart_failure_with_reduced_ejection_fraction
H-1203	-0.6396215558052063	▁high - risk _ patient ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction
D-1203	-0.6396215558052063	high-risk_patient heart_ failure reduced ejection_fraction
P-1203	-0.1545 -0.0396 -0.0086 -1.7267 -0.8947 -1.7566 -0.5817 -1.6194 -0.8841 -0.0055 -0.8417 -0.1329 -0.0705 -0.8938 -0.0148 -1.1077 -0.1407
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat mir-25 transcription_factor hand2 heart_failure
H-638	-0.7266844511032104	▁N fat ▁mi R -25 ▁tran scription _ factor ▁Hand 2 ▁heart _ ▁failure
D-638	-0.7266844511032104	Nfat miR-25 transcription_factor Hand2 heart_ failure
P-638	-2.1112 -0.1533 -1.9694 -1.3255 -0.0149 -0.1899 -0.7028 -0.7019 -0.0469 -0.0868 -0.0709 -1.4812 -0.9974 -1.4191 -0.0664 -0.2893
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression type_i_regulatory_subunit ri hf
H-1429	-0.330121248960495	▁regulator y _ ▁sub un it ▁ HF
D-1429	-0.330121248960495	regulatory_ subunit HF
P-1429	-0.7928 -0.0347 -0.3954 -0.7816 -0.2109 -0.4197 -0.3370 -0.0192 -0.0740 -0.2359
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary_heart_disease stroke heart_failure
H-1564	-0.6559070348739624	▁corona ry _ heart _ ▁disease ▁stroke ▁heart _ ▁failure
D-1564	-0.6559070348739624	coronary_heart_ disease stroke heart_ failure
P-1564	-0.0537 -0.0583 -0.5876 -1.4663 -0.7918 -3.5338 -0.0950 -0.1159 -0.4226 -0.6647 -0.0348 -0.0463
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf_inhibition cardiac_function remodeling
H-458	-0.7547745108604431	▁VE GF _ ▁inhibi tion ▁b ▁cardiac _ function ▁remodel ing
D-458	-0.7547745108604431	VEGF_ inhibition b cardiac_function remodeling
P-458	-0.7538 -0.0317 -1.6575 -0.0206 -0.0168 -2.7474 -0.7837 -0.7687 -1.3456 -1.4692 -0.0501 -0.1009 -0.0661
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing β-blocker sst2
H-400	-0.5419022440910339	▁β - block er ▁s ST 2
D-400	-0.5419022440910339	β-blocker sST2
P-400	-2.0830 -0.0356 -0.1584 -0.6506 -0.2473 -0.6633 -0.1067 -0.7705 -0.1617
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change readmissions follow-up heart_failure readmission
H-720	-1.1685106754302979	▁read missions ▁heart _ ▁failure _ ▁read mission _ quality
D-720	-1.1685106754302979	readmissions heart_ failure_ readmission_quality
P-720	-1.3975 -0.0096 -0.9267 -0.5423 -2.2062 -0.3426 -3.5112 -0.1143 -1.4495 -1.3396 -1.9827 -0.1997
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality_of_life mlhf_questionnaire
H-1991	-1.692907452583313	
D-1991	-1.692907452583313	
P-1991	-3.2757 -0.1101
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart_failure hf morbidity mortality
H-199	-0.5917379260063171	▁Pediatri c _ heart _ ▁failure _ HF ▁morbi d ity ▁mortal ity
D-199	-0.5917379260063171	Pediatric_heart_ failure_HF morbidity mortality
P-199	-1.2297 -0.0127 -0.7385 -0.8549 -0.1520 -1.7047 -1.6054 -0.1770 -0.2552 -0.0094 -0.0204 -1.0134 -0.0028 -0.8813 -0.2186
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation resistin correlated ejection_fraction
H-938	-0.42272400856018066	▁resist in ▁decline ▁e je ction _ fraction
D-938	-0.42272400856018066	resistin decline ejection_fraction
P-938	-0.0051 -0.1460 -2.3082 -0.2522 -0.0176 -0.1231 -1.0952 -0.0037 -0.1575 -0.1187
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients heart_failure diagnostic medication follow-up
H-732	-1.8615025281906128	▁heart _ ▁failure ▁medication
D-732	-1.8615025281906128	heart_ failure medication
P-732	-3.4332 -1.7327 -2.6230 -2.7705 -0.3371 -0.2725
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline outcomes ecct cardiac_transplant
H-711	-0.7737076282501221	▁EC CT ▁cardiac _ ▁transplant ▁recipient s
D-711	-0.7737076282501221	ECCT cardiac_ transplant recipients
P-711	-2.1518 -0.8672 -0.8479 -0.6803 -0.4847 -1.7217 -0.0293 -0.0769 -0.1036
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet exercise_rehabilitation patients chf
H-1884	-0.44522812962532043	▁c PET _ ▁gu iding _ ▁exercise _ ▁rehabilita tion ▁CHF
D-1884	-0.44522812962532043	cPET_ guiding_ exercise_ rehabilitation CHF
P-1884	-0.9350 -0.3039 -1.1464 -0.1570 -0.0429 -0.1495 -0.7184 -0.3416 -1.5319 -0.0116 -0.3300 -0.0709 -0.0489
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing medications heart_failure
H-1121	-0.6625449657440186	▁pre scribi ng ▁guide line - re com mend ed _ ▁medication s ▁heart _ ▁failure
D-1121	-0.6625449657440186	prescribing guideline-recommended_ medications heart_ failure
P-1121	-4.6500 -0.1153 -0.0258 -0.1042 -0.0029 -0.6102 -0.0127 -0.0055 -0.0017 -0.0249 -1.2773 -0.6877 -0.0487 -1.6364 -0.9651 -1.5035 -0.1279 -0.1260
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart_failure hf cardiovascular hospitalization
H-1074	-0.763975977897644	▁Heart _ ▁failure _ HF ▁cardiovascular _ hospital ization
D-1074	-0.763975977897644	Heart_ failure_HF cardiovascular_hospitalization
P-1074	-0.5415 -0.4146 -2.4204 -1.9943 -0.2669 -1.4065 -0.4235 -0.0117 -0.1695 -0.6363 -0.1185
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate_ii lvads patients
H-776	-0.3844698369503021	▁mal function ing ▁Heart Mate _ II _ L VAD s
D-776	-0.3844698369503021	malfunctioning HeartMate_II_LVADs
P-776	-1.3865 -0.3236 -0.1121 -0.1292 -0.3767 -0.3469 -0.6052 -0.3538 -0.9213 -0.0115 -0.0949 -0.1936 -0.1429
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient asymptomatic follow-up
H-599	-1.309123158454895	
D-599	-1.309123158454895	
P-599	-2.5268 -0.0915
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal_dnx plasma
H-1381	-0.3747731149196625	▁Ren al _ ▁DN x ▁circula ting _ ▁plasma ▁CHF - IN V ▁rabbi ts
D-1381	-0.3747731149196625	Renal_ DNx circulating_ plasma CHF-INV rabbits
P-1381	-0.0616 -0.0018 -0.5493 -0.3453 -0.0347 -0.1631 -0.1748 -0.5169 -0.1836 -2.5590 -0.0378 -0.4472 -0.7034 -0.2341 -0.0043 -0.0732 -0.2810
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical outcomes hfpef
H-1525	-0.614538311958313	▁EH ▁ HF p EF
D-1525	-0.614538311958313	EH HFpEF
P-1525	-2.3124 -1.6086 -0.1943 -0.0216 -0.0671 -0.0285 -0.0691
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction pump driveline pump curative
H-774	-0.5462443828582764	▁pump _ ▁failure ▁drive line _ ▁injury ▁isola ted ▁pump _ ▁replace ment
D-774	-0.5462443828582764	pump_ failure driveline_ injury isolated pump_ replacement
P-774	-0.9541 -1.9265 -0.8852 -0.0046 -0.0112 -1.0853 -0.5149 -1.0419 -0.0044 -0.7041 -0.3293 -0.0927 -0.0424 -0.4932 -0.1039
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based therapies patients fes
H-1333	-0.47432440519332886	▁evidence - based _ therapie s
D-1333	-0.47432440519332886	evidence-based_therapies
P-1333	-1.1502 -0.0379 -0.0182 -0.6027 -0.0251 -0.0120 -1.8587 -0.0897
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin sitagliptin
H-1828	-0.37708309292793274	▁h HF ▁sax ag lip tin ▁si tag lip tin
D-1828	-0.37708309292793274	hHF saxagliptin sitagliptin
P-1828	-0.0760 -0.7304 -0.2067 -0.0303 -1.3841 -1.3531 -0.1149 -0.0173 -0.1235 -0.3492 -0.0879 -0.0516
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase myocardium
H-171	-0.9392420649528503	▁band _ of _ activa ted ▁Cas pas e ▁pace d ▁my o car dium
D-171	-0.9392420649528503	band_of_activated Caspase paced myocardium
P-171	-4.0565 -3.1817 -1.3684 -0.3414 -0.3781 -0.0739 -0.3795 -0.0909 -0.3326 -0.0656 -0.1653 -4.2294 -0.0699 -0.0852 -0.9463 -0.0639 -0.1384
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic inflammatory abdominal
H-1285	-1.2155051231384277	▁ ische mic _ in flam ma tory ▁abdominal _ problem s ▁MT
D-1285	-1.2155051231384277	ischemic_inflammatory abdominal_problems MT
P-1285	-1.8282 -2.1623 -0.9108 -0.6970 -0.1048 -0.1915 -0.5120 -0.1411 -5.6247 -0.3843 -2.9159 -1.3178 -0.5311 -0.6716 -0.2396
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal_dysfunction morbidity
H-719	-0.3091973066329956	▁renal _ dis function ▁post - trans plant _ ▁morbi d ity
D-719	-0.3091973066329956	renal_disfunction post-transplant_ morbidity
P-719	-0.4689 -0.5186 -0.5425 -0.1609 -1.2340 -0.0080 -0.0014 -0.0297 -0.8079 -0.2001 -0.0583 -0.0585 -0.0447 -0.1952
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline embase cinahl
H-62	-0.8587914109230042	▁Med Line ▁ EMBA SE ▁c INA HL
D-62	-0.8587914109230042	MedLine EMBASE cINAHL
P-62	-1.3336 -0.5035 -0.3609 -0.0193 -4.1339 -1.0318 -0.1581 -0.9511 -0.0411 -0.0547
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations acr cms
H-140	-0.5402783155441284	▁a CR ▁CMS _ ▁metri cs
D-140	-0.5402783155441284	aCR CMS_ metrics
P-140	-0.5733 -0.4979 -0.3996 -1.8909 -0.6813 -0.0798 -0.1171 -0.0822
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up hf deaths
H-1771	-0.7004347443580627	▁ HF
D-1771	-0.7004347443580627	HF
P-1771	-0.8727 -0.1413 -1.6003 -0.1874
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia heart_disease
H-40	-1.2780426740646362	▁an emia ▁heart _ ▁disease
D-40	-1.2780426740646362	anemia heart_ disease
P-40	-1.2506 -0.0820 -4.8961 -0.6050 -1.9999 -0.0374 -0.0754
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital discharge
H-302	-0.9616488218307495	▁sur vi val ▁hospital _ dis charge
D-302	-0.9616488218307495	survival hospital_discharge
P-302	-3.3038 -0.0393 -0.0614 -3.0874 -1.5108 -0.0592 -0.0425 -0.4726 -0.0777
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart_failure disease medical
H-2008	-1.2890006303787231	▁Heart ▁failure _ management _ program s ▁medical ▁resource
D-2008	-1.2890006303787231	Heart failure_management_programs medical resource
P-2008	-0.3413 -3.7338 -0.3623 -2.0662 -1.6478 -1.9718 -0.9548 -0.2912 -0.7013 -2.0036 -0.1050
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.43359577655792236	▁HD L - bound ▁malo ndi alde hy de ▁HD L - indu ced _ no ▁production ▁EC
D-252	-0.43359577655792236	HDL-bound malondialdehyde HDL-induced_no production EC
P-252	-0.1470 -0.6526 -0.0586 -0.0136 -0.5994 -0.1895 -0.0773 -3.4082 -0.1366 -0.0161 -0.1965 -0.0105 -0.0019 -0.0250 -0.3095 -1.6132 -0.3403 -0.7018 -0.0464 -0.1282
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow_up hf
H-627	-0.8662415146827698	▁media n ▁ HF
D-627	-0.8662415146827698	median HF
P-627	-0.7809 -0.0612 -3.8899 -0.2728 -0.1253 -0.0674
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses patients
H-1021	-1.221917748451233	▁ NP _ ▁assessment ▁ED
D-1021	-1.221917748451233	NP_ assessment ED
P-1021	-2.4938 -0.4693 -0.8561 -1.9500 -1.6952 -0.8962 -0.1929
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients trastuzumab
H-676	-0.21799983084201813	▁tras tuz um ab
D-676	-0.21799983084201813	trastuzumab
P-676	-0.9654 -0.0590 -0.1166 -0.0259 -0.0808 -0.0602
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients lvad implantation
H-531	-0.9002412557601929	▁l VAD _ ▁implant ation
D-531	-0.9002412557601929	lVAD_ implantation
P-531	-3.3316 -0.4576 -0.7816 -0.5831 -0.0421 -0.9644 -0.1414
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna genotyped
H-1454	-0.36294329166412354	▁pre - H CT ▁germ line _ DNA ▁geno type
D-1454	-0.36294329166412354	pre-HCT germline_DNA genotype
P-1454	-0.0896 -0.0107 -1.0926 -0.2706 -0.1636 -0.0372 -0.7495 -0.1978 -0.0746 -0.0150 -1.6086 -0.0455
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient clinical symptoms
H-1468	-1.4050602912902832	▁clinic al _ 症状
D-1468	-1.4050602912902832	clinical_症状
P-1468	-3.5481 -0.0317 -0.5634 -2.5766 -1.6634 -0.0473
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients randomized
H-1874	-0.9613069891929626	
D-1874	-0.9613069891929626	
P-1874	-1.8314 -0.0913
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients cad cad
H-1189	-0.6592093706130981	▁deriva tion _ co hor t ▁CAD
D-1189	-0.6592093706130981	derivation_cohort CAD
P-1189	-0.8788 -0.0157 -0.2945 -0.1958 -0.0108 -0.1127 -1.3993 -2.8257 -0.1996
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients blood medication
H-729	-0.9774326086044312	▁blood ▁work _ ▁draw n ▁medication
D-729	-0.9774326086044312	blood work_ drawn medication
P-729	-2.1174 -2.4859 -1.8365 -0.5889 -0.1129 -0.2949 -0.2784 -0.1046
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs functional_capacity peak_vo2
H-123	-0.7738496661186218	▁c PC s ▁functional _ capaci ty pe ak ▁VO 2
D-123	-0.7738496661186218	cPCs functional_capacitypeak VO2
P-123	-0.7405 -1.0141 -0.5256 -2.0927 -1.3308 -0.3911 -2.0264 -0.5187 -0.0057 -0.5369 -0.3024 -0.2185 -0.3568
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck_stent chronic_myocardial_ischemia heart_failure
H-502	-0.4536539316177368	▁bottle ne ck _ ▁sten t _ model ▁chronic ▁my o card ial _ ische mia ▁heart _ ▁failure ▁pig s
D-502	-0.4536539316177368	bottleneck_ stent_model chronic myocardial_ischemia heart_ failure pigs
P-502	-0.0306 -0.0113 -0.0031 -0.4122 -1.5556 -0.0642 -1.7341 -0.3829 -0.4934 -1.2219 -0.0937 -0.5395 -0.0231 -0.1016 -1.7848 -0.0602 -0.0928 -0.4339 -1.2187 -0.0359 -0.0262 -0.0381 -0.0763
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal_bleeding patients ventricular_assist_devices cardiac nurse
H-1656	-0.3714291751384735	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices ▁cardiac _ ▁nurse
D-1656	-0.3714291751384735	Gastrointestinal_ bleeding ventricular_assist devices cardiac_ nurse
P-1656	-0.1948 -0.1155 -0.5661 -0.0466 -0.1953 -0.8097 -0.0660 -0.0353 -0.2790 -0.2348 -0.0508 -0.0738 -0.0225 -3.4899 -0.0156 -0.4748 -0.2005 -0.0907 -0.0955
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv_filling_pressure stable severe_systolic_hf
H-489	-0.5322429537773132	▁LV ▁fill ing _ ▁pressure ▁severe ▁sy sto lic ▁ HF
D-489	-0.5322429537773132	LV filling_ pressure severe systolic HF
P-489	-0.5451 -0.5745 -0.0271 -0.1987 -0.0847 -2.4107 -1.2899 -0.3461 -0.1043 -1.2174 -0.0002 -0.0425 -0.0779
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise adverse_events coronary_artery_disease cad
H-1899	-1.2288013696670532	▁exercise ▁advers e _ ▁events ▁corona ry _ ▁arter y _ 疾患 CAD
D-1899	-1.2288013696670532	exercise adverse_ events coronary_ artery_疾患CAD
P-1899	-3.1229 -4.4648 -0.0439 -0.6785 -0.6706 -0.0588 -0.1098 -0.3918 -1.2192 -0.1857 -0.2060 -4.9700 -2.0740 -0.1548 -0.0811
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote_monitoring hospital discharge patients heart_failure meta-analysis
H-146	-0.8714215755462646	▁remote ▁hospital ▁dis charge ▁patients ▁heart _ ▁failure ▁network ▁meta - analys is
D-146	-0.8714215755462646	remote hospital discharge patients heart_ failure network meta-analysis
P-146	-0.5385 -4.0314 -0.6538 -0.0166 -2.4794 -0.7556 -0.2201 -1.7318 -0.3564 -1.9891 -0.0640 -0.0135 -0.0524 -0.0959 -0.0729
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ambulatory patients heart_failure functional_capacity outcomes
H-695	-0.9864533543586731	▁Solu ble _ ▁ST 2 ▁ambula tory _ ▁patients ▁heart _ ▁failure
D-695	-0.9864533543586731	Soluble_ ST2 ambulatory_ patients heart_ failure
P-695	-3.0763 -0.0128 -0.3336 -1.9453 -0.0639 -1.6351 -0.0042 -1.4815 -1.0399 -0.8867 -0.3867 -2.0492 -0.7079 -0.1875
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac_overexpression mammalian_enabled mena heart_failure
H-1809	-0.7966310977935791	▁Card iac ▁Mamma lian ▁Men a ▁heart _ ▁failure ▁mi ce
D-1809	-0.7966310977935791	Cardiac Mammalian Mena heart_ failure mice
P-1809	-1.6195 -0.4258 -0.6086 -0.1451 -5.0522 -0.0072 -0.4879 -0.4843 -1.0310 -0.4084 -0.0022 -0.0347 -0.0494
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin_hypophosphorylation myocardial_dd
H-771	-0.5030706524848938	▁Tit in ▁hypo phos phor y lation ▁my o card ial _ DD
D-771	-0.5030706524848938	Titin hypophosphorylation myocardial_DD
P-771	-0.0348 -0.2667 -1.6131 -0.3208 -0.9582 -1.0507 -0.0232 -0.3661 -0.1207 -0.8047 -0.1055 -1.3641 -0.1573 -0.0718 -0.2883
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline echocardiograms evidence reverse_remodeling
H-907	-0.3510687053203583	▁base line ▁e cho card i ogram ▁rever se _ ▁remodel ing
D-907	-0.3510687053203583	baseline echocardiogram reverse_ remodeling
P-907	-0.5238 -0.0352 -0.2678 -0.0491 -0.6929 -0.3543 -0.0212 -1.3548 -0.0129 -0.5872 -0.8072 -0.0587 -0.0742 -0.0756
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas bridge_to_transplantation destination_therapy
H-1999	-0.7097258567810059	▁L VAS ▁ bridge ▁to ▁transplant ation ▁destination ▁ therapy
D-1999	-0.7097258567810059	LVAS bridge to transplantation destination therapy
P-1999	-2.3035 -0.1131 -2.9320 -0.0133 -1.3759 -0.2370 -0.0178 -0.0897 -1.2521 -0.0138 -0.0893 -0.0792
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis chronic_heart_failure tachycardia
H-164	-0.6140130758285522	▁apo pto sis ▁can ine _ model ▁chronic _ heart _ ▁failure ▁ta chy car dia
D-164	-0.6140130758285522	apoptosis canine_model chronic_heart_ failure tachycardia
P-164	-1.8584 -0.2158 -0.7675 -1.0570 -0.0013 -0.5518 -0.3040 -0.6535 -0.2315 -1.8858 -0.5248 -2.0407 -0.3029 -0.0526 -0.2889 -0.0129 -0.1516 -0.1512
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 prognosis heart_failure
H-399	-1.2513108253479004	▁con centra tions _ of _ solu ble ▁s st 2
D-399	-1.2513108253479004	concentrations_of_soluble sst2
P-399	-2.8921 -0.0013 -0.0150 -3.0413 -0.6141 -0.5136 -0.4968 -0.0616 -2.1048 -2.6716 -0.0783 -3.7091 -0.0675
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker uptitration hfpef
H-183	-0.9126725196838379	▁ RAS - ▁β - block er ▁up tit ration ▁ HF p EF
D-183	-0.9126725196838379	RAS- β-blocker uptitration HFpEF
P-183	-0.9843 -0.0722 -0.3422 -5.5384 -0.0285 -0.8264 -1.8013 -1.3819 -2.4463 -0.7154 -0.0958 -0.0083 -0.0067 -0.0913 -0.0221 -0.2418
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham_heart_study hf ef
H-1103	-0.4899827837944031	▁Fram ing ham _ ▁Heart _ ▁Study ▁ HF ▁EF
D-1103	-0.4899827837944031	Framingham_ Heart_ Study HF EF
P-1103	-0.3045 -0.0130 -0.0098 -0.4981 -1.2653 -0.2495 -0.2874 -2.2509 -0.0165 -0.8705 -0.0553 -0.0588
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence acp clinical_practice_guidelines
H-35	-0.9241309762001038	▁guide line ▁a CP ▁clinic al _ prac tice ▁guidelines
D-35	-0.9241309762001038	guideline aCP clinical_practice guidelines
P-35	-2.5726 -0.0190 -1.4826 -0.0110 -0.2856 -0.0171 -0.2105 -2.1888 -1.1615 -1.8069 -1.1856 -0.1482
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics symptoms patients heart_failure hf
H-1199	-0.6030323505401611	▁di ure tics ▁con ges tive _ ▁symptoms ▁heart _ ▁failure HF
D-1199	-0.6030323505401611	diuretics congestive_ symptoms heart_ failureHF
P-1199	-0.3840 -0.0443 -1.1149 -1.6912 -0.0433 -0.0618 -0.4809 -1.4314 -0.6367 -0.3681 -1.0009 -1.0487 -0.0670 -0.0691
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations congestive_heart_failure
H-208	-0.3528352677822113	▁ED ▁in tuba tions ▁con ges tive _ heart _ ▁failure
D-208	-0.3528352677822113	ED intubations congestive_heart_ failure
P-208	-0.1708 -0.8951 -0.0016 -0.0072 -0.0103 -0.0303 -0.0708 -0.2889 -0.8858 -0.8173 -1.1159 -0.1465 -0.1464
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east rhythm_control_therapy cardiovascular complications
H-1648	-0.6219731569290161	▁e ast ▁ rhythm _ control _ therapy ▁cardiovascular _ ▁complica tions ▁AF
D-1648	-0.6219731569290161	east rhythm_control_therapy cardiovascular_ complications AF
P-1648	-2.8650 -0.1051 -1.2136 -0.3973 -0.3521 -0.0232 -0.6547 -0.7683 -1.0539 -0.6670 -0.4774 -0.0220 -0.4828 -0.0417 -0.2054
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac_hypertrophy energy_metabolism
H-1778	-0.3383788466453552	▁Card iac _ ▁hyper trop hy ▁energy ▁metabolism
D-1778	-0.3383788466453552	Cardiac_ hypertrophy energy metabolism
P-1778	-1.0416 -0.1652 -0.2966 -0.5360 -0.0094 -0.4591 -0.0494 -0.7574 -0.0368 -0.0322
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients clinical radiological hf hospitalization
H-560	-0.7651345729827881	▁radi ological _ ▁sign s ▁ HF
D-560	-0.7651345729827881	radiological_ signs HF
P-560	-2.0861 -0.7373 -0.6422 -2.0346 -0.0564 -0.3808 -0.0017 -0.8523 -0.0948
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil orally doxorubicin
H-959	-0.3417555093765259	▁Nico rand il ▁do xor ubi cin
D-959	-0.3417555093765259	Nicorandil doxorubicin
P-959	-0.0107 -0.0133 -0.1837 -0.3174 -0.3316 -0.9578 -0.9066 -0.3020 -0.0527
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty heart_failure health
H-621	-1.3855223655700684	▁risk _ of _ heart _ ▁failure ▁ aging ▁body
D-621	-1.3855223655700684	risk_of_heart_ failure aging body
P-621	-2.8451 -2.2859 -1.9565 -0.6274 -0.5646 -0.2109 -2.1599 -3.4586 -0.2692 -0.0926 -1.9944 -0.1612
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart heart_failure arrhythmias
H-747	-1.2284696102142334	▁Heart _ T 2
D-747	-1.2284696102142334	Heart_T2
P-747	-0.4842 -0.6600 -1.5872 -0.0084 -4.4963 -0.1347
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs osprey
H-1611	-0.7999284267425537	▁o spre y ▁network s
D-1611	-0.7999284267425537	osprey networks
P-1611	-4.6486 -0.0031 -0.0264 -0.6032 -0.2297 -0.0440 -0.0444
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol exercise training baseline hgb
H-843	-0.47450634837150574	▁HR Qo L ▁base line ▁H gb
D-843	-0.47450634837150574	HRQoL baseline Hgb
P-843	-1.1036 -0.1852 -0.4940 -0.2765 -0.0017 -2.1283 -0.0035 -0.0396 -0.0381
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc outcomes outcome admission discharge
H-1401	-0.619809627532959	▁NO c ▁outcome s ▁ad mission _ dis charge
D-1401	-0.619809627532959	NOc outcomes admission_discharge
P-1401	-1.1729 -1.3854 -0.6271 -0.2258 -0.8565 -0.0284 -1.3703 -0.7136 -0.0033 -0.2103 -0.2244
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter_ablation sinus_rhythm
H-945	-0.7273673415184021	▁AF - free _ ▁probabil ity ▁cat heter ▁ab lation ▁maintenance ▁sinus _ rhythm
D-945	-0.7273673415184021	AF-free_ probability catheter ablation maintenance sinus_rhythm
P-945	-1.1954 -0.2890 -0.0594 -2.0007 -2.3200 -0.0285 -1.2335 -0.0097 -0.2239 -0.0016 -0.5288 -2.4873 -0.8177 -0.1232 -0.1139 -0.2053
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease accounting cardiac_transplants
H-982	-0.4764385521411896	▁pa e dia tric _ ▁cardiac _ ▁transplant s
D-982	-0.4764385521411896	paediatric_ cardiac_ transplants
P-982	-0.6476 -0.1161 -0.0178 -0.1352 -0.3082 -1.9530 -0.5835 -0.2823 -0.0711 -1.0396 -0.0865
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient patients discharged hf
H-1400	-0.4757620096206665	▁in patient ▁records ▁ HF
D-1400	-0.4757620096206665	inpatient records HF
P-1400	-0.2044 -0.1534 -1.2510 -1.1191 -0.1259 -0.3538 -0.1228
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis mortality patients
H-68	-0.9836443662643433	▁i CD - HF
D-68	-0.9836443662643433	iCD-HF
P-68	-2.5363 -0.5939 -0.0571 -0.0161 -2.5417 -0.1569
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients pneumonia surgical conditions
H-5	-0.6427539587020874	▁pneu monia ▁sur g ical ▁conditions
D-5	-0.6427539587020874	pneumonia surgical conditions
P-5	-0.4749 -3.3922 -0.5659 -0.2251 -0.0541 -0.3427 -0.0298 -0.0575
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients therapy hospitalized cardiovascular
H-1223	-1.6395819187164307	▁Patient s ▁cardiovascular
D-1223	-1.6395819187164307	Patients cardiovascular
P-1223	-5.1553 -0.3133 -1.0288 -1.5025 -0.1980
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report aric hf
H-290	-0.43326592445373535	▁laborator y _ report _ model ▁a RIC _ HF
D-290	-0.43326592445373535	laboratory_report_model aRIC_HF
P-290	-0.5908 -0.0332 -0.7121 -0.2063 -1.2514 -0.3526 -0.6644 -0.0105 -0.3994 -0.1977 -0.6436 -0.1372
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients implantation crt
H-848	-0.723510205745697	▁device _ ▁implant ation ▁c RT
D-848	-0.723510205745697	device_ implantation cRT
P-848	-0.4010 -1.0741 -0.2067 -0.0666 -0.9189 -0.5895 -2.4547 -0.0766
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis therapy
H-1467	-1.132081151008606	
D-1467	-1.132081151008606	
P-1467	-2.1593 -0.1049
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-1.1428484916687012	
D-1852	-1.1428484916687012	
P-1852	-2.1926 -0.0931
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical change
H-792	-1.1187142133712769	▁clinic al ▁change
D-792	-1.1187142133712769	clinical change
P-792	-4.1138 -0.0370 -1.3717 -0.0325 -0.0387
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit_index
H-1008	-0.7307413816452026	▁deficit _ index
D-1008	-0.7307413816452026	deficit_index
P-1008	-0.0870 -1.2286 -0.0934 -1.9428 -0.3019
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare policy
H-1716	-0.7987021207809448	▁Medica re ▁post - a cute _ care _ transfer ▁policy
D-1716	-0.7987021207809448	Medicare post-acute_care_transfer policy
P-1716	-0.2953 -0.0102 -0.1229 -0.0095 -0.0054 -0.0022 -0.4949 -3.1921 -1.4633 -1.4620 -0.2167 -2.7958 -0.3128
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.6495898365974426	▁QR S
D-892	-0.6495898365974426	QRS
P-892	-0.4673 -1.8971 -0.2079 -0.0261
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.7097408771514893	▁ED _ ▁visit s ▁CHF
D-216	-0.7097408771514893	ED_ visits CHF
P-216	-2.4980 -1.4852 -0.7845 -0.0529 -0.0275 -0.0357 -0.0844
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-1.3892544507980347	▁nutrition _ element s ▁vegetables ▁whole ▁grain _ in take ▁mortal ity
D-692	-1.3892544507980347	nutrition_elements vegetables whole grain_intake mortality
P-692	-4.7710 -2.5094 -2.9346 -0.0071 -2.6994 -3.9824 -0.0828 -0.7220 -0.7209 -0.0020 -0.6958 -0.0063 -0.0365 -0.2795
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-1.1769311428070068	
D-619	-1.1769311428070068	
P-619	-2.3195 -0.0343
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.7616279125213623	▁groups ▁internal _ ▁consiste ncy ▁test - re test ▁reli ability
D-1508	-0.7616279125213623	groups internal_ consistency test-retest reliability
P-1508	-4.5759 -1.8593 -0.2135 -2.5772 -0.0113 -0.0672 -0.0227 -0.0027 -0.0059 -0.4306 -0.0057 -0.0276 -0.1016
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.8042153716087341	▁ir on
D-49	-0.8042153716087341	iron
P-49	-1.1367 -0.0477 -1.9355 -0.0970
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic right_ventricular_contractile_reserve patients pulmonary_hypertension
H-821	-0.6614848375320435	▁right ▁vent ri cular _ contract ile _ ▁reserve ▁pulmonar y _ ▁hyper tension
D-821	-0.6614848375320435	right ventricular_contractile_ reserve pulmonary_ hypertension
P-821	-2.1020 -1.2726 -0.2872 -0.0756 -0.1160 -0.8220 -2.9815 -0.2411 -0.1789 -0.8480 -0.0117 -0.3145 -1.2247 -0.0022 -0.0422 -0.0637
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt_intervals sd_of_all_qt_intervals sdqt
H-1439	-0.9648025631904602	▁ QT ▁interval s ▁SD QT
D-1439	-0.9648025631904602	QT intervals SDQT
P-1439	-0.5767 -0.1669 -3.9901 -0.0343 -0.2876 -2.0900 -0.2888 -0.2840
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac_catheterization patient extubated transferred
H-1297	-0.26196277141571045	▁emergency ▁cardiac _ ▁cat heter ization ▁ex tuba ted ▁intermedi ate _ care
D-1297	-0.26196277141571045	emergency cardiac_ catheterization extubated intermediate_care
P-1297	-0.0409 -0.7406 -0.2768 -1.6906 -0.0134 -0.3026 -0.0488 -0.0001 -0.0275 -0.0802 -0.0491 -0.4980 -0.0805 -0.0286 -0.0516
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise training patients chronic_heart_failure high-density_lipoprotein
H-245	-0.8816777467727661	▁exercise _ training ▁chronic _ heart _ ▁failure ▁high - dens ity _ ▁lipo prote in
D-245	-0.8816777467727661	exercise_training chronic_heart_ failure high-density_ lipoprotein
P-245	-2.9002 -2.3932 -0.6763 -1.6276 -0.1485 -1.0955 -0.4792 -1.1555 -0.6670 -0.0472 -0.0090 -0.0078 -0.5343 -0.5636 -1.6214 -0.1583 -1.6669 -0.1187
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin acute anthracycline-induced_cardiotoxicity
H-931	-0.4775316119194031	▁resist in ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic ity
D-931	-0.4775316119194031	resistin acute anthracycline-induced cardiotoxicity
P-931	-0.0367 -0.1974 -0.0986 -0.0174 -0.4764 -0.0151 -2.2334 -2.1045 -0.9645 -0.0072 -0.0565 -0.4034 -0.7571 -0.1023 -0.0734 -0.0967
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat sympathetic_outflow parasympathetic_activity
H-1869	-0.5364225506782532	▁BAT ▁sympa the tic _ out flow ▁para sy mpa the tic ▁activity
D-1869	-0.5364225506782532	BAT sympathetic_outflow parasympathetic activity
P-1869	-1.1991 -3.8126 -0.0604 -0.1546 -0.3309 -0.2389 -0.0005 -0.0503 -0.4213 -0.0549 -0.4034 -0.0479 -1.1236 -0.0612 -0.0868
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1_mapping clinically myocardial_fibrosis
H-1065	-0.9595327973365784	▁t 1 _ ma pping ▁my o card ial _ ▁fibro sis
D-1065	-0.9595327973365784	t1_mapping myocardial_ fibrosis
P-1065	-1.6520 -0.4113 -2.2864 -2.0044 -0.0154 -3.4575 -0.2147 -2.6454 -0.1628 -0.0568 -0.0480 -0.3816 -0.0525 -0.0447
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute autonomic_nervous_system qtv hf patients
H-1447	-0.8745624423027039	▁a cute ▁autonomi c _ system _ modul ation ▁Q TV ▁ HF
D-1447	-0.8745624423027039	acute autonomic_system_modulation QTV HF
P-1447	-0.3454 -0.0046 -4.0117 -0.4741 -0.3335 -4.4654 -1.3194 -0.2604 -0.0504 -0.5112 -0.0759 -0.5442 -0.0081 -0.5407 -0.1734
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart_rate aortic blood_flow doxorubicin
H-960	-0.3114299774169922	▁Heart _ rati o ▁a or tic _ ▁blood ▁flow ▁do xor ubi cin
D-960	-0.3114299774169922	Heart_ratio aortic_ blood flow doxorubicin
P-960	-0.4998 -0.9435 -0.9605 -0.1683 -0.0989 -0.0138 -0.0519 -0.0953 -0.3884 -0.2841 -0.5887 -0.0621 -0.3240 -0.4224 -0.0226 -0.0587
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo bivp correlated rs_synchrony
H-327	-0.384291410446167	▁ RV PO ▁bi VP ▁RS ▁synchron y ▁CS
D-327	-0.384291410446167	RVPO biVP RS synchrony CS
P-327	-0.2571 -0.4763 -0.9152 -0.6986 -0.0741 -1.3742 -0.0500 -0.0604 -0.0387 -0.0441 -0.2384
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac_resynchronization_therapy patients heart_failure
H-903	-0.5518551468849182	▁cardiac ▁re syn chron ization _ therapy ▁di al ysis - dependent _ ▁patients ▁heart _ ▁failure
D-903	-0.5518551468849182	cardiac resynchronization_therapy dialysis-dependent_ patients heart_ failure
P-903	-0.0768 -0.9118 -0.0096 -0.0043 -0.3880 -1.5073 -0.2809 -0.0231 -0.0140 -0.0727 -0.5597 -0.0399 -1.7219 -1.8023 -0.2112 -1.0271 -1.6916 -0.0366 -0.1064
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular_death hf hospitalization exercise training patients btes
H-1933	-0.8225414156913757	▁cardiovascular _ ▁смерти ▁ HF _ hospital ization ▁exercise _ training ▁lower _ b tes
D-1933	-0.8225414156913757	cardiovascular_ смерти HF_hospitalization exercise_training lower_btes
P-1933	-0.7816 -0.6998 -2.4806 -0.1049 -0.0004 -1.9042 -0.0447 -0.2197 -0.0931 -0.9140 -0.7067 -1.5182 -0.3770 -3.3192 -0.7236 -0.0454 -0.0502
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal_muscle correlated vo2_max
H-1500	-0.8017787337303162	▁skelet al _ ▁muscle _ mas ▁cor related ▁poor er ▁VO 2 ▁max
D-1500	-0.8017787337303162	skeletal_ muscle_mas correlated poorer VO2 max
P-1500	-0.3524 -0.0281 -0.2622 -2.4717 -0.8645 -2.7679 -2.4254 -0.0394 -0.5834 -0.1268 -0.2435 -0.0336 -1.5787 -0.1920 -0.0571
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ventricular-arterial_coupling
H-526	-0.5561516880989075	▁e es ▁vent ri cular - arte rial ▁coup ling ▁SV
D-526	-0.5561516880989075	ees ventricular-arterial coupling SV
P-526	-1.1124 -0.0067 -0.5390 -0.2823 -0.0640 -0.4985 -0.0230 -0.0479 -3.9306 -0.3836 -0.1445 -0.0244 -0.1732
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized double-blind active placebo
H-77	-1.1723705530166626	▁double - blind ▁active _ ▁treatment ▁place bo
D-77	-1.1723705530166626	double-blind active_ treatment placebo
P-77	-4.3529 -0.0245 -0.0040 -2.0485 -1.0518 -3.8008 -0.1897 -0.0049 -0.0485 -0.1982
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial pde2 expression activity hf
H-1213	-0.9350415468215942	▁My o card ial _ p de 2 ▁expression ▁ HF
D-1213	-0.9350415468215942	Myocardial_pde2 expression HF
P-1213	-0.6704 -0.0698 -1.0535 -0.0882 -0.2184 -2.1279 -2.6718 -0.0464 -1.0026 -2.7980 -1.2054 -0.0599 -0.1434
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic_failure cardiomyopathic
H-986	-0.6218580603599548	▁dia sto lic _ ▁failure ▁cardio my o pathi c _ ▁restriction ▁flow
D-986	-0.6218580603599548	diastolic_ failure cardiomyopathic_ restriction flow
P-986	-1.4457 -0.6939 -0.4589 -0.6537 -1.1816 -0.1004 -1.3217 -0.4726 -0.0940 -1.2377 -1.1236 -0.3652 -0.0356 -0.0614 -0.0818
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical outcomes hospitalisations readmissions mortality
H-1850	-0.4159042239189148	▁hospital isation s ▁read missions ▁mortal ity
D-1850	-0.4159042239189148	hospitalisations readmissions mortality
P-1850	-3.0522 -0.0096 -0.0901 -0.1918 -0.0176 -0.2424 -0.0050 -0.0619 -0.0726
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial exercise training heart_failure hf patients
H-1925	-0.7804980278015137	▁psycho social _ factor ▁exercise _ training ▁heart _ ▁failure HF
D-1925	-0.7804980278015137	psychosocial_factor exercise_training heart_ failureHF
P-1925	-1.2497 -0.3511 -1.0158 -0.2688 -0.5217 -0.5378 -0.8927 -0.6313 -0.3064 -2.6104 -0.9987 -0.6803 -0.0819
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic_nervous_system activity qtv
H-1436	-0.6698229908943176	▁autonomi c _ system _ activ ity ▁Q TV
D-1436	-0.6698229908943176	autonomic_system_activity QTV
P-1436	-0.4168 -0.2342 -0.2862 -3.8902 -1.5979 -0.3061 -0.2598 -0.1854 -0.0282 -0.0493 -0.1139
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump pump pump_thrombosis hemolysis
H-2004	-0.6284354329109192	▁pump ▁mal function s ▁pump _ thro mbo sis ▁hem ol ysis
D-2004	-0.6284354329109192	pump malfunctions pump_thrombosis hemolysis
P-2004	-0.0048 -3.9181 -0.0735 -0.0670 -0.0130 -1.1761 -0.2078 -0.1952 -1.7106 -0.1247 -0.4965 -0.1759 -0.5988 -0.0359
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients atrial_fibrillation pacemaker
H-883	-0.6022229790687561	▁at rial _ fi bril lation ▁pace maker
D-883	-0.6022229790687561	atrial_fibrillation pacemaker
P-883	-3.2212 -0.0501 -0.4041 -0.6188 -0.0534 -0.0084 -1.0312 -0.5503 -0.0447 -0.0401
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body_mass_index crf exercise
H-1768	-0.3950539529323578	▁body _ index ▁c RF ▁tre ad m ill _ ▁exercise
D-1768	-0.3950539529323578	body_index cRF treadmill_ exercise
P-1768	-0.0119 -0.7730 -0.3692 -0.5363 -0.0133 -0.3108 -0.0064 -0.0705 -0.0132 -0.6293 -0.9830 -1.3095 -0.1093
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial_tissue pka
H-1426	-0.38611480593681335	▁human ▁my o card ial _ ▁tissu e ▁p KA ▁sub un its
D-1426	-0.38611480593681335	human myocardial_ tissue pKA subunits
P-1426	-0.3883 -1.6800 -0.1807 -0.6047 -0.0266 -0.1710 -0.1181 -0.1556 -0.8360 -0.5022 -0.9258 -0.0513 -0.0012 -0.0503 -0.1000
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world_health_organization hf
H-1791	-0.6174164414405823	▁electronic _ ▁database s ▁world _ health _ organisation ▁ HF
D-1791	-0.6174164414405823	electronic_ databases world_health_organisation HF
P-1791	-0.2522 -0.2426 -2.5229 -0.0480 -1.8302 -0.1006 -1.4007 -0.1380 -0.5446 -0.4897 -0.0243 -0.2711 -0.1615
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition compliance exercise injections patients
H-1321	-0.8063138127326965	▁compliance ▁exercise ▁inject ions
D-1321	-0.8063138127326965	compliance exercise injections
P-1321	-3.4844 -0.3705 -0.2144 -0.0436 -0.6779 -0.0470
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.9745205640792847	
D-626	-0.9745205640792847	
P-626	-1.8732 -0.0758
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac_stress β-ar drive
H-1219	-1.092794418334961	▁cardiac _ ▁stress ▁anta gon izing ▁β - AR ▁drive
D-1219	-1.092794418334961	cardiac_ stress antagonizing β-AR drive
P-1219	-3.8664 -0.9811 -0.5787 -2.0626 -0.0016 -0.0337 -4.4145 -0.0180 -0.1417 -0.7814 -0.1397 -0.0940
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics_rounds
H-1681	-0.42527925968170166	▁e thi cs _ ▁Round s
D-1681	-0.42527925968170166	ethics_ Rounds
P-1681	-1.9703 -0.0830 -0.0198 -0.6345 -0.1309 -0.0161 -0.5141 -0.0337
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss btes exercise
H-1928	-0.9978564977645874	▁PS SS ▁social _ support
D-1928	-0.9978564977645874	PSSS social_support
P-1928	-3.3789 -0.7821 -0.1570 -0.4782 -0.4767 -1.5564 -0.1557
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol mortality
H-650	-0.9251925349235535	▁bis o pro lol
D-650	-0.9251925349235535	bisoprolol
P-650	-1.5113 -0.2436 -0.0823 -0.5606 -2.8384 -0.3150
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty health outcomes
H-623	-0.8480047583580017	▁Fra il ty
D-623	-0.8480047583580017	Frailty
P-623	-0.9524 -0.2130 -0.5962 -2.4116 -0.0669
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf intubation
H-221	-0.651142418384552	▁ED _ ▁visit s ▁CHF ▁in tub ation _ ▁rates
D-221	-0.651142418384552	ED_ visits CHF intubation_ rates
P-221	-3.0919 -1.4443 -0.9208 -0.0139 -0.0265 -0.0072 -0.0008 -0.1096 -1.4807 -0.3863 -0.2388 -0.0928
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician conditions hospital discharge
H-1422	-0.890524685382843	▁physician _ ▁continu ity
D-1422	-0.890524685382843	physician_ continuity
P-1422	-0.2442 -0.8265 -0.6691 -0.0024 -3.3720 -0.2289
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare hospitalizations
H-1714	-0.3486888110637665	▁Medica re ▁fee - for - service ▁hospital ization s
D-1714	-0.3486888110637665	Medicare fee-for-service hospitalizations
P-1714	-0.0658 -0.0091 -0.1403 -0.0462 -0.0110 -0.0140 -0.0053 -2.9152 -0.4832 -0.3714 -0.0481 -0.0746
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical therapeutic
H-1368	-0.41569626331329346	▁clinic al ▁ therapeut ic
D-1368	-0.41569626331329346	clinical therapeutic
P-1368	-0.2295 -0.1063 -1.0983 -0.0069 -0.0692 -1.3259 -0.0737
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients prognosis
H-1315	-0.823570966720581	▁high - risk
D-1315	-0.823570966720581	high-risk
P-1315	-0.1231 -0.0265 -0.0147 -3.7647 -0.1887
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.8279334306716919	▁exercise _ ▁attend ance ▁die t ▁ad her ence
D-1983	-0.8279334306716919	exercise_ attendance diet adherence
P-1983	-0.5167 -1.3551 -0.4990 -0.0016 -3.6634 -0.0466 -0.7762 -0.1989 -0.0097 -1.9675 -0.0726
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.6570454239845276	
D-1862	-0.6570454239845276	
P-1862	-1.2641 -0.0499
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.4453229308128357	▁parallel - group ▁single - co hor t _ ▁study ▁hypothe tical
D-2013	-0.4453229308128357	parallel-group single-cohort_ study hypothetical
P-2013	-0.9478 -0.0594 -0.0098 -0.0605 -0.0115 -0.0010 -0.0103 -0.2527 -0.7085 -2.2631 -0.3659 -0.0247 -1.4297 -0.0896
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal_dnx cardiac autonomic_balance chf sympathetic_tone
H-1382	-0.2618864178657532	▁renal ▁DN x ▁cardiac _ ▁autonomi c ▁balance ▁CHF ▁sympa the tic _ ▁tone
D-1382	-0.2618864178657532	renal DNx cardiac_ autonomic balance CHF sympathetic_ tone
P-1382	-0.0020 -0.5104 -0.0806 -0.0166 -0.6606 -0.1902 -0.5665 -0.2519 -0.0647 -0.0148 -0.0826 -0.3599 -1.1218 -0.1554 -0.0493 -0.0629
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia patients heart_disease clinical_practice_guideline american_college_of_physicians
H-29	-0.8588969111442566	▁an emia ▁clinic al _ prac tice _ ▁guide line ▁American ▁College _ of _ ▁Physic ians
D-29	-0.8588969111442566	anemia clinical_practice_ guideline American College_of_ Physicians
P-29	-1.2234 -0.0119 -5.1920 -0.0048 -0.1178 -0.7807 -0.2355 -1.6267 -0.6342 -0.0092 -3.0368 -2.5362 -0.1503 -0.0238 -0.0349 -0.5135 -0.0035 -0.1049 -0.0790
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence end-stage_renal_disease outpatients systolic_heart_failure
H-386	-0.3265964984893799	▁end - s tage ▁renal _ ▁disease ▁out patient s ▁sy sto lic _ heart _ ▁failure
D-386	-0.3265964984893799	end-stage renal_ disease outpatients systolic_heart_ failure
P-386	-0.0663 -0.0636 -0.1482 -0.0023 -0.3881 -0.4148 -1.3361 -0.4110 -0.0008 -0.0093 -0.0180 -0.0250 -0.7661 -0.2215 -0.7111 -0.8051 -0.6841 -0.0581 -0.0758
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic_neurotransmission acetylcholinesterase_inhibition
H-1135	-0.5629239082336426	▁para sy mpa the tic _ ▁neuro trans mission ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.5629239082336426	parasympathetic_ neurotransmission acetylcholinesterase inhibition
P-1135	-0.0096 -0.4566 -0.0487 -0.2317 -0.0323 -0.7666 -0.0380 -0.0008 -0.0142 -0.0304 -0.0177 -0.0645 -3.4749 -0.1728 -3.4804 -1.7176 -0.5372 -0.0347 -0.0909 -0.0390
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart_rate_reduction ivabradine left_ventricle heart_failure patients
H-515	-0.9748886227607727	▁heart _ rati o ▁i va bra dine ▁left _ ▁vent ric le ▁heart _ ▁failure
D-515	-0.9748886227607727	heart_ratio ivabradine left_ ventricle heart_ failure
P-515	-2.3171 -1.2717 -2.3947 -0.6789 -0.3602 -0.5294 -0.0891 -0.0313 -0.0353 -0.4157 -3.4055 -2.0329 -0.5502 -0.1789 -0.5417 -1.9049 -0.6168 -0.1938
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart_failure pathophysiology diagnosis medical_treatment nursing
H-2018	-0.5205956101417542	▁Heart _ fail ure ▁Path o phy si ology ▁medical _ ▁Treatment _ guide lines ▁Nur sing ▁Management
D-2018	-0.5205956101417542	Heart_failure Pathophysiology medical_ Treatment_guidelines Nursing Management
P-2018	-0.2982 -0.2946 -0.4586 -0.0205 -2.4720 -0.2785 -0.0116 -0.9223 -0.0008 -0.2773 -0.9857 -1.2937 -1.2024 -0.5121 -0.0086 -0.1468 -0.0032 -1.1789 -0.0146 -0.0315
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis medical heart_failure canadian_cardiovascular_society
H-198	-0.7253265976905823	▁medical _ management _ of _ heart _ ▁failure _ of _ children ▁Canadian ▁Card io vas cular _ ▁Society ▁guidelines
D-198	-0.7253265976905823	medical_management_of_heart_ failure_of_children Canadian Cardiovascular_ Society guidelines
P-198	-0.7050 -0.4507 -0.1036 -1.8150 -0.1918 -0.4428 -0.2759 -0.1124 -1.7759 -2.1454 -1.9788 -0.0407 -0.8572 -0.2703 -2.6401 -0.5182 -0.6881 -0.1205 -0.2991 -0.6094 -0.5190 -0.0344 -0.0882
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers neurohormonal_stimulation inflammation endothelial_dysfunction
H-13	-0.14055943489074707	▁neuro hormon al ▁stimul ation ▁ inflammation ▁en dot heli al ▁dys function
D-13	-0.14055943489074707	neurohormonal stimulation inflammation endothelial dysfunction
P-13	-0.2280 -0.0608 -0.0132 -0.8140 -0.0168 -0.1281 -0.0004 -0.0133 -0.1917 -0.0204 -0.0015 -0.4998 -0.0242 -0.0323 -0.0639
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic reverse_remodeling cardiac_resynchronization_therapy
H-426	-0.5107360482215881	▁e cho car dio graphic ▁rever se _ ▁remodel ing ▁cardiac ▁re syn chron ization _ therapy
D-426	-0.5107360482215881	echocardiographic reverse_ remodeling cardiac resynchronization_therapy
P-426	-0.9366 -0.0356 -0.8034 -2.7198 -0.6216 -0.0530 -0.0059 -0.9946 -0.1001 -0.0165 -0.0285 -1.2171 -0.0002 -0.0003 -0.1689 -1.6136 -0.1851 -0.1557 -0.0476
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal pathophysiology congestive_heart_failure chf
H-634	-0.5112295746803284	▁Neuro hormon al _ ab normal ities ▁pat ho phy si ology ▁con ges tive _ heart _ ▁failure
D-634	-0.5112295746803284	Neurohormonal_abnormalities pathophysiology congestive_heart_ failure
P-634	-0.6027 -0.2090 -0.0143 -0.8868 -0.7623 -0.0129 -0.0185 -1.8007 -0.0407 -0.0269 -1.1248 -0.0047 -0.0150 -0.0248 -0.1086 -0.0686 -1.5322 -0.1400 -1.8537 -1.4227 -0.0660
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas therapeutic heart_failure
H-1485	-1.1073986291885376	▁mi RNA s ▁heart _ ▁failure
D-1485	-1.1073986291885376	miRNAs heart_ failure
P-1485	-2.6906 -0.0017 -0.1798 -3.6398 -0.4562 -1.7730 -0.0352 -0.0828
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv_dysfunction correlated lean_body_mass
H-1164	-1.1769050359725952	▁ RV _ dis function ▁weight _ rati o
D-1164	-1.1769050359725952	RV_disfunction weight_ratio
P-1164	-0.2890 -0.4213 -1.2391 -0.9906 -0.4111 -4.5134 -1.7759 -1.9083 -0.0331 -0.9535 -0.4108
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity mortality quality_of_life patients hf
H-2023	-0.7720779776573181	▁morbi d ity _ ▁mortal ity
D-2023	-0.7720779776573181	morbidity_ mortality
P-2023	-0.0889 -0.0822 -0.1694 -2.8419 -0.5559 -0.0038 -2.2991 -0.1354
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary exercise prognostically heart_failure
H-1274	-1.0761115550994873	▁cardio pul mon ary _ ▁exercise _ ▁variable s
D-1274	-1.0761115550994873	cardiopulmonary_ exercise_ variables
P-1274	-0.3782 -0.5050 -1.2410 -0.1051 -0.7815 -2.7836 -1.4695 -1.2243 -0.0484 -3.1334 -0.1673
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad_variant congestive_heart_failure
H-1670	-1.0737087726593018	▁po tent _ ▁inhibi tion ▁L - type _ ca 2 _ ▁current s ▁Rad _ variant ▁con ges tive _ heart _ ▁failure
D-1670	-1.0737087726593018	potent_ inhibition L-type_ca2_ currents Rad_variant congestive_heart_ failure
P-1670	-3.8292 -0.0032 -0.3532 -0.7459 -0.0053 -0.9891 -0.0173 -0.0030 -0.4884 -0.0320 -0.2600 -2.7383 -7.0282 -0.0597 -0.1905 -2.3912 -1.3853 -0.0254 -0.0764 -0.1033 -0.1876 -2.4192 -1.3332 -3.0637 -0.0939 -0.0938
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical radiological hf quality_of_life
H-565	-0.5276087522506714	▁radi ological _ ▁sign s ▁ HF
D-565	-0.5276087522506714	radiological_ signs HF
P-565	-0.0621 -0.5666 -0.5174 -1.2914 -0.0222 -0.4014 -0.0025 -1.7875 -0.0973
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right_ventricle rv cardiac_function medical
H-1091	-0.9973142147064209	▁right ▁vent ric le ▁normal ▁cardiac _ function ▁medical
D-1091	-0.9973142147064209	right ventricle normal cardiac_function medical
P-1091	-0.2923 -2.3096 -0.6107 -0.4198 -3.9027 -0.7551 -0.8474 -0.8024 -0.2500 -0.6730 -0.1073
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness sickle_cell_disease anemia
H-1682	-0.7684303522109985	▁Jehovah ' s _ ▁Wit ness ▁sick le _ cell _ ▁disease ▁life - th rea te ning ▁an emia
D-1682	-0.7684303522109985	Jehovah's_ Witness sickle_cell_ disease life-threatening anemia
P-1682	-0.1478 -3.6164 -1.0300 -1.5713 -0.4234 -0.0438 -0.0264 -0.2093 -0.4895 -2.1446 -1.3870 -2.2207 -1.7633 -0.1071 -0.2147 -0.2632 -0.4435 -0.2537 -0.1606 -0.0013 -0.1243 -0.2636
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri_scanner baseline heart_failure
H-1057	-2.185995101928711	
D-1057	-2.185995101928711	
P-1057	-4.0698 -0.3022
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive_heart_failure chf
H-209	-0.6088542938232422	▁con ges tive _ heart _ ▁failure CH F
D-209	-0.6088542938232422	congestive_heart_ failureCHF
P-209	-0.5192 -0.0441 -0.0311 -0.1062 -1.2790 -0.1345 -1.9805 -2.3501 -0.2007 -0.0260 -0.0260
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes costs patients heart_failure hf
H-1721	-1.8754520416259766	
D-1721	-1.8754520416259766	
P-1721	-3.7224 -0.0285
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin_subproteome diseased heart
H-99	-0.485592782497406	▁chr omat in _ ▁sub prote ome ▁disease d ▁mouse _ heart
D-99	-0.485592782497406	chromatin_ subproteome diseased mouse_heart
P-99	-1.9543 -0.0567 -0.7865 -0.2198 -0.2868 -0.0703 -0.0878 -1.2920 -0.1774 -0.1244 -0.7568 -0.8552 -0.0344 -0.0958
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome heart_failure fontan
H-1493	-0.3266352415084839	▁muscle - was ting _ ▁syndrome ▁acquire d _ heart _ ▁failure ▁Font an
D-1493	-0.3266352415084839	muscle-wasting_ syndrome acquired_heart_ failure Fontan
P-1493	-0.5332 -0.2291 -1.3518 -0.0126 -0.6503 -0.0347 -0.0150 -0.0075 -0.2078 -0.5961 -0.3443 -0.8549 -0.0530 -0.0254 -0.2289 -0.0816
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash mortality heart_failure health
H-684	-1.0968619585037231	▁Mediterrane an ▁DAS h _ ▁die t _ ▁score s ▁mortal ity ▁heart _ ▁failure
D-684	-1.0968619585037231	Mediterranean DASh_ diet_ scores mortality heart_ failure
P-684	-1.8726 -0.0032 -0.1588 -1.0468 -0.4805 -3.3157 -0.1044 -0.4890 -0.8026 -0.0428 -0.8256 -0.0023 -2.0280 -0.0722 -6.0680 -1.1662 -0.1680
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential_effect lvef mortality
H-118	-0.45688217878341675	▁LV EF ▁long - term _ ▁mortal ity
D-118	-0.45688217878341675	LVEF long-term_ mortality
P-118	-0.9733 -0.1826 -0.7851 -0.0691 -0.0554 -0.1022 -1.0341 -0.0080 -1.1381 -0.2210
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt nt-probnp hf
H-291	-0.4342350363731384	▁c t n t ▁NT - pro b NP ▁ HF _ risk _ pred ion
D-291	-0.4342350363731384	ctnt NT-probNP HF_risk_predion
P-291	-0.3160 -0.5068 -0.3333 -0.4546 -0.0884 -0.0183 -0.0013 -1.0604 -0.1004 -0.1080 -0.0132 -0.9955 -0.4974 -0.8631 -0.3345 -1.9439 -0.0890 -0.0922
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital mortality patients bnp mortality
H-195	-0.42439088225364685	▁in hospital _ ▁mortal ity ▁media n ▁b NP _ level
D-195	-0.42439088225364685	inhospital_ mortality median bNP_level
P-195	-0.3508 -0.0066 -0.3214 -0.0923 -0.0040 -0.9501 -0.0153 -1.4394 -0.3366 -1.1552 -0.0963 -0.6405 -0.1086
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health_buddy_program hospital hospitalized
H-1626	-0.829173743724823	▁health _ ▁Budd y _ program ▁ED ▁hospital ized
D-1626	-0.829173743724823	health_ Buddy_program ED hospitalized
P-1626	-0.6287 -1.3998 -1.0526 -0.0305 -1.0800 -0.3422 -0.1189 -1.1374 -3.0603 -0.1312 -0.1393
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin breast_cancer patients cardiotoxicity
H-936	-0.3807108998298645	▁resist in _ ▁levels ▁an thra cycli ne - tre ated ▁breast _ cancer ▁cardio toxic ity
D-936	-0.3807108998298645	resistin_ levels anthracycline-treated breast_cancer cardiotoxicity
P-936	-0.0785 -0.2378 -2.0502 -0.5533 -0.0048 -0.0032 -1.1482 -0.9266 -0.3865 -0.0147 -0.1313 -0.1149 -0.4038 -0.3435 -0.1982 -0.3517 -0.0698 -0.0804 -0.1360
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health_buddy_program telehealth
H-1622	-0.5608286261558533	▁health ▁Budd y _ program ▁content - driv en ▁tele health _ system ▁care
D-1622	-0.5608286261558533	health Buddy_program content-driven telehealth_system care
P-1622	-0.4399 -1.7089 -0.0085 -1.7099 -0.3012 -0.9604 -0.0303 -0.0054 -0.0371 -0.0120 -0.2143 -2.5897 -0.0491 -0.0418 -0.7776 -0.0872
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality deaths acs consultation operation
H-1287	-0.5229474306106567	▁Mor t ality
D-1287	-0.5229474306106567	Mortality
P-1287	-0.4301 -0.0545 -0.0071 -2.0201 -0.1029
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic patients heart_failure
H-1740	-1.2759335041046143	▁con tempor ary _ therapeut ic _ ▁options
D-1740	-1.2759335041046143	contemporary_therapeutic_ options
P-1740	-3.9467 -0.0339 -0.0064 -0.9445 -0.2025 -0.0193 -2.0213 -2.0694 -3.4208 -0.0945
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine furosemide outcome
H-586	-0.4950528144836426	▁do bu tamine ▁fur os em ide _ ▁dose ▁oxygen _ ▁flow
D-586	-0.4950528144836426	dobutamine furosemide_ dose oxygen_ flow
P-586	-0.3561 -0.0161 -0.2147 -0.6759 -0.8763 -0.1629 -0.1494 -1.3968 -0.3352 -0.3014 -1.5095 -0.7368 -0.1272 -0.0723
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs outcomes patients diabetes
H-130	-0.9190396070480347	▁differenti al _ ▁relations ▁c PC s ▁diabetes
D-130	-0.9190396070480347	differential_ relations cPCs diabetes
P-130	-1.4509 -0.0092 -0.7406 -0.5813 -1.9843 -0.1014 -0.4247 -3.7165 -0.0663 -0.1154
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.937861979007721	
D-727	-0.937861979007721	
P-727	-1.8428 -0.0329
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients consultation abdominal
H-1284	-1.5838477611541748	
D-1284	-1.5838477611541748	
P-1284	-2.8946 -0.2731
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic complication
H-1661	-1.1963623762130737	▁diagnostic ▁procedure s
D-1661	-1.1963623762130737	diagnostic procedures
P-1661	-1.2444 -3.6126 -0.0228 -1.0333 -0.0687
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.4148300588130951	▁Thi r ty - day _ ▁mortal ity
D-2001	-0.4148300588130951	Thirty-day_ mortality
P-2001	-1.1457 -0.1697 -0.0584 -0.0268 -0.1217 -0.3334 -0.2593 -0.0061 -1.8478 -0.1793
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.8377689123153687	▁fut ility ▁data ▁safety _ board
D-850	-0.8377689123153687	futility data safety_board
P-850	-1.6202 -0.1959 -0.0396 -2.4425 -1.1704 -1.0769 -0.0578 -0.0990
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic acute_rv_failure left_ventricular_dysfunction
H-1092	-1.2101980447769165	▁a cute ▁ RV _ ▁failure ▁left _ ▁vent ri cular _ ▁dys function
D-1092	-1.2101980447769165	acute RV_ failure left_ ventricular_ dysfunction
P-1092	-2.0437 -0.0097 -2.2308 -0.5643 -1.8662 -1.2255 -0.0718 -0.5169 -6.9870 -1.6019 -0.2300 -0.6853 -0.9273 -0.0438 -0.1408 -0.2180
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left_ventricular_ejection_time acute_heart_failure precapillary_pulmonary_hypertension
H-576	-0.475206196308136	▁Le ft _ ▁vent ri cular _ ▁e je ction ▁a cute _ heart _ ▁failure ▁pre cap illa ry _ ▁pulmonar y _ ▁hyper tension
D-576	-0.475206196308136	Left_ ventricular_ ejection acute_heart_ failure precapillary_ pulmonary_ hypertension
P-576	-0.9781 -0.0001 -0.7529 -2.4056 -0.2126 -0.0227 -0.4677 -0.9194 -0.0147 -0.0051 -1.6508 -0.0042 -0.7871 -0.4678 -0.3837 -0.2625 -0.0109 -0.4913 -0.0768 -0.0260 -0.5108 -0.7093 -0.0094 -0.7802 -1.1393 -0.0009 -0.0916 -0.1243
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical aortic_valve_insufficiency left_ventricular_assist_device implantation
H-541	-0.559747040271759	▁a or tic _ val ve _ insu ffi cie ncy ▁left ▁vent ri cular _ assist ance
D-541	-0.559747040271759	aortic_valve_insufficiency left ventricular_assistance
P-541	-0.1433 -0.0433 -0.0824 -0.0924 -0.7772 -0.3756 -0.2854 -0.6182 -0.2093 -2.1646 -0.0172 -0.0272 -2.5508 -0.1593 -0.0077 -0.1021 -0.0367 -2.8822 -0.5533 -0.0668
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection_fraction clinical cardiac_resynchronization_therapy mild_heart_failure
H-750	-0.4413542151451111	▁e je ction _ fraction ▁cardiac _ ▁re syn chron ization _ therapy ▁mild _ heart _ ▁failure
D-750	-0.4413542151451111	ejection_fraction cardiac_ resynchronization_therapy mild_heart_ failure
P-750	-0.1880 -0.0087 -0.0028 -0.7986 -0.0021 -0.5149 -0.4496 -0.7768 -0.0043 -0.0024 -0.1489 -0.6216 -0.1026 -0.0842 -0.2864 -0.5890 -1.2389 -2.8894 -0.0370 -0.0811
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular_pacing left_heart_twist strain right_heart_failure
H-318	-0.5764743089675903	▁bi ven tri cular _ pa cing ▁left _ heart ▁twist _ ▁strain ▁por cine _ model ▁right _ heart _ ▁failure
D-318	-0.5764743089675903	biventricular_pacing left_heart twist_ strain porcine_model right_heart_ failure
P-318	-0.0396 -0.1278 -0.4241 -0.1767 -0.4260 -0.8808 -0.0020 -0.3612 -0.4113 -2.1428 -0.0654 -2.4405 -0.2491 -0.1843 -0.0083 -1.3870 -0.3210 -0.0314 -0.3268 -1.0955 -0.7996 -1.7448 -0.0305 -0.1590
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial_diastolic_dysfunction dd collagen_deposition titin
H-761	-0.2735433578491211	▁my o card ial _ dia sto lic _ ▁dys function ▁collage n ▁de position ▁titi n
D-761	-0.2735433578491211	myocardial_diastolic_ dysfunction collagen deposition titin
P-761	-0.0835 -0.1082 -0.6945 -0.0383 -0.1314 -0.1459 -0.2000 -0.5124 -0.3439 -0.5181 -0.1410 -0.5922 -0.0304 -0.9951 -0.0034 -0.0007 -0.0274 -0.5633 -0.0674
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress_doppler_echocardiography prognostic pulmonary_hypertension patients
H-832	-0.5277660489082336	▁Stress ▁do pp ler _ e cho card i ography ▁pulmonar y _ ▁hyper tension
D-832	-0.5277660489082336	Stress doppler_echocardiography pulmonary_ hypertension
P-832	-1.2854 -2.2919 -0.0020 -0.1831 -0.4084 -0.6580 -0.5281 -1.0667 -0.2989 -0.2879 -0.0401 -0.0076 -0.4257 -0.7454 -0.0319 -0.5957 -0.1152
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated septal wall avd free_wall_cs vvd
H-329	-0.4498995244503021	▁sept al _ wall _ ▁CS ▁free _ wall ▁VVD
D-329	-0.4498995244503021	septal_wall_ CS free_wall VVD
P-329	-1.0772 -0.0120 -0.1477 -0.2078 -0.4964 -1.7352 -0.0834 -0.3678 -0.3015 -0.6628 -0.1641 -0.1428
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein_kinase_a guanylate_cyclase contractile_response
H-418	-0.8003990054130554	▁inhibi tion ▁protein _ ▁kina se ▁solu ble _ ▁gua ny late _ ▁cy cla se ▁contract ile _ ▁response
D-418	-0.8003990054130554	inhibition protein_ kinase soluble_ guanylate_ cyclase contractile_ response
P-418	-0.7011 -0.0176 -0.0956 -1.7352 -0.0124 -0.1273 -4.4950 -0.0421 -0.4506 -0.3813 -0.7858 -2.9329 -0.5782 -0.0189 -0.0920 -0.3783 -0.0008 -1.6554 -1.2750 -1.4288 -0.2550 -0.1496
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed_up adverse_events death transplantation circulatory_assist_device
H-1162	-0.7546102404594421	▁advers e _ ▁events ▁death _ ▁transplant ation ▁circula tory _ assist ▁device
D-1162	-0.7546102404594421	adverse_ events death_ transplantation circulatory_assist device
P-1162	-4.2942 -0.0192 -0.8657 -0.8450 -1.1855 -1.6512 -0.3109 -0.0129 -0.0398 -0.0020 -0.0835 -0.0148 -1.8862 -0.0489 -0.0595
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic diastolic_mitral_leaflet_motions organic lesion
H-351	-0.5356470346450806	▁sy sto lic ▁dia sto lic _ ▁mit ral _ le a flet _ ▁motion s ▁clear ▁organic _ les ion
D-351	-0.5356470346450806	systolic diastolic_ mitral_leaflet_ motions clear organic_lesion
P-351	-0.0197 -0.0672 -0.0235 -0.5774 -0.1963 -0.0556 -0.7666 -2.4602 -0.0332 -0.3346 -2.1164 -0.1878 -0.0019 -1.2465 -0.5265 -0.0459 -0.8865 -0.1480 -1.2768 -1.1232 -0.1300 -0.0220 -0.0743
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating_progenitor_cells outcome heart_failure patients longitudinal
H-119	-0.49002593755722046	▁circula ting _ pro gen itor _ cell s ▁outcome ▁heart _ ▁failure
D-119	-0.49002593755722046	circulating_progenitor_cells outcome heart_ failure
P-119	-0.1672 -0.1088 -0.1814 -0.4250 -0.2713 -0.0776 -0.5840 -0.1953 -0.0561 -0.6271 -0.4794 -0.3315 -2.7126 -1.0327 -0.1004
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary_outcome sympathetic_activity myocardial_washout
H-1115	-0.895227313041687	▁sympa the tic ▁activity ▁i - MI BG ▁my o card ial ▁was hout
D-1115	-0.895227313041687	sympathetic activity i-MIBG myocardial washout
P-1115	-2.0856 -0.0554 -0.0434 -1.0779 -0.8240 -0.3804 -0.9913 -0.6093 -1.0450 -0.1884 -2.2171 -0.0150 -4.5446 -0.0211 -0.0600 -0.1652
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student_t_test confidence_intervals cis regression_analyses
H-215	-0.7939184308052063	▁student ▁t _ test ▁ci s ▁re gression
D-215	-0.7939184308052063	student t_test cis regression
P-215	-1.3705 -0.2411 -0.9014 -0.3131 -4.2261 -0.0500 -0.0241 -0.0034 -0.7265 -0.0830
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left_pulmonary_artery right_pulmonary_artery
H-597	-0.4036601185798645	▁pulmonar y _ ▁arter y
D-597	-0.4036601185798645	pulmonary_ artery
P-597	-0.7783 -0.0250 -0.9926 -0.1297 -0.1371 -0.6361 -0.1269
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle_cohort_study canada
H-1951	-0.440867155790329	▁ proof - of - princip le _ co hor t
D-1951	-0.440867155790329	proof-of-principle_cohort
P-1951	-1.2571 -0.2123 -0.0511 -0.1402 -0.0237 -0.1450 -0.3924 -0.9542 -0.1846 -0.0339 -0.2487 -1.9507 -0.1373
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr_reduction beta_blockers exercise_capacity hfref
H-1937	-0.5624773502349854	▁HR _ re duction ▁beta _ block ers ▁exercise _ capaci tation
D-1937	-0.5624773502349854	HR_reduction beta_blockers exercise_capacitation
P-1937	-0.3231 -1.7319 -0.7849 -0.0001 -0.1028 -0.3407 -0.7575 -0.0046 -0.0070 -0.5879 -0.0932 -1.4683 -1.5581 -0.1147
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv_strain strain echocardiography baseline ablation
H-946	-0.41677340865135193	▁LV ▁strain _ rati o ▁e cho card i ography ▁base line ▁ab lation
D-946	-0.41677340865135193	LV strain_ratio echocardiography baseline ablation
P-946	-0.2761 -1.0599 -1.8325 -1.3471 -0.0927 -0.1358 -0.0445 -0.7065 -0.3870 -0.1993 -0.4313 -0.0040 -0.0115 -0.0019 -0.0510 -0.0871
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs functional_capacity outcomes heart_failure hf
H-121	-0.6544193625450134	▁serial _ ▁measure ments ▁c PC s ▁functional _ capaci ty ▁heart _ ▁failure HF
D-121	-0.6544193625450134	serial_ measurements cPCs functional_capacity heart_ failureHF
P-121	-2.2783 -0.6338 -1.2613 -0.0246 -0.7174 -0.0298 -0.3197 -0.2302 -0.6095 -0.2612 -0.7734 -0.3770 -0.3133 -2.3722 -0.7355 -0.0706 -0.1172
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure_ulcers surgical patients
H-6	-0.5016553401947021	▁pressure _ ▁ul cer s ▁sur g ical _ ▁patients
D-6	-0.5016553401947021	pressure_ ulcers surgical_ patients
P-6	-0.1405 -0.4237 -0.2393 -0.5245 -0.1172 -0.6792 -0.0487 -0.0213 -1.6074 -1.3398 -0.6865 -0.1916
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical echocardiographic invasive hemodynamic outcome
H-1527	-0.3867408335208893	▁clinic al ▁e cho car dio graphic ▁invasi ve _ hem o dynamic
D-1527	-0.3867408335208893	clinical echocardiographic invasive_hemodynamic
P-1527	-1.0664 -0.8774 -0.1174 -0.0231 -0.3739 -1.9422 -0.0998 -0.0054 -0.0262 -0.2176 -0.6510 -0.1543 -0.0008 -0.2131 -0.0326
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf atrial_explants cells explants
H-1341	-0.2650115191936493	▁CHF ▁at rial _ ex plant s ▁c - K it _ cell s ▁sham _ ▁ex plant s
D-1341	-0.2650115191936493	CHF atrial_explants c-Kit_cells sham_ explants
P-1341	-0.0084 -1.1028 -0.0113 -0.3152 -0.9240 -0.0013 -0.0693 -0.0273 -0.2014 -0.8745 -0.1959 -0.2588 -0.1753 -0.1524 -0.0091 -0.5553 -0.5603 -0.0001 -0.0355 -0.0401 -0.0469
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left_bundle-branch_block lbbb
H-886	-0.30635300278663635	▁bund le - bran ch _ ▁block LB BB ▁non - LB BB
D-886	-0.30635300278663635	bundle-branch_ blockLBBB non-LBBB
P-886	-0.0414 -0.0288 -0.0354 -0.0098 -0.0124 -0.4646 -0.6723 -2.2464 -0.3685 -0.4318 -0.0095 -0.0731 -0.1092 -0.0249 -0.0672
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac mena_deletion cardiac_dysfunction hypertrophy
H-1811	-0.3285335302352905	▁cardiac _ Men a ▁dele tion ▁cardiac _ dis function ▁con duction ▁ab normal ities ▁hyper trop hy
D-1811	-0.3285335302352905	cardiac_Mena deletion cardiac_disfunction conduction abnormalities hypertrophy
P-1811	-0.0147 -0.6052 -1.5198 -0.1072 -0.3102 -0.0205 -0.1234 -0.2103 -1.1256 -0.2064 -0.0909 -0.0028 -0.7728 -0.0097 -0.0266 -0.1218 -0.0034 -1.1873 -0.0238 -0.0882
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd congestive_heart_failure chf
H-902	-0.48650288581848145	▁re frac tory ▁end - s tage ▁con ges tive _ heart _ ▁failure
D-902	-0.48650288581848145	refractory end-stage congestive_heart_ failure
P-902	-1.2342 -0.0002 -0.0039 -1.2489 -0.0309 -0.0583 -0.0011 -0.2181 -0.1018 -0.0598 -0.1834 -1.2291 -0.3113 -1.7557 -1.2230 -0.1242
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta_blockers mortality patients heart_failure
H-649	-1.6989322900772095	▁beta _ block ers ▁heart _ ▁failure
D-649	-1.6989322900772095	beta_blockers heart_ failure
P-649	-2.8336 -1.4683 -1.1798 -0.0839 -6.1118 -0.8794 -2.6083 -0.0637 -0.0615
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic patients heart_failure québec canada
H-1233	-1.861399531364441	▁economic _ impact
D-1233	-1.861399531364441	economic_impact
P-1233	-0.2094 -2.9387 -0.0308 -5.8008 -0.3273
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients trastuzumab cardiac comorbidities
H-682	-0.45247429609298706	▁tras tuz um ab ▁cardiac _ com rbi di ties
D-682	-0.45247429609298706	trastuzumab cardiac_comrbidities
P-682	-0.4971 -0.0146 -0.0170 -0.0234 -0.0154 -0.8702 -1.3536 -0.8708 -0.6472 -0.1255 -0.8763 -0.1185
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype perioperative deaths
H-279	-0.7023504972457886	▁per i operativ e
D-279	-0.7023504972457886	perioperative
P-279	-1.5886 -0.4929 -0.0059 -0.4220 -1.5912 -0.1136
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf valve_plasty mva
H-369	-0.5988641381263733	▁ HF ▁val ve ▁plast y ▁MS ▁m VA
D-369	-0.5988641381263733	HF valve plasty MS mVA
P-369	-1.0903 -0.0085 -2.4715 -0.0106 -0.5331 -0.1883 -1.0148 -0.9145 -0.0106 -0.2267 -0.1186
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression_models comorbidities
H-662	-0.7016817927360535	▁demo graphic s ▁insurance _ status ▁como rbi di ties
D-662	-0.7016817927360535	demographics insurance_status comorbidities
P-662	-5.4199 -0.3716 -0.2160 -0.0381 -1.7575 -0.0792 -0.2790 -0.0018 -0.1483 -0.0317 -0.0299 -0.0472
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms patients nyha
H-1893	-1.241947889328003	
D-1893	-1.241947889328003	
P-1893	-2.4069 -0.0770
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline st2 interquartile_range
H-701	-0.761660099029541	▁base line ▁ST 2 ▁level ▁inter quart ile
D-701	-0.761660099029541	baseline ST2 level interquartile
P-701	-0.1152 -0.0024 -2.4951 -0.0293 -2.7354 -1.6287 -0.0007 -0.0444 -0.4695 -0.0959
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin heart_failure breast_cancer
H-927	-0.36797040700912476	▁human ▁resist in ▁che mo therapy - indu ced ▁heart _ ▁failure ▁human ized ▁male _ mi ce ▁breast _ cancer
D-927	-0.36797040700912476	human resistin chemotherapy-induced heart_ failure humanized male_mice breast_cancer
P-927	-1.1105 -1.2368 -0.0458 -0.1829 -0.0560 -0.0694 -0.6575 -0.0033 -0.0066 -0.2977 -0.3050 -0.2387 -0.0499 -0.0825 -0.8695 -1.0013 -0.3954 -0.0133 -0.1584 -1.4447 -0.1077 -0.0419 -0.0886
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome death hospitalization heart_failure
H-849	-1.79947030544281	_ ef fica cy _ ▁outcome s ▁com posit e _ of _ ▁death
D-849	-1.79947030544281	_efficacy_ outcomes composite_of_ death
P-849	-6.6949 -3.2782 -0.1826 -0.3099 -2.4573 -0.7699 -1.1450 -3.0426 -0.0015 -0.0312 -2.2225 -0.8732 -1.0115 -0.8736 -5.5425 -0.3552
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing outcomes hospitalized hf
H-1402	-1.880476474761963	
D-1402	-1.880476474761963	
P-1402	-3.6895 -0.0714
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic diagnostic fluid_overload
H-1071	-0.6129244565963745	▁ therapeut ic _ function s ▁fluid _ over load
D-1071	-0.6129244565963745	therapeutic_functions fluid_overload
P-1071	-1.0045 -0.0067 -0.0290 -0.8585 -0.6689 -0.0347 -2.9751 -0.5232 -1.0400 -0.0058 -0.1298 -0.0789
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome change hospitalized heart_failure
H-1395	-0.9254521131515503	▁Nur sing - sensitiv e ▁outcome _ ▁change _ ▁score s ▁hospital ized ▁older _ adult ▁heart _ ▁failure
D-1395	-0.9254521131515503	Nursing-sensitive outcome_ change_ scores hospitalized older_adult heart_ failure
P-1395	-1.3398 -0.0073 -0.1468 -0.0031 -0.8894 -1.1507 -1.0455 -2.7828 -1.0730 -2.1435 -0.0084 -0.2236 -0.0975 -2.9721 -0.6151 -1.7278 -0.8889 -0.1908 -1.8181 -0.2097 -0.1006
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients chronic_organ_failure
H-793	-1.0887726545333862	▁test - re test _ re test _ re test _ ▁reli ability ▁Time d ▁up _ go ▁test ▁patients ▁advanced _ organ _ ▁failure
D-793	-1.0887726545333862	test-retest_retest_retest_ reliability Timed up_go test patients advanced_organ_ failure
P-793	-2.7674 -0.6357 -0.0176 -0.0081 -2.0746 -0.6312 -0.0212 -1.5849 -1.4679 -0.0455 -1.8030 -3.0065 -0.0008 -0.8327 -0.0249 -0.8220 -0.8956 -1.5294 -1.1242 -3.3615 -0.8507 -0.4695 -2.3007 -1.0426 -1.7073 -0.0947 -0.2767
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up outcomes mortality
H-1637	-0.6517941951751709	▁black _ race ▁mortal ity
D-1637	-0.6517941951751709	black_race mortality
P-1637	-0.0537 -0.7602 -0.9754 -2.5579 -0.0037 -0.0652 -0.1465
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter invasive surgery
H-553	-0.6677833199501038	▁trans cat heter
D-553	-0.6677833199501038	transcatheter
P-553	-0.0133 -0.0552 -0.0373 -3.1206 -0.1126
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation heart_iron
H-748	-1.0051124095916748	▁che lation _ ▁regime ns ▁heart ▁ir on
D-748	-1.0051124095916748	chelation_ regimens heart iron
P-748	-0.5724 -0.0096 -1.6641 -0.1852 -0.4046 -3.3394 -1.0258 -0.1454 -2.4643 -0.2404
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise clinical outcomes
H-1926	-0.35834184288978577	▁social _ support ▁barrier s ▁exercise ▁ad her ence ▁clinic al ▁outcome s
D-1926	-0.35834184288978577	social_support barriers exercise adherence clinical outcomes
P-1926	-0.1317 -1.1494 -0.7759 -0.9546 -0.0181 -0.0753 -0.7081 -0.0924 -0.0147 -0.0244 -0.0441 -1.2380 -0.0240 -0.0303 -0.0941
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine dilated_cardiomyopathy patients heart_failure
H-1257	-0.6816498041152954	▁Chinese _ ▁herbal _ medicin e ▁dil ated _ ▁cardio my o pathy ▁heart _ ▁failure
D-1257	-0.6816498041152954	Chinese_ herbal_medicine dilated_ cardiomyopathy heart_ failure
P-1257	-0.8133 -0.7654 -2.2403 -0.4733 -0.6864 -1.7049 -0.3476 -0.0959 -0.0443 -0.5129 -2.1631 -0.2656 -0.0755 -0.1956 -0.4828 -1.2288 -0.0417 -0.1324
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient implantable_cardioverter-defibrillator
H-1856	-0.3903011679649353	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1856	-0.3903011679649353	implantable cardioverter-defibrillator_deactivation
P-1856	-0.9577 -0.0073 -0.8246 -0.0406 -0.4821 -0.2789 -0.0060 -0.1644 -1.5385 -0.2971 -0.0560 -0.2301 -0.1183 -0.1583 -0.0615 -1.3296 -0.0845
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein genes western_blot dna_fragmentation tunel
H-167	-0.46919187903404236	▁protein _ ▁levels ▁Western ▁blot ▁DNA _ ▁fragment ation ▁TU NEL ▁auto psy
D-167	-0.46919187903404236	protein_ levels Western blot DNA_ fragmentation TUNEL autopsy
P-167	-0.5966 -1.7747 -1.1625 -0.5419 -0.1711 -0.3864 -1.2029 -0.0558 -0.0170 -0.4067 -0.1567 -0.2535 -0.0433 -0.1552 -0.1135
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart_failure leading mortality western society cardiovascular_diseases
H-1480	-1.2979909181594849	▁Heart _ of _ ▁mortal ity ▁western _ ▁society ▁cardiovascular _ ▁заболевания s
D-1480	-1.2979909181594849	Heart_of_ mortality western_ society cardiovascular_ заболеванияs
P-1480	-1.3364 -0.3449 -6.1189 -0.0101 -3.2224 -0.0029 -2.8733 -0.5427 -0.6054 -0.5166 -0.2618 -2.3618 -1.1139 -0.0550 -0.1037
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef sodium ventricular vascular_stiffness
H-917	-0.4918629229068756	▁H FP EF ▁dieta ry ▁so dium ▁restriction ▁vent ri cular ▁vas cular _ ▁sti ff ness
D-917	-0.4918629229068756	HFPEF dietary sodium restriction ventricular vascular_ stiffness
P-917	-0.6855 -0.0151 -0.4943 -2.1796 -0.0125 -0.3642 -0.1423 -1.8807 -0.0525 -0.3531 -0.0508 -0.2370 -0.1063 -1.1149 -0.3850 -0.3037 -0.1365 -0.6522 -0.1792
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated cardiac_filling_pressures adverse_outcomes
H-1532	-0.6317341923713684	▁EH ▁cardiac _ ▁fill ing _ ▁pressure s
D-1532	-0.6317341923713684	EH cardiac_ filling_ pressures
P-1532	-0.6866 -2.3500 -0.4789 -0.9981 -0.0566 -0.2843 -0.5084 -0.2193 -0.6472 -0.0879
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical_delay dyssynchronous_heart_failure
H-1146	-0.4538750946521759	▁electro me chan ical _ de lay ▁dys syn chron ous _ heart _ ▁failure ▁computa tional
D-1146	-0.4538750946521759	electromechanical_delay dyssynchronous_heart_ failure computational
P-1146	-3.4249 -0.0023 -0.0002 -0.0314 -0.4363 -0.3091 -0.0015 -0.0155 -0.0016 -0.0003 -0.1518 -0.2167 -0.5463 -0.3271 -1.2711 -0.2777 -0.0019 -1.4666 -0.1413
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis pacing-induced_dilated_cardiomyopathy
H-165	-0.4834059774875641	▁apo pto sis ▁pa cing - indu ced _ ▁dil ated _ ▁cardio my o pathy
D-165	-0.4834059774875641	apoptosis pacing-induced_ dilated_ cardiomyopathy
P-165	-0.3907 -0.0854 -0.5285 -0.0376 -0.0726 -0.1281 -0.0027 -0.0379 -0.1963 -3.2403 -0.6171 -0.0459 -1.1955 -1.7016 -0.2344 -0.0725 -0.0257 -0.0885
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic_heart_failure chf sympathetic_tone autonomic_imbalance
H-1370	-0.5209179520606995	▁chronic _ heart _ ▁failure _ CH F ▁sympa the tic _ ▁tone ▁autonomi c _ ▁im balance
D-1370	-0.5209179520606995	chronic_heart_ failure_CHF sympathetic_ tone autonomic_ imbalance
P-1370	-0.1279 -0.3980 -1.4972 -0.1917 -1.2489 -3.3161 -0.3614 -0.3196 -0.0775 -0.0179 -0.1397 -0.2579 -0.2011 -0.0009 -0.3614 -1.2078 -0.4867 -0.0008 -0.1028 -0.1032
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right_atrium prolapse tricuspid_valve stenotic_physiology
H-596	-0.32687053084373474	▁right _ at rium _ ▁mass ▁pro lapse ▁tri cus pid _ ▁val ve ▁ste no tic _ ▁physio log y
D-596	-0.32687053084373474	right_atrium_ mass prolapse tricuspid_ valve stenotic_ physiology
P-596	-1.4517 -1.1640 -0.2133 -0.0019 -0.6654 -0.7922 -0.0026 -0.0198 -0.1151 -0.4500 -0.0069 -0.1795 -0.9065 -0.0751 -0.0008 -0.0792 -0.0720 -0.2296 -0.3460 -0.0400 -0.5729 -0.0492 -0.0843
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary_outcome functional_capacity 6-minute_walk_test 6mwt
H-571	-1.1548380851745605	▁functional _ capaci ty
D-571	-1.1548380851745605	functional_capacity
P-571	-2.6905 -0.6282 -0.4140 -0.6924 -2.4338 -0.0702
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan_failure systolic_ventricular_function liver_disease
H-224	-0.8443741202354431	▁Font an _ ▁failure ▁sy sto lic _ ▁vent ri cular _ function ▁ liver _ مرض
D-224	-0.8443741202354431	Fontan_ failure systolic_ ventricular_function liver_مرض
P-224	-0.2353 -0.9140 -1.1746 -3.9629 -0.9340 -0.0888 -0.5837 -0.1663 -0.7523 -0.1997 -0.0167 -1.6879 -0.3745 -0.4250 -0.0441 -1.7944 -2.5137 -0.0508 -0.1243
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western_blots monoclonal_antibodies ser83 phosphorylation hf
H-1431	-0.36068329215049744	▁Western ▁blot s ▁mono clo nal _ anti bo dies ▁Ser 83 ▁ phos phor y lation ▁ HF
D-1431	-0.36068329215049744	Western blots monoclonal_antibodies Ser83 phosphorylation HF
P-1431	-0.6248 -0.4963 -0.0895 -0.1452 -0.0030 -0.3440 -0.5147 -0.5685 -0.1706 -0.2621 -0.3186 -0.3829 -0.1781 -0.0048 -1.2146 -1.8353 -0.0251 -0.2500 -0.0001 -0.0400 -0.1063
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac_catheterization thrombotic_obstruction right_coronary_artery
H-1292	-0.2689187228679657	▁cardiac _ ▁cat heter ization ▁ thro mbo tic _ ▁ob struct ion ▁right ▁corona ry ▁arter y
D-1292	-0.2689187228679657	cardiac_ catheterization thrombotic_ obstruction right coronary artery
P-1292	-0.0490 -0.5397 -0.6272 -0.0023 -0.2954 -0.1682 -0.0030 -0.1261 -0.8465 -0.2793 -0.8489 -0.0029 -0.0107 -0.0481 -0.6408 -0.0698 -0.4654 -0.2080 -0.0597 -0.0874
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative serum_albumin patients left_ventricular_assist_device implantation
H-528	-0.9105907678604126	▁pre operativ e ▁se rum ▁album in _ level s ▁left ▁vent ri cular _ assist ance
D-528	-0.9105907678604126	preoperative serum albumin_levels left ventricular_assistance
P-528	-0.0385 -0.0120 -0.2114 -0.1240 -0.0007 -0.8069 -0.0690 -2.9095 -1.4937 -1.1653 -1.8302 -2.7685 -0.6248 -0.0229 -0.2667 -0.0476 -3.8854 -0.8795 -0.1446
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully_magnetically_levitated_left_ventricular_assist_system hf
H-1992	-0.4623032808303833	▁magnet ically _ ▁Lev itate d ▁Le ft _ ▁Vent ri cular _ assist _ system ▁Tre ating ▁Advanced ▁ HF
D-1992	-0.4623032808303833	magnetically_ Levitated Left_ Ventricular_assist_system Treating Advanced HF
P-1992	-1.7930 -0.0865 -1.0094 -0.4903 -0.1731 -0.0308 -0.6473 -0.0005 -0.0710 -1.6929 -0.3688 -0.0208 -0.0966 -0.0858 -1.8807 -0.0812 -0.5684 -0.0004 -0.3005 -0.9418 -0.0017 -0.2097 -0.0817
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.656024158000946	▁cost - effect ive
D-614	-0.656024158000946	cost-effective
P-614	-0.2717 -0.0476 -0.0045 -0.0175 -3.4844 -0.1104
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients randomization
H-851	-0.7505167126655579	▁study ▁ closure
D-851	-0.7505167126655579	study closure
P-851	-0.3195 -1.7603 -0.0027 -1.5348 -0.1352
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac nurses
H-1662	-0.709552526473999	▁cardiac _ ▁nurse s
D-1662	-0.709552526473999	cardiac_ nurses
P-1662	-0.2262 -0.5049 -1.1796 -0.0157 -2.2881 -0.0428
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations patients patients
H-1282	-0.4078657031059265	▁consultation s ▁procedure s
D-1282	-0.4078657031059265	consultations procedures
P-1282	-0.5203 -0.0796 -0.7929 -0.0325 -0.9701 -0.0519
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion mortality
H-50	-0.5525675415992737	▁trans fusion _ ▁thre s hold s ▁mortal ity
D-50	-0.5525675415992737	transfusion_ thresholds mortality
P-50	-0.0837 -0.7847 -0.6047 -1.6524 -0.3101 -0.8258 -0.0820 -0.2220 -0.0092 -1.4077 -0.0960
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart_failure
H-1539	-0.9040805101394653	▁risk _ of _ heart _ ▁failure ▁expose d ▁group ▁control
D-1539	-0.9040805101394653	risk_of_heart_ failure exposed group control
P-1539	-1.9558 -1.2416 -0.4170 -0.0858 -0.6757 -0.3192 -2.1749 -1.4828 -0.0062 -1.5203 -0.0349 -1.7023 -0.1365
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c_statistics
H-383	-0.8129029870033264	▁concorda nce _ ▁c ▁statistic s ▁UM / VA / VA - RT
D-383	-0.8129029870033264	concordance_ c statistics UM/VA/VA-RT
P-383	-1.9782 -0.0899 -0.8788 -0.8885 -1.3666 -0.0385 -0.0115 -0.2989 -0.0293 -2.6520 -0.7306 -0.3616 -0.8684 -1.5409 -0.4597
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological cardiovascular bound
H-1875	-0.6745354533195496	▁neurologi cal ▁cardiovascular _ event - free _ rate
D-1875	-0.6745354533195496	neurological cardiovascular_event-free_rate
P-1875	-0.8454 -0.0862 -2.3883 -0.4093 -1.0680 -0.2385 -0.0122 -0.5434 -1.2589 -0.5167 -0.0531
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets tac hf
H-1050	-0.513845682144165	▁ BET s ▁mouse ▁ TAC ▁human ▁ HF
D-1050	-0.513845682144165	BETs mouse TAC human HF
P-1050	-1.1255 -0.8073 -0.4370 -0.0702 -0.2740 -0.0035 -2.0347 -0.6675 -0.0026 -0.0181 -0.2121
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech_republic
H-1972	-0.8838757276535034	▁Czech _ ▁Republic
D-1972	-0.8838757276535034	Czech_ Republic
P-1972	-1.0179 -0.9628 -0.5775 -1.6316 -0.2295
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical nitrite vascular
H-414	-0.5427824854850769	▁chemical ▁in st ability ▁co genera tion ▁nit rite ▁vas cular
D-414	-0.5427824854850769	chemical instability cogeneration nitrite vascular
P-414	-2.6078 -0.2540 -0.0025 -0.0049 -1.2642 -0.0047 -0.0142 -0.2129 -0.9169 -0.0416 -0.0188 -1.6393 -0.0745
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients madit-crt
H-858	-1.3056672811508179	▁MAD - C RT ▁device
D-858	-1.3056672811508179	MAD-CRT device
P-858	-0.8788 -3.6424 -1.3043 -0.3748 -2.8124 -0.0920 -0.0349
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up patients hf
H-1106	-0.653380811214447	▁ HF
D-1106	-0.653380811214447	HF
P-1106	-1.7036 -0.1716 -0.6647 -0.0736
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized dopamine nesiritide
H-76	-1.0763481855392456	▁dop amine ▁nesi riti de
D-76	-1.0763481855392456	dopamine nesiritide
P-76	-3.6287 -0.8051 -0.5400 -0.0044 -0.9994 -1.5146 -0.0423
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal_membrane_oxygenation refractory_right_heart_failure
H-1290	-0.46940547227859497	▁Extra corp o real _ ▁membran e _ ▁oxygen ation ▁in far ction - related ▁re frac tory ▁right _ heart _ ▁failure
D-1290	-0.46940547227859497	Extracorporeal_ membrane_ oxygenation infarction-related refractory right_heart_ failure
P-1290	-0.9134 -0.0027 -0.0971 -0.1386 -0.3794 -0.1173 -0.0150 -0.7033 -0.7336 -0.0178 -0.4508 -0.0220 -0.0173 -1.6100 -0.0620 -0.1324 -0.0002 -0.0219 -1.3926 -0.1147 -1.3790 -0.8112 -2.3339 -0.0826 -0.1864
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california_office_of_statewide_health_planning_and_development_patient_discharge_data_nonpublic_file
H-136	-0.6427395343780518	▁office _ of _ state wide _ health _ plan ning _ and _ develop ment ▁Patient _ dis charge
D-136	-0.6427395343780518	office_of_statewide_health_planning_and_development Patient_discharge
P-136	-2.7196 -1.5307 -0.2147 -0.1079 -0.1692 -0.0828 -0.0449 -1.3395 -0.1809 -0.0078 -0.0055 -1.0528 -2.1632 -0.3470 -0.6865 -0.2998 -1.2260 -0.6035 -0.0107 -0.0369 -1.2594 -0.0510
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional_ms lv_dilatation functional_ms
H-368	-0.9809099435806274	▁LV ▁di la tation ▁functional ▁MS
D-368	-0.9809099435806274	LV dilatation functional MS
P-368	-4.1251 -0.7155 -0.0753 -0.0005 -1.8648 -0.6629 -0.2202 -0.1830
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol linear_mixed_models intention-to-treat
H-838	-1.438021183013916	▁treatment ▁HR Qo L
D-838	-1.438021183013916	treatment HRQoL
P-838	-1.6764 -4.8186 -0.0260 -0.2450 -1.7864 -0.0758
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic_effect beta_blockers heart_failure
H-648	-0.9896557331085205	▁in o tropi c _ effect ▁beta _ block ers ▁treatment ▁heart _ ▁failure
D-648	-0.9896557331085205	inotropic_effect beta_blockers treatment heart_ failure
P-648	-3.1530 -0.5281 -0.1480 -1.4765 -2.5588 -0.5307 -0.4482 -0.8731 -0.6447 -0.0324 -2.3329 -1.1351 -0.4986 -1.3461 -0.0628 -0.0653
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients clinical echocardiography baseline shunt implantation
H-1954	-0.5283313393592834	▁e cho card i ography ▁shu nt _ ▁implant ation
D-1954	-0.5283313393592834	echocardiography shunt_ implantation
P-1954	-0.9069 -0.0646 -2.2300 -0.7819 -0.2373 -0.1599 -0.3723 -1.3285 -0.1030 -0.0493 -0.0367 -0.0696
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy_metabolism heart_failure hypertrophied heart
H-1779	-0.6287118196487427	▁energy ▁metabolism ▁hyper trop hi ed _ heart
D-1779	-0.6287118196487427	energy metabolism hypertrophied_heart
P-1779	-0.0248 -1.0958 -3.3610 -0.0555 -0.1121 -0.0532 -0.8957 -0.4457 -0.0571 -0.1862
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality_of_life seattle_heart_failure_model
H-2012	-0.7363751530647278	▁resource _ ▁use ▁quality _ of _ life ▁time - var ying ▁Seattle ▁Heart _ fail ure
D-2012	-0.7363751530647278	resource_ use quality_of_life time-varying Seattle Heart_failure
P-2012	-0.1128 -2.2213 -1.9213 -4.4380 -0.7433 -0.0116 -0.1442 -0.8022 -0.3204 -0.0294 -0.0242 -0.1808 -0.0586 -1.3858 -0.0594 -0.2996 -0.0951 -1.0144 -0.1286
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation therapy heart_disease rate_control
H-1652	-0.6169268488883972	▁antico ag ulation ▁under ly ing _ heart _ ▁disease ▁rate
D-1652	-0.6169268488883972	anticoagulation underlying_heart_ disease rate
P-1652	-0.4389 -0.2830 -0.0163 -0.7258 -0.0837 -0.0390 -0.8804 -0.4237 -0.5307 -3.8646 -0.0009 -0.6735 -0.0596
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients physicians hospitals new_jersey new_york
H-212	-1.0732421875	▁ED ▁physician s ▁subur ban _ hospital s ▁New ▁Jersey
D-212	-1.0732421875	ED physicians suburban_hospitals New Jersey
P-212	-3.5298 -4.4455 -0.1134 -1.4275 -0.0230 -1.3825 -0.0693 -0.0373 -0.2118 -0.2626 -1.2851 -0.0911
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology hf diagnosis medical nursing
H-2021	-0.488325297832489	▁pat ho phy si ology ▁ HF ▁medical ▁management ▁nur sing
D-2021	-0.488325297832489	pathophysiology HF medical management nursing
P-2021	-0.4810 -0.2234 -0.1631 -1.6881 -0.0031 -0.2346 -0.0041 -0.1155 -1.8643 -0.5880 -0.0014 -0.9359 -0.0459
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change paco2 cerebral blood_flow perfusion carotid
H-1350	-0.6220808625221252	▁Paco 2 ▁cerebral _ ▁blood ▁flow ▁caro tid _ ▁bo dies
D-1350	-0.6220808625221252	Paco2 cerebral_ blood flow carotid_ bodies
P-1350	-3.1069 -0.0649 -0.0305 -0.6157 -2.1089 -0.2554 -0.8403 -0.0434 -0.4052 -0.5213 -0.0158 -0.0159 -0.0628
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline mechanical_cardiac_support renal_function
H-1388	-0.6482651233673096	▁base line ▁mechanic al _ ▁cardiac _ support ▁renal _ function
D-1388	-0.6482651233673096	baseline mechanical_ cardiac_support renal_function
P-1388	-0.0876 -0.0058 -0.0824 -0.0046 -0.2779 -4.1697 -0.5289 -0.7497 -0.0076 -1.0822 -1.2261 -0.0841 -0.1208
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart_failure protein_kinase_a expression
H-1423	-0.5730255246162415	▁human _ heart _ ▁failure ▁alter ed ▁protein _ ▁kina se ▁sub un it ▁expression ▁post - trans la tional _ state
D-1423	-0.5730255246162415	human_heart_ failure altered protein_ kinase subunit expression post-translational_state
P-1423	-1.5107 -0.6820 -2.6086 -0.8753 -0.8422 -1.1013 -0.0028 -0.3819 -1.0174 -0.0205 -0.0616 -0.8579 -0.0258 -0.2003 -2.0472 -0.0060 -0.0173 -0.0004 -0.1064 -0.0009 -0.8901 -0.0614 -0.1335 -0.3014
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ecmo patients vad ecmo vad
H-1390	-1.0316388607025146	▁EC mo _ group ▁ VAD ▁EC mo + VAD
D-1390	-1.0316388607025146	ECmo_group VAD ECmo+VAD
P-1390	-1.1635 -0.3327 -1.8269 -0.9568 -0.4834 -0.1355 -1.5236 -1.1601 -3.1788 -0.3666 -0.8144 -0.4374
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox_regression cardiovascular_events psoriasis
H-1558	-0.46955421566963196	▁co x ▁re gression ▁cardiovascular _ ▁events ▁psoriasis
D-1558	-0.46955421566963196	cox regression cardiovascular_ events psoriasis
P-1558	-0.3175 -0.0220 -1.0406 -0.0100 -1.4861 -0.2979 -0.7597 -0.1275 -0.4362 -0.1981
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients pad ankle-brachial_index
H-1568	-0.5194470882415771	▁ PAD ▁an kle - bra chi al ▁index
D-1568	-0.5194470882415771	PAD ankle-brachial index
P-1568	-1.7544 -0.1891 -0.1682 -0.0234 -0.1621 -0.2788 -1.6097 -0.0776 -1.0030 -0.2176 -0.2301
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause_hospitalisations sts
H-160	-0.7831221222877502	▁hospital isation s ▁s TS
D-160	-0.7831221222877502	hospitalisations sTS
P-160	-4.0581 -0.0083 -0.0755 -0.3882 -0.3218 -0.5557 -0.0742
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr_reduction ivabradine tac ea
H-525	-0.9055324196815491	▁I sol ated ▁HR ▁re duction ▁i va bra dine ▁ TAC
D-525	-0.9055324196815491	Isolated HR reduction ivabradine TAC
P-525	-5.6074 -1.5000 -0.0324 -0.2221 -2.3031 -0.0015 -0.1800 -0.8771 -0.1368 -0.0135 -0.6932 -0.0007 -0.8945 -0.2152
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective_studies cpg hf
H-1845	-1.3489139080047607	▁implementation _ con vention s ▁class _ I ▁C PG ▁recommendations ▁ HF
D-1845	-1.3489139080047607	implementation_conventions class_I CPG recommendations HF
P-1845	-6.0647 -1.3061 -3.6980 -0.3233 -0.4761 -0.4564 -0.3753 -3.1994 -2.7774 -0.0328 -1.2159 -0.1791 -0.0019 -0.0338 -0.0933
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality morbidity health-care budget
H-1075	-0.5975942611694336	▁mortal ity ▁cancer s ▁health - care ▁budget
D-1075	-0.5975942611694336	mortality cancers health-care budget
P-1075	-1.1438 -0.0482 -2.5671 -1.4368 -0.1642 -0.1225 -0.0956 -0.0901 -0.0512 -0.2565
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp circulation hf patients
H-1513	-0.8618806600570679	▁NT - pro b NP ▁circulation ▁ HF
D-1513	-0.8618806600570679	NT-probNP circulation HF
P-1513	-2.1300 -0.0998 -0.0046 -3.4706 -0.5007 -0.1413 -0.5826 -0.0032 -1.2364 -0.4496
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients systolic_function therapeutic
H-1070	-0.6558611392974854	▁patients ▁pres er ved ▁sy sto lic _ function ▁ therapeut ic
D-1070	-0.6558611392974854	patients preserved systolic_function therapeutic
P-1070	-2.5726 -0.3211 -0.0847 -0.0564 -0.7727 -0.6013 -0.4737 -0.4251 -0.5445 -1.5331 -0.0422 -0.0480 -1.5729 -0.1337
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation flow-mediated_dilatation
H-259	-0.42328235507011414	▁HD L - indu ced ▁NO ▁production ▁flow - media ted _ di la tation
D-259	-0.42328235507011414	HDL-induced NO production flow-mediated_dilatation
P-259	-0.8599 -1.2079 -0.1088 -0.0003 -0.0111 -1.7482 -0.1339 -0.0002 -0.0344 -0.0137 -0.4019 -0.3240 -0.9374 -0.0561 -0.0033 -1.2394 -0.1155
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp sensitivity
H-271	-0.46031591296195984	▁cut off _ level ▁NT - pro b NP
D-271	-0.46031591296195984	cutoff_level NT-probNP
P-271	-0.4002 -0.0841 -0.8589 -0.1241 -0.5283 -0.0143 -0.0016 -0.9396 -0.0804 -1.7576 -0.2743
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ahf risk_stratification
H-58	-1.004287600517273	▁patients ▁a HF
D-58	-1.004287600517273	patients aHF
P-58	-1.6731 -1.1614 -0.0434 -1.9586 -0.1850
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients patients
H-267	-0.9568052291870117	
D-267	-0.9568052291870117	
P-267	-1.8386 -0.0750
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.8819541931152344	▁ HF ▁co hor t
D-1002	-0.8819541931152344	HF cohort
P-1002	-2.5082 -0.3229 -3.1169 -0.0046 -0.1456 -0.0225 -0.0530
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd patients
H-65	-1.2646312713623047	▁studies ▁i CD
D-65	-1.2646312713623047	studies iCD
P-65	-2.1434 -1.0616 -0.9009 -2.0605 -0.1567
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions hospital
H-144	-0.5234907865524292	▁computing _ ▁read missions ▁hospital _ ▁ranking ▁pay - for - per form ance
D-144	-0.5234907865524292	computing_ readmissions hospital_ ranking pay-for-performance
P-144	-1.1090 -0.4605 -3.2538 -0.0095 -1.2959 -1.2717 -0.1306 -0.4056 -0.0210 -0.0737 -0.0894 -0.0038 -0.0092 -0.0008 -0.1093 -0.1321
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic clinicians patients
H-1124	-0.9411012530326843	▁non tre at ment
D-1124	-0.9411012530326843	nontreatment
P-1124	-3.2261 -0.0633 -0.0244 -0.0138 -2.2342 -0.0848
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations cox_models st2 functional_capacity outcomes
H-700	-1.0621975660324097	▁co x _ model s
D-700	-1.0621975660324097	cox_models
P-700	-0.2683 -0.0219 -1.5379 -1.3616 -0.3776 -3.7226 -0.1454
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise_intolerance heart_failure exercise diagnosis prognosis therapeutic
H-1272	-0.8345150947570801	▁exercise ▁in tolerance _ in tolerance ▁heart _ ▁failure
D-1272	-0.8345150947570801	exercise intolerance_intolerance heart_ failure
P-1272	-0.1958 -0.9710 -0.0015 -1.6886 -1.0824 -0.0845 -2.8212 -0.2926 -0.6415 -1.2187 -0.1819
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis patients diastolic_blood_pressure body_mass_index
H-1560	-1.0122835636138916	▁p sori asis
D-1560	-1.0122835636138916	psoriasis
P-1560	-0.8458 -0.0321 -0.5688 -3.4357 -0.1789
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp nt-probnp diagnostic prognostic biomarkers patients heart_failure
H-1365	-0.9119693040847778	▁b NP ▁NT - pro b NP
D-1365	-0.9119693040847778	bNP NT-probNP
P-1365	-1.2396 -0.3808 -1.3675 -0.0283 -0.0011 -0.9149 -0.0535 -3.9410 -0.2810
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional_ms ring_annuloplasty ischemic_mr lv_dilatation
H-366	-0.2622513771057129	▁functional ▁MS ▁ring _ ▁ann ulo plast y ▁ ische mic ▁MR ▁LV ▁di la tation
D-366	-0.2622513771057129	functional MS ring_ annuloplasty ischemic MR LV dilatation
P-366	-0.6716 -0.7285 -0.0796 -0.8777 -0.4306 -0.2747 -0.0454 -0.0282 -0.2092 -0.0690 -0.0256 -0.8899 -0.0194 -0.2497 -0.0153 -0.0004 -0.0542 -0.0517
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin_receptor_antagonist tolvaptan heart_failure patients
H-1194	-0.4170491099357605	▁vaso press in _ ▁receptor _ ▁anta gon ist ▁to lv ap tan
D-1194	-0.4170491099357605	vasopressin_ receptor_ antagonist tolvaptan
P-1194	-0.0110 -0.0453 -0.3665 -0.7738 -0.0239 -0.8048 -0.1547 -0.0560 -0.2538 -0.0050 -0.0144 -0.0534 -0.0282 -3.5587 -0.1061
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse_correlation pro-adrenomedullin mr-proadm ffm
H-15	-0.5853961110115051	▁pro - ad re nom edu llin MR - pro AD M ▁F FM
D-15	-0.5853961110115051	pro-adrenomedullinMR-proADM FFM
P-15	-0.0581 -0.0169 -0.0023 -0.3346 -1.0215 -4.8774 -0.1795 -0.9876 -0.0068 -0.0034 -0.4771 -0.7925 -0.4423 -0.0920 -0.0424 -0.0320
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin_receptor st2 beta-blocker therapy chronic_heart_failure
H-398	-0.8224547505378723	▁inter le u kin _ ▁receptor _ ▁family ▁member ▁ST 2 ▁beta - block er _ therapy
D-398	-0.8224547505378723	interleukin_ receptor_ family member ST2 beta-blocker_therapy
P-398	-0.0182 -0.6169 -0.1810 -2.5319 -0.8875 -0.1220 -1.1419 -1.2306 -3.5524 -0.1745 -0.0116 -0.0232 -0.0192 -0.1636 -0.1348 -0.8715 -0.3781 -3.3796 -0.1881
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new_york_heart_association_classification 6-min_walk_test quality-of-life
H-2005	-1.7142407894134521	▁New ▁York _ heart _ association
D-2005	-1.7142407894134521	New York_heart_association
P-2005	-4.0512 -2.3872 -0.2153 -2.1470 -0.2769 -1.0708 -3.3112 -0.2543
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular_assist_device extracorporeal_membrane_oxygenation renal_function heart_failure
H-1383	-0.5503093004226685	▁vent ri cular _ assist ▁device ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁pediatr ic _ heart _ ▁failure
D-1383	-0.5503093004226685	ventricular_assist device extracorporeal_ membrane_ oxygenation pediatric_heart_ failure
P-1383	-0.0077 -0.1768 -0.0347 -0.5252 -0.0133 -1.4253 -0.1493 -0.0071 -0.1127 -0.0727 -0.1549 -0.3948 -0.0222 -1.0289 -0.7585 -0.0714 -0.0955 -0.0049 -0.5776 -1.0801 -1.1105 -5.1360 -0.0818 -0.1654
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory_fitness body_mass_index heart_failure mortality cooper_center_longitudinal_study
H-1765	-0.8565375804901123	▁Card i ore spira tory _ ▁fitness ▁body ▁mass _ ▁index ▁heart _ ▁failure _ ▁mortal ity ▁Cooper _ center
D-1765	-0.8565375804901123	Cardiorespiratory_ fitness body mass_ index heart_ failure_ mortality Cooper_center
P-1765	-1.1400 -1.1785 -1.7480 -0.0384 -0.0046 -0.3036 -1.4683 -0.0424 -1.0371 -0.4387 -1.5337 -0.1713 -0.1187 -2.5920 -0.4663 -3.6803 -0.0065 -0.5063 -0.8160 -0.8737 -0.6094 -0.0698
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug_test patients copd chf crf
H-806	-0.9500682950019836	▁TU G _ test ▁advanced _ ▁COP D ▁CHF ▁c RF
D-806	-0.9500682950019836	TUG_test advanced_ COPD CHF cRF
P-806	-0.5244 -2.4584 -1.2978 -0.1900 -2.7294 -0.4981 -1.0111 -1.9370 -0.0770 -1.2278 -0.0118 -0.3449 -0.0432
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical activity cardiovascular obesity diabetes_mellitus hypertension hyperlipidaemia
H-1898	-0.48219212889671326	▁physical _ activ ity ▁cardiovascular _ risk _ factor ▁diabetes ▁mell itus ▁hyper tension ▁hyper li pida emia
D-1898	-0.48219212889671326	physical_activity cardiovascular_risk_factor diabetes mellitus hypertension hyperlipidaemia
P-1898	-0.1287 -1.0455 -1.0338 -0.3479 -2.0793 -0.4127 -0.5260 -1.3973 -0.0773 -1.3491 -0.1646 -0.0292 -0.1006 -0.1066 -0.4609 -0.0673 -0.1981 -0.0026 -0.0591 -0.0573
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol cxl-1020 myocytes hearts
H-419	-0.8476120829582214	▁iso prot eren ol ▁c XL -10 20 ▁my o cy tes ▁fail ing ▁heart s
D-419	-0.8476120829582214	isoproterenol cXL-1020 myocytes failing hearts
P-419	-0.0099 -0.2897 -4.7846 -1.0942 -3.1417 -0.0181 -0.4472 -0.0379 -0.8169 -0.0729 -0.3649 -0.0910 -1.8493 -0.0382 -1.8244 -0.2104 -0.0461 -0.1196
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients hf spontaneous_vt qt_intervals
H-1445	-0.30085644125938416	▁ HF ▁spontane ous ▁ VT ▁beat - to - beat ▁ QT
D-1445	-0.30085644125938416	HF spontaneous VT beat-to-beat QT
P-1445	-0.4642 -0.0335 -1.7199 -0.0062 -0.2880 -0.0082 -0.0372 -0.0669 -0.0608 -0.0884 -0.0284 -0.4130 -0.0231 -0.8142 -0.4607
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients heart_failure systolic_heart_failure
H-725	-1.061649203300476	▁heart _ ▁failure ▁sy sto lic _ heart ▁failure
D-725	-1.061649203300476	heart_ failure systolic_heart failure
P-725	-5.2244 -0.8619 -0.9724 -0.2134 -0.0643 -0.3257 -0.1683 -0.8141 -2.8978 -0.0470 -0.0889
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular_dysfunction outcome patients heartmate_ii
H-305	-0.7690494656562805	▁bi ven tri cular _ ▁dys function ▁isola ted ▁Heart Mate ▁II
D-305	-0.7690494656562805	biventricular_ dysfunction isolated HeartMate II
P-305	-0.0303 -0.3736 -1.7320 -1.7996 -0.9761 -1.5483 -0.5133 -0.3926 -0.0115 -1.5875 -0.1168 -1.4100 -0.0985 -0.1766
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf symptom cardiac_murmurs blood_pressure
H-356	-0.5345249772071838	▁ HF ▁cardiac _ ▁mur mur s ▁re duction ▁blood _ ▁pressure
D-356	-0.5345249772071838	HF cardiac_ murmurs reduction blood_ pressure
P-356	-1.2634 -0.0176 -1.1290 -0.2620 -0.4722 -0.0053 -0.2452 -0.6691 -0.0003 -1.2608 -0.3636 -0.6447 -0.7857 -0.3643
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional_ms medical_treatment surgical
H-376	-0.5733593106269836	▁Fun ction al ▁MS ▁medical ▁treatment ▁sur g ical
D-376	-0.5733593106269836	Functional MS medical treatment surgical
P-376	-0.3020 -0.0017 -0.0184 -1.0741 -0.4038 -3.4196 -0.5095 -0.0359 -0.0027 -0.4904 -0.0488
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular_assist_devices therapies
H-203	-0.4111819565296173	▁management ▁vent ri cular _ assist ▁devices ▁device ▁ therapie s
D-203	-0.4111819565296173	management ventricular_assist devices device therapies
P-203	-2.9887 -0.1773 -0.2149 -0.1393 -0.1456 -0.0120 -0.9546 -0.1219 -0.4788 -0.0094 -0.0424 -0.0162 -0.0441
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal_dysfunction mechanical_cardiac_support
H-1394	-1.017787218093872	▁renal _ dis function ▁mechanic al _ ▁cardiac
D-1394	-1.017787218093872	renal_disfunction mechanical_ cardiac
P-1394	-0.2700 -0.8619 -1.0243 -0.3934 -0.0493 -0.0080 -0.2150 -5.5693 -1.7508 -0.0359
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted patients adverse_events follow-up
H-1956	-1.040579915046692	▁device
D-1956	-1.040579915046692	device
P-1956	-0.3273 -2.6944 -0.1001
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients left_ventricular_dilatation dysfunction
H-1746	-1.3576961755752563	▁en roll ment ▁left _ ▁vent ri cular _ di la tation ▁dys function
D-1746	-1.3576961755752563	enrollment left_ ventricular_dilatation dysfunction
P-1746	-4.4326 -0.0015 -0.0484 -3.5961 -0.3791 -7.2969 -1.1454 -0.3944 -0.1936 -1.7673 -1.1961 -0.0430 -0.8316 -0.1028 -0.1659 -0.1284
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb patients hf
H-1351	-1.596358299255371	▁ PB ▁ PB ▁ HF
D-1351	-1.596358299255371	PB PB HF
P-1351	-0.7130 -0.0202 -1.2299 -3.2673 -1.5828 -0.3996 -4.7994 -0.7586
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade evidence anemia patients heart_disease
H-38	-1.3680919408798218	▁an emia ▁patients ▁heart _ ▁disease
D-38	-1.3680919408798218	anemia patients heart_ disease
P-38	-3.0296 -0.0360 -2.8102 -1.6728 -0.3562 -2.8327 -0.1357 -0.0715
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up lvad patients heart_failure
H-548	-1.5266516208648682	▁CF _ L VAD _ ▁patients ▁AI ▁heart _ ▁failure
D-548	-1.5266516208648682	CF_LVAD_ patients AI heart_ failure
P-548	-0.1589 -0.9288 -4.3302 -0.0740 -4.0937 -1.5614 -3.0408 -1.1032 -1.0780 -1.8373 -0.0570 -0.0564
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing mandate accountable outcomes nursing
H-1396	-1.489588975906372	▁social ▁mandat e
D-1396	-1.489588975906372	social mandate
P-1396	-0.9956 -2.9501 -0.0597 -2.8720 -0.5706
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical patient hemodynamically cpr
H-1294	-1.0751581192016602	▁TRE at ment ▁hem o dynamic ally _ ▁uns table
D-1294	-1.0751581192016602	TREatment hemodynamically_ unstable
P-1294	-3.9303 -0.4769 -0.0966 -2.1939 -0.0405 -0.0023 -0.3979 -1.2393 -0.6815 -0.0287 -3.7860 -0.0277
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory_factor_analysis cfa
H-1506	-0.9324767589569092	▁explora tory _ factor _ analyse ▁c fa
D-1506	-0.9324767589569092	exploratory_factor_analyse cfa
P-1506	-0.6902 -0.0004 -0.4933 -0.0718 -2.3171 -1.9182 -2.1096 -1.5017 -0.1159 -0.1064
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline rhythm-control rate-control
H-1237	-0.3100534975528717	▁ rhythm - control ▁rate - control
D-1237	-0.3100534975528717	rhythm-control rate-control
P-1237	-1.2258 -0.4052 -0.1743 -0.0032 -0.0204 -0.3258 -0.0039 -0.4447 -0.1873
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart_failure hf chronic disease
H-2019	-0.902988612651825	▁Heart _ ▁failure _ HF
D-2019	-0.902988612651825	Heart_ failure_HF
P-2019	-0.3301 -0.5043 -2.2001 -1.5622 -0.1974 -1.3930 -0.1338
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes heart_failure hf
H-555	-1.8681542873382568	
D-555	-1.8681542873382568	
P-555	-3.6538 -0.0825
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin health outcomes
H-43	-1.0130172967910767	▁study _ design ▁hem o glob in _ level ▁health
D-43	-1.0130172967910767	study_design hemoglobin_level health
P-43	-3.0815 -2.1536 -0.0161 -0.6584 -0.0343 -0.6239 -0.4373 -0.6655 -0.7738 -0.2638 -3.3719 -0.0760
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf epidemiology health hf
H-1790	-0.7425631284713745	▁ HF ▁epidemi ology ▁health _ service s ▁ HF
D-1790	-0.7425631284713745	HF epidemiology health_services HF
P-1790	-0.2683 -0.0201 -1.3352 -0.0087 -1.3136 -1.1336 -0.0419 -2.0545 -1.3229 -0.0927 -0.8767 -0.4425
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates coagulability
H-1113	-0.7421165704727173	▁se rum _ ▁factors ▁coa gul ability
D-1113	-0.7421165704727173	serum_ factors coagulability
P-1113	-2.3071 -0.0014 -1.4965 -1.4949 -0.9866 -0.1249 -0.1121 -0.0668 -0.0889
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital rehospitalization
H-1719	-0.705647885799408	▁hospital ▁length _ of _ ▁stay ▁re hospital ization
D-1719	-0.705647885799408	hospital length_of_ stay rehospitalization
P-1719	-2.2519 -3.1003 -1.2491 -0.0977 -0.1344 -0.2930 -0.2859 -0.0141 -0.2186 -0.0365 -0.0806
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac_death
H-1905	-0.8684316277503967	▁sud den _ ▁cardiac _ ▁смерти
D-1905	-0.8684316277503967	sudden_ cardiac_ смерти
P-1905	-0.5951 -0.0066 -0.2223 -2.4185 -0.1358 -1.8106 -1.5586 -0.2000
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital mortality
H-1692	-1.4083110094070435	▁com posit e _ ▁measure
D-1692	-1.4083110094070435	composite_ measure
P-1692	-2.7448 -0.0039 -0.0119 -0.7701 -1.2576 -4.8498 -0.2202
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration chf
H-683	-0.43567121028900146	▁administration ▁tras tuz um ab - related ▁CHF
D-683	-0.43567121028900146	administration trastuzumab-related CHF
P-683	-2.1916 -0.4623 -0.0159 -0.1230 -0.0403 -1.1907 -0.0661 -0.1578 -0.0472 -0.0618
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.48308873176574707	▁long - term _ ▁survival
D-272	-0.48308873176574707	long-term_ survival
P-272	-0.5695 -0.1476 -0.0655 -0.2868 -1.4849 -0.7471 -0.0801
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-1.386225700378418	▁hospital s
D-142	-1.386225700378418	hospitals
P-142	-2.3732 -0.4298 -2.4798 -0.2622
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.3641352355480194	▁research _ studie s ▁bio mark er - guide d ▁clinic al ▁trial s
D-1476	-0.3641352355480194	research_studies biomarker-guided clinical trials
P-1476	-0.3134 -2.1920 -1.2471 -0.1982 -0.1158 -0.0127 -0.1496 -0.2244 -0.0020 -0.0706 -0.2334 -0.1419 -0.8012 -0.0075 -0.0249 -0.0914
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.7542724609375	▁medical _ ▁records
D-1131	-0.7542724609375	medical_ records
P-1131	-0.2139 -1.1588 -0.1164 -2.1938 -0.0885
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.5768306255340576	
D-1979	-1.5768306255340576	
P-1979	-3.0623 -0.0913
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac_angiogenesis in_vivo_coronary_perfusion cardiac_fibrosis
H-454	-0.36871984601020813	▁cardiac _ ▁ang io gene sis ▁in ▁vivo _ ▁corona ry _ per fusion ▁cardiac ▁fibro sis
D-454	-0.36871984601020813	cardiac_ angiogenesis in vivo_ coronary_perfusion cardiac fibrosis
P-454	-0.6566 -0.7111 -1.6161 -0.4569 -0.2169 -0.3180 -0.0643 -0.0009 -0.8399 -0.5294 -0.0377 -0.2015 -0.1373 -0.0025 -0.1135 -0.8839 -0.1271 -0.0613 -0.0308
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients heart_failure hf preserved_left_ventricular_ejection_fraction hfpef
H-1300	-1.4375157356262207	▁heart _ ▁failure ▁ha p EF
D-1300	-1.4375157356262207	heart_ failure hapEF
P-1300	-1.2280 -0.4013 -1.7045 -3.9611 -1.5887 -1.7336 -0.7946 -0.0882
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal_pro-b-type_natriuretic_peptides plasma heart_failure patients
H-1510	-0.5943601131439209	▁Circula ting ▁N - termin al ▁pro - B - type ▁na tri ure tic _ pe pti des ▁plasma _ of _ heart _ ▁failure
D-1510	-0.5943601131439209	Circulating N-terminal pro-B-type natriuretic_peptides plasma_of_heart_ failure
P-1510	-0.2600 -0.0378 -4.0220 -0.0247 -0.0092 -0.0012 -0.1672 -0.0155 -0.6356 -0.0967 -0.0990 -0.0127 -0.2547 -0.3516 -0.9769 -0.1641 -0.2791 -0.6182 -1.1393 -0.2169 -2.6311 -0.0858 -0.6886 -0.5534 -0.6259 -1.6683 -0.8574 -0.1493
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine myocyte collagen left_ventricle
H-1141	-0.34857577085494995	▁Pyr ido stig mine ▁my o cy te ▁collage n _ ▁den s ity ▁sur vi ving ▁left _ ▁vent ric le
D-1141	-0.34857577085494995	Pyridostigmine myocyte collagen_ density surviving left_ ventricle
P-1141	-0.0027 -0.0748 -0.0010 -0.0105 -0.0834 -0.0360 -0.0912 -0.2232 -0.2411 -0.1057 -0.4183 -0.3795 -0.4306 -0.0336 -1.0747 -0.0097 -0.0132 -0.1321 -0.2219 -2.7820 -0.6783 -1.2252 -0.0307 -0.0663
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection_fraction ef infarct collateral_growth myocardial_perfusion
H-506	-0.4217255413532257	▁e je ction _ fraction ▁in far ct _ ▁size ▁col lateral _ ▁growth ▁my o card ial _ per fusion
D-506	-0.4217255413532257	ejection_fraction infarct_ size collateral_ growth myocardial_perfusion
P-506	-0.8777 -0.0160 -0.0030 -0.7512 -0.0080 -2.7128 -0.0043 -0.0342 -1.5913 -0.8167 -0.0009 -0.0000 -0.7988 -0.5435 -0.1562 -0.0862 -0.5651 -0.0656 -0.3600 -0.1311 -0.0052 -0.0413 -0.1305
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart_failure hf elevated sympathetic_activity parasympathetic_control heart
H-1133	-1.1914938688278198	▁Heart _ ▁failure _ HF
D-1133	-1.1914938688278198	Heart_ failure_HF
P-1133	-0.3204 -0.5281 -1.0750 -2.7240 -0.0725 -3.4667 -0.1538
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial_fibrillation congestive_heart_failure cost rhythm-control rate-control
H-1230	-0.2727994918823242	▁at rial _ fi bril lation ▁con ges tive _ heart _ ▁failure ▁ rhythm - control ▁rate - control
D-1230	-0.2727994918823242	atrial_fibrillation congestive_heart_ failure rhythm-control rate-control
P-1230	-1.6546 -0.0119 -0.3524 -0.8182 -0.0147 -0.0019 -0.0150 -0.0476 -0.0400 -0.0714 -0.3557 -0.2476 -0.2749 -0.3047 -0.0807 -0.1034 -0.0039 -0.1449 -0.2362 -0.0027 -1.1304 -0.0888
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients end-stage_heart_failure implantation ventricular_assist_device
H-1657	-0.8861849904060364	▁end - s tage _ heart _ ▁failure ▁long - term _ wind _ assist ance _ ▁device
D-1657	-0.8861849904060364	end-stage_heart_ failure long-term_wind_assistance_ device
P-1657	-0.4314 -0.0581 -0.3086 -0.0017 -0.5950 -1.1727 -0.5615 -1.3637 -2.3871 -0.0358 -0.0135 -0.1578 -4.4476 -0.8881 -0.2798 -1.5288 -1.5865 -1.3945 -0.2073 -0.3042
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp xo-mediated_ros mitochondrial_respiration contractile_function
H-471	-0.3300572633743286	▁ATP _ ▁demand ▁ XO - media ted ▁ ROS ▁mito cho ndri al _ ▁respira tion ▁contract ile
D-471	-0.3300572633743286	ATP_ demand XO-mediated ROS mitochondrial_ respiration contractile
P-471	-0.0806 -2.3844 -0.0465 -0.8339 -0.0035 -0.0168 -0.0767 -0.0141 -0.4661 -0.1968 -0.0382 -0.4895 -0.5931 -0.0051 -0.2084 -0.1916 -0.0154 -0.0010 -0.5441 -0.4278 -0.2976
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors adenylyl_cyclase g-protein_coupling
H-1406	-0.38601192831993103	▁a den yl _ ▁cy cla se ▁differenti al _ G - prote in ▁coup ling
D-1406	-0.38601192831993103	adenyl_ cyclase differential_G-protein coupling
P-1406	-0.8404 -0.0086 -0.0229 -1.4345 -0.0028 -0.0081 -0.1667 -0.0007 -0.0014 -0.4344 -1.7416 -0.1467 -0.8214 -0.1178 -0.9009 -0.0717 -0.1293 -0.0983
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality patients implantable_cardiac_defibrillator meta-analysis
H-59	-0.35706669092178345	▁pred ic tors _ of _ ▁mortal ity ▁implant able _ ▁cardiac _ de fi br illa tor
D-59	-0.35706669092178345	predictors_of_ mortality implantable_ cardiac_defibrillator
P-59	-2.6701 -0.0815 -0.0987 -1.2574 -0.4756 -0.0634 -0.3110 -0.0101 -0.2676 -0.0131 -0.1917 -0.1805 -0.0356 -0.1838 -0.0278 -0.3934 -0.1040 -0.0444 -0.6822 -0.0495
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise_intolerance symptom chronic_hfpef quality_of_life qol
H-1975	-0.6133580207824707	▁exercise _ in tolerance ▁chronic _ ▁H FP EF ▁reduce d ▁quality _ of _ life Q OL
D-1975	-0.6133580207824707	exercise_intolerance chronic_ HFPEF reduced quality_of_lifeQOL
P-1975	-0.3318 -0.5115 -0.3296 -0.0012 -0.2691 -0.3251 -2.4204 -0.0480 -0.4270 -2.3413 -0.0087 -2.2233 -0.5975 -0.0899 -0.0634 -0.9785 -1.1422 -0.0248 -0.0222 -0.1117
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling_pathways pressure-overload-induced_heart_failure
H-877	-0.4830712378025055	▁signal ing _ path ways ▁pressure - over load - indu ced _ heart _ ▁failure
D-877	-0.4830712378025055	signaling_pathways pressure-overload-induced_heart_ failure
P-877	-2.6943 -0.2052 -0.1693 -0.0680 -0.0376 -0.0160 -0.0929 -0.0082 -0.0058 -0.5462 -0.0167 -0.0711 -0.7923 -0.3810 -0.7800 -2.6464 -0.0457 -0.1187
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization patients heart_failure ventricular_tachycardia
H-1434	-0.8169058561325073	▁auto no mic _ modul ation ▁repo lar ization _ in st ability ▁heart _ ▁failure ▁pro ne ▁vent ri cular _ ta chy car dia
D-1434	-0.8169058561325073	autonomic_modulation repolarization_instability heart_ failure prone ventricular_tachycardia
P-1434	-4.9403 -0.1152 -1.7677 -2.0031 -0.8513 -0.0289 -1.3827 -1.6462 -0.0315 -1.2855 -0.4303 -0.0003 -0.0073 -0.6458 -0.6839 -1.3255 -0.3666 -0.2477 -1.9399 -0.7448 -0.0699 -0.5515 -1.0711 -0.2349 -0.2440 -0.0170 -0.1243 -0.1160
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients systolic_hf etiology coronary_angiography
H-1184	-0.3779357969760895	▁sy sto lic ▁ HF ▁un clear _ ▁et i ology ▁corona ry ▁ang i ography
D-1184	-0.3779357969760895	systolic HF unclear_ etiology coronary angiography
P-1184	-0.0700 -0.2147 -0.0828 -1.1901 -0.0005 -2.1232 -0.0008 -0.7672 -0.2055 -0.0597 -0.0012 -0.0015 -0.0577 -1.3339 -0.3755 -0.0432 -0.2003 -0.0750
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence schfi_v.6.2 clinical
H-1509	-0.9180529117584229	▁ SCH fi ▁clinic al _ prac tice
D-1509	-0.9180529117584229	SCHfi clinical_practice
P-1509	-2.6537 -1.4989 -2.1818 -1.4703 -0.0153 -0.4568 -0.0745 -0.0861 -0.6483 -0.0949
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy_substrate_metabolism hearts aac
H-1781	-0.4494692087173462	▁energy ▁substrat e ▁metabolism ▁isola ted ▁working _ heart s ▁a AC
D-1781	-0.4494692087173462	energy substrate metabolism isolated working_hearts aAC
P-1781	-0.0499 -1.8335 -0.0575 -1.5498 -0.9599 -0.0022 -0.0322 -0.1849 -0.4398 -0.1662 -0.7603 -0.1978 -0.0096 -0.0490
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes_mellitus cardiovascular_disease baseline
H-630	-1.0409398078918457	▁diabetes ▁mell itus ▁cardiovascular _ مرض
D-630	-1.0409398078918457	diabetes mellitus cardiovascular_مرض
P-630	-3.2562 -1.3413 -0.1496 -0.1515 -0.7354 -2.4208 -0.2025 -0.0703
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence parasympathetic therapeutic hf
H-1134	-0.46807265281677246	▁para sy mpa the tic _ function ▁slow ▁ HF ▁e volution
D-1134	-0.46807265281677246	parasympathetic_function slow HF evolution
P-1134	-1.3091 -1.0319 -0.1639 -0.2565 -0.0680 -0.3603 -0.5153 -0.2021 -0.9173 -0.0106 -1.6229 -0.0003 -0.0365 -0.0585
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients hfpef adverse_outcomes
H-237	-0.5875663161277771	▁ HF p EF ▁advers e _ ▁outcome s
D-237	-0.5875663161277771	HFpEF adverse_ outcomes
P-237	-0.7604 -0.1472 -0.0303 -0.1296 -2.3417 -0.1706 -1.5523 -0.3922 -0.0048 -0.7135 -0.2206
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical revascularization revascularization
H-1603	-0.5077221989631653	▁sur g ical _ re vas cular ization ▁cat heter - based _ re vas cular ization
D-1603	-0.5077221989631653	surgical_revascularization catheter-based_revascularization
P-1603	-2.0314 -0.5610 -1.6315 -1.0732 -0.4000 -0.0358 -0.0407 -0.4701 -0.4825 -0.0022 -0.0266 -0.0189 -1.5439 -0.1653 -0.0138 -0.0259 -0.3766 -0.6494 -0.0979
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf_antagonists nbdmard
H-607	-0.2972073554992676	▁HR ▁t NF _ ▁anta gon ists ▁n b DM ARD
D-607	-0.2972073554992676	HR tNF_ antagonists nbDMARD
P-607	-0.1928 -0.7073 -0.0523 -0.6044 -0.1025 -0.0551 -0.8112 -0.0152 -0.0017 -0.6543 -0.0592 -0.4416 -0.1661
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd psoriasis hazard_ratio confidence_interval
H-1563	-0.6603583097457886	▁risk _ of _ ▁incident ▁CV d ▁psoriasis
D-1563	-0.6603583097457886	risk_of_ incident CVd psoriasis
P-1563	-0.6900 -1.1781 -1.3300 -0.2469 -0.1192 -1.1038 -1.1264 -0.1049 -0.4263 -0.2779
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence bnp patients pad bnp hf
H-1572	-0.8798657059669495	▁high _ b NP _ ▁levels ▁ PAD ▁routine _ b NP _ ▁measure ments ▁ HF
D-1572	-0.8798657059669495	high_bNP_ levels PAD routine_bNP_ measurements HF
P-1572	-4.2144 -1.3949 -1.3215 -0.4625 -1.2167 -1.7005 -0.4308 -0.0072 -2.4678 -0.8706 -0.9849 -0.0904 -0.4113 -0.8639 -0.0253 -0.1205 -0.0085 -0.0348 -0.0909
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based nucleolin protein_expression
H-96	-1.035292148590088	▁Mor pho lino - based _ ▁knock down _ of ▁nucleo line ▁a boli shed ▁protein _ ▁expression ▁gross ▁ morph ological
D-96	-1.035292148590088	Morpholino-based_ knockdown_of nucleoline abolished protein_ expression gross morphological
P-96	-0.2422 -0.1855 -0.8508 -1.7115 -1.2129 -2.6611 -2.7806 -0.0151 -3.1000 -1.1806 -0.2962 -3.1893 -3.3236 -0.0016 -0.0096 -0.3152 -0.7792 -1.0875 -0.1641 -0.4668 -0.0110 -0.2051 -0.9683 -0.0892
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical rule cad systolic_hf
H-1185	-0.5682312250137329	▁clinic al _ pred ion ▁rule ▁CAD ▁sy sto lic _ HF
D-1185	-0.5682312250137329	clinical_predion rule CAD systolic_HF
P-1185	-0.1834 -0.0244 -0.1564 -1.2770 -1.4425 -0.5569 -1.4426 -1.0781 -0.9285 -0.2678 -0.3298 -0.0263 -0.0724 -0.1692
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam_study psoriasis cardiovascular outcomes
H-1556	-0.5069917440414429	▁population - based ▁Rotterdam _ ▁Study ▁psoriasis ▁cardiovascular ▁outcome s
D-1556	-0.5069917440414429	population-based Rotterdam_ Study psoriasis cardiovascular outcomes
P-1556	-1.9554 -0.0244 -0.0069 -0.2354 -1.3618 -1.0336 -0.3951 -0.1491 -0.7901 -0.0095 -0.0414 -0.0813
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality readmission
H-207	-0.9608379006385803	▁cognitive _ ▁im pair ment ▁6- mont h _ ▁mortal ity
D-207	-0.9608379006385803	cognitive_ impairment 6-month_ mortality
P-207	-0.5601 -1.2084 -0.4917 -0.0267 -0.2509 -3.9952 -0.1428 -0.0341 -0.4829 -1.9270 -0.1203 -3.1356 -0.1151
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes exercise training patients ambulatory hf
H-1631	-0.7855837345123291	▁race ▁exercise _ training ▁ambula tory ▁ HF
D-1631	-0.7855837345123291	race exercise_training ambulatory HF
P-1631	-0.7775 -3.2171 -1.7726 -0.6334 -0.0613 -0.0065 -0.9937 -0.0015 -0.0914 -0.3008
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline hgb exercise training kccq
H-841	-0.5299736261367798	▁base line _ h gb ▁exercise _ training ▁k cc q ▁sub sca les
D-841	-0.5299736261367798	baseline_hgb exercise_training kccq subscales
P-841	-0.2583 -0.0010 -0.6455 -0.9343 -0.0027 -0.2657 -0.7457 -0.5888 -1.1988 -0.4439 -1.4258 -0.5091 -0.0001 -0.0161 -1.3296 -0.1142
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic histological gastrointestinal
H-1359	-1.2142791748046875	▁sono graphic ▁his t ological ▁gastro inte stin al _ region s
D-1359	-1.2142791748046875	sonographic histological gastrointestinal_regions
P-1359	-4.2986 -1.8905 -3.3675 -0.1140 -0.2280 -2.3224 -1.3592 -1.3928 -0.1721 -1.3629 -0.2386 -0.0483 -0.0916 -0.1134
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications acs patients patients vad
H-1286	-0.5512570738792419	▁a cs ▁procedure s ▁MT ▁ VAD
D-1286	-0.5512570738792419	acs procedures MT VAD
P-1286	-0.3645 -1.1696 -1.7752 -0.0826 -0.6821 -0.7470 -0.0225 -0.0340 -0.0837
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital cardiac hospital south_dakota
H-1577	-0.4164159595966339	▁general _ hospital ▁cardiac _ special ty _ hospital
D-1577	-0.4164159595966339	general_hospital cardiac_specialty_hospital
P-1577	-0.2239 -0.9513 -0.0118 -0.8347 -0.1380 -0.1323 -0.0106 -0.8374 -0.0113 -1.2842 -0.1451
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise haemodynamic pulmonary
H-1277	-0.07334049046039581	▁ha emo dynamic ▁pulmonar y ▁per i pher al ▁ab normal ities
D-1277	-0.07334049046039581	haemodynamic pulmonary peripheral abnormalities
P-1277	-0.0407 -0.2499 -0.0020 -0.0202 -0.0131 -0.0137 -0.1516 -0.0003 -0.0090 -0.3016 -0.0180 -0.0127 -0.0702 -0.1238
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo egfr egfr
H-1392	-0.7804255485534668	▁EC mo ▁e G FR
D-1392	-0.7804255485534668	ECmo eGFR
P-1392	-0.7996 -0.4682 -1.5291 -0.8539 -0.6621 -0.8232 -0.3268
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia rv_function
H-1159	-0.4571976363658905	▁ HF - related ▁cache xia ▁ RV ▁body ▁composition
D-1159	-0.4571976363658905	HF-related cachexia RV body composition
P-1159	-0.4118 -0.2116 -0.0524 -0.0982 -0.6575 -0.2035 -0.0611 -0.0668 -1.3778 -2.2038 -0.0652 -0.0765
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule patients cad patients cad
H-1191	-1.9594227075576782	
D-1191	-1.9594227075576782	
P-1191	-3.7519 -0.1669
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic rule prospectively
H-1188	-0.9289969801902771	▁diagnostic _ ▁rule
D-1188	-0.9289969801902771	diagnostic_ rule
P-1188	-0.1960 -1.3719 -1.7399 -1.1812 -0.1560
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute_hf
H-1018	-0.5790270566940308	▁a cute _ HF
D-1018	-0.5790270566940308	acute_HF
P-1018	-1.3261 -0.0038 -0.4379 -0.0453 -1.4936 -0.1675
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart_failure hf condition morbidity mortality
H-1487	-0.8734113574028015	▁Heart _ ▁failure _ HF
D-1487	-0.8734113574028015	Heart_ failure_HF
P-1487	-0.4807 -0.5095 -1.7680 -1.8600 -0.2658 -1.1381 -0.0917
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo_sternotomy cardiopulmonary_bypass
H-775	-0.7409530878067017	▁pump - ex change _ techniek ▁redo ▁ster no to my ▁cardio pul mon ary _ ▁by pass
D-775	-0.7409530878067017	pump-exchange_techniek redo sternotomy cardiopulmonary_ bypass
P-775	-1.7092 -0.1575 -0.0057 -0.0004 -2.2183 -2.0157 -0.2548 -2.6349 -0.0416 -0.9145 -1.3756 -0.0108 -0.1528 -0.8795 -0.0863 -0.7346 -1.3566 -0.0098 -0.1068 -0.1537
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical_treatment hf hf symptom mva
H-371	-0.9867995381355286	▁aggressiv e ▁medical _ 治療 ▁ HF ▁ HF ▁MS
D-371	-0.9867995381355286	aggressive medical_治療 HF HF MS
P-371	-1.3635 -0.1866 -0.6034 -2.5834 -2.7056 -0.3567 -0.0017 -2.0946 -0.0244 -0.2518 -1.4669 -0.2030
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic parasympathetic_activity hf symptoms disease
H-1868	-0.5694389939308167	▁sympa the tic ▁para sy mpa the tic _ activ ity ▁ HF
D-1868	-0.5694389939308167	sympathetic parasympathetic_activity HF
P-1868	-0.6695 -0.0755 -0.0589 -0.9600 -0.9309 -0.1400 -0.3347 -0.0481 -0.5970 -0.2592 -0.1255 -0.0498 -0.0047 -4.1882 -0.0995
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical_treatment hf functional_ms medical_treatment
H-354	-1.3354706764221191	▁medical ▁ HF
D-354	-1.3354706764221191	medical HF
P-354	-1.7726 -3.6072 -0.0243 -1.1725 -0.1008
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf transition compensated_lv_hypertrophy hf hhd
H-283	-0.8622316718101501	▁mouse ▁ HF _ model ▁compensa ted ▁LV _ ▁hyper trop hy ▁ HF ▁h HD
D-283	-0.8622316718101501	mouse HF_model compensated LV_ hypertrophy HF hHD
P-283	-2.5983 -0.9275 -0.0526 -2.6641 -0.7642 -0.2714 -0.0604 -1.4848 -0.2909 -0.8779 -0.0189 -2.3626 -0.1554 -0.0013 -2.4866 -0.0856 -0.0913 -0.3262
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic_myocardial_ischemia heart_failure therapeutic
H-503	-1.1839230060577393	▁chronic _ me o card ial _ ische mia ▁heart _ ▁failure
D-503	-1.1839230060577393	chronic_meocardial_ischemia heart_ failure
P-503	-2.8028 -0.4345 -5.0216 -0.2074 -0.8142 -0.0395 -0.0622 -4.3240 -0.1425 -0.1039 -0.2217 -1.5341 -0.7735 -0.0929
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone hyperkalemia acute_kidney_injury
H-445	-0.4089204668998718	▁Spir ono lac tone ▁hyper kal emia ▁a cute ▁ki dne y
D-445	-0.4089204668998718	Spironolactone hyperkalemia acute kidney
P-445	-0.2578 -0.2876 -0.1110 -0.1282 -0.5825 -0.6179 -0.0808 -0.0187 -0.0033 -1.2230 -0.9721 -0.0253 -1.2626 -0.1542
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients systolic_blood_pressure renal_impairment hypertension
H-1529	-1.5122119188308716	▁EH ▁renal ▁im pair ment ▁hyper tension
D-1529	-1.5122119188308716	EH renal impairment hypertension
P-1529	-1.8607 -4.3826 -2.9741 -0.0018 -0.1141 -3.9381 -0.0275 -0.0745 -0.2365
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular_venous_pressure peripheral_oedema patient
H-1895	-0.23234686255455017	▁jugu lar ▁ve nous _ ▁pressure ▁per i pher al _ ▁oed ema ▁volume
D-1895	-0.23234686255455017	jugular venous_ pressure peripheral_ oedema volume
P-1895	-0.0009 -0.0884 -1.2593 -0.0759 -0.4684 -0.0901 -0.0088 -0.0737 -0.0000 -0.0039 -0.3340 -0.8924 -0.0028 -0.0347 -0.3138 -0.0704
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic_peptide biomarkers point_of_care poc
H-1023	-0.32625138759613037	▁na tri ure tic _ pe pti de ▁bio mark ers ▁point _ of _ care
D-1023	-0.32625138759613037	natriuretic_peptide biomarkers point_of_care
P-1023	-0.0926 -0.0187 -0.0510 -0.9677 -0.2001 -0.1732 -0.1271 -0.4456 -1.7299 -0.0080 -0.0330 -0.3306 -0.5273 -0.2093 -0.0360 -0.5522 -0.3146 -0.0556
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical_cardiac_support renal_function end-stage_heart_failure
H-1384	-0.767845094203949	▁mechanic al ▁cardiac _ support ▁renal _ function ▁end - s tage _ heart _ ▁failure
D-1384	-0.767845094203949	mechanical cardiac_support renal_function end-stage_heart_ failure
P-1384	-0.0113 -0.0349 -5.5183 -0.4278 -0.9533 -0.0740 -0.4000 -0.3619 -0.3555 -0.0416 -0.0822 -0.0006 -0.2658 -1.0801 -0.6595 -3.3531 -0.0634 -0.1381
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
H-1352	-0.5111612677574158	▁antico a gul ants ▁anti plate let _ ▁drugs ▁treat ing ▁heart _ ▁failure ▁at rial _ fi bril lation
D-1352	-0.5111612677574158	anticoagulants antiplatelet_ drugs treating heart_ failure atrial_fibrillation
P-1352	-1.0245 -0.6192 -0.3080 -0.0033 -0.0111 -0.2140 -0.7523 -1.0918 -1.0507 -2.3960 -0.0139 -0.2083 -0.4855 -1.3686 -0.3358 -0.0100 -0.2263 -0.8948 -0.0101 -0.0013 -0.1323 -0.0876
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-333	-0.3883571922779083	▁functional ▁mit ral _ ▁sten osis ▁ring _ ▁ann ulo plast y ▁ ische mic _ ▁mit ral ▁re gur gi tation
D-333	-0.3883571922779083	functional mitral_ stenosis ring_ annuloplasty ischemic_ mitral regurgitation
P-333	-0.3110 -2.4484 -0.0104 -0.3229 -0.1408 -0.0009 -0.0202 -0.5225 -0.5303 -0.1471 -0.1017 -0.0185 -0.2881 -0.0478 -0.0234 -0.3795 -2.7084 -0.0522 -1.0719 -0.0010 -0.0309 -0.0008 -0.0791 -0.0628
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up deaths heart_transplantations lv_assist_device_implantations heart_failure admissions
H-434	-0.8702273964881897	▁heart _ plant ations LV _ assist _ ▁device _ ▁implant ations ▁heart _ fail ▁ad missions
D-434	-0.8702273964881897	heart_plantationsLV_assist_ device_ implantations heart_fail admissions
P-434	-2.7678 -0.8651 -1.6977 -0.0332 -2.9094 -0.2172 -0.0288 -1.2835 -1.0759 -0.5889 -0.3171 -0.0087 -0.4626 -0.2082 -3.7161 -0.2119 -0.0153 -0.0427 -0.0841
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis heart_failure_with_preserved_ejection_fraction clinical doppler_echocardiography
H-21	-0.4882235825061798	▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁clinic al _ do pp ler _ e cho card i ography
D-21	-0.4882235825061798	heart_ failure preserved_ejection_fraction clinical_doppler_echocardiography
P-21	-1.7325 -0.4783 -1.9245 -1.4150 -0.0453 -0.0280 -0.7445 -1.1051 -0.0531 -0.0134 -0.8638 -0.0025 -0.0803 -0.0119 -1.3799 -0.4996 -0.0014 -0.2758 -0.3385 -0.6995 -0.2555 -0.2323 -0.1561 -0.1364 -0.1216 -0.0989
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-1.1115115880966187	▁national ▁patient _ ▁safety _ initiative s
D-7	-1.1115115880966187	national patient_ safety_initiatives
P-7	-1.2328 -2.9368 -0.2916 -2.3803 -1.6596 -0.1473 -0.0185 -1.1915 -0.1451
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.3164302408695221	▁clinic al _ care ▁mal adapt ive _ ▁molecular _ process es
D-1473	-0.3164302408695221	clinical_care maladaptive_ molecular_processes
P-1473	-2.1174 -0.0099 -0.2477 -0.3750 -0.0265 -0.0679 -0.0024 -0.2226 -0.8439 -0.2270 -0.1600 -0.0171 -0.0707 -0.0418
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs outcomes
H-2009	-1.1244642734527588	▁long - term ▁costs ▁survival
D-2009	-1.1244642734527588	long-term costs survival
P-2009	-3.2849 -0.0698 -0.1165 -1.1716 -2.2628 -0.8005 -0.1652
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi mi hf
H-1104	-0.5586482286453247	▁early - ons et ▁MI ▁ HF
D-1104	-0.5586482286453247	early-onset MI HF
P-1104	-0.7587 -0.0382 -0.0845 -0.2870 -1.4658 -2.1384 -0.0260 -0.0926 -0.1366
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling emd
H-1151	-0.4305116832256317	▁ HF - indu ced _ ▁remodel ing ▁EM D ▁prolong ation
D-1151	-0.4305116832256317	HF-induced_ remodeling EMD prolongation
P-1151	-0.9461 -0.4349 -0.1010 -0.0016 -0.0586 -0.6832 -1.3906 -0.0836 -0.3619 -0.8278 -0.8709 -0.0472 -0.0493 -0.1705
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular conditions patients hf
H-694	-1.22287118434906	▁cardiovascular _ ▁conditions ▁ HF
D-694	-1.22287118434906	cardiovascular_ conditions HF
P-694	-4.6048 -0.9689 -1.6773 -1.1042 -0.0173 -0.0730 -0.1146
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary_outcomes
H-620	-0.5799785256385803	▁sustain ability ▁commission ing ▁hospital - ▁community - based ▁programme s
D-620	-0.5799785256385803	sustainability commissioning hospital- community-based programmes
P-620	-0.3507 -0.0711 -0.1500 -0.0478 -0.1411 -0.3371 -2.9229 -0.0638 -0.0161 -2.9409 -0.0194 -0.2744 -0.2046
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based patient outcomes
H-85	-0.9226057529449463	▁practice s ▁evidence - based _ prac tice s
D-85	-0.9226057529449463	practices evidence-based_practices
P-85	-0.2424 -1.8661 -5.2928 -0.0274 -0.0115 -0.7108 -0.7923 -0.0418 -0.0047 -1.0111 -0.1478
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients heartmate_ii lvad
H-303	-0.7537007331848145	▁isola ted ▁Heart Mate _ II _ L VAD
D-303	-0.7537007331848145	isolated HeartMate_II_LVAD
P-303	-3.8280 -0.0152 -0.6482 -0.1915 -0.6605 -0.3833 -0.4886 -1.8296 -0.0094 -0.1754 -0.0611
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin lvad postoperative
H-536	-1.0616086721420288	▁normal ization ▁album in _ ▁levels ▁post operativ e _ ▁survival
D-536	-1.0616086721420288	normalization albumin_ levels postoperative_ survival
P-536	-4.2050 -0.2908 -1.4107 -0.5514 -1.5833 -0.4633 -2.0844 -0.0237 -0.3465 -0.8404 -1.7579 -0.0615 -0.1820
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling_pathway remodelling
H-994	-0.2680302858352661	▁Raf - MEK 1/2 - ER k 1/2 ▁signal ling _ path way ▁mal adapt ive ▁remodel ling
D-994	-0.2680302858352661	Raf-MEK1/2-ERk1/2 signalling_pathway maladaptive remodelling
P-994	-0.0331 -0.0620 -0.0120 -0.8199 -0.0449 -0.1348 -0.2168 -0.8275 -0.0529 -0.0967 -0.3114 -0.0719 -0.1019 -0.8917 -0.0255 -0.0049 -1.4860 -0.0236 -0.0809 -0.0623
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary congenital heart death
H-1906	-0.7720878720283508	▁her edit ary ▁con geni tal _ ▁ab normal ities ▁heart ▁non trau matic _ ▁death
D-1906	-0.7720878720283508	hereditary congenital_ abnormalities heart nontraumatic_ death
P-1906	-0.6962 -2.0268 -0.1037 -0.2477 -0.0016 -0.0219 -0.3085 -1.1999 -0.0816 -0.0452 -1.8651 -0.1933 -0.0778 -0.0682 -0.1692 -4.6840 -1.5468 -0.5602
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health health u.s. drug administration
H-1830	-0.9561604261398315	▁health _ system _ data ▁partners ▁u . s ▁Food _ drug _ administration ▁Mini - S enti nel
D-1830	-0.9561604261398315	health_system_data partners u.s Food_drug_administration Mini-Sentinel
P-1830	-0.0571 -1.0963 -3.0900 -3.3862 -0.1455 -2.6317 -0.7298 -0.2067 -0.4472 -0.4405 -0.9749 -2.8177 -0.7737 -0.1528 -1.6879 -0.0073 -0.2025 -0.0124 -0.0098 -1.0569 -0.1528
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate heart_failure
H-1544	-1.8839713335037231	▁Bis phos phon ate ▁heart _ ▁failure
D-1544	-1.8839713335037231	Bisphosphonate heart_ failure
P-1544	-1.7101 -0.0133 -1.2566 -3.3614 -4.2931 -1.0844 -2.8522 -2.3200 -0.0647
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global_left_ventricular_longitudinal_systolic_strain cardiovascular_events patients atrial_fibrillation
H-808	-0.5637344717979431	▁left ▁vent ri cular _ ▁longitud in al _ ▁sy sto lic _ ▁strain ▁cardiovascular _ ▁events ▁at rial _ fi bril lation
D-808	-0.5637344717979431	left ventricular_ longitudinal_ systolic_ strain cardiovascular_ events atrial_fibrillation
P-808	-0.4879 -3.1164 -0.1893 -0.0406 -0.7671 -0.1019 -0.0197 -0.0167 -0.1764 -3.5736 -0.1026 -0.1565 -0.5782 -0.4598 -0.8384 -0.4960 -0.8490 -0.3788 -0.0124 -0.2186 -1.2495 -0.0235 -0.0040 -0.0705 -0.1657
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine_oxidase_inhibition left_ventricular systolic diastolic_function cardiac_volume_overload
H-469	-0.8977954983711243	▁Xan thi ne ▁oxid ase _ ▁inhibi tion ▁left ▁vent ri cular _ ▁sy sto lic ▁dia sto lic ▁cardiac _ ▁volume
D-469	-0.8977954983711243	Xanthine oxidase_ inhibition left ventricular_ systolic diastolic cardiac_ volume
P-469	-0.0021 -0.4487 -0.2117 -0.3931 -3.9011 -1.7057 -0.3235 -0.0329 -0.9372 -0.9554 -1.5267 -0.4638 -0.6873 -4.4094 -0.2897 -0.4714 -1.5090 -0.3374 -0.3605 -0.1932 -0.8119 -0.2773 -1.1330 -0.1651
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection nt-probnp antibodies terminal
H-1521	-0.3857889771461487	▁immun o det ection ▁NT - pro b NP ▁anti bo dies ▁terminal _ region s
D-1521	-0.3857889771461487	immunodetection NT-probNP antibodies terminal_regions
P-1521	-0.5731 -0.0239 -0.2022 -0.0013 -1.4665 -0.0285 -0.0013 -1.6947 -0.0693 -0.0245 -0.3177 -0.2568 -0.2726 -1.1329 -0.6474 -0.0585 -0.0424 -0.1307
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd clinical hospitalizations complications therapy end-stage_hf
H-895	-0.4597086012363434	▁PD ▁clinic al ▁status ▁hospital ization s ▁ therapy ▁severe ▁end - s tage ▁ HF
D-895	-0.4597086012363434	PD clinical status hospitalizations therapy severe end-stage HF
P-895	-0.4125 -1.2021 -0.0043 -0.6720 -0.4534 -0.2800 -0.1697 -2.8859 -0.1500 -0.3606 -0.5013 -0.0970 -0.2427 -0.0007 -0.7174 -0.0004 -0.0251 -0.0996
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone diagnosed systolic_heart_failure clinical
H-439	-0.6579084396362305	▁spi rono lac tone ▁sy sto lic _ heart _ ▁failure
D-439	-0.6579084396362305	spironolactone systolic_heart_ failure
P-439	-1.9841 -0.0146 -0.0898 -0.0359 -0.1658 -0.2006 -0.3770 -0.1319 -1.0549 -0.3356 -2.1300 -1.9739 -0.0587
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking cardiac_rehabilitation functional_capacity outcomes patients heart_failure
H-574	-1.5685374736785889	▁Nordic _ walk ▁cardiac _ rehabilit tion _ care
D-574	-1.5685374736785889	Nordic_walk cardiac_rehabilittion_care
P-574	-0.4565 -1.4442 -5.3254 -1.9246 -0.3023 -0.4356 -0.4194 -2.9403 -0.9503 -2.9357 -0.1197
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report patients aortic_valve surgery post-lvad_ai
H-544	-0.521497905254364	▁a or tic _ val ve _ ▁surgery ▁new - ons et ▁post - L VAD ▁AI
D-544	-0.521497905254364	aortic_valve_ surgery new-onset post-LVAD AI
P-544	-0.6498 -0.0346 -0.1680 -0.0842 -1.5383 -0.3589 -0.6912 -2.8725 -0.8951 -0.0644 -0.0252 -0.2337 -0.5481 -0.0078 -0.4758 -0.0079 -1.1857 -0.0130 -0.0544
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications outpatients heart_failure ncdr_pinnacle
H-658	-1.3977910280227661	▁medication s ▁heart _ ▁failure ▁NC DR ▁PIN NA CLE
D-658	-1.3977910280227661	medications heart_ failure NCDR PINNACLE
P-658	-6.7730 -0.4719 -3.7576 -0.5955 -2.3102 -0.0381 -0.3208 -0.9875 -0.2335 -0.7730 -0.3971 -0.1153
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart_failure clinical medicine prevalence coronary_disease
H-980	-0.7072612643241882	▁Heart _ ▁failure ▁a ther omat ous _ ▁corona ry _ ▁disease
D-980	-0.7072612643241882	Heart_ failure atheromatous_ coronary_ disease
P-980	-0.8240 -0.7295 -1.6847 -1.8906 -0.0042 -0.0507 -0.3449 -0.2389 -0.2046 -0.2676 -0.7924 -2.7190 -0.0715 -0.0790
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical symptoms hfpef symptoms breathlessness fluid_retention
H-1891	-0.6638990640640259	▁ HF p EF ▁fatigue ▁fluid ▁re tention
D-1891	-0.6638990640640259	HFpEF fatigue fluid retention
P-1891	-1.2204 -0.9802 -0.2442 -0.9839 -1.4328 -0.0649 -1.4692 -0.0034 -0.0978 -0.1421
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic hfpef medical_history physical_examination
H-1892	-0.6660122871398926	▁diagnostic _ test ▁ HF p EF
D-1892	-0.6660122871398926	diagnostic_test HFpEF
P-1892	-0.5915 -0.9953 -0.1528 -0.1102 -0.0061 -0.0616 -0.1964 -3.7168 -0.1635
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart hr_reduction patients systolic_heart_failure
H-527	-0.5746092200279236	▁un load ing _ of _ the _ heart ▁isola ted _ HR _ re duction ▁sy sto lic _ heart _ ▁failure
D-527	-0.5746092200279236	unloading_of_the_heart isolated_HR_reduction systolic_heart_ failure
P-527	-0.4883 -0.0003 -0.0071 -2.7881 -0.4598 -0.6849 -0.8630 -1.1645 -0.3070 -0.1540 -0.0016 -0.1279 -0.6900 -1.6729 -0.6782 -0.0003 -0.1777 -0.1801 -0.9838 -0.2274 -0.8982 -0.7688 -0.7767 -0.0533 -0.2111
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape functional_enrichment_analysis david
H-1612	-0.9820147156715393	▁network ▁Cy to scape
D-1612	-0.9820147156715393	network Cytoscape
P-1612	-2.3531 -0.8145 -0.0092 -0.0569 -2.5727 -0.0857
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin insulin_resistance monocytes inflammatory
H-928	-0.3073657751083374	▁circula ting ▁media tor ▁insulin ▁resist ance ▁human ▁mono cy tes ▁infla mma tory ▁stimul i
D-928	-0.3073657751083374	circulating mediator insulin resistance human monocytes inflammatory stimuli
P-928	-1.2858 -0.0539 -0.6778 -0.1225 -0.1530 -0.7770 -0.0015 -0.4716 -0.0080 -0.0015 -0.0053 -0.0179 -0.3118 -0.0153 -1.3287 -0.1092 -0.0529 -0.1388
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension diabetes ischemic etiology
H-1635	-0.3546299636363983	▁black s ▁hyper tension ▁diabetes ▁ ische mic _ ▁et i ology ▁white s
D-1635	-0.3546299636363983	blacks hypertension diabetes ischemic_ etiology whites
P-1635	-0.8971 -0.4683 -0.2923 -0.0198 -0.2119 -0.0851 -0.0792 -0.0608 -0.6953 -0.5250 -0.0933 -0.0035 -2.0284 -0.0615 -0.0539 -0.0988
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp patients acute_heart_failure
H-262	-1.057381272315979	▁predict ive _ ▁cut off _ valu e ▁NT - pro b NP _ test ▁long - term _ ▁survival ▁ED _ patient ▁a cute _ heart ▁failure
D-262	-1.057381272315979	predictive_ cutoff_value NT-probNP_test long-term_ survival ED_patient acute_heart failure
P-262	-6.0658 -0.0897 -1.0567 -0.6982 -0.0055 -0.1946 -1.7381 -0.3867 -0.0819 -0.0095 -0.0017 -1.0907 -0.1246 -1.5275 -0.8734 -3.3359 -0.0259 -0.0339 -0.1881 -1.9991 -1.4683 -2.3056 -1.4152 -0.2308 -0.0032 -0.4188 -1.0440 -5.0622 -0.1040 -0.1419
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative_stress gtpase rac1 activity hearts
H-281	-0.5900130271911621	▁o xi da tive _ ▁stress ▁GT Pas e _ ▁Rac 1 ▁heart s ▁ ANS ▁mi ce
D-281	-0.5900130271911621	oxidative_ stress GTPase_ Rac1 hearts ANS mice
P-281	-0.1010 -0.0136 -0.1121 -0.0660 -1.0940 -0.4033 -2.5194 -0.0678 -0.0364 -0.6412 -0.0594 -0.3063 -1.1349 -0.1287 -2.9775 -0.0156 -1.8952 -0.0666 -0.0361 -0.1251
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart_failure hf latin_america health hf
H-1789	-1.4085578918457031	▁Heart _ of _ HF
D-1789	-1.4085578918457031	Heart_of_HF
P-1789	-1.2502 -0.3032 -4.9955 -0.0250 -0.6265 -2.5140 -0.1455
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right_heart_circulation right_heart_failure
H-1459	-1.694858431816101	▁figure s ▁right _ heart _ ▁circulation
D-1459	-1.694858431816101	figures right_heart_ circulation
P-1459	-7.0445 -1.4298 -0.3319 -0.3789 -3.1840 -0.3657 -0.3262 -2.0445 -0.1482
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan_circulation skeletal_muscle metabolic
H-1494	-0.6831575036048889	▁Font an _ ▁circulation _ ▁exhibi t ▁skelet al _ 肌肉 ▁mass ▁metabol ic ▁ab normal ities
D-1494	-0.6831575036048889	Fontan_ circulation_ exhibit skeletal_肌肉 mass metabolic abnormalities
P-1494	-0.6087 -0.0738 -0.7130 -0.0866 -2.6765 -1.1821 -0.1796 -0.8353 -0.0704 -0.1378 -2.6380 -2.2101 -0.0051 -0.0155 -1.3294 -0.0204 -0.0125 -0.0741 -0.1112
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid_receptor_antagonists
H-1709	-0.929389476776123	▁hypothe sis - genera ting _ ▁finding s ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁race
D-1709	-0.929389476776123	hypothesis-generating_ findings mineralocorticoid_ receptor_ antagonists race
P-1709	-4.0442 -0.1428 -0.2453 -0.0056 -0.1119 -0.9174 -3.1169 -0.0252 -1.3321 -0.2822 -2.1892 -2.7701 -3.5081 -0.2268 -0.0742 -0.3848 -0.1988 -0.0825 -0.4365 -0.1946 -0.0297 -0.1278
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients fontan_circulation svr cardiac_index
H-232	-0.5553541779518127	▁fail ing ▁Font an _ ▁circulation ▁cardiac _ index ▁pediatr ic _ co hor t
D-232	-0.5553541779518127	failing Fontan_ circulation cardiac_index pediatric_cohort
P-232	-2.6622 -0.1849 -1.7224 -0.1458 -0.2952 -0.0599 -1.6462 -0.3604 -0.6689 -0.3682 -0.0133 -0.9342 -0.2622 -0.0008 -0.0378 -0.0431 -0.0357
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death hf hospitalization crt hazard_ratio
H-755	-1.2001497745513916	▁ HF _ hospital ization ▁c RT haz ard
D-755	-1.2001497745513916	HF_hospitalization cRThazard
P-755	-1.4870 -0.1296 -2.8787 -0.0223 -0.7278 -1.1326 -2.0009 -1.2549 -0.1207 -3.2294 -0.2176
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative_care patients terminal disease therapeutic
H-1820	-0.7653176188468933	▁palli ative _ care ▁patients ▁advanced _ مرض ▁ therapeut ic
D-1820	-0.7653176188468933	palliative_care patients advanced_مرض therapeutic
P-1820	-0.0059 -0.0042 -0.4971 -0.2594 -2.6543 -2.0452 -0.2365 -2.4136 -0.8240 -0.0060 -0.0363 -0.9089 -0.0577
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization medicare discharged nursing
H-1710	-0.4551885724067688	▁re hospital ization ▁medica re ▁fee - for - service _ ▁beneficiar ies ▁skille d _ nur sing
D-1710	-0.4551885724067688	rehospitalization medicare fee-for-service_ beneficiaries skilled_nursing
P-1710	-1.4789 -0.0022 -0.0543 -0.0052 -0.0041 -0.0343 -0.0438 -0.0161 -0.0076 -0.0010 -2.0907 -1.1071 -0.0435 -0.1779 -0.0035 -0.2802 -0.7897 -0.3705 -2.4606 -0.1327
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients lvad patients biventricular_support
H-297	-0.8759714365005493	▁isola ted _ L VAD ▁bi ven tri cular
D-297	-0.8759714365005493	isolated_LVAD biventricular
P-297	-3.2956 -0.0059 -0.3903 -3.4847 -0.0303 -0.4891 -0.0785 -0.1002 -0.3179 -1.2616 -0.1816
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.7407153248786926	▁trial ▁control _ group
D-158	-0.7407153248786926	trial control_group
P-158	-0.4741 -1.3808 -1.2915 -0.8220 -0.2629 -0.2130
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-1.47765052318573	
D-86	-1.47765052318573	
P-86	-2.8597 -0.0956
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end_point cardiovascular_death cardiac_transplant secondary_end_point death
H-1757	-0.8940370678901672	▁cardiovascular _ ▁смерти ▁urgent _ ▁cardiac _ ▁transplant
D-1757	-0.8940370678901672	cardiovascular_ смерти urgent_ cardiac_ transplant
P-1757	-2.2435 -0.7091 -3.3896 -0.4676 -0.3228 -0.2589 -0.2489 -0.1661 -1.0562 -0.0776
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis clinical prognostic diastolic_dysfunction leading hfpef
H-26	-0.47025495767593384	▁clinic al _ prog nosti c _ dia sto lic _ ▁dys function ▁H FP EF
D-26	-0.47025495767593384	clinical_prognostic_diastolic_ dysfunction HFPEF
P-26	-0.4742 -0.0683 -0.8303 -1.5561 -0.1515 -0.0288 -0.7387 -0.2435 -0.9583 -1.8399 -0.1537 -0.9344 -0.0428 -0.2519 -0.0087 -0.0467 -0.0370 -0.0999
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf_with_preserved_ejection_fraction hfpef hypertension
H-1076	-0.5498062372207642	▁ HF ▁pres er ved _ e je ction _ fraction HF p EF ▁hyper tension
D-1076	-0.5498062372207642	HF preserved_ejection_fractionHFpEF hypertension
P-1076	-2.0148 -0.0118 -4.4629 -0.1432 -0.0972 -0.3506 -0.6686 -0.4674 -0.0403 -0.3933 -0.0221 -0.3856 -0.0096 -0.0223 -0.5857 -0.0178 -0.0369 -0.1662
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes myocardial_ischemic_events patients cardiac_resynchronization_therapy
H-101	-0.6600030660629272	▁my o card ial _ ische mic _ ▁events ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.6600030660629272	myocardial_ischemic_ events cardiac resynchronization therapy
P-101	-2.3323 -0.5608 -0.4719 -0.0864 -0.3910 -2.3813 -0.1453 -0.8318 -1.2174 -0.0120 -1.0118 -0.0004 -0.0008 -0.1391 -2.0953 -0.0257 -0.0396 -0.1373
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic_tone pyridostigmine ventricular_dysfunction heart_failure
H-1132	-0.6876412630081177	▁para sy mpa the tic _ ▁tone ▁py rido stig mine ▁vent ri cular _ ▁dys function ▁heart _ ▁failure
D-1132	-0.6876412630081177	parasympathetic_ tone pyridostigmine ventricular_ dysfunction heart_ failure
P-1132	-0.0404 -2.5135 -0.0592 -0.9944 -0.0956 -0.3098 -0.3400 -0.1934 -0.0283 -0.0023 -0.0101 -0.0291 -1.0458 -0.4460 -0.7510 -1.6087 -0.0629 -4.3423 -0.5560 -1.5883 -0.0321 -0.0787
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp hf patient plasma immunoprecipitation mass_spectrometric_analysis
H-1515	-0.5510311722755432	▁NT - pro b NP ▁ HF ▁patient _ ▁plasma ▁immun o preci pit ation ▁mass ▁spec tro metric
D-1515	-0.5510311722755432	NT-probNP HF patient_ plasma immunoprecipitation mass spectrometric
P-1515	-0.2718 -0.0519 -0.0026 -1.5948 -0.2621 -0.5845 -0.0254 -4.0525 -1.0135 -0.5650 -0.0083 -0.2175 -0.5026 -0.0115 -0.1360 -0.0124 -0.6898 -0.0982 -0.2028 -1.0236 -0.2449
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade cardiac_angiogenesis heart_failure vegf_signaling_pathway
H-459	-0.6668689250946045	▁β - Block ade ▁cardiac _ ▁ang io gene sis ▁heart _ ▁failure ▁VE GF ▁signal ing _ path way
D-459	-0.6668689250946045	β-Blockade cardiac_ angiogenesis heart_ failure VEGF signaling_pathway
P-459	-1.5895 -0.1516 -0.1922 -2.0667 -0.1671 -1.0680 -0.5136 -1.6093 -1.6681 -0.5037 -0.1276 -0.6260 -1.2313 -0.6736 -0.0100 -0.7279 -0.3174 -1.0315 -0.1454 -0.0383 -0.1157 -0.0965
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end_points nyha_functional_class quality-of-life 6-minute_hall_walk
H-1873	-0.9926839470863342	▁NY HA ▁functional _ class ▁quality - of - life _ ▁score ▁hall ▁walk
D-1873	-0.9926839470863342	NYHA functional_class quality-of-life_ score hall walk
P-1873	-3.5147 -0.6050 -4.2623 -0.4426 -0.0345 -0.2806 -0.0483 -0.0007 -0.0287 -0.0382 -0.9668 -1.9177 -0.5635 -0.3318 -2.5805 -0.2670
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated_proteins chromatin_structure changing dna gene_expression_profile
H-90	-0.4426783621311188	▁Chro mat in - as soci ated _ ▁protein s ▁chr omat in _ structure ▁DNA ▁gene ▁expression ▁profile
D-90	-0.4426783621311188	Chromatin-associated_ proteins chromatin_structure DNA gene expression profile
P-90	-0.1420 -0.0058 -0.4633 -0.6247 -0.0977 -0.0001 -0.3060 -0.7977 -1.4297 -0.4058 -0.0705 -0.0430 -0.4738 -1.0038 -1.3587 -0.0225 -0.3134 -0.9442 -0.6603 -0.0420 -0.0912
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients heart_failure hf heart_failure_adherence_and_retention_trial hart
H-238	-0.45465826988220215	▁heart _ fail ure _ ad her ence ▁re tention _ Tri al HAR T
D-238	-0.45465826988220215	heart_failure_adherence retention_TrialHART
P-238	-1.6114 -0.5069 -2.1062 -0.0299 -0.7750 -0.1253 -0.0656 -0.0050 -0.5546 -0.0024 -0.1305 -1.1804 -0.0125 -0.3935 -0.1168 -0.0316 -0.0814
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective_beta-blockers cardiac_sympathetic_activity hemostasis patients heart_failure
H-1110	-0.9401419162750244	▁non sel ective ▁beta - block ers ▁cardiac _ ▁sympa the tic _ activ ity ▁hemos tas is ▁heart _ ▁failure
D-1110	-0.9401419162750244	nonselective beta-blockers cardiac_ sympathetic_activity hemostasis heart_ failure
P-1110	-1.3200 -0.0182 -0.0183 -5.8105 -0.0733 -0.2674 -0.1103 -0.0543 -0.7737 -2.9974 -0.2452 -2.2640 -1.7411 -0.3594 -0.1439 -0.0450 -0.0523 -2.3713 -0.5964 -0.6864 -1.5032 -0.0763 -0.0956
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right_ventricle leads stroke_volume shortens left_ventricular_ejection_time lvet
H-578	-0.7735904455184937	▁right ▁vent ric le ▁over load ▁stroke _ ▁volume ▁left ▁vent ri cular _ e je ction _ ▁time
D-578	-0.7735904455184937	right ventricle overload stroke_ volume left ventricular_ejection_ time
P-578	-0.4114 -1.0941 -1.3517 -0.8126 -0.5094 -0.0002 -1.2410 -1.7571 -0.0648 -0.1683 -2.5909 -1.1950 -0.1339 -0.4703 -0.6496 -0.4088 -0.0415 -1.3475 -0.9980 -0.8828 -0.1167
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial_infarction left_anterior_descending_coronary_artery_occlusion
H-1338	-0.5079346299171448	▁My o card ial _ in far ction ▁left ▁anterior _ ▁descend ing ▁corona ry _ ▁arter y ▁oc clusi on
D-1338	-0.5079346299171448	Myocardial_infarction left anterior_ descending coronary_ artery occlusion
P-1338	-1.5481 -0.2144 -1.2038 -0.0472 -0.4432 -0.5831 -0.0218 -0.0211 -0.2855 -3.4177 -0.5426 -0.3251 -0.0178 -0.2747 -0.1064 -0.9133 -0.5820 -0.8315 -0.0111 -0.0022 -0.1084 -0.0904 -0.0911
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic_receptor_blockade mortality all-cause_hospitalizations patients heart_failure hf
H-1424	-0.8849563002586365	▁β - Ad r energi c _ ▁receptor _ ▁block ade ▁hospital ization s ▁heart _ ▁failure HF
D-1424	-0.8849563002586365	β-Adrenergic_ receptor_ blockade hospitalizations heart_ failureHF
P-1424	-1.0008 -0.0892 -0.9890 -0.4689 -1.8092 -0.2072 -0.5296 -0.6465 -0.4468 -1.3501 -0.2213 -2.7831 -0.6494 -1.0788 -1.3643 -0.2678 -2.9445 -0.5216 -0.1583 -0.1729
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-1.0212785005569458	
D-609	-1.0212785005569458	
P-609	-1.9589 -0.0836
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission patients
H-1581	-1.2445813417434692	▁re duction ▁30- day _ ▁read mission _ ▁rate
D-1581	-1.2445813417434692	reduction 30-day_ readmission_ rate
P-1581	-6.6045 -0.0025 -1.3037 -0.1111 -0.0943 -2.1602 -0.1703 -0.6702 -1.0539 -1.2289 -0.2909
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis systemic followed_up
H-1559	-0.7848412394523621	▁psoriasis ▁system ic _ UV _ ▁treatment
D-1559	-0.7848412394523621	psoriasis systemic_UV_ treatment
P-1559	-0.3383 -0.5066 -0.0488 -0.7552 -1.3482 -1.1650 -2.4453 -0.3534 -0.1029
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions remodelling leading heart_failure
H-991	-0.4921031892299652	▁stress ▁conditions ▁mal adapt ive _ ▁remodel ling ▁heart ▁failure
D-991	-0.4921031892299652	stress conditions maladaptive_ remodelling heart failure
P-991	-0.6683 -0.6857 -0.0286 -0.0272 -0.0028 -0.5645 -0.2354 -0.0246 -0.2880 -3.3089 -0.0233 -0.0478
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality lcx lad disease
H-513	-0.4299680292606354	▁mortal ity ▁ LC X ▁ LAD ▁two - ves sel _ ▁disease
D-513	-0.4299680292606354	mortality LCX LAD two-vessel_ disease
P-513	-0.4145 -0.0105 -0.0998 -0.0018 -0.6161 -0.0714 -0.0006 -0.2758 -0.0217 -0.0284 -0.0309 -0.2387 -3.3955 -1.0058 -0.2382
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr acr cms correlated
H-141	-0.6862229704856873	▁p PR ▁a CR ▁CMS
D-141	-0.6862229704856873	pPR aCR CMS
P-141	-1.0935 -0.8771 -0.2641 -0.3852 -0.4198 -1.5847 -0.1792
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous symptoms patients heart_failure
H-51	-0.7182033658027649	▁Intra ven ous ▁ir on ▁heart _ ▁failure ▁ir on _ de fici en cy
D-51	-0.7182033658027649	Intravenous iron heart_ failure iron_deficiency
P-51	-0.1776 -0.0040 -0.2914 -2.3646 -0.2157 -4.5214 -0.5904 -2.2310 -0.0225 -0.0541 -0.3868 -0.2294 -0.0022 -0.7847 -0.0369 -0.0959 -0.2009
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv_dysfunction prognosis hf
H-1160	-0.8087834119796753	▁ RV _ ▁dys function ▁weight _ ▁loss ▁ab normal _ ▁body _ ▁composition
D-1160	-0.8087834119796753	RV_ dysfunction weight_ loss abnormal_ body_ composition
P-1160	-0.3635 -0.4060 -1.5598 -1.3960 -0.1193 -0.6911 -1.8321 -1.4424 -0.4593 -0.0049 -0.8709 -0.1558 -1.0794 -0.2414 -1.9088 -0.4096
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet sensitivity specificity death icu
H-584	-1.2103395462036133	▁L VET _ at ▁entry ▁ ICU
D-584	-1.2103395462036133	LVET_at entry ICU
P-584	-1.7133 -0.0112 -4.3506 -1.3882 -0.1047 -2.7805 -0.2698 -0.1104 -0.1645
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ischemic_heart_failure
H-1613	-1.0444730520248413	▁non - ische mic ▁ ische mic
D-1613	-1.0444730520248413	non-ischemic ischemic
P-1613	-2.6273 -0.0697 -0.3346 -0.1758 -1.7817 -0.2342 -0.1278 -3.9311 -0.1183
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient symptomatic therapeutic exercise hemodynamic
H-1179	-0.38370540738105774	▁ex er tion ▁ab normal ▁exercise ▁hem o dynamic
D-1179	-0.38370540738105774	exertion abnormal exercise hemodynamic
P-1179	-0.3156 -0.0608 -0.0259 -0.8680 -0.0066 -0.8526 -1.5424 -0.0244 -0.0010 -0.4767 -0.0467
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait therapy lokomat heart_failure patients
H-1912	-0.47263848781585693	▁robot - assist ed _ ▁ga it _ therapy ▁Lok omat _ system ▁heart _ ▁failure
D-1912	-0.47263848781585693	robot-assisted_ gait_therapy Lokomat_system heart_ failure
P-1912	-1.5343 -0.1130 -0.0004 -0.0168 -0.5504 -0.4540 -1.0792 -0.6996 -0.1449 -0.0711 -0.0197 -1.0734 -0.1334 -0.0918 -0.9240 -0.9502 -0.5206 -0.1306
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf patients emergency_department intubated
H-210	-1.2894538640975952	▁CHF _ ▁patients ▁emergency _ ▁department
D-210	-1.2894538640975952	CHF_ patients emergency_ department
P-210	-0.7337 -3.3130 -1.6541 -0.0692 -0.5004 -0.2387 -3.6018 -0.2046
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut inflammation heart_failure patients heart_failure
H-1363	-1.0943020582199097	▁gut ▁ inflammation ▁dieta ry _ intervention s ▁heart _ ▁failure
D-1363	-1.0943020582199097	gut inflammation dietary_interventions heart_ failure
P-1363	-1.5339 -0.7277 -0.0238 -3.9195 -0.0613 -1.5248 -0.6241 -0.0605 -0.1078 -0.7441 -2.6368 -2.0009 -0.2608
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart_failure emergency_department patient outcomes
H-462	-0.6748987436294556	▁he art _ ▁failure ▁Emer gen cy _ ▁Department ED ▁ED _ ▁volume ▁patient ▁outcome s
D-462	-0.6748987436294556	heart_ failure Emergency_ DepartmentED ED_ volume patient outcomes
P-462	-3.4418 -0.8582 -0.3191 -0.4631 -1.0775 -0.0371 -0.0034 -0.1341 -0.3368 -0.7399 -0.5527 -1.6437 -0.0302 -2.0961 -0.2816 -0.0355 -0.0402 -0.0571
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients diagnosis congestive_heart_failure
H-1578	-0.7765488624572754	▁con ges tive _ heart _ ▁failure
D-1578	-0.7765488624572754	congestive_heart_ failure
P-1578	-1.2148 -0.1007 -0.1309 -0.1965 -2.2810 -0.5517 -2.3987 -0.0647 -0.0499
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial_structure sarcomeric_microstructure
H-1250	-0.8470732569694519	▁mito cho ndri al _ structure s ▁sar come ric _ micro structure
D-1250	-0.8470732569694519	mitochondrial_structures sarcomeric_microstructure
P-1250	-0.2041 -1.7592 -0.2445 -0.0100 -0.5967 -1.0033 -3.7314 -1.6306 -1.5446 -1.5112 -0.2264 -0.0620 -0.0523 -0.0382 -0.0918
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy hdl chf-nyha-iiib hdl
H-258	-0.977588951587677	▁ET ▁CHF - NY HA - III b ▁HD L _ function
D-258	-0.977588951587677	ET CHF-NYHA-IIIb HDL_function
P-258	-3.0330 -6.0575 -0.1883 -0.0528 -0.3441 -0.3139 -0.0607 -0.0441 -0.2515 -0.9505 -1.1037 -0.8521 -0.3258 -0.1083
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician follow-up discharge death readmission patients heart_failure
H-1413	-1.560811161994934	▁e ar ly ▁physician _ ▁follow - up _ dis charge
D-1413	-1.560811161994934	early physician_ follow-up_discharge
P-1413	-6.3953 -0.0286 -0.1214 -1.5981 -1.2026 -2.8716 -0.0733 -0.0040 -1.1984 -1.1505 -0.0348 -5.4358 -0.1762
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis patients chf therapeutic neurohormonal_systems
H-635	-0.7731659412384033	▁CHF ▁ therapeut ic _ ▁interrupt ion ▁activa ted _ ▁neuro hormon al ▁systems
D-635	-0.7731659412384033	CHF therapeutic_ interruption activated_ neurohormonal systems
P-635	-4.8582 -2.7828 -0.0482 -0.0102 -0.5792 -0.0284 -0.0106 -0.6967 -0.0183 -0.4813 -1.7904 -0.1661 -0.0134 -0.7612 -0.0839 -0.0416
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients uptitration heart_rate renal_function spironolactone
H-180	-0.8663244843482971	▁up tit ration ▁heart ▁rate ▁renal _ function ▁spi rono lac tone
D-180	-0.8663244843482971	uptitration heart rate renal_function spironolactone
P-180	-2.4101 -0.9887 -0.1805 -4.5771 -0.6949 -0.0760 -2.1753 -0.4692 -0.1437 -0.0562 -0.0843 -0.0245 -0.0719 -0.1762
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence micrornas mirnas pathogenesis heart_failure
H-1481	-1.1962940692901611	▁micro RNA s _ mi RNA s ▁progression _ of ▁heart _ ▁failure
D-1481	-1.1962940692901611	microRNAs_miRNAs progression_of heart_ failure
P-1481	-4.4523 -0.0050 -0.0956 -3.6237 -0.0972 -0.0004 -0.0325 -3.0156 -0.8292 -0.1159 -3.5910 -0.2376 -1.7378 -0.0458 -0.0648
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient implantable_cardioverter-defibrillator
H-1859	-0.8575198650360107	▁a im ▁implant able _ de fi br illa tor _ de activa tion
D-1859	-0.8575198650360107	aim implantable_defibrillator_deactivation
P-1859	-1.3726 -1.0760 -4.2071 -0.0090 -0.6097 -2.0718 -0.2898 -1.7016 -0.3878 -0.1395 -0.3581 -0.0971 -0.6645 -0.0388 -0.6287 -0.0684
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive patients pulmonary_hypertension heart_failure
H-577	-0.9463821053504944	▁pulmonar y _ ▁hyper tension PH ▁heart _ ▁failure
D-577	-0.9463821053504944	pulmonary_ hypertensionPH heart_ failure
P-577	-1.4112 -0.0069 -0.3434 -1.7209 -0.0312 -3.1440 -2.5673 -0.5866 -0.5291 -0.0245 -0.0453
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory hf patients left_ventricular_ejection_fraction
H-122	-1.3828260898590088	▁consenti ng ▁ambula tory ▁ HF
D-122	-1.3828260898590088	consenting ambulatory HF
P-122	-5.4342 -0.0259 -0.0160 -0.0019 -0.3944 -0.0045 -5.1153 -0.0704
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker patients resting_hr bpm p_value
H-1941	-1.039433240890503	▁Beta - block er _ ▁dose ▁rest ing _ HR
D-1941	-1.039433240890503	Beta-blocker_ dose resting_HR
P-1941	-0.1405 -0.0112 -0.0336 -0.7436 -3.0357 -0.2013 -4.1753 -0.3210 -0.9991 -0.2597 -2.3944 -0.1578
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt_variability qtv repolarization qtv cardiac_death
H-1435	-0.7647799253463745	▁ QT _ ▁variabil ity ▁Q TV ▁repo lar ization _ la bility ▁Q TV ▁risk _ pred or ▁sud den _ ▁cardiac _ ▁death
D-1435	-0.7647799253463745	QT_ variability QTV repolarization_lability QTV risk_predor sudden_ cardiac_ death
P-1435	-2.0336 -0.5660 -1.9112 -0.7904 -0.0240 -2.8695 -0.5841 -0.6237 -0.7697 -0.0213 -0.7746 -0.3813 -0.0004 -0.5239 -0.1918 -0.7868 -0.7448 -0.7780 -1.8032 -0.0556 -0.0037 -0.9955 -0.6675 -0.6468 -1.9173 -0.0336 -0.1506
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients heart_failure_and_reduced_ejection_fraction
H-668	-1.4507619142532349	▁practice - level _ of _ care ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction
D-668	-1.4507619142532349	practice-level_of_care heart_ failure reduced ejection_fraction
P-668	-3.0801 -2.3073 -0.1084 -4.2899 -3.6117 -0.2451 -2.5312 -5.0558 -0.9128 -2.4093 -0.4756 -0.0232 -1.1572 -0.3674 -0.1442 -0.4446 -0.0088 -0.0977 -0.2941
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis patients adverse_events echocardiographic outcomes
H-914	-0.9217923283576965	▁di al ysis ▁advers e _ ▁events ▁e cho car dio graphic
D-914	-0.9217923283576965	dialysis adverse_ events echocardiographic
P-914	-0.1963 -0.0396 -0.0887 -3.9981 -0.3805 -1.0763 -1.0044 -0.1286 -0.1787 -1.5254 -1.4560 -1.9967 -0.7433 -0.0926
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 healthy heart_muscle cells phenotype pathological hypertrophy
H-641	-0.5321620106697083	▁mu tant _ mi ce ▁over express ing ▁Hand 2 ▁heart _ ▁muscle _ cell s ▁path ological _ ▁hyper trop hy
D-641	-0.5321620106697083	mutant_mice overexpressing Hand2 heart_ muscle_cells pathological_ hypertrophy
P-641	-0.0713 -0.2046 -0.8358 -0.4279 -0.0137 -0.5596 -0.0193 -0.0192 -0.0969 -0.1485 -3.5832 -0.3609 -2.4721 -0.9511 -0.1333 -0.1172 -0.0352 -0.1173 -1.1090 -0.9616 -0.0024 -0.3979 -0.0272 -0.1068
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new_zealand renal_dnx pacing-induced_chf
H-1373	-0.5734044313430786	▁white _ ▁rabbi ts ▁renal ▁DN x ▁pa cing - indu ced ▁CHF
D-1373	-0.5734044313430786	white_ rabbits renal DNx pacing-induced CHF
P-1373	-6.9010 -1.0994 -0.1002 -0.0034 -0.0125 -0.1847 -0.0243 -0.0117 -0.0067 -0.0720 -0.0003 -0.0044 -0.0119 -0.0301 -0.1386
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
H-1647	-0.42547720670700073	▁cat heter ▁ab lation ▁anti ar rhythm ic ▁drugs ▁ rhythm _ control ▁ therapy
D-1647	-0.42547720670700073	catheter ablation antiarrhythmic drugs rhythm_control therapy
P-1647	-0.9700 -0.0106 -0.2149 -0.0003 -0.0100 -0.1662 -1.0465 -0.0925 -1.2969 -0.3376 -0.3165 -0.8802 -0.0141 -1.5801 -0.0302 -0.0482 -0.2185
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage poc
H-1029	-1.2029037475585938	▁process es _ of _ care _ ▁delivery
D-1029	-1.2029037475585938	processes_of_care_ delivery
P-1029	-1.5126 -0.6896 -3.0938 -0.1078 -0.1281 -1.0648 -2.0269 -0.1973 -2.9730 -0.2351
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker uptitration clinical outcome patients hfref hfpef
H-185	-0.6694469451904297	RAS - block er ▁up tit ration ▁clinic al _ ▁outcome ▁ HF p EF
D-185	-0.6694469451904297	RAS-blocker uptitration clinical_ outcome HFpEF
P-185	-1.3231 -0.0583 -0.1689 -0.7261 -1.6647 -0.8293 -0.1016 -0.4546 -0.0219 -1.2441 -0.1442 -2.3169 -1.2857 -0.6750 -0.1806 -0.0543 -0.1312
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac_failure death patients type_2_diabetes diabetes heart_failure
H-652	-1.550257921218872	▁Card iac _ ▁failure ▁diabetes ▁diabetes ▁heart _ ▁failure
D-652	-1.550257921218872	Cardiac_ failure diabetes diabetes heart_ failure
P-652	-3.5283 -0.5744 -0.5141 -2.0903 -1.9339 -4.3163 -2.5191 -0.4437 -0.9225 -0.1044 -0.1058
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal_echocardiography shunts thrombosis
H-1957	-0.9550108909606934	▁trans o es op hage al _ e cho card i ography ▁shu nts ▁ thro mbo sis ▁migration
D-1957	-0.9550108909606934	transoesophageal_echocardiography shunts thrombosis migration
P-1957	-0.1088 -0.3101 -1.2841 -3.6024 -1.4952 -0.3683 -0.3682 -0.6401 -0.3373 -1.1980 -0.3799 -0.3609 -2.2326 -0.0060 -0.4408 -0.1183 -1.0435 -5.4989 -0.0971 -0.0517 -0.1129
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial_tonometry lvet prognostic patients precapillary_ph heart_failure
H-579	-0.6138840913772583	▁arterial _ ▁ton ometr y ▁l VET _ car ries ▁pre cap illa ry _ ▁PH ▁heart _ ▁failure
D-579	-0.6138840913772583	arterial_ tonometry lVET_carries precapillary_ PH heart_ failure
P-579	-0.1144 -0.1856 -2.4565 -0.0285 -0.0350 -3.9683 -0.0363 -0.7690 -0.3947 -0.0077 -0.0274 -0.3701 -0.1857 -0.0640 -0.3703 -0.7805 -0.4446 -0.7765 -1.6576 -0.0574 -0.1617
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf shift chronic_heart_failure chronic_heart_failure cardiology
H-1964	-0.9404071569442749	▁para DIG m - HF ▁chronic _ heart _ ▁failure ▁Chro nic _ heart _ ▁failure ▁card i ology
D-1964	-0.9404071569442749	paraDIGm-HF chronic_heart_ failure Chronic_heart_ failure cardiology
P-1964	-5.9060 -1.6640 -0.4799 -0.2348 -0.0047 -2.2841 -0.1780 -0.9295 -0.3570 -1.2869 -3.8550 -0.0223 -0.0220 -0.8408 -0.2819 -0.6374 -0.3319 -0.2679 -0.0015 -0.0330 -0.1300
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin exercise training health patients chronic_heart_failure hf-action randomized
H-833	-0.7273306250572205	▁Hem o glob in ▁health ▁status ▁patients ▁chronic _ heart _ ▁failure ▁ HF - AC TION ▁random ized _ control led _ ▁trial
D-833	-0.7273306250572205	Hemoglobin health status patients chronic_heart_ failure HF-ACTION randomized_controlled_ trial
P-833	-0.2892 -0.0183 -0.0540 -0.3036 -2.7049 -0.7507 -2.3041 -1.1677 -0.1731 -0.6565 -0.6470 -5.5447 -0.5384 -0.0036 -0.0754 -0.2513 -0.7347 -1.3534 -0.4109 -0.2811 -0.0719 -0.0785 -0.2161 -0.1007 -0.0965 -0.0841
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese zsf1 heart_failure_with_preserved_ejection_fraction
H-770	-0.6335422992706299	▁Z SF 1 ▁rat s ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-770	-0.6335422992706299	ZSF1 rats heart_ failure preserved ejection_fraction
P-770	-1.5219 -0.2830 -0.9309 -0.8427 -0.0776 -2.2018 -0.7054 -2.3750 -0.0244 -0.0660 -0.1189 -0.7747 -0.2074 -0.0848 -0.9596 -0.0142 -0.1243 -0.0912
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk heart adipose_tissue cachectic_heart_failure patients prospective_study
H-8	-0.77403724193573	▁cross - talk ▁heart ▁adi pose _ ▁tissu e ▁cache ctic _ heart _ ▁failure ▁body
D-8	-0.77403724193573	cross-talk heart adipose_ tissue cachectic_heart_ failure body
P-8	-3.2420 -0.2868 -0.0283 -3.1952 -1.2898 -0.0619 -0.2984 -0.7078 -0.0548 -0.0040 -0.2687 -0.3220 -0.7173 -0.3124 -1.3438 -0.5953 -1.0583 -0.1459
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems_proteomics cardiac_chromatin nucleolin cellular_plasticity cardiomyocytes
H-88	-0.8038699626922607	▁systems ▁prote o mics ▁cardiac _ ▁chr omat in ▁nucleo lin ▁regulator _ of _ ▁growth ▁cardio my o cy tes
D-88	-0.8038699626922607	systems proteomics cardiac_ chromatin nucleolin regulator_of_ growth cardiomyocytes
P-88	-2.3766 -2.7530 -0.3764 -0.0868 -0.0698 -0.4634 -0.0115 -0.0033 -0.2099 -0.3140 -1.1225 -1.2946 -2.9308 -0.5114 -1.0877 -0.5902 -2.3969 -0.1235 -1.3064 -0.1347 -0.1365 -0.1089 -0.0802
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac_dysfunction subcellular metoprolol heart_failure myocardial_infarction
H-1546	-0.41052886843681335	▁cardiac _ dis function ▁sub cel lular _ ▁altera tions ▁met o pro lol ▁heart _ ▁failure ▁my o card ial _ in far ction
D-1546	-0.41052886843681335	cardiac_disfunction subcellular_ alterations metoprolol heart_ failure myocardial_infarction
P-1546	-0.0406 -0.9794 -0.6887 -0.5112 -0.1133 -0.0312 -0.0261 -2.2548 -1.6168 -0.0048 -0.1476 -0.0326 -0.0062 -0.0676 -0.9973 -0.6011 -0.6343 -0.1742 -0.0501 -0.6512 -0.0998 -0.4613 -0.6453 -0.0028 -0.0475 -0.0545 -0.1439
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping mri tidal_respiration myocardial_t1 heart_failure
H-1054	-0.4485693573951721	▁t 1- ma pping ▁m RI ▁tid al _ ▁respira tion ▁my o card ial _ ▁T 1 ▁s win e ▁heart _ ▁failure
D-1054	-0.4485693573951721	t1-mapping mRI tidal_ respiration myocardial_ T1 swine heart_ failure
P-1054	-1.9741 -0.7792 -0.4483 -0.0167 -2.6240 -0.6190 -0.5176 -0.0027 -0.2174 -0.0782 -0.0086 -0.0765 -0.0554 -0.2651 -0.0041 -0.4039 -0.7221 -0.0540 -0.0216 -0.0064 -0.2069 -0.4290 -0.7094 -1.2259 -0.0570 -0.1397
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial_collagen collagen_cross-linking titin isoforms phosphorylation
H-764	-0.17237955331802368	▁My o card ial ▁collage n ▁collage n ▁titi n ▁iso form s ▁ phos phor y lation
D-764	-0.17237955331802368	Myocardial collagen collagen titin isoforms phosphorylation
P-764	-0.5480 -0.0104 -0.2418 -0.0468 -0.1204 -0.1712 -0.5704 -0.0398 -0.6869 -0.0296 -0.0175 -0.0132 -0.0786 -0.1724 -0.0003 -0.0872 -0.5329 -0.0092 -0.0190 -0.0521
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart_magnetic_resonance_imaging chelation compliance heart_disease patients thalassaemia_major
H-744	-0.520339846611023	▁heart ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation _ ▁choice s ▁risk ▁tha lassa emia
D-744	-0.520339846611023	heart magnetic_ resonance_ imaging chelation_ choices risk thalassaemia
P-744	-0.6716 -0.6468 -0.1440 -0.4567 -0.1613 -0.0204 -0.1821 -4.0361 -0.0937 -0.0498 -0.0008 -0.6612 -0.4932 -0.0528 -0.5884 -1.1537 -0.4967 -0.0747 -0.3484 -0.0746
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv_diastolic_dysfunction filling_pressures non-invasively doppler_echocardiography
H-28	-0.3842829167842865	▁LV _ dia sto lic _ dis function ▁fill ing _ ▁pressure s ▁do pp ler _ e cho card i ography
D-28	-0.3842829167842865	LV_diastolic_disfunction filling_ pressures doppler_echocardiography
P-28	-0.2619 -1.6957 -0.4953 -0.1366 -0.4776 -0.6071 -1.1092 -0.1666 -0.0439 -0.0169 -0.1767 -0.2481 -0.0619 -0.8981 -0.0011 -0.3853 -0.4055 -0.5976 -0.1847 -0.5996 -0.1381 -0.1519 -0.0974 -0.2659
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac_magnetic_resonance_postcontrast_t1_time outcome patients heart_failure preserved_ejection_fraction
H-733	-0.5634065866470337	▁Card iac _ ▁magnetic _ ▁res on ance ▁post contra st _ ▁T 1 ▁time ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-733	-0.5634065866470337	Cardiac_ magnetic_ resonance postcontrast_ T1 time heart_ failure preserved ejection_fraction
P-733	-0.2513 -0.2142 -0.2722 -0.7132 -0.1197 -0.3767 -0.0701 -0.0183 -0.3518 -0.0027 -0.0028 -1.1349 -1.9995 -0.1141 -3.3588 -2.2136 -0.3287 -2.0200 -0.0078 -0.1447 -0.1813 -0.7211 -0.1739 -0.1017 -0.7631 -0.0049 -0.0483 -0.0659
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs clinical
H-2015	-0.9157091379165649	▁internal _ ▁external _ ▁valid ity ▁costs ▁clinic al _ ▁trial s
D-2015	-0.9157091379165649	internal_ external_ validity costs clinical_ trials
P-2015	-1.4357 -2.5358 -2.6512 -0.1801 -1.2512 -0.0033 -3.4239 -0.5809 -0.0066 -0.4465 -0.1593 -0.0492 -0.0209 -0.0752
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins subproteome
H-94	-1.1150709390640259	▁protein s
D-94	-1.1150709390640259	proteins
P-94	-1.5704 -0.1925 -2.6419 -0.0555
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy patients follow-up
H-861	-0.46942076086997986	▁in appropria te _ therapy
D-861	-0.46942076086997986	inappropriate_therapy
P-861	-0.9636 -0.0074 -0.1116 -1.0425 -0.1099 -0.9885 -0.0625
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm_control_therapy
H-1645	-0.5189518928527832	▁ Rhythm _ control _ therapy
D-1645	-0.5189518928527832	Rhythm_control_therapy
P-1645	-0.1656 -0.0588 -0.3425 -0.0223 -0.5264 -0.3283 -2.4297 -0.2781
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis medical hf
H-200	-0.7285386919975281	▁medical _ management ▁ HF ▁in fan cy ▁adolesce nce
D-200	-0.7285386919975281	medical_management HF infancy adolescence
P-200	-4.8945 -1.7534 -0.0726 -0.4004 -0.0087 -0.3632 -0.0275 -0.0083 -0.9183 -0.1101 -0.0516 -0.1339
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician patient admission admission
H-1417	-1.4055097103118896	▁familiar ▁physician ▁index ▁ad mission
D-1417	-1.4055097103118896	familiar physician index admission
P-1417	-2.3813 -3.9974 -0.2401 -0.0933 -0.0071 -2.2999 -0.8194
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma collected hf patients
H-1514	-1.148943543434143	▁Plas ma ▁ HF
D-1514	-1.148943543434143	Plasma HF
P-1514	-1.0927 -0.1945 -2.7108 -0.0425 -2.7830 -0.0701
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular_disease baseline
H-1767	-1.9530062675476074	▁cardiovascular _ مرض ▁base line
D-1767	-1.9530062675476074	cardiovascular_مرض baseline
P-1767	-5.4199 -0.8338 -4.9738 -0.1409 -0.0050 -2.2118 -0.0859
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital_compare ami mortality
H-1697	-0.6865434646606445	▁hospital _ com posit e ▁ AMI _ ▁mortal ity
D-1697	-0.6865434646606445	hospital_composite AMI_ mortality
P-1697	-3.0332 -0.9076 -1.4161 -0.0019 -0.0127 -0.3246 -0.1367 -0.6448 -0.5137 -0.0078 -1.0803 -0.1592
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause_readmissions
H-726	-1.217498540878296	
D-726	-1.217498540878296	
P-726	-2.4093 -0.0257
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients beta-blocker therapy
H-1939	-0.9076277017593384	▁quality _ of _ care _ programm e ▁guide line - re com mend ed ▁beta - block er _ therapy
D-1939	-0.9076277017593384	quality_of_care_programme guideline-recommended beta-blocker_therapy
P-1939	-3.8879 -1.4274 -0.1201 -0.0840 -0.6556 -4.0707 -0.3587 -1.2575 -2.2374 -0.0045 -0.3541 -0.0668 -0.0102 -0.0057 -0.0459 -3.6259 -0.0204 -0.1442 -0.5258 -0.7895 -0.6769 -0.0814 -0.4247
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs patients oht transplant vad
H-1288	-0.7529929876327515	▁a cs ▁o HT ▁ bridge d ▁transplant ▁MT ▁ VAD
D-1288	-0.7529929876327515	acs oHT bridged transplant MT VAD
P-1288	-0.5947 -1.6651 -2.7203 -0.5229 -0.5532 -0.0012 -0.5755 -1.6932 -0.7964 -0.4752 -0.0053 -0.0532 -0.1327
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis cardiovascular_disease cvd
H-1555	-0.9206261038780212	▁p sori asis ▁risk _ factor ▁cardiovascular _ ▁disease CV D
D-1555	-0.9206261038780212	psoriasis risk_factor cardiovascular_ diseaseCVD
P-1555	-2.2845 -0.2510 -0.3371 -2.1024 -0.9755 -0.0122 -0.0970 -0.6383 -3.6804 -0.5086 -0.8022 -0.2106 -0.0685
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal likelihood_ratio
H-487	-0.9558022618293762	▁cut off ▁negative _ pred ive _ valu e ▁e / e ' sept al ▁negative _ like li hood _ rati o
D-487	-0.9558022618293762	cutoff negative_predive_value e/e'septal negative_likelihood_ratio
P-487	-2.1180 -0.2017 -0.9901 -0.8390 -3.5366 -0.1316 -0.3973 -0.5763 -0.1411 -1.0682 -2.7267 -0.0239 -4.7256 -0.0368 -0.0468 -0.0623 -0.5419 -3.5710 -0.0559 -0.0315 -0.9737 -0.5436 -0.0058 -0.2905 -0.2592
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal hospital hf patients cms conditions
H-139	-0.9109617471694946	▁hospital _ rate ▁ HF ▁CMS _ metric
D-139	-0.9109617471694946	hospital_rate HF CMS_metric
P-139	-3.7223 -0.4064 -0.6264 -0.3778 -0.0015 -0.8056 -0.8720 -0.0022 -2.1890 -0.1065
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients cardiovascular_disease drs
H-1838	-1.3460413217544556	▁patients ▁d RS _ ▁deci les
D-1838	-1.3460413217544556	patients dRS_ deciles
P-1838	-4.4607 -3.3538 -0.8069 -1.2731 -0.6971 -0.0161 -0.0758 -0.0847
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes hypertrophic
H-1217	-0.40342992544174194	▁p de 2- over express ing ▁cardio my o cy tes ▁no re pine ph rine - indu ced ▁hyper trop hic
D-1217	-0.40342992544174194	pde2-overexpressing cardiomyocytes norepinephrine-induced hypertrophic
P-1217	-0.9498 -0.4596 -1.1412 -0.0256 -0.0685 -0.0300 -0.0725 -0.4371 -1.0203 -0.9366 -0.8692 -0.0513 -0.0297 -0.1353 -0.9807 -0.0183 -0.3049 -0.0086 -0.0669 -0.5054 -0.0064 -0.0200 -1.4750 -0.0694
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty heart_failure hf
H-622	-0.9314913749694824	▁fra il ty ▁risk _ of _ heart _ ▁failure
D-622	-0.9314913749694824	frailty risk_of_heart_ failure
P-622	-1.8881 -0.2363 -0.3114 -0.4272 -0.9858 -2.0244 -0.1669 -0.3590 -0.2331 -2.9664 -1.4935 -0.0857
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline patients resting_hr bpm
H-1940	-0.7148470282554626	▁base line
D-1940	-0.7148470282554626	baseline
P-1940	-0.0805 -0.0062 -2.6744 -0.0983
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart_failure patients bisphosphonates
H-1535	-1.8710556030273438	▁heart ▁failure ▁bis phos phon ates
D-1535	-1.8710556030273438	heart failure bisphosphonates
P-1535	-6.6700 -5.5633 -1.6924 -0.0143 -0.6314 -0.2161 -0.0961 -0.0850
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt gdmt bat
H-1871	-0.7668478488922119	▁GD MT ▁BAT
D-1871	-0.7668478488922119	GDMT BAT
P-1871	-1.0261 -0.2069 -2.3505 -0.2138 -0.0368
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients β-blocker patients uptitration
H-179	-1.7466866970062256	▁ RAS - ▁β - block er _ ▁dose
D-179	-1.7466866970062256	RAS- β-blocker_ dose
P-179	-0.2190 -0.0400 -0.1998 -7.0969 -0.0353 -1.1408 -1.9380 -3.1158 -0.6654 -4.1096 -0.6531
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression bax bcl-2 proteins pacing
H-170	-0.7005165815353394	▁expression ▁Bax ▁b cl -2 ▁protein s
D-170	-0.7005165815353394	expression Bax bcl-2 proteins
P-170	-2.3134 -0.2147 -0.6157 -0.0188 -0.4342 -0.9111 -0.0712 -1.4911 -0.2343
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas cardiac_remodeling heart_failure
H-1483	-0.49167701601982117	▁mi RNA s ▁cardiac _ ▁remodel ing ▁heart _ ▁failure
D-1483	-0.49167701601982117	miRNAs cardiac_ remodeling heart_ failure
P-1483	-1.9531 -0.0003 -0.2001 -0.0342 -0.5478 -0.7660 -0.0204 -0.3677 -0.1449 -1.6391 -0.1732 -0.0532
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate alendronate heart_failure
H-1545	-1.2607399225234985	▁ale ndr onate ▁risk _ of _ heart _ ▁failure
D-1545	-1.2607399225234985	alendronate risk_of_heart_ failure
P-1545	-3.0914 -0.1932 -1.0882 -3.3636 -2.6002 -0.2927 -0.3067 -0.4360 -0.7172 -2.7363 -0.1975 -0.1059
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported heart_failure clcnka snp
H-1804	-1.2976018190383911	▁risk _ of _ heart _ ▁failure ▁CL CN KA ▁s NP
D-1804	-1.2976018190383911	risk_of_heart_ failure CLCNKA sNP
P-1804	-5.7676 -2.2263 -0.2614 -0.1086 -0.6945 -0.6902 -4.8379 -0.3848 -0.3921 -0.3095 -2.0437 -0.0050 -0.3661 -0.0787
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation anti-inflammatory chf
H-1362	-0.4709955155849457	▁regula tion _ of ▁feed ing ▁nutrition al ▁anti - in flam ma tory _ effect s ▁CHF
D-1362	-0.4709955155849457	regulation_of feeding nutritional anti-inflammatory_effects CHF
P-1362	-0.0089 -0.0056 -0.9269 -0.1774 -1.4156 -0.0118 -1.4375 -0.4590 -0.2184 -0.0131 -0.1783 -0.0108 -1.0370 -0.0841 -0.8799 -0.4062 -0.2723 -1.7693 -0.0412 -0.0668
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical diastolic_dysfunction mortality
H-25	-0.6227222681045532	▁clinic al _ dia sto lic _ ▁dys function
D-25	-0.6227222681045532	clinical_diastolic_ dysfunction
P-25	-0.6504 -0.0033 -0.2541 -0.2959 -0.3790 -1.0569 -0.1762 -1.2179 -0.0646 -2.6888 -0.0627
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction_pathways engage signalling_proteins
H-993	-0.3416444659233093	▁trans duction _ path ways ▁signal ling _ ▁protein s
D-993	-0.3416444659233093	transduction_pathways signalling_ proteins
P-993	-0.0071 -0.2230 -0.4030 -0.0582 -0.0514 -1.5962 -0.2204 -0.1217 -1.2891 -0.0661 -0.0278 -0.0357
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf patients rheumatoid_arthritis ra
H-602	-1.3133281469345093	▁re current ▁ HF ▁rhe um ato id _ ar thri tis RA
D-602	-1.3133281469345093	recurrent HF rheumatoid_arthritisRA
P-602	-3.0273 -0.0154 -0.5296 -0.0069 -5.6675 -0.0421 -2.1221 -4.0266 -0.1410 -0.2870 -0.6150 -0.4456 -2.3674 -0.1734 -0.2329
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa immunoassays nt-probnp
H-1516	-0.7051798701286316	▁Alpha LIS a ▁immun o assa ys ▁NT - pro B NP
D-1516	-0.7051798701286316	AlphaLISa immunoassays NT-proBNP
P-1516	-4.7942 -0.8098 -0.7950 -1.0990 -0.1086 -0.2967 -0.2322 -0.3417 -0.0112 -0.0010 -1.2641 -0.0026 -0.0326 -0.0838
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac_angiogenesis therapy cardiac_function remodeling
H-460	-0.7176966667175293	▁β - Block er - indu ced ▁cardiac _ ▁ang io gene sis ▁cardiac _ function ▁remodel ing
D-460	-0.7176966667175293	β-Blocker-induced cardiac_ angiogenesis cardiac_function remodeling
P-460	-0.9846 -0.0795 -0.5466 -0.6325 -0.4795 -0.0070 -0.2004 -2.4658 -0.5367 -0.5153 -1.7688 -0.9102 -0.2498 -1.4889 -0.4121 -1.6598 -1.1152 -0.0353 -0.1189 -0.1470
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic_adult_fontan saf patients catheterization
H-226	-0.9227710962295532	▁symptom a tic _ adult _ ▁Font an _ SAF
D-226	-0.9227710962295532	symptomatic_adult_ Fontan_SAF
P-226	-3.5589 -0.3728 -0.0232 -0.6224 -0.5234 -0.1260 -0.7817 -0.2500 -1.5793 -0.8724 -2.1003 -0.2629
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory icd patients mortality multivariable_regression
H-63	-0.47843578457832336	▁ambula tory ▁I CD _ ▁patients ▁predict or ▁mortal ity ▁multi vari able ▁re gression
D-63	-0.47843578457832336	ambulatory ICD_ patients predictor mortality multivariable regression
P-63	-0.0903 -0.0041 -1.6006 -0.0217 -2.6258 -0.4910 -0.2815 -0.1692 -1.4379 -0.0078 -0.0764 -0.0108 -0.0406 -1.0530 -0.0006 -0.0543 -0.1678
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes patients preserved_ejection_fraction hfpef
H-1328	-0.5271856188774109	▁f es ▁pres er ved _ e je ction _ fraction HF p EF
D-1328	-0.5271856188774109	fes preserved_ejection_fractionHFpEF
P-1328	-1.3278 -1.1243 -1.9243 -0.1157 -0.0604 -0.1225 -0.9535 -1.7872 -0.2175 -0.3839 -0.0668 -0.1709 -0.0024 -0.0185 -0.0559 -0.1033
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity doxorubicin anti-neoplastic_agent
H-955	-0.38920149207115173	▁cardio toxic ity ▁do xor ubi cin ▁anti - neo plast ic _ agent
D-955	-0.38920149207115173	cardiotoxicity doxorubicin anti-neoplastic_agent
P-955	-0.0563 -1.6479 -1.1842 -0.0845 -0.0103 -0.0351 -0.0971 -0.0171 -0.0350 -0.0454 -0.0390 -0.0291 -0.5792 -0.0284 -2.2163 -0.1223
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence vad acs consultations operations mortality morbidity
H-1289	-0.707285463809967	▁MT ▁ VAD _ group ▁a CS ▁operation s ▁high ▁mortal ity ▁morbi d ity
D-1289	-0.707285463809967	MT VAD_group aCS operations high mortality morbidity
P-1289	-2.3652 -0.7045 -0.0397 -1.8139 -0.8596 -0.9761 -0.8536 -2.8852 -0.0126 -0.1991 -0.8810 -0.0158 -0.1297 -0.0395 -0.0406 -0.0540 -0.1539
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician follow-up discharge physician outcomes patients heart_failure
H-1421	-1.2146495580673218	▁physician _ dis charge ▁physician _ ▁continu ity ▁patients ▁heart _ ▁failure
D-1421	-1.2146495580673218	physician_discharge physician_ continuity patients heart_ failure
P-1421	-0.8996 -2.1059 -2.2363 -0.1527 -1.9149 -1.0358 -0.9880 -0.0024 -2.5430 -1.9414 -0.8422 -2.2376 -0.0334 -0.0719
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients sinus_rhythm antiplatelet_agents anticoagulants
H-1354	-0.5727836489677429	▁sinus ▁ rhythm ▁anti plate let _ agent ▁antico a gul ants ▁ef fica cy
D-1354	-0.5727836489677429	sinus rhythm antiplatelet_agent anticoagulants efficacy
P-1354	-0.7924 -1.4859 -0.0277 -0.0180 -0.4948 -1.9866 -0.4425 -0.4458 -0.2391 -0.4369 -0.1524 -0.0124 -1.4128 -0.0032 -0.1351 -1.4424 -0.2093
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death c-statistics biological_phenotype deficit_index
H-1011	-0.5275478959083557	▁c - stat istic s ▁bi ological _ ▁ph eno type ▁deficit _ index
D-1011	-0.5275478959083557	c-statistics biological_ phenotype deficit_index
P-1011	-4.6196 -0.5394 -0.0396 -0.0065 -0.0768 -0.0794 -0.0774 -0.5517 -0.8964 -0.0107 -0.0279 -0.0107 -1.0138 -0.1777 -0.1451 -0.1679
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients heart_failure left_ventricular ejection_fraction
H-22	-0.9410482048988342	▁heart _ ▁failure ▁pres er ved ▁left _ ▁vent ri cular LV ▁e je ction _ fraction
D-22	-0.9410482048988342	heart_ failure preserved left_ ventricularLV ejection_fraction
P-22	-4.0061 -0.7730 -1.3114 -0.9230 -0.0515 -0.0394 -0.5280 -0.1128 -4.4077 -0.8157 -0.1983 -1.4086 -1.7838 -0.0152 -0.0807 -1.0958 -0.0155 -0.1167 -0.1966
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
H-966	-0.27136141061782837	▁nic oran dil ▁cy to toxic _ effect ▁do xor ubi cin ▁solid ▁Eh r lich _ ▁car cino ma
D-966	-0.27136141061782837	nicorandil cytotoxic_effect doxorubicin solid Ehrlich_ carcinoma
P-966	-0.1751 -0.0203 -0.1888 -0.0128 -0.0108 -0.2732 -2.2585 -0.1542 -0.1402 -0.0176 -0.0298 -0.1197 -0.5774 -0.5443 -0.0107 -0.1696 -0.0568 -0.7626 -0.0451 -0.1472 -0.1596 -0.0956
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported patient implantable_cardioverter-defibrillator
H-1858	-0.6286593079566956	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1858	-0.6286593079566956	implantable cardioverter-defibrillator_deactivation
P-1858	-4.9540 -0.0091 -0.9580 -0.0663 -0.6664 -0.3836 -0.0081 -0.3352 -1.9241 -0.2207 -0.0716 -0.4466 -0.1313 -0.0849 -0.0393 -0.3405 -0.0477
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal_denervation dnx chf patients symptomatic
H-1371	-1.7887729406356812	▁Ren al _ ▁den er va tion ▁CHF
D-1371	-1.7887729406356812	Renal_ denervation CHF
P-1371	-1.7037 -0.0281 -0.1878 -2.5535 -2.6681 -3.9469 -0.1049 -3.2757 -3.2291 -0.1899
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv_diastolic_dysfunction combination figure hfpef
H-24	-0.5985146760940552	▁LV _ dia sto lic _ ▁dys function ▁H FP EF
D-24	-0.5985146760940552	LV_diastolic_ dysfunction HFPEF
P-24	-0.1845 -0.9762 -0.3173 -0.5338 -0.7022 -0.3105 -0.5696 -0.0351 -3.5394 -0.0531 -0.3230 -0.0550 -0.1812
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic_peptides point_of_care ambulatory
H-1019	-0.28226935863494873	▁na tri ure tic _ pe pti des ▁emergency ▁ambula tory
D-1019	-0.28226935863494873	natriuretic_peptides emergency ambulatory
P-1019	-0.0265 -0.0826 -0.0760 -1.0298 -0.3808 -0.1115 -0.0484 -0.6401 -0.4000 -0.2326 -0.0020 -0.5901 -0.0490
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas cardiac benign_tumors left_atrium right_atrium
H-593	-0.42145323753356934	▁My xo mas ▁cardiac _ ▁benign _ ▁tumor s ▁left _ at rium ▁right _ at rium
D-593	-0.42145323753356934	Myxomas cardiac_ benign_ tumors left_atrium right_atrium
P-593	-1.9854 -0.0064 -0.0214 -0.1657 -0.8387 -0.7576 -0.5457 -0.7108 -0.0783 -0.5569 -0.8926 -0.1929 -0.0002 -0.3901 -0.5756 -0.0674 -0.0002 -0.0481 -0.1736
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs hf_with_reduced_ejection_fraction hfref
H-1077	-1.0084317922592163	▁life ▁sa ving _ drug ▁ HF _ e je ction _ fraction HF r EF
D-1077	-1.0084317922592163	life saving_drug HF_ejection_fractionHFrEF
P-1077	-0.6690 -5.3763 -0.0127 -0.4915 -0.6967 -0.9686 -0.0028 -5.0405 -2.7192 -0.6251 -0.0538 -0.8895 -0.0934 -0.3605 -0.0822 -0.0199 -0.0207 -0.0293
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 hypertensive obese zsf1 hypertensive diabetic
H-766	-0.7306850552558899	▁lean ▁z SF 1 _ group ▁hyper tensi ve ▁obes e ▁Z SF 1 _ group ▁hyper tensi ve ▁diabet ic
D-766	-0.7306850552558899	lean zSF1_group hypertensive obese ZSF1_group hypertensive diabetic
P-766	-0.1341 -2.2056 -0.3201 -1.3457 -2.7367 -0.7852 -1.0604 -0.2128 -0.0238 -0.4997 -0.0346 -1.8684 -0.0284 -0.6235 -2.7407 -1.2398 -0.5832 -0.0660 -0.0742 -0.0367 -0.0219 -0.0496 -0.1145
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal_bleeding reported patients ventricular_assist_devices
H-1659	-0.3710852265357971	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices
D-1659	-0.3710852265357971	Gastrointestinal_ bleeding ventricular_assist devices
P-1659	-0.4528 -0.2281 -0.5197 -0.0403 -0.2879 -0.6079 -0.1286 -0.0738 -0.3338 -0.2887 -0.1114 -0.1075 -0.0296 -2.5662 -0.0364 -0.1247
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia acute_kidney_injury spironolactone clinical
H-444	-0.6118112802505493	▁severe ▁hyper kal emia ▁a cute ▁ki dne y _ ▁injury ▁spi rono lac tone ▁clinic al _ ▁trial s
D-444	-0.6118112802505493	severe hyperkalemia acute kidney_ injury spironolactone clinical_ trials
P-444	-5.4211 -0.8686 -0.2230 -0.0192 -0.0813 -0.0016 -0.8260 -0.2752 -0.0114 -1.2391 -0.4020 -0.0062 -0.0045 -0.0446 -0.0369 -1.9966 -0.0232 -1.2495 -0.6402 -0.0218 -0.0236 -0.0442
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients heart_failure elevated left_atrial_pressure symptoms hospital admission
H-1949	-1.0370302200317383	▁heart _ ▁failure ▁eleva ted ▁left _ at rial _ ▁pressure
D-1949	-1.0370302200317383	heart_ failure elevated left_atrial_ pressure
P-1949	-1.2167 -0.8419 -0.9029 -2.0124 -0.0516 -2.7793 -0.0685 -0.2146 -0.0589 -0.1728 -1.1938 -3.7698 -0.1982
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic bnp nt-probnp patients coronary_artery_disease cad
H-1366	-0.6539952158927917	▁diagnostic _ ▁role s ▁b NP ▁NT - pro B NP ▁corona ry _ ▁arter y _ مرض CAD
D-1366	-0.6539952158927917	diagnostic_ roles bNP NT-proBNP coronary_ artery_مرضCAD
P-1366	-0.7604 -1.3656 -0.2146 -0.0094 -1.1550 -0.1292 -0.3001 -0.0096 -0.0016 -0.8821 -0.0182 -0.0468 -0.0526 -0.4465 -1.2431 -0.2405 -0.4727 -3.7562 -2.4458 -0.1179 -0.0661
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial pde2 intracellular antiadrenergic therapeutic hf
H-1220	-0.6500107049942017	▁my o card ial _ p DE 2 ▁intra cel lular ▁anti ad r energi c _ strategi ▁ HF
D-1220	-0.6500107049942017	myocardial_pDE2 intracellular antiadrenergic_strategi HF
P-1220	-0.5469 -0.4266 -0.6525 -0.0706 -0.3345 -2.2302 -1.5504 -0.0460 -0.3759 -0.1046 -0.0211 -0.6946 -0.4908 -0.4432 -1.3177 -0.4329 -1.0858 -0.7707 -2.5522 -0.0022 -0.0304 -0.1202
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart hospitalization death patients preserved_left_ventricular_ejection_fraction
H-235	-1.3905823230743408	▁heart ▁failure - related _ hospital ization ▁patients ▁pres er ved ▁left _ velo cular _ e je ction _ fraction
D-235	-1.3905823230743408	heart failure-related_hospitalization patients preserved left_velocular_ejection_fraction
P-235	-2.6647 -4.2813 -1.2354 -0.0742 -2.4580 -0.0105 -0.1748 -2.5167 -1.8981 -0.0554 -0.0431 -0.2137 -0.2186 -5.7110 -5.8901 -0.3465 -1.4557 -0.3890 -0.8162 -1.1799 -0.0106 -0.1376 -0.2025
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened lvet icu admission prognostic patients precapillary_ph heart_failure
H-590	-0.6204196810722351	▁short en ed _ l VET ▁ ICU ▁ad mission ▁pre cap illa ry _ PH ▁heart _ ▁failure
D-590	-0.6204196810722351	shortened_lVET ICU admission precapillary_PH heart_ failure
P-590	-2.1517 -0.1305 -0.0312 -0.5553 -3.1620 -0.0524 -0.3851 -0.0022 -0.4745 -0.0129 -0.2305 -0.6213 -0.3553 -0.0544 -0.3980 -1.3397 -0.4311 -0.9755 -1.4493 -0.0788 -0.1371
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian_enabled mena cytoskeletal_actin_dynamics heart_failure hf
H-1810	-0.9197164177894592	▁Mamma lian _ ▁enabled _ Men a ▁cy tos kelet al _ ▁act in _ ▁dynamic s ▁heart _ ▁failure
D-1810	-0.9197164177894592	Mammalian_ enabled_Mena cytoskeletal_ actin_ dynamics heart_ failure
P-1810	-1.4943 -0.3046 -1.1469 -5.7077 -2.4370 -0.4133 -0.0023 -0.5394 -0.4905 -0.0809 -0.0112 -0.1560 -0.7640 -0.2287 -1.6730 -0.3366 -0.0269 -0.0908 -0.1861 -3.7209 -0.3823 -0.0405
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations refractory_congestive_heart_failure peritoneal_dialysis
H-893	-0.4822608530521393	▁re frac tory _ con ges tive _ heart _ ▁failure ▁per ito ne al _ di al ysis
D-893	-0.4822608530521393	refractory_congestive_heart_ failure peritoneal_dialysis
P-893	-0.3915 -0.0028 -0.0866 -0.8615 -0.4610 -1.1262 -0.1840 -0.0671 -1.6878 -0.2359 -1.6283 -0.0143 -0.2765 -0.4661 -0.0074 -0.0873 -1.7290 -0.0387 -0.6439 -0.0693 -0.0622
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_reserve
H-916	-0.4757560193538666	▁Heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁H FP EF ▁cardiovascular _ ▁reserve
D-916	-0.4757560193538666	Heart_ failure preserved_ejection_fraction HFPEF cardiovascular_ reserve
P-916	-0.5824 -0.4655 -1.4192 -2.0575 -0.0591 -0.0419 -0.2061 -0.6126 -0.5212 -0.0356 -0.1466 -0.0123 -2.1674 -0.0330 -0.1889 -0.7619 -0.0382 -0.0820 -0.0505 -0.0332
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence heart_failure_with_preserved_ejection_fraction hfpef prognosis
H-23	-0.5578615665435791	▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁H FP EF
D-23	-0.5578615665435791	heart_ failure preserved_ejection_fraction HFPEF
P-23	-1.4987 -0.3353 -1.8831 -0.4783 -0.0851 -0.0677 -0.1339 -0.7121 -0.6635 -0.0608 -0.1595 -0.0454 -2.0015 -0.0380 -0.1060 -1.1525 -0.0620
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-337	-0.5843655467033386	▁Fun ction al _ ▁mit ral _ ▁sten osis ▁m ▁ring _ ▁ann ulo plast y ▁ ische mic _ ▁mit ral ▁re gur gi tation MR
D-337	-0.5843655467033386	Functional_ mitral_ stenosis m ring_ annuloplasty ischemic_ mitral regurgitationMR
P-337	-0.3770 -0.0055 -0.1631 -0.4210 -5.0647 -0.0192 -0.0901 -0.3508 -0.0034 -3.0552 -0.4875 -0.7759 -0.2429 -0.1674 -0.0345 -0.0101 -0.2329 -0.0409 -0.0277 -0.2532 -2.8660 -0.0243 -1.2406 -0.0024 -0.0293 -0.0009 -0.7897 -0.1063 -0.0642
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni_inhibitors angiotensin-receptor_neprilysin_inhibitors
H-1966	-0.4778972268104553	▁AR NI _ ▁inhibi tors angi oten sin - recept or ▁nepri ly sin _ ▁inhibi tors
D-1966	-0.4778972268104553	ARNI_ inhibitorsangiotensin-receptor neprilysin_ inhibitors
P-1966	-2.4844 -0.6613 -1.5088 -0.0986 -0.0079 -0.1711 -0.4345 -0.8679 -0.7696 -0.1313 -0.1778 -0.0684 -0.4770 -0.6812 -0.4368 -0.0090 -0.0101 -0.0496 -0.0348
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial irs1 irs2 heart_failure p38alpha mapk insulin_resistance
H-651	-0.4741426110267639	▁my o card ial _ ▁loss ▁I RS 1 ▁i RS 2 ▁heart _ ▁failure ▁p 38 al pha ▁MA PK ▁insulin ▁resist ance
D-651	-0.4741426110267639	myocardial_ loss IRS1 iRS2 heart_ failure p38alpha MAPK insulin resistance
P-651	-1.5310 -0.1538 -1.3125 -0.0256 -1.3987 -0.1423 -0.8158 -0.0046 -0.8728 -1.1016 -0.0355 -0.0557 -1.2811 -0.6300 -0.3626 -0.0036 -0.1327 -0.0571 -0.0022 -1.1315 -0.0061 -0.0043 -1.0188 -0.0002 -0.0412 -0.2065
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_morbidity mortality
H-236	-0.5527949929237366	▁Heart _ ▁failure ▁pres er ved ▁e je ction _ fraction HF p EF ▁cardiovascular _ ▁morbi d ity ▁mortal ity
D-236	-0.5527949929237366	Heart_ failure preserved ejection_fractionHFpEF cardiovascular_ morbidity mortality
P-236	-0.4458 -0.2877 -2.4468 -3.2901 -0.1262 -0.0779 -3.4825 -0.2606 -0.0204 -0.3699 -0.1022 -0.2903 -0.0062 -0.0882 -0.1889 -0.2980 -0.2831 -0.0345 -0.0525 -0.4619 -0.0040 -0.0203 -0.0765
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.8587042689323425	▁process _ re design ▁context ual ▁framework
D-1851	-0.8587042689323425	process_redesign contextual framework
P-1851	-3.3514 -0.8076 -0.0382 -0.0024 -2.5491 -0.0222 -0.8310 -0.0404 -0.0861
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.43657368421554565	▁pe ak ▁aero bic _ ▁capacity ▁left - hand _ ▁grip _ ▁strength ▁wa ist _ ▁circum ferenc e ▁anxiety
D-573	-0.43657368421554565	peak aerobic_ capacity left-hand_ grip_ strength waist_ circumference anxiety
P-573	-0.0448 -0.0197 -0.9012 -0.1232 -0.8245 -2.2254 -0.1733 -0.0285 -0.0087 -0.1686 -0.1582 -0.6789 -1.8068 -0.4704 -0.0173 -0.7266 -0.1137 -0.0036 -0.1840 -0.7977 -0.0392 -0.0905
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ecct
H-713	-0.8618949055671692	▁clinic al _ ▁variable s ▁ec CT
D-713	-0.8618949055671692	clinical_ variables ecCT
P-713	-0.7699 -0.0237 -0.7944 -0.4422 -0.0195 -4.4496 -1.0621 -0.0591 -0.1365
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant exercise
H-1883	-0.6609119772911072	▁control ▁group ▁exercise
D-1883	-0.6609119772911072	control group exercise
P-1883	-0.3458 -1.2289 -0.0397 -1.6653 -0.0249
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.5994775891304016	▁circula ting _ form s ▁NT - pro B NP
D-1512	-0.5994775891304016	circulating_forms NT-proBNP
P-1512	-2.0569 -0.0557 -0.3141 -0.3964 -0.0256 -1.0900 -0.0327 -0.0018 -1.9450 -0.0726 -0.9818 -0.2211
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf pb bp
H-1348	-0.7822960019111633	▁PV f ▁ PB _ ▁cycle ▁low ▁BP
D-1348	-0.7822960019111633	PVf PB_ cycle low BP
P-1348	-1.0191 -1.3385 -0.7500 -0.0672 -2.2372 -1.0473 -0.8076 -0.3959 -0.0534 -0.1068
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg crt clinical
H-881	-0.7564013600349426	▁e CG _ ▁parameter s ▁c RT
D-881	-0.7564013600349426	eCG_ parameters cRT
P-881	-2.0974 -0.0865 -1.6722 -0.3383 -0.0163 -0.7960 -0.8259 -0.8812 -0.0936
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients sst2 cardiovascular_event
H-407	-0.8419995903968811	▁s ST 2 ▁low - dos e _ ▁BB ▁cardiovascular _ event _ rate
D-407	-0.8419995903968811	sST2 low-dose_ BB cardiovascular_event_rate
P-407	-0.0962 -1.6573 -0.3407 -0.8910 -0.0115 -0.7826 -0.0786 -1.1230 -1.9668 -0.7625 -0.5932 -1.0510 -0.7422 -0.9645 -1.9762 -0.4348
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up hf hospitalization
H-690	-0.9840742945671082	▁ HF _ hospital ization
D-690	-0.9840742945671082	HF_hospitalization
P-690	-0.8868 -0.1237 -2.0692 -0.0325 -0.4554 -3.2374 -0.0834
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination exercise peak_vo2 joint
H-1985	-0.4598466157913208	▁exercise ▁pe ak _ vo 2 jo int _ effect
D-1985	-0.4598466157913208	exercise peak_vo2joint_effect
P-1985	-0.4369 -2.6881 -0.0139 -0.1069 -0.2947 -0.2593 -0.5448 -0.0041 -0.4298 -0.0435 -0.4275 -0.2688
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone clinical medications
H-447	-0.7214382290840149	▁spi rono lac tone ▁guide line - re com mend ed
D-447	-0.7214382290840149	spironolactone guideline-recommended
P-447	-4.0511 -0.0274 -0.1782 -0.0759 -0.6576 -0.0028 -0.2328 -0.0019 -0.0077 -0.0011 -0.0349 -3.9512 -0.1561
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions patients heart_disease
H-48	-0.5846887230873108	▁trans fusion s ▁heart _ ▁disease
D-48	-0.5846887230873108	transfusions heart_ disease
P-48	-0.2563 -0.0703 -0.2847 -0.9374 -0.9225 -1.7434 -0.3721 -0.0908
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast_cancer patients chf reported clinical
H-681	-0.840308666229248	▁breast _ cancer s ▁tras tuz um b - related _ ▁CHF ▁clinic al _ ▁trial s
D-681	-0.840308666229248	breast_cancers trastuzumb-related_ CHF clinical_ trials
P-681	-4.7266 -1.4061 -0.0713 -4.6860 -0.4691 -0.0030 -0.0769 -0.0256 -0.9869 -0.0939 -0.8927 -0.7392 -0.5266 -0.0099 -1.0106 -0.1103 -0.0135 -0.0344 -0.0832
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas_city_cardiomyopathy_questionnaire patients heart_failure reduced_ejection_fraction
H-779	-0.862541139125824	▁Kansas _ city ▁Card i om _ ▁Question naire ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-779	-0.862541139125824	Kansas_city Cardiom_ Questionnaire heart_ failure preserved ejection_fraction
P-779	-0.0824 -1.4209 -0.1320 -3.0358 -0.0627 -0.1571 -2.3281 -5.3148 -0.0187 -0.5284 -0.4301 -1.2263 -2.2251 -0.1314 -0.0987 -0.2362 -0.0792 -0.0536 -1.1799 -0.0026 -0.0409 -0.1910
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue_doppler left_ventricular_filling_pressure patients stable severe_systolic_heart_failure
H-479	-0.8709696531295776	▁tissu e ▁do pp ler _ ▁imagin g ▁left ▁vent ri cular _ ▁fill ing _ ▁pressure ▁sy sto lic _ heart _ ▁failure
D-479	-0.8709696531295776	tissue doppler_ imaging left ventricular_ filling_ pressure systolic_heart_ failure
P-479	-0.5788 -0.9771 -1.0018 -0.0008 -0.3263 -0.7298 -1.2665 -0.0282 -0.0638 -4.1682 -1.0922 -0.1115 -0.9008 -1.3081 -0.0889 -0.4137 -1.4245 -2.3180 -0.1733 -0.9735 -0.2855 -0.8278 -1.3932 -2.0431 -0.0632 -0.0864
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart_failure hypertensive_heart_disease angiotensin_ii infusion nephrectomy salt_loading
H-273	-0.4166566729545593	▁heart ▁failure _ mi ce ▁hyper tensi ve _ heart _ مرض ▁ang io ten sin ▁II ▁in fusion ▁nep hr ecto my ▁salt ▁load ing
D-273	-0.4166566729545593	heart failure_mice hypertensive_heart_مرض angiotensin II infusion nephrectomy salt loading
P-273	-0.1452 -0.4103 -0.3593 -0.2237 -0.0010 -0.4407 -0.8544 -0.0477 -0.2423 -2.0254 -0.2436 -3.2319 -0.0058 -0.1062 -0.1887 -0.0712 -0.6032 -0.0588 -0.0013 -0.0121 -0.1033 -0.3862 -1.0503 -0.0005 -0.6207 -0.0145 -0.1074 -0.1105
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 hearts acute β-ar
H-1218	-0.5142548084259033	▁p de 2 ▁fail ing _ heart s ▁a cute ▁β - AR _ stimul ation
D-1218	-0.5142548084259033	pde2 failing_hearts acute β-AR_stimulation
P-1218	-1.7201 -0.3607 -0.0599 -0.0758 -0.0175 -0.6788 -0.3527 -0.0777 -1.5159 -0.0048 -1.3203 -0.0088 -0.3041 -2.0795 -0.1944 -0.1354 -0.1953 -0.1548
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote_monitoring rm heart_failure
H-148	-0.9932156205177307	▁remote _ monitor ing _ RM
D-148	-0.9932156205177307	remote_monitoring_RM
P-148	-0.5934 -0.7798 -0.0968 -1.7994 -0.4986 -0.8700 -3.1630 -0.1447
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic clinical pharmacologic
H-1470	-0.3340485692024231	▁ pharma c ologic _ ▁treatment ▁clinic al _ ▁trial s ▁ pharma c ologic ▁target s
D-1470	-0.3340485692024231	pharmacologic_ treatment clinical_ trials pharmacologic targets
P-1470	-0.2614 -0.0227 -0.1083 -0.1920 -1.1018 -2.0417 -0.4706 -0.0304 -0.3210 -0.1029 -0.0143 -0.8602 -0.0013 -0.0187 -0.0745 -0.5632 -0.0750 -0.0307 -0.0563
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence chronic_heart_failure hungary
H-646	-2.1602940559387207	▁chronic _ aga in st _ se ctor
D-646	-2.1602940559387207	chronic_against_sector
P-646	-1.7797 -0.3398 -7.4348 -0.0283 -0.0619 -0.1285 -7.7835 -0.6678 -3.0344 -0.3441
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr diuretics hypertension patients esrd
H-397	-0.4978797137737274	▁low ▁e G FR ▁di ure tics ▁un control led _ ▁hyper tension ▁ES RD
D-397	-0.4978797137737274	low eGFR diuretics uncontrolled_ hypertension ESRD
P-397	-0.1436 -0.0625 -0.5473 -0.1238 -2.8935 -0.1122 -0.9416 -0.0200 -0.0016 -0.0069 -0.8567 -0.3938 -0.0100 -2.0499 -0.0276 -0.0421 -0.2310
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv_dysfunction cardiac_cachexia
H-1168	-0.585276186466217	▁ RV ▁dys function ▁cardiac _ ▁cache xia
D-1168	-0.585276186466217	RV dysfunction cardiac_ cachexia
P-1168	-0.7236 -0.3889 -1.2034 -0.1122 -0.0070 -0.3874 -0.0681 -0.2148 -2.5387 -0.2087
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart_failure hf death crt-d
H-105	-1.684286117553711	▁time - dependent _ analyse s ▁IE ▁risk ▁heart _ ▁failure ▁ HF ▁c RT - D
D-105	-1.684286117553711	time-dependent_analyses IE risk heart_ failure HF cRT-D
P-105	-5.6587 -0.2075 -0.0112 -2.1762 -1.3657 -2.0860 -3.7956 -3.4096 -4.3101 -0.5838 -2.4487 -2.3412 -0.0009 -2.2722 -0.0278 -0.0364 -0.5335 -0.4367 -0.2998
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence prevalence heart_failure leading death hospitalisation
H-1664	-1.2673869132995605	▁heart _ ▁failure ▁hospital isation ▁el der ly
D-1664	-1.2673869132995605	heart_ failure hospitalisation elderly
P-1664	-2.8493 -0.7861 -4.1311 -1.4782 -0.0144 -3.1451 -0.0282 -0.0747 -0.0720 -0.0949
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients narrow_qrs_complex crt patients
H-846	-0.5807258486747742	▁mechanic al _ dis syn chron y ▁n arrow ▁QR S _ ▁complex ▁c RT
D-846	-0.5807258486747742	mechanical_dissynchrony narrow QRS_ complex cRT
P-846	-0.3486 -0.0093 -0.2368 -1.5798 -0.0185 -0.0003 -0.2008 -3.1317 -0.0003 -0.4641 -0.7333 -0.8716 -0.1160 -1.1654 -0.4001 -0.2692 -0.3267
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians patient anemic patients heart_disease
H-34	-1.0749527215957642	▁clinic ians ▁a ne mic ▁ir on - d eficient ▁adult _ patient s
D-34	-1.0749527215957642	clinicians anemic iron-deficient adult_patients
P-34	-4.2267 -0.3050 -0.4326 -0.0748 -0.2320 -1.5035 -0.1488 -0.1112 -0.1984 -0.6947 -1.9292 -1.7209 -2.0205 -0.5962 -2.7532 -0.2516
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid_intima-media_thickness psoriasis
H-1561	-0.7394145727157593	▁caro tid ▁intim a - media ▁thi ck
D-1561	-0.7394145727157593	carotid intima-media thick
P-1561	-0.5489 -0.0897 -0.1235 -0.0181 -0.0335 -0.0064 -1.1262 -0.0066 -5.3274 -0.1139
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis patients disease atherosclerosis cardiovascular_events psoriasis
H-1565	-1.0148365497589111	▁p sori asis ▁patients ▁at hero sc ler osis ▁cardiovascular ▁events ▁psoriasis
D-1565	-1.0148365497589111	psoriasis patients atherosclerosis cardiovascular events psoriasis
P-1565	-3.6573 -0.0136 -0.2276 -3.5884 -2.7650 -0.1325 -0.5050 -0.6323 -0.0178 -0.0506 -1.8885 -0.4751 -0.0962 -0.1579
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary_occlusion collateral_growth stent
H-510	-0.16351395845413208	▁corona ry ▁oc clusi on ▁col lateral _ ▁growth ▁sten t ▁oc clusi on
D-510	-0.16351395845413208	coronary occlusion collateral_ growth stent occlusion
P-510	-0.0454 -0.1882 -0.3991 -0.0145 -0.0399 -0.1421 -0.0001 -0.6368 -0.3245 -0.1452 -0.0510 -0.5370 -0.0005 -0.0142 -0.0366 -0.0410
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration patients hr_reduction beta-blocker therapy
H-1947	-0.9571899771690369	▁aggressiv e _ ▁dose ▁up tit ration ▁HR _ re duction ▁beta - block er
D-1947	-0.9571899771690369	aggressive_ dose uptitration HR_reduction beta-blocker
P-1947	-3.1639 -0.2522 -2.1652 -0.3702 -0.4472 -0.2237 -0.0443 -4.3503 -1.4601 -0.5548 -0.0011 -0.1040 -0.0126 -0.0709 -0.2101 -2.7321 -0.1095
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab chf nontrastuzumab_users
H-678	-0.7671067714691162	▁tras tuz um ab
D-678	-0.7671067714691162	trastuzumab
P-678	-0.1784 -0.0076 -0.0312 -0.0128 -4.2365 -0.1362
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care outpatient acute_heart_failure
H-1026	-0.8108335137367249	▁Point - of - care _ system s ▁ED ▁community _ out patient _ setting s ▁a cute _ heart _ ▁failure
D-1026	-0.8108335137367249	Point-of-care_systems ED community_outpatient_settings acute_heart_ failure
P-1026	-2.6706 -0.0730 -0.0036 -0.0080 -0.0073 -3.1918 -0.1049 -0.0878 -3.2203 -1.0693 -0.9494 -0.0677 -0.0356 -1.2324 -0.0463 -0.0045 -0.2306 -0.0061 -0.1525 -1.0248 -1.2528 -3.5639 -0.0806 -0.3760
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus mortality hazard_ratio confidence_interval
H-129	-0.7524391412734985	▁o - C FU s ▁reduce d _ ▁mortal ity haz ard _ rati o
D-129	-0.7524391412734985	o-CFUs reduced_ mortalityhazard_ratio
P-129	-3.6197 -0.2401 -2.0117 -0.7402 -0.8146 -2.3845 -0.0421 -0.2868 -1.2181 -0.0229 -0.2510 -0.0312 -0.2387 -0.0811 -0.0208 -0.6758 -0.1122
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline isoprenaline infusion sdqt hf patients
H-1443	-0.5557481646537781	▁iso pren a line _ in fusion ▁SD QT ▁ HF
D-1443	-0.5557481646537781	isoprenaline_infusion SDQT HF
P-1443	-0.1432 -0.0781 -0.0856 -0.0062 -1.3998 -0.7863 -0.0013 -0.0266 -2.1294 -1.4092 -0.6820 -0.4148 -0.0624
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf remodeling emd dyssynchronous_failing_heart
H-1150	-0.47540372610092163	▁ HF _ ▁remodel ing ▁EM d ▁dys syn chron ous _ ▁fail ing _ heart
D-1150	-0.47540372610092163	HF_ remodeling EMd dyssynchronous_ failing_heart
P-1150	-0.4365 -0.0343 -3.1056 -0.0516 -0.0078 -0.6467 -0.7738 -0.0010 -0.0008 -0.0014 -0.5381 -0.9156 -0.9454 -0.0427 -0.2388 -0.5754 -0.0685 -0.1732
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery medical_treatment hf hypertension vasodilators diuretics
H-355	-0.5631652474403381	▁surgery ▁ HF ▁hyper tension ▁vaso dila tors ▁di ure tics
D-355	-0.5631652474403381	surgery HF hypertension vasodilators diuretics
P-355	-2.6368 -1.7795 -0.0077 -1.5829 -0.0305 -0.1819 -0.0394 -0.0247 -0.0669 -0.0681 -0.7375 -0.0803 -0.0849
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute_heart_failure ahf symptoms heart_failure hf
H-1466	-0.8181043267250061	▁a cute _ heart _ ▁failure
D-1466	-0.8181043267250061	acute_heart_ failure
P-1466	-0.3758 -0.1117 -0.2374 -0.6970 -0.1969 -1.3381 -3.4694 -0.1186
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical clinical outcomes aldosterone_antagonist heart_failure
H-1734	-0.5063837170600891	▁clinic al _ ▁trial s ▁al do ster one _ ▁anta gon ist ▁heart _ ▁failure
D-1734	-0.5063837170600891	clinical_ trials aldosterone_ antagonist heart_ failure
P-1734	-0.4256 -0.0063 -1.3187 -2.9435 -0.0270 -0.1992 -0.4419 -0.2882 -0.1900 -0.2946 -0.0657 -0.0405 -0.1353 -0.1161 -0.5148 -2.0362 -0.0311 -0.0405
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis post-myocardial_infarction heart heart_failure
H-449	-0.7936999797821045	▁ang io gene sis ▁post - my o card ial _ in far ction _ heart ▁progression ▁heart _ ▁failure
D-449	-0.7936999797821045	angiogenesis post-myocardial_infarction_heart progression heart_ failure
P-449	-0.7393 -3.0452 -1.2325 -0.7654 -0.0037 -0.0231 -1.4990 -0.7622 -2.0005 -0.0724 -0.3451 -0.6439 -0.0210 -0.3230 -1.7798 -0.3849 -0.0440 -1.6918 -0.6509 -1.3420 -0.0231 -0.0686
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea total_arterial_compliance tac end-systolic_elastance ees baseline
H-520	-0.7020050883293152	▁arterial _ ▁compliance ▁ TAC ▁end - sy sto lic _ ▁elastan ce ▁e es
D-520	-0.7020050883293152	arterial_ compliance TAC end-systolic_ elastance ees
P-520	-1.3651 -1.5626 -0.2358 -2.7401 -0.0007 -0.1718 -0.0107 -1.0765 -0.8140 -0.8772 -0.5439 -0.0755 -0.0805 -1.8036 -0.0058 -0.4256 -0.1446
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart_failure preserved_ejection_fraction myocardial_infarction
H-1098	-0.3344133496284485	▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction ▁my o card ial _ in far ction ▁community
D-1098	-0.3344133496284485	heart_ failure preserved ejection_fraction myocardial_infarction community
P-1098	-0.7519 -0.7412 -0.6360 -1.4592 -0.0609 -0.0100 -0.2225 -0.0385 -0.0251 -0.7824 -0.0064 -0.2313 -0.1193 -0.6610 -0.0452 -0.2495 -0.5563 -0.0029 -0.0551 -0.2824 -0.3458 -0.0741
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal_dysfunction all-cause_mortality cardiovascular_events postoperative cabg
H-978	-0.5007399320602417	▁Ren al _ dis function ▁all - ca use ▁mortal ity ▁cardiovascular _ ▁events ▁primary ▁isola ted _ ca BG
D-978	-0.5007399320602417	Renal_disfunction all-cause mortality cardiovascular_ events primary isolated_caBG
P-978	-1.0227 -0.0146 -0.3164 -0.8147 -0.1095 -4.0822 -0.0119 -0.0009 -0.0278 -0.7030 -0.0064 -0.0075 -1.0315 -0.3124 -0.9612 -0.3104 -0.0021 -0.3902 -0.5634 -0.1421 -0.0684 -0.1171
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular_support heartmate_ii lvad centrimag rvad mortality hospital discharge
H-304	-0.7076154947280884	▁bi ven tri cular _ support ▁Heart Mate _ II _ L VAD ▁Centri Mag _ r VAD
D-304	-0.7076154947280884	biventricular_support HeartMate_II_LVAD CentriMag_rVAD
P-304	-0.6031 -0.0808 -0.4227 -0.3024 -1.5471 -1.0031 -0.6253 -0.1443 -1.0475 -0.4343 -0.7794 -2.1528 -0.0051 -0.1091 -0.2785 -0.1419 -2.4219 -0.3648 -1.4665 -0.2217
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic congestive_heart_failure haematopoietic_cell_transplantation
H-1448	-0.48499107360839844	▁an thra cycli ne ▁con ges tive _ heart _ ▁failure ▁ha e mato po ie tic _ cell ▁transplant ation
D-1448	-0.48499107360839844	anthracycline congestive_heart_ failure haematopoietic_cell transplantation
P-1448	-0.0837 -0.0316 -1.3274 -0.2012 -0.2203 -0.0121 -0.0638 -0.3531 -0.5012 -0.5289 -0.6173 -0.0014 -0.1287 -0.0344 -0.7499 -3.5968 -0.0569 -0.2736 -0.7553 -1.4438 -0.0225 -0.0738 -0.0770
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical coronary_artery_disease patients systolic_heart_failure etiology
H-1181	-0.5477420091629028	▁corona ry _ ▁arter y _ ▁disease ▁sy sto lic _ heart _ ▁failure ▁un clear ▁et i ology
D-1181	-0.5477420091629028	coronary_ artery_ disease systolic_heart_ failure unclear etiology
P-1181	-0.8318 -0.0934 -0.6096 -1.2129 -0.0317 -1.0977 -2.8490 -0.0272 -0.0168 -0.2682 -0.1637 -0.8354 -0.4623 -1.8107 -0.1200 -0.0001 -0.5763 -0.4211 -0.0021 -0.0311 -0.0417
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular diabetes_mellitus atrial_fibrillation coronary_artery_disease hfpef
H-1890	-0.44901904463768005	▁cardiovascular _ factor ▁diabetes ▁mell itus ▁at rial _ fi bril lation ▁corona ry _ ▁arter y ▁ HF p EF
D-1890	-0.44901904463768005	cardiovascular_factor diabetes mellitus atrial_fibrillation coronary_ artery HFpEF
P-1890	-0.5043 -0.5999 -1.3728 -0.5984 -0.2642 -0.0187 -0.0333 -0.0006 -0.3503 -0.8390 -0.0030 -0.0006 -0.0052 -0.0597 -0.5498 -0.2935 -0.2913 -3.9643 -0.0078 -0.0211 -0.0511 -0.4446 -0.0540
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal_dysfunction mortality myocardial_infarction coronary_artery_bypass_grafting cabg
H-969	-0.5091156959533691	▁Ren al _ dis function ▁my o card ial _ in far ction ▁corona ry _ ▁arter y _ ▁by pass _ ▁graf ting CA BG
D-969	-0.5091156959533691	Renal_disfunction myocardial_infarction coronary_ artery_ bypass_ graftingCABG
P-969	-0.3137 -0.0106 -0.6036 -0.4351 -0.1213 -2.2374 -0.0324 -0.2075 -0.0070 -0.2808 -0.6068 -0.0010 -0.0367 -0.0301 -0.0509 -0.5054 -1.3390 -0.5132 -0.2452 -3.4498 -0.0705 -0.3750 -0.5153 -0.0424 -1.8596 -0.0066 -0.2007 -0.1577
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt implants transseptal_catheterisation transoesophageal_echocardiographic general_anaesthesia
H-1953	-0.7076517343521118	▁Shu nt ▁trans sept al _ ▁cat heter isation ▁trans o es op hage al _ e cho car dio graphic ▁general ▁ana es the sia
D-1953	-0.7076517343521118	Shunt transseptal_ catheterisation transoesophageal_echocardiographic general anaesthesia
P-1953	-0.7756 -0.1221 -0.6767 -0.0351 -0.1829 -0.7987 -0.3373 -0.0015 -0.0196 -0.0004 -3.3999 -0.3377 -0.8399 -0.4883 -0.0961 -1.0813 -0.9532 -0.0376 -0.9406 -2.8769 -4.1677 -0.9751 -0.2220 -0.0483 -0.0497 -0.2045 -0.0833 -0.0622
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective lvas
H-1995	-1.1895073652267456	▁single - arm
D-1995	-1.1895073652267456	single-arm
P-1995	-1.9879 -0.0223 -0.0054 -3.5633 -0.3687
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl chf vascular
H-260	-0.6970261335372925	▁HD L _ function ▁CHF ▁ET ▁HD L - media ted _ vas cular
D-260	-0.6970261335372925	HDL_function CHF ET HDL-mediated_vascular
P-260	-0.6597 -0.7009 -0.8212 -0.3856 -0.5502 -3.6252 -0.5765 -0.6038 -0.0371 -0.0145 -0.0780 -0.3101 -0.6566 -0.0128 -2.0722 -0.0480
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf hf mortality
H-1774	-0.92039954662323	▁ HF _ risk _ factor ▁un fit _ ▁men
D-1774	-0.92039954662323	HF_risk_factor unfit_ men
P-1774	-0.4271 -0.0389 -1.2003 -0.9883 -1.0787 -0.1052 -4.8051 -0.0014 -0.7733 -1.1626 -0.3207 -0.1432
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician hf cpgs
H-1853	-1.0418246984481812	▁implementation ▁strategie s ▁physician ▁ad her ence ▁ HF _ PG s
D-1853	-1.0418246984481812	implementation strategies physician adherence HF_PGs
P-1853	-5.9723 -3.5181 -0.0249 -0.7877 -0.0399 -0.3159 -0.0117 -0.2737 -0.0029 -0.6707 -2.4250 -0.0468 -0.0662 -0.4298
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ea tac ees patients
H-522	-0.5813517570495605	▁base line ▁Ea ▁ TAC ▁HR ▁i va bra dine ▁place bo - tre ated
D-522	-0.5813517570495605	baseline Ea TAC HR ivabradine placebo-treated
P-522	-2.0146 -0.0303 -0.3061 -0.6147 -0.0009 -3.1580 -0.7649 -0.5687 -0.0530 -0.0156 -1.0312 -0.0083 -0.0458 -0.0026 -0.0660 -1.1033 -0.0991
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant erc epicatechin muscle
H-1256	-0.9660648107528687	▁ ERC ▁pure _ epi cate chin
D-1256	-0.9660648107528687	ERC pure_epicatechin
P-1256	-1.3594 -0.3142 -1.9185 -0.8125 -1.0203 -0.0024 -0.0946 -2.9921 -0.1805
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients hfpef prospective
H-736	-1.3367266654968262	
D-736	-1.3367266654968262	
P-736	-2.6021 -0.0714
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth health outcomes medicare
H-1628	-0.42111602425575256	▁Care ▁management ▁content - driv en ▁tele health ▁technology ▁high - co st ▁Medica re ▁beneficiar ies
D-1628	-0.42111602425575256	Care management content-driven telehealth technology high-cost Medicare beneficiaries
P-1628	-1.9003 -1.6660 -1.1997 -0.0090 -0.0060 -0.0118 -0.0647 -0.1735 -1.4182 -0.8470 -0.0118 -0.0055 -0.0715 -0.1431 -0.0041 -0.3007 -0.0393 -0.0619 -0.0672
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine nesiritide placebo
H-78	-0.3712562024593353	▁dop amine ▁nesi riti de ▁poole d ▁place bo
D-78	-0.3712562024593353	dopamine nesiritide pooled placebo
P-78	-0.0021 -0.0300 -0.0832 -0.0005 -0.0587 -0.2890 -0.0043 -1.7784 -0.0061 -1.7567 -0.0749
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician nonprescribing patient
H-1127	-0.5831160545349121	▁Clinic ians ▁non pre scribi ng ▁chart _ review
D-1127	-0.5831160545349121	Clinicians nonprescribing chart_review
P-1127	-0.9113 -2.5641 -1.4206 -0.0053 -0.0498 -0.0101 -0.0084 -0.5461 -0.4367 -0.4015 -0.0603
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical nonprescribing patients
H-1128	-0.6894516348838806	▁bio medic al ▁reasons ▁non pre scribi ng
D-1128	-0.6894516348838806	biomedical reasons nonprescribing
P-1128	-0.0762 -0.0072 -0.0020 -2.9812 -0.5188 -0.0028 -0.0810 -0.0252 -3.0721 -0.1280
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf hospitalization cardiovascular_mortality
H-1639	-0.42374059557914734	▁black _ race ▁ HF _ hospital ization ▁cardiovascular _ ▁mortal ity
D-1639	-0.42374059557914734	black_race HF_hospitalization cardiovascular_ mortality
P-1639	-0.0431 -0.4343 -0.8056 -0.4102 -0.0100 -1.6346 -0.0375 -0.2362 -1.5427 -0.5050 -0.0757 -0.0048 -0.0556 -0.1369
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr vad ecmo vad ecmo
H-1393	-0.8464899063110352	▁e G FR ▁ VAD _ group ▁EC MO _ group
D-1393	-0.8464899063110352	eGFR VAD_group ECMO_group
P-1393	-0.1833 -1.3334 -0.5444 -0.5286 -0.1822 -1.6529 -1.1413 -0.0622 -1.2107 -1.2318 -2.1593 -0.2669 -0.5074
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline embase cochrane clinical
H-41	-0.3832627832889557	▁MED line ▁ EMBA SE ▁co ch rane ▁clinic al _ registri es ▁technical ▁ad visor s
D-41	-0.3832627832889557	MEDline EMBASE cochrane clinical_registries technical advisors
P-41	-0.1035 -0.5468 -0.1506 -0.0003 -0.6780 -0.2637 -0.0091 -0.0004 -2.1147 -0.0108 -0.0899 -2.7026 -0.0121 -0.0173 -0.3227 -0.0001 -0.0884 -0.0998 -0.0713
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients severe_hf prognostic hf
H-1764	-1.1317038536071777	▁ HF
D-1764	-1.1317038536071777	HF
P-1764	-2.5968 -0.5961 -1.1604 -0.1734
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine vascular_endothelial_growth_factor protein left_ventricle myocardial_angiogenesis
H-1142	-0.5233945846557617	▁Pyr ido stig mine ▁vas cular _ ▁en dot heli al _ ▁growth _ factor _ ▁protein ▁left _ ▁vent ric le ▁my o card ial _ ▁ang io gene sis
D-1142	-0.5233945846557617	Pyridostigmine vascular_ endothelial_ growth_factor_ protein left_ ventricle myocardial_ angiogenesis
P-1142	-0.0134 -0.0874 -0.0004 -0.0253 -0.0098 -0.0045 -1.6208 -0.2962 -0.3544 -0.0282 -0.0046 -0.3292 -2.6069 -0.6385 -0.0045 -0.9181 -1.2695 -0.2141 -0.3548 -1.7355 -1.2336 -0.6426 -0.1769 -0.0716 -1.6017 -0.0878 -0.3705 -1.2279 -0.7099 -0.2902 -0.2269 -0.0483 -0.0683
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline crf hf mortality hf
H-1775	-0.5567810535430908	▁base line _ c RF ▁ HF _ ▁mortal ity _ risk
D-1775	-0.5567810535430908	baseline_cRF HF_ mortality_risk
P-1775	-0.0490 -0.0041 -0.8763 -2.1600 -0.1823 -0.1187 -0.0584 -0.3738 -0.8966 -0.0049 -1.2231 -0.3218 -1.4694 -0.0565
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise health cardiac_disease heart_failure
H-1904	-2.212261915206909	
D-1904	-2.212261915206909	
P-1904	-4.3773 -0.0472
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait therapy lokomat heart_failure patients
H-1921	-0.5014479756355286	▁Robot - assist ed _ ▁ga it _ therapy ▁Lok omat _ system ▁heart _ ▁failure
D-1921	-0.5014479756355286	Robot-assisted_ gait_therapy Lokomat_system heart_ failure
P-1921	-0.9470 -0.0878 -0.0004 -0.0283 -0.7252 -0.6498 -1.3745 -0.5113 -0.2489 -0.0836 -0.0358 -0.7257 -0.2135 -0.1248 -0.4938 -1.8702 -0.7651 -0.1404
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 n2bus s12884 pevk
H-769	-0.8539129495620728	▁elastic _ n 2 Bu s _ ▁segment ▁PE V K
D-769	-0.8539129495620728	elastic_n2Bus_ segment PEVK
P-769	-0.8491 -0.5823 -1.4570 -0.1394 -1.4121 -0.0414 -1.2288 -0.4373 -0.7550 -2.2796 -1.3805 -0.2118 -0.3266
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests cardiac_growth disease chromatin remodeling
H-92	-0.43668174743652344	▁cardiac _ ▁growth _ plast ity ▁disease ▁recap it ulat es ▁development al ▁chr omat in _ ▁remodel ing
D-92	-0.43668174743652344	cardiac_ growth_plastity disease recapitulates developmental chromatin_ remodeling
P-92	-0.1706 -0.9844 -1.3835 -2.5024 -0.4040 -0.1221 -0.1231 -0.0386 -0.0600 -0.0009 -0.0566 -0.0795 -0.0486 -0.3014 -0.0026 -0.2033 -1.3253 -0.1112 -0.0324 -1.1676 -0.0523
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium expression pka downstream_signaling
H-1433	-0.4660731852054596	▁my o car dium ▁display s ▁post - trans la tional ▁p KA ▁down stream _ signal ing
D-1433	-0.4660731852054596	myocardium displays post-translational pKA downstream_signaling
P-1433	-0.2636 -0.1556 -0.1857 -0.4171 -1.2368 -0.7570 -0.1551 -0.0065 -0.0003 -0.2962 -0.0004 -3.7937 -0.2789 -0.1718 -0.0001 -0.8393 -0.3042 -0.1803 -0.1113 -0.1675
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 hno cxl-1051 t1
H-416	-0.5800089836120605	▁c XL -10 20 ▁H NO ▁in active ▁C XL -10 51
D-416	-0.5800089836120605	cXL-1020 HNO inactive CXL-1051
P-416	-2.1773 -0.1079 -0.1824 -0.0835 -1.7597 -1.2034 -0.0540 -0.0133 -1.4050 -0.0078 -0.1359 -0.0511 -0.8334 -0.1055
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics chromatin-associated_proteins disease
H-93	-0.36413508653640747	▁quantitat ive _ ▁prote o mics ▁chr omat in - as soci ated _ ▁protein s ▁detergent
D-93	-0.36413508653640747	quantitative_ proteomics chromatin-associated_ proteins detergent
P-93	-0.4663 -0.0329 -1.0036 -1.2039 -0.3217 -0.0067 -0.0619 -0.0070 -0.3277 -0.1310 -0.0159 -0.0000 -0.1496 -0.2761 -0.6240 -0.0545 -0.1969 -1.9073 -0.1315
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients chf international_classification_of_diseases
H-213	-0.6801451444625854	▁CHF ▁classifica tion _ of _ ▁Disease s ▁Nin th _ re vision ▁code s
D-213	-0.6801451444625854	CHF classification_of_ Diseases Ninth_revision codes
P-213	-3.8156 -5.1310 -0.0358 -1.0759 -0.0388 -0.0429 -0.7818 -0.0221 -0.0474 -0.0033 -0.2585 -0.1715 -0.0005 -0.0347 -0.0251 -0.0205 -0.0570
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis idiopathic_dilated_cardiomyopathy
H-1742	-0.7208661437034607	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy _ co hor t
D-1742	-0.7208661437034607	idiopathic dilated_ cardiomyopathy_cohort
P-1742	-1.1613 -0.0938 -0.3518 -0.9695 -2.1226 -0.2628 -0.0868 -0.4889 -2.6208 -0.5614 -0.2748 -2.7513 -0.0885 -0.0023 -0.1393 -0.1897 -0.0891
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy atrial_fibrillation patients carvedilol metoprolol
H-867	-0.2810833752155304	▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-867	-0.2810833752155304	atrial_fibrillation carvedilol metoprolol
P-867	-2.1380 -0.0647 -0.2777 -0.5798 -0.0254 -0.0027 -0.5477 -0.0394 -0.0187 -0.3391 -0.0568 -0.0091 -0.0118 -0.0482 -0.0569
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv_dysfunction body_mass_index fat_mass cachexia
H-1163	-0.7760301828384399	▁ RV _ ▁dys function ▁lower _ ▁body _ ▁mass ▁index ▁cache xia
D-1163	-0.7760301828384399	RV_ dysfunction lower_ body_ mass index cachexia
P-1163	-0.1259 -0.3866 -0.9174 -1.0050 -0.0811 -0.7150 -0.6385 -1.4010 -0.8358 -1.7256 -0.9314 -2.0522 -0.4409 -0.1717 -0.2122
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients heartmate_ii biventricular_support heartmate_ii implantation
H-300	-0.51003098487854	▁Heart Mate _ II ▁ insertion ▁bi ven tri cular _ support ▁Heart Mate _ II ▁implant ation
D-300	-0.51003098487854	HeartMate_II insertion biventricular_support HeartMate_II implantation
P-300	-1.7432 -0.6981 -1.1672 -0.7688 -0.7132 -0.0023 -0.0999 -0.0362 -0.0744 -0.2169 -0.5500 -0.7095 -0.4626 -0.3775 -0.9102 -0.7108 -0.7716 -0.0474 -0.0546 -0.0861
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic acute_hf adverse_event chronic_hf
H-1016	-0.5032978653907776	▁ pharma c ologic ▁a cute _ HF ▁advers e _ ▁event _ rate ▁chronic _ HF
D-1016	-0.5032978653907776	pharmacologic acute_HF adverse_ event_rate chronic_HF
P-1016	-1.1700 -0.0584 -0.0420 -0.1943 -0.8090 -0.0018 -0.8561 -0.0596 -0.2540 -0.0332 -0.4708 -2.0733 -1.3936 -0.7441 -0.5067 -0.8004 -0.0037 -0.0393 -0.0522
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf_antagonists hf hospital admissions nbdmards ra
H-611	-0.30415016412734985	▁t NF _ ▁anta gon ists ▁ HF _ hospital ▁ad missions ▁n b DM ARD s ▁RA
D-611	-0.30415016412734985	tNF_ antagonists HF_hospital admissions nbDMARDs RA
P-611	-0.5138 -0.0597 -0.8608 -0.0748 -0.1432 -0.5181 -0.2229 -0.0131 -1.5398 -0.1163 -1.2693 -0.0379 -0.0137 -0.0016 -0.2424 -0.0152 -0.1488 -0.0308 -0.1314 -0.1293
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil mitochondrial_dysfunction heart_failure cardioprotection
H-954	-0.562526285648346	▁Nico rand il ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin - indu ced _ heart _ ▁failure ▁cardio protec tion
D-954	-0.562526285648346	Nicorandil mitochondrial_ dysfunction doxorubicin-induced_heart_ failure cardioprotection
P-954	-0.0155 -1.1198 -0.4420 -0.0785 -4.7956 -0.3927 -0.0081 -0.6061 -0.6091 -0.0153 -0.0088 -0.0188 -0.0685 -1.6291 -0.1723 -0.0119 -0.0234 -0.4332 -0.4623 -0.2519 -1.3873 -1.4454 -0.3848 -0.0084 -0.1656 -0.0712
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient functional_ms patient valve_plasty degenerative_mr dilated disease
H-367	-0.41233962774276733	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive _ ▁MR ▁LV
D-367	-0.41233962774276733	functional MS valve plasty degenerative_ MR LV
P-367	-0.1585 -0.0675 -2.3899 -0.0026 -0.5995 -0.0593 -0.0676 -0.0000 -0.0085 -0.7852 -0.0685 -0.5589 -0.8679 -0.1389
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient st-segment-elevation_mis killip_class comorbid conditions
H-1105	-0.5374289155006409	▁ST - seg ment - elevat ion _ ▁MI s ▁Kill ip ▁conditions
D-1105	-0.5374289155006409	ST-segment-elevation_ MIs Killip conditions
P-1105	-5.1892 -0.0498 -0.0004 -0.1153 -0.0379 -0.0009 -0.0112 -0.1064 -0.7620 -0.0152 -1.0708 -0.0054 -0.6192 -0.0222 -0.0555
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate left_ventricular_assist_system lvas patients heart_failure
H-1993	-0.8267937898635864	▁Heart Mate ▁left _ ▁vent ri cular _ assist _ system ▁l VAS
D-1993	-0.8267937898635864	HeartMate left_ ventricular_assist_system lVAS
P-1993	-0.2550 -0.8228 -1.8335 -0.1749 -3.2810 -0.3688 -0.1212 -0.1404 -0.0135 -2.1677 -0.0610 -1.2379 -0.0945 -1.7201 -0.1096
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect heart_failure patients implantable_cardioverter-defibrillator
H-1860	-0.8416370153427124	▁ground ed _ the ory ▁heart _ ▁failure _ ▁patients ▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.8416370153427124	grounded_theory heart_ failure_ patients implantable cardioverter-defibrillator
P-1860	-4.7088 -0.5716 -0.3285 -0.3010 -0.0096 -5.0753 -0.5082 -0.3344 -2.5312 -1.6479 -0.0259 -0.0097 -1.1085 -0.0561 -0.5720 -0.4815 -0.0102 -0.0379 -0.5847 -0.2258 -0.0271 -0.1350 -0.0667
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated baseline nt-probnp mr-proanp mr-proadm
H-17	-0.3429248631000519	▁base line ▁NT - pro B NP ▁MR - pro AN P ▁MR - pro AD M
D-17	-0.3429248631000519	baseline NT-proBNP MR-proANP MR-proADM
P-17	-0.0611 -0.0097 -0.0978 -0.0161 -0.0031 -2.1861 -0.0659 -0.0196 -0.0150 -0.0064 -0.4015 -1.2299 -0.0109 -0.0152 -0.0130 -1.2475 -0.8715 -0.0229 -0.2223
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial_elastance ea pulsatile_afterload heart pressure_volume_relation
H-517	-0.7850812077522278	▁arterial _ ▁elastan ce ▁pulsa tile _ ▁after load ▁pressure
D-517	-0.7850812077522278	arterial_ elastance pulsatile_ afterload pressure
P-517	-0.1476 -1.0868 -0.4450 -0.0674 -1.4791 -0.0042 -0.3557 -0.7907 -0.0000 -1.1552 -3.7918 -0.0975
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology myocardial_infarction mi outcomes heart_failure hf
H-1099	-0.6184970140457153	▁epidemi ology ▁my o card ial _ in far ction
D-1099	-0.6184970140457153	epidemiology myocardial_infarction
P-1099	-0.0543 -0.0099 -0.1704 -0.0957 -0.8625 -0.0154 -0.0911 -0.4759 -0.0023 -0.0503 -5.4518 -0.1424
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic admission brain_natriuretic_peptide bnp creatinine natremia
H-585	-0.7654306888580322	▁ad mission ▁brain ▁na tri ure tic _ pe pti de ▁b NP ▁creati nine ▁na trem ia
D-585	-0.7654306888580322	admission brain natriuretic_peptide bNP creatinine natremia
P-585	-5.9290 -0.0445 -2.0117 -0.0650 -0.0115 -0.1010 -1.1123 -0.2581 -0.1351 -0.4647 -0.9807 -2.4713 -0.1144 -0.0316 -0.0095 -0.2311 -0.0046 -1.1513 -0.0889 -0.0922
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end_stage_heart_failure heart_failure public health patient europe north_america
H-1663	-1.2685993909835815	▁management _ of ▁end _ state _ heart _ ▁failure ▁public _ health _ problem
D-1663	-1.2685993909835815	management_of end_state_heart_ failure public_health_problem
P-1663	-2.9343 -1.8211 -0.5741 -1.2166 -0.3617 -3.2387 -0.1729 -1.4265 -0.3407 -1.2757 -1.3768 -0.1002 -1.2077 -1.8375 -1.3610 -2.0811 -0.2398
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ras asymptomatic clinically hypertension nephropathy congestive_heart_failure
H-1597	-0.5707204341888428	▁ RAS ▁hyper tension ▁nep hro pathy ▁con ges tive _ heart _ ▁failure
D-1597	-0.5707204341888428	RAS hypertension nephropathy congestive_heart_ failure
P-1597	-2.5769 -0.1807 -0.9217 -0.0200 -2.6407 -0.0497 -0.1417 -0.0059 -0.0417 -0.1673 -0.2180 -0.5205 -0.7817 -0.5404 -0.0704 -0.2542
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric_focusing riα ser77 ser83 in_vivo phosphorylation
H-1430	-0.7051037549972534	▁iso electric _ ▁focus ing ▁RI α ▁ser 77 ▁ser 83 ▁vivo ▁ phos phor y lation
D-1430	-0.7051037549972534	isoelectric_ focusing RIα ser77 ser83 vivo phosphorylation
P-1430	-1.1042 -0.6372 -1.0247 -0.5818 -0.0413 -0.5035 -0.3372 -0.6222 -0.5229 -1.3336 -0.6920 -0.2099 -0.9981 -0.0096 -1.2461 -2.2947 -0.1138 -1.0216 -0.1024
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care_of_heart_failure_index_version_6.2 schfi_v.6.2 psychometric
H-1504	-0.515005886554718	▁Self - Car e _ of _ heart _ fail ure _ index
D-1504	-0.515005886554718	Self-Care_of_heart_failure_index
P-1504	-0.7666 -0.0244 -0.3323 -0.0313 -0.4934 -0.0356 -0.6381 -0.8198 -0.0372 -0.2756 -0.1705 -0.2767 -0.0862 -3.5993 -0.1380
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt sd_of_rr_intervals sdrr qtv heart_rate_variability
H-1440	-0.9217811822891235	▁SD QT ▁ RR _ ▁interval s ▁Q TV ▁heart _ rati o
D-1440	-0.9217811822891235	SDQT RR_ intervals QTV heart_ratio
P-1440	-0.0424 -0.6113 -3.9645 -0.5529 -1.7746 -0.1836 -0.0084 -0.9953 -0.4943 -0.1544 -1.0806 -2.0483 -0.2590 -1.0457 -0.6115
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart_rate_reduction exercise heart_failure_with_reduced_ejection_fraction beta-blocker
H-1935	-0.7288874983787537	▁Heart _ re duction ▁exercise _ per form ance ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction ▁beta - block er ▁hypo - respons e
D-1935	-0.7288874983787537	Heart_reduction exercise_performance heart_ failure reduced ejection_fraction beta-blocker hypo-response
P-1935	-0.6085 -0.7544 -1.1657 -0.0004 -0.1405 -2.3129 -3.0656 -1.3597 -0.5598 -5.1546 -0.1775 -1.2821 -1.9951 -0.0027 -0.1478 -0.0049 -0.0080 -0.4680 -0.0031 -0.0545 -0.0222 -0.6142 -0.1412 -0.6057 -0.1483 -0.0000 -0.0403 -0.1130 -0.1871
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart_failure cardiology-cardiovascular_surgery_consensus_report heart_failure disease
H-1818	-0.6324299573898315	▁heart _ ▁failure ▁mechanic al _ support ▁devices ▁Card i ology - Car dio vas cular _ Sur ger y _ con en sus _ report ▁Heart _ ▁failure ▁progressive _ مرض
D-1818	-0.6324299573898315	heart_ failure mechanical_support devices Cardiology-Cardiovascular_Surgery_conensus_report Heart_ failure progressive_مرض
P-1818	-1.4402 -0.4791 -1.2483 -0.2877 -0.0027 -0.3051 -0.5793 -1.1324 -0.3549 -0.1408 -0.0051 -0.4832 -0.3179 -3.2137 -0.4363 -0.0404 -0.0545 -0.3302 -0.4246 -0.0621 -1.7001 -0.2341 -1.0330 -0.0040 -1.1039 -0.5432 -0.2797 -0.3887 -2.1696 -0.0602 -0.4241 -2.0796 -0.0801 -0.0639
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed patients hf drug_treatment paf biosynthetic_enzymes lyso-paf-at
H-1271	-0.7882336378097534	▁ HF ▁ HF _ drug _ ▁treatment ▁PA F ▁bio syn the tic _ ▁enzym es ▁lys o - PA F - AT
D-1271	-0.7882336378097534	HF HF_drug_ treatment PAF biosynthetic_ enzymes lyso-PAF-AT
P-1271	-0.3674 -0.0123 -2.5743 -0.0258 -4.7503 -2.7648 -2.8733 -1.7946 -0.5632 -0.3476 -0.3435 -0.0166 -0.3341 -0.9896 -1.0315 -0.0226 -0.0276 -0.0012 -0.0173 -0.0288 -0.2219 -0.2288 -0.1869 -0.0419 -0.4892 -0.4390
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician evidence
H-1842	-0.9417534470558167	▁physician ▁ad her ence
D-1842	-0.9417534470558167	physician adherence
P-1842	-2.5537 -0.0519 -0.2918 -0.0139 -2.5487 -0.1905
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses magnet
H-87	-0.9279667735099792	▁volunt ary _ ▁testimoni es
D-87	-0.9279667735099792	voluntary_ testimonies
P-87	-0.7696 -0.0372 -0.7193 -0.0754 -0.0052 -4.6631 -0.2260
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized exercise exercise
H-1981	-1.434069275856018	▁exercise
D-1981	-1.434069275856018	exercise
P-1981	-2.3828 -1.8111 -0.1084
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality hospitals
H-1695	-0.4243013262748718	▁risk - ad just ed _ ▁mortal ity
D-1695	-0.4243013262748718	risk-adjusted_ mortality
P-1695	-0.7467 -0.1321 -0.0039 -0.0188 -0.0264 -0.1039 -0.5759 -0.0165 -2.2787 -0.3401
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ejection_fraction
H-1236	-1.1771042346954346	▁patients ▁e je ction
D-1236	-1.1771042346954346	patients ejection
P-1236	-3.2288 -0.7555 -0.2234 -0.0700 -2.6555 -0.1295
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence hf ami mortality
H-1314	-0.48791176080703735	▁incide nce ▁ HF ▁complicat ing ▁ AMI ▁high _ ▁mortal ity
D-1314	-0.48791176080703735	incidence HF complicating AMI high_ mortality
P-1314	-3.4919 -0.7317 -0.1589 -0.0114 -0.9099 -0.0244 -0.0593 -0.0033 -0.1841 -0.3888 -0.7722 -0.0033 -0.0225 -0.0692
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician mortality hf physicians
H-1731	-0.5176599025726318	▁Physic ian _ ▁volume ▁ HF ▁low - volu me _ institution s ▁non car dio logist _ ▁physician s
D-1731	-0.5176599025726318	Physician_ volume HF low-volume_institutions noncardiologist_ physicians
P-1731	-0.7743 -0.4498 -0.3709 -0.1082 -0.8412 -0.0111 -1.9512 -0.0135 -0.0072 -0.0026 -2.3974 -0.1134 -0.0097 -0.0316 -0.0228 -0.4594 -0.9224 -1.4958 -1.2481 -0.0598 -0.0412 -0.0567
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 sst2 outcomes
H-406	-0.7123944163322449	▁s ST 2/ low - dos e ▁BB ▁s ST 2/ high - dos e _ ▁BB
D-406	-0.7123944163322449	sST2/low-dose BB sST2/high-dose_ BB
P-406	-0.0883 -1.4064 -1.1999 -0.9335 -0.0200 -1.6856 -0.0589 -0.3461 -1.4459 -0.4798 -0.9562 -0.8578 -0.0221 -0.1818 -0.0231 -1.9478 -1.3663 -0.3114 -0.2049
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate_analysis gls
H-817	-1.8244588375091553	▁g ls
D-817	-1.8244588375091553	gls
P-817	-2.3215 -2.7612 -1.9761 -0.2391
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf chf patients intubated
H-214	-1.339538812637329	▁CHF _ visit s
D-214	-1.339538812637329	CHF_visits
P-214	-0.8458 -2.0329 -1.3344 -1.3155 -2.4265 -0.0822
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv_ejection_fraction pcwp
H-483	-0.5436248183250427	▁LV ▁e je ction _ fraction ▁PC WP
D-483	-0.5436248183250427	LV ejection_fraction PCWP
P-483	-0.9611 -1.4457 -0.0594 -0.0183 -0.7049 -0.0272 -0.4033 -1.1422 -0.5531 -0.1210
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients t1_times cardiac_events
H-740	-1.0223265886306763	▁cardiac _ event s
D-740	-1.0223265886306763	cardiac_events
P-740	-2.9271 -0.8698 -1.4210 -0.2705 -0.5539 -0.0916
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin genomic_reprogramming disease
H-100	-0.6895807385444641	▁Vali da tion _ system ▁zebra fish ▁Nu cle olin ▁genom ic ▁re programm ing _ ▁events ▁disease
D-100	-0.6895807385444641	Validation_system zebrafish Nucleolin genomic reprogramming_ events disease
P-100	-2.8968 -0.0503 -0.0106 -2.0226 -0.1992 -0.0557 -0.0099 -3.4978 -0.0034 -0.0656 -0.0625 -0.0226 -1.4548 -0.0041 -0.0357 -1.8428 -0.3017 -0.9473 -0.0627 -0.2454
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr vad ecmo vad renal_function
H-1391	-0.9611113667488098	▁e G FR ▁ VAD _ group ▁EC MO + VAD ▁renal _ function
D-1391	-0.9611113667488098	eGFR VAD_group ECMO+VAD renal_function
P-1391	-0.1659 -0.9181 -0.5779 -0.4651 -0.0208 -2.1239 -1.3624 -0.2955 -0.5320 -3.1891 -0.0414 -1.5951 -1.8411 -1.8585 -0.0653 -0.3256
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic tests cardiac_magnetic_resonance_imaging t1_mapping invasive_hemodynamic_assessments baseline
H-737	-0.5058874487876892	▁cardiac _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁t 1 _ ma pping ▁invasi ve _ hem o dynamic
D-737	-0.5058874487876892	cardiac_ magnetic_ resonance_ imaging t1_mapping invasive_hemodynamic
P-737	-0.1776 -0.3207 -0.9377 -0.0548 -0.3335 -0.1316 -0.0184 -0.2468 -3.4430 -0.0357 -1.2691 -0.0317 -1.4677 -0.9094 -0.0075 -0.0078 -0.0682 -0.0438 -1.0136 -0.3690 -0.0059 -0.7099 -0.0321
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-868	-0.4950903058052063	▁m ADI t - C RT ▁multi center ▁Automat ic _ ▁Def ib rilla tor _ ▁Implant ation ▁Card iac _ re syn chron ization _ therapy
D-868	-0.4950903058052063	mADIt-CRT multicenter Automatic_ Defibrillator_ Implantation Cardiac_resynchronization_therapy
P-868	-2.4764 -0.8092 -0.5319 -0.0407 -1.9174 -0.0577 -0.8760 -0.0056 -0.6924 -0.0027 -0.1284 -2.5891 -0.2376 -0.2034 -0.0253 -0.3483 -0.0453 -0.0653 -0.1453 -0.0127 -0.1916 -0.1795 -0.0032 -0.0007 -0.4255 -1.2307 -0.7350 -0.3265 -0.0541
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs septal qrs resynchronization
H-486	-0.7720571160316467	▁a UC s ▁e / e sept al ▁e / eme an ▁s ' sept al ▁QR S ▁re syn chron ization
D-486	-0.7720571160316467	aUCs e/eseptal e/emean s'septal QRS resynchronization
P-486	-4.5226 -0.3167 -0.1495 -0.8034 -3.5714 -0.0813 -0.2658 -0.0368 -0.9248 -1.2772 -0.0068 -0.0080 -0.5258 -2.7065 -0.1258 -0.1064 -0.0154 -1.5536 -0.8826 -0.0052 -0.0005 -0.3430 -0.1494 -0.1508
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective diuretics morbidity mortality
H-1200	-0.6191763877868652	▁di ure tics ▁ HF - related ▁morbi d ity
D-1200	-0.6191763877868652	diuretics HF-related morbidity
P-1200	-0.5238 -0.1146 -0.8331 -0.6388 -0.0124 -0.2502 -0.0374 -2.4243 -0.0913 -0.0864 -2.2949 -0.1229
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians public health air cardiovascular health lead hospitalisation death
H-1808	-0.9341270327568054	▁public _ health ▁air ▁pollution ▁industrial _ ▁areas ▁hospital isation
D-1808	-0.9341270327568054	public_health air pollution industrial_ areas hospitalisation
P-1808	-0.3317 -0.5837 -1.5330 -0.3390 -0.3801 -2.0274 -1.1712 -1.2525 -2.5941 -0.0156 -0.8057 -0.1755
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital readmission patients heart_failure follow-up
H-731	-1.9593483209609985	▁hospital ▁heart _ ▁failure ▁follow - up
D-731	-1.9593483209609985	hospital heart_ failure follow-up
P-731	-3.7488 -6.0003 -0.4803 -2.7994 -3.1953 -0.0869 -0.0089 -1.2265 -0.0877
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health_care clinically gastrointestinal_bleeding
H-1658	-0.8560096025466919	▁devices ▁gastro inte stin al _ ▁ble ed ing
D-1658	-0.8560096025466919	devices gastrointestinal_ bleeding
P-1658	-4.0332 -1.7122 -0.8846 -1.0560 -0.0692 -0.2992 -0.7819 -0.1231 -0.0770 -0.3180 -0.0618
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol metoprolol therapy heart_failure patients
H-857	-0.32240352034568787	▁car vedi lol ▁met o pro lol ▁heart _ ▁failure ▁devices
D-857	-0.32240352034568787	carvedilol metoprolol heart_ failure devices
P-857	-0.1954 -0.0318 -0.0293 -0.3958 -0.0750 -0.0073 -0.0847 -0.8106 -1.0220 -0.9408 -0.4959 -0.0395 -0.0631
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc_occlusion correlated rs rs_synchrony
H-326	-0.21923522651195526	▁IV C ▁oc clusi on ▁twist ▁ap ical _ ro tation ▁RS ▁synchron y ▁CS
D-326	-0.21923522651195526	IVC occlusion twist apical_rotation RS synchrony CS
P-326	-0.0747 -1.1458 -0.0013 -0.0022 -0.0694 -0.1597 -0.1492 -0.0023 -0.7469 -0.7729 -0.0053 -0.0017 -0.0906 -0.0307 -0.3116 -0.0572 -0.1055
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic_regression primary_outcome secondary_outcome death
H-973	-0.8235816359519958	▁Log istic _ re gression _ model s ▁seconda ry _ ▁outcome _ of _ ▁death ▁con found ers
D-973	-0.8235816359519958	Logistic_regression_models secondary_ outcome_of_ death confounders
P-973	-0.4411 -0.0080 -1.0198 -0.5905 -0.0002 -3.0138 -1.4918 -0.6514 -1.9967 -0.0084 -1.1257 -0.3023 -2.8747 -0.3252 -0.1994 -2.0956 -0.9759 -0.0151 -0.0052 -0.0660 -0.0884
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart_failure hf risk_stratification inpatient outpatient
H-378	-0.9436666369438171	▁heart _ ▁failure _ HF ▁risk _ ▁strat ification _ ▁models ▁in patient ▁out patient _ model s
D-378	-0.9436666369438171	heart_ failure_HF risk_ stratification_ models inpatient outpatient_models
P-378	-0.5014 -0.3628 -3.7048 -1.2727 -0.0888 -2.9032 -0.4565 -0.6134 -0.0952 -1.3018 -1.1663 -0.1138 -0.0010 -3.0296 -0.0481 -0.9398 -1.2633 -0.7838 -0.1402 -0.0867
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity mortality hfpef patients hf reduced_ef
H-1301	-0.44079282879829407	▁Morbi d ity ▁ HF p EF
D-1301	-0.44079282879829407	Morbidity HFpEF
P-1301	-0.0622 -0.0248 -0.0858 -0.5821 -0.0177 -0.1013 -0.0559 -2.8288 -0.2087
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission hospital congestive_heart_failure united_states
H-1574	-0.954014241695404	▁con ges tive _ heart _ ▁failure
D-1574	-0.954014241695404	congestive_heart_ failure
P-1574	-3.0862 -0.1342 -0.0592 -0.0908 -1.3444 -0.2777 -3.2391 -0.2783 -0.0763
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet bromodomain-containing_protein_4 brd4 cardiac
H-1045	-0.5306459665298462	▁ BET ▁bro modo main - conta ining _ ▁protein BR d 4 ▁cardiac _ ▁tissu es
D-1045	-0.5306459665298462	BET bromodomain-containing_ proteinBRd4 cardiac_ tissues
P-1045	-1.4761 -0.0511 -0.0923 -0.0521 -0.3448 -0.3953 -1.7490 -0.0361 -0.3961 -0.3187 -1.5924 -0.9773 -0.5931 -0.0211 -1.2066 -0.5675 -0.0968 -0.0396 -0.0763
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence biomarkers pathophysiology chronic_hf therapeutic
H-1474	-0.33046790957450867	▁molecular _ bio mark ers ▁pat ho phy si ology ▁chronic ▁ HF
D-1474	-0.33046790957450867	molecular_biomarkers pathophysiology chronic HF
P-1474	-0.4287 -0.2524 -0.7320 -0.0265 -0.0132 -0.1579 -0.0793 -0.1124 -1.1922 -0.0019 -0.0482 -0.6991 -0.0003 -1.1398 -0.0732
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency_department acute_heart_failure clinical patient collins
H-56	-0.7367620468139648	▁emergency _ ▁department ▁a cute _ heart _ ▁failure _ ▁clinic al _ ▁trial s ▁en roll ment
D-56	-0.7367620468139648	emergency_ department acute_heart_ failure_ clinical_ trials enrollment
P-56	-0.1298 -0.5673 -0.2510 -0.0375 -0.0011 -0.0868 -2.9744 -0.2532 -5.0607 -1.1213 -1.5193 -0.0884 -0.4642 -0.6064 -0.0081 -1.0431 -0.1775 -0.0473 -0.1805 -0.1176
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence intravenous exercise_tolerance quality_of_life patients heart_failure
H-46	-0.8994923830032349	▁intra ven ous _ ▁ir on ▁exercise _ tolerance ▁heart _ ▁failure
D-46	-0.8994923830032349	intravenous_ iron exercise_tolerance heart_ failure
P-46	-2.8094 -0.0104 -0.3628 -0.3051 -0.5702 -0.0462 -1.3143 -1.3344 -0.0090 -3.2119 -0.8609 -1.6147 -0.0683 -0.0753
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare inpatient hf admissions acute hospitals united_states
H-1723	-0.3345927298069	▁Medica re ▁in patient _ data ▁ HF ▁ad missions ▁a cute _ hospital s
D-1723	-0.3345927298069	Medicare inpatient_data HF admissions acute_hospitals
P-1723	-0.0605 -0.0015 -0.3433 -0.0026 -1.2712 -0.1885 -0.4677 -0.0777 -0.3242 -0.0138 -0.0404 -0.0032 -0.2681 -1.6630 -0.0460 -0.5771 -0.3393
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg congenital accessory ion_channelopathies cardiomyopathy
H-1909	-0.3202957510948181	▁e CG ▁con geni tal _ accesso ry _ path ways ▁ion _ ▁channel o pathi es ▁cardio my o pathy
D-1909	-0.3202957510948181	eCG congenital_accessory_pathways ion_ channelopathies cardiomyopathy
P-1909	-1.4188 -0.0885 -0.2929 -0.0009 -0.0764 -0.5353 -1.0472 -0.0357 -0.3066 -0.1648 -0.0332 -0.0375 -0.1959 -1.6327 -0.7267 -0.0952 -0.0170 -0.0338 -0.3056 -0.1198 -0.0914 -0.0147 -0.0961
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf hhd salt_loading uninephrectomy ang_ii_infusion
H-275	-0.3604990541934967	▁mouse ▁ HF _ model ▁H HD ▁salt ▁load ing ▁un ine ph r ecto my ▁ANG ▁II ▁in fusion
D-275	-0.3604990541934967	mouse HF_model HHD salt loading uninephrectomy ANG II infusion
P-275	-0.1653 -0.3085 -0.0022 -1.6222 -0.4370 -1.8982 -0.3429 -0.0317 -0.1481 -0.0151 -0.0241 -0.0024 -0.1759 -0.1960 -0.0954 -0.9898 -0.0975 -1.0492 -0.1075 -0.0028 -0.0769 -0.1423
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report mitral_valve_plasty degenerative_mitral_regurgitation
H-335	-0.35541895031929016	▁mit ral _ plast y ▁de genera tive _ ▁mit ral _ re gur gi tation
D-335	-0.35541895031929016	mitral_plasty degenerative_ mitral_regurgitation
P-335	-2.4637 -0.0118 -0.1006 -0.4894 -0.0306 -0.2135 -0.0002 -0.0255 -0.7217 -1.3534 -0.0641 -0.3088 -0.5091 -0.0007 -0.0198 -0.0023 -0.0373 -0.0449
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating_agents patients anemia heart_disease
H-52	-1.1370590925216675	▁er y thro po ies is - stimul ating _ agent s ▁an emia ▁heart
D-52	-1.1370590925216675	erythropoiesis-stimulating_agents anemia heart
P-52	-0.3242 -0.1283 -2.4487 -0.7845 -3.7010 -1.1920 -0.6850 -0.1529 -0.0485 -0.9372 -0.5443 -1.1871 -4.0211 -0.0167 -0.8048 -2.1872 -0.1668
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients idiopathic_dilated_cardiomyopathy tuscany evidence-based
H-1739	-0.5572562217712402	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁Tu sca ny ▁evidence - based ▁management
D-1739	-0.5572562217712402	idiopathic_ dilated_ cardiomyopathy Tuscany evidence-based management
P-1739	-0.9794 -0.1850 -0.3259 -0.5134 -0.2983 -2.4758 -0.3461 -0.0124 -1.1201 -2.7807 -0.5202 -0.2751 -0.9776 -0.0001 -0.0417 -0.0857 -0.0143 -0.0053 -0.6680 -0.0440 -0.0335
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs québec_health_insurance_board costs ontario_case_costing_initiative
H-1235	-0.6806368827819824	▁in - t rial _ ▁resource _ ▁utiliza tion ▁unit ▁costs ▁Québec _ health _ board ▁disease - specific _ ▁costs ▁Ontario _ case ▁Cost ing _ initiative
D-1235	-0.6806368827819824	in-trial_ resource_ utilization unit costs Québec_health_board disease-specific_ costs Ontario_case Costing_initiative
P-1235	-0.6883 -1.7336 -0.1028 -0.0028 -1.3279 -0.2261 -0.9247 -1.2800 -0.0042 -0.4818 -0.7223 -0.1617 -0.5923 -1.4993 -0.2732 -2.2394 -2.1709 -0.1246 -0.1904 -1.0069 -0.4362 -0.0293 -1.8749 -0.2281 -0.8203 -0.1423 -0.4524 -0.5823 -0.0409 -0.0594
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf_with_preserved_ejection_fraction pef uptitration hospitalization
H-176	-0.31680768728256226	▁ HF ▁pres er ved ▁e je ction _ fraction ▁p EF ▁up tit ration ▁hospital ization
D-176	-0.31680768728256226	HF preserved ejection_fraction pEF uptitration hospitalization
P-176	-0.7053 -0.0098 -0.1381 -0.1046 -0.0531 -0.9597 -0.7125 -0.3183 -0.5462 -0.0373 -0.7478 -0.0106 -0.3703 -0.6997 -0.0547 -0.0654 -0.2702 -0.0560 -0.1600
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf heart_failure t2d type_2_diabetes skm skeletal_muscle
H-1244	-0.8846807479858398	heart _ ▁failure ▁t 2 d ▁type ▁2 ▁diabetes ▁Sk m ▁s kelet al _ ▁muscle
D-1244	-0.8846807479858398	heart_ failure t2d type 2 diabetes Skm skeletal_ muscle
P-1244	-2.8873 -1.0739 -0.5674 -0.9499 -0.0074 -0.7288 -2.6261 -1.7164 -0.0584 -1.2707 -0.3282 -1.5031 -0.0055 -0.0066 -0.3094 -0.9878 -0.7226 -0.1747
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras neprilysin_inhibition change stable chronic_heart_failure systolic_dysfunction
H-1971	-0.8913314342498779	▁ RAS ▁nepri ly sin _ ▁inhibi tion ▁chronic _ heart _ ▁failure ▁sy sto lic _ ▁dys function
D-1971	-0.8913314342498779	RAS neprilysin_ inhibition chronic_heart_ failure systolic_ dysfunction
P-1971	-3.2944 -0.2539 -1.1916 -0.4179 -0.3907 -1.0569 -0.0048 -0.0113 -2.8639 -0.2962 -1.2684 -0.6864 -2.3221 -0.1023 -0.0900 -1.3967 -0.3522 -1.1503 -0.0592 -1.0673 -0.4415
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping tidal_respiration administration gadolinium-chelate_contrast_agent
H-1058	-0.5120230913162231	▁t 1- ma pping _ se que nce ▁tid al _ ▁respira tion ▁ gado lini um - che late _ agent
D-1058	-0.5120230913162231	t1-mapping_sequence tidal_ respiration gadolinium-chelate_agent
P-1058	-1.2610 -0.2069 -0.0821 -0.0082 -0.3924 -0.3529 -0.0281 -2.1560 -0.0155 -0.0014 -0.2590 -0.0709 -0.0147 -1.1301 -0.0235 -0.4148 -0.1162 -0.2271 -0.0197 -2.2730 -0.3449 -2.2905 -0.4511 -0.1485
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf pyridostigmine basal_heart_rate sympathetic_control_of_heart_rate
H-1140	-0.3951747715473175	▁ HF _ ▁rat s ▁py rido stig mine ▁bas al _ heart ▁rate ▁va gal ▁sympa the tic _ control _ of _ heart ▁rate
D-1140	-0.3951747715473175	HF_ rats pyridostigmine basal_heart rate vagal sympathetic_control_of_heart rate
P-1140	-0.5934 -0.3617 -2.0058 -0.1644 -0.0116 -0.0155 -0.0030 -0.0010 -0.0111 -0.0039 -0.0010 -0.2030 -1.6253 -0.7838 -0.0011 -0.0005 -0.0252 -0.0551 -0.0463 -0.4013 -0.0153 -1.7979 -0.9100 -0.1583 -0.8011 -0.7737 -0.0588 -0.2357
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report dapc dystrophin-associated_protein_complex sarcomeric_microstructure baseline
H-1253	-0.6002721190452576	▁DAP c ▁d trop hin - as soci ated _ ▁protein _ ▁complex ▁sar come ric _ micro structure ▁base line
D-1253	-0.6002721190452576	DAPc dtrophin-associated_ protein_ complex sarcomeric_microstructure baseline
P-1253	-0.9850 -2.4613 -4.2182 -0.1685 -0.8634 -0.2489 -0.0563 -0.0000 -0.7874 -0.1024 -1.2477 -0.8009 -0.0133 -0.0051 -0.2387 -0.6581 -0.4670 -0.1223 -0.1850 -0.0945 -0.0013 -0.0343 -0.0465
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary_exercise_test quality_of_life muscular peak_quadriceps_force
H-1915	-0.8037030100822449	▁cardio pul mon ary _ velo city ▁pe ak _ ▁quadri cep s
D-1915	-0.8037030100822449	cardiopulmonary_velocity peak_ quadriceps
P-1915	-0.0242 -0.1788 -0.1841 -0.3137 -1.2739 -6.0950 -0.1284 -0.3929 -0.0169 -0.2728 -1.1022 -0.2670 -0.0796 -1.5276 -0.1984
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine nesiritide acute_heart_failure renal_dysfunction rose acute_heart_failure randomized
H-71	-0.5600904226303101	▁low - dos e ▁dop amine ▁low - dos e ▁nesi riti de ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁a cute _ heart _ ▁failure ▁random ized ▁trial
D-71	-0.5600904226303101	low-dose dopamine low-dose nesiritide acute_heart_ failure renal_ dysfunction acute_heart_ failure randomized trial
P-71	-0.8799 -0.0633 -0.6393 -0.2378 -2.1501 -0.1031 -4.3803 -0.0064 -0.1384 -0.0310 -0.3837 -0.0097 -0.4697 -0.0553 -0.0060 -0.3608 -0.8584 -0.3819 -0.6228 -0.0181 -0.4225 -1.4234 -0.0266 -0.2573 -0.0130 -0.0844 -0.8783 -0.2883 -1.7393 -0.2603 -0.2872 -1.3556 -0.1598 -0.0511
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction
H-941	-0.4836747646331787	▁cat heter ▁ab lation ▁at rial _ fi bril lation ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-941	-0.4836747646331787	catheter ablation atrial_fibrillation heart_ failure preserved ejection_fraction
P-941	-2.4691 -0.2605 -0.4161 -0.0018 -0.9620 -0.0201 -0.1646 -0.7951 -0.0168 -0.0002 -0.2526 -0.7642 -2.3241 -0.1732 -0.2128 -0.3250 -0.6995 -0.1636 -0.1160 -0.7798 -0.0037 -0.0737 -0.1301
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial titin_hypophosphorylation heart_failure_with_preserved_ejection_fraction metabolic
H-759	-0.4561161994934082	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction ▁rat ▁metabol ic _ risk
D-759	-0.4561161994934082	Myocardial titin hypophosphorylation heart_ failure preserved ejection_fraction rat metabolic_risk
P-759	-0.4286 -0.0418 -0.4694 -0.0682 -0.7871 -0.0961 -1.4763 -1.6478 -1.3539 -0.6922 -0.0048 -0.4081 -0.3531 -0.6250 -0.5583 -0.0517 -0.0274 -0.2036 -0.0297 -0.0113 -0.6817 -0.0718 -0.0012 -0.0680 -0.0166 -0.7201 -1.5380 -0.5956 -0.2001
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized af_ablation
H-953	-1.6164530515670776	▁AF ▁ab lation
D-953	-1.6164530515670776	AF ablation
P-953	-6.4568 -0.9745 -0.0049 -0.4647 -0.1813
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection_fraction patients
H-909	-1.0156306028366089	▁e je ction _ fraction
D-909	-1.0156306028366089	ejection_fraction
P-909	-2.9957 -0.9585 -0.5051 -1.3221 -0.0031 -1.2136 -0.1112
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence economic lvad outcomes
H-317	-1.0617144107818604	▁economic _ model
D-317	-1.0617144107818604	economic_model
P-317	-0.0641 -1.0462 -0.6801 -3.4642 -0.0538
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic crt
H-428	-0.9305877685546875	▁com bi ning _ ▁parameter s ▁multi para metric ▁e cho car dio graphic _ ▁score
D-428	-0.9305877685546875	combining_ parameters multiparametric echocardiographic_ score
P-428	-3.0061 -0.4352 -0.0293 -0.9318 -0.6406 -0.0121 -2.0988 -0.0731 -0.0091 -0.3497 -0.2886 -1.7775 -2.2617 -1.1377 -0.5596 -0.6448 -2.2994 -0.1953
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change readmission follow-up follow-up
H-724	-1.5873221158981323	▁initiative ▁follow - up
D-724	-1.5873221158981323	initiative follow-up
P-724	-6.1976 -0.6833 -0.0219 -0.0093 -2.5248 -0.0870
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf mi reduced_ejection_fraction ef
H-1100	-1.2340965270996094	▁trend s ▁ HF
D-1100	-1.2340965270996094	trends HF
P-1100	-0.9544 -0.0444 -0.4319 -0.0019 -5.4507 -0.5214
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients heartmate_ii lvad centrimag rvad
H-298	-0.550198495388031	▁Heart Mate _ II _ L VAD ▁temporar y ▁Centri Mag _ R VAD
D-298	-0.550198495388031	HeartMate_II_LVAD temporary CentriMag_RVAD
P-298	-1.6409 -0.1811 -0.6095 -0.5434 -0.5387 -2.5282 -0.0025 -0.0123 -0.0093 -0.1819 -0.3078 -0.0957 -1.9970 -0.0020 -0.0686 -0.0842
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients hfpef kccq health prognostic
H-791	-0.7328165769577026	▁ HF p EF ▁k cc q ▁health _ status
D-791	-0.7328165769577026	HFpEF kccq health_status
P-791	-0.7879 -0.0974 -0.0364 -0.1728 -0.7590 -0.1620 -0.8958 -2.3679 -2.3119 -0.0384 -1.0642 -0.1000
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic_heart_failure yield atrial cells
H-1334	-0.38032007217407227	▁Chro nic _ heart _ ▁failure ▁transform ing ▁growth _ factor ▁beta - dependent _ ▁yi eld ▁at rial ▁ex plant - der i ved ▁c - K it _ cell s
D-1334	-0.38032007217407227	Chronic_heart_ failure transforming growth_factor beta-dependent_ yield atrial explant-derived c-Kit_cells
P-1334	-0.0156 -0.0030 -0.4960 -1.1625 -0.9284 -1.4432 -0.2174 -0.0103 -0.3931 -1.3233 -0.0110 -0.0994 -0.0050 -0.0417 -1.0798 -0.2511 -0.0000 -3.2521 -0.0015 -0.4980 -0.0005 -0.0654 -0.0188 -0.0446 -0.0389 -0.0071 -0.0578 -0.5403 -0.0406 -0.4348 -0.2338 -0.0433 -0.0650 -0.1077
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality inpatient admissions hospital emergency_department
H-1623	-0.46080222725868225	▁Mor t ality ▁in patient ▁ad missions ▁hospital _ ▁days ▁emergency _ ▁department
D-1623	-0.46080222725868225	Mortality inpatient admissions hospital_ days emergency_ department
P-1623	-0.7840 -0.1089 -0.0729 -0.3344 -0.0451 -0.3860 -0.0122 -0.2583 -0.9816 -0.3668 -0.0180 -0.5486 -1.3339 -1.4963 -0.1652
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv_failure diagnostic left_ventricular_dysfunction
H-1093	-1.0260969400405884	▁ RV _ ▁failure ▁management _ procedure s ▁intr in sic ▁left _ ▁vent ri cular _ ▁dys function
D-1093	-1.0260969400405884	RV_ failure management_procedures intrinsic left_ ventricular_ dysfunction
P-1093	-0.1751 -0.4098 -1.8650 -0.8964 -2.2688 -3.2547 -1.6746 -0.0197 -2.0026 -0.0145 -0.0019 -1.8834 -0.2157 -4.8565 -0.6383 -0.1641 -0.3770 -0.4761 -0.0206 -0.0875 -0.2458
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients baseline serum_creatinine serum_potassium
H-441	-0.45872703194618225	▁base line ▁se rum _ rati nine ▁se rum _ po tas s ium
D-441	-0.45872703194618225	baseline serum_ratinine serum_potassium
P-441	-0.0087 -0.0024 -0.3170 -0.0021 -0.6085 -0.4008 -0.1731 -0.9823 -0.0004 -0.9165 -0.3510 -0.5946 -0.9498 -0.8836 -1.0413 -0.1075
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd diuretic peripheral_edema functional_class
H-899	-0.3357497751712799	▁PD _ ▁initiat ion ▁di ure tic _ ▁response ▁per i pher al _ ▁ed ema ▁functional
D-899	-0.3357497751712799	PD_ initiation diuretic_ response peripheral_ edema functional
P-899	-0.0990 -1.3198 -0.3117 -0.0016 -0.3802 -0.0242 -0.0878 -0.6306 -1.0894 -0.0031 -0.0895 -0.0002 -0.0043 -1.0053 -0.2096 -0.0001 -0.0632 -0.9593 -0.1003
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia patients chronic_heart_failure hf prevalence outcomes
H-834	-0.7898212671279907	▁an emia ▁chronic _ heart _ ▁failure HF
D-834	-0.7898212671279907	anemia chronic_heart_ failureHF
P-834	-0.8869 -0.0027 -1.4234 -0.1857 -1.1273 -0.3357 -1.7404 -0.7970 -1.2933 -0.1057
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel_inhibition hemodynamic exercise_tolerance heart_failure_with_preserved_ejection_fraction randomized
H-1170	-0.4596233665943146	▁If - chan nel _ ▁inhibi tion ▁hem o dynamic _ status ▁exercise ▁ tolerance ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-1170	-0.4596233665943146	If-channel_ inhibition hemodynamic_status exercise tolerance heart_ failure preserved ejection_fraction
P-1170	-3.2811 -0.2155 -0.0026 -0.1385 -1.3326 -0.5719 -0.0407 -1.2753 -0.0916 -0.0027 -1.5189 -0.0602 -0.0052 -0.6668 -0.0007 -0.1199 -0.3882 -1.0574 -0.0157 -0.1649 -0.2113 -0.5049 -0.0673 -0.0310 -0.8341 -0.0049 -0.1937 -0.0719
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_hypertrophy
H-1777	-0.39898985624313354	▁Card iac ▁insulin - re si stance ▁mito cho ndri al _ ener gy ▁sy sto lic _ heart _ ▁failure ▁pressure - over load ▁hyper trop hy
D-1777	-0.39898985624313354	Cardiac insulin-resistance mitochondrial_energy systolic_heart_ failure pressure-overload hypertrophy
P-1777	-0.5966 -0.0634 -1.2592 -0.2857 -0.0207 -0.1585 -0.0001 -0.0192 -0.7820 -0.0748 -0.0036 -0.7245 -0.1865 -0.2426 -0.8817 -0.0200 -0.2095 -0.1883 -0.8537 -0.6530 -2.9542 -0.0017 -0.0973 -0.0180 -0.0023 -0.6720 -0.0008 -0.8408 -0.0344 -0.1247
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic cardiac_resynchronization_therapy crt
H-427	-0.5206772685050964	▁e cho car dio graphic _ pred ors ▁response ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-427	-0.5206772685050964	echocardiographic_predors response cardiac_resynchronization_therapy cRT
P-427	-0.0242 -0.0360 -0.5366 -1.8141 -0.1363 -1.4066 -0.7919 -0.3631 -0.4391 -1.2257 -0.3255 -0.6178 -0.0006 -0.0012 -0.1595 -0.5778 -0.5344 -1.8439 -0.0324 -0.0383 -0.0291
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp antibodies nonterminal_epitopes
H-1519	-0.256663054227829	▁circula ting ▁NT - pro B NP ▁anti bo dies ▁non gly cos yla ted ▁non termin al ▁e pito pes
D-1519	-0.256663054227829	circulating NT-proBNP antibodies nonglycosylated nonterminal epitopes
P-1519	-0.3441 -0.0186 -0.0143 -0.0155 -0.0012 -1.3949 -0.0988 -0.0217 -0.3532 -0.4381 -0.0422 -1.7685 -0.0227 -0.1873 -0.0286 -0.0594 -0.1558 -0.0008 -0.7025 -0.0226 -0.0557 -0.0587 -0.0980
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods_study exercise patients heart_failure
H-615	-2.31244158744812	▁exercise _ programm e
D-615	-2.31244158744812	exercise_programme
P-615	-7.6891 -2.5538 -0.4545 -0.8816 -2.0344 -0.2613
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref exercise resting_hr bpm beta-blocker therapy
H-1946	-0.6627026796340942	▁ons et ▁H Fr EF ▁exercise _ ▁performance ▁rest ing ▁HR ▁beta - block er _ therapy
D-1946	-0.6627026796340942	onset HFrEF exercise_ performance resting HR beta-blocker_therapy
P-1946	-4.6661 -0.0179 -1.0457 -0.0360 -0.6400 -0.1540 -1.1524 -1.2189 -0.4919 -0.0250 -0.0839 -1.1940 -0.0143 -0.1300 -0.1325 -1.4032 -0.0814 -0.0414 -0.0628
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage_heart_failure mechanical_cardiac_support
H-1386	-1.0131056308746338	▁end - s tage _ heart _ ▁failure ▁pediatr ic ▁mechanic al _ ▁cardiac
D-1386	-1.0131056308746338	end-stage_heart_ failure pediatric mechanical_ cardiac
P-1386	-7.3279 -0.0717 -0.0874 -0.0024 -0.6801 -1.0252 -0.7756 -2.3754 -0.2751 -0.0235 -0.0292 -0.0045 -0.1664 -1.0387 -2.2308 -0.0958
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard tnf_antagonist baseline covariates
H-606	-0.23734883964061737	▁n b DM ARD ▁t NF _ ▁anta gon ist ▁base line _ co varia tes
D-606	-0.23734883964061737	nbDMARD tNF_ antagonist baseline_covariates
P-606	-0.1707 -0.0095 -1.1622 -0.0405 -0.9050 -0.0760 -0.4395 -0.0576 -0.2296 -0.1595 -0.0006 -0.0033 -0.6316 -0.0800 -0.1464 -0.0153 -0.0681 -0.0769
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac_mrna inflammatory cell_adhesion_genes retn
H-934	-0.5792791247367859	▁Hum - Re t n _ mi ce ▁cardiac ▁m RNA _ level ▁infla mma tory ▁cell ▁a dhe sion _ ▁gene s ▁Ret n _ mi ce
D-934	-0.5792791247367859	Hum-Retn_mice cardiac mRNA_level inflammatory cell adhesion_ genes Retn_mice
P-934	-0.1112 -0.2126 -0.5238 -0.0252 -0.0050 -0.6432 -0.5218 -0.0183 -0.4809 -0.2985 -0.0009 -3.8960 -0.6143 -0.9524 -0.2816 -0.0152 -1.6438 -0.6248 -0.0003 -0.0296 -0.3775 -0.4355 -0.0406 -0.0700 -0.0115 -1.4853 -3.6196 -0.0112 -0.2101 -0.2178
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline follow-up paf activity metabolic enzymes patients heart_failure healthy
H-1266	-1.2140541076660156	▁base line ▁PA F ▁metabol ic _ ▁enzym es ▁heart _ ▁failure
D-1266	-1.2140541076660156	baseline PAF metabolic_ enzymes heart_ failure
P-1266	-1.8964 -0.3053 -4.4123 -0.8844 -0.2376 -0.0740 -0.4738 -0.2044 -0.0248 -1.8112 -0.7219 -3.8991 -1.7143 -0.3373
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin_subproteomes heart_failure proteins chromatin_structure
H-91	-0.8728236556053162	▁chr omat in _ ▁sub prote om es ▁heart _ ▁failure ▁chr omat in _ ▁structure
D-91	-0.8728236556053162	chromatin_ subproteomes heart_ failure chromatin_ structure
P-91	-2.9798 -0.0421 -0.4402 -0.3081 -0.3961 -0.1181 -0.5046 -0.6611 -0.1086 -0.4948 -3.3180 -3.3941 -0.0594 -0.6228 -0.4100 -1.5498 -0.1364 -0.1670
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients heart_failure heart_failure nurses follow-up cardiology mortality
H-1896	-0.8265308141708374	▁heart _ ▁failure ▁nurse s ▁card i ology
D-1896	-0.8265308141708374	heart_ failure nurses cardiology
P-1896	-0.8872 -0.8295 -1.0453 -2.0024 -0.0118 -1.3492 -0.4206 -0.0057 -1.4444 -0.2692
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_balance
H-1138	-0.5913836359977722	▁py rido stig mine ▁administration ▁met hy la tropi ne ▁propra no lol ▁cardiac ▁sympa t hova gal _ ▁balance
D-1138	-0.5913836359977722	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_ balance
P-1138	-0.0308 -0.0247 -0.0007 -0.0078 -3.1853 -0.3067 -0.0873 -0.2559 -0.0022 -2.2652 -0.0032 -0.0041 -0.0222 -0.0079 -4.7649 -0.1464 -0.2187 -0.2135 -1.1719 -0.1330 -0.0784 -0.0795
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative renal_dysfunction stroke myocardial_infarction heart_failure cabg
H-970	-0.5250937938690186	▁pre operativ e ▁renal _ ▁dys function ▁early ▁risk _ of _ ▁stroke ▁my o card ial _ in far ction ▁heart _ ▁failure
D-970	-0.5250937938690186	preoperative renal_ dysfunction early risk_of_ stroke myocardial_infarction heart_ failure
P-970	-0.0757 -0.0040 -0.1226 -0.1069 -0.4852 -1.0573 -0.0242 -0.8228 -0.8367 -2.1779 -1.2426 -0.8748 -0.2447 -0.7161 -0.1188 -0.3947 -0.0519 -0.1786 -0.6099 -0.0158 -0.1342 -0.5218 -0.3319 -1.5348 -0.7310 -0.2377
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin protein-c phosphorylation troponin_i phosphorylation hf
H-1427	-0.34935262799263	▁my os in ▁ binding _ ▁protein - C ▁ phos phor y lation ▁Ser 23 /24 ▁trop onin _ I ▁ phos phor y lation ▁ HF
D-1427	-0.34935262799263	myosin binding_ protein-C phosphorylation Ser23/24 troponin_I phosphorylation HF
P-1427	-1.0102 -0.0326 -0.4580 -1.4984 -0.0061 -0.4361 -0.7055 -0.1062 -1.1190 -0.2858 -0.0056 -0.2772 -1.2759 -0.0138 -0.4111 -0.0497 -0.0162 -0.0581 -0.0903 -0.6432 -1.4080 -0.0857 -0.0007 -0.0585 -0.1801 -0.0103 -0.0919 -0.0001 -0.0439 -0.1025
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab adjuvant outcomes cardiotoxicity congestive_heart_failure chf
H-670	-0.41832271218299866	▁tras tuz um ab ▁ad ju vant _ setting ▁cardio toxic ity ▁con ges tive _ heart _ ▁failure CH F
D-670	-0.41832271218299866	trastuzumab adjuvant_setting cardiotoxicity congestive_heart_ failureCHF
P-670	-0.0483 -0.0063 -0.0124 -0.0195 -1.0333 -0.0054 -0.0060 -0.6627 -0.0854 -0.0089 -0.6340 -0.1157 -0.0146 -0.0180 -0.1830 -0.1654 -1.5603 -0.3506 -2.6841 -1.7805 -0.1067 -0.0370 -0.0832
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 hearts beta-adrenergic_responses cardiomyocytes
H-1207	-0.9271429181098938	▁Pho s pho dies tera se -2 ▁human ▁fail ing _ heart s ▁blu nts ▁beta - ad r energi c ▁cardio my o cy tes
D-1207	-0.9271429181098938	Phosphodiesterase-2 human failing_hearts blunts beta-adrenergic cardiomyocytes
P-1207	-0.5064 -0.9806 -3.8965 -4.0952 -0.3551 -0.4667 -2.5501 -4.5651 -0.0393 -0.0085 -0.9172 -0.3009 -0.7123 -0.0047 -0.0016 -0.0854 -0.0238 -0.0275 -0.9334 -2.7291 -0.9988 -0.3765 -0.3971 -0.2725 -0.3034 -0.1980 -0.0681 -0.1460
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox_hazard_models esrd death composite_end_point esrd death esrd
H-391	-1.3905476331710815	▁co x _ ▁hazard _ model s ▁ES RD
D-391	-1.3905476331710815	cox_ hazard_models ESRD
P-391	-0.3493 -0.0030 -1.4488 -2.4221 -1.0675 -1.7549 -0.9426 -3.0515 -0.1637 -3.5868 -0.5058
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-1.0569443702697754	
D-557	-1.0569443702697754	
P-557	-2.0658 -0.0481
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.5555313229560852	▁de activa tion
D-1864	-0.5555313229560852	deactivation
P-1864	-1.4683 -0.0443 -0.0235 -1.1823 -0.0592
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs physicians hospital
H-1729	-0.44075194001197815	▁costs ▁high - volu me _ ▁physician s
D-1729	-0.44075194001197815	costs high-volume_ physicians
P-1729	-0.3868 -0.1215 -0.0150 -0.0750 -0.0014 -0.6715 -2.0443 -0.0134 -1.0036 -0.0749
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf proteins
H-1361	-0.5738365054130554	▁nutrition al _ ab normal ities ▁CHF ▁fat ▁car bo hydrat es ▁protein s ▁water
D-1361	-0.5738365054130554	nutritional_abnormalities CHF fat carbohydrates proteins water
P-1361	-2.0926 -0.0331 -0.6108 -1.0030 -0.0095 -0.0048 -1.4487 -1.3397 -1.1817 -0.0234 -0.0594 -0.0757 -0.3285 -0.0345 -0.1294 -1.2814 -0.0990
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin resistin
H-932	-0.45463570952415466	▁do xor ubi cin ▁se rum ▁resist in ▁Hum - Re t n _ mi ce
D-932	-0.45463570952415466	doxorubicin serum resistin Hum-Retn_mice
P-932	-0.0051 -0.0333 -0.0449 -0.0972 -3.4816 -0.0058 -0.9737 -0.5918 -1.2325 -0.0841 -0.6334 -0.0962 -0.0215 -0.3787 -0.2283 -0.1483 -0.0770 -0.0499
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior_vena_cava ivc
H-321	-1.3131885528564453	▁pig s ▁inferior ▁ve na _ ca va IV C
D-321	-1.3131885528564453	pigs inferior vena_cavaIVC
P-321	-6.3238 -0.1926 -0.8935 -0.0357 -0.0367 -1.3830 -0.0648 -0.3628 -2.0469 -0.5309 -3.5865 -0.3011
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery rheumatic surgery mva
H-359	-1.031093716621399	▁direct _ observa tion ▁rhe u matic ▁MS
D-359	-1.031093716621399	direct_observation rheumatic MS
P-359	-0.2173 -1.3073 -1.8266 -0.3659 -1.7076 -0.0059 -0.0028 -4.0321 -0.6927 -0.1527
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university_of_connecticut_heart_failure_center heart_failure nurse_practitioner
H-728	-0.5983020067214966	▁university _ of _ connect i cut ▁heart _ fail ure _ center ▁cardio logist ▁heart _ ▁failure ▁nurse _ prac ti tioner
D-728	-0.5983020067214966	university_of_connecticut heart_failure_center cardiologist heart_ failure nurse_practitioner
P-728	-2.5328 -1.7333 -0.1354 -0.1951 -1.1743 -0.0706 -0.0584 -2.0585 -0.0945 -0.2488 -0.0893 -0.4411 -0.2845 -0.0730 -0.0798 -0.2432 -0.2579 -1.9348 -0.8931 -1.4818 -0.1494 -0.5924 -0.0144 -0.0438 -0.0775
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo_inhibition cardiomyocyte_bioenergetics lv_function chronic_acf
H-472	-0.5563589930534363	▁ XO _ ▁inhibi tion ▁cardio my o cy te _ ▁bio ener gy ▁LV ▁chronic ▁A CF ▁rat
D-472	-0.5563589930534363	XO_ inhibition cardiomyocyte_ bioenergy LV chronic ACF rat
P-472	-0.5792 -0.0467 -2.2572 -0.1926 -0.0242 -0.0315 -0.3038 -1.3032 -1.1566 -2.1775 -0.1377 -0.3238 -0.0797 -0.9240 -0.6500 -0.5667 -0.5151 -0.0267 -0.1678 -0.1120 -0.1076
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients heart_failure hf cardiopulmonary_exercise_test anaerobic_threshold
H-1753	-0.7337313890457153	▁heart _ ▁failure _ HF ▁maximal ▁cardio pul mon ary _ test ▁ana ero bic _ ▁thre s hold
D-1753	-0.7337313890457153	heart_ failure_HF maximal cardiopulmonary_test anaerobic_ threshold
P-1753	-0.9878 -0.4506 -2.0316 -2.1380 -0.0215 -2.4589 -0.3293 -0.0545 -0.1742 -0.0565 -0.3336 -2.8707 -0.0156 -0.0062 -0.4958 -0.1696 -1.0061 -0.4857 -0.6597 -0.6253 -0.0372
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr protein_kinase_r-like_er_kinase perk calreticulin chop hf
H-1084	-0.6894018650054932	▁u PR _ effect ors ▁protein ▁kina se ▁R - like ▁ER _ ▁kina se ▁per k ▁cal ret icul in ▁CHO p ▁ HF
D-1084	-0.6894018650054932	uPR_effectors protein kinase R-like ER_ kinase perk calreticulin CHOp HF
P-1084	-0.7209 -0.0045 -3.1145 -0.8821 -0.0348 -0.0269 -0.7605 -0.0487 -2.7215 -0.0531 -0.2894 -0.8441 -1.4653 -0.0123 -0.0094 -3.1015 -0.3927 -0.0187 -0.0206 -0.0070 -0.3042 -0.7522 -0.5548 -0.9303 -0.0075 -1.3411 -0.1952
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol thromboembolic_events patients heart_failure β2-receptor_haplotype
H-1120	-0.5673002600669861	▁car vedi lol ▁ thro mbo e mbol ic _ ▁events ▁heart _ ▁failure ▁β 2- recept or ▁ha plo type
D-1120	-0.5673002600669861	carvedilol thromboembolic_ events heart_ failure β2-receptor haplotype
P-1120	-0.2548 -0.0330 -0.1956 -0.5407 -0.0168 -0.9644 -1.4045 -0.0540 -0.1600 -1.1959 -0.8478 -0.9481 -1.2044 -1.1578 -0.0541 -0.3478 -0.4009 -0.2666 -0.0971 -0.0155 -2.0280 -0.6876 -0.1724
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf pyridostigmine stroke_volume ejection_fraction cardiac_output contractility left_ventricle
H-1144	-0.6470045447349548	▁ HF _ ▁rat s ▁py rido stig mine ▁e je ction _ fraction ▁cardiac _ ▁output ▁contract ility ▁left _ ▁vent ric le
D-1144	-0.6470045447349548	HF_ rats pyridostigmine ejection_fraction cardiac_ output contractility left_ ventricle
P-1144	-1.3090 -0.0548 -3.9299 -1.1470 -0.0229 -0.3262 -0.0049 -0.0022 -0.0155 -0.2215 -0.1093 -0.0445 -0.7978 -0.0122 -0.5156 -1.2210 -0.1436 -0.0377 -0.2266 -0.4435 -0.2725 -4.0576 -0.4513 -1.3264 -0.0400 -0.0884
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory
H-1324	-0.36969953775405884	▁e cho car dio graphic _ ▁measure s ▁N - termin al ▁pro - bra in ▁na tri ure tic _ pe pti de ▁infla mma tory _ ▁marker s
D-1324	-0.36969953775405884	echocardiographic_ measures N-terminal pro-brain natriuretic_peptide inflammatory_ markers
P-1324	-1.2287 -0.1981 -1.4168 -0.5452 -0.2921 -2.4236 -0.9261 -0.0072 -0.2984 -0.0178 -0.0388 -0.0007 -0.6502 -0.0510 -0.2428 -0.0311 -0.0729 -0.0122 -0.0557 -0.3821 -0.1565 -0.2002 -0.1974 -0.6375 -0.0004 -0.4773 -0.0156 -0.4256 -0.7077 -0.0127 -0.0263 -0.0818
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled_trials rcts observational_cohort_studies contemporaneous_control_group
H-152	-0.378629207611084	▁random ised - control led _ ▁trial s RC T s ▁observation al _ co hor t
D-152	-0.378629207611084	randomised-controlled_ trialsRCTs observational_cohort
P-152	-0.2892 -0.2066 -0.1070 -0.0020 -0.0771 -0.9435 -0.0463 -0.0188 -0.3659 -0.5746 -0.1715 -0.4017 -0.0035 -0.0940 -0.2044 -0.0043 -0.1462 -3.4542 -0.0831
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone_receptor_antagonists randomized morbidity mortality symptomatic_systolic_heart_failure
H-438	-0.7037427425384521	▁al do ster one _ ▁receptor _ ▁anta gon ists ▁morbi d ity _ ▁mortal ity ▁symptom a tic ▁sy sto lic _ heart _ ▁failure
D-438	-0.7037427425384521	aldosterone_ receptor_ antagonists morbidity_ mortality symptomatic systolic_heart_ failure
P-438	-0.7180 -0.4460 -1.0698 -0.1127 -0.5484 -0.0735 -0.3908 -0.3018 -0.0742 -1.4889 -1.9787 -0.0100 -0.1370 -3.7013 -0.5883 -0.0021 -0.1913 -0.0622 -0.0171 -2.0317 -0.2867 -1.6721 -0.1187 -0.4570 -0.5867 -2.5233 -0.0552 -0.0615
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic nhs chronic disease exercise acute hospital
H-613	-0.8267903327941895	▁economic _ ▁climate ▁NH S ▁behaviour al - change _ intervention s ▁chronic _ مرض ▁exercise _ facil ity ▁a cute _ hospital
D-613	-0.8267903327941895	economic_ climate NHS behavioural-change_interventions chronic_مرض exercise_facility acute_hospital
P-613	-0.0960 -1.3986 -0.2190 -3.2829 -1.2122 -0.1016 -0.0187 -0.0822 -0.0039 -1.7755 -1.6661 -0.0387 -0.0261 -0.1163 -1.9272 -0.4762 -0.9773 -2.5176 -0.8650 -0.1000 -0.0002 -1.4707 -0.1014 -1.9366 -0.2598
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients hf crt implantation complications
H-912	-0.4048628509044647	▁di al ysis - dependent ▁ HF ▁c RT _ ▁implant ation
D-912	-0.4048628509044647	dialysis-dependent HF cRT_ implantation
P-912	-0.0767 -0.0083 -0.0623 -0.0957 -0.0363 -1.7058 -0.0015 -1.8175 -0.1398 -0.9772 -0.1515 -0.1588 -0.3802 -0.0563
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients vad patients ecmo vad patients ecmo
H-1389	-1.1566424369812012	▁ VAD _ group ▁EC mo _ group
D-1389	-1.1566424369812012	VAD_group ECmo_group
P-1389	-1.2763 -0.3944 -1.6178 -1.3890 -0.1517 -1.0331 -1.3978 -3.4687 -0.5817 -0.2559
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health followed_up hf hospitalization death contact
H-687	-0.8814876079559326	▁women _ health _ initiative ▁ HF _ hospital ization
D-687	-0.8814876079559326	women_health_initiative HF_hospitalization
P-687	-3.7378 -0.8223 -1.0487 -0.7630 -0.1080 -0.8612 -0.0438 -1.3564 -0.0274 -0.1419 -1.4780 -0.1893
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf patients hct city_of_hope
H-1452	-0.8431656360626221	▁post - H CT _ ▁CHF
D-1452	-0.8431656360626221	post-HCT_ CHF
P-1452	-2.6154 -0.0094 -1.5117 -0.1080 -0.1515 -0.4202 -1.8709 -0.0583
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv pathophysiologic rv_dysfunction
H-1094	-1.2349233627319336	▁ RV _ dis function
D-1094	-1.2349233627319336	RV_disfunction
P-1094	-1.3910 -1.5425 -2.0335 -1.8895 -0.8646 -0.7558 -0.1676
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak_oxygen_consumption pulse patients
H-1918	-0.3320903182029724	▁Peak _ ▁consum p tion ▁oxygen _ ▁puls e
D-1918	-0.3320903182029724	Peak_ consumption oxygen_ pulse
P-1918	-0.3346 -0.3797 -1.6639 -0.0041 -0.0335 -0.0746 -0.4814 -0.1390 -0.0727 -0.3788 -0.0906
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths stroke hospitalisations heart_failure follow-up
H-816	-0.6073793172836304	▁CV _ ▁death s ▁non - fa tal _ ▁stroke ▁hospital isation s ▁heart _ ▁failure
D-816	-0.6073793172836304	CV_ deaths non-fatal_ stroke hospitalisations heart_ failure
P-816	-0.4139 -2.9444 -2.6317 -0.0686 -0.0130 -0.0095 -0.0038 -0.0120 -0.0624 -0.7693 -0.3957 -0.0053 -0.1338 -0.1663 -0.3300 -2.5617 -0.3312 -0.0804
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac_deaths atherosclerotic_cad
H-1907	-0.5135626196861267	▁middle - a ged _ ▁recrea tional _ ▁ath letes ▁sud den _ ▁cardiac _ ▁death s ▁a ther os cle ro tic ▁CAD
D-1907	-0.5135626196861267	middle-aged_ recreational_ athletes sudden_ cardiac_ deaths atherosclerotic CAD
P-1907	-2.7808 -0.0717 -0.0185 -0.0052 -0.9091 -0.5113 -0.0045 -0.6535 -2.3244 -0.0033 -0.0044 -0.0035 -0.2490 -0.1165 -0.2648 -0.7805 -0.1032 -2.3394 -0.0117 -0.1853 -0.2027 -0.1373 -0.0573 -1.4147 -0.0427 -0.1573
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic biomarkers molecular_dysfunction chronic_hf
H-1477	-0.6137334108352661	▁bio mark ers ▁molecular _ ▁dys function ▁chronic ▁ HF
D-1477	-0.6137334108352661	biomarkers molecular_ dysfunction chronic HF
P-1477	-5.2257 -0.0838 -0.0594 -0.1105 -0.5815 -0.4859 -0.0428 -0.0793 -0.5651 -0.0005 -0.0755 -0.0550
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air cardiovascular health acute_myocardial_infarction
H-1806	-1.0581351518630981	▁Ambient ▁air ▁pollution ▁cardiovascular _ health ▁a cute _ my o card ial _ in far ction
D-1806	-1.0581351518630981	Ambient air pollution cardiovascular_health acute_myocardial_infarction
P-1806	-0.9162 -1.9089 -1.2110 -1.9987 -0.6835 -1.3599 -0.5472 -0.0171 -0.5592 -6.2557 -0.9114 -2.6396 -0.1160 -0.1829 -0.3132 -0.0103 -0.1777 -0.0988 -0.1972
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east rhythm_control_therapy diagnosis cardiovascular complications
H-1655	-0.7378160357475281	▁ rhythm _ control _ therapy ▁AF ▁cardiovascular _ ▁complica tions ▁AF
D-1655	-0.7378160357475281	rhythm_control_therapy AF cardiovascular_ complications AF
P-1655	-1.3292 -2.8741 -0.3214 -0.0184 -0.6189 -0.2761 -2.2300 -0.5467 -0.7241 -0.1269 -0.0157 -1.1154 -0.0458 -0.0866
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a upr downregulation cardiac genes hf
H-1089	-0.4400101602077484	▁s CN 5 a ▁tran script ▁u PR ▁down regul ation ▁cardiac _ ▁gene s ▁ HF
D-1089	-0.4400101602077484	sCN5a transcript uPR downregulation cardiac_ genes HF
P-1089	-1.0058 -1.1850 -0.1374 -0.4995 -0.1379 -0.0044 -0.1711 -0.0376 -0.1993 -0.0386 -0.0113 -3.8630 -0.3927 -0.4604 -0.0508 -0.0443 -0.0005 -0.0372 -0.0834
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected clinical death medical hospitalization hf clinic outpatients
H-379	-1.152756929397583	▁medical _ hospital ization ▁ HF
D-379	-1.152756929397583	medical_hospitalization HF
P-379	-6.2911 -0.9071 -0.1128 -0.2151 -0.1544 -0.0037 -1.4166 -0.1213
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective patients rule sensitivity specificity cad sensitivity cad
H-1192	-1.053049921989441	▁prospect ive _ ▁valida tion _ co hor t
D-1192	-1.053049921989441	prospective_ validation_cohort
P-1192	-3.9992 -0.0038 -1.0470 -0.9062 -0.0073 -0.5656 -0.2120 -0.0027 -0.2305 -4.5091 -0.1000
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin inflammation hepatic prognosis patients lvad implantation
H-540	-0.9963893294334412	▁album in _ ▁levels ▁ inflammation ▁he pati c _ function
D-540	-0.9963893294334412	albumin_ levels inflammation hepatic_function
P-540	-0.2668 -0.1118 -2.8331 -1.2187 -0.6273 -0.0061 -0.2254 -0.0080 -0.3815 -2.6305 -0.9590 -3.2312 -0.4536
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse pasp downward regression_line shift pasp tapse
H-496	-1.1428332328796387	▁t p _ the ory ▁down ward ▁re gression _ ▁line _ ▁shift ▁non sur viv ors ▁higher ▁PAS P
D-496	-1.1428332328796387	tp_theory downward regression_ line_ shift nonsurvivors higher PASP
P-496	-2.8867 -2.0028 -4.3372 -4.9367 -0.0080 -1.0173 -0.0683 -0.9433 -0.0023 -0.7735 -0.9196 -1.8324 -0.1564 -0.9243 -0.0164 -0.0012 -0.0266 -1.5060 -0.2217 -0.2865 -2.1911 -0.0841
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome gls beat cox_proportional_hazards_analyses
H-814	-0.7838870882987976	▁m AIN _ o UTC OME _ me as ures ▁g LS ▁index ▁beat _ ▁method ▁CV _ event ▁co x ▁proportion al _ ▁hazard s
D-814	-0.7838870882987976	mAIN_oUTCOME_measures gLS index beat_ method CV_event cox proportional_ hazards
P-814	-5.3825 -0.4438 -0.3122 -1.4564 -0.0045 -0.5840 -0.9104 -0.0353 -2.9044 -0.1772 -0.5142 -1.0950 -0.1291 -0.1702 -0.3926 -2.0112 -0.1055 -2.0061 -1.2843 -0.3819 -0.0045 -0.0591 -0.0030 -0.1645 -0.7243 -0.0868 -0.3434 -0.2627
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts mena cardiac_injury mena hf pathophysiology
H-1817	-0.8943241238594055	▁heart s ▁Men a ▁cardiac _ ▁injury ▁ HF ▁pat ho phy si ology
D-1817	-0.8943241238594055	hearts Mena cardiac_ injury HF pathophysiology
P-1817	-0.6714 -0.4715 -1.8728 -0.0538 -0.9235 -0.9771 -1.4364 -0.7091 -0.1335 -4.8019 -0.2473 -0.2047 -1.5511 -0.0044 -0.1046 -0.1459
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted_county minnesota mi diagnosed hf followed-up
H-1102	-0.997018039226532	▁Ol m sted _ ▁County ▁MI ▁ HF
D-1102	-0.997018039226532	Olmsted_ County MI HF
P-1102	-1.1622 -0.0051 -0.0067 -0.9934 -1.4086 -3.5635 -1.8839 -0.2368 -0.2612 -0.4490
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted left_ventricle_end-diastolic_pressure
H-1340	-0.8260341286659241	▁CHF - develop ed ▁in far cted _ animal ▁left ▁vent ric le _ ▁end - dia sto lic _ ▁pressure ▁scar
D-1340	-0.8260341286659241	CHF-developed infarcted_animal left ventricle_ end-diastolic_ pressure scar
P-1340	-0.0555 -2.5877 -0.5366 -0.0138 -0.1858 -0.0002 -1.1741 -0.9618 -0.4630 -0.1709 -3.5098 -1.1151 -1.1849 -1.5294 -1.1411 -0.1361 -0.0079 -0.9042 -0.8825 -0.4952 -0.7938 -0.2548 -1.6284 -0.0921
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ischemic_heart_failure biomarkers heart_failure
H-1615	-0.8603463768959045	▁non - ische mic ▁ ische mic _ heart _ ▁failure ▁bio mark ers
D-1615	-0.8603463768959045	non-ischemic ischemic_heart_ failure biomarkers
P-1615	-2.8402 -0.0442 -0.3475 -0.0868 -1.2323 -0.1319 -0.0389 -1.5977 -1.3028 -0.6681 -2.1272 -0.1854 -0.0047 -0.0249 -3.0159 -0.1172
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis expenditure b_natriuretic_peptides nps
H-10	-0.47242656350135803	▁li poly sis ▁energy ▁ex pendi ture ▁a - ▁na tri ure tic _ pe pti des NP s ▁CC
D-10	-0.47242656350135803	lipolysis energy expenditure a- natriuretic_peptidesNPs CC
P-10	-0.2462 -0.0099 -0.3543 -0.1220 -0.4040 -0.0002 -0.0541 -2.0671 -0.1412 -1.8755 -0.0373 -0.1506 -0.3253 -0.4873 -0.2767 -0.2463 -1.0039 -1.5781 -0.0026 -0.8384 -0.0402 -0.1321
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration neurohumoral_blockers hf hospitalization patients co-morbidity
H-184	-0.5533139109611511	▁neuro hu moral _ block ers ▁ HF _ hospital ization ▁low ▁co - mor bid ity _ ▁burde n
D-184	-0.5533139109611511	neurohumoral_blockers HF_hospitalization low co-morbidity_ burden
P-184	-0.1332 -0.0498 -3.2192 -0.4969 -0.6234 -0.0283 -0.0701 -0.0014 -2.7228 -0.0305 -0.3100 -0.9002 -1.0697 -0.0913 -0.3791 -0.8220 -0.0141 -0.9884 -0.0873 -0.0570 -0.0451 -0.0333
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq kaplan-meier_curves death all-cause_hospitalization
H-784	-0.8654501438140869	▁K cc q ▁Ka plan - Me ier _ ▁cur ves
D-784	-0.8654501438140869	Kccq Kaplan-Meier_ curves
P-784	-1.3273 -0.3898 -1.0015 -1.8658 -0.0127 -0.0154 -0.4266 -0.1169 -0.7330 -0.4742 -0.1878 -4.4193 -0.2805
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right_ventricular rv left_ventricular_assist_device lvad outcomes
H-294	-0.9349882006645203	▁right ▁vent ri cular ▁ RV ▁left ▁vent ri cular _ assist _ ▁device ▁l VAD
D-294	-0.9349882006645203	right ventricular RV left ventricular_assist_ device lVAD
P-294	-0.4802 -2.0120 -0.0757 -0.0140 -3.6689 -0.2657 -1.2710 -4.1420 -0.1404 -0.0463 -0.4806 -0.0126 -1.3043 -1.5875 -1.1446 -0.0044 -0.1130 -0.0667
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence adjusted_odds_ratio hazard_ratio death hf ami admission discharge
H-1308	-0.6712720990180969	▁temporal ▁incide nce ▁odds _ rati o _ haz ard _ ▁ratio ▁ HF ▁ AMI ▁dis charge
D-1308	-0.6712720990180969	temporal incidence odds_ratio_hazard_ ratio HF AMI discharge
P-1308	-3.2951 -2.0094 -0.1218 -1.7509 -0.5112 -0.3897 -0.0280 -1.4006 -0.0844 -0.0326 -0.1230 -0.8049 -0.2449 -0.0231 -1.4033 -0.0333 -0.8903 -0.0065 -0.0718 -0.2008
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone_therapy exercise_rehabilitation patients chronic_heart_failure testosterone double-blind randomized
H-1316	-0.782153844833374	▁Test o ster one _ therapy ▁exercise _ ▁rehabilita tion ▁chronic _ heart _ ▁failure ▁low ▁testosteron e _ status
D-1316	-0.782153844833374	Testosterone_therapy exercise_ rehabilitation chronic_heart_ failure low testosterone_status
P-1316	-4.0823 -0.0259 -0.2191 -0.0716 -1.6169 -0.2174 -1.1821 -0.5835 -0.6028 -0.0049 -1.6167 -0.1816 -0.7295 -0.4469 -1.8753 -0.7371 -0.7583 -0.0223 -1.5044 -0.0925 -0.5547 -0.0815
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox_proportional_hazards_models health health hazard_ratios confidence_intervals
H-689	-0.6742434501647949	▁co x ▁proportion al _ ▁hazard s ▁demo graphic s ▁health _ status
D-689	-0.6742434501647949	cox proportional_ hazards demographics health_status
P-689	-0.0763 -0.0072 -0.5672 -0.0049 -0.0680 -3.5858 -0.2800 -2.2365 -0.0131 -0.0636 -0.0101 -0.5673 -0.3147 -2.1185 -0.2004
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ami complications heart_failure kidney_infection uti complications rehospitalization
H-1718	-0.6869791746139526	▁ AMI ▁heart ▁failure ▁ki dne y ▁infection ▁ UTI
D-1718	-0.6869791746139526	AMI heart failure kidney infection UTI
P-1718	-1.3439 -0.0337 -3.8875 -0.7207 -0.0641 -0.0466 -0.0067 -1.4215 -0.0427 -0.0003 -0.4825 -0.1934
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 c_statistic net_reclassification_improvement integrated_discrimination_improvement
H-705	-0.900157630443573	▁re class ification _ of ▁risk ▁c ▁statistic ▁net ▁re class ification _ of _ risk ▁integrat ed ▁discrimina tion
D-705	-0.900157630443573	reclassification_of risk c statistic net reclassification_of_risk integrated discrimination
P-705	-1.3399 -0.0011 -0.1134 -1.9863 -1.1201 -0.8928 -2.6184 -0.9178 -0.4544 -0.3838 -0.0009 -0.0482 -1.2761 -2.4465 -0.1090 -2.6966 -0.1231 -0.0012 -1.0072 -0.1904 -1.7174 -0.3586
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ras doppler_ultrasonography tomographic_angiography magnetic_resonance_angiography
H-1599	-0.28720033168792725	▁ RAS ▁do pp ler _ ▁ultra son ography ▁com put ed ▁to mo graphic _ ang i ography ▁magnetic _ ▁res on ance _ ang i ography
D-1599	-0.28720033168792725	RAS doppler_ ultrasonography computed tomographic_angiography magnetic_ resonance_angiography
P-1599	-2.3296 -0.1045 -0.7662 -0.0014 -0.1748 -0.4802 -0.0504 -0.0203 -0.1149 -0.4784 -0.0020 -0.0162 -0.0216 -0.0067 -0.0840 -0.0971 -0.7826 -0.6374 -0.0602 -0.0013 -0.2192 -0.5694 -0.0476 -0.0216 -0.4263 -0.6259 -0.2383 -0.0308 -0.0871 -0.1197
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d therapy
H-107	-0.6322689652442932	▁c RT - D ▁IE _ risk ▁de fi br illa tor - on ly _ therapy
D-107	-0.6322689652442932	cRT-D IE_risk defibrillator-only_therapy
P-107	-1.5585 -0.3222 -0.0542 -0.9354 -2.6952 -2.1762 -0.3359 -0.1498 -0.0047 -0.7611 -0.5048 -0.0260 -0.2219 -0.0652 -0.3199 -0.6677 -0.6075 -0.4841 -0.1229
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients terminal diagnostic follow-up
H-1819	-1.1109411716461182	▁diagnostic _ procedure
D-1819	-1.1109411716461182	diagnostic_procedure
P-1819	-1.9516 -1.5524 -0.1118 -1.8567 -0.0822
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence lvad transplantation patients budget
H-316	-0.8747583627700806	▁l VAD ▁transplant ation ▁e ligi bility _ status ▁program ▁budget
D-316	-0.8747583627700806	lVAD transplantation eligibility_status program budget
P-316	-2.9525 -0.2943 -2.3092 -0.0462 -0.9328 -0.0020 -0.0228 -1.0845 -0.0584 -1.1082 -2.3926 -0.0731 -0.0954
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia postoperative mortality patients left_ventricular_assist_device lvad implantation
H-530	-0.5842812657356262	▁hypo album in emia ▁post operativ e _ ▁mortal ity ▁left ▁vent ri cular _ assist _ ▁device ▁l VAD
D-530	-0.5842812657356262	hypoalbuminemia postoperative_ mortality left ventricular_assist_ device lVAD
P-530	-0.0432 -0.8313 -0.1237 -0.0269 -0.0200 -0.0097 -0.3473 -0.5124 -0.1316 -0.0052 -0.0570 -3.5469 -0.8734 -0.0629 -0.1744 -0.0286 -1.4430 -2.3933 -1.6359 -0.0025 -0.4002 -0.1847
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left_ventricular_ejection_fraction mortality patients heart_failure heart_failure_survey israel
H-110	-0.8242554068565369	▁left _ ▁vent ri cular _ e je ction _ fraction ▁long - term _ ▁mortal ity ▁heart _ fail ure _ ▁Survey
D-110	-0.8242554068565369	left_ ventricular_ejection_fraction long-term_ mortality heart_failure_ Survey
P-110	-2.1589 -0.6697 -4.2986 -0.5602 -0.3400 -0.1831 -0.8573 -0.1779 -0.0825 -1.4250 -0.2679 -2.8822 -0.0309 -0.0241 -0.1435 -1.2116 -0.0038 -0.7678 -0.2064 -0.7848 -0.0669 -1.3866 -0.2840 -1.5255 -0.2673
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic renal_underperfusion renin-_angiotensin-aldosterone_pathway
H-1596	-0.8002498149871826	▁renal _ under per fusion ▁re nin - ▁ang io ten sin - al do ster one _ path way
D-1596	-0.8002498149871826	renal_underperfusion renin- angiotensin-aldosterone_pathway
P-1596	-2.7133 -0.9847 -0.7677 -0.0118 -0.0227 -0.0244 -0.1053 -0.0426 -0.1958 -1.4988 -0.6937 -0.7285 -1.1466 -0.0749 -4.0638 -2.3910 -0.8027 -0.8092 -0.0332 -0.1182 -0.1760 -0.2008
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary_endpoints therapy atrial_fibrillation atrial_tachyarrhythmias atp shock_therapy
H-860	-0.5086348652839661	▁at rial _ fi bril lation ▁at rial _ ta chy ar rhythm ias ▁ATP ▁shock _ therapy
D-860	-0.5086348652839661	atrial_fibrillation atrial_tachyarrhythmias ATP shock_therapy
P-860	-2.4761 -0.0077 -0.4624 -0.7587 -0.0063 -0.0024 -0.0933 -0.0040 -0.2348 -2.1910 -0.1955 -0.0553 -0.4548 -1.8859 -0.0402 -0.2605 -0.9282 -0.0369 -0.0354 -0.0433
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous coronary_revascularization hemodynamically stable patient intensive_care_unit icu
H-1293	-0.4470698833465576	▁per cuta ne ous ▁corona ry _ re vas cular ization ▁hem o dynamic ally
D-1293	-0.4470698833465576	percutaneous coronary_revascularization hemodynamically
P-1293	-0.0478 -0.0006 -0.1256 -0.0644 -0.5898 -0.1191 -0.6431 -0.8950 -0.0312 -0.0411 -0.4380 -0.3036 -0.0110 -0.0005 -1.5765 -2.6580 -0.0549
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil cardioprotection apoptotic_signaling_pathway dna_fragmentation mitochondrial
H-965	-0.40329062938690186	▁nic oran dil ▁cardio protec tion ▁apo pto tic _ ▁signal ing _ path way ▁DNA _ ▁fragment ation ▁mito cho ndri al ▁ultra struct ural
D-965	-0.40329062938690186	nicorandil cardioprotection apoptotic_ signaling_pathway DNA_ fragmentation mitochondrial ultrastructural
P-965	-0.5744 -0.0213 -0.1851 -0.7168 -0.1019 -0.0049 -0.1431 -0.0080 -0.1503 -0.1545 -0.8169 -0.2055 -0.3077 -0.3780 -0.0836 -0.1450 -3.1103 -0.8753 -0.0225 -0.0032 -0.7442 -0.1159 -0.0053 -1.5983 -0.0055 -0.0006 -0.7299 -0.0841
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity diabetes_mellitus metabolic comorbidities heart_failure_with_preserved_ejection_fraction
H-760	-0.8351597189903259	▁ob es ity ▁diabetes ▁mell itus ▁metabol ic _ risk _ factor s ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-760	-0.8351597189903259	obesity diabetes mellitus metabolic_risk_factors heart_ failure preserved ejection_fraction
P-760	-3.5107 -0.0368 -0.2141 -0.1244 -0.5241 -0.0552 -0.0572 -0.0049 -0.5807 -1.0348 -0.9195 -0.2456 -0.5678 -5.0639 -0.7777 -5.8296 -0.0156 -0.3437 -0.1927 -0.7284 -0.1852 -0.1028 -0.4626 -0.0014 -0.0362 -0.0984
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
H-869	-0.42124879360198975	▁prote o mics ▁pressure - over load - indu ced _ heart _ ▁failure ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.42124879360198975	proteomics pressure-overload-induced_heart_ failure mitochondrial-targeted peptides
P-869	-2.8371 -0.1603 -0.0235 -0.0167 -0.0432 -0.0037 -0.0009 -0.2753 -0.0522 -0.0352 -0.7715 -0.7606 -0.4028 -1.2981 -0.0003 -1.5506 -1.1352 -0.0082 -0.0531 -0.0055 -0.0030 -0.0031 -0.9425 -0.0245 -0.7551 -0.0557 -0.1557
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular_endothelial_growth_factor vegf transition compensatory_hypertrophy cardiac_failure
H-450	-0.851398229598999	▁inhibi tion ▁vas cular _ ▁en dot heli al _ ▁growth _ factor VE GF ▁compensa tory _ ▁hyper trop hy ▁cardiac _ ▁failure
D-450	-0.851398229598999	inhibition vascular_ endothelial_ growth_factorVEGF compensatory_ hypertrophy cardiac_ failure
P-450	-1.0180 -0.0337 -0.2718 -0.0164 -0.7724 -0.4132 -1.4620 -0.1411 -0.0032 -0.2674 -4.3720 -0.4400 -0.0119 -2.0124 -0.0309 -1.0517 -0.0028 -0.3847 -2.8177 -0.0141 -1.4394 -0.0012 -1.0644 -3.9174 -0.0523 -0.1243
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ic multicenter_automatic_defibrillator_implantation_trial-cardiac_resynchronization_therapy
H-103	-0.5023002028465271	▁IC ▁multi center _ automat ic _ de ib rilla tor _ ▁Implant ation _ Tri al - Card iac _ re syn chron ization _ therapy
D-103	-0.5023002028465271	IC multicenter_automatic_deibrillator_ Implantation_Trial-Cardiac_resynchronization_therapy
P-103	-3.0166 -0.9502 -0.0072 -0.5416 -0.2673 -0.0028 -0.0278 -2.5289 -0.5959 -0.8637 -0.0473 -0.1340 -0.0834 -0.0233 -0.4721 -1.7392 -0.0118 -0.2107 -0.0145 -0.2804 -0.1674 -0.5192 -0.0004 -0.0001 -0.1517 -0.9683 -0.7607 -0.0982 -0.0819
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle_tracking_echocardiography ste bivp acute right_ventricular_pressure_overload rvpo
H-320	-0.801048755645752	▁spec kle ▁track ing ▁e cho card i ography ▁ STE ▁bi VP ▁a cute ▁right _ wind ri cular _ ▁pressure _ over load RV PO
D-320	-0.801048755645752	speckle tracking echocardiography STE biVP acute right_windricular_ pressure_overloadRVPO
P-320	-0.1160 -0.0296 -0.2206 -0.0179 -0.3570 -0.0589 -0.8393 -0.7171 -0.1932 -2.9306 -0.0071 -0.7485 -0.0810 -1.1534 -0.0002 -0.9899 -0.3104 -3.7104 -1.9302 -1.0919 -0.3986 -3.6176 -3.0145 -0.4252 -0.0038 -0.1105 -0.0785 -0.0148 -0.0637
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary_exercise_testing echocardiographic myocardial_function left_ventricular_filling exercise
H-1174	-0.614655613899231	▁Card io pul mon ary ▁e cho car dio graphic ▁my o card ial _ function ▁left ▁vent ri cular _ ▁fill ing
D-1174	-0.614655613899231	Cardiopulmonary echocardiographic myocardial_function left ventricular_ filling
P-1174	-1.2152 -0.9460 -1.8359 -0.1838 -0.2304 -1.6128 -0.0122 -0.0417 -0.2579 -1.1258 -0.7467 -0.0375 -0.2810 -0.1051 -0.6504 -1.9152 -0.0042 -1.1813 -0.1842 -0.0708 -1.3338 -0.4539 -0.0116 -0.8663 -0.0628
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health_buddy_program admissions chronic_obstructive_pulmonary_disease mortality congestive_heart_failure
H-1627	-0.8724451065063477	▁health _ ▁Budd y _ program ▁chronic _ ob struct ive _ ▁pulmonar y _ مرض ▁mortal ity ▁con ges tive _ heart _ ▁failure
D-1627	-0.8724451065063477	health_ Buddy_program chronic_obstructive_ pulmonary_مرض mortality congestive_heart_ failure
P-1627	-0.6365 -1.0062 -1.1314 -0.0079 -2.0484 -0.3093 -1.9671 -0.7063 -1.2989 -0.0363 -0.0870 -0.3403 -1.5428 -0.0462 -0.9000 -3.8956 -0.5997 -0.0039 -0.0469 -0.0238 -0.0447 -0.0596 -2.0359 -1.0656 -3.4742 -0.0712 -0.1704
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr_variability risk_stratification
H-1587	-0.5526534914970398	▁HR ▁dynamic s ▁time - doma in ▁HR ▁variabil ity ▁risk _ ▁strat ification
D-1587	-0.5526534914970398	HR dynamics time-domain HR variability risk_ stratification
P-1587	-0.1881 -0.7832 -0.1028 -0.6488 -0.0169 -0.0009 -0.0167 -3.1402 -2.3085 -0.0433 -0.0773 -1.0233 -0.1635 -0.0766 -0.0825 -0.1701
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ami hazard_ratio mortality
H-1313	-1.0715808868408203	▁o c curr ence ▁ HF ▁index ▁ AMI
D-1313	-1.0715808868408203	occurrence HF index AMI
P-1313	-4.2757 -0.9166 -0.0199 -0.0071 -1.5182 -0.0273 -0.0532 -0.1439 -0.0073 -4.2894 -0.5289
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients preserved_lvef lvef
H-114	-0.8677459955215454	▁LV EF
D-114	-0.8677459955215454	LVEF
P-114	-2.8890 -0.1249 -0.3873 -0.0698
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr mrna_splice cardiac hf
H-1088	-0.8870323896408081	▁u PR ▁na + ▁channel ▁m RNA _ ▁sp lice _ variant s ▁re duction ▁cardiac ▁na + ▁current ▁human ▁ HF
D-1088	-0.8870323896408081	uPR na+ channel mRNA_ splice_variants reduction cardiac na+ current human HF
P-1088	-0.2631 -0.1435 -0.3671 -3.6289 -0.1758 -0.1921 -0.0515 -0.8337 -0.1112 -0.0305 -3.2888 -0.5255 -0.0196 -2.5971 -0.0002 -0.3430 -1.5707 -3.3646 -2.7367 -0.8427 -0.0601 -0.0004 -0.0593 -0.0827
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic neurohormonal symptoms fluid_overload
H-1201	-0.39472267031669617	▁di ure tic _ ef fica cy ▁advers e ▁neuro hormon al _ activa tion ▁con gestion - like ▁fluid _ over load
D-1201	-0.39472267031669617	diuretic_efficacy adverse neurohormonal_activation congestion-like fluid_overload
P-1201	-0.4521 -0.0251 -0.8868 -0.7765 -0.9851 -0.0406 -0.1696 -0.1619 -0.0222 -0.2479 -0.2787 -0.0446 -0.4256 -0.9314 -0.0316 -1.1742 -0.0011 -0.2902 -0.0522 -1.0375 -0.8041 -0.7740 -0.0035 -0.1267 -0.1249
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis pathogenesis heart_failure
H-173	-0.8202011585235596	▁apo pto sis ▁path ogen es is _ of _ heart _ ▁failure
D-173	-0.8202011585235596	apoptosis pathogenesis_of_heart_ failure
P-173	-0.5288 -0.1665 -0.8834 -0.1003 -0.1283 -0.1211 -3.5264 -1.4599 -0.4516 -0.4940 -0.8091 -0.3163 -1.1118 -1.9741 -0.2315
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets transcriptional_pause_release pathological
H-1052	-0.5307831168174744	▁ BET s ▁tran scription al _ ▁pause _ release ▁tran scription ▁path ological ▁stress
D-1052	-0.5307831168174744	BETs transcriptional_ pause_release transcription pathological stress
P-1052	-0.9466 -0.0644 -0.8862 -0.3403 -0.3826 -0.4239 -0.8355 -0.6307 -0.4318 -0.9219 -0.5656 -0.6881 -0.6585 -0.1217 -0.9425 -0.0589 -0.1241
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv_fractional_shortening lung incidence
H-278	-0.38692471385002136	▁ ANS _ mi ce ▁LV ▁ fraction al _ short en ing ▁lung _ weight
D-278	-0.38692471385002136	ANS_mice LV fractional_shortening lung_weight
P-278	-1.7509 -0.3831 -0.6505 -0.2962 -0.0247 -0.1052 -0.5576 -0.0003 -0.0270 -0.3461 -0.6658 -0.3843 -0.1773 -0.0199 -0.9393 -0.1958 -0.1491 -0.2917
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef bnp hf patients prognostic significance bnp ef
H-188	-2.4189906120300293	▁ec b NP ▁ HF
D-188	-2.4189906120300293	ecbNP HF
P-188	-5.6960 -2.0794 -2.1389 -2.7106 -0.0279 -3.7264 -0.5538
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration hr_reduction bpm p_value
H-1942	-0.636024534702301	▁dose ▁up tit ration ▁HR _ re duction
D-1942	-0.636024534702301	dose uptitration HR_reduction
P-1942	-0.3370 -0.2526 -0.2038 -0.0728 -1.4270 -2.1720 -0.2470 -0.0003 -1.5272 -0.1206
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg atherosclerotic_cad cardiac_death
H-1910	-0.5628567934036255	▁e CG ▁a ther os cle ro tic _ ▁CAD ▁sud den ▁cardiac _ ▁death
D-1910	-0.5628567934036255	eCG atherosclerotic_ CAD sudden cardiac_ death
P-1910	-2.9953 -0.1909 -0.2568 -0.0048 -0.3648 -0.2008 -0.1009 -0.0970 -0.1544 -1.1254 -0.0042 -0.0033 -0.8555 -0.7059 -2.3695 -0.0276 -0.1114
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic_heart_failure spironolactone hospitalization death
H-446	-0.506780207157135	▁incident ▁sy sto lic _ heart _ ▁failure ▁spi rono lac tone ▁hospital ization
D-446	-0.506780207157135	incident systolic_heart_ failure spironolactone hospitalization
P-446	-0.8275 -0.7949 -0.1659 -0.4272 -0.1027 -0.7415 -0.2889 -0.6975 -0.4932 -0.0057 -0.0550 -0.0499 -1.4805 -0.2347 -1.5960 -0.1473
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk scn5a kv4.3 mrna mrna_splice
H-1087	-0.6838710308074951	▁per k _ ▁inhibi tion ▁full - leng th ▁s CN 5 a ▁Kv 4.3 ▁m RNA _ level ▁na + ▁channel ▁m RNA ▁sp lice
D-1087	-0.6838710308074951	perk_ inhibition full-length sCN5a Kv4.3 mRNA_level na+ channel mRNA splice
P-1087	-1.1350 -0.2571 -1.4287 -0.1331 -0.0089 -3.0180 -0.0037 -0.0000 -0.0005 -0.5740 -0.2869 -0.2711 -0.5729 -0.4419 -0.2716 -0.0057 -0.0083 -3.2259 -0.7432 -0.6465 -4.7239 -0.2320 -0.0805 -0.0088 -0.3563 -0.0292 -0.5954 -0.0894
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction rad_variant q66p congestive_heart_failure
H-1673	-0.9105615019798279	▁dys function ▁natural ly ▁occur ring ▁Rad _ variant _ Q 66 P ▁con ges tive _ heart _ ▁failure
D-1673	-0.9105615019798279	dysfunction naturally occurring Rad_variant_Q66P congestive_heart_ failure
P-1673	-5.5982 -0.1969 -0.1511 -0.1192 -1.1463 -0.0255 -0.2040 -0.8748 -0.4946 -4.3299 -2.4853 -0.0627 -1.0148 -0.0061 -0.0539 -0.0294 -0.0761 -1.4064 -0.5311 -0.7969 -0.3308 -0.0984
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional_enrichment_analysis regulation cell_death degs
H-1614	-0.7942356467247009	▁functional _ ▁en rich ment _ analyse ▁programme d _ cell _ ▁death ▁common ▁DE G s
D-1614	-0.7942356467247009	functional_ enrichment_analyse programmed_cell_ death common DEGs
P-1614	-5.2171 -0.7338 -0.3823 -0.0005 -0.0092 -1.3543 -2.7001 -0.7060 -0.0138 -0.0445 -0.4456 -0.1805 -0.8861 -1.1023 -1.0281 -0.0856 -0.0230 -0.0366 -0.1411
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated mena_expression correlates hf mena cardiac pathophysiology
H-1812	-0.9692766666412354	▁Men a ▁expression ▁ HF
D-1812	-0.9692766666412354	Mena expression HF
P-1812	-0.1776 -0.0439 -1.3284 -0.1895 -0.0067 -4.6588 -0.3800
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized follow-up
H-1751	-0.5173406004905701	▁control led _ ▁random ized _ ▁trial s
D-1751	-0.5173406004905701	controlled_ randomized_ trials
P-1751	-0.2438 -0.0364 -0.8744 -0.2131 -0.1462 -0.7602 -0.0293 -0.0102 -2.7834 -0.0763
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence intestinal patients chf
H-1358	-0.7893455624580383	▁intestinal _ morph ology ▁ab sor p tion _ function ▁CHF
D-1358	-0.7893455624580383	intestinal_morphology absorption_function CHF
P-1358	-6.2065 -0.6166 -0.0136 -0.0509 -0.2492 -0.0850 -0.4843 -0.1431 -0.6252 -0.5547 -1.1204 -0.0544 -0.0576
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc nps clinical
H-1024	-0.6748543977737427	▁ NP _ ▁measure ment ▁ NP s ▁clinic al _ care ▁emergency
D-1024	-0.6748543977737427	NP_ measurement NPs clinical_care emergency
P-1024	-0.5352 -0.0424 -2.2687 -0.2999 -0.0240 -2.3401 -0.0942 -0.1270 -0.3401 -0.0109 -0.1725 -0.6916 -2.7911 -0.2324 -0.1527
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab chf nontrastuzumab_users hazard_ratio
H-679	-1.0927772521972656	▁Tras tuz um ab ▁CHF ▁non tras tuz um ab
D-679	-1.0927772521972656	Trastuzumab CHF nontrastuzumab
P-679	-1.0557 -0.0193 -0.0490 -0.0508 -1.9765 -2.2619 -0.0492 -0.0054 -0.0205 -0.1307 -7.2656 -0.2286
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients atrial_fibrillation heart_failure hf stroke anticoagulation patients
H-1353	-0.6499120593070984	▁at rial _ fi bril lation _ AF ▁heart _ ▁failure ▁ HF ▁progress ▁antico ag ulation
D-1353	-0.6499120593070984	atrial_fibrillation_AF heart_ failure HF progress anticoagulation
P-1353	-0.5262 -0.0411 -0.4660 -0.3623 -0.0212 -0.0016 -2.2325 -0.0369 -1.8870 -0.3196 -0.6214 -2.2461 -0.0001 -2.1364 -0.5689 -0.1149 -0.0117 -0.6450 -0.1094
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan_failure circulatory hemodynamic portal_hypertension cardiac_output
H-234	-0.35464438796043396	▁Font an _ ▁failure ▁circula tory _ de rang ement ▁hem o dynamic ▁portal _ ▁hyper tension ▁aug ment ▁cardiac _ ▁output
D-234	-0.35464438796043396	Fontan_ failure circulatory_derangement hemodynamic portal_ hypertension augment cardiac_ output
P-234	-0.2704 -0.0437 -0.5489 -0.6546 -0.7864 -0.0011 -0.7800 -0.3770 -0.0032 -0.0196 -0.5351 -0.0236 -0.0010 -0.0064 -0.8116 -0.4640 -0.0054 -1.5314 -0.0122 -0.3380 -1.1837 -0.0426 -0.0408 -0.0309
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination echocardiographic lv_reverse_remodeling sensitivity specificity
H-433	-0.5142390131950378	▁e cho car dio graphic _ ▁score ▁LV ▁rever se _ ▁remodel ing
D-433	-0.5142390131950378	echocardiographic_ score LV reverse_ remodeling
P-433	-0.0565 -0.0337 -1.0728 -1.8444 -0.9304 -0.7757 -0.1368 -0.0647 -0.0385 -0.0187 -0.9036 -0.2914 -0.0541 -1.0739 -0.4183
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential_effect lvef mortality hospitalization acute decompensated_hf
H-112	-0.3244733512401581	▁LV EF ▁long - term _ ▁mortal ity ▁a cute _ de com pensa ted _ HF
D-112	-0.3244733512401581	LVEF long-term_ mortality acute_decompensated_HF
P-112	-0.9504 -0.2690 -1.7539 -0.0261 -0.0161 -0.1179 -1.0923 -0.0157 -0.5251 -0.0067 -0.2430 -0.2176 -0.0449 -0.0052 -0.0580 -0.5142 -0.0161 -0.1211 -0.1718
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck_stent myocardial_infarction antiplatelet_medication
H-508	-0.5029876828193665	▁bottle ne ck _ ▁sten t ▁tim ing ▁my o card ial _ in far ction ▁anti plate let ▁medication
D-508	-0.5029876828193665	bottleneck_ stent timing myocardial_infarction antiplatelet medication
P-508	-0.7846 -0.0423 -0.0026 -0.6619 -0.1248 -0.0673 -1.5987 -0.0057 -0.7969 -0.3177 -0.7990 -0.0189 -0.2226 -0.6509 -0.0009 -0.0080 -0.1439 -0.4458 -2.0782 -2.0502 -0.0460 -0.1987
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt_loading uninephrectomy ang_ii_infusion cardiac_function hf
H-282	-0.4084871709346771	▁salt ▁load ing ▁un ine ph r ecto my ▁ANG ▁II ▁in fusion _ ▁mouse _ model ▁cardiac _ function ▁ HF
D-282	-0.4084871709346771	salt loading uninephrectomy ANG II infusion_ mouse_model cardiac_function HF
P-282	-0.1756 -0.8949 -0.0313 -0.0526 -0.0032 -0.0768 -0.0429 -0.0266 -0.6101 -0.2819 -0.3830 -0.0575 -0.0051 -0.6012 -0.4715 -1.5617 -0.5128 -0.0160 -1.1959 -0.5017 -2.1027 -0.0389 -0.0475 -0.1124
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients biventricular_support heartmate_ii lvad centrimag right_ventricular_assist_device rvad
H-296	-0.7104322910308838	▁bi ven tri cular _ support ▁Heart Mate _ II ▁l VAD ▁Centri Mag ▁right _ ▁vent ri cular _ assist _ ▁device R VAD
D-296	-0.7104322910308838	biventricular_support HeartMate_II lVAD CentriMag right_ ventricular_assist_ deviceRVAD
P-296	-0.2019 -0.0949 -0.3841 -0.1938 -1.3481 -0.7301 -2.4495 -0.1134 -1.6887 -0.6017 -2.1272 -0.0045 -0.1437 -0.0396 -0.0945 -0.1605 -2.7751 -0.0641 -0.0086 -0.0958 -0.0122 -1.9801 -1.2715 -2.4574 -0.0010 -0.0305 -0.1092
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood_pressure arm_cuff stroke_volume ejection_fraction end-diastolic_volume echocardiography
H-521	-0.2778800129890442	▁Blood _ ▁pressure ▁arm ▁cu ff ▁stroke _ ▁volume ▁e je ction _ fraction ▁end - dia sto lic _ ▁volume ▁e cho card i ography
D-521	-0.2778800129890442	Blood_ pressure arm cuff stroke_ volume ejection_fraction end-diastolic_ volume echocardiography
P-521	-0.2685 -1.6192 -0.1307 -0.4038 -0.2270 -0.0035 -0.1443 -0.9629 -0.4324 -0.1948 -0.0058 -0.0072 -0.5587 -0.0221 -0.0401 -0.0248 -0.0053 -0.3071 -0.9580 -0.7822 -0.1002 -0.0169 -0.0116 -0.0910 -0.0592 -0.1698 -0.1263 -0.1072
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis heart_failure myocardial_tissue left_ventricular trichrome_blue_histologic_analysis
H-1060	-0.6589188575744629	▁fibro sis _ of _ heart _ ▁failure _ my o card ial _ ▁tissu e ▁left _ ▁vent ri cular _ ▁tissu e ▁tri ch rom e ▁blue ▁his t ologic
D-1060	-0.6589188575744629	fibrosis_of_heart_ failure_myocardial_ tissue left_ ventricular_ tissue trichrome blue histologic
P-1060	-0.0003 -0.1381 -2.7908 -0.3222 -0.7534 -0.6872 -0.2893 -0.8373 -0.3497 -3.6499 -0.0556 -0.3838 -0.0250 -0.0779 -0.4132 -0.1535 -0.3337 -0.2427 -4.2349 -0.3261 -0.0570 -0.6133 -2.2498 -0.1414 -0.1482 -0.0014 -0.0257 -0.0159 -1.5284 -0.7738 -0.0510 -0.1265 -0.4553 -0.1511
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas_city_cardiomyopathy_questionnaire kccq hf_with_reduced_ef patients hfpef
H-781	-0.8517444133758545	▁Kansas ▁City _ city _ card i om _ ▁Question naire ▁ HF p EF
D-781	-0.8517444133758545	Kansas City_city_cardiom_ Questionnaire HFpEF
P-781	-0.0143 -0.7075 -0.7803 -2.5745 -0.5419 -1.0841 -0.0798 -0.2372 -2.0971 -2.4360 -0.0110 -1.1558 -0.8261 -0.1137 -1.6685 -0.0563 -0.0956
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes patients atrial_fibrillation early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial
H-1642	-0.6143926978111267	▁at rial _ fi bril lation ▁at rial _ fi bril lation ▁Stro ke
D-1642	-0.6143926978111267	atrial_fibrillation atrial_fibrillation Stroke
P-1642	-1.6710 -0.0360 -0.2433 -0.5683 -0.0425 -0.0026 -4.4247 -0.0582 -0.0755 -0.3247 -0.0090 -0.0033 -0.3901 -0.0133 -1.9315 -0.0362
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid_annular_plane_systolic_excursion pulmonary_arterial_systolic_pressure heart_failure right_ventricular_contractile_function prognosis
H-491	-0.9772461652755737	▁tri cus pid ▁ann ular _ ▁plane ▁sy sto lic _ excursion ▁pulmonar y _ ▁arterial _ ▁sy sto lic _ press ion ▁heart _ ▁failure ▁right ▁vent ri cular _ contract ile
D-491	-0.9772461652755737	tricuspid annular_ plane systolic_excursion pulmonary_ arterial_ systolic_pression heart_ failure right ventricular_contractile
P-491	-1.4011 -0.2557 -0.0827 -0.4835 -0.0019 -0.8021 -0.8629 -1.6704 -1.1591 -2.2413 -1.2211 -0.6460 -0.0003 -0.0025 -0.8694 -1.3429 -0.1797 -1.6902 -0.0125 -0.4073 -0.0879 -3.5714 -2.3587 -0.6513 -0.9056 -2.8476 -1.3636 -2.9411 -0.5000 -0.0994 -0.4181 -1.3049 -0.7711 -0.7363 -0.3140
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients physicians readmission hospital
H-1728	-0.8488660454750061	▁high - volu me _ ▁physician s
D-1728	-0.8488660454750061	high-volume_ physicians
P-1728	-0.7752 -0.0235 -0.0405 -0.0031 -0.6194 -2.8544 -0.0456 -3.1319 -0.1462
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology comorbidities patients outcomes
H-564	-0.43079522252082825	▁di ver gent ▁et i ology ▁como rbi di ties
D-564	-0.43079522252082825	divergent etiology comorbidities
P-564	-0.1197 -0.0081 -0.0184 -0.5752 -0.2142 -0.0036 -0.8876 -0.0742 -0.0657 -0.0120 -3.1322 -0.0585
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise training outcomes hf patients exercise training therapy clinical
H-1934	-0.6751213669776917	▁exercise _ training ▁ therapy
D-1934	-0.6751213669776917	exercise_training therapy
P-1934	-0.0162 -1.5512 -0.5830 -1.1949 -0.2106 -1.0351 -0.1350
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins expression cardiac_hypertrophy proteins nucleolin
H-95	-1.21365487575531	▁cardiac _ ▁hyper trop hy
D-95	-1.21365487575531	cardiac_ hypertrophy
P-95	-1.4247 -0.8112 -0.6284 -0.0162 -0.5552 -4.6743 -0.3855
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial_dd muscle titin_hypophosphorylation
H-768	-0.42156726121902466	▁my o card ial _ DD ▁high ▁muscle _ ▁strip ▁sti ff ness ▁titi n ▁hypo phos phor y lation
D-768	-0.42156726121902466	myocardial_DD high muscle_ strip stiffness titin hypophosphorylation
P-768	-0.4038 -0.1267 -0.2748 -0.0135 -1.0708 -0.6938 -0.3780 -0.3336 -0.5403 -0.1428 -0.1635 -0.0690 -0.6593 -0.0807 -0.0623 -1.7770 -0.5144 -0.6392 -1.1766 -0.0108 -0.0467 -0.0969
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right_ventricular rv prognosis patients heart_failure hf
H-1158	-1.2990444898605347	▁right _ ▁vent ri cular _ RV ▁body _ ▁composition
D-1158	-1.2990444898605347	right_ ventricular_RV body_ composition
P-1158	-1.9033 -0.4514 -4.5120 -0.1157 -0.0127 -0.6785 -0.7571 -0.5405 -1.5120 -1.6502 -3.3528 -0.1024
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni cardiovascular_mortality hospitalization heart_failure quality_of_life
H-1969	-0.7036193013191223	▁AR NI ▁cardiovascular _ ▁mortal ity ▁hospital ization ▁heart _ ▁failure
D-1969	-0.7036193013191223	ARNI cardiovascular_ mortality hospitalization heart_ failure
P-1969	-3.9525 -1.0894 -0.6102 -0.4852 -0.1204 -0.0036 -0.1314 -0.1106 -0.4426 -0.2032 -0.8865 -0.9247 -0.1869
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional_ms patients valve_plasty degenerative_mr dilated disease
H-340	-0.4577905833721161	▁functional ▁MS ▁val ve ▁plast y ▁ann ular _ size _ re duction ▁de genera tive _ ▁MR ▁LV ▁dil ated
D-340	-0.4577905833721161	functional MS valve plasty annular_size_reduction degenerative_ MR LV dilated
P-340	-0.1148 -0.1327 -2.7090 -0.0042 -0.2323 -0.0441 -0.0005 -0.0001 -0.3810 -1.0064 -1.2975 -0.4751 -0.0001 -0.0582 -0.0001 -0.0108 -0.3076 -0.3706 -0.5866 -0.6615 -0.0044 -1.9930 -0.1387
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus cells functional_capacity mortality nondiabetic patients
H-131	-0.9893767237663269	▁ EO - C FU s ▁lower ▁CD 34 _ ve g FR 2 _ cell s ▁functional _ capaci ty ▁non dia be tic _ ▁patients
D-131	-0.9893767237663269	EO-CFUs lower CD34_vegFR2_cells functional_capacity nondiabetic_ patients
P-131	-1.1652 -0.1555 -0.0645 -1.5892 -0.1519 -0.5491 -1.6612 -0.1126 -0.3021 -3.0168 -1.0864 -1.5314 -3.6668 -0.1655 -1.8410 -0.3305 -0.0227 -4.3274 -2.2532 -0.4501 -0.4946 -0.3193 -0.0034 -0.2863 -0.2104 -1.5117 -1.1303 -0.1301 -0.1628
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action correlation baseline hgb baseline hrqol kccq
H-842	-0.30731678009033203	▁ HF - AC TION _ co hor t ▁base line _ ▁H gb ▁base line _ HR Qo L ▁K CC Q
D-842	-0.30731678009033203	HF-ACTION_cohort baseline_ Hgb baseline_HRQoL KCCQ
P-842	-0.1349 -0.0355 -0.0307 -0.7262 -0.3042 -0.9133 -0.3378 -0.0046 -0.0454 -0.0002 -0.0008 -0.6798 -1.4766 -0.0021 -0.0045 -0.0007 -0.4489 -0.5388 -0.0181 -0.0699 -0.9595 -0.1167 -0.7697 -0.0051 -0.0590
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty prognostic heart_failure hf biological_phenotype
H-1001	-0.6680888533592224	▁Fra il ty ▁heart _ ▁failure ▁bi ological _ ▁ph eno type ▁accumula tion _ of _ ▁deficit s
D-1001	-0.6680888533592224	Frailty heart_ failure biological_ phenotype accumulation_of_ deficits
P-1001	-1.7872 -0.0920 -0.0930 -1.8607 -0.4143 -0.6933 -3.8439 -0.0843 -0.9810 -0.6484 -0.0111 -0.0074 -0.9232 -0.0241 -0.9937 -0.1811 -0.4265 -0.8216 -0.0452 -0.0639 -0.0339
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report functional_ms patient valve_plasty degenerative_mr dilated disease
H-375	-0.5832300782203674	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive _ ▁MR ▁LV
D-375	-0.5832300782203674	functional MS valve plasty degenerative_ MR LV
P-375	-0.2328 -0.2621 -3.4898 -0.0034 -0.8807 -0.0574 -0.0946 -0.0001 -0.0078 -0.9238 -0.0959 -1.1315 -0.8893 -0.0960
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based prognosis idiopathic_dilated_cardiomyopathy
H-1750	-0.6466581225395203	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1750	-0.6466581225395203	idiopathic dilated_ cardiomyopathy
P-1750	-1.3414 -1.1845 -0.4370 -0.8049 -2.1203 -0.4251 -0.0877 -0.3838 -1.1303 -0.2713 -0.0884 -0.1027 -0.0290
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological remodelling heart cardiac_hypertrophy hf death fibrosis inflammation
H-1035	-0.295876145362854	▁path ological _ ▁remodel ling ▁heart ▁cardiac ▁hyper trop hy ▁ HF ▁fibro sis ▁ inflammation
D-1035	-0.295876145362854	pathological_ remodelling heart cardiac hypertrophy HF fibrosis inflammation
P-1035	-0.0712 -0.1741 -1.6030 -0.0542 -0.0507 -1.6324 -0.0486 -0.5287 -0.0032 -0.1093 -0.1216 -0.0042 -0.1933 -0.3767 -0.0658 -0.0017 -0.1720 -0.1150
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined_training peak_work_rate peak_quadriceps_force
H-1917	-0.43481290340423584	▁pe ak _ work _ rate ▁pe ak _ ▁quadri cep s _ force
D-1917	-0.43481290340423584	peak_work_rate peak_ quadriceps_force
P-1917	-0.5902 -0.0090 -0.2287 -1.2074 -1.0482 -1.0194 -0.0089 -0.0104 -0.2110 -0.7430 -0.0469 -0.2046 -1.0025 -0.2408 -0.1801 -0.2059
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients exercise anaerobic_metabolism peak_respiratory_quotient
H-1756	-1.0252457857131958	▁exercise ▁ana ero bic _ ▁metabolism pe ak _ ▁respirator y
D-1756	-1.0252457857131958	exercise anaerobic_ metabolismpeak_ respiratory
P-1756	-6.1618 -1.6994 -0.0589 -0.1552 -0.7854 -1.1355 -1.0862 -0.0055 -0.2200 -0.5731 -0.0120 -1.3213 -0.1137
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.0833569765090942	▁virtual _ co hor ts ▁resource _ ▁use ▁costs
D-2014	-1.0833569765090942	virtual_cohorts resource_ use costs
P-2014	-1.1112 -0.5885 -0.0518 -0.0092 -0.0145 -0.1700 -2.0238 -3.4214 -0.4758 -3.7811 -0.2695
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ef
H-192	-1.71603524684906	▁patients ▁border line
D-192	-1.71603524684906	patients borderline
P-192	-4.8743 -0.3009 -0.0042 -3.2870 -0.1136
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker uptitrations patients hfref hfpef hospital admission
H-177	-0.7085813879966736	▁ RAS - ▁β - block er ▁up ti tra tions ▁H Fr EF ▁ HF p EF ▁hospital ▁ad mission
D-177	-0.7085813879966736	RAS- β-blocker uptitrations HFrEF HFpEF hospital admission
P-177	-0.6989 -0.0617 -0.2791 -6.0043 -0.0190 -2.9179 -0.6436 -1.4041 -0.1792 -0.0248 -0.0303 -1.2367 -0.0895 -0.4262 -0.3050 -0.0188 -0.1166 -1.2158 -0.1371 -0.0288 -0.0433 -0.0798 -0.3367
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american_college_of_cardiology american_heart_association patients ras patients ras
H-1604	-0.8404598832130432	▁American ▁College _ of _ ▁Card i ology _ American _ ▁Heart _ Association ▁guidelines ▁ RAS
D-1604	-0.8404598832130432	American College_of_ Cardiology_American_ Heart_Association guidelines RAS
P-1604	-2.4701 -2.3951 -0.3139 -0.0094 -0.0168 -2.2590 -0.4805 -0.0023 -0.8773 -0.1870 -0.1071 -1.2875 -0.6589 -1.1150 -0.7877 -2.1451 -0.1479 -0.4899 -0.2183
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp plasma patients dyspnea left_ventricular_dysfunction admission
H-265	-0.9831482768058777	▁NT - pro b NP _ level ▁plasma ▁dys pne a ▁left ▁vent ri cular _ ▁dys function ▁ad mission ▁ED
D-265	-0.9831482768058777	NT-probNP_level plasma dyspnea left ventricular_ dysfunction admission ED
P-265	-0.8538 -0.0401 -0.0024 -2.1143 -0.5498 -2.2901 -1.0654 -3.3494 -1.9428 -0.1252 -0.2129 -0.0489 -4.2787 -1.1767 -0.4680 -0.4928 -1.5801 -0.2637 -0.5302 -0.0021 -1.0194 -0.0807 -0.1246
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable_cardioverter-defibrillator physicians heart_failure patients
H-1857	-0.8342989087104797	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1857	-0.8342989087104797	implantable cardioverter-defibrillator_deactivation
P-1857	-2.5091 -0.0052 -0.9201 -0.0463 -0.5533 -0.3124 -0.0073 -0.7034 -2.4613 -0.5120 -0.0843 -0.2593 -0.1152 -0.3292 -0.0935 -5.0252 -0.2460
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating_progenitor_cells cpcs endothelial prognostic cardiovascular_diseases
H-120	-0.38484182953834534	▁Circula ting _ pro gen itor _ cell s ▁c PC s ▁en dot heli al _ ▁repair ▁cardiovascular _ مرض s
D-120	-0.38484182953834534	Circulating_progenitor_cells cPCs endothelial_ repair cardiovascular_مرضs
P-120	-0.1313 -0.0434 -0.4686 -0.4602 -0.1660 -0.0118 -0.4872 -0.1316 -0.0194 -1.4060 -0.0741 -0.2099 -0.0033 -0.3675 -0.0239 -0.0018 -0.7986 -0.1369 -0.5293 -0.7473 -2.0039 -0.9177 -0.0572 -0.0392
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile_function lv_dilatation lv_end-diastolic_pressure wall_stress lung
H-476	-0.589145839214325	▁contract ile _ function ▁LV _ di la tation ▁end - dia sto lic _ press _ wall _ ▁stress ▁lung
D-476	-0.589145839214325	contractile_function LV_dilatation end-diastolic_press_wall_ stress lung
P-476	-0.0010 -0.4568 -1.0963 -0.2707 -0.1638 -0.9937 -0.4989 -0.0417 -0.0010 -2.1639 -0.0144 -0.0056 -0.5698 -0.8471 -0.3319 -1.5698 -1.7737 -0.0238 -0.4176 -0.7387 -0.0044 -1.4271 -0.1388
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv_remodeling diastolic xo_inhibition symptoms hospitalizations patients severe_heart_failure
H-478	-0.7073028683662415	▁LV ▁remodel ing ▁dia sto lic _ ▁properties ▁ XO _ ▁inhibi tion ▁hospital ization s
D-478	-0.7073028683662415	LV remodeling diastolic_ properties XO_ inhibition hospitalizations
P-478	-0.0474 -1.3881 -0.0225 -0.2494 -0.4087 -0.1163 -2.0086 -0.0210 -0.4472 -0.0602 -2.0329 -0.0954 -0.0749 -1.3008 -0.2668 -0.3387 -3.5094 -0.3431
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped snp rs10927887 ka_renal_chloride_channel_gene clcnka
H-1802	-0.8148320317268372	▁Cau ca sian ▁s NP _ ▁rs 109 27 887 ▁Ka ▁renal _ ▁chlor ide _ ▁channel _ ▁gene CL CN KA
D-1802	-0.8148320317268372	Caucasian sNP_ rs10927887 Ka renal_ chloride_ channel_ geneCLCNKA
P-1802	-4.4348 -0.0019 -0.0036 -1.1462 -0.0044 -1.7112 -0.0995 -0.0440 -0.2120 -0.1032 -0.6974 -0.0065 -0.2191 -2.3073 -2.9115 -0.8854 -0.7819 -0.6209 -2.6805 -0.2165 -0.2092 -0.0331 -0.0551 -0.1707
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular_assist_device vad extracorporeal_membrane_oxygenation ecmo renal_function
H-1385	-0.5145325064659119	▁vent ri cular _ assist _ ▁device ▁ VAD ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁ec MO ▁renal _ function
D-1385	-0.5145325064659119	ventricular_assist_ device VAD extracorporeal_ membrane_ oxygenation ecMO renal_function
P-1385	-0.1792 -0.1307 -0.0353 -0.2574 -0.0165 -0.9787 -1.6759 -3.1382 -0.0010 -0.0604 -0.0176 -0.3937 -0.2002 -0.1682 -0.3001 -0.0189 -0.5746 -1.6951 -0.1475 -1.0814 -0.4882 -0.0191 -0.6777 -0.7049 -0.1532 -0.2642
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac_magnetic_resonance amyloidotic diagnosis multiple_myeloma osteomedullary_biopsy
H-999	-0.3514271378517151	▁cardiac ▁magnetic _ ▁res on ance ▁a my lo ido tic _ ▁pattern ▁multiple _ ▁mye loma ▁osteo me dulla ry _ ▁bio psy
D-999	-0.3514271378517151	cardiac magnetic_ resonance amyloidotic_ pattern multiple_ myeloma osteomedullary_ biopsy
P-999	-0.0059 -0.8689 -0.1595 -0.0563 -0.0238 -0.0019 -0.0157 -0.0215 -0.0629 -0.4478 -0.9625 -0.4477 -0.1435 -0.4602 -0.7322 -2.3109 -0.7895 -0.0099 -0.0190 -0.0441 -0.1832 -0.8302 -0.4021 -0.0551 -0.0321 -0.0506
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis hfpef clinical echo-doppler_cardiography invasive_haemodynamic_assessment
H-1303	-0.3589460849761963	▁ HF p EF ▁e cho - D opp ler _ card i ography ▁invasi ve ▁ha emo dynamic
D-1303	-0.3589460849761963	HFpEF echo-Doppler_cardiography invasive haemodynamic
P-1303	-0.5587 -0.1883 -0.0194 -0.2249 -2.6500 -0.0814 -0.0320 -0.9108 -0.0396 -0.2351 -0.1103 -0.4916 -0.0344 -0.1658 -0.0104 -0.0311 -0.0284 -0.8735 -0.0046 -0.8009 -0.0466
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable_cardioverter-defibrillators icds mortality cardiac_resynchronization_therapy crt symptoms mortality
H-1068	-0.4888816177845001	▁Implant able ▁cardio ver ter - de fi br illa tors IC d s ▁cardiac ▁re syn chron ization _ therapy C RT
D-1068	-0.4888816177845001	Implantable cardioverter-defibrillatorsICds cardiac resynchronization_therapyCRT
P-1068	-0.9595 -0.0053 -0.5998 -0.0533 -1.9292 -0.1520 -0.0121 -0.1324 -1.1543 -0.4019 -0.0233 -0.2285 -0.8896 -0.0299 -0.0291 -1.0032 -0.0016 -0.0023 -0.2120 -1.0881 -0.2505 -2.1039 -0.0190 -0.8342 -0.1071
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular_endothelial_growth_factor_blockade beta-blocker therapy cardiac_function angiogenesis remodeling heart_failure
H-448	-0.829404890537262	▁Vas cular _ ▁en dot heli al _ ▁growth _ factor _ block ade ▁beta - block er _ therapy ▁cardiac _ function ▁ang io gene sis ▁remodel ing ▁heart _ ▁failure
D-448	-0.829404890537262	Vascular_ endothelial_ growth_factor_blockade beta-blocker_therapy cardiac_function angiogenesis remodeling heart_ failure
P-448	-0.0679 -0.0146 -0.7775 -2.3140 -1.9607 -0.0922 -0.0031 -0.2044 -4.0636 -0.3187 -0.0166 -0.5260 -1.4512 -0.2760 -0.3168 -0.0090 -0.0912 -0.2193 -1.0869 -0.1889 -0.1206 -2.7667 -4.8394 -0.0554 -0.5100 -0.0642 -0.1661 -1.1134 -0.0104 -0.1341 -0.6401 -3.5870 -0.0606 -0.1330
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash diastolic_function ventricular-arterial_coupling hypertensive_heart_failure_with_preserved_ejection_fraction
H-915	-0.4716499447822571	▁low - so dium ▁DAS H _ ▁die t ▁dia sto lic _ function ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve _ heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-915	-0.4716499447822571	low-sodium DASH_ diet diastolic_function ventricular-arterial_ coupling hypertensive_heart_ failure preserved ejection_fraction
P-915	-0.5608 -0.0750 -0.1466 -0.2204 -0.3604 -0.4949 -1.2049 -3.0295 -0.0792 -0.0676 -0.0391 -0.3699 -1.3760 -0.6132 -0.0080 -0.2457 -0.0315 -0.3879 -0.1666 -0.1606 -0.7919 -0.0153 -0.3386 -0.1164 -0.3437 -0.0536 -0.2064 -0.5526 -0.7665 -3.9571 -0.0082 -0.1454 -0.0575 -0.4999 -0.0848 -0.0193 -1.0324 -0.0017 -0.0936 -0.1430
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt dt btt patients
H-314	-0.6541852355003357	▁b t ▁ DT ▁cost - effect ive ness _ limit s
D-314	-0.6541852355003357	bt DT cost-effectiveness_limits
P-314	-1.0302 -1.2171 -0.6522 -0.0352 -0.2910 -0.0711 -0.0068 -0.0698 -0.8970 -2.2031 -0.2731 -0.0611 -2.2667 -0.0841
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure health income hf
H-1800	-1.0388824939727783	▁ex pendi ture ▁health ▁per ▁capita ▁gross _ national ▁income _ per ▁capita ▁ HF
D-1800	-1.0388824939727783	expenditure health per capita gross_national income_per capita HF
P-1800	-5.1626 -0.0033 -0.0596 -2.6920 -1.1691 -0.0050 -2.5356 -0.3832 -1.1130 -0.3638 -1.7970 -0.1076 -0.0303 -1.2836 -0.2316 -0.5579 -0.1660
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood_pressure therapy patients ras
H-1600	-0.37975600361824036	▁blood _ control ▁goal - direct ed ▁lipid - lo wering _ therapy ▁smoking _ ▁ces s ation ▁ RAS
D-1600	-0.37975600361824036	blood_control goal-directed lipid-lowering_therapy smoking_ cessation RAS
P-1600	-0.6222 -0.7986 -0.8706 -1.3930 -0.0049 -0.0034 -0.0046 -0.0723 -0.0525 -0.0151 -0.0550 -0.4655 -0.5811 -0.0043 -0.1766 -0.8188 -0.0189 -0.1724 -2.0615 -0.0346 -0.0302 -0.0984
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical bnp inhospital mortality
H-196	-0.6363930702209473	▁b NP ▁in hospital _ ▁mortal ity
D-196	-0.6363930702209473	bNP inhospital_ mortality
P-196	-1.4200 -1.8961 -0.2359 -0.0117 -0.3354 -0.6386 -0.0063 -1.1323 -0.0513
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt atrial_pacing
H-1442	-0.4889983534812927	▁SD QT ▁ HF VT ▁ HF VT ▁H Nor m _ ▁group ▁fixed - rate _ at rial _ pa cing
D-1442	-0.4889983534812927	SDQT HFVT HFVT HNorm_ group fixed-rate_atrial_pacing
P-1442	-0.0660 -1.4248 -0.0349 -0.0077 -0.1972 -0.7035 -0.0598 -1.2034 -2.8132 -0.7187 -0.0021 -1.4723 -1.0332 -0.0057 -0.0146 -0.0148 -0.6310 -0.0736 -0.0016 -0.3155 -0.4569 -0.0124 -0.2556 -0.2175
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies crt-d heart_failure death
H-108	-1.2148916721343994	▁i s ▁c RT - D _ ▁recipient s
D-108	-1.2148916721343994	is cRT-D_ recipients
P-108	-4.1606 -0.1508 -0.5668 -0.1555 -0.0508 -0.9290 -3.2848 -0.0522 -0.0126 -3.6944 -0.3062
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals patients hfpef
H-952	-1.687207579612732	▁AF
D-952	-1.687207579612732	AF
P-952	-1.1701 -3.8217 -0.0699
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients frail frail biological_phenotype
H-1007	-0.6785829663276672	▁fra il ▁bi ological _ ▁ph eno type
D-1007	-0.6785829663276672	frail biological_ phenotype
P-1007	-3.5671 -0.0881 -1.8158 -0.2012 -0.7162 -0.2601 -0.0120 -0.0069 -0.0819 -0.0365
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients hfpef longitudinal cardiac_event
H-738	-0.7208525538444519	▁H FP EF ▁longitud in al _ ▁outcome - monitor ing _ ▁phase ▁cardiac
D-738	-0.7208525538444519	HFPEF longitudinal_ outcome-monitoring_ phase cardiac
P-738	-4.1728 -0.2233 -1.6323 -0.0302 -0.0139 -0.0361 -1.1984 -0.9664 -0.0629 -0.0011 -0.0201 -1.3832 -0.1200 -0.0954 -1.5163 -0.0613
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician outcomes patients outcomes medically diseases hf
H-1722	-0.7860637307167053	▁Physic ian _ ▁volume ▁ HF
D-1722	-0.7860637307167053	Physician_ volume HF
P-1722	-0.3053 -0.4245 -0.7766 -0.0595 -3.8349 -0.2208 -0.5677 -0.0990
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping myocardial heart_failure
H-1063	-0.7397089600563049	▁t 1- ma pping ▁diffuse _ ▁my o card ial _ ▁changes ▁heart _ ▁failure ▁contrast _ agent ▁breath - hold ing
D-1063	-0.7397089600563049	t1-mapping diffuse_ myocardial_ changes heart_ failure contrast_agent breath-holding
P-1063	-1.9257 -0.2771 -0.1577 -0.0456 -2.4388 -0.7293 -2.3192 -0.1451 -1.1013 -0.0554 -0.8130 -2.1330 -0.4425 -0.8967 -3.0765 -0.0646 -0.5302 -0.0601 -0.1814 -0.1093 -0.0233 -0.0319 -0.0615 -0.1337
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone patients hf-ref hyperkalemia patients
H-1224	-0.24612054228782654	▁e pler en one ▁ HF - RE F ▁induc ing ▁hyper kal emia ▁W RF
D-1224	-0.24612054228782654	eplerenone HF-REF inducing hyperkalemia WRF
P-1224	-0.2105 -0.0111 -0.7717 -0.1156 -0.0664 -0.0248 -0.0240 -0.5038 -0.0860 -0.1323 -0.0130 -1.3268 -0.3019 -0.0453 -0.5353 -0.0176 -0.1081 -0.1360
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients exercise-induced_pasp pasp patients pasp
H-827	-0.7193314433097839	▁exercise - indu ced ▁PAS P
D-827	-0.7193314433097839	exercise-induced PASP
P-827	-1.0046 -0.1374 -0.0018 -0.0277 -0.8540 -0.9516 -2.6362 -0.1414
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm outcomes discharged admission heart_failure
H-149	-1.7005131244659424	▁RM ▁strategie s ▁dis charge d
D-149	-1.7005131244659424	RM strategies discharged
P-149	-2.5322 -3.0537 -0.0056 -2.9640 -0.0014 -0.1512 -4.8007 -0.0953
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients lbbb implantable primary_outcome primary_outcome
H-887	-0.3709959387779236	▁ LB BB ▁implant able _ ▁cardio ver ter _ de fi br illa tor - C RT
D-887	-0.3709959387779236	LBBB implantable_ cardioverter_defibrillator-CRT
P-887	-0.4265 -0.2055 -1.0334 -0.1489 -0.0056 -0.7391 -0.7572 -0.0490 -0.3221 -0.1326 -0.1977 -0.0286 -0.7644 -0.3780 -0.0282 -0.6543 -0.2431 -0.0650 -1.1579 -0.0828
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs_morphology cardiac_resynchronization_therapy crt
H-880	-0.37588292360305786	▁QR s ▁ morph ology ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-880	-0.37588292360305786	QRs morphology cardiac_resynchronization_therapy cRT
P-880	-0.0569 -0.8581 -0.5958 -0.0067 -0.0173 -0.2322 -0.7770 -0.6925 -0.0031 -0.0015 -0.3623 -0.6965 -0.4255 -1.5549 -0.0115 -0.0369 -0.0613
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene pathological heart_disease transcription_factors driving gene
H-639	-1.0227298736572266	▁aber rant ▁re activa tion ▁em bry o nic _ ▁gene ▁programs ▁path ological _ heart _ مرض ▁tran scription ▁factors
D-639	-1.0227298736572266	aberrant reactivation embryonic_ gene programs pathological_heart_مرض transcription factors
P-639	-6.5333 -0.4802 -0.4617 -0.0216 -0.0158 -0.1281 -0.0179 -0.0603 -0.2390 -0.1659 -1.4497 -2.3328 -0.0066 -0.0934 -0.3209 -1.0808 -2.1331 -2.5014 -1.5027 -0.1760 -1.1692 -2.3763 -0.2559
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard_error_of_measurement mdc clinical change
H-807	-0.4222523272037506	▁standard _ error _ of _ ▁measure ment ▁m DC
D-807	-0.4222523272037506	standard_error_of_ measurement mDC
P-807	-0.1822 -0.5644 -0.8462 -0.3926 -0.0700 -0.0344 -0.4289 -0.0529 -0.5629 -0.0462 -1.5101 -0.3763
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients sst2 sst2 odds_ratios cardiovascular_events
H-409	-0.8055081367492676	▁s ST 2/ low - dos e ▁BB ▁s ST 2/ high - dos e _ ▁BB ▁cardiovascular _ ▁events
D-409	-0.8055081367492676	sST2/low-dose BB sST2/high-dose_ BB cardiovascular_ events
P-409	-0.0585 -1.7313 -1.0436 -0.8633 -0.0393 -1.7494 -0.1074 -0.2716 -0.8695 -0.4722 -0.9447 -1.4109 -0.0229 -0.3500 -0.0242 -1.8431 -2.8225 -0.3166 -1.1702 -1.3768 -0.0661 -0.1671
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal_flow_pump hemocompatibility blood-flow pulse
H-1994	-0.40865403413772583	▁centri fu gal _ ▁flow _ pump ▁hem o com pati bility ▁magnet ically ▁le vita ted _ ro tor ▁blood - flow _ path s ▁artificial _ ▁puls e
D-1994	-0.40865403413772583	centrifugal_ flow_pump hemocompatibility magnetically levitated_rotor blood-flow_paths artificial_ pulse
P-1994	-0.0008 -0.0025 -0.0129 -0.2420 -0.6478 -0.3958 -0.1396 -3.4973 -0.0270 -0.0972 -0.0095 -0.0092 -0.0442 -0.0258 -0.0192 -0.0029 -0.0171 -0.6223 -0.4452 -0.0083 -3.4543 -0.1112 -0.0022 -0.8100 -0.1340 -0.0299 -0.0383 -0.6651 -1.3673 -0.1156 -0.0330 -0.0493
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis biomedical biomedical patients dcm heart_failure
H-1264	-1.0152279138565063	▁bio medic al _ ▁treatment ▁d CM ▁heart _ ▁failure
D-1264	-1.0152279138565063	biomedical_ treatment dCM heart_ failure
P-1264	-0.1967 -0.0499 -0.0031 -2.2654 -1.8893 -2.8198 -0.2517 -1.3784 -0.7472 -2.3325 -0.1524 -0.0964
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic patients reverse_remodeling crt clinical outcomes
H-436	-0.48640596866607666	▁multi para metric ▁e cho car dio graphic _ ▁score ▁rever se _ ▁remodel ing ▁c RT ▁clinic al _ ▁outcome s
D-436	-0.48640596866607666	multiparametric echocardiographic_ score reverse_ remodeling cRT clinical_ outcomes
P-436	-1.7731 -0.0667 -0.0055 -0.0290 -0.0842 -0.6079 -0.9593 -0.5548 -1.0125 -0.3059 -0.3238 -0.0048 -0.9583 -0.1699 -0.0088 -2.4588 -0.0281 -0.2100 -0.0235 -1.6475 -0.3619 -0.0086 -0.0286 -0.0424
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient emergency_department acute_heart_failure ahf clinical
H-57	-0.8526783585548401	▁emergency _ ▁department ▁a cute _ heart _ ▁failure ▁a HF ▁clinic al _ ▁studies
D-57	-0.8526783585548401	emergency_ department acute_heart_ failure aHF clinical_ studies
P-57	-2.5800 -0.8304 -0.7936 -0.0932 -0.1062 -0.0688 -1.5025 -0.1657 -3.6986 -1.0486 -0.0101 -0.8091 -0.0077 -0.9317 -1.7060 -0.0484 -0.0946
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire implanted pacemakers ventricularly beats heart_failure
H-1056	-0.9378073811531067	▁York shire ▁s win e ▁pace makers ▁vent ri cular ly _ ▁pace d
D-1056	-0.9378073811531067	Yorkshire swine pacemakers ventricularly_ paced
P-1056	-2.4826 -0.0348 -0.2941 -0.1365 -0.2324 -0.0363 -0.0639 -0.2245 -0.1085 -0.0056 -0.7586 -3.5582 -1.7952 -0.3837 -4.5499 -0.3403
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart_rate ivabradine afterload patients systolic_heart_failure
H-516	-0.5600957870483398	▁isola ted _ heart _ rate _ HR ▁i va bra dine ▁after load ▁sy sto lic _ heart _ ▁failure
D-516	-0.5600957870483398	isolated_heart_rate_HR ivabradine afterload systolic_heart_ failure
P-516	-0.1831 -0.0084 -0.4785 -0.8053 -0.1953 -1.1234 -1.9698 -1.6067 -0.0964 -0.1807 -0.0393 -0.0107 -2.7741 -0.0019 -0.4969 -0.0488 -0.6807 -0.1069 -0.5366 -0.5229 -0.8089 -0.1115 -0.0953
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial_complex_v_activity phosphocreatine atp
H-1786	-1.1416285037994385	▁mito cho ndri al _ ▁complex _ V ▁activity ▁post - A AC ▁ phos pho creati ne ▁ATP
D-1786	-1.1416285037994385	mitochondrial_ complex_V activity post-AAC phosphocreatine ATP
P-1786	-0.5084 -2.9687 -0.6308 -0.0046 -0.6785 -0.4995 -1.1447 -2.2351 -0.4510 -2.4930 -0.0039 -0.4438 -0.2167 -1.4110 -0.0264 -1.8691 -4.3949 -1.4809 -2.0197 -0.1986 -0.2950
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal_muscle sarcomere patients heart_failure type_2_diabetes
H-1243	-0.7228294610977173	▁skelet al _ ▁muscle _ ▁sar com ere _ ▁structure ▁heart _ ▁failure ▁type ▁2 ▁diabetes ▁e pica tech in - rich ▁coco a
D-1243	-0.7228294610977173	skeletal_ muscle_ sarcomere_ structure heart_ failure type 2 diabetes epicatechin-rich cocoa
P-1243	-0.1485 -0.0258 -0.2857 -4.6792 -0.0969 -0.4370 -0.1802 -2.3387 -3.0168 -1.0696 -0.9734 -0.5752 -0.4882 -0.2686 -1.1475 -0.0406 -2.3992 -0.0032 -0.0259 -0.1392 -0.0856 -0.0006 -0.2460 -0.0202 -0.0322 -0.0698
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 cardioprotective_signaling myocardium biomarker heart_failure hf
H-696	-0.41730859875679016	▁ST 2 ▁cardio protec tive _ signal ing ▁my o car dium ▁bio mark er ▁heart _ ▁failure
D-696	-0.41730859875679016	ST2 cardioprotective_signaling myocardium biomarker heart_ failure
P-696	-3.0774 -0.0302 -0.0352 -0.0535 -0.0136 -0.2496 -0.4927 -0.1370 -0.0808 -0.0101 -0.0132 -0.0556 -0.4189 -0.0051 -0.5351 -0.5371 -0.4496 -1.5772 -0.5351 -0.0393
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi metoprolol elevated plasma_norepinephrine dopamine elevated epinephrine
H-1550	-0.5440379977226257	▁MI _ animal ▁met o pro lol ▁plasma ▁no re pine ph rine ▁dop amine ▁e pine ph rine
D-1550	-0.5440379977226257	MI_animal metoprolol plasma norepinephrine dopamine epinephrine
P-1550	-2.3817 -4.4140 -1.7174 -0.5788 -0.0194 -0.0104 -0.0714 -0.4921 -0.1979 -0.3259 -0.3475 -0.4731 -0.0145 -0.0027 -0.0222 -0.1421 -0.0024 -0.0509 -0.0068 -0.0471 -0.1064
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular_outcomes_in_renal_atherosclerotic_lesions coral stenting ras
H-1602	-0.4661896824836731	▁Card io vas cular _ out com es ▁Ren al _ ▁Ath eros cle ro tic _ Les ions ▁CO RAL ▁sten ting ▁ RAS
D-1602	-0.4661896824836731	Cardiovascular_outcomes Renal_ Atherosclerotic_Lesions CORAL stenting RAS
P-1602	-0.6909 -0.4700 -0.1451 -0.0828 -0.5167 -0.1888 -0.0085 -0.0295 -0.1621 -0.0048 -0.0511 -0.2494 -0.1378 -0.3429 -3.8292 -0.1602 -0.0376 -0.9412 -0.1516 -2.7991 -0.0029 -1.2431 -0.0372 -0.0728 -0.0016 -0.0690 -0.1613
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality heart_failure hf implantable_cardioverter_defibrillators icds
H-60	-0.6201086640357971	▁mortal ity ▁heart _ ▁failure ▁implant able _ ▁cardio ver ter _ de fi br illa tors IC D s
D-60	-0.6201086640357971	mortality heart_ failure implantable_ cardioverter_defibrillatorsICDs
P-60	-4.4779 -0.0815 -1.9027 -0.1739 -1.4213 -1.6775 -0.0091 -0.2455 -0.7778 -0.0427 -0.3110 -0.1102 -0.1416 -0.0383 -0.7413 -0.2269 -0.0133 -0.1244 -1.0356 -0.0215 -0.0407 -0.0278
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary_approaches_to_stop_hypertension dash mortality postmenopausal hf
H-686	-0.5691823959350586	▁Mediterrane an _ diet ary _ app ro ach es ▁Stop _ ▁Hyper tension DAS H ▁die t _ ▁score s ▁mortal ity ▁post meno paus al _ النساء HF
D-686	-0.5691823959350586	Mediterranean_dietary_approaches Stop_ HypertensionDASH diet_ scores mortality postmenopausal_النساءHF
P-686	-0.1025 -0.0017 -2.1527 -1.2196 -0.0178 -0.3005 -0.2063 -0.2344 -0.2720 -0.0197 -0.9699 -0.0893 -1.0066 -0.0611 -0.9193 -0.5800 -3.4016 -0.0772 -0.4845 -0.0959 -0.0721 -1.0526 -0.0120 -0.0355 -0.0415 -0.0003 -0.0013 -0.7794 -2.7314 -0.9701 -0.1062 -0.1990
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc diagnostic
H-1025	-1.1971007585525513	▁ NP _ level
D-1025	-1.1971007585525513	NP_level
P-1025	-2.6925 -0.7128 -1.4221 -0.9230 -1.3635 -0.0686
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized medical
H-1977	-2.351010799407959	
D-1977	-2.351010799407959	
P-1977	-4.6589 -0.0431
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline embase psycinfo
H-151	-0.4220789670944214	▁electronic _ ▁database s ▁MED LINE ▁ EMBA SE ▁Psy c INFO
D-151	-0.4220789670944214	electronic_ databases MEDLINE EMBASE PsycINFO
P-151	-0.5094 -0.6656 -1.1304 -0.1098 -1.2958 -0.9190 -0.0671 -0.0005 -0.5126 -0.0528 -0.0314 -0.0247 -0.5640 -0.0262
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality readmissions costs patient physician hospital
H-1725	-0.46145099401474	▁patient - level ▁re gression ▁risk - ad just ed _ ▁mortal ity ▁read missions ▁costs
D-1725	-0.46145099401474	patient-level regression risk-adjusted_ mortality readmissions costs
P-1725	-0.1654 -0.0131 -0.0045 -0.7892 -0.0000 -0.8574 -0.0164 -0.0028 -0.0109 -0.0137 -0.0626 -1.7118 -0.0083 -0.5254 -0.0098 -0.4423 -3.5608 -0.1117
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients lbbb qrs implantable
H-890	-0.4589884877204895	▁ LB BB ▁QR s ▁implant able ▁cardio ver ter _ de fi br illa tor - C RT
D-890	-0.4589884877204895	LBBB QRs implantable cardioverter_defibrillator-CRT
P-890	-0.4123 -0.2855 -0.4939 -3.1652 -1.5940 -0.1348 -0.0077 -1.0607 -0.0585 -0.1840 -0.1316 -0.1833 -0.0085 -0.4909 -0.2744 -0.0144 -0.6401 -0.3727 -0.0196 -0.0788 -0.0277
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography cardiac cardiac_function
H-453	-0.4981405735015869	▁e cho card i ography ▁reduce d ▁cardiac _ ▁diameter s ▁b - tre ated ▁vehicle - tre ated ▁rat s
D-453	-0.4981405735015869	echocardiography reduced cardiac_ diameters b-treated vehicle-treated rats
P-453	-0.1736 -0.1021 -1.0253 -0.7738 -0.3813 -3.5063 -0.0062 -0.0747 -0.9706 -0.3012 -0.1732 -2.2182 -0.1033 -0.0021 -0.0250 -1.0620 -0.0438 -0.0035 -0.0553 -0.2189 -0.0200 -0.0637 -0.1529
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality_of_life functional_capacity
H-618	-0.5315680503845215	▁quality _ of _ life ▁functional _ capaci ty
D-618	-0.5315680503845215	quality_of_life functional_capacity
P-618	-1.0340 -0.9492 -0.1155 -0.0547 -1.3541 -0.1739 -0.5840 -0.2998 -0.7340 -0.4877 -0.0603
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic interatrial_shunting patients heart_failure_with_reduced_ejection_fraction
H-1950	-0.6790229082107544	▁ therapeut ic ▁left - to - right ▁inter at rial _ ▁sh unting ▁heart _ ▁failure ▁e je ction _ fraction
D-1950	-0.6790229082107544	therapeutic left-to-right interatrial_ shunting heart_ failure ejection_fraction
P-1950	-3.7957 -0.7623 -0.0742 -0.3119 -0.0224 -0.0876 -0.0378 -0.0062 -0.7657 -0.0645 -0.0509 -0.3651 -1.5221 -0.5921 -0.9608 -0.8320 -2.4698 -2.1757 -0.0695 -0.1247 -0.9794 -0.0092 -0.0606 -0.1563
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart_failure hypertension mitral_regurgitation mitral_stenosis medical_treatment heart_failure
H-336	-0.5107011198997498	▁heart _ ▁failure ▁severe ▁hyper tension ▁mit ral _ re gur gi tation ▁mit ral _ ▁sten osis
D-336	-0.5107011198997498	heart_ failure severe hypertension mitral_regurgitation mitral_ stenosis
P-336	-0.4575 -1.0816 -0.8455 -1.9391 -1.1321 -0.0037 -0.4420 -0.0150 -0.4974 -0.7419 -0.0025 -0.0470 -0.0018 -0.0329 -0.0152 -0.3787 -0.3804 -0.0031 -2.1069 -0.0895
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists renin-angiotensin-aldosterone sympathetic_nervous_systems clinical outcomes chf
H-636	-0.802462100982666	▁anta gon ists ▁re nin - angi oten sin - al do ster one ▁sympa the tic _ system ▁CHF
D-636	-0.802462100982666	antagonists renin-angiotensin-aldosterone sympathetic_system CHF
P-636	-1.6801 -0.1356 -1.1779 -0.0574 -0.0860 -0.0172 -0.0110 -0.0901 -1.6228 -0.7003 -0.2000 -3.2633 -1.3846 -0.1011 -0.0056 -0.0562 -0.1685 -0.1589 -4.8891 -1.7583 -0.0289 -0.0612
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced_pasp clinical prognostic pulmonary_hypertension patients right_ventricular_contractile_reserve
H-831	-0.7505107522010803	▁exercise - indu ced _ ▁PAS P ▁pulmonar y _ ▁hyper tension ▁vent ri cular _ contract ile _ ▁reserve
D-831	-0.7505107522010803	exercise-induced_ PASP pulmonary_ hypertension ventricular_contractile_ reserve
P-831	-0.6964 -0.3621 -0.0045 -0.0173 -1.1272 -0.8727 -0.7452 -0.6910 -0.0118 -0.8776 -0.3295 -0.0042 -3.8323 -0.5372 -0.1879 -0.2826 -1.2626 -3.5085 -0.8155 -0.2338 -0.0483 -0.0632
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients followed_up composite_primary_outcome cardiovascular_death stroke heart_failure myocardial_infarction
H-1650	-0.9374107122421265	▁cardiovascular _ ▁death ▁heart _ ▁failure ▁my o card ial _ in far ction
D-1650	-0.9374107122421265	cardiovascular_ death heart_ failure myocardial_infarction
P-1650	-2.7362 -1.1870 -2.4265 -4.9696 -0.3744 -1.6024 -0.2194 -0.0628 -0.3458 -0.0717 -0.2524 -0.4992 -0.0011 -0.0654 -0.0569 -0.1276
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients implantable_cardioverter-defibrillator heart_function_clinic university_health_network toronto canada
H-1861	-0.6293213367462158	▁implant able ▁cardio ver ter - de fi br illa tor ▁Heart _ ▁Fun ction _ ▁Clinic ▁university _ health _ net work Tor onto
D-1861	-0.6293213367462158	implantable cardioverter-defibrillator Heart_ Function_ Clinic university_health_networkToronto
P-1861	-1.6436 -0.0035 -0.5538 -0.0428 -0.5307 -0.2481 -0.0081 -0.1025 -0.9687 -0.1772 -0.0143 -0.4514 -0.1125 -1.4018 -0.0042 -0.5464 -0.3707 -4.6271 -0.3563 -0.8713 -0.5832 -0.6674 -0.4364 -1.1592 -0.0011 -1.0470 -0.0624
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk scn5a kv4.3 mrnas transient_receptor_potential_cation_channel_m7 trpm7 mrna
H-1086	-0.7531476020812988	▁per k _ activa tion ▁s CN 5 a ▁Kv 4.3 ▁channel ▁m RNA ▁trans ient _ ▁receptor ▁ cation ▁channel ▁m 7 TR PM 7 ▁channel ▁m RNA
D-1086	-0.7531476020812988	perk_activation sCN5a Kv4.3 channel mRNA transient_ receptor cation channel m7TRPM7 channel mRNA
P-1086	-1.3082 -0.3012 -2.4364 -0.5831 -0.0054 -1.1255 -0.3265 -0.1099 -0.3592 -0.6164 -0.2224 -0.0671 -0.0464 -0.0038 -0.3337 -0.0029 -1.2465 -0.5312 -5.4983 -0.1119 -1.7080 -2.3263 -0.1907 -2.1017 -0.0919 -1.1792 -0.2485 -0.0278 -0.0007 -0.0915 -0.1456
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization_therapy crt morbidity mortality chronic_systolic_heart_failure wide_qrs_complex
H-845	-0.7524356842041016	▁Card iac - re syn chron ization _ therapy ▁c RT ▁morbi d ity _ ▁mortal ity ▁chronic _ ▁sy sto lic _ heart _ ▁failure ▁QR S
D-845	-0.7524356842041016	Cardiac-resynchronization_therapy cRT morbidity_ mortality chronic_ systolic_heart_ failure QRS
P-845	-1.2719 -0.3976 -0.1220 -0.0158 -0.0169 -0.0013 -0.2219 -0.6861 -0.9835 -1.6482 -0.0394 -2.1538 -0.0097 -0.0935 -3.4381 -1.4367 -0.0027 -0.0923 -1.0375 -1.1013 -0.0981 -0.8512 -0.0575 -1.0913 -0.5633 -4.4034 -0.0382 -0.5000 -0.1505 -0.0497
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients systolic_hf cxl-1020 right_heart_filling_pressures systemic_vascular_resistance cardiac stroke_volume_index
H-423	-0.9488188028335571	▁sy sto lic _ HF ▁left _ right _ heart _ ▁fill ing _ ▁pressure s ▁system ic _ vas cular _ ▁resist ance ▁cardiac ▁stroke
D-423	-0.9488188028335571	systolic_HF left_right_heart_ filling_ pressures systemic_vascular_ resistance cardiac stroke
P-423	-0.0953 -0.3724 -0.0293 -0.8601 -0.0897 -5.2400 -2.6395 -1.5883 -0.8999 -3.8886 -1.6926 -0.1176 -0.0183 -0.5258 -0.3113 -1.9344 -0.0185 -0.0262 -0.4382 -1.0903 -0.0249 -0.7513 -0.4117 -0.0004 -0.0222 -2.7427 -0.6040 -0.1337
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf hf epidemiology rheumatic_fever
H-1799	-1.0357720851898193	▁ HF _ risk _ factor ▁ HF _ ▁epidemi ology ▁SH _ c d ▁rhe u matic _ ▁fe ver
D-1799	-1.0357720851898193	HF_risk_factor HF_ epidemiology SH_cd rheumatic_ fever
P-1799	-0.7224 -0.0399 -1.8000 -2.6472 -0.7229 -0.1757 -0.2784 -0.0307 -2.3648 -0.0834 -0.0076 -2.5321 -3.5132 -3.4794 -3.7809 -0.0289 -0.0233 -0.1746 -0.6486 -0.0574 -0.0089 -0.2978 -0.4048
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise training exercise exercise_capacity qol obese patients hfpef
H-1976	-0.6381101608276367	▁calor ic _ ▁restriction ▁aero bic _ ▁exercise _ exe rci se ▁Q OL
D-1976	-0.6381101608276367	caloric_ restriction aerobic_ exercise_exercise QOL
P-1976	-0.0593 -0.0627 -1.6546 -0.0382 -0.0725 -0.0128 -0.3107 -1.1533 -0.3426 -2.6662 -0.0025 -0.0659 -1.5778 -0.1358 -1.9750 -0.0799
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac myocyte-specific_mena_overexpression cardiac pathology
H-1813	-0.6368242502212524	▁mi ce ▁cardiac _ my o cy te - sensitiv ▁Men a _ ▁over expression ▁t g t et Men a ▁cardiac _ path ology
D-1813	-0.6368242502212524	mice cardiac_myocyte-sensitiv Mena_ overexpression tgtetMena cardiac_pathology
P-1813	-3.2898 -0.0122 -0.0081 -0.4407 -1.2988 -0.0964 -0.1947 -0.3345 -1.8387 -2.7064 -0.4712 -0.0266 -2.0900 -0.6885 -0.1130 -0.5415 -0.0461 -0.3908 -1.9007 -0.3701 -0.0113 -0.0064 -0.1127 -0.0684 -0.0058 -0.0343 -0.0969
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient patients heart_failure hospital discharge readmissions patient follow-up
H-722	-0.8469319939613342	▁out patient _ ▁assessment s ▁patients ▁heart _ ▁failure ▁hospital ▁dis charge ▁read missions
D-722	-0.8469319939613342	outpatient_ assessments patients heart_ failure hospital discharge readmissions
P-722	-1.0543 -0.0048 -1.3427 -0.2679 -0.0287 -1.4224 -2.3067 -0.2989 -2.1401 -0.4116 -0.3241 -0.0036 -1.5738 -0.0324 -2.2055 -0.1333
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline hgb correlated baseline kccq hgb exercise training hrqol
H-839	-0.5627580285072327	▁base line _ h gb ▁base line _ k cc q _ ▁scale s ▁exercise _ training ▁HR Qo L
D-839	-0.5627580285072327	baseline_hgb baseline_kccq_ scales exercise_training HRQoL
P-839	-0.0020 -0.0019 -0.7163 -2.5162 -0.0065 -0.0270 -0.0020 -0.6089 -1.7687 -0.0740 -0.7443 -0.4930 -0.0288 -0.0093 -1.8059 -0.5265 -1.3712 -1.4699 -0.0139 -0.1061 -0.0184 -0.0700
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms hfpef diastolic_filling_time heart_rate symptoms
H-1172	-0.5957255959510803	▁ HF p EF ▁dia sto lic _ ▁fill ing _ ▁time ▁control ling ▁heart _ ▁rate
D-1172	-0.5957255959510803	HFpEF diastolic_ filling_ time controlling heart_ rate
P-1172	-0.9362 -0.1327 -0.2444 -0.9616 -2.6323 -0.5145 -0.5030 -1.4388 -0.1301 -0.0080 -0.6045 -0.5324 -0.1645 -0.0415 -0.8958 -0.6361 -0.5095 -0.3470 -0.0859
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic_heart_failure hf hemodynamic syndrome dysfunction molecular_pathways
H-1472	-0.7110522389411926	▁chronic _ heart _ ▁failure _ HF ▁pure ly ▁hem o dynamic _ ▁disorder ▁syndrome ▁dys function ▁inter connect ed ▁molecular _ path ways
D-1472	-0.7110522389411926	chronic_heart_ failure_HF purely hemodynamic_ disorder syndrome dysfunction interconnected molecular_pathways
P-1472	-0.1728 -0.3082 -1.5847 -0.2087 -1.9155 -3.5111 -0.2965 -3.1637 -0.1316 -0.1930 -0.0992 -0.0012 -0.5163 -1.8720 -0.6050 -0.4183 -0.1501 -0.6187 -0.0146 -0.0328 -1.1581 -1.2460 -0.1092 -0.0054 -0.0584 -0.0968
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international_right_heart_foundation_working_group step syndrome right_heart_failure
H-1458	-1.2671446800231934	▁international ▁right _ heart _ ▁Foundation _ work ing _ group
D-1458	-1.2671446800231934	international right_heart_ Foundation_working_group
P-1458	-4.0581 -0.9277 -0.1054 -1.9625 -0.2592 -3.6271 -1.5070 -0.1160 -0.1943 -0.5923 -0.0770 -2.8507 -0.1957
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications patients heart_failure_and_reduced_ejection_fraction outpatient
H-667	-0.47079622745513916	▁guide line - re com mend ed ▁medication s ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction ▁out patient
D-667	-0.47079622745513916	guideline-recommended medications heart_ failure reduced ejection_fraction outpatient
P-667	-1.2828 -0.0025 -0.3668 -0.0022 -0.0039 -0.0018 -0.0161 -1.4197 -0.2511 -0.9788 -1.0774 -1.0131 -0.2312 -0.0116 -0.8125 -0.2989 -0.0448 -1.1906 -0.0161 -0.3895 -0.0059 -1.2579 -0.1532
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate unfolded_protein_response upr scn5a remodeling hf
H-1081	-0.4192539155483246	▁tru nca ted ▁na + ▁channel s ▁un fold ed _ ▁protein _ ▁response ▁u PR ▁s CN 5 a ▁electric _ ▁remodel ing ▁ HF
D-1081	-0.4192539155483246	truncated na+ channels unfolded_ protein_ response uPR sCN5a electric_ remodeling HF
P-1081	-0.7097 -0.0068 -0.0404 -0.4618 -2.5053 -0.6524 -0.2163 -0.0084 -0.0003 -0.0070 -0.3302 -1.1626 -1.0676 -0.5303 -0.5053 -0.0168 -0.7548 -0.3703 -0.0300 -0.8865 -0.0074 -0.5970 -0.6885 -0.0089 -0.0714 -0.0016 -0.0399 -0.0619
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac_hypertrophy pressure-overload abdominal_aortic_constriction aac
H-1780	-0.45036494731903076	▁cardiac _ ▁hyper trop hy ▁pressure - over load ▁abdominal _ a or tic _ con stri ction
D-1780	-0.45036494731903076	cardiac_ hypertrophy pressure-overload abdominal_aortic_constriction
P-1780	-0.7678 -0.6922 -0.8939 -0.0109 -0.3565 -0.0262 -0.1887 -0.0023 -0.0004 -0.0959 -0.7352 -0.6805 -2.4735 -0.4171 -0.2247 -0.0749 -0.0235 -0.0224 -1.1818 -0.1389
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk_stratification antiplatelet_agents combination anticoagulants vascular_diseases
H-1355	-0.612921416759491	▁risk _ ▁strat ification ▁anti plate let _ agent ▁antico a gul ants ▁vas cular _ مرض s
D-1355	-0.612921416759491	risk_ stratification antiplatelet_agent anticoagulants vascular_مرضs
P-1355	-0.5491 -1.5286 -0.0391 -0.0997 -0.0107 -0.1269 -2.5916 -0.3533 -0.7732 -0.7478 -0.5626 -0.2125 -0.0134 -1.5822 -0.0197 -0.6283 -1.8493 -0.3661 -0.1046 -0.0997
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol lv_contractile_function xo-mediated_ros myofilament sensitivity
H-477	-0.46094608306884766	▁allo puri nol ▁LV ▁contract ile _ function ▁ XO - media ted ▁ ROS ▁my o fila ment _ ca (2 +)
D-477	-0.46094608306884766	allopurinol LV contractile_function XO-mediated ROS myofilament_ca(2+)
P-477	-0.4260 -0.0236 -0.0696 -0.1335 -0.0141 -1.0690 -1.3936 -0.2178 -1.0708 -0.1441 -0.0076 -0.1470 -0.0166 -0.4496 -0.1558 -1.3995 -0.0134 -0.1282 -0.1428 -0.7859 -0.0231 -1.0677 -0.0036 -2.4320 -0.1886
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial_index pulse-wave coronary_artery_calcium_scores
H-1562	-0.4617605209350586	▁cru de ▁an kle - bra chi al _ index ▁puls e - wa ve _ velo city ▁corona ry _ ▁arter y ▁calci um
D-1562	-0.4617605209350586	crude ankle-brachial_index pulse-wave_velocity coronary_ artery calcium
P-1562	-0.5157 -0.1280 -0.0449 -0.0514 -0.0682 -0.1028 -1.1140 -0.0872 -0.9032 -0.2123 -0.0147 -0.0374 -0.0652 -0.0044 -0.0470 -0.6594 -0.1572 -0.0863 -0.0016 -0.1389 -0.7547 -5.3335 -0.5406 -0.2295 -0.0179 -1.0429 -0.1086
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber_dynamics myofiber_shortening emd dyssynchronous_hf
H-1156	-0.3109935224056244	▁my o fi ber ▁dynamic s ▁my o fi ber ▁short en ing ▁prolong ed ▁EM d ▁dys syn chron ous ▁ HF
D-1156	-0.3109935224056244	myofiber dynamics myofiber shortening prolonged EMd dyssynchronous HF
P-1156	-0.1096 -0.2763 -0.1791 -0.0198 -0.8426 -0.0909 -1.5952 -0.0322 -0.0636 -0.0035 -0.6486 -0.0571 -0.0264 -1.3285 -0.0081 -0.6086 -1.0381 -0.0122 -0.0010 -0.0002 -0.2276 -0.4661 -0.0002 -0.0405 -0.0989
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan_failure hemodynamically heart_failure systemic_vascular_resistance svr cardiac_index
H-225	-0.6047530174255371	▁Font an _ ▁failure ▁hem o dynamic ally ▁traditional ▁heart _ ▁failure ▁low ▁system ic _ ▁vas cular _ ▁resist ance ▁s VR _ index ▁pres er ved _ ▁cardiac _ index
D-225	-0.6047530174255371	Fontan_ failure hemodynamically traditional heart_ failure low systemic_ vascular_ resistance sVR_index preserved_ cardiac_index
P-225	-0.0946 -0.1755 -1.4086 -1.2054 -2.2189 -0.0078 -0.0005 -1.1952 -2.1002 -0.2083 -0.3657 -0.0962 -0.6933 -0.0868 -0.0791 -0.2209 -2.7728 -0.1629 -0.2931 -1.0541 -0.0017 -1.4488 -0.0450 -1.9443 -0.5015 -0.0057 -0.0568 -0.0195 -0.2979 -0.2883 -0.7023 -0.6699 -0.0535 -0.0864
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow_up ffm patients
H-16	-0.9861059188842773	▁follow ▁up ▁body _ weight ▁FM ▁f FM
D-16	-0.9861059188842773	follow up body_weight FM fFM
P-16	-1.3387 -0.0515 -0.1780 -1.0743 -0.0579 -2.4838 -1.3494 -1.3328 -1.9494 -0.0453
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical activity crf hf mortality
H-1776	-0.6699018478393555	▁physical _ activ ity ▁ HF _ ▁mortal ity
D-1776	-0.6699018478393555	physical_activity HF_ mortality
P-1776	-0.0990 -1.0994 -0.4081 -0.2114 -3.2129 -0.5096 -1.0057 -0.6790 -0.0075 -0.0499 -0.0865
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential_analysis cluster_analysis
H-1610	-0.698466956615448	▁data ▁process ing ▁differenti al _ ▁analysis ▁package s ▁R ▁Clu ster
D-1610	-0.698466956615448	data processing differential_ analysis packages R Cluster
P-1610	-1.8237 -0.8553 -0.0134 -0.4410 -0.0005 -0.7104 -1.5165 -0.1452 -0.0029 -1.2091 -1.0915 -0.0233 -1.8948 -0.0509
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization medicare hospital medicare policy
H-1715	-0.49912357330322266	▁re hospital ization ▁Medica re _ hospital _ ▁claims ▁Medica re ▁post - a cute _ care _ policy
D-1715	-0.49912357330322266	rehospitalization Medicare_hospital_ claims Medicare post-acute_care_policy
P-1715	-1.1970 -0.0154 -0.1091 -0.0103 -0.0007 -1.1635 -0.1974 -0.4990 -0.1060 -0.2028 -0.0043 -0.1570 -0.0048 -0.0052 -0.0023 -0.1667 -3.7132 -0.8308 -0.8726 -0.8748 -0.3486
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients heart_transplant prospectively ecct
H-710	-1.0507254600524902	▁isola ted _ heart _ ▁transplant
D-710	-1.0507254600524902	isolated_heart_ transplant
P-710	-3.4674 -0.0356 -0.2307 -1.9828 -0.5035 -0.4329 -1.6565 -0.0964
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate_ratio therapy patient comorbidities
H-663	-0.9480213522911072	▁media n ▁rate _ rati o
D-663	-0.9480213522911072	median rate_ratio
P-663	-0.7118 -0.0939 -1.6273 -0.4708 -0.1156 -0.0486 -4.1437 -0.3724
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic patients severe_heart_failure financial
H-1242	-1.5480608940124512	▁ therapeut ic _ strate gy ▁AF ▁severe _ heart _ ▁failure ▁financial
D-1242	-1.5480608940124512	therapeutic_strategy AF severe_heart_ failure financial
P-1242	-2.7856 -0.0710 -0.0406 -1.6278 -0.6307 -2.9188 -4.9000 -3.0876 -0.4672 -0.6382 -1.1704 -2.1340 -0.0209 -2.6252 -0.1029
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians patients heart_failure equitable therapeutic
H-1823	-1.3311350345611572	▁physician s ▁advanced _ heart _ ▁failure
D-1823	-1.3311350345611572	physicians advanced_heart_ failure
P-1823	-1.7980 -0.1572 -2.5732 -0.4343 -1.6493 -0.5621 -3.1032 -1.5442 -0.1589
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart_failure compliance etidronate alendronate
H-1543	-0.46804678440093994	▁risk _ of _ heart _ ▁failure ▁re fill ▁compliance ▁et id rona te ▁ale ndr onate
D-1543	-0.46804678440093994	risk_of_heart_ failure refill compliance etidronate alendronate
P-1543	-0.4011 -1.3580 -0.2556 -0.1875 -0.2001 -0.2670 -1.4505 -0.0687 -0.0015 -0.9209 -0.0125 -0.6820 -0.0220 -0.0110 -2.4913 -0.0473 -0.1539 -0.2582 -0.1036
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis metabolic_exercise cardiac kidney
H-1762	-0.6225447058677673	▁metabol ic ▁exercise ▁cardiac ▁ki dne y ▁index ▁score
D-1762	-0.6225447058677673	metabolic exercise cardiac kidney index score
P-1762	-1.9800 -0.0071 -1.7282 -0.0122 -0.8083 -0.0178 -0.0148 -0.4445 -1.5625 -0.1299 -0.1426
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular_pathways patients chronic_heart_failure chf
H-249	-1.111777663230896	▁et ▁HD L - media ted _ protec ive _ effect s ▁molecular _ path ways ▁chronic _ heart _ ▁failure
D-249	-1.111777663230896	et HDL-mediated_protecive_effects molecular_pathways chronic_heart_ failure
P-249	-2.7597 -6.7663 -0.7525 -0.2062 -0.0306 -0.0492 -0.7046 -1.5921 -0.4829 -1.0246 -0.2440 -0.1921 -0.5582 -0.2182 -0.0813 -0.0132 -1.5817 -0.0863 -1.3436 -0.5023 -5.6166 -0.6938 -0.0710
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic_receptor_blocker_therapy myocardial_perfusion neoangiogenesis heart
H-451	-0.6267366409301758	▁β - ad r energi c _ ▁receptor _ block er _ therapy ▁my o card ial _ per fusion ▁neo angi ogen es is ▁fail ing _ heart
D-451	-0.6267366409301758	β-adrenergic_ receptor_blocker_therapy myocardial_perfusion neoangiogenesis failing_heart
P-451	-0.0592 -0.0886 -0.0137 -0.4526 -2.0262 -0.1000 -0.9602 -0.7248 -0.3692 -0.8879 -0.8971 -1.0232 -1.1915 -1.0224 -0.0470 -1.2281 -0.0886 -0.2155 -0.3597 -0.0017 -0.0050 -0.5936 -2.5736 -0.1589 -3.3700 -0.0037 -0.0103 -0.4109 -0.2799 -0.0881 -0.1778
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary_endpoint intermacs interagency_registry_for_mechanically_assisted_circulatory_support
H-1996	-0.6082375049591064	▁inter age ncy _ ▁Registr y ▁mechanic ally _ assist ed _ ▁Circula tory _ support
D-1996	-0.6082375049591064	interagency_ Registry mechanically_assisted_ Circulatory_support
P-1996	-2.8857 -3.7834 -0.0147 -0.2258 -0.9207 -0.0247 -0.6289 -0.1525 -0.2897 -0.0166 -0.0500 -0.0849 -0.3178 -0.0121 -0.5509 -0.6654 -0.2307 -0.0938
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1260	-0.6370184421539307	▁Meta - analys is ▁left ▁vent ri cular _ e je ction _ fraction ▁left ▁vent ri cular _ dia sto lic _ ▁end _ ▁diameter
D-1260	-0.6370184421539307	Meta-analysis left ventricular_ejection_fraction left ventricular_diastolic_ end_ diameter
P-1260	-5.8432 -0.0721 -0.0623 -0.2299 -1.0200 -2.5455 -0.2271 -0.2596 -0.2288 -0.8110 -0.1689 -0.0766 -0.2710 -0.0370 -0.0332 -1.5113 -0.1833 -0.0710 -0.1522 -0.1892 -0.0558 -0.3243 -0.2099 -1.2048 -0.4970 -1.2951 -0.1171 -0.1397
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients left_ventricular_ejection_fraction heart_failure_with_preserved_ejection_fraction hfpef
H-1887	-0.7628794312477112	▁left ▁vent ri cular _ e je ction _ fraction ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-1887	-0.7628794312477112	left ventricular_ejection_fraction heart_ failure preserved_ejection_fractionHFpEF
P-1887	-2.0337 -4.0892 -0.3603 -0.1894 -0.2543 -0.6546 -0.1463 -0.1876 -0.5089 -0.0141 -4.0746 -0.4852 -2.6236 -2.5153 -0.2387 -0.0662 -0.1517 -0.4883 -0.6360 -0.0987 -0.3394 -0.0725 -0.1794 -0.0043 -0.0208 -0.0448 -0.1198
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence clinical outcomes concentric_left_ventricular_hypertrophy heart_failure_with_preserved_ejection_fraction
H-1523	-1.250972867012024	▁pre val ence ▁ecce n tric ▁concentr ic _ centr ic _ ▁left _ thrombophlebitis _ ▁hyper trop hy _ heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-1523	-1.250972867012024	prevalence eccentric concentric_centric_ left_thrombophlebitis_ hypertrophy_heart_ failure preserved ejection_fraction
P-1523	-5.5896 -0.0087 -0.0650 -1.4658 -0.0095 -0.0035 -3.1831 -0.0116 -0.7037 -5.5313 -0.0256 -0.3752 -1.6895 -0.1562 -6.8729 -1.3584 -4.5097 -0.0350 -0.9638 -3.0707 -1.8496 -0.6166 -1.2202 -0.0093 -0.0626 -0.0482 -0.8389 -0.1204 -0.0504 -0.6879 -0.0008 -0.0692 -0.0792
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a angii hypoxia expression upr downregulation
H-1085	-0.740327775478363	▁s CN 5 a ▁ang II ▁hypo xia ▁ex ogen ous _ variant s ▁u PR ▁down regul ation ▁na +
D-1085	-0.740327775478363	sCN5a angII hypoxia exogenous_variants uPR downregulation na+
P-1085	-1.4291 -1.6366 -0.5793 -0.7133 -0.5897 -0.3626 -0.1595 -0.0958 -0.0488 -0.0016 -0.0305 -2.0740 -0.4770 -0.1536 -0.4991 -0.0071 -0.0839 -0.0242 -0.0308 -0.3794 -5.4458 -1.7898 -0.4161
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas hf hyperkalemia hypokalemia spironolactone clinical
H-1708	-0.652925431728363	▁ HF ▁hyper kal emia ▁hypo kal emia ▁spi rono lac tone
D-1708	-0.652925431728363	HF hyperkalemia hypokalemia spironolactone
P-1708	-2.0603 -0.0560 -0.8520 -0.0889 -0.0133 -0.6531 -2.7239 -0.0546 -0.0213 -0.0039 -0.0319 -0.0173 -2.4289 -0.1356
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic_function hfpef patients long_axis_function exercise
H-1888	-1.0780222415924072	▁sy sto lic _ function ▁ HF p EF ▁long ▁a xis _ function ▁exercise
D-1888	-1.0780222415924072	systolic_function HFpEF long axis_function exercise
P-1888	-4.1990 -2.6834 -1.4709 -1.0635 -0.4253 -0.1052 -0.0036 -0.0479 -0.0769 -3.7978 -1.6211 -0.0235 -1.2359 -0.4136 -0.9562 -0.0587 -0.1439
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors g-protein-coupled_receptor kinase-2 downregulation
H-1407	-0.5538095235824585	▁receptor s ▁g - prote in - co up led _ ▁receptor _ ▁kina se -2 ▁desen sit ization ▁down regul ation
D-1407	-0.5538095235824585	receptors g-protein-coupled_ receptor_ kinase-2 desensitization downregulation
P-1407	-2.4108 -1.0824 -0.6361 -0.1011 -0.2333 -0.0539 -0.1662 -0.0017 -0.0526 -0.0116 -0.6934 -0.1826 -1.4642 -0.6497 -0.0665 -1.5493 -2.1569 -0.1995 -0.0749 -0.0250 -0.0237 -0.0147 -1.3036 -0.1378
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp nonterminal_epitopes central_glycosylated_region
H-1522	-0.35040801763534546	▁NT - pro b NP _ as say ▁non termin al _ ▁e pito pes ▁central ▁gly cos yla ted _ region
D-1522	-0.35040801763534546	NT-probNP_assay nonterminal_ epitopes central glycosylated_region
P-1522	-0.2440 -0.0324 -0.0020 -1.2017 -0.3532 -1.5921 -0.1721 -0.0023 -0.2546 -0.6061 -0.0009 -0.5785 -0.6283 -0.0212 -0.0943 -0.0517 -0.0499 -0.0102 -0.3010 -0.0351 -0.3701 -0.3625 -1.2323 -0.2133
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo dopamine nesiritide secondary_end_points renal_function clinical outcomes
H-82	-0.3907245397567749	▁low - dos e ▁dop amine ▁nesi riti de ▁de con gestion ▁renal _ function
D-82	-0.3907245397567749	low-dose dopamine nesiritide decongestion renal_function
P-82	-0.6144 -0.0540 -0.7472 -0.1559 -1.3681 -0.1731 -0.0942 -0.0033 -0.2467 -0.2903 -0.0002 -0.0012 -0.0021 -0.8100 -1.1193 -0.9340 -0.0281
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate_logistic_regression_analysis bnp patients diastolic_dysfunction
H-1571	-1.5423451662063599	▁logistic ▁re gression
D-1571	-1.5423451662063599	logistic regression
P-1571	-2.9876 -0.8698 -0.0015 -3.7507 -0.1021
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart patients hfpef hf_with_reduced_ejection_fraction hfref
H-240	-0.8996204137802124	▁H ART ▁ HF p EF ▁ HF _ e je ction _ fraction HF r EF
D-240	-0.8996204137802124	HART HFpEF HF_ejection_fractionHFrEF
P-240	-1.8780 -0.0042 -0.3263 -0.0049 -3.3213 -0.1859 -0.4525 -0.0145 -4.6747 -2.8093 -1.1146 -0.1782 -1.1016 -0.1638 -0.1940 -0.2799 -0.0397 -0.2058 -0.1436
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf multivariate-adjusted_odds_ratio mortality hazard_ratio mortality
H-1312	-0.752585768699646	▁con current _ HF ▁odds _ rati o ▁28- day _ ▁mortal ity ▁hazard _ rati o
D-1312	-0.752585768699646	concurrent_HF odds_ratio 28-day_ mortality hazard_ratio
P-1312	-0.6699 -0.0009 -0.9359 -0.0436 -5.3019 -0.7444 -0.2140 -0.0704 -1.0838 -0.0816 -0.5837 -0.0886 -0.0154 -0.3343 -0.6456 -0.0158 -0.0172 -3.1094 -0.3429
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular_matrix left_ventricular biopsies tissuefaxs correlated t1_time
H-741	-0.5026091933250427	▁Extra cel lular _ ▁matri x ▁left _ ▁vent ri cular _ ▁bio psi es ▁T issue FAX S ▁technology
D-741	-0.5026091933250427	Extracellular_ matrix left_ ventricular_ biopsies TissueFAXS technology
P-741	-1.8097 -0.0278 -0.0772 -0.3866 -0.1451 -0.0775 -0.0156 -0.2707 -3.1140 -0.1760 -0.0467 -0.1206 -1.1717 -0.3560 -0.0083 -1.0040 -0.0045 -0.0955 -1.2190 -0.0605 -0.7466 -0.1237
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left_ventricular_assist_devices lvads patients heart_failure incidence pump_dysfunction pump
H-773	-0.7914039492607117	▁left ▁vent ri cular _ assist _ ▁devices ▁l VAD s ▁patients ▁advanced _ heart _ ▁failure ▁pump _ ▁replace ment
D-773	-0.7914039492607117	left ventricular_assist_ devices lVADs patients advanced_heart_ failure pump_ replacement
P-773	-0.0607 -2.1052 -0.2387 -0.0379 -0.1803 -0.0185 -1.6708 -1.5579 -1.8758 -0.0085 -0.0378 -3.3960 -0.2856 -0.5221 -1.0464 -0.4657 -2.3859 -0.0360 -0.5121 -1.5024 -0.0270 -0.1310 -0.0998
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone_morphogenetic_protein_4 expression rrna_transcription shift heterochromatic_chromatin
H-98	-0.5038890242576599	▁defect s ▁per tur bed ▁bone ▁mor pho gene tic _ ▁protein _ 4 ▁expression ▁r RNA ▁tran scription ▁hetero ch ro matic _ ▁chr omat in
D-98	-0.5038890242576599	defects perturbed bone morphogenetic_ protein_4 expression rRNA transcription heterochromatic_ chromatin
P-98	-4.3464 -0.1284 -0.0644 -0.0009 -0.0139 -0.0211 -0.8819 -1.0246 -1.1107 -0.5066 -0.2090 -0.8924 -1.9459 -0.6961 -0.0106 -0.0675 -0.0019 -0.1001 -0.0397 -1.2890 -0.0433 -0.0395 -0.1505 -0.4684 -0.1926 -0.0089 -0.1896 -0.1165 -0.0524
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated resistin biomarker anthracycline-induced_cardiotoxicity heart_failure macrophages
H-939	-0.4099203050136566	▁eleva ted ▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic ity ▁heart _ ▁failure ▁macro pha ges
D-939	-0.4099203050136566	elevated resistin anthracycline-induced_ cardiotoxicity heart_ failure macrophages
P-939	-0.0313 -0.0451 -0.5786 -0.0571 -0.0191 -0.0034 -0.4446 -0.9876 -0.5301 -0.0023 -0.0112 -0.8540 -0.0857 -0.4865 -0.0458 -0.4440 -0.6371 -3.8757 -0.1745 -0.0078 -0.0540 -0.0205 -0.0321
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin_cytoskeleton mitochondrial_function metabolism glycolysis gluconeogenesis citrate_cycle
H-873	-0.3897625207901001	▁act in _ ▁cy tos kelet on ▁mito cho ndri al _ function ▁intermedi ate _ ▁metabolism ▁gly col ysis _ glu cone ogen es is ▁cit rate
D-873	-0.3897625207901001	actin_ cytoskeleton mitochondrial_function intermediate_ metabolism glycolysis_gluconeogenesis citrate
P-873	-0.0071 -0.0641 -1.1961 -0.0572 -0.3535 -0.0091 -0.0431 -0.0054 -0.5379 -0.0936 -0.0123 -0.6061 -0.5411 -0.0871 -0.0139 -1.1882 -0.2922 -0.0015 -0.0077 -0.6274 -1.5599 -0.2588 -0.1358 -1.3548 -0.0349 -1.2212 -0.0023 -0.0050 -1.2955 -0.0800
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced_hf cxl-1020 contractility end-systolic_elastance venoarterial_dilation
H-421	-0.36962777376174927	▁ta chy pac ing - indu ced ▁ HF ▁contract ility ▁end - sy sto lic ▁elastan ce ▁ve no arte rial ▁di lation
D-421	-0.36962777376174927	tachypacing-induced HF contractility end-systolic elastance venoarterial dilation
P-421	-2.4023 -0.1924 -0.0021 -0.0260 -0.1486 -0.0048 -0.0060 -0.1079 -0.0038 -0.2717 -0.0286 -0.1829 -0.0143 -1.3266 -1.0529 -0.5766 -0.6936 -0.1848 -0.0011 -0.0381 -0.0595 -0.0415 -2.0526 -0.0012 -0.0496 -0.1410
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable_models st2 outcomes clinical amino-terminal_pro-b-type_natriuretic_peptide
H-704	-0.3790985643863678	▁ST 2 ▁clinic al _ ▁variable s ▁amino - termin al _ pro - B - type ▁na tri ure tic _ pe pti de
D-704	-0.3790985643863678	ST2 clinical_ variables amino-terminal_pro-B-type natriuretic_peptide
P-704	-1.4443 -0.0685 -2.9465 -0.0125 -0.6831 -0.3883 -0.0525 -0.0053 -0.0319 -0.5101 -0.0016 -0.9918 -0.3428 -0.1155 -0.5032 -0.1214 -0.0229 -0.0180 -0.0257 -0.2141 -0.4926 -0.4100 -0.1981 -0.0452 -0.4201 -0.1038 -0.0658
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal diagnostic clinical
H-1304	-0.38877421617507935	▁diagnostic _ ▁approach es ▁clinic al _ ▁trial s
D-1304	-0.38877421617507935	diagnostic_ approaches clinical_ trials
P-1304	-0.4875 -0.7883 -1.2930 -0.0443 -0.0897 -0.0120 -0.3351 -0.0748 -0.0176 -1.0907 -0.0435
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up patients
H-1538	-0.6115338206291199	▁ale ndr onate ▁et id rona te ▁ra lo xi fen e - tre ated
D-1538	-0.6115338206291199	alendronate etidronate raloxifene-treated
P-1538	-5.1373 -0.0391 -0.2075 -0.6768 -0.5898 -0.0120 -0.0212 -0.0227 -0.0157 -0.0825 -1.3567 -0.0256 -1.1215 -0.0098 -0.1807 -0.8202 -0.0769
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable patients qrs_duration
H-891	-0.2813917398452759	▁implant able _ ▁cardio ver ter _ de fi br illa tor - C RT ▁non - LB BB ▁QR S ▁du ration
D-891	-0.2813917398452759	implantable_ cardioverter_defibrillator-CRT non-LBBB QRS duration
P-891	-0.4432 -0.0049 -0.7277 -0.7113 -0.0489 -0.2241 -0.1389 -0.1905 -0.0226 -0.8209 -0.1942 -0.0165 -0.4488 -0.7878 -0.0867 -0.2896 -0.0061 -0.0073 -0.2838 -0.0193 -0.5267 -0.7778 -0.0297 -0.1938 -0.0339
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq patients hfpef
H-790	-0.6837891340255737	▁k cc q _ ▁domain s ▁ HF p EF ▁c ron bach
D-790	-0.6837891340255737	kccq_ domains HFpEF cronbach
P-790	-1.2048 -0.0731 -0.6088 -1.5512 -0.3000 -0.0203 -0.4383 -0.0596 -0.0490 -0.5810 -3.6256 -0.0030 -0.0013 -1.6244 -0.1164
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change correlation hospitals longitudinal
H-138	-2.2269253730773926	▁ metric
D-138	-2.2269253730773926	metric
P-138	-3.4088 -0.0949 -4.8880 -0.5160
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin sitagliptin follow-up
H-1833	-0.9225038290023804	▁sax ag lip tin ▁si tag lip tin ▁follow - up _ data ▁pair wise
D-1833	-0.9225038290023804	saxagliptin sitagliptin follow-up_data pairwise
P-1833	-0.0291 -0.0615 -2.2001 -3.5240 -1.1877 -0.0799 -0.7149 -2.1377 -3.9014 -0.0519 -0.0123 -0.4428 -0.4175 -0.0217 -0.3280 -0.4814 -0.0906
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia medline cochrane_library
H-31	-0.615175724029541	▁an emia ▁ir on _ de fici en cy ▁MED line ▁co ch rane _ ▁Library
D-31	-0.615175724029541	anemia iron_deficiency MEDline cochrane_ Library
P-31	-4.7885 -0.0219 -0.9686 -0.0815 -0.1002 -0.1181 -0.0018 -0.6878 -0.0441 -1.2850 -1.0174 -0.1874 -0.0042 -0.0018 -1.3457 -0.2144 -0.0323 -0.1725
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley randomized acf allopurinol
H-473	-0.41575485467910767	▁Spr a gue - Da w ley ▁rat s ▁sham ▁a CF ▁allo puri nol
D-473	-0.41575485467910767	Sprague-Dawley rats sham aCF allopurinol
P-473	-0.2201 -0.0649 -0.0075 -0.0468 -0.2743 -0.0038 -0.0072 -2.3556 -0.0296 -0.0678 -2.4798 -0.0533 -0.1230 -0.0107 -0.0584 -1.1073 -0.1579
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 sst2 odds_ratio cardiovascular_event
H-408	-1.119617223739624	▁s ST 2 ▁low - dos e _ ▁BB ▁cardiovascular _ event
D-408	-1.119617223739624	sST2 low-dose_ BB cardiovascular_event
P-408	-0.2790 -2.0251 -0.7671 -2.8877 -0.0634 -2.1613 -0.1002 -1.7537 -1.9447 -1.0552 -0.7753 -1.6331 -0.1259 -0.1030
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 myocardial_collagen myocardial
H-1064	-0.8056836128234863	▁my o card ial _ ▁collage n ▁traditional ▁my o card ial ▁de lay ed _ ▁enhance ment _ ▁imagin g
D-1064	-0.8056836128234863	myocardial_ collagen traditional myocardial delayed_ enhancement_ imaging
P-1064	-3.5940 -0.2388 -1.3321 -0.1127 -0.2207 -0.2400 -0.2285 -4.9840 -0.5836 -0.0523 -1.1965 -0.0789 -2.7759 -0.0001 -0.0113 -0.2367 -1.4171 -0.0260 -0.8533 -0.2876 -0.0039 -0.0382 -0.0186
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical biomedical patients dcm heart_failure pubmed
H-1259	-0.9657835960388184	▁bio medic al _ ▁treatment ▁d CM ▁heart _ ▁failure
D-1259	-0.9657835960388184	biomedical_ treatment dCM heart_ failure
P-1259	-0.2026 -0.0287 -0.0010 -2.7915 -1.7168 -1.1797 -0.1994 -2.2777 -0.4063 -1.8564 -0.8484 -0.0809
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine bnp furosemide dobutamine norepinephrine outcome
H-587	-0.49337878823280334	▁se rum ▁levels ▁creati nine ▁b NP ▁fur os em ide _ ▁dose ▁oxygen ▁flow ▁dobu tamine ▁no re pine ph rine
D-587	-0.49337878823280334	serum levels creatinine bNP furosemide_ dose oxygen flow dobutamine norepinephrine
P-587	-1.0286 -0.0007 -3.0181 -0.2710 -0.0057 -2.1170 -0.2514 -0.0032 -0.1241 -0.0535 -0.2811 -1.6949 -0.4800 -0.0594 -0.2375 -0.1197 -0.1040 -0.0850 -0.0707 -0.0461 -0.1278 -0.0100 -1.5917 -0.0596
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular_pacing bivp cardiac_output cardiac surgery patients
H-319	-0.9886182546615601	▁bi ven tri cular _ pa cing ▁bi VP ▁cardiac _ co
D-319	-0.9886182546615601	biventricular_pacing biVP cardiac_co
P-319	-0.2162 -0.2170 -0.9995 -0.3897 -0.2640 -0.2714 -0.0426 -1.6894 -0.1511 -0.0360 -0.7290 -7.2806 -1.4497 -0.1047
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart_failure hf therapies outcomes patients hf preserved_left_ventricular_ejection_fraction lvef
H-111	-0.6819197535514832	▁con tempor ary _ heart _ ▁failure ▁ HF ▁ therapie s ▁ HF ▁pres er ved ▁left _ ▁vent ri cular _ e je ction _ fraction LV EF
D-111	-0.6819197535514832	contemporary_heart_ failure HF therapies HF preserved left_ ventricular_ejection_fractionLVEF
P-111	-0.1464 -0.0000 -0.0023 -0.2147 -0.5817 -0.1433 -2.4599 -1.2154 -0.1043 -2.5125 -0.0531 -0.0115 -1.6606 -0.3104 -0.5772 -0.0678 -0.0228 -0.1348 -0.2523 -6.4365 -0.8136 -0.5920 -0.2483 -1.1394 -0.4333 -0.4413 -0.7759 -0.2219 -0.1051 -0.0012 -0.0192 -0.1229
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients systolic_hf the_danish_heart_failure_database esrd danish_registry_on_dialysis
H-389	-0.6127229332923889	▁sy sto lic _ HF ▁Danish _ heart _ fail ure ▁ES RD ▁Danish _ ▁Registr y _ on _ Dia lys is
D-389	-0.6127229332923889	systolic_HF Danish_heart_failure ESRD Danish_ Registry_on_Dialysis
P-389	-1.5532 -0.3552 -0.1636 -0.5207 -0.1991 -1.0302 -0.8320 -2.0236 -0.1392 -0.4861 -0.0517 -2.2498 -0.0908 -0.4156 -0.7277 -0.7664 -0.0273 -0.5656 -0.1467 -0.2902 -0.8867 -0.3583 -1.1978 -0.1284 -0.1120
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy trastuzumab comorbidities chf international_classification_of_diseases healthcare_common_procedure_coding_system_codes
H-674	-0.4805879592895508	▁tras tuz um ab _ ▁use ▁como rbi di ties ▁CHF ▁international _ ▁Classifica tion _ of _ ▁Disease s ▁health care ▁Common _ procedure _ co ding _ system ▁code s
D-674	-0.4805879592895508	trastuzumab_ use comorbidities CHF international_ Classification_of_ Diseases healthcare Common_procedure_coding_system codes
P-674	-1.0156 -0.0030 -0.0154 -0.0067 -1.6126 -1.3842 -1.9566 -0.0020 -0.0422 -0.0129 -1.3512 -2.5343 -0.3040 -0.7762 -0.0035 -0.2031 -0.0106 -0.2365 -0.1095 -0.0066 -0.5568 -0.0842 -0.4609 -0.0649 -0.8064 -0.7392 -0.5907 -0.0161 -0.4756 -0.0646 -0.7367 -0.0321 -0.0543 -0.0711
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation consultation consultation operation
H-1283	-1.3399126529693604	▁transplant ation
D-1283	-1.3399126529693604	transplantation
P-1283	-1.3054 -0.0170 -3.8459 -0.1913
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths crt hazard_ratio
H-853	-1.037835955619812	▁c RT _ group ▁hazard _ ▁ratio
D-853	-1.037835955619812	cRT_group hazard_ ratio
P-853	-1.3192 -0.7830 -1.2558 -1.3236 -2.0649 -0.4484 -0.5435 -1.4668 -0.1353
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones adipokines fat_free_mass ffm fat_mass
H-11	-0.8805760741233826	▁neuro hormon es ▁adi pok ines ▁body _ ▁composition ▁progressive _ rati o ▁fat _ free ▁mass FM
D-11	-0.8805760741233826	neurohormones adipokines body_ composition progressive_ratio fat_free massFM
P-11	-0.0544 -0.0389 -0.1281 -0.1095 -0.0336 -0.0089 -0.0806 -1.9562 -0.5149 -3.0777 -1.2296 -4.2170 -0.0303 -2.4527 -0.8114 -1.1317 -0.4988 -1.0714 -0.0909 -0.0752
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule expression regulation rad q66p rgk_protein in_vivo
H-1678	-0.6794757843017578	▁expression ▁mis tar ge ting ▁regula tion ▁Rad _ Q 66 p ▁R GK _ ▁protein
D-1678	-0.6794757843017578	expression mistargeting regulation Rad_Q66p RGK_ protein
P-1678	-3.1335 -0.5074 -0.0022 -0.0129 -0.0310 -1.3618 -0.0056 -0.3316 -1.4841 -0.7009 -0.0452 -1.1017 -1.3326 -0.0222 -0.5261 -0.3254 -1.2160 -0.0905
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac_plasma_membrane s1pr1 β1ar heart_failure
H-1411	-0.9363500475883484	▁cardiac _ plasma _ ▁membran e ▁s 1 PR 1 ▁counter balance ▁β 1 AR _ ▁over stimul ation ▁heart _ ▁failure
D-1411	-0.9363500475883484	cardiac_plasma_ membrane s1PR1 counterbalance β1AR_ overstimulation heart_ failure
P-1411	-1.0523 -0.4935 -2.1732 -1.2171 -0.3999 -0.0390 -1.5343 -0.0496 -0.0326 -0.7368 -4.5688 -0.4193 -3.5851 -0.4324 -1.4221 -1.6915 -0.5120 -0.1203 -0.0422 -0.1182 -0.4043 -1.3405 -0.0420 -0.0454
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa immunoassays antibodies c_termini nt-probnp
H-1518	-0.5636776089668274	▁Alpha LIS a ▁immun o assa ys ▁anti bo dies ▁extreme ▁N ▁c ▁termini ▁circula ting ▁NT - pro b NP
D-1518	-0.5636776089668274	AlphaLISa immunoassays antibodies extreme N c termini circulating NT-probNP
P-1518	-0.0476 -0.2208 -1.2099 -0.0929 -0.1692 -0.3488 -0.1935 -0.0140 -0.0194 -0.2463 -2.4734 -0.3223 -4.1309 -0.0787 -1.6725 -0.0272 -0.1107 -0.0267 -0.0013 -1.4502 -0.0178 -0.0361 -0.0546
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully_magnetically_levitated_lvas mortality seattle heart_failure
H-2002	-0.6196637153625488	▁fully ▁magnet ically ▁le vita ted _ velo city _ risk ▁Seattle _ ▁Heart _ ▁Fail ure _ model - pred i cted _ ▁survival
D-2002	-0.6196637153625488	fully magnetically levitated_velocity_risk Seattle_ Heart_ Failure_model-predicted_ survival
P-2002	-1.5585 -0.9865 -0.0250 -0.4514 -0.0123 -0.0195 -0.1489 -2.7533 -0.9496 -0.9728 -2.6277 -0.0241 -0.4234 -2.1896 -0.1187 -0.9272 -0.0414 -0.5039 -0.1254 -0.4724 -0.0056 -0.0193 -0.0216 -0.3178 -0.8026 -0.0933 -0.1393
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte_hypertrophy heart_failure global_gene_expression dna genomic
H-89	-0.981579601764679	▁My o cy te _ ▁hyper trop hy _ ▁antecede nt _ to ▁heart _ ▁failure ▁global _ ▁gene ▁expression ▁DNA _ access i bility
D-89	-0.981579601764679	Myocyte_ hypertrophy_ antecedent_to heart_ failure global_ gene expression DNA_accessibility
P-89	-0.5909 -0.0943 -0.4092 -1.3298 -1.1387 -1.3579 -0.0322 -1.6367 -2.3290 -0.0971 -0.1992 -1.2676 -2.1021 -0.3567 -0.3927 -2.8759 -0.9799 -0.8888 -0.3933 -2.3720 -0.7549 -2.5561 -0.1623 -0.0374 -0.0003 -1.9381 -0.2097
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter_ablation patients compensated_hfpef left_ventricular ejection_fraction
H-944	-0.8421728014945984	▁Cat heter ▁ab lation _ for ▁AF ▁compensa ted ▁H FP EF ▁le ft _ ▁vent ri cular _ LV _ ▁e je ction _ fraction
D-944	-0.8421728014945984	Catheter ablation_for AF compensated HFPEF left_ ventricular_LV_ ejection_fraction
P-944	-1.8562 -0.0060 -0.1204 -0.0008 -3.1071 -2.3400 -0.1802 -0.1228 -0.0071 -2.2262 -0.1840 -0.5465 -1.5945 -0.0017 -0.4328 -4.4542 -0.7263 -0.0237 -1.0752 -0.7487 -1.3901 -0.6867 -0.0103 -0.0135 -1.4612 -0.0026 -0.1357 -0.1264
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients new_york_heart_association nyha chronic_heart_failure reduced_ejection_fraction
H-1952	-1.1473389863967896	▁New ▁York _ heart _ association _ NY HA ▁chronic _ heart _ ▁failure ▁reduce d _ e je ction _ fraction ▁Canadian
D-1952	-1.1473389863967896	New York_heart_association_NYHA chronic_heart_ failure reduced_ejection_fraction Canadian
P-1952	-2.6313 -1.7250 -0.2576 -2.9506 -0.3006 -0.8494 -3.4825 -0.7561 -0.0195 -1.6285 -0.1058 -1.1132 -0.7114 -5.6152 -1.3454 -0.0108 -0.9132 -0.7005 -0.1272 -0.0735 -0.4708 -0.0179 -1.9497 -0.6641 -0.2636
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient primary_end_point rehospitalization stroke myocardial_infarction heart_failure cabg
H-972	-0.4634164869785309	▁Swedish _ national _ in patient _ ▁Registr y ▁re hospital ization ▁stroke ▁my o card ial _ in far ction ▁heart _ ▁failure
D-972	-0.4634164869785309	Swedish_national_inpatient_ Registry rehospitalization stroke myocardial_infarction heart_ failure
P-972	-0.4913 -1.0880 -0.9821 -0.1059 -0.1462 -0.2307 -0.0975 -1.0839 -0.0125 -0.0509 -0.0005 -0.1362 -2.3469 -0.4236 -0.2378 -0.2746 -0.0337 -0.1852 -0.7374 -0.0074 -0.1476 -0.0968 -0.2806 -1.6977 -0.9669 -0.1871
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized heart_failure saxagliptin sitagliptin antihyperglycemic_drugs retrospective_cohort_study
H-1826	-0.5776939988136292	▁Hospital ized _ ▁Heart _ ▁Fail ure ▁Sax ag lip tin ▁Si tag lip tin ▁anti hy per gly ce mic _ drug s
D-1826	-0.5776939988136292	Hospitalized_ Heart_ Failure Saxagliptin Sitagliptin antihyperglycemic_drugs
P-1826	-2.1804 -0.0336 -0.2140 -1.4024 -0.1218 -0.4039 -0.0106 -0.5924 -0.0134 -0.6313 -1.2787 -1.2831 -0.0082 -0.0811 -0.9250 -0.5342 -1.0801 -0.0970 -2.5996 -0.0400 -0.7020 -0.1491 -0.1240 -0.1087 -0.3308 -0.0744
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox_proportional_hazards_models death transplantation lv_assist_device_implantation heart_failure hospitalization follow-up
H-431	-1.1314297914505005	▁co x ▁proportion al _ ▁hazard s _ model s ▁score ▁death ▁transplant ation ▁LV _ assist _ ▁device _ ▁implant ation ▁heart _ مستشفى
D-431	-1.1314297914505005	cox proportional_ hazards_models score death transplantation LV_assist_ device_ implantation heart_مستشفى
P-431	-0.1150 -0.0050 -0.8256 -0.0038 -0.1741 -1.0161 -0.1448 -3.5717 -1.7602 -0.6846 -4.4655 -2.9156 -1.6955 -0.0129 -0.1254 -0.7146 -0.0503 -1.2518 -1.1375 -1.4891 -0.8907 -0.0856 -0.1203 -0.6927 -5.7879 -0.6482 -0.1639
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil phosphocreatine adenine_nucleotides mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity
H-964	-0.4961944818496704	▁Nico rand il ▁ phos pho creati ne ▁a den ine ▁nucleo ti des ▁mito cho ndri al _ ▁oxid ative _ phos phor y lation _ capaci ty ▁creati ne ▁kina se
D-964	-0.4961944818496704	Nicorandil phosphocreatine adenine nucleotides mitochondrial_ oxidative_phosphorylation_capacity creatine kinase
P-964	-0.0338 -0.2846 -0.2914 -0.1070 -0.0008 -0.4528 -1.4170 -0.3295 -0.0189 -0.0009 -0.0026 -0.4361 -0.0531 -0.1828 -0.2173 -1.5679 -0.3771 -0.0208 -1.0192 -1.4743 -0.1309 -0.8420 -0.0644 -1.0033 -1.8779 -0.0860 -2.1039 -0.5446 -0.5313 -0.0124 -0.1911 -0.9322 -0.1131 -0.5687 -0.0770
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass_correlation_coefficient icc kappa_coefficient standard_error_of_measurement minimal_detectable_change mdc
H-801	-0.45153284072875977	▁intra class ▁corre lation _ co e ffi cient IC c ▁ka ppa _ co e ffi cient ▁standard ▁error _ of _ ▁measure ment ▁m DC
D-801	-0.45153284072875977	intraclass correlation_coefficientICc kappa_coefficient standard error_of_ measurement mDC
P-801	-0.5136 -0.0130 -0.4887 -0.0163 -0.4517 -0.0396 -0.1742 -0.0070 -0.0151 -2.5817 -1.3397 -0.0569 -0.0041 -1.3955 -0.0189 -0.0082 -0.0035 -0.0081 -0.0963 -1.3696 -1.1245 -0.0178 -0.7984 -0.0437 -0.0201 -1.9032 -0.2495 -0.1836 -0.1518
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise training outcomes chronic_heart_failure heart_failure_-_a_controlled_trial_investigating_outcomes_in_exercise_training hf-action
H-1629	-0.5205800533294678	▁exercise _ training ▁chronic _ heart _ fail ure ▁control led _ Tri al _ ▁Investiga ting _ out com es ▁exercise _ tra i N ing HF - AC TION
D-1629	-0.5205800533294678	exercise_training chronic_heart_failure controlled_Trial_ Investigating_outcomes exercise_traiNingHF-ACTION
P-1629	-1.7937 -2.0289 -0.9283 -0.6302 -0.6451 -0.2566 -0.2949 -1.6346 -0.0273 -1.1068 -0.0040 -0.0488 -1.9103 -0.0051 -0.2685 -0.6764 -0.1816 -0.9514 -0.1881 -0.0276 -0.0424 -0.7936 -0.3437 -0.1314 -0.3864 -1.0982 -0.0683 -0.2715 -0.0318 -0.0883 -0.0797 -0.0940 -0.1414
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes myocardium conditions
H-990	-0.4067074954509735	▁cardio my o cy tes ▁mechanic al ▁humor al _ stimul i ▁my o car dium ▁work load
D-990	-0.4067074954509735	cardiomyocytes mechanical humoral_stimuli myocardium workload
P-990	-0.0432 -0.0629 -0.6539 -0.2509 -0.3837 -0.0192 -0.0041 -0.1531 -0.0625 -1.2003 -0.6262 -0.0381 -0.2421 -0.0144 -0.0374 -1.1334 -1.8865 -0.0049 -1.0443 -0.2729
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular_support rvads explanted
H-301	-0.8752737641334534	▁bi ven tri cular _ support
D-301	-0.8752737641334534	biventricular_support
P-301	-0.2098 -0.3385 -0.4585 -0.6451 -0.7107 -0.5858 -3.7677 -0.2860
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy sst2 patients chronic_heart_failure
H-411	-1.0766139030456543	▁BB ▁ therapy ▁ex er ted _ ▁dose - related _ bene fit s ▁s ST 2 _ me chan ism ▁chronic _ heart _ ▁failure
D-411	-1.0766139030456543	BB therapy exerted_ dose-related_benefits sST2_mechanism chronic_heart_ failure
P-411	-0.4707 -2.3409 -0.1622 -4.7696 -0.0430 -0.0140 -1.4179 -0.3022 -0.0400 -0.0846 -2.2580 -2.0501 -0.5396 -0.4984 -0.1826 -0.5557 -0.0209 -3.2246 -0.9898 -1.2948 -0.2759 -0.7848 -0.3061 -1.9377 -1.4933 -2.3503 -1.6014 -0.1361
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf phenotype cardiac explant progenitors regulation
H-1337	-0.3752537965774536	▁CHF ▁cardiac _ ▁ex plant ▁c - K it _ pro geni tors ▁e luci date ▁mechanism s ▁regula tion
D-1337	-0.3752537965774536	CHF cardiac_ explant c-Kit_progenitors elucidate mechanisms regulation
P-1337	-1.4579 -2.1185 -0.5638 -0.8483 -0.0003 -0.0219 -0.1547 -0.3626 -0.1113 -0.4101 -0.9778 -0.0167 -0.0156 -0.1289 -0.0021 -0.0599 -0.2442 -0.0507 -0.5362 -0.0069 -0.0905 -0.0767
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd outpatients systolic_hf patients egfr
H-396	-0.5731779336929321	▁ES RD ▁sy sto lic _ HF ▁e G FR
D-396	-0.5731779336929321	ESRD systolic_HF eGFR
P-396	-1.9129 -0.2617 -0.8645 -0.4787 -0.2857 -0.5403 -0.0116 -0.0606 -0.3238 -1.0379 -0.8917 -0.2087
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions training patients out-patient follow-up patient health_care
H-1579	-0.6436116695404053	▁transition s _ of _ care _ program ▁self - management _ training ▁out - patient _ ▁follow - up
D-1579	-0.6436116695404053	transitions_of_care_program self-management_training out-patient_ follow-up
P-1579	-0.0744 -0.1571 -0.8762 -0.0695 -0.0320 -0.3532 -2.7401 -0.6723 -1.5491 -0.0223 -0.0005 -2.3775 -0.7079 -0.2506 -0.0915 -0.0092 -0.7152 -0.4317 -0.5561 -0.0043 -2.0475 -0.4214
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno_donor myocardial_function evidence hf
H-425	-0.6849915385246277	▁functional _ ef fica cy ▁pure ▁H NO _ ▁donor ▁my o card ial _ function ▁ HF
D-425	-0.6849915385246277	functional_efficacy pure HNO_ donor myocardial_function HF
P-425	-5.4944 -0.4010 -0.6188 -0.0680 -0.1350 -0.4378 -1.4016 -0.5967 -0.8302 -0.0490 -1.4645 -0.0794 -0.1978 -0.0740 -0.5216 -0.5151 -0.6312 -0.0223 -0.0957 -0.0657
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel apoptotic_cells tunel-positive_cells
H-172	-0.5290782451629639	▁TU nel _ as say ▁apo pto tic _ cell s ▁TU NEL - posi tive _ cell s ▁pace d
D-172	-0.5290782451629639	TUnel_assay apoptotic_cells TUNEL-positive_cells paced
P-172	-0.2582 -2.2366 -0.8692 -0.1835 -0.0029 -1.9002 -0.0779 -0.1998 -0.1306 -0.0940 -0.0371 -2.5160 -1.3689 -0.1059 -0.0288 -0.0124 -0.4070 -0.0672 -0.0185 -0.0578 -0.1282 -1.3207 -0.1474
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse pasp step rv_function lv_dysfunction
H-501	-1.5579160451889038	▁length - force _ ▁relationship ▁ RV _ function
D-501	-1.5579160451889038	length-force_ relationship RV_function
P-501	-4.6642 -0.3259 -0.0095 -1.2921 -3.2075 -0.2135 -0.0594 -1.9156 -1.7359 -3.3078 -0.4058
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological_phenotype clinically deficit_index medical frailty
H-1013	-0.6006485223770142	▁bi ological _ ▁ph eno type ▁medical _ ▁records ▁as certa in _ fra il ty
D-1013	-0.6006485223770142	biological_ phenotype medical_ records ascertain_frailty
P-1013	-0.0268 -0.1025 -0.4735 -1.3066 -0.0717 -0.0048 -5.8983 -0.4725 -0.2596 -0.6007 -0.0112 -0.0035 -0.4208 -0.8789 -0.0539 -0.1568 -0.0127 -0.0569
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia intravenous atropine cardiac vagal_tone
H-1380	-0.2444888949394226	▁ta chy car dia ▁intra ven ous ▁a tropi ne ▁cardiac _ ▁va gal _ ▁tone ▁CHF - DN x ▁CHF - IN V
D-1380	-0.2444888949394226	tachycardia intravenous atropine cardiac_ vagal_ tone CHF-DNx CHF-INV
P-1380	-0.1304 -0.1100 -0.2053 -0.0078 -0.0082 -0.0033 -0.3562 -0.6713 -0.0052 -1.3772 -0.0085 -0.4555 -0.5912 -0.0295 -0.6611 -0.1860 -0.0173 -0.0189 -0.3289 -0.1800 -0.0559 -0.0070 -0.0685 -0.3941 -0.4386 -0.0409
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions readmission patients congestive_heart_failure south_dakota
H-1583	-0.9120920896530151	▁transition s _ of _ care ▁program ▁con ges tive _ heart _ ▁failure ▁non - urban ized ▁Mid we stern ▁state ▁South ▁Da kota
D-1583	-0.9120920896530151	transitions_of_care program congestive_heart_ failure non-urbanized Midwestern state South Dakota
P-1583	-1.5458 -0.0634 -1.8094 -0.0673 -0.0255 -0.6511 -2.4537 -2.5228 -0.8442 -0.0597 -0.2447 -2.1945 -1.0118 -2.6693 -1.6148 -0.0635 -0.0039 -0.1465 -2.9532 -0.1243 -0.0059 -2.2986 -0.4227 -0.4828 -0.0001 -0.1135 -0.2335
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts hh medical all-cause_mortality discharged patients heart_failure
H-162	-1.3113452196121216	▁s ▁ HH ▁medical _ support ▁office _ ▁hours
D-162	-1.3113452196121216	s HH medical_support office_ hours
P-162	-1.4639 -1.0912 -0.0028 -2.0316 -1.2515 -0.6967 -1.0255 -1.6476 -0.1985 -4.7505 -0.2650
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically myocardial_infarction heart_failure randomized bisoprolol
H-452	-0.36095061898231506	▁sur g ically ▁induc ed ▁my o card ial _ in far ction ▁heart _ ▁failure _ ▁rat s ▁bis o pro lol ▁vehicle
D-452	-0.36095061898231506	surgically induced myocardial_infarction heart_ failure_ rats bisoprolol vehicle
P-452	-0.9182 -0.0470 -0.0891 -0.4172 -0.0275 -0.3500 -0.1791 -0.7841 -0.0747 -0.2382 -0.7520 -0.0060 -0.0847 -0.1074 -0.9376 -0.9034 -2.0426 -0.1265 -0.0132 -0.4355 -0.0369 -0.0080 -0.0275 -0.6761 -0.0384 -0.0637
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt elevated acute β-adrenoceptor_blockade esmolol
H-1444	-0.7812083959579468	▁SD QT ▁ HF VT ▁H Nor m _ ▁group ▁a cute ▁β - ad re no cept or _ ▁block ade ▁es mol ol
D-1444	-0.7812083959579468	SDQT HFVT HNorm_ group acute β-adrenoceptor_ blockade esmolol
P-1444	-0.1369 -1.7780 -0.1725 -0.0018 -0.8210 -1.5064 -0.8976 -0.0011 -2.0496 -0.8746 -0.0884 -0.0024 -0.3840 -0.0196 -0.0071 -0.8096 -0.7981 -3.9910 -2.7671 -0.4956 -0.8544 -1.0456 -0.2695 -0.0157 -0.9897 -0.0925 -0.2226
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission disease heart_failure hf acute_myocardial_infarction ami pneumonia
H-137	-2.32260799407959	▁ stu dy _ design
D-137	-2.32260799407959	study_design
P-137	-5.3021 -3.3043 -0.1034 -1.4681 -0.2597 -5.6726 -0.1481
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal_dialysis pd diuretic volume_overload heart_failure hf
H-894	-0.4520634412765503	▁Peri tone al _ ▁di al ysis ▁di ure tic _ ▁resist ant _ ▁volume _ ▁over load ▁heart _ ▁failure
D-894	-0.4520634412765503	Peritoneal_ dialysis diuretic_ resistant_ volume_ overload heart_ failure
P-894	-0.0529 -0.0129 -0.0179 -0.4198 -1.5907 -0.0201 -0.0678 -2.0807 -0.1110 -0.0664 -0.1454 -2.4650 -0.0948 -0.0985 -0.2099 -0.3763 -0.6768 -0.0037 -0.1292 -0.3527 -1.0591 -0.3090 -0.0368
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report stable hno_donor cxl-1020 myoctyes hearts patients heart_failure hf
H-415	-0.9348681569099426	▁ha no _ ▁donor ▁isola ted _ my oc ty es ▁intact _ heart s ▁ HF
D-415	-0.9348681569099426	hano_ donor isolated_myoctyes intact_hearts HF
P-415	-4.5206 -1.6905 -1.1868 -0.1253 -2.6863 -0.0021 -0.8296 -1.1564 -0.0490 -0.0132 -0.2689 -0.0112 -0.1774 -0.2441 -0.2441 -4.1169 -0.2027 -0.1359 -0.1016
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral_artery_disease pad heart_failure hf prevalence hf patients pad
H-1567	-0.8578177094459534	▁Peri pher al _ ▁arter y _ PAD ▁heart _ ▁failure ▁ HF
D-1567	-0.8578177094459534	Peripheral_ artery_PAD heart_ failure HF
P-1567	-0.4027 -0.0008 -0.0254 -0.4274 -3.0435 -0.0950 -0.5767 -3.4212 -2.0635 -0.2612 -1.0135 -0.3924 -0.0026 -0.9725 -0.1688
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients heart_failure_with_preserved_ejection_fraction hfpef heart_failure obese
H-1974	-0.8778753876686096	▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁H FP EF ▁heart _ ▁failure ▁over weight
D-1974	-0.8778753876686096	heart_ failure preserved_ejection_fraction HFPEF heart_ failure overweight
P-1974	-1.8879 -0.6919 -2.2378 -0.8489 -0.1203 -0.0698 -0.1323 -0.8917 -1.1759 -0.2566 -0.2771 -0.1356 -3.0539 -0.0682 -0.1770 -2.3915 -0.4804 -2.1793 -0.5226 -0.0158 -1.6253 -0.0736
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal_dysfunction prognostic heart_failure hf dysfunction end-stage_renal_disease esrd
H-387	-0.7568919658660889	▁Ren al _ ▁dys function ▁heart _ ▁failure _ HF ▁dys function ▁end - s tage ▁renal _ مرض ES RD
D-387	-0.7568919658660889	Renal_ dysfunction heart_ failure_HF dysfunction end-stage renal_مرضESRD
P-387	-1.3930 -0.0218 -0.5853 -1.8503 -0.0643 -2.0034 -0.2293 -0.4674 -2.7985 -0.0268 -3.3843 -0.0397 -0.0206 -0.0418 -0.0877 -0.0003 -0.4761 -0.2527 -1.7908 -1.6026 -0.0626 -0.1070 -0.1023
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil heart_rate aortic blood_flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
H-963	-0.3546608090400696	▁Nico rand il ▁a or tic _ ▁blood ▁flow ▁mito cho ndri al _ ▁oxid ative _ ▁stress ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.3546608090400696	Nicorandil aortic_ blood flow mitochondrial_ oxidative_ stress doxorubicin cardiotoxicity
P-963	-0.0236 -0.0387 -0.0842 -1.6734 -0.1231 -0.0525 -0.2365 -1.5538 -0.2902 -0.0075 -1.4374 -0.1755 -0.0040 -0.9840 -0.4721 -0.0127 -0.5227 -0.5764 -0.0281 -0.0020 -0.0403 -0.4386 -0.4297 -0.2055 -0.0139 -0.0320 -0.1175
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral_muscle_pump cardiac_filling exercise subpulmonary_ventricle fontan_circulation
H-1492	-0.34888312220573425	▁per i pher al _ ▁muscle _ pump ▁cardiac _ ▁fill ing ▁sub pul mon ary _ ▁vent ric le ▁Font an _ ▁circulation
D-1492	-0.34888312220573425	peripheral_ muscle_pump cardiac_ filling subpulmonary_ ventricle Fontan_ circulation
P-1492	-0.0096 -0.6544 -0.0001 -0.0061 -0.2317 -1.6112 -0.3748 -0.2467 -0.2420 -0.8855 -0.0519 -0.0062 -0.1511 -0.0289 -0.1278 -0.0116 -0.1634 -1.6941 -1.1770 -0.3115 -0.0129 -0.0212 -0.7967 -0.1249 -0.0666 -0.0631
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression_analysis echocardiographic lv_reverse_remodeling lv_end-systolic_volume
H-430	-0.4582982361316681	▁e cho car dio graphic _ ▁score ▁LV ▁rever se _ ▁remodel ing ▁LV ▁end - sy sto lic ▁volume
D-430	-0.4582982361316681	echocardiographic_ score LV reverse_ remodeling LV end-systolic volume
P-430	-0.3465 -0.1299 -0.3568 -1.2048 -0.5068 -0.3296 -0.3588 -0.0603 -0.0171 -0.0028 -0.4450 -0.4598 -0.0380 -0.9465 -0.3995 -0.0134 -0.3700 -0.4630 -0.0761 -3.3874 -0.0669 -0.1034
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology national_cardiovascular_disease_registry_practice_innovation_and_clinical_excellence_registry
H-660	-0.9751681685447693	▁Card i ology _ prac tice s ▁national _ card io vas cular _ dia ▁Registr y _ prac tice _ innovation ▁Clinic al _ excellence
D-660	-0.9751681685447693	Cardiology_practices national_cardiovascular_dia Registry_practice_innovation Clinical_excellence
P-660	-1.9705 -2.2022 -0.0230 -1.1602 -0.7952 -0.1383 -0.1611 -1.6776 -0.4343 -0.9357 -1.4103 -0.6813 -0.1541 -0.0556 -3.9719 -3.7075 -0.0336 -0.9274 -1.6884 -0.0938 -1.3366 -1.1818 -0.5853 -0.0014 -0.2176 -0.4410 -1.2631 -0.0562
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed heart_failure left_ventricular_ejection_fraction spironolactone kaiser_permanente northern_california
H-440	-0.9627379775047302	▁heart _ ▁failure ▁left _ ▁vent ri cular _ ▁e je ction ▁spi rono lac tone
D-440	-0.9627379775047302	heart_ failure left_ ventricular_ ejection spironolactone
P-440	-4.3816 -0.7938 -2.3433 -0.1704 -0.2187 -4.2248 -0.4410 -0.3441 -0.2435 -1.0567 -0.0133 -0.0520 -0.9685 -0.0049 -0.0888 -0.0379 -1.8797 -0.0662
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical_examination patient bmi heart_rate rhythm blood_pressure auscultation rule valvular_disease pulmonary_congestion
H-1894	-0.8764316439628601	▁physical _ ▁examina tion ▁b mi ▁weight ▁heart ▁rate ▁ rhythm ▁ly ing ▁standing _ ▁blood _ ▁pressure ▁pulmonar y _ con gestion
D-1894	-0.8764316439628601	physical_ examination bmi weight heart rate rhythm lying standing_ blood_ pressure pulmonary_congestion
P-1894	-0.7474 -1.2093 -1.2448 -0.0228 -2.1850 -2.1315 -2.1318 -1.3774 -0.1865 -1.8089 -0.0273 -0.0025 -0.0102 -0.2566 -0.2915 -1.3475 -0.6156 -0.3943 -4.8228 -0.0320 -0.3937 -0.2310 -0.0107 -0.2079 -0.2217
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial_extracellular_matrix cardiac_magnetic_resonance t1_mapping pathobiology pathophysiology prognosis
H-735	-0.3771725296974182	▁my o card ial _ extra cel lular _ ▁matri x ▁cardiac _ ▁magnetic _ ▁res on ance _ ▁T 1 _ ma pping ▁path obi ology pat ho phy si ology ▁prognos is
D-735	-0.3771725296974182	myocardial_extracellular_ matrix cardiac_ magnetic_ resonance_ T1_mapping pathobiologypathophysiology prognosis
P-735	-0.1113 -0.3307 -0.6707 -0.0326 -0.2310 -0.6219 -0.0766 -0.0407 -0.5730 -0.0371 -0.1489 -0.0002 -0.9112 -0.2581 -0.1194 -0.1265 -0.0225 -0.0011 -0.8741 -0.4462 -0.0626 -2.4530 -1.5995 -0.0204 -0.0627 -0.1798 -0.0070 -1.3822 -0.2890 -0.0443 -1.4247 -0.0008 -0.2061 -0.1148 -0.0346 -0.0630
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial_shunting patients heart_failure_with_reduced_ejection_fraction proof-of-principle_cohort_study
H-1948	-0.882820188999176	▁un direct ional ▁left - to - right ▁inter at rial _ ▁sh unting ▁patients ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction
D-1948	-0.882820188999176	undirectional left-to-right interatrial_ shunting patients heart_ failure reduced ejection_fraction
P-1948	-6.6996 -0.0102 -0.1045 -0.4681 -0.0067 -0.0805 -0.0198 -0.0018 -0.3553 -0.0204 -0.0173 -0.5822 -2.0646 -0.6709 -3.1881 -1.3726 -0.5437 -1.7382 -2.8297 -0.0165 -0.3465 -0.0682 -0.1091 -0.6395 -0.0111 -1.6600 -0.2111
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone_antagonist therapy chronic_advanced_heart_failure patients post-myocardial_infarction heart_failure patients
H-1738	-0.8124240040779114	▁al do ster one _ ▁anta gon ist _ therapy ▁chronic _ ▁advanced _ heart _ ▁failure ▁post - my o card ial _ in far ction _ heart _ ▁failure
D-1738	-0.8124240040779114	aldosterone_ antagonist_therapy chronic_ advanced_heart_ failure post-myocardial_infarction_heart_ failure
P-1738	-0.9237 -0.3373 -0.7987 -0.2225 -0.7096 -0.9592 -0.2091 -0.2620 -0.5196 -0.3789 -2.3530 -0.7744 -1.8594 -0.3508 -2.1091 -0.6853 -1.7435 -0.1013 -0.0169 -0.2786 -0.4932 -1.7711 -0.3094 -0.2189 -0.8076 -0.0317 -0.1958 -0.4943 -1.5383 -0.5205 -1.1996 -3.0779 -0.5589
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative renal_dysfunction cardiovascular_events stroke myocardial_infarction heart_failure death isolated_coronary_artery_bypass_grafting
H-968	-0.4253910779953003	▁pre operativ e ▁renal _ ▁dys function ▁cardiovascular _ ▁events stro ke ▁my o card ial _ in far ction ▁heart _ ▁failure ▁isola ted ▁corona ry _ ▁arter y _ ▁by pass ▁graf ting
D-968	-0.4253910779953003	preoperative renal_ dysfunction cardiovascular_ eventsstroke myocardial_infarction heart_ failure isolated coronary_ artery_ bypass grafting
P-968	-0.1117 -0.0020 -0.1521 -0.0163 -0.5967 -0.8387 -0.0249 -0.1960 -1.1112 -0.3182 -3.6737 -0.0004 -0.3881 -0.1117 -0.1392 -0.0118 -0.2884 -0.9250 -0.0032 -0.1243 -0.0499 -1.0930 -0.3470 -0.1706 -0.0015 -0.1351 -0.0710 -0.4699 -0.5617 -0.1598 -0.3519 -1.8756 -0.0307 -1.1902 -0.0303 -0.1168 -0.0510
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical outcomes heart_failure charm candesartan_in_heart_failure_assessment_of_reduction_in_mortality_and_morbidity
H-554	-0.9132728576660156	▁clinic al ▁heart _ ▁failure ▁CHA RM _ programm e Can des ar tan ▁Heart _ ▁Fail ure _ ▁Assessment ▁Mor t ality ▁Morbi d ity
D-554	-0.9132728576660156	clinical heart_ failure CHARM_programmeCandesartan Heart_ Failure_ Assessment Mortality Morbidity
P-554	-2.3979 -0.2766 -6.5901 -0.3204 -2.1015 -2.4733 -0.2445 -1.2488 -0.4457 -0.8550 -1.2745 -0.0106 -0.0052 -0.0045 -1.2163 -0.1494 -0.8323 -0.0208 -2.9408 -0.6195 -0.6164 -0.0169 -0.0018 -0.7752 -0.0104 -0.0144 -0.0582 -0.0506
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.9500806331634521	▁single - procedure ▁drug - free
D-947	-0.9500806331634521	single-procedure drug-free
P-947	-5.5209 -0.0293 -0.1839 -0.2771 -0.0702 -0.0125 -1.4210 -0.0857
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc frame patient consultation patients
H-1027	-1.0076197385787964	▁protocol - driv en ▁PO C _ test ▁ NP ▁patient _ ▁consultation ▁ED
D-1027	-1.0076197385787964	protocol-driven POC_test NP patient_ consultation ED
P-1027	-0.0964 -0.0981 -0.0118 -0.0477 -1.9384 -0.9023 -2.5643 -0.8992 -0.5309 -0.0008 -2.0320 -0.9873 -0.2907 -2.5403 -2.8023 -0.3794
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician mortality internists cardiologists
H-1730	-0.5716437697410583	▁physician _ ▁volume ▁mortal ity ▁intern ists ▁cardio logist s
D-1730	-0.5716437697410583	physician_ volume mortality internists cardiologists
P-1730	-0.0568 -0.5803 -0.0959 -3.8848 -0.0147 -0.0715 -1.0858 -0.4375 -0.3733 -0.0699 -0.1105 -0.0786
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle_walk_test hand baseline
H-1322	-0.545992910861969	▁shu ttle ▁walk _ test ▁body ▁mass ▁hand _ ▁grip _ ▁strength ▁base line
D-1322	-0.545992910861969	shuttle walk_test body mass hand_ grip_ strength baseline
P-1322	-0.0257 -0.0013 -2.7076 -0.6254 -0.1439 -0.0668 -0.7688 -0.0911 -0.2905 -0.1479 -1.4246 -1.4496 -0.8197 -0.0018 -0.0849 -0.0863
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological capillary coronary_perfusion
H-457	-0.5727362632751465	▁cap illa ry ▁corona ry _ per fusion ▁ad - F lk ▁rat s ▁b - tre ated ▁ad - C ▁rat s
D-457	-0.5727362632751465	capillary coronary_perfusion ad-Flk rats b-treated ad-C rats
P-457	-5.0248 -0.1206 -0.0499 -1.1430 -0.0563 -0.4571 -0.1223 -0.0034 -0.4636 -0.0666 -0.5786 -0.0801 -0.2341 -0.0136 -1.7467 -0.0675 -0.0013 -0.1868 -1.9457 -0.0598 -1.5495 -0.0708 -0.0085 -0.0784 -0.1892
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence exercise cell_senescence active osteoporosis
H-1901	-1.405103087425232	▁exercise ▁cell ▁se nesc ence
D-1901	-1.405103087425232	exercise cell senescence
P-1901	-0.8445 -4.4492 -0.4043 -0.0011 -0.0024 -3.9392 -0.1952
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet patient subvalvular annular_ms
H-374	-0.9304055571556091	▁le a flet ▁serial ▁evaluation ▁sub val vu lar ▁ann ular _ ▁MS ▁fixed _ ▁ring _ size
D-374	-0.9304055571556091	leaflet serial evaluation subvalvular annular_ MS fixed_ ring_size
P-374	-0.1406 -0.0165 -0.0001 -2.8180 -1.2673 -1.5357 -0.3202 -0.8161 -0.3967 -2.2499 -0.0036 -0.5525 -1.2486 -0.2640 -0.4235 -3.0681 -1.8927 -1.3309 -0.0813 -0.1818
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes chronic_heart_failure hf exercise training
H-1630	-1.0343761444091797	▁strength _ of _ ▁race ▁con tempor ary ▁chronic _ heart _ ▁failure _ HF ▁exercise
D-1630	-1.0343761444091797	strength_of_ race contemporary chronic_heart_ failure_HF exercise
P-1630	-1.0156 -1.0007 -0.3350 -0.2294 -0.7162 -5.4214 -0.0230 -0.0015 -0.6659 -0.0509 -0.9745 -0.1684 -4.0791 -1.6198 -0.2982 -0.1061 -1.8335 -0.0796
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic pediatric_fontan patients catheterization
H-227	-0.8197139501571655	▁as ym pto matic ▁pediatr ic ▁Font an _ PF ▁cat heter ization
D-227	-0.8197139501571655	asymptomatic pediatric Fontan_PF catheterization
P-227	-3.6935 -0.1058 -0.0098 -0.0199 -0.0248 -0.0127 -1.0698 -0.1014 -2.1577 -0.2851 -2.9827 -0.0064 -0.2813 -1.4205 -0.1245
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous_nonfailing hf combinations remodeling
H-1152	-0.5224137902259827	▁dys syn chron ous _ ▁non fail ing ▁ HF ▁can ine _ ▁electro me chan ics
D-1152	-0.5224137902259827	dyssynchronous_ nonfailing HF canine_ electromechanics
P-1152	-2.0874 -0.0273 -0.0028 -0.2835 -0.8298 -1.1227 -0.0105 -0.0519 -0.0355 -0.0039 -2.3535 -0.0053 -0.4561 -1.0827 -0.0081 -0.0004 -0.2005 -1.1820 -0.1822
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia hf health-related_quality_of_life hrqol hf
H-835	-0.6406615376472473	▁an emia ▁ HF ▁health - related _ quality _ of _ life HR Qo L
D-835	-0.6406615376472473	anemia HF health-related_quality_of_lifeHRQoL
P-835	-0.2267 -0.0010 -1.5562 -0.0100 -1.7854 -0.2284 -0.0202 -1.1643 -0.7515 -1.1990 -0.0840 -0.0576 -1.3095 -1.8082 -0.0702 -0.1065 -1.0632 -0.0901
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese patients clinically stable hfpef exercise training peak_vo2
H-1990	-0.7924792170524597	▁h f f f ▁calor ic _ ▁restriction ▁aero bic _ training ▁pe ak _ vo 2
D-1990	-0.7924792170524597	hfff caloric_ restriction aerobic_training peak_vo2
P-1990	-5.6241 -0.4943 -0.7932 -1.2982 -0.8927 -0.1613 -1.2925 -0.1824 -0.0113 -0.0356 -0.7296 -2.7810 -0.0078 -0.0042 -0.1406 -0.2736 -0.0695 -0.1517 -0.1135
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell_therapy chronic_heart_failure chf disease progenitor_cells
H-1336	-0.6265683770179749	▁cell _ therapy ▁chronic _ heart _ ▁failure ▁ex plant - der i ved _ pro gen itor _ cell s
D-1336	-0.6265683770179749	cell_therapy chronic_heart_ failure explant-derived_progenitor_cells
P-1336	-3.8377 -1.2030 -0.0351 -0.1676 -0.3630 -0.8893 -0.3549 -2.6013 -2.8913 -0.0025 -0.0901 -0.0133 -0.0679 -0.1051 -0.2077 -0.3538 -0.1409 -0.0357 -0.6227 -0.1428 -0.0741 -0.1317 -0.0796
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the_lancet anoop_shah air heart_failure morbidity mortality
H-1807	-0.8528510332107544	▁Lance t ▁air ▁pollution ▁heart _ ▁failure ▁high ▁morbi d ity ▁mortal ity
D-1807	-0.8528510332107544	Lancet air pollution heart_ failure high morbidity mortality
P-1807	-2.1865 -0.0479 -0.0954 -2.2857 -3.0185 -0.6224 -0.9162 -0.6631 -0.1397 -0.0234 -0.0350 -1.9655 -0.0052 -0.4435 -0.3448
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients hr_variability mortality ami diagnosis chf lv_dysfunction
H-1586	-1.0672383308410645	▁ab normal _ HR _ ▁variabil ity ▁ AMI ▁ diagnos is ▁CHF / LV _ ▁dys function
D-1586	-1.0672383308410645	abnormal_HR_ variability AMI diagnosis CHF/LV_ dysfunction
P-1586	-6.1908 -0.0279 -1.0204 -0.5677 -1.4956 -0.0536 -0.0068 -2.3487 -1.3412 -2.3345 -1.2905 -0.2675 -0.1020 -1.5725 -0.0569 -0.9071 -1.3343 -0.2142 -0.1074 -0.1051
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_failure atherosclerosis_risk_in_communities
H-284	-0.6163339018821716	▁Tro ponin _ t ▁N - termin al ▁pro - B - type ▁na tri ure tic _ pe pti de ▁bio mark er ▁heart _ ▁failure _ risk ▁at hero sc ler osis _ risk
D-284	-0.6163339018821716	Troponin_t N-terminal pro-B-type natriuretic_peptide biomarker heart_ failure_risk atherosclerosis_risk
P-284	-0.0920 -0.0013 -1.3771 -1.8712 -1.4889 -0.0232 -0.0379 -0.0009 -0.1833 -0.0193 -0.5136 -0.0939 -0.1463 -0.0191 -0.0960 -0.1985 -0.5840 -0.1779 -0.2538 -0.2698 -0.4979 -2.6828 -0.0019 -0.2308 -4.2433 -0.2448 -1.9846 -0.7240 -0.5838 -1.2316 -0.1602 -0.2729 -1.3103 -0.0644 -0.7483 -0.5219 -0.3903 -0.0789
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ventricular_assist_devices cardiac nurses gastrointestinal_bleeding
H-1660	-0.4502813220024109	▁vent ri cular _ assist ▁devices ▁cardiac _ ▁nurse s ▁gastro inte stin al _ ▁ble ed ing
D-1660	-0.4502813220024109	ventricular_assist devices cardiac_ nurses gastrointestinal_ bleeding
P-1660	-0.1969 -0.4291 -0.0987 -0.4196 -0.0202 -1.4726 -1.8442 -0.8178 -0.0854 -0.0752 -1.0249 -0.2270 -0.5184 -0.0289 -0.2259 -1.1596 -0.1256 -0.0653 -0.0809 -0.0897
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended_criteria_cardiac_transplant ecct transplant donors transplant comorbidity
H-708	-1.5531352758407593	▁ex tende d _ cri me ▁cardiac _ ▁transplant ▁ec CT ▁transplant _ pool
D-708	-1.5531352758407593	extended_crime cardiac_ transplant ecCT transplant_pool
P-708	-6.8353 -0.0062 -0.0132 -1.9258 -1.5105 -0.2495 -0.0195 -0.6158 -1.0214 -5.0661 -0.3127 -0.7980 -1.4875 -0.3859 -4.4147 -0.1882
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective hf patients hf_with_reduced_ef ef hfpef ef
H-782	-1.1360902786254883	▁prospect ive ▁ HF _ ▁registr y ▁ HF
D-782	-1.1360902786254883	prospective HF_ registry HF
P-782	-2.3407 -0.0012 -0.0441 -0.0127 -1.6437 -0.5401 -0.0835 -0.3187 -0.0897 -7.2812 -0.1415
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes mortality hospitalization mortality cardiovascular_mortality hf hospitalization cox_models exercise training
H-1633	-0.8286195993423462	mortal ity _ hospital ization ▁cardiovascular _ ▁mortal ity HF _ hospital ization
D-1633	-0.8286195993423462	mortality_hospitalization cardiovascular_ mortalityHF_hospitalization
P-1633	-5.8819 -0.0238 -1.9420 -0.0165 -0.1493 -0.1457 -0.0869 -0.8631 -0.0081 -1.0139 -1.1080 -0.0337 -0.1300 -0.7765 -0.2500
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american_college_of_physicians acp evidence clinical anemia patients heart_disease
H-30	-0.6876233220100403	▁American _ col _ of _ ▁Physic ians ▁an emia ▁ir on _ de fici en cy ▁heart _ مرض
D-30	-0.6876233220100403	American_col_of_ Physicians anemia iron_deficiency heart_مرض
P-30	-1.5669 -0.2763 -0.5458 -1.6097 -0.0160 -0.0040 -1.3527 -0.0019 -4.0025 -0.0741 -0.0818 -0.0207 -0.1624 -0.1501 -0.0021 -0.7761 -0.0127 -1.2872 -1.6823 -1.3288 -0.0857 -0.0879
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat n-terminal_pro-brain_natriuretic_peptide hospitalized hf
H-1877	-0.3975125253200531	▁BAT ▁N - termin al _ pro - bra in ▁na tri ure tic _ pe pti de ▁ HF
D-1877	-0.3975125253200531	BAT N-terminal_pro-brain natriuretic_peptide HF
P-1877	-1.1018 -2.8531 -0.0143 -0.0609 -0.0007 -0.5632 -0.7417 -0.1587 -0.6323 -0.0300 -0.0621 -0.0211 -0.1343 -0.1408 -0.4007 -0.1676 -0.0751 -0.1628 -1.2534 -0.0508 -0.0528 -0.0671
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum systolic lv_posterior_wall lv_internal_diameter metoprolol
H-1549	-0.5741139650344849	▁MI - indu ced ▁sept um _ sy sto lic _ ▁thi ck ness ▁LV ▁posterior _ wall _ ▁thi ck ness ▁LV ▁internal _ ▁diameter ▁met o pro lol
D-1549	-0.5741139650344849	MI-induced septum_systolic_ thickness LV posterior_wall_ thickness LV internal_ diameter metoprolol
P-1549	-0.8652 -0.5796 -0.0201 -0.0355 -0.5850 -0.0026 -2.8509 -2.0312 -1.3405 -0.0994 -0.9847 -0.3411 -0.0106 -0.3083 -0.2297 -3.1112 -0.3762 -0.5147 -0.8771 -0.3753 -0.0010 -0.0711 -0.2026 -0.0033 -0.5324 -1.1281 -0.5497 -0.0250 -0.0052 -0.0260 -0.0603 -0.2279
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_tone
H-1139	-0.5298430323600769	▁ta chy car dic ▁met hy la tropi ne ▁va gal _ ▁tone ▁bra dy car dic ▁propra no lol ▁sympa the tic _ ▁tone
D-1139	-0.5298430323600769	tachycardic methylatropine vagal_ tone bradycardic propranolol sympathetic_ tone
P-1139	-0.2349 -0.2739 -1.0686 -0.6353 -4.9308 -0.1887 -0.1715 -0.0046 -0.9086 -0.0049 -0.0027 -0.4559 -0.8893 -0.2370 -0.0429 -0.3802 -0.3819 -2.0113 -0.0076 -0.0208 -0.0082 -0.1479 -0.2267 -0.6808 -0.2885 -0.0416 -0.0608
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox_regression covariates spironolactone death hospitalization hyperkalemia acute_kidney_injury
H-442	-0.7064687609672546	▁co x ▁re gression ▁spi rono lac tone _ ▁use ▁hospital ization ▁severe ▁hyper kal emia ▁a cute ▁ki dne y _ ▁injury
D-442	-0.7064687609672546	cox regression spironolactone_ use hospitalization severe hyperkalemia acute kidney_ injury
P-442	-0.1386 -0.0096 -0.2048 -0.0005 -2.9004 -0.0445 -0.4856 -0.2241 -2.9708 -3.3802 -0.7676 -0.2678 -0.0735 -1.8880 -0.1016 -0.0218 -0.0353 -0.0021 -0.9211 -0.3233 -0.0445 -1.9318 -0.6636 -0.0725 -0.1879
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients acute_rv_failure chronic_pulmonary_arterial_hypertension pah acute pulmonary_embolism
H-1095	-0.7506085634231567	▁a cute _ RV _ ▁failure ▁chronic ▁pulmonar y _ ▁arterial _ ▁hyper tension PA H ▁a cute ▁pulmonar y _ e mbol ism
D-1095	-0.7506085634231567	acute_RV_ failure chronic pulmonary_ arterial_ hypertensionPAH acute pulmonary_embolism
P-1095	-1.3031 -0.0111 -0.4511 -2.2311 -0.9396 -0.3778 -0.4764 -0.6017 -0.0139 -0.4719 -0.6456 -0.2023 -4.9333 -0.0082 -2.4913 -0.7796 -0.0305 -0.0036 -1.3579 -0.0133 -0.0739 -1.7484 -0.0013 -0.0374 -0.1865 -0.1250
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity oxidative_stress dna_fragmentation
H-962	-0.6909695267677307	▁mito cho ndri al ▁oxid ative _ phos phor y lation _ capaci ty ▁creati ne ▁kina se ▁oxid ative ▁stress _ ▁marker s ▁DNA _ ▁fragment ation ▁ultra struct ural
D-962	-0.6909695267677307	mitochondrial oxidative_phosphorylation_capacity creatine kinase oxidative stress_ markers DNA_ fragmentation ultrastructural
P-962	-0.0006 -0.7763 -0.0960 -0.0057 -2.1779 -0.0706 -0.5484 -1.2801 -1.0107 -2.5259 -0.0150 -1.4268 -0.8194 -0.7206 -0.0041 -0.1746 -0.2226 -0.2565 -0.1608 -0.0355 -1.6890 -0.5906 -1.4325 -0.0562 -0.1372 -2.1280 -3.2078 -0.1350 -0.3687 -0.0101 -0.0005 -0.6726 -0.0456
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac_resynchronization_therapy crt mild_heart_failure hf patients qrs_prolongation ejection_fraction ef
H-751	-0.5831448435783386	▁cardiac ▁re syn chron ization _ therapy ▁c RT ▁mild _ heart _ ▁failure ▁QR S ▁e je ction _ fraction
D-751	-0.5831448435783386	cardiac resynchronization_therapy cRT mild_heart_ failure QRS ejection_fraction
P-751	-0.4362 -0.5362 -0.0050 -0.0027 -0.2047 -0.8681 -1.0775 -2.6020 -0.0369 -0.9434 -0.4745 -0.2109 -0.2998 -1.8048 -0.3910 -0.4592 -0.7895 -0.1074 -0.0562 -0.8528 -0.0199 -1.1240 -0.1096
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional_flow_reserve positron_emission_tomography ischemia bottleneck_stenting left_ventricle lad
H-509	-0.5523638725280762	▁Fra ction _ ▁flow _ ▁reserve ▁measure ments ▁posi tron _ ▁e mission _ ▁tom ography _ ▁imagin g ▁severe ▁ ische mia ▁bottle ne ck ▁sten ting ▁left _ ▁vent ric le ▁proxima l ▁ LAD
D-509	-0.5523638725280762	Fraction_ flow_ reserve measurements positron_ emission_ tomography_ imaging severe ischemia bottleneck stenting left_ ventricle proximal LAD
P-509	-0.5678 -0.0004 -1.8136 -0.9104 -0.1730 -0.2202 -2.9078 -0.1188 -0.0092 -0.0039 -0.8299 -0.8132 -0.0609 -0.2225 -0.8153 -0.1691 -1.3914 -1.3379 -0.0078 -1.4661 -0.2033 -0.0347 -0.0218 -0.0040 -0.0173 -0.0027 -0.7727 -0.0238 -0.0462 -0.6197 -3.6798 -1.3014 -0.5324 -0.0030 -0.0005 -0.2460 -0.0007 -0.1292 -0.0639
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2007	-0.8132860660552979	▁economic _ analys is ▁Patient _ management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁cost - E ff ective ness _ model
D-2007	-0.8132860660552979	economic_analysis Patient_management_ Interventions Heart_ Failure cost-Effectiveness_model
P-2007	-0.6965 -0.5708 -0.7588 -0.2215 -4.4072 -0.3737 -0.4723 -0.2078 -1.1427 -0.0041 -0.0682 -0.0835 -1.0205 -0.0194 -0.0971 -0.0587 -1.6351 -1.1937 -0.0709 -0.6546 -2.3810 -0.4271 -2.6083 -0.3453
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin_inhibitors natriuretic_peptide atrial_natriuretic_peptide b-type_natriuretic_peptide
H-1462	-0.3358412981033325	▁Ne pri ly sin _ ▁inhibi tors ▁na tri ure tic _ pe pti de ▁break down ▁at rial ▁na tri ure tic _ pe pti de ▁b - type ▁na tri ure tic _ pe pti de
D-1462	-0.3358412981033325	Neprilysin_ inhibitors natriuretic_peptide breakdown atrial natriuretic_peptide b-type natriuretic_peptide
P-1462	-0.7753 -0.0214 -3.3818 -0.2373 -1.0210 -0.0498 -0.0263 -0.0126 -0.1560 -0.7621 -0.3020 -0.1695 -0.0795 -0.1460 -1.1141 -0.8215 -0.0125 -0.5598 -0.0026 -0.2244 -0.0294 -0.1557 -0.1880 -0.1812 -0.0869 -0.0249 -0.2470 -1.0224 -0.0380 -0.0584 -0.0753 -0.0434 -0.1440 -0.3227 -0.1842 -0.0982 -0.0259 -0.4088 -0.1420 -0.0819
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional_electrical_stimulation peripheral_muscles endothelial_function clinical heart_failure patients preserved_left_ventricular_ejection_fraction
H-1326	-0.7926523685455322	▁Fun ction al _ elektr al _ stimul ation ▁per i pher al _ ▁muscle s ▁en dot heli al _ function ▁heart _ ▁failure _ ▁patients ▁pres er ved ▁left _ ▁vent ri cular _ e je ction
D-1326	-0.7926523685455322	Functional_elektral_stimulation peripheral_ muscles endothelial_function heart_ failure_ patients preserved left_ ventricular_ejection
P-1326	-1.3586 -0.0096 -0.8766 -0.9023 -1.4053 -0.1171 -0.4765 -0.1415 -0.0080 -0.0177 -0.1643 -0.0006 -0.0142 -0.2266 -0.8991 -0.0158 -0.0102 -0.2000 -0.0021 -0.0012 -1.0727 -0.4074 -4.2899 -1.0621 -1.0548 -4.4963 -2.1696 -0.1088 -0.0327 -0.0152 -0.0759 -0.2416 -5.8141 -0.5089 -0.5040 -0.6632 -0.9291 -0.2001 -0.1578 -1.7122 -0.1349
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.7771080732345581	▁base line ▁SD QT - to - SD RR _ rati o ▁ HF VT ▁ HF VT ▁h Nor m
D-1441	-0.7771080732345581	baseline SDQT-to-SDRR_ratio HFVT HFVT hNorm
P-1441	-0.3040 -0.0024 -0.0496 -1.5778 -0.1069 -0.0337 -0.0061 -0.0193 -0.1443 -0.7855 -0.5951 -0.1221 -0.0127 -0.0068 -0.3164 -2.7305 -1.2732 -4.4089 -3.5499 -0.7462 -0.0043 -0.9638 -0.1139
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular wall_stiffness
H-1148	-0.8458109498023987	▁alter ed ▁vent ri cular _ structure ▁fiber _ she et ▁ orientation ▁handling ▁slow ed ▁con duction ▁wall ▁sti ff ness
D-1148	-0.8458109498023987	altered ventricular_structure fiber_sheet orientation handling slowed conduction wall stiffness
P-1148	-3.1388 -0.0932 -0.0920 -1.0404 -0.1276 -1.2674 -1.4891 -1.7453 -1.7194 -0.0067 -0.0373 -1.2082 -0.0008 -3.6577 -0.5351 -0.0706 -0.8587 -0.0171 -1.7778 -0.8247 -0.0855 -0.2722 -0.1114 -0.1226
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad q66p cardiomyopathy
H-1677	-0.666785717010498	▁Rad ▁Q 66 p ▁cardio my o pathy ▁l - type ▁channel - dependent _ process es
D-1677	-0.666785717010498	Rad Q66p cardiomyopathy l-type channel-dependent_processes
P-1677	-0.6920 -2.9370 -0.0437 -0.9901 -0.0295 -0.6738 -0.3713 -0.0879 -3.3837 -0.1583 -0.0097 -1.6728 -0.2796 -0.0026 -0.6996 -0.3166 -0.0598 -0.1299 -0.1310
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin chemotherapy elevated cardiotoxicity
H-937	-0.6307637095451355	▁se rum ▁resist in ▁an thra cycli ne - conta ining _ Che mo therapy ▁cardio toxic ity
D-937	-0.6307637095451355	serum resistin anthracycline-containing_Chemotherapy cardiotoxicity
P-937	-0.0661 -0.0005 -0.1178 -0.1191 -1.7911 -0.0186 -1.5386 -1.9793 -0.3417 -0.4074 -0.0939 -0.0735 -1.7044 -0.0802 -0.7053 -0.1173 -3.2348 -0.1650 -0.0284 -0.0323
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients sst2 titrated cardiovascular_event
H-405	-0.8302440643310547	▁s st 2 ▁ti tra ted ▁high - dos e _ ▁BB ▁cardiovascular _ event _ ▁rate ▁lo west ▁cum ul ative _ ▁hazard
D-405	-0.8302440643310547	sst2 titrated high-dose_ BB cardiovascular_event_ rate lowest cumulative_ hazard
P-405	-0.1194 -2.2597 -0.0934 -2.8823 -0.0022 -0.0400 -0.1025 -0.0080 -0.6694 -0.0840 -1.2854 -2.2102 -1.4604 -0.5816 -1.3213 -1.0410 -0.6963 -2.4850 -0.0048 -3.1912 -0.0446 -0.0117 -0.3048 -0.4481 -0.0497 -0.1892
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative patients preoperative hypoalbuminemia albumin
H-533	-0.7438321709632874	▁post operativ e ▁hypo album in emia ▁normal _ album in _ ▁concentration
D-533	-0.7438321709632874	postoperative hypoalbuminemia normal_albumin_ concentration
P-533	-0.3940 -0.0138 -0.6248 -1.6769 -1.5154 -0.1706 -0.0819 -3.1767 -0.5270 -0.0301 -0.0416 -2.0076 -0.1343 -0.6894 -0.0734
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration renin-angiotensin_system_blocker beta-blocker therapy patients hospitalized heart_failure preserved_left_ventricular_ejection_fractions
H-174	-0.7196637988090515	▁re nin - angi oten sin _ system _ ▁block er ▁beta - block er ▁ therapy ▁heart _ ▁failure ▁pres er ved ▁left ▁vent ri cular _ e je ction
D-174	-0.7196637988090515	renin-angiotensin_system_ blocker beta-blocker therapy heart_ failure preserved left ventricular_ejection
P-174	-0.0026 -0.0787 -0.0255 -0.1154 -1.2612 -0.5067 -1.6106 -0.0952 -1.2241 -0.7202 -1.1890 -0.0739 -0.0084 -0.0563 -0.1264 -2.1537 -0.0268 -0.3480 -1.6349 -1.3444 -0.4357 -0.0509 -0.0217 -0.2145 -5.0008 -0.7222 -1.1981 -0.5719 -1.0740 -0.2427 -0.2214 -1.2403 -0.1525
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use_of_exercise_and_medical_therapies_to_improve_cardiac_function_among_patients_with_exertional_shortness_of_breath_due_to_lung_congestion
H-1180	-0.6810008883476257	▁exercise ▁medical _ therapie s ▁Card iac _ ▁Fun ction ▁ex er tional ▁Short ness _ of _ ▁Breath _ ▁Du e ▁Lung _ con gestion
D-1180	-0.6810008883476257	exercise medical_therapies Cardiac_ Function exertional Shortness_of_ Breath_ Due Lung_congestion
P-1180	-0.5343 -2.3011 -0.7699 -0.3228 -0.0086 -3.0626 -0.0620 -0.1447 -1.1518 -0.0035 -2.4139 -0.0263 -0.0044 -1.5030 -0.2605 -1.1874 -0.8412 -0.8991 -0.0739 -0.8706 -1.4903 -0.0037 -0.2694 -0.4604 -0.1001 -0.0007 -0.2496 -0.0524
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse hospitalization physician discharge patients hospitalized heart_failure
H-206	-1.2577186822891235	▁nurse ▁assessment ▁cognitive _ ▁im pair ment ▁hospital ization ▁physician ▁dis charge ▁co hor t ▁el der ly ▁patients ▁heart _ ▁failure
D-206	-1.2577186822891235	nurse assessment cognitive_ impairment hospitalization physician discharge cohort elderly patients heart_ failure
P-206	-0.1660 -3.9846 -0.8293 -0.5681 -0.8728 -0.0252 -0.1047 -2.1409 -0.1364 -1.5718 -3.1675 -0.0028 -3.5984 -0.0028 -0.1721 -4.9631 -0.0221 -0.0940 -2.4971 -1.5768 -0.7237 -2.5350 -0.0840 -0.3462
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients heart_failure heart cardiologists cardiovascular surgeons medical patient
H-1822	-0.8166923522949219	▁heart _ team ▁cardio logist s ▁cardiovascular _ ▁surge ons ▁medical
D-1822	-0.8166923522949219	heart_team cardiologists cardiovascular_ surgeons medical
P-1822	-4.8866 -0.5930 -0.2842 -1.0081 -0.1340 -0.2018 -0.1214 -0.8652 -0.5019 -0.0119 -0.6240 -1.3144 -0.0704
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action randomized patients hf ejection_fraction exercise training
H-1632	-1.2742000818252563	▁ HF - AC TION ▁ HF ▁ HF ▁e je ction ▁ fraction
D-1632	-1.2742000818252563	HF-ACTION HF HF ejection fraction
P-1632	-0.2194 -0.3470 -0.3564 -0.8034 -0.9636 -0.7313 -0.3804 -4.1928 -0.9996 -4.6317 -0.4178 -0.0672 -1.6332 -0.0075 -4.2546 -0.3813
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates alendronate etidronate heart_failure compliance
H-1542	-0.49503985047340393	▁bis phos phon ates ▁ale ndr onate ▁et id rona te ▁risk _ of _ heart _ fail
D-1542	-0.49503985047340393	bisphosphonates alendronate etidronate risk_of_heart_fail
P-1542	-0.3367 -0.0204 -0.5249 -0.0960 -0.2020 -0.0040 -0.0337 -0.0020 -0.4757 -0.0131 -0.0045 -0.2296 -0.9172 -0.0572 -0.1018 -0.2706 -1.0876 -2.9649 -2.5033 -0.0554
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute_rv_failure pulmonary_embolism mortality diagnostic
H-1097	-0.6914149522781372	▁a cute ▁ RV _ ▁failure ▁pulmonar y _ e mbol ism
D-1097	-0.6914149522781372	acute RV_ failure pulmonary_embolism
P-1097	-0.5026 -0.0135 -1.6944 -0.1627 -1.3009 -0.7459 -0.0649 -0.0083 -0.1329 -1.2753 -0.0024 -0.0214 -3.3913 -0.3633
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse pasp downward hfref hfpef prognostic resolution
H-500	-0.7559211254119873	▁T AP se ▁PAS P ▁non sur viv ors ▁H Fr EF ▁ HF p EF
D-500	-0.7559211254119873	TAPse PASP nonsurvivors HFrEF HFpEF
P-500	-2.1007 -0.6080 -1.4062 -4.6147 -0.8807 -0.7496 -0.0189 -0.0040 -0.0171 -0.9132 -0.0910 -0.1401 -0.2715 -0.0014 -0.0072 -0.5318 -1.0928 -0.1576
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine patients dilated_cardiomyopathy dcm heart_failure
H-1258	-0.555991530418396	▁Chinese _ medicin e ▁ad ju nc tive _ ▁treatment ▁dil ated _ ▁cardio my o pathy DC M ▁heart _ ▁failure
D-1258	-0.555991530418396	Chinese_medicine adjunctive_ treatment dilated_ cardiomyopathyDCM heart_ failure
P-1258	-1.6918 -0.6659 -1.5048 -1.1059 -1.1060 -0.0067 -0.0021 -0.0057 -0.3894 -0.8319 -0.6377 -0.0514 -0.0654 -0.2540 -1.8643 -0.5094 -0.0464 -0.6492 -0.4615 -0.0823 -0.5833 -0.7227 -0.0431 -0.0629
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex_sensitivity heart_rate_variability hrv renal_dnx
H-1376	-0.574374258518219	▁Baro re flex _ sensitiv ity ▁time ▁domain ▁heart _ ▁rate _ ▁variabil ity HR V ▁CHF - IN V ▁sham - IN V ▁renal ▁DN x
D-1376	-0.574374258518219	Baroreflex_sensitivity time domain heart_ rate_ variabilityHRV CHF-INV sham-INV renal DNx
P-1376	-0.2373 -0.0162 -0.1240 -1.0415 -0.0071 -0.0034 -0.1026 -0.9659 -0.7018 -0.4527 -0.9147 -1.1263 -0.4293 -0.0129 -3.6560 -0.2240 -0.0515 -0.1213 -0.6615 -0.9377 -0.0305 -0.3375 -0.6794 -1.3522 -1.0968 -0.9082 -0.2682 -0.0691 -0.1273
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension diabetes_mellitus grade systolic diastolic_murmurs apex
H-347	-0.2623099386692047	▁hyper tension ▁diabetes ▁mell itus ▁sy sto lic _ ▁mur mur s
D-347	-0.2623099386692047	hypertension diabetes mellitus systolic_ murmurs
P-347	-0.6006 -0.0023 -0.1945 -0.1632 -0.0294 -0.1074 -0.0379 -0.0964 -1.0143 -0.6208 -0.0088 -0.1012 -0.6341 -0.0615
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective nicorandil hemodynamic mitochondrial_dysfunction administration doxorubicin
H-956	-0.29803362488746643	▁cardio protec tive _ effect ▁nic oran dil ▁hem o dynamic ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin ▁rat s
D-956	-0.29803362488746643	cardioprotective_effect nicorandil hemodynamic mitochondrial_ dysfunction doxorubicin rats
P-956	-0.0280 -0.5004 -0.0172 -0.6340 -0.1014 -0.8470 -0.0457 -0.1020 -0.3565 -0.0194 -0.0004 -1.2364 -1.5557 -0.0952 -0.0054 -0.3145 -0.3085 -0.0101 -0.7923 -0.0511 -0.0414 -0.4201 -0.1073 -0.0257 -0.0680 -0.0653
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left_bundle_branch_block remodeling dyssynchronous_heart_failure hf heart
H-1147	-0.5571105480194092	▁bund le _ ▁bran ch _ ▁block ▁electric al _ activa tion ▁dys syn chron ous _ heart _ ▁failure ▁electro me chan ical _ ▁behavior
D-1147	-0.5571105480194092	bundle_ branch_ block electrical_activation dyssynchronous_heart_ failure electromechanical_ behavior
P-1147	-3.6220 -0.1497 -0.7543 -1.9890 -0.0027 -0.6094 -0.4420 -0.0548 -0.0032 -0.2245 -0.6187 -0.0119 -0.0906 -0.0010 -0.0005 -0.0855 -0.1812 -0.7861 -0.2386 -2.1891 -0.2722 -0.0055 -0.0000 -0.0043 -0.6347 -0.6121 -1.8828 -0.1325
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in_vivo mir-25 antagomir cardiac_dysfunction murine myocardium heart_failure
H-643	-0.5291380882263184	▁in ▁vivo ▁inhibi tion ▁mi R -25 ▁anta go mir ▁spontane ous ▁cardiac _ ▁dys function ▁mur ine ▁my o car dium ▁heart _ ▁failure ▁Hand 2- dependent
D-643	-0.5291380882263184	in vivo inhibition miR-25 antagomir spontaneous cardiac_ dysfunction murine myocardium heart_ failure Hand2-dependent
P-643	-0.8326 -0.0653 -0.1083 -0.0124 -0.4303 -0.4715 -0.0470 -3.6129 -0.0233 -0.3405 -0.0231 -0.0058 -0.3005 -0.4860 -0.1864 -0.0234 -0.0088 -0.0057 -2.1883 -0.0690 -0.2570 -0.8109 -1.1559 -1.1835 -2.1232 -0.1103 -0.2685 -0.0544 -0.5103 -0.1591
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated nt-probnp admission all-cause_mortality patients acute_hf admission
H-270	-0.512662410736084	▁NT - pro b NP ▁ad mission ▁all - ca use _ ▁mortal ity ▁a cute ▁ HF
D-270	-0.512662410736084	NT-probNP admission all-cause_ mortality acute HF
P-270	-0.2906 -0.0282 -0.0038 -1.4849 -0.2815 -2.9633 -0.0254 -2.8860 -0.0105 -0.0009 -0.0381 -0.3828 -0.2077 -0.0076 -0.1136 -0.0024 -1.1750 -0.0025 -0.1938 -0.1548
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic proteins histone_acetyltransferases epigenetic histone_deacetylases cardiac disease
H-1041	-0.302884578704834	▁epi gene tic _ writer _ ▁protein s hi stone ▁a ce tyl transfer as es ▁epi gene tic _ eras ers hi stone ▁de ace ty las es ▁cardiac
D-1041	-0.302884578704834	epigenetic_writer_ proteinshistone acetyltransferases epigenetic_erasershistone deacetylases cardiac
P-1041	-0.0259 -0.0088 -0.0330 -1.0662 -0.2984 -1.0896 -0.2064 -0.0203 -0.1984 -0.0189 -0.2223 -0.0449 -0.2005 -0.8630 -0.8321 -0.0203 -0.0145 -0.0019 -0.0330 -0.7461 -0.0957 -0.0094 -0.1754 -0.1300 -0.6637 -0.1890 -0.1609 -0.1782 -0.0027 -0.0064 -2.0351 -0.1012
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic_cell_transplantation hct congestive_heart_failure chf anthracyclines
H-1449	-0.7740527987480164	▁ha e mato po ie tic _ cell _ ▁transplant ation ▁ha e mato po ie tic _ cell _ ▁transplant ation ▁h CT _ ▁sur viv ors ▁con ges tive _ heart _ ▁failure CH F ▁pre - H CT ▁an thra cycli nes
D-1449	-0.7740527987480164	haematopoietic_cell_ transplantation haematopoietic_cell_ transplantation hCT_ survivors congestive_heart_ failureCHF pre-HCT anthracyclines
P-1449	-0.0888 -0.2367 -0.0308 -0.7428 -3.4826 -0.0264 -0.5534 -2.7674 -1.4177 -0.3492 -0.0201 -2.8416 -0.0435 -0.0081 -0.1872 -1.5081 -0.0269 -0.1508 -3.0515 -0.8055 -1.2164 -0.0312 -1.6031 -0.0605 -2.9107 -1.3168 -0.0002 -0.0320 -0.0350 -0.0246 -0.0717 -0.1218 -2.2694 -0.4690 -2.8017 -3.2858 -0.1673 -0.0604 -0.0025 -0.1885 -0.1146 -0.1516 -0.0021 -0.5612 -0.3265 -0.1365 -0.0804
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol nonselective_β-blocker selective_β-blocker metoprolol thromboembolic_events heart_failure
H-1111	-0.9354057312011719	▁car vedi lol ▁non sel ective ▁β - block er ▁β - block er _ met o pro lol ▁ thro mbo e mbol ic _ ▁events ▁heart _ ▁failure
D-1111	-0.9354057312011719	carvedilol nonselective β-blocker β-blocker_metoprolol thromboembolic_ events heart_ failure
P-1111	-0.6461 -0.0153 -0.0496 -3.0761 -0.0219 -0.0126 -0.2388 -0.0238 -0.1640 -1.3447 -4.7887 -0.0318 -0.6438 -1.8222 -3.8004 -1.5991 -0.2959 -0.1666 -0.1947 -0.4430 -0.0695 -0.7724 -2.0611 -0.1412 -0.3788 -0.5619 -1.5601 -0.6777 -0.5387 -3.4257 -0.1119 -0.2550
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ami pna mortality
H-1700	-1.4364415407180786	▁quality ▁ HF ▁ AMI ▁p na
D-1700	-1.4364415407180786	quality HF AMI pna
P-1700	-5.2281 -0.4428 -0.0752 -0.4943 -0.0463 -1.5992 -1.0747 -3.8460 -0.1214
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline cardiac_transplant ecct
H-716	-1.022552728652954	▁base line _ cri me ▁cardiac _ ▁transplant _ ▁survival
D-716	-1.022552728652954	baseline_crime cardiac_ transplant_ survival
P-716	-0.4223 -0.0051 -2.3084 -3.4334 -0.6766 -0.1003 -0.5112 -1.0737 -0.7186 -2.1334 -0.7894 -0.0982
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients heart_failure hf evidence outcomes hf
H-685	-1.0594518184661865	▁dieta ry _ ▁recommendations ▁patients ▁heart _ ▁failure ▁ HF
D-685	-1.0594518184661865	dietary_ recommendations patients heart_ failure HF
P-685	-1.6819 -0.0779 -1.4666 -1.2955 -2.2345 -2.3440 -0.2077 -1.6392 -1.4942 -0.0013 -0.2236 -0.0471
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling arrhythmia ami hr_variability arrhythmia
H-1590	-0.5558286905288696	▁ar rhythm ia _ ▁substrat e ▁ AMI ▁HR _ ▁variabil ity
D-1590	-0.5558286905288696	arrhythmia_ substrate AMI HR_ variability
P-1590	-0.4730 -0.1164 -0.8627 -0.7921 -0.0105 -0.0230 -0.4121 -0.0043 -0.1398 -2.0511 -0.1313 -0.0031 -2.5209 -0.2413
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients hypertension compensated_hfpef dash sodium
H-919	-0.813707709312439	▁treated ▁hyper tension ▁compensa ted ▁H FP EF ▁DAS h / S RD tar get ▁so dium
D-919	-0.813707709312439	treated hypertension compensated HFPEF DASh/SRDtarget sodium
P-919	-3.0296 -0.3460 -0.0216 -0.0065 -0.0139 -0.4930 -0.0274 -0.7070 -0.0901 -0.8828 -1.7384 -0.4664 -0.6388 -4.7442 -0.0011 -0.2110 -0.3435 -1.6329 -0.0664
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd dyssynchronous_hf remodeling insignificantly
H-1154	-0.36033838987350464	▁de rang ed _ ca (2 +) ▁handling ▁EM d ▁dys syn chron ous ▁ HF ▁remodel ing
D-1154	-0.36033838987350464	deranged_ca(2+) handling EMd dyssynchronous HF remodeling
P-1154	-0.9663 -0.0030 -0.0015 -0.8383 -0.0224 -1.1244 -0.0145 -0.0410 -1.6846 -0.8044 -0.0070 -0.0008 -0.0003 -0.1314 -0.6123 -0.0002 -0.4828 -0.0096 -0.3365 -0.1253
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ejection_fraction cardiac_index inotropes medical transplant
H-1997	-0.46827569603919983	▁e je ction _ fraction ▁cardiac _ index ▁in o trop es ▁in ot rope
D-1997	-0.46827569603919983	ejection_fraction cardiac_index inotropes inotrope
P-1997	-0.1517 -0.0202 -0.0365 -1.3725 -0.0038 -0.0736 -0.5546 -0.7414 -0.1749 -0.2048 -0.0676 -1.5961 -0.0210 -0.3101 -0.0228 -2.4335 -0.1759
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced_cardiotoxicity resistin retn
H-933	-0.31062546372413635	▁do xor ubi cin - indu ced _ ▁cardio toxic ity ▁Hum - Re t n _ mi ce ▁litt er mate ▁human ▁resist in
D-933	-0.31062546372413635	doxorubicin-induced_ cardiotoxicity Hum-Retn_mice littermate human resistin
P-933	-0.0022 -0.0251 -0.0719 -1.1796 -0.2081 -0.0035 -0.0599 -0.5213 -0.1790 -1.7112 -0.4176 -0.0513 -0.0441 -0.2000 -0.0428 -0.0103 -0.7475 -0.2352 -0.0360 -0.0010 -0.0387 -0.1680 -1.0726 -0.7745 -0.1238 -0.3919 -0.0697
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic_dysfunction pathophysiology hfpef cardiovascular_function
H-1302	-0.5428315997123718	▁dia sto lic _ dis function ▁pat ho phy si ology ▁ HF p EF ▁non - dia sto lic _ ▁ab normal ities ▁cardiovascular
D-1302	-0.5428315997123718	diastolic_disfunction pathophysiology HFpEF non-diastolic_ abnormalities cardiovascular
P-1302	-1.2176 -0.9988 -2.4614 -0.3527 -1.1657 -0.0836 -0.1750 -0.0355 -0.0920 -1.6991 -0.0098 -0.1962 -0.0018 -0.0078 -0.0317 -1.8501 -0.0124 -0.0054 -0.3166 -0.4181 -0.3572 -1.0160 -0.0123 -0.0099 -0.0211 -2.0412 -0.0675
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp phosphomimic ser77 ser83 riα proteins riα
H-1432	-0.6451066732406616	▁8- flu o - c AMP ▁ binding ▁wild ▁type ▁ phos pho mi mic ▁Ser 77 ▁ser 83 ▁mu tant ▁RI α ▁double _ mu tant ▁ WT _ ri α
D-1432	-0.6451066732406616	8-fluo-cAMP binding wild type phosphomimic Ser77 ser83 mutant RIα double_mutant WT_riα
P-1432	-0.4205 -0.0258 -0.3632 -0.1564 -1.3793 -0.2542 -0.1275 -0.0036 -1.4450 -0.7766 -0.0116 -0.0044 -0.2743 -0.1640 -1.2070 -0.3093 -0.2235 -0.8913 -0.6322 -1.8273 -0.1771 -1.3593 -1.5429 -2.3425 -0.2012 -0.3329 -0.0849 -0.1670 -0.7791 -0.6749 -1.4214 -1.8584 -0.1856 -0.3095
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density_lipoprotein hdl endothelial_cell nitric_oxide
H-246	-0.5823379158973694	▁high - dens ity ▁lipo prote in HD L ▁en dot heli al - protec tive ▁en dot heli al _ cell ▁ni tric ▁oxid e NO
D-246	-0.5823379158973694	high-density lipoproteinHDL endothelial-protective endothelial_cell nitric oxideNO
P-246	-0.5371 -0.1289 -0.0169 -0.0214 -0.0667 -3.4440 -0.1388 -1.9977 -0.3327 -0.0085 -0.2104 -0.0345 -0.0028 -0.2404 -0.0176 -0.0276 -2.7530 -0.5057 -0.1571 -0.0039 -0.6785 -0.2401 -1.6718 -0.1251 -0.2020 -0.1029 -2.1234 -0.9978 -0.1004
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis patients hf hospitalization all-cause_hospitalization mortality hf hospitalization death
H-910	-0.7640183568000793	▁Dia lys is ▁ HF ▁hospital ization
D-910	-0.7640183568000793	Dialysis HF hospitalization
P-910	-0.7231 -0.0401 -0.2644 -2.3983 -0.0165 -0.6760 -0.2227 -2.4183 -0.1167
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome admission discharge hospitalized heart_failure hf nursing_outcomes_classification noc
H-1398	-0.8868680000305176	▁outcome s ▁ad mission ▁to ▁dis charge ▁hospital ized _ hospital ized _ hospital ized _ hospital ized _ hospital ized _ hospital ized _ person s ▁heart _ ▁failure _ HF ▁Nur sing _ out com es ▁Classifica tion NO C
D-1398	-0.8868680000305176	outcomes admission to discharge hospitalized_hospitalized_hospitalized_hospitalized_hospitalized_hospitalized_persons heart_ failure_HF Nursing_outcomes ClassificationNOC
P-1398	-3.6274 -0.5822 -0.0260 -0.0072 -1.2690 -0.0136 -0.0008 -0.1454 -0.0696 -1.0005 -1.7411 -0.1335 -0.3432 -2.3042 -0.2318 -0.2732 -2.4187 -0.3688 -0.2297 -2.5322 -0.5339 -0.2293 -2.7451 -0.7281 -0.2194 -4.5459 -1.0145 -1.2232 -0.2625 -3.6310 -2.0055 -0.1406 -0.7752 -0.0090 -0.3409 -0.4621 -0.0435 -0.2607 -1.4533 -0.0156 -0.5642 -0.2703 -0.0938 -0.1367
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort_study saxagliptin sitagliptin antihyperglycemic_agents
H-1840	-0.7726287841796875	▁h HF ▁sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic _ agent
D-1840	-0.7726287841796875	hHF saxagliptin sitagliptin antihyperglycemic_agent
P-1840	-0.5790 -2.4302 -0.5939 -0.0189 -1.0797 -2.5323 -0.3035 -0.0103 -0.2092 -0.9552 -0.0132 -0.8181 -0.1403 -2.8317 -0.0673 -1.5553 -0.7720 -0.1497 -0.3508 -0.0419
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate_analysis preoperative albumin mortality lvad implantation hazard_ratio confidence_interval
H-535	-0.49451929330825806	▁pre operativ e ▁album in ▁mortal ity ▁L VAD _ ▁implant ation
D-535	-0.49451929330825806	preoperative albumin mortality LVAD_ implantation
P-535	-0.0349 -0.0096 -0.2033 -0.7160 -0.1806 -0.1392 -0.0149 -1.8690 -0.0066 -2.1971 -0.2945 -0.1160 -1.0177 -0.1240
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients systolic_heart_failure qrs_duration crt death hospitalization heart_failure mortality
H-854	-0.8519493937492371	▁sy sto lic _ heart _ ▁failure ▁QR S _ ▁du ration ▁c RT ▁rate _ of _ hospital ization ▁heart _ ▁failure
D-854	-0.8519493937492371	systolic_heart_ failure QRS_ duration cRT rate_of_hospitalization heart_ failure
P-854	-0.6440 -0.5364 -0.2860 -0.2433 -1.0922 -0.3147 -1.4571 -0.0543 -0.7884 -1.1197 -0.2487 -0.0078 -3.3201 -1.2059 -1.9465 -2.2770 -0.1438 -0.2910 -1.5280 -0.2547 -0.9171 -0.1310 -1.8692 -0.4946 -0.1272
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially_expressed_genes degs ischemic_heart_failure healthy diagnosis heart_failure
H-1608	-0.9973246455192566	▁differenti ally _ ▁express ed _ ▁gene s ▁non - ische mic ▁ ische mic _ heart _ ▁failure ▁healthy _ control
D-1608	-0.9973246455192566	differentially_ expressed_ genes non-ischemic ischemic_heart_ failure healthy_control
P-1608	-5.3440 -0.3857 -1.5229 -1.6086 -0.0070 -0.4308 -0.6912 -0.0175 -0.7850 -0.0171 -0.1372 -0.0226 -1.7504 -0.1260 -0.0327 -1.2703 -3.3164 -0.8829 -2.3340 -0.1213 -0.8478 -0.0416 -2.0906 -0.1526
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse_events reoperation bleeding driveline infection gastrointestinal_bleeding stroke rankin_score
H-2003	-0.2181522250175476	▁re opera tion ▁drive line _ ▁infection ▁gastro inte stin al ▁ble ed ing ▁de bilitat ing _ ▁stroke
D-2003	-0.2181522250175476	reoperation driveline_ infection gastrointestinal bleeding debilitating_ stroke
P-2003	-0.6238 -0.0157 -0.0111 -0.1719 -0.0233 -0.5611 -0.9777 -0.0020 -0.0210 -0.2308 -0.0072 -0.7571 -0.0282 -0.0248 -0.0310 -0.0002 -0.0020 -0.8249 -0.1115 -0.1251 -0.0307
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox_regression_models propensity_score oral glucocorticoid hf hospitalisations loop_diuretics
H-605	-0.5649335980415344	▁co x ▁re gression _ ▁models ▁pro pens ity _ ▁score ▁de cile ▁oral ▁gluco cor tico id _ ▁dos age ▁ HF _ hospital isation s ▁loop _ di ure tics
D-605	-0.5649335980415344	cox regression_ models propensity_ score decile oral glucocorticoid_ dosage HF_hospitalisations loop_diuretics
P-605	-0.0809 -0.0038 -0.2246 -0.0012 -2.0605 -1.4325 -0.0007 -0.0086 -0.0119 -0.4488 -0.2342 -0.0415 -0.0004 -0.0015 -0.2210 -0.4876 -1.3812 -3.3659 -1.1230 -1.4845 -0.0293 -0.0648 -0.0002 -1.6463 -0.1754 -0.0453 -0.0672 -0.3964 -0.2436 -1.9276 -0.5888 -1.2492 -0.0744 -0.0846
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin_resistance type_2_diabetes insulin_receptor_substrates_1 irs1 irs2 cellular_metabolism
H-653	-0.6069257259368896	▁insulin _ ▁resist ance ▁type ▁2 ▁diabetes ▁insulin _ ▁receptor _ ▁substrat es ▁i RS 2 ▁insulin - signal ing _ element s ▁regula ting ▁cel lular ▁metabolism
D-653	-0.6069257259368896	insulin_ resistance type 2 diabetes insulin_ receptor_ substrates iRS2 insulin-signaling_elements regulating cellular metabolism
P-653	-1.0969 -0.5680 -0.3579 -0.0005 -0.3289 -0.5322 -0.0306 -0.0051 -0.5442 -0.2417 -0.7929 -0.1244 -0.0833 -3.0457 -0.2200 -2.0095 -0.1259 -0.1036 -0.0055 -0.1300 -1.5753 -1.3575 -0.0214 -1.6167 -0.1056 -1.5306 -0.0004 -1.0280 -0.5450 -0.0805
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous_hf electromechanical_delay emd myocyte_depolarization myofiber_shortening
H-1149	-0.3016340136528015	▁dys syn chron ous ▁ HF ▁electro me chan ical _ de lay EM D ▁local ▁my o cy te ▁de po lar ization ▁my o fi ber ▁short en ing _ ▁ons et
D-1149	-0.3016340136528015	dyssynchronous HF electromechanical_delayEMD local myocyte depolarization myofiber shortening_ onset
P-1149	-0.2735 -0.0036 -0.0002 -0.4028 -0.3828 -0.0004 -0.0007 -0.0076 -0.0002 -0.0068 -0.1556 -0.4082 -0.0004 -2.4041 -0.8721 -0.2381 -0.3253 -0.1453 -1.4558 -0.9644 -0.6024 -0.0045 -0.0403 -0.0677 -0.0580 -0.0170 -0.0426 -0.0144 -0.1417 -0.0488 -0.1480 -0.7231 -0.6123 -0.0484 -0.1127 -0.1286
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta_blockers all-cause_mortality readmissions heart_failure_with_reduced_ejection_fraction hfref heart_rate
H-1936	-0.9256197214126587	▁Beta _ block ers ▁read missions ▁heart _ ▁failure ▁e je ction _ fraction HF r EF ▁heart _ rate
D-1936	-0.9256197214126587	Beta_blockers readmissions heart_ failure ejection_fractionHFrEF heart_rate
P-1936	-1.0074 -0.9345 -1.4241 -0.0293 -2.4009 -0.0173 -0.2011 -0.3142 -1.4299 -3.2844 -0.3406 -0.1679 -1.2734 -0.1620 -4.1174 -0.0662 -0.1251 -0.8568 -0.3508 -0.7846 -0.9957 -0.0800
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional_electrical_stimulation fes exercise_capacity quality_of_life endothelial_function chronic_heart_failure systolic_function
H-1327	-0.5921669006347656	▁Fun ction al _ elektr al _ stimul ation ▁f es ▁exercise _ capaci ty ▁emotional ▁stress ▁en dot heli al _ function ▁chronic _ heart _ ▁failure ▁sy sto lic _ function
D-1327	-0.5921669006347656	Functional_elektral_stimulation fes exercise_capacity emotional stress endothelial_function chronic_heart_ failure systolic_function
P-1327	-0.8088 -0.0029 -0.0889 -0.5408 -1.0936 -0.0270 -0.1683 -0.1833 -0.0129 -1.6483 -0.8206 -0.1072 -1.1891 -0.6547 -0.8398 -0.0382 -0.2974 -0.0270 -0.0896 -0.0050 -0.0007 -0.8291 -0.6190 -1.0265 -0.6870 -0.6995 -1.2093 -1.7990 -2.4811 -0.2322 -0.9359 -0.9914 -0.4729 -0.0560 -0.0428
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report patient right_atrial_myxoma massive_embolism pulmonary_arteries surgically right_atrial pulmonary_embolectomy
H-595	-0.5168481469154358	▁right _ at rial _ my xo ma ▁pulmonar y _ ▁arteri es ▁right _ at rial _ ▁mass ▁remo val ▁pulmonar y _ e mbol ecto my
D-595	-0.5168481469154358	right_atrial_myxoma pulmonary_ arteries right_atrial_ mass removal pulmonary_embolectomy
P-595	-2.6681 -1.6384 -0.3761 -0.0079 -0.2256 -3.6602 -0.1516 -0.1342 -0.0864 -0.0051 -0.5103 -0.1228 -0.0278 -0.6897 -0.5214 -0.0981 -0.0033 -0.1200 -0.6226 -0.6828 -0.0156 -0.0003 -0.0061 -0.3913 -1.4684 -0.0021 -0.3317 -0.8457 -0.0649 -0.0265
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant patients pd hf clinical
H-896	-0.5619362592697144	▁transplant ▁in elig ible ▁patients ▁ HF ▁volume ▁management ▁clinic al _ data ▁pre - PD ▁initiat ion
D-896	-0.5619362592697144	transplant ineligible patients HF volume management clinical_data pre-PD initiation
P-896	-0.3307 -0.9296 -0.0002 -0.0109 -0.9489 -0.1186 -0.0133 -0.5461 -1.9255 -1.2121 -0.0408 -1.8437 -0.0909 -1.1503 -0.0050 -0.8215 -1.0661 -0.0039 -0.1408 -0.0398
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker clinical therapeutic
H-1478	-0.29691189527511597	▁statistic al _ standard s ▁bio mark er - guide d ▁clinic al _ ▁trial s ▁multi mark er - based
D-1478	-0.29691189527511597	statistical_standards biomarker-guided clinical_ trials multimarker-based
P-1478	-0.0259 -0.0748 -0.3843 -0.0122 -0.0019 -0.0168 -0.0051 -0.1206 -0.1433 -0.0010 -0.0159 -0.2100 -0.0167 -0.2649 -1.0927 -1.2779 -0.9201 -0.0205 -0.0511 -0.0585 -0.0176 -2.0053 -0.0920
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf incidence liver nodularity
H-231	-0.7072005867958069	▁ SAF _ co hor t ▁ab normal ▁ liver _ ▁texture s ▁no du lar ity
D-231	-0.7072005867958069	SAF_cohort abnormal liver_ textures nodularity
P-231	-1.2894 -0.0313 -2.6616 -0.0735 -0.0138 -0.0820 -0.0262 -0.0343 -1.5734 -0.2103 -0.5462 -1.3436 -2.3431 -1.2753 -0.0824 -1.0761 -0.0784 -0.3638 -0.3321
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty biological_phenotype physical activity
H-1004	-0.6066218614578247	▁Fra il ty ▁bi ological _ ▁ph eno type ▁we ak ▁grip _ streng th ▁physical _ ▁exhaust ion ▁low ▁activity ▁un inten tional _ weight
D-1004	-0.6066218614578247	Frailty biological_ phenotype weak grip_strength physical_ exhaustion low activity unintentional_weight
P-1004	-3.4660 -0.3990 -0.6297 -0.9940 -0.1360 -0.4876 -0.2075 -0.2300 -0.0030 -0.0762 -0.0032 -0.3698 -0.6784 -1.5213 -1.1025 -0.0103 -0.9575 -0.6444 -0.0848 -0.9184 -0.8233 -0.2419 -0.0016 -0.0052 -0.8436 -0.4048 -1.6030 -0.1423
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d patients ic crt-d ies
H-109	-1.4692482948303223	▁c RT - D ▁IE ▁IC
D-109	-1.4692482948303223	cRT-D IE IC
P-109	-3.5899 -0.3669 -0.0769 -0.5779 -3.0619 -2.5639 -1.3837 -0.1328
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds discharge patients heart_failure outcomes driven readmissions
H-467	-1.005231499671936	▁low - volu me _ ▁ED s ▁dis charge ▁patients ▁heart _ ▁failure ▁home
D-467	-1.005231499671936	low-volume_ EDs discharge patients heart_ failure home
P-467	-4.8186 -0.0083 -0.0202 -0.0012 -0.9928 -1.5848 -0.6147 -0.1567 -0.0011 -1.7487 -0.3264 -0.6410 -1.8254 -0.6675 -2.5783 -0.0982
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs_morphology outcomes cardiac_resynchronization_therapy resynchronization-defibrillation_for_ambulatory_heart_failure_trial raft
H-879	-0.31390708684921265	▁QR s ▁ morph ology ▁cardiac ▁re syn chron ization _ therapy ▁re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart _ ▁Fail ure _ Tri al RAF T
D-879	-0.31390708684921265	QRs morphology cardiac resynchronization_therapy resynchronization-Defibrillation Ambulatory_ Heart_ Failure_TrialRAFT
P-879	-0.0284 -0.8729 -0.6892 -0.0060 -0.0073 -0.3119 -0.1106 -0.0005 -0.0004 -0.1287 -0.6980 -2.1468 -0.1965 -0.0005 -0.0020 -0.1547 -0.7784 -0.8404 -0.9633 -0.1927 -0.0063 -0.1051 -0.0048 -0.0180 -0.0989 -0.5584 -0.0621 -0.6301 -0.0789 -0.1643 -0.5642 -0.0119 -0.5868 -0.1607 -0.0496 -0.0712
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute_right_heart_failure therapy refractory_cardiogenic_shock heart extra_corporeal_membrane_oxygenation ecmo cpr icu
H-1295	-0.58528071641922	▁a cute ▁right _ heart _ ▁failure ▁ therapy ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁heart _ team ▁corpore al _ ▁membran e _ ▁oxygen ation ▁c PR ICU
D-1295	-0.58528071641922	acute right_heart_ failure therapy refractory_ cardiogenic_ shock heart_team corporeal_ membrane_ oxygenation cPRICU
P-1295	-0.3074 -0.0035 -1.0545 -0.3810 -2.0433 -0.6808 -1.6962 -0.5480 -0.0044 -0.0323 -0.0007 -0.0354 -0.2310 -0.5568 -0.1878 -0.0450 -0.0960 -0.2794 -2.9333 -0.5684 -0.0051 -0.8144 -0.0098 -0.4141 -0.3183 -0.0224 -0.8233 -1.7232 -0.1350 -2.8880 -0.0382 -0.7326 -0.0860 -0.2041
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency_room undiagnosed heart_disease symptoms hf surgical_palliation
H-201	-0.9908900856971741	▁office - based ▁emergency _ room _ prac tice s ▁un diagnos ed _ heart _ ▁заболевания ▁ HF
D-201	-0.9908900856971741	office-based emergency_room_practices undiagnosed_heart_ заболевания HF
P-201	-4.0985 -0.0489 -0.0492 -1.1941 -0.2877 -0.6431 -1.7001 -1.1244 -0.0453 -2.1184 -1.2234 -0.0422 -0.0028 -0.7048 -0.8707 -0.5669 -2.9402 -1.7883 -0.0483 -1.0550 -0.2564
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene_expression bax pacing bcl-2 mrna expression heart_failure bcl-2 bax
H-168	-0.8735769391059875	▁Bax ▁b cl -2 ▁m RNA _ ▁expression ▁moderat e _ heart _ ▁failure ▁b cl - 2/ Ba x
D-168	-0.8735769391059875	Bax bcl-2 mRNA_ expression moderate_heart_ failure bcl-2/Bax
P-168	-3.2711 -1.6302 -0.0366 -0.3799 -0.0688 -0.0067 -2.6547 -0.8301 -2.1683 -0.0155 -0.9882 -0.6395 -0.8528 -1.7988 -0.7879 -0.0078 -0.0646 -0.1024 -2.0690 -0.0123 -0.6949 -0.1384
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart_magnetic_resonance_imaging chelation patient compliance heart_failure arrhythmias
H-745	-0.6545807123184204	▁heart ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation _ ▁choice s ▁single - institution _ co hor t ▁heart _ ▁failure ▁ar rhythm ias
D-745	-0.6545807123184204	heart magnetic_ resonance_ imaging chelation_ choices single-institution_cohort heart_ failure arrhythmias
P-745	-0.8326 -0.3594 -0.1527 -0.2864 -0.0753 -0.0119 -0.1656 -2.6115 -0.0349 -0.0135 -0.0022 -0.6770 -1.4563 -0.0374 -4.2635 -0.0247 -0.0005 -1.4730 -0.3440 -0.0007 -0.1021 -2.5966 -0.5656 -2.2764 -0.1807 -0.0210 -0.2680 -0.0917 -0.0577
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl hno inotropic lusitropic vasodilator in_vivo camp
H-413	-0.6168681979179382	▁ni tro x yl _ h NO ▁Angeli s ▁salt ▁ex ert s ▁positive ▁in o tropi c ▁ lusi tropi c ▁vaso dila tor _ effect ▁c AMP
D-413	-0.6168681979179382	nitroxyl_hNO Angelis salt exerts positive inotropic lusitropic vasodilator_effect cAMP
P-413	-0.0033 -0.0677 -0.3401 -0.4211 -2.2320 -2.8964 -1.0092 -0.7032 -2.9179 -0.0340 -2.2785 -0.0132 -0.0382 -0.0388 -0.1751 -1.0059 -0.0049 -0.8563 -0.1690 -0.0024 -0.0441 -0.4885 -0.0010 -0.0185 -0.0268 -2.3317 -0.4414 -0.3059 -0.0036 -0.1396 -0.1147
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection_fraction ef patients nyha_class_iiib symptoms right_ventricular_dysfunction
H-897	-1.0101052522659302	▁e je ction _ fraction _ EF ▁pre - PD
D-897	-1.0101052522659302	ejection_fraction_EF pre-PD
P-897	-0.4440 -0.1477 -0.0405 -0.9286 -0.1389 -3.7314 -1.2925 -0.2229 -0.0026 -0.0022 -5.0007 -0.1694
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs early-outgrowth_colony-forming_units eo-cfus cells
H-124	-0.5013298392295837	▁c PC s ▁early - out g row th ▁colon y - form ing _ ▁unit s EO - C FU s ▁circula ting ▁CD 34 ▁v EG FR 2 ▁CD 133 _ cell s
D-124	-0.5013298392295837	cPCs early-outgrowth colony-forming_ unitsEO-CFUs circulating CD34 vEGFR2 CD133_cells
P-124	-1.4095 -0.3461 -1.0824 -0.1591 -0.0453 -0.0331 -0.6838 -0.0320 -0.0279 -1.8822 -0.0292 -0.1927 -0.0025 -0.0696 -1.1136 -0.0453 -0.0454 -0.9132 -0.0385 -0.4861 -0.0803 -0.1069 -0.2975 -0.0345 -0.1992 -0.6689 -3.8861 -0.0655 -0.5305 -0.2118 -0.4567 -0.0415 -2.5499 -0.4389 -0.0256 -0.1175 -0.2005
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence clinical continuous-flow_lvads heartmate_ii hm_ii heartware btt dt patients
H-309	-0.6888329386711121	▁clinic al _ effect ive ness ▁continuo us - flow _ L VAD s ▁he art Mate ▁II ▁Heart War e ▁b TT ▁ DT
D-309	-0.6888329386711121	clinical_effectiveness continuous-flow_LVADs heartMate II HeartWare bTT DT
P-309	-2.8380 -0.1134 -1.1225 -0.1234 -0.5765 -0.6911 -0.2362 -0.0093 -0.0969 -0.0014 -0.2058 -3.7024 -0.0440 -0.2280 -2.8426 -0.3144 -0.1032 -1.2556 -1.2386 -0.2311 -0.0064 -1.7123 -0.1099 -0.5829 -0.0314 -0.1193 -0.0620
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy anticoagulation rate_control cardiovascular complications stroke cardiovascular_death acute_heart_failure patients atrial_fibrillation
H-1643	-0.8216125965118408	▁antico ag ulation ▁rate ▁control ▁cardiovascular _ ▁complica tions ▁a cute _ heart _ ▁failure ▁at rial _ fi bril lation AF
D-1643	-0.8216125965118408	anticoagulation rate control cardiovascular_ complications acute_heart_ failure atrial_fibrillationAF
P-1643	-2.0828 -0.2708 -0.0187 -0.2794 -3.5841 -3.7644 -0.8649 -1.2770 -0.0318 -0.9626 -0.0144 -0.3191 -1.3393 -0.5035 -1.7348 -0.8533 -0.0262 -0.1575 -0.7333 -0.0051 -0.0052 -0.7148 -0.1292 -0.0462
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients baseline ef ef core
H-753	-0.7392070293426514	▁base line ▁EF
D-753	-0.7392070293426514	baseline EF
P-753	-0.1698 -0.0031 -0.2196 -3.2181 -0.0856
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef bnp bnp inhospital mortality
H-197	-1.0868226289749146	▁b p ▁in hospital _ ▁mortal ity
D-197	-1.0868226289749146	bp inhospital_ mortality
P-197	-2.4172 -2.1391 -3.8663 -0.0555 -0.3027 -0.8168 -0.0049 -0.1241 -0.0550
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash mortality hf nonsignificant
H-693	-0.7686550617218018	▁DAS h _ die t _ ▁score s ▁ HF ▁Mediterrane an _ Die t ▁score s
D-693	-0.7686550617218018	DASh_diet_ scores HF Mediterranean_Diet scores
P-693	-0.9315 -0.8980 -0.6164 -3.8106 -0.2106 -0.5403 -0.0731 -0.0060 -0.9915 -0.0073 -1.9277 -0.0033 -0.2126 -2.3461 -0.0184 -1.9256 -0.0207 -0.0273 -0.0375
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal_muscle lean_mass z-score
H-1499	-0.9198712110519409	▁s kelet al _ massa ▁relative ▁appen di cular _ ▁lean _ ▁mass _ index ▁age - match ed ▁sex - match ed
D-1499	-0.9198712110519409	skeletal_massa relative appendicular_ lean_ mass_index age-matched sex-matched
P-1499	-2.2568 -0.0010 -0.0175 -0.7071 -3.7065 -2.6294 -0.1849 -0.0061 -0.0399 -0.1837 -3.7372 -0.1139 -2.9229 -1.1156 -0.3963 -0.7938 -0.0485 -0.0242 -0.0771 -1.4910 -0.0503 -0.1077 -0.0348 -1.8952 -0.4552
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 functional_capacity outcomes ambulatory patients hf
H-706	-0.5458170175552368	▁ST 2 ▁functional _ capaci ty ▁well - tre ated ▁co hor t ▁ambula tory ▁patients ▁ HF ▁re class ification _ of _ risk
D-706	-0.5458170175552368	ST2 functional_capacity well-treated cohort ambulatory patients HF reclassification_of_risk
P-706	-3.1071 -0.0473 -0.7269 -1.2432 -0.9985 -0.2706 -1.4361 -0.0248 -0.0014 -0.0168 -1.0378 -0.0042 -0.0880 -0.0497 -0.0027 -2.3889 -0.1500 -0.0002 -0.3950 -0.0004 -0.1553 -1.5560 -0.2086 -0.4210 -0.2281 -0.0740 -0.1046
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality_of_life all-cause_mortality mortality
H-561	-1.00777268409729	▁quality _ of _ life ▁all - ca use ▁mortal ity
D-561	-1.00777268409729	quality_of_life all-cause mortality
P-561	-1.2589 -1.3522 -0.0275 -0.0640 -0.9022 -4.7646 -0.0130 -0.0033 -0.0302 -1.6573 -0.0087 -2.8656 -0.1536
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene_expression cardiomyocytes jq1 drug genes
H-1046	-0.7082353234291077	▁culture d _ ▁cardio my o cy tes ▁J Q 1 ▁drug ▁ab roga ted ▁ phen yle ph rine - indu ced _ ▁gene s
D-1046	-0.7082353234291077	cultured_ cardiomyocytes JQ1 drug abrogated phenylephrine-induced_ genes
P-1046	-1.1922 -0.4198 -0.5547 -5.4638 -2.4754 -2.4596 -1.2571 -0.1323 -0.5586 -0.6126 -0.1786 -0.1660 -1.1005 -0.0066 -0.1068 -0.3420 -0.0430 -0.6328 -0.4438 -0.0337 -0.5056 -0.0006 -0.0152 -0.7573 -0.0969 -0.0102 -0.1853 -0.0797
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka polymorphism rs10927887 p.arg83gly heart_failure estimated_glomerular_filtration_rate renastur
H-1801	-0.7768370509147644	▁CL CN KA ▁poly morph ism ▁heart _ ▁failure ▁glo mer ular _ ▁filtr ation _ rate ▁RE NAS TUR
D-1801	-0.7768370509147644	CLCNKA polymorphism heart_ failure glomerular_ filtration_rate RENASTUR
P-1801	-0.2907 -3.1707 -0.7109 -0.2880 -0.0111 -0.0381 -2.5580 -1.2028 -2.5656 -0.0957 -0.5367 -0.0655 -0.2650 -1.0280 -0.0754 -0.4105 -0.8436 -1.0487 -0.0015 -0.8512 -0.8615 -0.1712
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular_diseases heart_failure hf incidence hf
H-285	-0.8137081265449524	▁cardiovascular _ 疾患 s ▁heart _ ▁failure ▁ HF
D-285	-0.8137081265449524	cardiovascular_疾患s heart_ failure HF
P-285	-0.1615 -0.3137 -2.9883 -0.1340 -0.4841 -0.2008 -1.8807 -1.7706 -0.0050 -0.9459 -0.0662
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac_vegf_expression endothelial_no_synthase_activation hearts
H-455	-0.5869514346122742	▁cardiac _ ve GF ▁Akt ▁en dot heli al _ no ▁synth ase _ activa tion ▁drug - un tre ated ▁fail ing _ heart s
D-455	-0.5869514346122742	cardiac_veGF Akt endothelial_no synthase_activation drug-untreated failing_hearts
P-455	-1.7530 -1.0705 -0.5836 -0.7678 -0.4611 -0.0045 -0.5110 -0.0009 -0.0014 -0.2965 -1.0910 -1.6423 -1.6491 -2.3603 -0.8586 -0.0175 -1.8361 -0.0276 -0.0231 -0.0004 -0.0455 -0.3619 -0.0183 -0.3977 -0.2440 -0.2964 -0.0767 -0.0380
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial exercise outcomes heart_failure patients heart_failure outcomes exercise training hf-action
H-1924	-0.7003623247146606	▁psycho social _ factor s ▁exercise _ ad her ence ▁Heart _ ▁Fail ure _ ▁Patient s ▁ HF - AC TION
D-1924	-0.7003623247146606	psychosocial_factors exercise_adherence Heart_ Failure_ Patients HF-ACTION
P-1924	-2.7196 -0.0740 -0.5029 -0.0180 -0.0136 -0.2888 -0.3713 -0.1190 -0.0291 -0.0020 -0.7044 -0.1541 -0.9029 -0.0227 -2.3411 -0.6133 -0.0193 -3.7584 -2.3657 -0.2189 -0.4380 -0.5087 -0.5118 -0.1110
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart_failure left_ventricular_systolic_dysfunction post_hoc_analysis
H-402	-1.6775987148284912	▁heart _ ▁failure ▁left ▁vent ri cular _ ▁sy sto lic _ ▁dys function
D-402	-1.6775987148284912	heart_ failure left ventricular_ systolic_ dysfunction
P-402	-3.6652 -1.2653 -1.9544 -0.1783 -5.5190 -1.5519 -0.3996 -0.1933 -4.2847 -0.4476 -3.4785 -0.4933 -1.2876 -0.2615 -1.7434 -0.1182
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients coronary_angiography diagnosis systolic_hf etiology ejection_fraction
H-1186	-0.26486101746559143	▁deriva tion _ co hor t ▁corona ry _ ▁ang i ography ▁sy sto lic _ HF ▁un clear ▁et i ology
D-1186	-0.26486101746559143	derivation_cohort coronary_ angiography systolic_HF unclear etiology
P-1186	-0.0455 -0.0051 -0.3998 -0.1813 -0.0015 -0.0802 -0.6694 -0.0446 -0.3616 -0.7584 -0.7794 -0.1013 -0.4056 -0.0323 -0.0857 -0.6020 -0.0312 -0.2762 -0.0001 -0.5175 -0.4863 -0.0061 -0.3910 -0.0946
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac insulin-resistance glycolysis glucose_oxidation plasma_membrane_translocation glucose
H-1784	-0.26379725337028503	▁cardiac ▁insulin - re si stance ▁insulin - stimul ated _ ▁rates ▁gly col ysis ▁gluco se ▁oxid ation ▁plasma ▁membran e ▁trans location ▁gluco se ▁transporter
D-1784	-0.26379725337028503	cardiac insulin-resistance insulin-stimulated_ rates glycolysis glucose oxidation plasma membrane translocation glucose transporter
P-1784	-0.4048 -0.4573 -0.0617 -0.0247 -0.0374 -0.0000 -0.6864 -0.0352 -0.0331 -0.1477 -0.8992 -0.7300 -0.0320 -0.0080 -0.7185 -0.0285 -0.7634 -0.1676 -0.0096 -0.0039 -0.7193 -0.0204 -0.8765 -0.0959 -0.0594 -0.1010 -0.4229 -0.0285 -0.0773
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells angiotensin_ii angii hypoxia scn5a mrna_splicing scn5a
H-1083	-0.3444523215293884	▁ang io ten sin ▁II ▁ang II ▁hypo xia ▁activa tors ▁ab normal ▁S CN 5 A ▁m RNA ▁s plic ing ▁over express ▁S CN 5 A
D-1083	-0.3444523215293884	angiotensin II angII hypoxia activators abnormal SCN5A mRNA splicing overexpress SCN5A
P-1083	-0.0029 -0.5876 -0.6472 -0.0667 -0.8744 -0.1067 -0.0678 -0.0436 -0.0190 -1.8532 -0.0155 -1.0033 -0.0103 -0.3987 -0.1444 -0.2290 -0.6527 -0.0777 -0.0016 -0.1583 -0.0092 -0.0300 -1.3173 -0.0113 -0.5718 -0.0834 -0.1263 -0.1726 -0.8572 -0.1937
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced_pasp right_ventricular_contractile_reserve patients exercise-induced_pasp
H-824	-0.7192103266716003	▁exercise - indu ced _ ▁PAS P ▁right ▁vent ri cular _ contract ile _ ▁reserve
D-824	-0.7192103266716003	exercise-induced_ PASP right ventricular_contractile_ reserve
P-824	-0.0420 -0.1024 -0.0087 -0.0179 -0.4100 -0.9386 -0.6076 -0.1268 -2.5650 -0.3433 -0.4787 -0.2717 -1.2437 -4.0024 -0.6004 -0.0537 -1.0306 -0.1022
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial_elastance ea end-systolic_elastance ees ventricular-arterial_coupling ees ea
H-922	-0.44925224781036377	▁arterial _ ▁elastan ce ▁end - sy sto lic _ ▁elastan ce ▁vent ri cular - arte rial _ ▁coup ling ▁ratio ▁E es
D-922	-0.44925224781036377	arterial_ elastance end-systolic_ elastance ventricular-arterial_ coupling ratio Ees
P-922	-0.4649 -1.7776 -2.7196 -0.0394 -0.1396 -0.0137 -0.2177 -0.0300 -0.1370 -0.5410 -0.5201 -0.0159 -1.0508 -0.0995 -0.0322 -0.3076 -0.0131 -0.0218 -0.4958 -0.0864 -0.0649 -0.0358 -0.7476 -0.0201 -1.8746 -0.2140
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline central_blood_pressure radial_arterial_tonometry cardiovascular_function echocardiographic invasively
H-920	-0.6684606671333313	▁base line ▁post - DAS h _ s rd _ s rd _ bra chi al ▁central _ ▁blood _ ▁pressure ▁radi al _ ▁arterial _ ▁ton ometr y ▁e cho car dio graphic
D-920	-0.6684606671333313	baseline post-DASh_srd_srd_brachial central_ blood_ pressure radial_ arterial_ tonometry echocardiographic
P-920	-1.0195 -0.0135 -0.0115 -0.0217 -0.0488 -0.7897 -1.6709 -0.9036 -0.5629 -0.3613 -2.5905 -0.2168 -0.2542 -0.5186 -0.2008 -0.0105 -0.0304 -0.1916 -2.5494 -0.7393 -0.7190 -0.0029 -0.0016 -0.5115 -2.7124 -0.1281 -4.7230 -0.1402 -0.0648 -0.0621 -0.0143 -0.1238 -0.4737 -0.7466 -0.8445 -0.0907
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene_expression_profile gse9128 gene_expression_omnibus non-ischemic_heart_failure ischemic
H-1609	-0.457279235124588	▁Gene ▁expression _ profil ▁g se 91 28 ▁Gene ▁Express ion ▁Omni bus ▁non - ische mic _ heart _ ▁failure ▁ ische mic
D-1609	-0.457279235124588	Gene expression_profil gse9128 Gene Expression Omnibus non-ischemic_heart_ failure ischemic
P-1609	-0.6236 -1.8615 -0.5404 -0.2950 -0.6549 -0.1570 -0.1043 -0.0742 -0.3305 -0.4386 -0.0048 -0.0607 -0.0089 -0.6400 -0.0145 -0.1152 -0.0767 -0.8368 -1.2465 -0.4684 -1.5216 -0.7423 -0.2191 -0.3887 -0.4224 -0.0427
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
H-1653	-0.4786511957645416	▁ rhythm _ control _ therapy ▁anti ar rhythm ic _ ▁drugs ▁cat heter ▁ab lation ▁electro car dio graphic _ ▁device
D-1653	-0.4786511957645416	rhythm_control_therapy antiarrhythmic_ drugs catheter ablation electrocardiographic_ device
P-1653	-1.4417 -0.2447 -1.1648 -0.0095 -1.6508 -0.5809 -0.0448 -0.0692 -0.1261 -0.0950 -1.2098 -0.6890 -0.1215 -0.0001 -0.1181 -0.0002 -0.0078 -0.0831 -0.1840 -0.4737 -1.2079 -0.9649 -0.7980 -0.2020
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures hospitalizations noncardiovascular diagnoses implantable_cardiac_arrhythmia_devices noncardiovascular drugs rate-control
H-1240	-0.33783042430877686	▁ex pendi tures ▁non car dio vas cular _ ▁diagnose s ▁implant able ▁cardiac _ ar rhythm ia ▁devices ▁non car dio vas cular _ ▁drugs ▁rate - control
D-1240	-0.33783042430877686	expenditures noncardiovascular_ diagnoses implantable cardiac_arrhythmia devices noncardiovascular_ drugs rate-control
P-1240	-1.9353 -0.0008 -0.0123 -0.0635 -0.0309 -0.3258 -0.3881 -0.0651 -1.8109 -0.6616 -0.0028 -0.0258 -0.0093 -0.0360 -0.2513 -0.4223 -0.0219 -0.3481 -0.8885 -0.0152 -0.0077 -0.0371 -0.0320 -0.1330 -0.4003 -1.2205 -0.0050 -0.0586 -0.0010 -1.2068 -0.0554
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence hf_with_reduced_ejection_fraction hfref hf_with_preserved_ejection_fraction hfpef
H-1488	-0.8929654955863953	▁ HF ▁reduce d _ e je ction _ fraction HF r EF
D-1488	-0.8929654955863953	HF reduced_ejection_fractionHFrEF
P-1488	-1.1038 -0.0149 -4.7835 -0.0273 -0.5398 -0.8831 -1.0078 -0.2095 -0.2531 -0.0856 -1.1966 -0.6168 -0.0241 -2.5468 -0.1018
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal_life_support therapy patients acute_ischemic_right_heart_failure refractory_cardiogenic_shock reperfusion therapy
H-1298	-0.5038574934005737	▁Extra corp o real _ life _ support ▁ brid ging _ therapy ▁a cute ▁ ische mic ▁right _ heart _ ▁failure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁reper fusion ▁ therapy
D-1298	-0.5038574934005737	Extracorporeal_life_support bridging_therapy acute ischemic right_heart_ failure refractory_ cardiogenic_ shock reperfusion therapy
P-1298	-2.6003 -0.0062 -0.0374 -0.0250 -0.4834 -0.9700 -0.8696 -0.7361 -0.4413 -0.0010 -0.0112 -0.5414 -0.1169 -0.2188 -0.0036 -1.6934 -0.2753 -0.0439 -2.0804 -0.1710 -2.9530 -0.7270 -0.4457 -0.0005 -0.0001 -0.0151 -0.6004 -0.4293 -0.2886 -0.0872 -0.1501 -0.4536 -0.0124 -0.0042 -1.4012 -0.0088 -0.1193 -0.1239
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart_failure reduced_left_ventricular_ejection_fraction fes exercise_capacity quality_of_life endothelial_function hfpef
H-1332	-0.5988044738769531	▁heart _ ▁failure ▁left ▁vent ri cular _ e je ction _ fraction ▁exercise _ capaci ty ▁emotional _ status ▁en dot heli al _ function ▁ HF p EF
D-1332	-0.5988044738769531	heart_ failure left ventricular_ejection_fraction exercise_capacity emotional_status endothelial_function HFpEF
P-1332	-0.0867 -1.0030 -0.4614 -1.0111 -4.9626 -0.5160 -1.0831 -0.1682 -0.8980 -0.1845 -0.1167 -0.5214 -0.0126 -0.7077 -1.0885 -0.5405 -0.6993 -0.7132 -1.2741 -0.0377 -0.3072 -1.0152 -0.0642 -0.0025 -0.8060 -0.4314 -0.2313 -0.0052 -0.0117 -0.1408 -0.0120 -0.0477
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.6241936087608337	▁in tub ation _ ▁rates
D-220	-0.6241936087608337	intubation_ rates
P-220	-0.1576 -0.0019 -0.0716 -1.3070 -0.7020 -2.0210 -0.1083
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts heart_mass transgenic
H-1814	-0.4617474377155304	▁heart s ▁ TTA ▁t g t et Men a _ mi ce ▁wild - type ▁litt er mates ▁trans ge nic _ mi ce
D-1814	-0.4617474377155304	hearts TTA tgtetMena_mice wild-type littermates transgenic_mice
P-1814	-1.0820 -0.3331 -1.8747 -0.0454 -2.0341 -0.3547 -0.4747 -2.2278 -0.2673 -0.0277 -0.5802 -0.2984 -0.0598 -0.3491 -0.0211 -0.0052 -0.1418 -0.0660 -0.1420 -1.1420 -0.0968 -0.2161 -0.2311 -0.1559 -0.0271 -0.1190 -0.0942
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene heart_failure
H-1541	-0.7246045470237732	▁ra lo xi fen e ▁mechanism _ of ▁action
D-1541	-0.7246045470237732	raloxifene mechanism_of action
P-1541	-0.0355 -0.0189 -0.0205 -0.1779 -0.1339 -0.6217 -1.8035 -0.0471 -0.6879 -4.1508 -0.2731
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients hfref exercise respiratory_gas_analysis baseline
H-1938	-1.2225641012191772	▁ons et _ ▁H Fr EF ▁exercise _ ▁protocol ▁respirator y _ gas
D-1938	-1.2225641012191772	onset_ HFrEF exercise_ protocol respiratory_gas
P-1938	-7.0418 -0.0348 -0.3361 -2.9398 -0.0277 -0.8606 -1.5793 -1.1504 -0.8829 -0.0273 -0.0119 -1.3871 -0.0617 -1.9468 -0.0501
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients drugs heart_failure biomedical nonprescribing patients
H-1126	-0.5426883101463318	▁guide line - re com mend ed ▁drugs ▁heart _ ▁failure ▁bio medic al _ ▁reasons
D-1126	-0.5426883101463318	guideline-recommended drugs heart_ failure biomedical_ reasons
P-1126	-1.4479 -0.0025 -0.2211 -0.0009 -0.0017 -0.0004 -0.0144 -0.9472 -0.9440 -0.4287 -0.3970 -1.3129 -0.0046 -0.0016 -1.9086 -0.5504 -1.4850 -0.0993
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients chronic_hf prevalence exercise hf hospitalization mortality exercise training
H-1641	-1.3383697271347046	▁black _ race ▁chronic _ HF ▁exercise _ per form ance ▁ HF
D-1641	-1.3383697271347046	black_race chronic_HF exercise_performance HF
P-1641	-0.2886 -0.9401 -0.8057 -5.3380 -0.6773 -0.2369 -4.4341 -0.8085 -1.3512 -1.7131 -0.1501 -0.1876 -0.0024 -2.9609 -0.1811
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean_mass adverse_outcome adipose_tissue cardioprotective hf
H-1169	-0.7253968715667725	▁was ting _ of _ weight ▁lean _ ▁mass ▁advers e ▁outcome ▁fat _ ▁loss ▁enhance d ▁cata bol ism ▁adi pose _ ▁tissu e ▁cardio protec tive
D-1169	-0.7253968715667725	wasting_of_weight lean_ mass adverse outcome fat_ loss enhanced catabolism adipose_ tissue cardioprotective
P-1169	-0.7617 -0.0134 -1.6589 -0.7308 -0.2167 -4.0293 -0.4046 -0.2158 -0.0445 -4.8255 -0.0128 -0.7316 -2.7160 -1.4549 -0.3914 -0.1811 -0.0820 -1.4154 -0.0969 -0.0127 -0.0035 -0.0019 -0.1430 -0.1254 -0.3522 -0.0052 -0.0392 -0.0135 -1.0193 -0.0626
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads heartmate_ii thoratec_corp pleasanton calif hvad heartware framingham
H-546	-0.7046176195144653	▁l VAD s ▁CF _ ▁devices ▁Thor a tec _ ▁Corp ▁Ple asan ton _ ▁Cali f ▁h VAD _ ▁devices ▁Heart War e ▁in t l ▁Fram ing ham ▁Mass
D-546	-0.7046176195144653	lVADs CF_ devices Thoratec_ Corp Pleasanton_ Calif hVAD_ devices HeartWare intl Framingham Mass
P-546	-3.8722 -0.0667 -0.5901 -6.8996 -0.9998 -0.7107 -1.2246 -0.0382 -0.0004 -0.4375 -0.2965 -0.0069 -0.0001 -0.0067 -2.0389 -0.0052 -0.0013 -1.3555 -0.4103 -0.5680 -0.4781 -0.3297 -0.4111 -0.0199 -1.4747 -0.0138 -0.0010 -0.0961 -0.0094 -0.0006 -0.6105 -0.2039 -0.0744
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts nucleolin chamber_patterning cardiac_looping myocyte_differentiation
H-97	-0.7763056755065918	▁heart s _ of _ fish ▁la cking _ nu cle olin ▁ab normal ▁cha mber _ ▁pattern ing ▁cardiac _ loop ing ▁my o cy te
D-97	-0.7763056755065918	hearts_of_fish lacking_nucleolin abnormal chamber_ patterning cardiac_looping myocyte
P-97	-0.3668 -0.1136 -4.0330 -1.0744 -1.0593 -0.6943 -0.9527 -0.0041 -1.0047 -1.0364 -0.0103 -0.0250 -1.5759 -0.0079 -0.3591 -0.0012 -1.2514 -0.3341 -0.7417 -3.6650 -0.2558 -0.9821 -0.1466 -0.8836 -0.0577 -0.3892 -0.6026 -0.7969 -0.0875
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma collected hf patients immunoreactive nt-probnp c-terminally nt-probnp
H-1520	-0.8198261260986328	▁ HF ▁immun ore active ▁NT - pro b NP ▁c - termin ally ▁tru nca ted _ ▁fragment s ▁NT - pro b NP _ ▁mole cule
D-1520	-0.8198261260986328	HF immunoreactive NT-probNP c-terminally truncated_ fragments NT-probNP_ molecule
P-1520	-1.2991 -0.0347 -0.9838 -1.2996 -0.1445 -0.6687 -0.0702 -0.0135 -3.3241 -0.4293 -3.5258 -0.0556 -0.0254 -0.0232 -1.4231 -0.0153 -0.0124 -0.6380 -3.9327 -0.0388 -1.4779 -0.0321 -0.0312 -1.9473 -0.3845 -1.0783 -1.0163 -0.5076 -0.0719 -0.0898
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma_nps adiponectin baseline ffm correlate nps adiponectin follow_up
H-19	-0.7795091271400452	▁plasma ▁ NP s ▁total _ ▁adi pon ect in ▁FM ▁f FM ▁ NP s ▁adi pon ect in
D-19	-0.7795091271400452	plasma NPs total_ adiponectin FM fFM NPs adiponectin
P-19	-3.0081 -0.6050 -0.0027 -0.0097 -0.8848 -0.4946 -0.2109 -0.0054 -1.2409 -0.5769 -1.5262 -2.8340 -1.0548 -1.5255 -0.0539 -0.0089 -1.0799 -0.0101 -0.6214 -0.5341 -0.7470 -0.1143
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages cardiomyocytes doxorubicin in_vitro resistin mrna protein_expression
H-935	-0.46929100155830383	▁Mac rop hage s ▁cardio my o cy tes ▁Hum - Re t n _ mi ce ▁do xor ubi cin ▁h Re t n _ human _ ▁resist in ▁m RNA ▁protein ▁expression
D-935	-0.46929100155830383	Macrophages cardiomyocytes Hum-Retn_mice doxorubicin hRetn_human_ resistin mRNA protein expression
P-935	-0.8191 -0.0127 -0.0156 -0.1287 -0.0375 -0.2440 -0.4258 -0.1811 -0.0582 -0.1448 -0.0999 -0.6961 -0.1628 -0.0171 -1.2680 -0.7122 -0.0655 -0.1381 -0.0751 -0.1392 -0.3503 -2.2444 -1.3666 -0.0229 -0.0044 -2.5178 -1.0538 -0.6324 -0.2449 -0.1716 -0.8849 -0.0002 -0.1967 -1.4708 -0.1962 -0.0951
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt_interval ecgs baseline atrial_pacing esmolol isoprenaline atropine infusion
H-1438	-0.5052927732467651	▁beat - to - beat ▁ QT _ ▁interval ▁surface _ e CG s at rial ▁pa cing ▁es mol ol ▁iso pren a line ▁a tropi ne ▁in fusion
D-1438	-0.5052927732467651	beat-to-beat QT_ interval surface_eCGsatrial pacing esmolol isoprenaline atropine infusion
P-1438	-0.0182 -0.0242 -0.0290 -0.0151 -0.0380 -0.6105 -0.0285 -0.9305 -0.1680 -0.7238 -0.6911 -1.5001 -0.1436 -0.7710 -2.7236 -0.1319 -0.8480 -0.0202 -0.8103 -0.1376 -3.5901 -0.0033 -0.0043 -0.1023 -0.0072 -0.0095 -0.0066 -1.2133 -0.3064 -0.0126 -0.4071 -0.1436
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic_tone parasympathetic_tone heart_rate intravenous_bolus metoprolol atropine
H-1378	-0.5725403428077698	▁withdraw al _ of _ ▁sympa the tic _ ▁tone ▁para sy mpa the tic _ ▁tone ▁heart ▁rate _ ▁response ▁intra ven ous ▁bol us _ of _ met o pro lol ▁a tropi ne
D-1378	-0.5725403428077698	withdrawal_of_ sympathetic_ tone parasympathetic_ tone heart rate_ response intravenous bolus_of_metoprolol atropine
P-1378	-0.3181 -0.0124 -2.0797 -3.4832 -0.4378 -2.5180 -0.0701 -0.1924 -0.3259 -0.2146 -0.0271 -0.2263 -0.0727 -0.1471 -0.0694 -0.0583 -0.5286 -0.1002 -0.7488 -4.0451 -0.8885 -1.0623 -0.0035 -0.3303 -0.3211 -0.1052 -1.7708 -0.1115 -0.5262 -0.3547 -0.1174 -0.0416 -0.1281 -0.0343 -0.0015 -0.1925 -0.0513 -0.0396
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef pathophysiologically hf_with_reduced_ef hfref hfref therapy
H-1533	-0.8911842703819275	▁EH _ de no tes ▁ HF p EF ▁ HF r EF ▁H Fr EF _ therapy
D-1533	-0.8911842703819275	EH_denotes HFpEF HFrEF HFrEF_therapy
P-1533	-0.0045 -3.0276 -0.0921 -0.0060 -0.0031 -0.0212 -0.0070 -0.6004 -0.1579 -0.7713 -0.1353 -7.0605 -0.0821 -2.6133 -0.2286 -0.3203 -2.3773 -0.0770 -0.1408 -0.0974
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse_event acute_myocardial_infarction congestive_heart_failure adverse_events
H-4	-0.5108922719955444	▁advers e _ ▁event _ ▁rates ▁a cute ▁my o card ial _ in far ction ▁con ges tive _ heart _ ▁failure ▁in - hospital ▁advers e _ ▁events
D-4	-0.5108922719955444	adverse_ event_ rates acute myocardial_infarction congestive_heart_ failure in-hospital adverse_ events
P-4	-0.3576 -0.0288 -0.8184 -1.0847 -0.8224 -1.4217 -0.0209 -0.0031 -4.2690 -0.3636 -1.4920 -0.0203 -0.1826 -0.4336 -0.0142 -0.1300 -0.0038 -0.0290 -0.0295 -0.0955 -0.5512 -0.5688 -0.8691 -0.6804 -0.0680 -0.0019 -0.5277 -0.0152 -1.0305 -0.0966 -0.2655 -0.0530
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence_interval
H-803	-0.7007929682731628	▁limit s _ of ▁agreement
D-803	-0.7007929682731628	limits_of agreement
P-803	-3.0604 -0.0265 -1.0182 -0.0498 -0.1174 -0.5600 -0.0731
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change follow-up readmissions hospital follow-up
H-721	-1.40047287940979	▁follow - up _ ▁visit s
D-721	-1.40047287940979	follow-up_ visits
P-721	-5.9827 -0.0213 -0.0135 -1.5253 -0.5269 -0.0120 -3.0027 -0.1194
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac jq1 bet pathological cardiac gene_expression
H-1049	-0.7488259673118591	▁cardiac _ ▁tissu e ▁ TAC - ▁sham - opera ted ▁J Q 1 ▁vehicle ▁ BET _ ▁inhibi tion ▁path ological _ ▁cardiac _ ▁gene ▁expression
D-1049	-0.7488259673118591	cardiac_ tissue TAC- sham-operated JQ1 vehicle BET_ inhibition pathological_ cardiac_ gene expression
P-1049	-1.6127 -1.0081 -0.4526 -0.3571 -0.5591 -0.0018 -0.1558 -1.0055 -0.0205 -0.0002 -0.0169 -0.4804 -0.1151 -0.0557 -2.1261 -0.0751 -0.0203 -2.1452 -0.4558 -0.0394 -0.7910 -0.3399 -0.2629 -3.0664 -0.2031 -4.4028 -0.7071 -1.1051 -0.1342
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power_spectral_analysis hf dnx
H-1377	-0.7131621837615967	▁power _ spec tral _ analyse ▁low - fre que ncy ▁low - fre que ncy ▁high - fre que ncy ▁ LF / HF _ rati o ▁CHF - in v ▁sham - in v ▁sham _ ▁levels ▁DN x
D-1377	-0.7131621837615967	power_spectral_analyse low-frequency low-frequency high-frequency LF/HF_ratio CHF-inv sham-inv sham_ levels DNx
P-1377	-0.1801 -0.8368 -1.5063 -0.0083 -2.7611 -1.9172 -0.3737 -0.0270 -0.0621 -0.1433 -0.0513 -1.8623 -0.0107 -0.1559 -0.1005 -0.1300 -1.7777 -0.0320 -0.0504 -0.0964 -0.1540 -2.8314 -0.0442 -2.3389 -0.0066 -3.0639 -1.6210 -0.0262 -0.6071 -0.0727 -0.8412 -0.9923 -0.0023 -0.5080 -0.9408 -0.6545 -0.4748 -2.2931 -0.5536 -0.0832 -0.0249 -0.1837 -0.2648
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal_pro-b-type_natriuretic_peptide nt-probnp misdiagnosis heart_failure hf
H-1511	-0.6355358958244324	▁non - termin al ▁pro - B - type ▁na tri ure tic _ pe pti de NT - pro B NP ▁mis diagnos is ▁heart _ ▁failure
D-1511	-0.6355358958244324	non-terminal pro-B-type natriuretic_peptideNT-proBNP misdiagnosis heart_ failure
P-1511	-3.1683 -0.2675 -0.0172 -0.0017 -0.7755 -0.0172 -0.8307 -0.1112 -0.0606 -0.0232 -0.3521 -0.8224 -1.0627 -0.4985 -0.1578 -0.3235 -0.9945 -0.5468 -0.0042 -0.0047 -0.7049 -0.0124 -1.0119 -0.0933 -0.1005 -2.2845 -0.3298 -3.2792 -1.1403 -0.0687
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action randomized patients left_ventricular_ejection_fraction new_york_heart_association_class_ii hf exercise training
H-698	-0.8848865628242493	▁ HF - AC TION ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁New ▁York _ ▁Heart _ association ▁IV ▁ HF ▁exercise _ training
D-698	-0.8848865628242493	HF-ACTION left_ ventricular_ejection fraction New York_ Heart_association IV HF exercise_training
P-698	-1.6798 -0.2133 -0.2510 -1.2202 -1.2712 -0.4579 -0.6750 -4.1237 -0.4848 -0.3397 -0.3880 -0.9576 -0.2023 -0.3039 -2.6079 -0.0042 -2.0993 -0.4602 -0.3491 -0.7296 -0.8048 -1.2008 -0.7515 -0.0752 -0.0053 -0.5800 -1.7611 -1.6751 -0.7434 -0.1305
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial_dd collagen_deposition titin obese diabetic zsf1 heart_failure_with_preserved_ejection_fraction
H-762	-0.5831922292709351	▁my o card ial _ DD ▁collage n _ de position ▁titi n _ ▁modification ▁obes e ▁diabet ic ▁Z SF 1 ▁rat s ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-762	-0.5831922292709351	myocardial_DD collagen_deposition titin_ modification obese diabetic ZSF1 rats heart_ failure preserved ejection_fraction
P-762	-0.1027 -0.0454 -0.9634 -0.0136 -1.9682 -0.0119 -0.1963 -0.4274 -1.3935 -0.2458 -0.0029 -0.1007 -0.0229 -2.3794 -0.9100 -2.0294 -0.1909 -0.0966 -0.0032 -1.0417 -0.0050 -0.1602 -0.6562 -0.0624 -0.9115 -0.6843 -4.0743 -0.0319 -0.0465 -0.0430 -0.8613 -0.0147 -0.0221 -1.5166 -0.0063 -0.2692 -0.0669
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac_magnetic_resonance_postcontrast_t1_time prognosis hfpef postcontrast_t1 biomarker hfpef
H-743	-0.3577807545661926	▁cardiac _ ▁magnetic _ ▁res on ance ▁post contra st _ ▁T 1 _ ▁time ▁H FP EF ▁post contra st _ ▁T 1 ▁bio mark er ▁H FP EF
D-743	-0.3577807545661926	cardiac_ magnetic_ resonance postcontrast_ T1_ time HFPEF postcontrast_ T1 biomarker HFPEF
P-743	-0.0449 -0.5035 -0.4109 -0.1155 -0.0771 -0.0228 -0.0039 -0.0189 -0.0042 -0.0032 -0.2776 -1.0339 -0.0524 -2.6166 -0.9829 -1.2838 -0.0102 -0.6231 -0.1732 -0.0681 -0.0038 -0.1337 -0.6811 -0.0445 -1.0951 -0.0071 -0.1818 -0.8277 -0.0164 -0.0355 -0.0235 -0.0720
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ventricular-arterial_coupling patients
H-524	-0.19366097450256348	▁contract ility ▁vent ri cular - arte rial _ ▁coup ling ▁i va bra dine - tre ated
D-524	-0.19366097450256348	contractility ventricular-arterial_ coupling ivabradine-treated
P-524	-0.0041 -0.0732 -0.0472 -0.1777 -0.0280 -0.1991 -0.0385 -0.0220 -0.8353 -0.0485 -0.2991 -0.0347 -0.1688 -0.0844 -0.0397 -0.4414 -0.0110 -0.1105 -1.0989 -0.1112
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 hypertrophy fibrosis ventricular_dysfunction gene
H-642	-0.3893892765045166	▁condition al _ ▁gene - tar get ed ▁Hand 2 _ mi ce ▁pressure - over load - indu ced ▁hyper trop hy ▁fibro sis ▁vent ri cular _ dis function ▁fet al _ ▁gene _ program
D-642	-0.3893892765045166	conditional_ gene-targeted Hand2_mice pressure-overload-induced hypertrophy fibrosis ventricular_disfunction fetal_ gene_program
P-642	-0.0088 -0.2979 -0.5261 -0.7309 -0.1107 -0.0026 -0.0063 -0.0053 -0.2834 -0.0347 -1.6784 -0.6412 -0.0197 -0.0179 -0.0625 -0.0091 -0.0038 -0.8294 -0.0370 -0.0207 -1.7002 -0.0189 -2.1622 -0.0038 -0.2076 -0.0046 -0.2504 -0.1269 -0.4612 -1.3731 -0.0454 -0.0146 -0.0059 -0.1873 -0.9236 -1.7992 -0.4581 -0.0321 -0.0846
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission nt-probnp patients acute_hf diagnosis
H-264	-0.7685877084732056	▁ad mission ▁NT - pro b NP ▁pre script ive _ 4- year _ ▁survival ▁ED ▁a cute ▁ HF
D-264	-0.7685877084732056	admission NT-probNP prescriptive_4-year_ survival ED acute HF
P-264	-1.1716 -0.0087 -0.2045 -0.0258 -0.0015 -1.1288 -0.0662 -0.6188 -0.0015 -0.0021 -1.2808 -3.1144 -0.0191 -0.7817 -3.3607 -1.9995 -0.6623 -0.0006 -1.1406 -0.0098 -1.1388 -0.1709
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical rule patients cad angiography patients systolic_hf cost
H-1193	-0.8533827066421509	▁clinic al _ ▁predict ion _ ▁rule ▁CAD ▁ang i ography ▁sy sto lic _ HF ▁cost
D-1193	-0.8533827066421509	clinical_ prediction_ rule CAD angiography systolic_HF cost
P-1193	-0.4558 -0.0200 -0.3560 -4.6251 -0.0040 -1.2327 -0.0030 -2.7070 -0.8645 -0.5738 -0.0636 -0.0349 -0.1456 -0.3958 -0.7635 -0.0268 -0.6186 -3.2437 -0.0800
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic cardiac cardiac gene signal_transduction pathological gene_expression hf
H-1053	-0.4262445569038391	▁epi gene tic _ ▁readers ▁cardiac _ ▁bi ology ▁cardiac _ ▁gene ▁control ▁chr omat in - dependent _ signal ▁trans duction ▁a bro gate ▁path ological ▁ HF
D-1053	-0.4262445569038391	epigenetic_ readers cardiac_ biology cardiac_ gene control chromatin-dependent_signal transduction abrogate pathological HF
P-1053	-0.2088 -0.0039 -0.0222 -0.8682 -0.0610 -0.0125 -0.1719 -1.1665 -0.0030 -1.6465 -0.1564 -1.4941 -0.4757 -0.0153 -0.0013 -0.0845 -0.1097 -0.0030 -0.3291 -0.7884 -0.4031 -0.0163 -0.0514 -0.0011 -0.0008 -0.2921 -0.0985 -2.7298 -0.0003 -1.8766 -0.1215
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic_blood_pressure elevated left_ventricular hypertrophy
H-277	-0.7649609446525574	▁Sy sto lic _ ▁blood _ ▁pressure ▁left _ ▁vent ri cular _ LV _ ▁hyper trop hy ▁AN ▁ ANS
D-277	-0.7649609446525574	Systolic_ blood_ pressure left_ ventricular_LV_ hypertrophy AN ANS
P-277	-1.3619 -0.1171 -0.1571 -0.4161 -1.0500 -1.7842 -0.1672 -0.2529 -0.5685 -3.3951 -0.4222 -0.1445 -0.6924 -1.0595 -1.9834 -0.6582 -0.0166 -0.2118 -0.8079 -0.8066 -0.0100 -1.2980 -0.2129
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up patients combined_end_point death heart_failure death cardiac_transplant
H-1747	-0.9259034395217896	▁follow - up ▁heart _ ▁failure ▁sud den _ ▁death ▁non card iac ▁cardiac _ ▁transplant
D-1747	-0.9259034395217896	follow-up heart_ failure sudden_ death noncardiac cardiac_ transplant
P-1747	-4.5050 -0.1232 -0.0226 -6.3871 -0.9332 -0.4839 -0.4736 -0.0107 -1.0157 -1.0423 -0.0583 -0.0104 -0.0090 -0.0443 -0.8721 -0.3755 -0.1947 -0.1048
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous revascularization angioplasty stenting clinical patients randomized clinical
H-1601	-0.4020704925060272	▁per cuta ne ous _ re vas cular ization ▁ang io plast y ▁sten ting
D-1601	-0.4020704925060272	percutaneous_revascularization angioplasty stenting
P-1601	-1.9807 -0.0046 -0.1611 -0.1535 -0.7843 -0.4961 -0.0166 -0.0423 -0.1963 -0.0056 -1.0185 -0.0212 -0.0205 -0.0068 -0.0247 -1.8748 -0.0274
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic_response heart_rate exercise baseline follow-up tests heart_rate exercise
H-1176	-0.8476725220680237	▁load - corre cted _ ▁chr ono tropi c _ ▁response ▁exercise ▁base line ▁follow - up _ test s
D-1176	-0.8476725220680237	load-corrected_ chronotropic_ response exercise baseline follow-up_tests
P-1176	-1.0119 -0.1291 -0.0021 -0.1248 -1.1679 -1.5264 -0.2197 -0.7660 -0.7326 -1.6433 -1.2652 -2.6135 -0.8406 -0.0018 -1.6316 -0.0116 -0.0177 -0.7101 -0.7456 -0.9362 -2.2689 -0.2821
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak_oxygen_consumption vo2max resting_hr bpm p_value
H-1943	-1.1728471517562866	▁Peak _ product ion _ VO 2 max ▁rest ing _ ▁HR
D-1943	-1.1728471517562866	Peak_production_VO2max resting_ HR
P-1943	-0.2144 -0.5183 -6.3715 -0.1584 -2.3359 -0.8607 -0.0199 -0.0025 -2.6449 -0.1539 -0.5330 -1.0187 -1.3624 -0.2254
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional_hazard_models negative_binomial_regression_models health
H-1624	-0.6135222911834717	▁co x - propor tional _ ▁hazard _ ▁models ▁negative ▁bi nom ial _ ▁re gression ▁models ▁intervention ▁survival _ ▁utiliza tion ▁demo graphic ▁health
D-1624	-0.6135222911834717	cox-proportional_ hazard_ models negative binomial_ regression models intervention survival_ utilization demographic health
P-1624	-0.1426 -0.0072 -0.0976 -0.0644 -0.0025 -0.5770 -4.6015 -1.1911 -1.4662 -0.0059 -0.4640 -0.4907 -0.0009 -0.3540 -0.3101 -0.0003 -1.7318 -0.0463 -0.9344 -1.8537 -1.3766 -0.0100 -0.0040 -0.0071 -0.1321 -0.5671 -0.1260
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients hf t2d erc vo2max maximum_oxygen_consumption skm biopsies
H-1251	-0.4550003111362457	▁ HF ▁t 2 d ▁ ERC ▁tre ad m ill _ test VO 2 max ▁oxygen _ ▁consum p tion ▁Sk M ▁bio psi es
D-1251	-0.4550003111362457	HF t2d ERC treadmill_testVO2max oxygen_ consumption SkM biopsies
P-1251	-0.3016 -0.0354 -1.2435 -0.0039 -0.3520 -1.2463 -0.5227 -0.0030 -0.0006 -0.0122 -0.0065 -1.5845 -0.3397 -1.4733 -0.0041 -0.0046 -3.2285 -0.3102 -0.0445 -0.0026 -0.0214 -0.4096 -0.9638 -0.4092 -0.0624 -0.0062 -0.0708 -0.0768
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient hospital gastrointestinal_bleeding patient ventricular_tachycardia terminal_heart_failure
H-1961	-0.5274168848991394	▁gastro inte stin al _ ▁ble ed ing ▁ince ssant ▁vent ri cular _ ta chy car dia ▁storm ▁terminal _ procedure
D-1961	-0.5274168848991394	gastrointestinal_ bleeding incessant ventricular_tachycardia storm terminal_procedure
P-1961	-1.1183 -0.0812 -0.7475 -0.0174 -0.4439 -0.1349 -0.0140 -0.0225 -0.8736 -0.0007 -0.9498 -0.4012 -0.1461 -0.3043 -1.5641 -0.1083 -0.5436 -0.0374 -0.0188 -0.0247 -0.1052 -4.7102 -0.1856 -0.1046
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic β-ar catecholamine infusions pde2 expression camp activity correlated cardiac β-ar_responsiveness
H-1214	-0.49451830983161926	▁Chro nic ▁β - AR _ stimul ation ▁cate chol amine ▁in fusion s ▁rat s ▁enhance d ▁P DE 2 ▁expression ▁c AMP ▁hydro ly tic _ activ ity ▁blu n ted _ ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.49451830983161926	Chronic β-AR_stimulation catecholamine infusions rats enhanced PDE2 expression cAMP hydrolytic_activity blunted_ cardiac β-AR responsiveness
P-1214	-1.0555 -0.0241 -1.7468 -0.0275 -0.3593 -3.7642 -1.0468 -0.0111 -0.0122 -0.0070 -0.1644 -0.2331 -0.0004 -0.1782 -1.0202 -0.0217 -1.4098 -0.2422 -0.2158 -0.4190 -0.0550 -0.7832 -0.0016 -0.0113 -1.0735 -1.7195 -0.7423 -1.8574 -0.2760 -0.2323 -0.0663 -0.0575 -0.0639 -0.4494 -0.1667 -0.2091 -0.0025 -0.0241 -0.6353 -0.0630 -0.2143 -0.1062
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild_hf qrs_prolongation lvef crt reverse_remodeling clinical systolic_dysfunction
H-758	-0.7115050554275513	▁ HF ▁QR S ▁prolong ation ▁LV EF ▁rever se _ ▁remodel ing
D-758	-0.7115050554275513	HF QRS prolongation LVEF reverse_ remodeling
P-758	-0.5612 -0.0249 -0.0964 -2.5082 -1.2490 -0.0138 -0.0694 -0.0103 -0.0654 -0.0018 -0.6499 -0.2341 -0.0171 -5.0746 -0.0965
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic_pah clinical hospitalized patients acute rv_decompensation pharmacologic therapies rv_failure pah
H-1096	-0.46477875113487244	▁chronic _ p AH ▁hospital ized ▁a cute ▁ RV _ de com pensa tion ▁ pharma c ologic ▁ therapie s ▁ RV _ ▁failure _ management ▁P AH
D-1096	-0.46477875113487244	chronic_pAH hospitalized acute RV_decompensation pharmacologic therapies RV_ failure_management PAH
P-1096	-0.1467 -0.7196 -2.1793 -0.0152 -2.1882 -0.0434 -2.1761 -0.0009 -0.2751 -0.0589 -0.6905 -0.3930 -0.0449 -0.0027 -0.0255 -0.0684 -0.0403 -0.0180 -0.2011 -0.6619 -0.0276 -0.0640 -0.0574 -0.0775 -0.7870 -1.0034 -0.5241 -0.0688 -2.0386 -0.0006 -0.0699 -0.2041
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up patients
H-268	-1.2668297290802002	▁patients ▁non - sur viv ors
D-268	-1.2668297290802002	patients non-survivors
P-268	-5.0011 -4.2811 -0.0041 -0.0173 -0.0053 -0.0866 -0.6422 -0.0969
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians patients patient clinician medication patient
H-1129	-0.7631471157073975	▁co management ▁clinic ians ▁non adh er ence ▁clinic ians ▁medication
D-1129	-0.7631471157073975	comanagement clinicians nonadherence clinicians medication
P-1129	-0.1846 -0.0145 -2.5022 -0.0247 -2.9477 -0.0034 -0.1814 -0.0295 -0.5312 -1.9277 -1.1278 -0.3339 -0.1122
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty gill_index hf
H-628	-1.0012431144714355	▁non - fra il _ ▁participants ▁severe _ fra il ty ▁Gill _ index ▁ HF
D-628	-1.0012431144714355	non-frail_ participants severe_frailty Gill_index HF
P-628	-0.7156 -0.0061 -0.0007 -0.0337 -4.4346 -1.5818 -4.6431 -0.4890 -0.6868 -0.0060 -1.6496 -0.2219 -0.5645 -0.3830 -2.3861 -0.0131 -0.0908 -0.1158
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty health_abc_short_physical_performance_battery habc_battery gill_index hf
H-625	-0.5632426142692566	▁health ▁ABC _ short _ phy al _ ▁Performance _ bat tery ▁Gill _ index ▁incident _ HF
D-625	-0.5632426142692566	health ABC_short_phyal_ Performance_battery Gill_index incident_HF
P-625	-3.3725 -1.2439 -0.9305 -0.2272 -0.0152 -1.6913 -0.0492 -0.0285 -0.9333 -0.1661 -0.1167 -0.0012 -0.2287 -0.3938 -0.3414 -0.1894 -0.8366 -0.3789 -0.0734 -0.0468
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients rv_support lvad patients cardiogenic_shock myocardial_infarction chronic_decompensated_heart_failure
H-295	-0.7584447860717773	▁ RV _ support ▁l VAD _ insertion ▁cardio ge nic _ ▁shock ▁my o card ial _ in far ction ▁chronic _ de com pensa ted _ heart _ ▁failure
D-295	-0.7584447860717773	RV_support lVAD_insertion cardiogenic_ shock myocardial_infarction chronic_decompensated_heart_ failure
P-295	-1.8487 -0.5651 -2.2899 -1.4179 -5.1761 -0.0272 -1.2187 -0.0091 -0.5335 -0.0919 -0.1369 -0.4253 -0.5355 -1.2476 -0.0972 -1.0326 -0.0550 -0.2089 -0.5981 -0.0101 -0.0339 -0.1160 -0.4912 -1.4680 -0.0395 -0.0035 -0.0671 -0.1240 -0.3276 -1.0863 -3.4217 -0.0734 -0.2511
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic_heart_failure chf multisystem_disease comorbidities anemia insulin_resistance autonomic_dysbalance cardiac_cachexia
H-1357	-0.6144659519195557	▁Chro nic _ heart _ ▁failure _ CH F ▁multi system _ ▁disease ▁an emia ▁insulin _ ▁resist ance ▁autonomi c _ dis balance ▁cardiac ▁cache xia
D-1357	-0.6144659519195557	Chronic_heart_ failure_CHF multisystem_ disease anemia insulin_ resistance autonomic_disbalance cardiac cachexia
P-1357	-0.2346 -0.0323 -0.1334 -1.7119 -0.1457 -1.7794 -2.2319 -0.4689 -0.5359 -0.1392 -0.0037 -0.9707 -3.6174 -0.1627 -0.0020 -0.0208 -0.5598 -0.1320 -0.0007 -0.0071 -0.1967 -0.2507 -4.1792 -0.0375 -0.0007 -0.1858 -0.0222 -0.0284 -0.0281
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine_oxidase xo left_ventricular myocytes volume_overload vo mitral_regurgitation aortocaval_fistula acf
H-470	-0.5827045440673828	▁Xan thi ne ▁oxid ase ▁ XO ▁rat ▁left _ ▁vent ri cular _ LV ▁my o cy tes ▁volume _ ▁over load ▁mit ral ▁re gur gi tation ▁a orto ca val _ fi stu la
D-470	-0.5827045440673828	Xanthine oxidase XO rat left_ ventricular_LV myocytes volume_ overload mitral regurgitation aortocaval_fistula
P-470	-0.0062 -0.0972 -0.1316 -0.1119 -0.0741 -3.5389 -0.0022 -1.8789 -0.1567 -0.6009 -1.6770 -0.1201 -0.0406 -1.9238 -1.2799 -3.4416 -0.0077 -0.1094 -0.1202 -0.2696 -1.6865 -0.7321 -0.0010 -2.2518 -0.0145 -0.6654 -0.0003 -0.0126 -0.0004 -0.0137 -0.0366 -0.0019 -0.1842 -0.2372 -0.9302 -0.0021 -0.0375 -0.2494 -0.0797
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese zsf1 heart_failure_with_preserved_ejection_fraction lung preserved_left_ventricular_ejection_fraction left_ventricular_dd
H-767	-0.868739664554596	▁obes e ▁z SF 1 _ group ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁lung _ weight ▁pres er ved ▁left _ ▁vent ri cular _ e je ction _ fraction ▁left _ ▁vent ri cular ▁ DD
D-767	-0.868739664554596	obese zSF1_group heart_ failure preserved_ejection_fraction lung_weight preserved left_ ventricular_ejection_fraction left_ ventricular DD
P-767	-0.7924 -0.1977 -1.2360 -0.1419 -0.8653 -3.5605 -1.3009 -4.2796 -0.5548 -1.1626 -2.4677 -0.0219 -0.0139 -0.7280 -0.8582 -0.3675 -0.0745 -0.3171 -0.0723 -0.9804 -1.0052 -0.5401 -1.4588 -0.0082 -0.0102 -0.6827 -0.2802 -3.6913 -0.4277 -0.2396 -0.8070 -0.9597 -0.1986 -0.2781 -0.5345 -0.0321 -0.1654 -0.1733 -5.7961 -0.2381 -0.0472 -1.2127 -0.0045 -0.1107 -0.1983
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients physicians mortality physicians hospitals
H-1727	-0.2750769257545471	▁high - volu me ▁physician s ▁low - volu me _ hospital s
D-1727	-0.2750769257545471	high-volume physicians low-volume_hospitals
P-1727	-0.2437 -0.0150 -0.0588 -0.0026 -2.0136 -0.0421 -0.0781 -0.0099 -0.0200 -0.0007 -0.9674 -0.3752 -0.0970 -0.0572 -0.1451
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western administrative health patients hf hospitalized ami
H-1307	-1.3265846967697144	▁western _ au ▁link ed ▁administrative _ ▁health _ data
D-1307	-1.3265846967697144	western_au linked administrative_ health_data
P-1307	-1.4238 -1.0576 -2.5017 -2.3966 -0.0136 -0.1402 -0.1514 -1.9119 -2.4087 -0.1132 -3.5976 -0.2027
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report connection patients disease healthcare conditions turkey
H-1825	-2.051661491394043	▁consensu s _ report
D-1825	-2.051661491394043	consensus_report
P-1825	-5.3357 -0.0312 -1.9316 -0.3740 -4.3700 -0.2674
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome prospective hospitalized hf nursing outcomes
H-1403	-0.8914405107498169	▁nur sing - sensitiv e _ ▁outcome s
D-1403	-0.8914405107498169	nursing-sensitive_ outcomes
P-1403	-1.4845 -0.0030 -0.0769 -0.0005 -0.2961 -2.3198 -0.6033 -0.8479 -3.1856 -0.0967
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence hf ami adjusted_odds_ratio
H-1310	-0.4598298668861389	▁bet we en ▁ HF ▁ AMI
D-1310	-0.4598298668861389	between HF AMI
P-1310	-0.6397 -0.1783 -0.0625 -0.2018 -0.0492 -0.7980 -0.3029 -1.7978 -0.1083
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas rnas expression genes messenger_rna repression
H-1482	-0.5274298787117004	▁mi RNA s ▁non co ding ▁ RNA s ▁regula te ▁expression ▁target ▁gene s ▁se que nce - specific ▁un trans la ted ▁messenger ▁ RNA ▁translation al _ re pression
D-1482	-0.5274298787117004	miRNAs noncoding RNAs regulate expression target genes sequence-specific untranslated messenger RNA translational_repression
P-1482	-1.1338 -0.0001 -0.1522 -2.9583 -0.0009 -0.0643 -0.5793 -0.0003 -0.1146 -0.5212 -0.5573 -0.2380 -1.2706 -0.3965 -0.0256 -0.5496 -0.0265 -0.9121 -0.2545 -0.5011 -3.3226 -0.0008 -0.1859 -0.0030 -0.6559 -0.5680 -0.0002 -2.2732 -0.0184 -0.2673 -0.1611 -0.0005 -0.1351 -0.0837
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse myocardial_t1 heart_failure
H-1055	-0.2727844715118408	▁free - bre a thing _ ▁puls e _ se que ncy ▁my o card ial _ ▁T 1 ▁s win e _ model ▁ta chy car dia - indu ced _ heart _ ▁failure
D-1055	-0.2727844715118408	free-breathing_ pulse_sequency myocardial_ T1 swine_model tachycardia-induced_heart_ failure
P-1055	-0.0150 -0.0256 -0.0119 -0.0195 -0.0272 -0.2313 -0.4593 -0.0196 -1.0180 -0.2816 -0.1335 -1.3169 -0.0437 -0.0189 -0.2404 -0.0028 -0.3138 -0.4631 -0.0389 -0.0828 -0.0974 -0.1594 -1.2442 -0.3496 -0.0948 -0.0291 -0.4655 -0.0491 -0.2523 -0.0008 -0.0205 -0.4615 -0.7051 -0.3307 -0.9594 -0.0388 -0.0712
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients hfpef ivabradine placebo double-blind
H-1173	-0.3103078305721283	▁ HF p EF ▁i va bra dine ▁place bo
D-1173	-0.3103078305721283	HFpEF ivabradine placebo
P-1173	-0.5479 -0.3375 -0.1078 -0.5719 -0.0105 -0.1281 -0.0873 -0.0062 -1.3473 -0.0167 -0.5041 -0.0586
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic new_york_heart_association_classes saf
H-229	-1.1950174570083618	▁ PF _ co hor t ▁New ▁York _ ▁Heart _ association
D-229	-1.1950174570083618	PF_cohort New York_ Heart_association
P-229	-1.3760 -1.1708 -3.0726 -0.1515 -0.0266 -0.1458 -2.8377 -0.5041 -0.2472 -2.0371 -0.4103 -1.3524 -3.1883 -0.2099
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective_cohort eds diagnosis heart_failure
H-463	-1.8722361326217651	▁ec s ▁ diagnos is ▁heart _ ▁failure
D-463	-1.8722361326217651	ecs diagnosis heart_ failure
P-463	-3.7112 -2.2755 -5.3860 -2.9373 -0.1395 -1.5893 -0.2674 -2.0224 -0.2588 -0.1351
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac cells cardiac cells cardiac_functions myocardial_infarction
H-1335	-0.3807641565799713	▁Card iac ▁c - K it _ cell s ▁cardiac ▁ex plant - der i ved _ cell s ▁cardiac _ function s ▁my o card ial _ in far ction
D-1335	-0.3807641565799713	Cardiac c-Kit_cells cardiac explant-derived_cells cardiac_functions myocardial_infarction
P-1335	-1.9942 -0.0170 -0.9947 -0.0493 -0.6228 -0.5448 -0.7463 -0.5218 -0.2080 -0.0197 -0.2762 -0.0004 -0.0839 -0.0245 -0.0530 -0.0212 -0.4842 -0.0885 -0.0128 -0.6581 -0.9738 -1.0728 -0.3508 -0.6757 -0.0943 -0.9652 -0.0802 -0.3311 -0.4705 -0.0070 -0.0211 -0.0396 -0.0616
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses pathophysiology hf nursing medical symptoms pathophysiologic
H-2022	-0.5659701228141785	▁pat ho phy si ology ▁ HF ▁medical _ management
D-2022	-0.5659701228141785	pathophysiology HF medical_management
P-2022	-1.0625 -0.1543 -0.1526 -0.9979 -0.0040 -0.6951 -0.0023 -1.4550 -0.8296 -0.0473 -1.3122 -0.0789
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 bets chromatin downstream_signalling rna polymerase_ii pol_ii
H-1043	-0.6094474196434021	▁inhibi tor ▁ BET s ▁chr omat in ▁down stream ▁signal ling ▁ RNA _ poly mera se ▁pol ▁II
D-1043	-0.6094474196434021	inhibitor BETs chromatin downstream signalling RNA_polymerase pol II
P-1043	-2.9798 -0.0084 -2.1604 -0.4165 -1.3068 -0.0810 -0.0129 -0.2612 -0.0249 -0.0000 -1.1925 -0.1147 -0.2313 -0.0046 -0.6975 -0.6398 -0.2732 -0.0397 -2.6221 -0.1692 -0.1241 -0.0469
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps adverse_outcomes patients heart_failure pulmonary_embolism diabetes chemotherapy
H-1022	-0.9590189456939697	▁ NP s ▁pulmonar y _ e mbol ism ▁diabetes
D-1022	-0.9590189456939697	NPs pulmonary_embolism diabetes
P-1022	-1.7201 -0.0181 -0.1110 -4.5858 -0.0062 -0.6644 -1.0720 -0.0013 -0.0429 -1.0444 -1.9348 -0.3073
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome heart_failure hf acute_myocardial_infarction ami pneumonia pna
H-1691	-0.8306358456611633	▁em pir ically _ de ved ▁com posit e _ quality _ ▁measure ▁heart _ ▁failure ▁a cute _ my o card ial _ in far ction ▁pneu monia
D-1691	-0.8306358456611633	empirically_deved composite_quality_ measure heart_ failure acute_myocardial_infarction pneumonia
P-1691	-4.7859 -0.0029 -0.0486 -0.8554 -3.7988 -1.0074 -1.1696 -0.0010 -0.0175 -0.2346 -1.5333 -0.4851 -1.7329 -0.6216 -0.3206 -0.6314 -0.1078 -0.0011 -0.3634 -4.2313 -0.4973 -1.0417 -0.0254 -0.0588 -0.5602 -0.0085 -0.0335 -0.1450 -0.7170 -0.6506 -0.0616
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal_dysfunction intestinal lead chronic inflammatory catabolic anabolic cardiac_cachexia terminal chf prognosis
H-1360	-0.4104810357093811	▁intestinal _ ▁barrier ▁chronic _ ▁infla mma tory _ state ▁cata bo lic _ ana bo lic _ ▁im balance ▁cardiac ▁cache xia ▁terminal _ ▁stage ▁CHF
D-1360	-0.4104810357093811	intestinal_ barrier chronic_ inflammatory_state catabolic_anabolic_ imbalance cardiac cachexia terminal_ stage CHF
P-1360	-0.0886 -1.2922 -1.8599 -0.8216 -0.4591 -0.5358 -0.4048 -0.0050 -0.7139 -0.2532 -0.0054 -0.0035 -0.1282 -0.7381 -0.0724 -0.0929 -0.0498 -0.6726 -0.9585 -0.0004 -0.0004 -0.2907 -0.0016 -0.9124 -0.6135 -0.3830 -0.1380 -0.2263 -0.1822
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic heart_failure_with_preserved_ejection_fraction hfpef patients health symptoms quality_of_life
H-780	-0.6544596552848816	▁epidemi c ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-780	-0.6544596552848816	epidemic heart_ failure preserved_ejection_fractionHFpEF
P-780	-2.0150 -0.0745 -1.7551 -0.2053 -1.8089 -0.1949 -0.0709 -0.0549 -0.2481 -0.6953 -0.8737 -0.3299 -0.2441 -0.1595 -0.9374 -0.0043 -0.1667 -2.5471 -0.0490
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic_adenosine_monophosphate camp cyclic_guanosine_monophosphate cgmp hearts
H-1209	-0.3048650324344635	▁di minis hed ▁ cycli c ▁ad enos ine _ ▁mono phos pha te ▁c AMP ▁aug mente d ▁ cycli c ▁gua no sine _ ▁mono phos pha te ▁c G MP ▁fail ing _ heart s
D-1209	-0.3048650324344635	diminished cyclic adenosine_ monophosphate cAMP augmented cyclic guanosine_ monophosphate cGMP failing_hearts
P-1209	-1.5219 -0.0032 -0.1378 -0.1131 -0.0018 -0.0874 -0.0817 -0.5179 -0.0580 -0.3677 -0.4209 -0.0112 -0.2577 -0.0320 -0.2785 -0.0017 -1.0652 -0.1713 -0.0005 -0.2133 -0.0019 -0.0275 -2.8321 -0.0094 -0.5991 -0.8161 -0.2215 -0.0012 -0.0449 -0.0718 -0.1752 -0.3269 -0.0858 -0.4495 -0.0268 -0.1974 -0.5765 -0.1934 -0.0978 -0.0969
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_pulmonary_disease diabetes_mellitus
H-1618	-0.5328245759010315	▁mortal ity ▁health care ▁utiliza tion _ effect s ▁care ▁management ▁tele health ▁con ges tive _ heart _ ▁failure ▁chronic ▁ob struct ive _ ▁pulmonar y _ مرض ▁diabetes ▁mell itus
D-1618	-0.5328245759010315	mortality healthcare utilization_effects care management telehealth congestive_heart_ failure chronic obstructive_ pulmonary_مرض diabetes mellitus
P-1618	-0.2135 -0.0096 -0.1635 -0.0034 -3.4190 -0.0061 -3.2874 -0.1722 -0.1647 -2.2549 -0.5327 -0.1553 -0.0863 -0.0442 -0.0076 -0.0140 -0.1844 -0.4997 -0.4738 -0.1413 -0.0231 -1.4807 -0.0088 -0.0262 -0.2135 -0.3325 -0.0735 -0.9995 -2.6761 -0.1075 -0.2877 -0.0005 -0.0225 -0.0300
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction hfpef
H-942	-0.7010501623153687	▁cat heter ▁ab lation ▁at rial _ fi bril lation _ AF ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction
D-942	-0.7010501623153687	catheter ablation atrial_fibrillation_AF heart_ failure preserved_ejection_fraction
P-942	-3.3969 -0.1989 -0.5810 -0.0021 -0.3545 -0.0066 -0.2191 -0.7402 -0.0066 -0.0002 -1.7996 -0.1506 -0.8766 -0.3312 -2.4953 -0.8572 -0.0993 -0.0918 -0.1061 -0.7741 -2.5944 -0.3615 -0.3239 -0.5559 -1.2454 -0.0583
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report patient diagnosis ischemic-hypertensive_cardiomyiopathy angina myocardial_ischemia coronary_arteries
H-998	-0.73788982629776	▁report ▁ ische mic - hy per tensi ve _ ▁cardio mio pathy ▁ang ina ▁induc ible ▁my o card ial _ ische mia ▁corona ry ▁arteri es
D-998	-0.73788982629776	report ischemic-hypertensive_ cardiomiopathy angina inducible myocardial_ischemia coronary arteries
P-998	-1.1830 -0.6801 -1.1595 -0.1463 -0.1469 -0.7704 -0.0428 -1.5397 -0.2442 -0.1350 -0.3250 -5.5430 -0.8575 -0.5102 -0.0485 -0.0038 -0.0294 -3.7270 -0.0884 -0.6691 -0.0388 -0.2062 -2.8938 -0.0360 -0.2242 -0.0434 -0.6550 -0.0314 -0.0882 -0.0699
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra methotrexate tnf_antagonist non-biological_disease_modifying_antirheumatic_drug nbdmard
H-604	-1.0091856718063354	▁RA ▁met ho tre xa te ▁t NF _ ▁anta gon ist ▁non - bi ological _ مرض _ mod ifying _ anti r heu matic _ drug n b DM ARD
D-604	-1.0091856718063354	RA methotrexate tNF_ antagonist non-biological_مرض_modifying_antirheumatic_drugnbDMARD
P-604	-1.3493 -2.0579 -0.1085 -0.0221 -0.1724 -0.0496 -0.9634 -0.1352 -1.0051 -0.0419 -0.1119 -0.1363 -0.5422 -0.0383 -0.5212 -0.2384 -1.7480 -2.3767 -5.1811 -0.2209 -0.0141 -2.0931 -0.2568 -5.8982 -6.2928 -0.0604 -0.6823 -0.1847 -1.4137 -0.0006 -0.1702 -0.0083 -0.0310 -0.1855
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate_cox_proportional_hazards_regression_modeling hospitalization acute_coronary_syndromes coronary_interventions patients
H-104	-0.7036342024803162	▁co x ▁proportion al _ ▁hazard s ▁re gression _ model ing ▁risk _ factor s ▁a cute _ ▁corona ry _ ▁syndrome s ▁corona ry _ intervention s
D-104	-0.7036342024803162	cox proportional_ hazards regression_modeling risk_factors acute_ coronary_ syndromes coronary_interventions
P-104	-0.0979 -0.0093 -0.5455 -0.0091 -0.2103 -1.4050 -0.2085 -0.5606 -0.0005 -2.1630 -0.9749 -0.1516 -1.2582 -1.8954 -0.1778 -0.2698 -4.8689 -0.1083 -0.3348 -2.9141 -0.0971 -1.1636 -0.1660 -0.0638 -0.0710 -0.0342 -0.8997 -0.4335 -0.0450 -0.3650 -0.3102
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate_receptor_1 s1pr1 β1-adrenergic_receptor β1ar g-protein-coupled_receptors heart
H-1405	-0.4260668158531189	▁sp hing os ine -1 - phos pha te ▁receptor ▁s 1 PR 1 ▁β 1- ad r energi c _ ▁receptor β 1 AR ▁g - prote in - co up led _ ▁receptor s ▁heart
D-1405	-0.4260668158531189	sphingosine-1-phosphate receptor s1PR1 β1-adrenergic_ receptorβ1AR g-protein-coupled_ receptors heart
P-1405	-0.0037 -1.0300 -0.7692 -0.3946 -1.6643 -0.3001 -0.0090 -0.0991 -0.0844 -0.3025 -0.7816 -0.0247 -0.0088 -2.2024 -0.0353 -0.2703 -0.0421 -0.5036 -3.6191 -0.4170 -1.6085 -0.0145 -0.3530 -0.0581 -0.0756 -0.2430 -0.0871 -0.0282 -0.0722 -0.0987 -0.0008 -0.0088 -0.0024 -0.1428 -0.1641 -0.1456 -0.8108 -0.0763 -0.0644
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal correlated pcwp p_values
H-484	-1.2294721603393555	▁e _ sept al ▁PC WP ▁e / e ' lateral ▁e / e ' me an
D-484	-1.2294721603393555	e_septal PCWP e/e'lateral e/e'mean
P-484	-0.7519 -6.2346 -0.1591 -0.0228 -0.2450 -2.8684 -0.4896 -1.2743 -0.0353 -5.0548 -0.3576 -0.3951 -0.9149 -0.0173 -3.6562 -0.0314 -0.0471 -0.5222 -0.2825
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy atrial_fibrillation patients carvedilol metoprolol
H-864	-0.3926781415939331	▁in appropria te _ therapy ▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-864	-0.3926781415939331	inappropriate_therapy atrial_fibrillation carvedilol metoprolol
P-864	-3.2082 -0.0142 -0.2817 -1.5424 -0.1359 -0.6677 -0.0367 -0.1229 -0.7980 -0.0280 -0.0031 -0.0631 -0.0219 -0.0283 -0.2588 -0.0945 -0.0200 -0.0838 -0.3176 -0.1267
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls lvef prognostic clinical echocardiographic systolic
H-820	-0.9024785757064819	▁g LS ▁LV EF ▁sa ▁predict ing ▁advers e ▁CV _ ▁events ▁convention al ▁clinic al ▁e cho car dio graphic _ ▁sy sto lic _ ▁parameter s ▁AF
D-820	-0.9024785757064819	gLS LVEF sa predicting adverse CV_ events conventional clinical echocardiographic_ systolic_ parameters AF
P-820	-0.6408 -1.3108 -0.1292 -0.0082 -1.0931 -4.5001 -0.0768 -0.0752 -0.0526 -0.4209 -2.6058 -0.3771 -4.6713 -0.0029 -1.0524 -0.0019 -0.4526 -0.1024 -1.4181 -1.4231 -0.9722 -0.4975 -1.8433 -0.2752 -0.9670 -2.2087 -0.3004 -0.0097 -0.3477 -0.0789 -0.0608
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia intravenous metoprolol cardiac sympathetic_tone
H-1379	-0.379204124212265	▁Brad y car dia ▁intra ven ous _ met o pro lol ▁cardiac _ ▁sympa the tic _ ▁tone ▁CHF - IN V ▁rabbi ts ▁sham - IN V ▁CHF - DN x
D-1379	-0.379204124212265	Bradycardia intravenous_metoprolol cardiac_ sympathetic_ tone CHF-INV rabbits sham-INV CHF-DNx
P-1379	-0.1380 -0.0164 -0.9970 -0.1890 -1.1169 -0.0055 -0.9564 -1.5976 -0.5301 -0.2045 -0.0466 -0.1188 -0.0070 -0.3067 -1.6073 -0.0752 -0.4392 -0.4941 -0.2032 -0.0991 -0.0281 -0.9148 -0.6788 -1.0673 -0.0060 -0.0030 -0.0612 -0.3283 -0.6372 -0.0758 -0.0146 -0.0027 -0.0663 -0.0697 -0.1696
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes patients prescribed pharmacological discharge left_ventricular_function
H-1849	-0.7148798704147339	▁c PG - re com mend ed ▁ pharma c ological _ ▁treatment ▁device
D-1849	-0.7148798704147339	cPG-recommended pharmacological_ treatment device
P-1849	-1.2776 -0.2732 -0.2086 -0.0041 -0.0070 -0.0011 -0.0069 -0.2181 -0.0042 -0.0854 -1.0841 -1.6440 -1.9708 -0.1212 -4.4437 -0.0882
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized walking cardiac_rehabilitation functional_capacity outcomes patients severe_heart_failure
H-569	-1.2938278913497925	▁random ized _ control led _ ▁trial ▁Nordic _ ▁walking ▁standard _ ▁cardiac _ rehabilit tion _ care ▁functional _ capaci ty
D-569	-1.2938278913497925	randomized_controlled_ trial Nordic_ walking standard_ cardiac_rehabilittion_care functional_capacity
P-569	-6.9530 -0.5557 -0.6390 -0.8650 -0.1868 -0.1978 -0.7453 -2.3204 -0.6577 -3.2878 -0.0615 -0.6293 -0.5682 -0.5943 -0.6326 -0.6782 -2.2874 -1.2507 -1.9360 -1.4844 -0.5670 -0.5640 -3.2588 -0.1309
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad q66p rad cav1.2 cav1.3 l-type_channel isoforms heart
H-1674	-0.6965818405151367	▁Rad _ Q 66 p ▁limit s ▁inhibi tory _ action ▁Rad _ on ca v 1.2 ▁ca v 1.3 ▁l - type _ ▁channel ▁iso form s ▁heart
D-1674	-0.6965818405151367	Rad_Q66p limits inhibitory_action Rad_oncav1.2 cav1.3 l-type_ channel isoforms heart
P-1674	-0.4369 -2.1985 -0.7951 -0.0648 -0.3295 -1.1672 -0.0077 -0.2391 -0.0097 -0.6501 -0.1083 -0.7503 -1.9231 -0.8235 -0.7753 -1.1887 -0.3791 -2.9728 -0.6134 -0.3865 -1.4789 -0.0669 -0.0048 -0.6126 -2.4969 -0.1106 -0.0172 -0.2650 -0.5765 -0.0354 -0.1095
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef lcx lad stenting infarcted left_ventricle lcx lad
H-512	-0.871877908706665	▁EF ▁ LC X _ model ▁ LAD _ model ▁sten ting ▁left _ ▁vent ric le ▁ LC X ▁ LAD
D-512	-0.871877908706665	EF LCX_model LAD_model stenting left_ ventricle LCX LAD
P-512	-0.7637 -1.1788 -0.0099 -1.2156 -3.9423 -0.4391 -0.1415 -0.0057 -3.1343 -1.0398 -0.7198 -0.0351 -1.6875 -0.3311 -1.3163 -0.6499 -0.2466 -0.3358 -0.1319 -1.0724 -0.9588 -0.0094 -1.3455 -0.2144
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas expression bhlh transcription_factor hand2 myocardium gene heart_failure
H-644	-0.5322495698928833	▁signal ling ▁casca des ▁micro RNA s ▁b HL h _ ▁tran scription _ factor ▁Hand 2 ▁post na tal ▁mamma lian _ ▁my o car dium ▁em bry o nic _ ▁gene s ▁heart
D-644	-0.5322495698928833	signalling cascades microRNAs bHLh_ transcription_factor Hand2 postnatal mammalian_ myocardium embryonic_ genes heart
P-644	-0.0285 -0.0338 -0.1616 -0.0042 -0.6283 -0.0001 -0.0499 -0.0136 -0.2649 -1.0546 -1.6128 -0.2151 -0.3569 -1.0649 -0.0294 -0.1633 -0.0277 -0.0010 -0.1203 -0.0006 -0.6186 -0.0226 -0.7469 -2.6314 -0.0552 -0.0807 -0.9123 -0.0314 -0.0052 -0.0138 -0.3430 -0.1107 -2.8492 -2.1190 -0.0558 -3.1911 -0.0747
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc dapc_protein sarcomeric_microstructure skm myofibre_regeneration
H-1254	-0.6040714383125305	ERC ▁induc ed _ ▁recovery ▁DAP C _ ▁protein ▁levels ▁sar come ric _ micro structure ▁marker s ▁Sk M ▁growth ▁my o fi bre _ ▁regenera tion
D-1254	-0.6040714383125305	ERC induced_ recovery DAPC_ protein levels sarcomeric_microstructure markers SkM growth myofibre_ regeneration
P-1254	-0.3986 -3.2172 -0.0051 -0.9971 -1.9067 -0.1957 -0.3837 -0.9262 -0.7220 -1.7860 -0.0007 -0.0530 -0.1402 -0.0941 -0.2418 -0.0327 -0.2688 -0.0016 -1.2552 -0.7109 -1.7854 -1.6460 -0.0106 -0.0147 -0.0404 -0.8292 -0.2930 -0.0108 -0.0900 -0.0647
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva surgical implantation leaflet leaflet edge-to-edge_anastomosis
H-360	-0.4730084240436554	▁m v ▁sur g ical _ ▁ring ▁implant ation ▁le a flet _ ▁motion ▁edge - to - ed ge ▁an asto mos is
D-360	-0.4730084240436554	mv surgical_ ring implantation leaflet_ motion edge-to-edge anastomosis
P-360	-1.7897 -3.1625 -0.9245 -0.0116 -0.0199 -0.7304 -0.1914 -0.4755 -0.0368 -0.1576 -0.0215 -0.0009 -0.6713 -2.5414 -0.5313 -0.0130 -0.0485 -0.1580 -0.0244 -0.0229 -0.2841 -0.0007 -0.0210 -0.3661 -0.0352 -0.0581
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart patients new_york_heart_association nyha hospitalized hf primary_outcome death hf hospitalization
H-239	-1.1383154392242432	▁H ART ▁New ▁York _ heart _ association ▁NY HA ▁ HF ▁ HF
D-239	-1.1383154392242432	HART New York_heart_association NYHA HF HF
P-239	-2.8424 -0.0412 -4.0956 -0.2857 -0.2551 -2.4147 -0.2037 -0.8074 -2.8513 -0.0031 -0.6177 -0.2148 -2.7411 -0.0369 -0.6105 -0.1919
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet bromodomain_proteins bets acetyl-lysine_reader_proteins hf pathogenesis hf
H-1038	-0.6163235902786255	▁ BET ▁bro modo main _ ▁protein s ▁bet s ▁a ce tyl - ly sine _ ▁reader _ ▁protein s ▁ HF
D-1038	-0.6163235902786255	BET bromodomain_ proteins bets acetyl-lysine_ reader_ proteins HF
P-1038	-0.8341 -0.0283 -2.5408 -0.0175 -0.2723 -0.2217 -1.3822 -0.0372 -1.2656 -0.1027 -0.0320 -0.0103 -0.0464 -0.0356 -3.5934 -1.5688 -0.2630 -0.8367 -0.1717 -0.7672 -0.0182 -0.0214 -0.0037 -1.0956 -0.2418
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in_vivo cardiac_function echocardiography diastolic_dysfunction systolic_dysfunction ejection_fraction
H-1783	-0.34661415219306946	▁cardiac _ function via ▁e cho card i ography ▁dia sto lic _ ▁dys function ▁E / E ▁sy sto lic _ ▁dys function ▁e je ction _ fraction
D-1783	-0.34661415219306946	cardiac_functionvia echocardiography diastolic_ dysfunction E/E systolic_ dysfunction ejection_fraction
P-1783	-0.1909 -0.4129 -0.9686 -1.1283 -0.0743 -0.0331 -0.1237 -0.0494 -0.2689 -0.0351 -0.0278 -0.2910 -0.2329 -0.1995 -0.0107 -0.6144 -1.6428 -0.0968 -2.5967 -0.2188 -0.1957 -0.1847 -0.2285 -0.0314 -0.1061 -0.0277 -0.0368 -0.5119 -0.0014 -0.1621 -0.0422
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone_antagonism heart_failure aldosterone neurohormone electrolytes heart_failure patients systolic_dysfunction
H-1733	-1.2984803915023804	▁al do ster one _ ▁anta gon ism ▁heart _ ▁failure ▁al do ster one ▁electro ly tes
D-1733	-1.2984803915023804	aldosterone_ antagonism heart_ failure aldosterone electrolytes
P-1733	-2.5281 -1.2613 -2.2454 -0.0964 -2.9082 -2.3532 -0.0353 -0.0153 -2.1331 -0.6591 -1.0585 -4.2398 -0.0468 -0.1752 -0.0397 -0.3424 -1.9782 -0.7762 -2.8909 -0.1866
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv_compliance lv_end-diastolic_volume lv_end-diastolic_pressure β_coefficient
H-1531	-1.4106804132461548	▁LV ▁end - dia sto lic _ ▁volume ▁LV _ ▁end - dia sto lic _ ▁pressure ▁h g ▁β _ co e ffi cient
D-1531	-1.4106804132461548	LV end-diastolic_ volume LV_ end-diastolic_ pressure hg β_coefficient
P-1531	-0.9499 -7.1410 -0.0297 -0.0067 -1.6506 -0.3691 -0.8485 -1.4310 -5.3321 -2.1419 -4.1843 -0.0379 -0.0049 -0.8425 -0.9794 -1.2925 -1.5984 -5.8771 -0.0187 -0.8985 -1.5642 -0.1061 -0.0385 -0.0032 -0.0037 -0.4327 -0.3055
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade clinical
H-202	-0.7948331832885742	▁Grad ing _ of _ re com mend ations _ evalua tion GRAD e
D-202	-0.7948331832885742	Grading_of_recommendations_evaluationGRADe
P-202	-0.9943 -0.1185 -0.5601 -2.1890 -0.0470 -0.0468 -0.0042 -0.0017 -0.0026 -2.3541 -1.1356 -0.1766 -3.0796 -0.3587 -1.5449 -0.1036
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf hospitalization
H-563	-0.9778516292572021	▁ HF _ hospital ization
D-563	-0.9778516292572021	HF_hospitalization
P-563	-1.2046 -0.4753 -2.6148 -0.0632 -0.3832 -1.9655 -0.1383
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right_heart_circulatory_failure disease right_heart
H-1460	-1.1055233478546143	▁uniform _ ▁nomen cla ture ▁right _ heart _ ▁circula tory _ ▁failure ▁con jo int _ éducation ▁mechanism s
D-1460	-1.1055233478546143	uniform_ nomenclature right_heart_ circulatory_ failure conjoint_éducation mechanisms
P-1460	-6.5016 -0.8611 -0.8501 -0.0050 -0.0400 -0.1568 -0.1701 -3.5746 -0.2675 -0.6157 -0.0158 -0.7046 -1.3414 -1.5992 -0.0121 -0.1263 -0.0652 -2.1227 -0.4880 -0.0288 -4.4767 -0.2981
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular_action_potentials excitation-contraction myocardium
H-1671	-0.7328627109527588	▁influ x ▁L - type ▁volta ge - ga ted _ ca (2 +) ▁channel s ▁plate au _ ▁phase ▁vent ri cular _ action _ ▁potential s ▁excita tion - con traction _ EC ▁coup ling ▁my o car dium
D-1671	-0.7328627109527588	influx L-type voltage-gated_ca(2+) channels plateau_ phase ventricular_action_ potentials excitation-contraction_EC coupling myocardium
P-1671	-5.4109 -0.0508 -2.0939 -0.0165 -0.0011 -0.0344 -0.0019 -0.1095 -0.0053 -0.0017 -2.4247 -0.0726 -3.3855 -0.0334 -2.0413 -0.3187 -0.0060 -0.0037 -1.0106 -0.7491 -0.0278 -0.2228 -0.1839 -1.0385 -0.0425 -2.7047 -0.9655 -0.1753 -0.9974 -0.0207 -0.2099 -0.0021 -0.0865 -2.8088 -1.6219 -1.5302 -0.0201 -0.1566 -0.0107 -0.0092 -0.5353 -0.1079 -0.2633
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1_receptors neprilysin renin-angiotensin-aldosteron ras vasodilatory diuretic natriuretic_peptides
H-1967	-0.4636920988559723	▁AT 1 ▁receptor s ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on ▁ RAS ▁a xis ▁natural ▁vaso dila tory ▁di ure tic ▁na tri ure tic _ pe pti des
D-1967	-0.4636920988559723	AT1 receptors neprilysin blocks renin-angiotensin-aldosteron RAS axis natural vasodilatory diuretic natriuretic_peptides
P-1967	-1.2197 -0.4858 -0.6099 -0.3300 -0.0603 -0.1238 -0.5007 -0.5601 -0.0513 -0.0073 -0.0321 -0.0225 -0.0183 -0.0765 -1.9900 -0.3704 -0.0648 -1.5196 -1.4202 -0.3146 -1.5703 -0.0076 -2.7019 -0.0001 -0.0205 -0.0353 -0.0236 -0.0065 -0.2050 -0.0380 -0.2461 -2.2190 -0.0312 -0.1300 -0.3873 -0.3419 -0.2349 -0.0624 -0.7491 -0.1545 -0.0683
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine exercise_capacity left_ventricular_filling patients heart_failure_with_preserved_ejection_fraction hfpef
H-1171	-0.5184683799743652	▁i va bra dine ▁exercise _ capaci ty ▁left ▁vent ri cular _ ▁fill ing ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction
D-1171	-0.5184683799743652	ivabradine exercise_capacity left ventricular_ filling heart_ failure preserved_ejection_fraction
P-1171	-0.0675 -0.3067 -0.0438 -0.0093 -1.1049 -1.2354 -0.4125 -1.9121 -0.0097 -1.4359 -0.1945 -0.1498 -0.7641 -0.1528 -0.0083 -0.4918 -0.3619 -1.9803 -0.1345 -0.0629 -0.0279 -0.3384 -0.8044 -1.6022 -0.1700 -0.4386 -0.2490 -0.5122 -0.0544
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood_transfusions erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_disease transfusion
H-42	-0.6525585055351257	▁blood ▁trans fusion s ▁ir on ▁er y thro po ies is - stimul ating _ agent ▁an emia ▁con ges tive _ heart _ ▁failure ▁corona ry _ heart _ مرض ▁trans fusion
D-42	-0.6525585055351257	blood transfusions iron erythropoiesis-stimulating_agent anemia congestive_heart_ failure coronary_heart_مرض transfusion
P-42	-4.5105 -0.0332 -0.0015 -0.2604 -0.0523 -0.0122 -0.0191 -0.1072 -0.5528 -0.6207 -3.8481 -0.7381 -0.8065 -0.1852 -0.0185 -0.6939 -0.5217 -0.4743 -0.0014 -0.0046 -0.0146 -0.0332 -0.8534 -0.5159 -0.9096 -0.1761 -0.0800 -0.0268 -0.1317 -2.2349 -0.4753 -3.9509 -0.0789 -0.0099 -0.4877 -0.0509
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate_analysis bnp estimated_glomerular_filtration_rate hypertension transmitral e-wave diastolic_mitral_annular_velocity
H-1570	-0.678993821144104	▁high ▁b NP ▁glo mer ular _ ▁filtr ation _ ▁rate ▁hyper tension ▁transmit ral ▁E - wa ve _ ear ly _ dia sto lic _ ▁mit ral _ velo city
D-1570	-0.678993821144104	high bNP glomerular_ filtration_ rate hypertension transmitral E-wave_early_diastolic_ mitral_velocity
P-1570	-3.2172 -2.5380 -0.8256 -0.1591 -0.2241 -0.0088 -0.6816 -0.4443 -0.0318 -0.7056 -0.6054 -0.1075 -0.0012 -0.0296 -0.0028 -2.2489 -0.0168 -0.0046 -0.0192 -2.0086 -0.7904 -0.0123 -0.9360 -0.0345 -0.0333 -0.1506 -0.3120 -4.1670 -0.0644 -0.1195 -1.0124 -0.0182 -1.4330 -0.1214
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade halt disease protein_kinase pka β-adrenergic_receptor
H-1425	-0.4899909496307373	▁β - block ade ▁c AMP - dependent _ ▁protein ▁kina se ▁down stream ▁β - ad r energi c _ ▁receptor ▁post - trans la tional
D-1425	-0.4899909496307373	β-blockade cAMP-dependent_ protein kinase downstream β-adrenergic_ receptor post-translational
P-1425	-0.5044 -0.0359 -0.1587 -1.3956 -0.4706 -0.0383 -0.1909 -0.0295 -1.2912 -1.2229 -1.0105 -0.1000 -2.0384 -0.0002 -0.4372 -0.0132 -0.0094 -0.5124 -0.8377 -0.2777 -0.4322 -0.2319 -0.7830 -0.0076 -0.0020 -0.0907 -0.0027 -1.8880 -0.1969
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence erythropoiesis-stimulating_agent therapy venous_thromboembolism
H-47	-0.7962717413902283	▁er y thro po ies is - stimul ating _ agent _ therapy ▁ve nous _ thro mbol ism
D-47	-0.7962717413902283	erythropoiesis-stimulating_agent_therapy venous_thrombolism
P-47	-0.5997 -0.0452 -1.0661 -1.2616 -4.3458 -1.1689 -0.4658 -0.1371 -0.0326 -0.1513 -0.0926 -0.6992 -0.4921 -1.4410 -2.0642 -0.4715 -0.1846 -1.6545 -0.2514 -0.0669 -0.0295
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical genetic chf area_under_the_curve auc genetic auc clinical auc
H-1456	-1.189507007598877	clin ical ▁CHF _ pred ive _ model ▁cur ve ▁genetic
D-1456	-1.189507007598877	clinical CHF_predive_model curve genetic
P-1456	-2.8527 -0.0037 -3.0725 -0.9536 -1.3276 -0.1681 -0.6606 -0.2704 -2.1944 -0.0134 -1.1057 -2.7757 -0.0651
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable_adjustment mortality hospitalization hazard_ratio cardiovascular_mortality hf hospitalization
H-1638	-0.7386690974235535	▁black _ race ▁mortal ity _ hospital ization haz ard _ ▁ratio ▁cardiovascular _ ▁mortal ity HF _ hospital ization
D-1638	-0.7386690974235535	black_race mortality_hospitalizationhazard_ ratio cardiovascular_ mortalityHF_hospitalization
P-1638	-0.0050 -0.9278 -0.6959 -3.7181 -0.0071 -2.6488 -0.1419 -0.1843 -0.2615 -0.0261 -0.2214 -1.3956 -1.0131 -0.1201 -1.3284 -0.0094 -0.6839 -2.2610 -0.0341 -0.2318 -0.2394 -0.0961
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous chronic_myocardial_ischemia stent polytetrafluoroethylene
H-504	-0.6063300967216492	▁per cuta ne ous ▁one - ves sel _ model ▁chronic ▁my o card ial _ ische mia ▁sten t ▁poly te tra flu oro e thy lene ▁bottle ne ck
D-504	-0.6063300967216492	percutaneous one-vessel_model chronic myocardial_ischemia stent polytetrafluoroethylene bottleneck
P-504	-0.2451 -0.0017 -0.0598 -0.0352 -1.9195 -0.0421 -1.0422 -0.0643 -1.2075 -0.3927 -0.0987 -3.5550 -0.3915 -1.2968 -0.0461 -0.2629 -4.4236 -0.1044 -0.0063 -0.0176 -0.7593 -0.0671 -0.0170 -0.1162 -0.3476 -1.7965 -0.4221 -0.2660 -0.6187 -0.0241 -0.0032 -0.2954 -0.0624
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers_for_medicare_and_medicaid_services cms hospital outcomes reported mortality readmission penalties
H-1031	-0.8239494562149048	▁center s ▁Medica re ▁and ▁Medica id _ service s ▁c ms ▁operation al ized ▁hospital ▁quality _ of _ care ▁outcome s ▁public ly ▁risk - standard ized _ ▁mortal ity ▁read mission ▁penal ties
D-1031	-0.8239494562149048	centers Medicare and Medicaid_services cms operationalized hospital quality_of_care outcomes publicly risk-standardized_ mortality readmission penalties
P-1031	-1.8624 -0.1654 -1.4611 -0.0022 -2.8001 -0.0159 -0.3621 -1.6970 -0.4838 -0.1338 -1.3331 -0.8779 -4.7981 -0.0042 -0.6826 -0.2719 -0.9567 -0.4442 -0.0124 -0.0394 -0.2306 -2.4289 -0.0021 -2.0377 -0.1432 -3.4705 -0.0277 -0.0006 -0.0246 -0.3736 -2.0777 -0.0138 -0.2281 -0.0523 -1.0119 -0.0015 -0.4480 -0.3327
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart_failure hf tumor_necrosis_factor tnf tnf_antagonists disease severe_hf
H-601	-0.6852752566337585	▁heart _ ▁failure ▁tumor _ ▁nec rosi s _ factor TN F _ α ▁t NF _ ▁anta gon ists ▁ HF
D-601	-0.6852752566337585	heart_ failure tumor_ necrosis_factorTNF_α tNF_ antagonists HF
P-601	-0.1966 -0.4958 -1.3820 -1.6449 -0.1882 -1.6388 -0.1043 -0.2122 -0.7738 -0.0158 -1.1278 -0.0949 -1.6660 -1.5588 -0.8306 -0.0190 -1.1645 -0.0318 -0.0503 -0.1826 -2.5245 -0.2614 -0.2418 -0.0400
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate signal_transduction transcription_factors pathological cardiomyocytes transcription_factors epigenetic chromatin_structure
H-1040	-0.6599039435386658	▁signal ▁trans duction ▁casca de ▁tran scription _ factor ▁path ological ▁cardio my o cy tes ▁tran scription _ factor ▁epi gene tic ▁chr omat in _ structure
D-1040	-0.6599039435386658	signal transduction cascade transcription_factor pathological cardiomyocytes transcription_factor epigenetic chromatin_structure
P-1040	-0.0196 -0.0493 -0.1078 -0.2863 -0.0053 -2.4487 -0.9830 -1.6156 -0.4685 -0.5870 -0.1299 -2.1558 -0.3378 -1.7187 -0.5273 -0.0868 -0.7547 -1.1584 -1.1774 -0.2215 -0.0397 -0.0185 -0.1012 -1.4897 -0.0048 -0.3878 -1.5259 -1.0433 -0.1798 -0.1668
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox_proportional_hazard_models covariates follow-up physician discharge primary_outcome death all-cause_readmission
H-1416	-0.5990084409713745	▁co x ▁proportion al _ ▁hazard _ ▁models ▁time - dependent ▁co varia tes ▁follow - up ▁familiar _ ▁physician ▁dis charge ▁urgent _ all - ca use _ ▁read mission
D-1416	-0.5990084409713745	cox proportional_ hazard_ models time-dependent covariates follow-up familiar_ physician discharge urgent_all-cause_ readmission
P-1416	-0.1080 -0.0056 -0.0684 -0.0034 -0.3160 -0.5745 -0.6829 -1.2367 -1.1534 -0.0159 -0.0135 -0.4731 -0.0323 -0.0065 -0.1377 -0.0133 -0.0042 -3.5653 -0.6510 -0.9579 -0.7783 -0.0050 -3.0451 -0.4165 -4.0072 -0.0862 -0.0010 -0.0742 -0.3628 -0.7515 -0.0440 -0.0487 -0.1274
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable_logistic_analysis peak_oxygen_uptake metabolic_exercise cardiac kidney prognostic hf_index
H-1760	-0.9352540373802185	▁logistic ▁analysis ▁pe ak _ ▁oxygen _ ▁up take ▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y _ index ▁score
D-1760	-0.9352540373802185	logistic analysis peak_ oxygen_ uptake metabolic_ exercise cardiac kidney_index score
P-1760	-0.8157 -3.3576 -4.2739 -0.0045 -0.2703 -1.3961 -0.4807 -0.4100 -0.0007 -0.4824 -0.0153 -1.8872 -0.1403 -0.0054 -1.4604 -0.0542 -0.0227 -0.6091 -0.1669 -2.3133 -2.2474 -0.1615
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular_dilatation
H-334	-0.6022586822509766	▁ann ular _ ▁size ▁re duction ▁surgery ▁dia sto lic _ ▁mit ral _ ▁val ve ▁te ther ing ▁anterior ▁le a flet ▁opening ▁posterior ly ▁dis place d _ ▁papil lar y _ ▁muscle ▁left ▁vent ri cular _ ▁di la tation
D-334	-0.6022586822509766	annular_ size reduction surgery diastolic_ mitral_ valve tethering anterior leaflet opening posteriorly displaced_ papillary_ muscle left ventricular_ dilatation
P-334	-0.0038 -0.0001 -1.3531 -1.2664 -0.3751 -0.0000 -0.5141 -0.0045 -0.0084 -0.2579 -0.2434 -1.6870 -0.0073 -0.1627 -4.3030 -0.0469 -0.3931 -0.0046 -0.0057 -0.0563 -1.0174 -0.0318 -0.0004 -0.1682 -0.3641 -1.0983 -0.1902 -0.0015 -0.0473 -0.8707 -1.3539 -0.4762 -0.3254 -0.7431 -0.9117 -0.1350 -5.1468 -0.2838 -0.0269 -0.4927 -2.4578 -0.0939 -0.0005 -0.0857 -0.0848
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients hypertensive_hfpef dash ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling
H-926	-0.4640105068683624	▁hyper tensi ve ▁H FP EF ▁so dium - re strict ed ▁DAS H _ Die t ▁vent ri cular _ dia sto lic _ function ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial ▁coup ling
D-926	-0.4640105068683624	hypertensive HFPEF sodium-restricted DASH_Diet ventricular_diastolic_function arterial_ elastance ventricular-arterial coupling
P-926	-0.2698 -1.0906 -0.0339 -0.4802 -0.1507 -0.3153 -0.0073 -0.0391 -0.0113 -0.0008 -0.0006 -0.0094 -0.1735 -0.3580 -2.0138 -2.9144 -0.0196 -0.0130 -0.1711 -0.0485 -1.0011 -0.2601 -0.0873 -0.9411 -2.2974 -0.6692 -0.0026 -1.3725 -1.5734 -0.7784 -0.0045 -0.1420 -0.0347 -0.3504 -0.0172 -0.0268 -0.5499 -0.1938 -0.0842 -0.0531
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf hct polymorphisms genes anthracycline metabolism iron_homeostasis anti-oxidant_defence myocardial_remodelling
H-1450	-0.4944227635860443	▁CHF ▁after _ h CT ▁poly morph ism s ▁an thra cycli ne ▁metabolism ▁ir on ▁home osta sis ▁anti - oxid ant _ de fen ce ▁my o card ial _ ▁remodel ling
D-1450	-0.4944227635860443	CHF after_hCT polymorphisms anthracycline metabolism iron homeostasis anti-oxidant_defence myocardial_ remodelling
P-1450	-0.4141 -6.7323 -1.2900 -1.2283 -0.6093 -1.8586 -0.0074 -0.0148 -0.0137 -0.0099 -0.0009 -0.3094 -0.4404 -1.3453 -0.0231 -0.0089 -0.5538 -0.0638 -0.0153 -0.0011 -0.0133 -0.0029 -0.0770 -0.1362 -0.4402 -0.0234 -0.0367 -0.0709 -0.0195 -1.0405 -0.0144 -0.7513 -0.0541 -0.0134 -0.1152 -0.0498
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate_logistic_regression_analysis rule cad stenosis 3-vessel_cad 2-vessel_cad left_anterior_descending_artery
H-1187	-1.1651082038879395	▁logistic ▁re gression ▁rule ▁severe _ CAD ▁diameter _ ▁sten osis ▁3- ves sel _ ▁CAD ▁proxima l ▁left _ order _ ▁arter y
D-1187	-1.1651082038879395	logistic regression rule severe_CAD diameter_ stenosis 3-vessel_ CAD proximal left_order_ artery
P-1187	-0.5367 -0.7807 -0.0009 -5.0200 -1.8952 -1.0366 -1.3216 -2.5234 -0.5193 -0.1685 -0.0163 -3.4593 -0.0088 -0.0177 -1.3003 -0.3997 -0.2047 -0.0057 -2.5323 -0.3454 -4.8379 -1.4862 -1.4851 -0.0763 -0.2503 -0.0640
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence mortality outcomes heart_failure acute_myocardial_infarction patients acute_myocardial_infarction western_australia
H-1305	-0.9953418970108032	▁incide nce _ ▁mortal ity ▁heart _ ▁failure ▁a cute _ ▁my o card ial _ in far ction ▁western _ Australia
D-1305	-0.9953418970108032	incidence_ mortality heart_ failure acute_ myocardial_infarction western_Australia
P-1305	-1.2253 -0.1398 -2.3665 -2.5994 -0.0050 -2.3768 -0.3827 -0.7716 -0.1821 -0.0033 -0.1718 -5.9642 -0.7258 -1.4314 -0.1033 -0.0914 -0.4286 -0.0067 -0.1646 -3.4745 -0.4484 -0.5421 -0.1203 -0.1628
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized_aldactone_evaluation_study symptomatic_chronic_advanced_heart_failure patients aldosterone_antagonist spironolactone mortality placebo
H-1735	-0.8087790012359619	▁Rand om ized _ al da cto ne _ ▁Evalua tion _ ▁Study ▁symptom a tic ▁chronic _ ▁advanced _ heart _ ▁failure _ ▁patients ▁al do ster one _ ▁anta gon ist ▁spi rono lac tone
D-1735	-0.8087790012359619	Randomized_aldactone_ Evaluation_ Study symptomatic chronic_ advanced_heart_ failure_ patients aldosterone_ antagonist spironolactone
P-1735	-4.5888 -1.8345 -0.1382 -1.8205 -0.5198 -0.6172 -0.3439 -0.6119 -0.8653 -1.2121 -0.0176 -1.5198 -0.7375 -0.9725 -0.0445 -0.0037 -0.7670 -0.7126 -1.0295 -0.1637 -1.2466 -0.4121 -1.6728 -3.9723 -0.9075 -0.1357 -0.2006 -0.6233 -0.0925 -0.5468 -0.0432 -0.0181 -0.3763 -0.0016 -0.0037 -0.0639 -0.0639 -2.4623 -0.1784
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.5227512121200562	▁medication
D-559	-1.5227512121200562	medication
P-559	-1.4674 -2.8199 -0.2810
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological diagnostic prognostic
H-1278	-1.0016779899597168	▁pat ho phy si ological _ ▁origin
D-1278	-1.0016779899597168	pathophysiological_ origin
P-1278	-0.2362 -0.4491 -0.4170 -1.4706 -0.2148 -1.1731 -2.3896 -2.6168 -0.0479
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad surgery patients albumin hypoalbuminemia surgery
H-534	-1.3665424585342407	▁l VAD _ ▁surgery ▁hypo album in emia
D-534	-1.3665424585342407	lVAD_ surgery hypoalbuminemia
P-534	-2.2878 -0.0962 -2.3053 -3.1150 -3.4583 -0.8893 -0.0787 -0.1419 -1.0620 -0.2308
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical hm_ii heartware patients economic hm_ii
H-310	-0.8503128290176392	▁scientific _ ▁literature ▁ HM ▁II ▁economic _ evalua tions
D-310	-0.8503128290176392	scientific_ literature HM II economic_evaluations
P-310	-0.4920 -0.9807 -1.3931 -0.8776 -0.0481 -1.6871 -0.5041 -1.1252 -0.1547 -1.3451 -1.5166 -0.0794
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate_model creatinine hazard_ratio confidence_interval mortality
H-717	-0.8117175698280334	▁creati nine haz ard _ ▁ratio ▁post - trans plant _ ▁mortal ity
D-717	-0.8117175698280334	creatininehazard_ ratio post-transplant_ mortality
P-717	-2.0983 -0.3214 -1.2702 -0.0306 -0.6384 -3.1594 -3.5858 -0.0224 -0.0048 -0.0061 -0.4549 -0.3800 -0.0091 -0.0864 -0.1079
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications implantation lvad_therapy transplantation btt dt medical_therapy
H-313	-0.5616170167922974	▁complica tions ▁l VAD _ therapy ▁transplant ation ▁e ligi bility _ status ▁device ▁b TT ▁medical ▁ therapy
D-313	-0.5616170167922974	complications lVAD_therapy transplantation eligibility_status device bTT medical therapy
P-313	-0.8642 -0.0725 -3.0294 -0.0197 -1.1252 -0.0418 -0.5636 -0.0178 -0.5439 -0.0005 -0.0066 -0.6458 -0.0437 -1.5952 -1.5795 -0.1487 -0.3209 -1.0300 -0.0224 -0.0840 -0.0387
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical artery_tonometry prospectively admission patients icu clinical
H-580	-0.8408095240592957	▁radi al _ ▁arter y _ ▁ton ometr y _ ▁variable s ▁ad mission
D-580	-0.8408095240592957	radial_ artery_ tonometry_ variables admission
P-580	-0.9831 -0.0042 -0.4045 -2.9468 -0.0843 -0.0588 -2.0820 -0.0374 -0.0432 -1.9999 -0.2716 -0.0325 -1.4651 -0.0089 -2.9486 -0.0822
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized hr_variability hr_variability clinical risk_stratification cardiac patients
H-1591	-0.6721392869949341	▁random ized _ ▁trial s ▁HR ▁variabil ity _ tur bul ence ▁risk _ ▁strat ification ▁cardiac
D-1591	-0.6721392869949341	randomized_ trials HR variability_turbulence risk_ stratification cardiac
P-1591	-1.3729 -0.1205 -1.1833 -0.3182 -0.0863 -0.0490 -0.5804 -0.0737 -0.8624 -0.3388 -0.0142 -0.0306 -1.8220 -0.4609 -2.2031 -0.7422 -0.4042 -1.7456 -0.3625
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine nesiritide renal_function patients acute_heart_failure renal_dysfunction
H-72	-0.7311275601387024	▁low - dos e ▁dop amine ▁low - dos e ▁nesi riti de ▁renal _ function
D-72	-0.7311275601387024	low-dose dopamine low-dose nesiritide renal_function
P-72	-0.2881 -0.0342 -1.3459 -0.2009 -3.5288 -0.2765 -0.4239 -0.0077 -0.2294 -0.0382 -1.1151 -0.0109 -0.8934 -0.4202 -1.2867 -2.0882 -0.9371 -0.0350
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death patients estimated_glomerular_filtration_rate odds_ratio confidence_interval
H-977	-0.7210448384284973	▁risk _ of _ ▁death ▁glo mer ular _ ▁filtr ation _ ▁rate
D-977	-0.7210448384284973	risk_of_ death glomerular_ filtration_ rate
P-977	-0.0665 -0.9974 -0.0527 -0.1264 -1.1380 -1.4800 -0.5231 -0.0152 -0.1416 -0.7644 -0.1984 -0.7583 -0.6986 -3.4463 -0.4087
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast_cancer patients medicare diagnosed breast_cancer chemotherapy seer-medicare texas medicare
H-672	-0.6667737364768982	▁Medica re _ ▁coverage ▁stage ▁I - III ▁breast _ cancer ▁che mo therapy ▁s EER - Medic are ▁Texas _ cancer _ ▁Registr y _ Medic are
D-672	-0.6667737364768982	Medicare_ coverage stage I-III breast_cancer chemotherapy sEER-Medicare Texas_cancer_ Registry_Medicare
P-672	-3.6668 -0.0047 -3.1235 -0.5025 -1.0772 -1.6519 -0.0233 -0.0261 -0.0532 -0.6898 -0.2269 -0.6724 -0.0047 -0.0711 -0.6289 -0.0041 -0.0289 -0.0037 -0.3080 -0.1503 -0.5293 -2.6575 -0.3785 -2.0784 -0.0081 -0.4899 -0.0492 -0.1807 -0.4609 -0.2525
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome_complex scaffold_protein drives kinases phosphorylation effector_molecules
H-995	-0.7713238596916199	▁signal o some ▁sc af fold _ ▁protein ▁kina ses ▁sequenti al ▁ phos phor y lation ▁effect or
D-995	-0.7713238596916199	signalosome scaffold_ protein kinases sequential phosphorylation effector
P-995	-0.2185 -1.8579 -2.1160 -0.1050 -0.0556 -0.0628 -0.5132 -0.3949 -1.3063 -0.0403 -0.0402 -0.0019 -1.5039 -0.0429 -0.5043 -3.3791 -0.0362 -1.6617 -0.3057 -1.9713 -0.0801
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully_magnetically_levitated_centrifugal-flow_chronic_lvas adverse_event quality_of_life functional_status
H-2006	-0.5818091034889221	▁fully ▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic _ L VAS
D-2006	-0.5818091034889221	fully magnetically levitated centrifugal-flow chronic_LVAS
P-2006	-2.6285 -0.2871 -0.0224 -0.1335 -0.0162 -0.0317 -0.0611 -0.0147 -0.0486 -0.1921 -0.0023 -3.2486 -0.1386 -1.3001 -0.0830 -1.6349 -0.0474
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased cardiomyocytes pde2 activity cgmp_synthesis nitric_oxide donors pde2_inhibition β-ar_responsiveness
H-1215	-0.7330434322357178	▁disease d _ ▁cardio my o cy tes ▁p de 2 ▁activity ▁c G MP ▁ni tric ▁oxid e _ ▁donor s ▁p de 2 ▁inhibi tion ▁β - AR
D-1215	-0.7330434322357178	diseased_ cardiomyocytes pde2 activity cGMP nitric oxide_ donors pde2 inhibition β-AR
P-1215	-1.0016 -0.2406 -1.0232 -0.9286 -1.1631 -2.9956 -0.4476 -0.1987 -1.2231 -1.7018 -0.0760 -1.0875 -0.0570 -0.9305 -2.0631 -0.2776 -0.0507 -0.6064 -0.1048 -1.0800 -0.4194 -0.3541 -1.7087 -1.3573 -0.1301 -1.3591 -0.0481 -0.0321 -0.0048 -0.1417 -0.5632 -0.0815
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection_fraction b-type_natriuretic_peptide patients hospitalized heart_failure inhospital outcomes get_with_the_guideline-heart_failure_registry
H-186	-0.5640267133712769	▁e je ction _ fraction ▁b - type ▁na tri ure tic _ pe pti de _ ▁levels ▁heart _ ▁failure ▁in hospital ▁outcome s ▁guide line - He art _ ▁Fail ure _ ▁Registr y
D-186	-0.5640267133712769	ejection_fraction b-type natriuretic_peptide_ levels heart_ failure inhospital outcomes guideline-Heart_ Failure_ Registry
P-186	-0.3147 -0.0685 -0.0125 -1.4298 -0.0041 -0.9094 -0.0505 -0.2512 -0.0273 -0.3284 -0.2783 -0.4755 -0.2709 -0.1649 -0.1861 -0.5765 -3.0128 -0.9356 -0.8598 -0.8012 -1.9949 -0.1733 -0.0200 -3.5688 -0.0082 -0.6904 -0.0033 -0.1702 -0.7176 -0.4547 -0.1233 -1.2308 -0.0354 -0.7903 -0.2666 -0.0278 -0.0346 -0.1647
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic_receptor sphingosine-1-phosphate_receptor_1 s1pr1 downregulation cardiac hypertrophic heart_failure s1pr1 cardiac gene therapy
H-1404	-0.5604520440101624	▁beta 1- ad r energi c ▁receptor ▁sp hing os ine -1 - phos pha te ▁receptor ▁s 1 PR _ ▁reciproc al _ ▁down regul ation ▁cardiac _ ▁hyper trop hic _ ▁response ▁heart _ ▁failure ▁s 1 PR 1 ▁cardiac _ ▁gene ▁ therapy
D-1404	-0.5604520440101624	beta1-adrenergic receptor sphingosine-1-phosphate receptor s1PR_ reciprocal_ downregulation cardiac_ hypertrophic_ response heart_ failure s1PR1 cardiac_ gene therapy
P-1404	-1.1237 -1.6618 -0.1601 -0.1450 -0.5502 -0.1688 -0.8957 -0.0216 -0.2833 -0.3090 -0.2023 -1.4405 -0.3190 -0.0044 -0.1085 -0.1723 -0.5752 -0.6798 -0.0376 -0.1249 -3.0665 -0.7473 -0.0010 -1.0826 -0.3802 -0.0151 -0.0307 -0.0126 -1.0575 -0.8874 -0.0020 -0.0079 -1.3348 -0.4589 -2.3425 -0.4172 -2.4798 -1.6873 -0.0191 -0.0141 -0.5772 -0.0412 -0.4245 -0.4718 -0.2009 -0.0174 -0.0832 -0.0573
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs hdl phosphorylation
H-251	-0.49611979722976685	▁EC s ▁HD L ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - Th r ▁PK c - β II - Ser ▁p 70 s 6 k - Ser
D-251	-0.49611979722976685	ECs HDL phosphorylation eNOS-Ser eNOS-Thr PKc-βII-Ser p70s6k-Ser
P-251	-0.7417 -1.5063 -1.6122 -1.0346 -0.0107 -0.0003 -0.0437 -0.5188 -0.0449 -0.0088 -0.0452 -0.0854 -0.8700 -0.0218 -0.0409 -0.0668 -0.2132 -0.0022 -0.0192 -2.2183 -0.2384 -2.3570 -0.3064 -0.0637 -0.0980 -0.0737 -0.1298 -1.1286 -0.0663 -1.9177 -0.0379 -0.5563 -0.5587 -0.2306
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts patients sts hh sts
H-155	-0.9139049649238586	▁s ts ▁ HM
D-155	-0.9139049649238586	sts HM
P-155	-2.6996 -0.2299 -0.4062 -1.1699 -0.9359 -0.0419
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular_myocytes sarcomere shortening
H-417	-0.5398877263069153	▁mouse ▁vent ri cular _ my o cy tes ▁sar com ere ▁pe ak _ ca (2 +) ▁trans ient
D-417	-0.5398877263069153	mouse ventricular_myocytes sarcomere peak_ca(2+) transient
P-417	-0.2715 -0.3869 -0.0894 -0.0682 -0.2436 -2.2773 -0.0603 -0.3492 -0.1247 -0.1802 -0.0427 -0.5544 -2.5099 -0.0871 -0.1373 -0.0719 -3.1118 -0.0858 -0.7586 -0.0025 -0.3798 -0.0845
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative alberta discharged hospital diagnosis heart_failure
H-1415	-0.6334335207939148	▁administrative _ ▁database s ▁province _ of _ ▁Albert a ▁dis charge d ▁ali ve ▁hospital ▁first - time ▁ diagnos is
D-1415	-0.6334335207939148	administrative_ databases province_of_ Alberta discharged alive hospital first-time diagnosis
P-1415	-0.5846 -0.7501 -1.8762 -0.0278 -2.0698 -1.4827 -0.0992 -0.7907 -0.0571 -0.0139 -1.0297 -0.0021 -0.0717 -0.1774 -0.0274 -0.2097 -1.2559 -0.0120 -0.2778 -1.2423 -0.1910 -0.1179 -2.7383 -0.0972
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp 6-minute_walking_distance peak_o2
H-829	-1.0247224569320679	▁low ▁pas p ▁pe ak ▁o 2 ▁per ▁kilogram
D-829	-1.0247224569320679	low pasp peak o2 per kilogram
P-829	-1.3094 -3.7468 -0.2291 -0.7551 -0.0751 -0.0549 -0.0315 -1.8405 -0.9699 -2.0865 -0.1732
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates crt death hf hospitalization hazard_ratio lvef
H-757	-0.6201069355010986	▁c RT _ on _ ▁assign ment ▁time ▁to ▁death ▁ HF _ hospital ization haz ard _ rati o ▁LV EF
D-757	-0.6201069355010986	cRT_on_ assignment time to death HF_hospitalizationhazard_ratio LVEF
P-757	-0.8930 -0.4199 -1.0856 -0.1601 -1.1394 -0.2914 -0.0070 -2.1490 -2.5370 -0.6519 -0.6976 -0.0158 -1.5490 -0.0588 -1.0172 -1.4725 -0.0572 -0.1768 -0.3476 -0.0363 -0.0294 -0.0311 -0.0121 -0.0470
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart_failure histologically myocardial_collagen healthy heart_failure
H-1062	-0.9745151996612549	▁heart _ ▁failure ▁my o card ial _ ▁collage n ▁tissu e
D-1062	-0.9745151996612549	heart_ failure myocardial_ collagen tissue
P-1062	-3.3819 -1.2431 -1.4646 -1.3792 -0.1549 -0.3483 -0.0168 -0.5125 -0.0223 -0.1142 -0.4688 -0.0655 -4.2037 -0.2674
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko cardiac irs1 irs2 proteins heart_failure cardiac_energy_metabolism_gene_expression p38α mitogen-activated_protein_kinase p38
H-656	-0.5925467014312744	▁L - D KO _ mi ce ▁cardiac ▁I RS 1 ▁I RS 2 _ ▁protein s ▁heart _ ▁failure ▁im pair ed ▁cardiac _ ener gy _ ▁metabolism ▁p 38 α ▁mit ogen - activa ted _ ▁protein ▁kina se
D-656	-0.5925467014312744	L-DKO_mice cardiac IRS1 IRS2_ proteins heart_ failure impaired cardiac_energy_ metabolism p38α mitogen-activated_ protein kinase
P-656	-3.1086 -0.1121 -1.1630 -0.2233 -1.9719 -0.6273 -0.0119 -0.1439 -1.0000 -0.0066 -1.6392 -1.4983 -0.0271 -0.0457 -2.4012 -0.7367 -0.0602 -0.2251 -0.4983 -1.7857 -1.1278 -0.0007 -0.0084 -0.0803 -0.3321 -0.4353 -0.3637 -1.7287 -0.7186 -0.1537 -0.0897 -0.3271 -0.8680 -0.2436 -0.1074 -0.0209 -0.0610 -0.4495 -0.4976 -0.2515 -0.0160 -0.2146 -0.0971
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil heart_failure hemodynamic mitochondrial_dysfunction antitumor activity
H-967	-0.31946274638175964	▁nic oran dil ▁do xor ubi cin - indu ced _ heart _ ▁failure ▁hem o dynamic _ ▁perturba tions ▁mito cho ndri al _ ▁dys function ▁ultra struct ural ▁anti tum or _ activ ity
D-967	-0.31946274638175964	nicorandil doxorubicin-induced_heart_ failure hemodynamic_ perturbations mitochondrial_ dysfunction ultrastructural antitumor_activity
P-967	-0.6207 -0.0140 -0.1716 -0.0079 -0.0096 -0.0284 -0.6750 -0.1594 -0.0036 -0.0515 -0.2722 -0.4904 -0.3160 -1.1384 -2.7222 -0.0102 -0.0027 -1.0747 -0.4951 -0.0051 -0.0013 -0.4362 -0.0442 -0.0040 -0.4959 -0.6255 -0.0074 -0.0081 -0.0050 -0.0018 -0.0176 -0.0180 -0.0907 -1.8300 -0.0858 -0.0721 -0.0816 -0.0459
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm_control_therapy diagnosis atrial sinus_rhythm rhythm_control symptoms rate_control
H-1646	-1.000740647315979	▁ Rhythm _ control _ therapy ▁ diagnos is ▁AF ▁at rial _ ▁structure ▁sinus ▁ rhythm ▁de lay ed ▁ rhythm _ control
D-1646	-1.000740647315979	Rhythm_control_therapy diagnosis AF atrial_ structure sinus rhythm delayed rhythm_control
P-1646	-1.2520 -0.7121 -0.6131 -0.0419 -1.3459 -0.1689 -3.9498 -5.7020 -0.0334 -2.9928 -2.3695 -0.0094 -0.7872 -0.3954 -0.2547 -0.6237 -0.0486 -0.8371 -0.0003 -0.0033 -0.9868 -0.2757 -1.1720 -0.0142 -1.2896 -0.1399
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative_risk rr heart_failure bisphophonates rr confidence_interval hazard_ratio
H-1540	-1.182813286781311	▁relative _ risk _ RR _ of _ heart _ ▁failure ▁bis pho phon ates ▁cru de _ RR
D-1540	-1.182813286781311	relative_risk_RR_of_heart_ failure bisphophonates crude_RR
P-1540	-0.7481 -0.8232 -1.0407 -1.9054 -1.7212 -3.4731 -0.0965 -0.3906 -0.6902 -0.2764 -0.6940 -4.3007 -0.1926 -1.7561 -1.7735 -0.0264 -0.0126 -0.6760 -0.1963 -3.8011 -0.2443
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician heart_failure clinical_practice_guideline cpg outcomes heart_failure hf
H-1841	-0.7241077423095703	▁physician ▁ad her ence ▁guide line _ ▁recommendations ▁heart _ ▁failure
D-1841	-0.7241077423095703	physician adherence guideline_ recommendations heart_ failure
P-1841	-1.8232 -0.0448 -0.0206 -0.0025 -0.0654 -0.0041 -1.0949 -1.3533 -0.5327 -0.3201 -0.9008 -3.1063 -0.1445
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute_heart_failure renal_dysfunction dopamine nesiritide renal_function diuretic therapy
H-83	-0.4955883026123047	▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁low - dos e _ ▁dop amine ▁low - dos e ▁nesi riti de ▁de con gestion ▁renal _ function ▁di ure tic ▁ therapy
D-83	-0.4955883026123047	acute_heart_ failure renal_ dysfunction low-dose_ dopamine low-dose nesiritide decongestion renal_function diuretic therapy
P-83	-0.1866 -0.0024 -1.1452 -1.3775 -0.4945 -0.4308 -0.0128 -0.6308 -0.3895 -0.0124 -0.0045 -0.0211 -0.2026 -0.0353 -2.2867 -0.7060 -0.1678 -1.1875 -0.0088 -0.0818 -0.0164 -1.2095 -0.0074 -0.7910 -1.7946 -0.0003 -0.0032 -0.0610 -1.1216 -1.2021 -0.0471 -0.0375 -0.8508 -1.6428 -0.0558 -0.0551 -0.0558
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf prospective dual-energy_x-ray_absorptiometry echocardiography blood
H-1161	-0.4440975487232208	▁ HF ▁s kin fold _ ▁thi ck ness ▁dual - ener gy _ ▁X - ray _ ab sor pti ometr y ▁e cho card i ography ▁blood
D-1161	-0.4440975487232208	HF skinfold_ thickness dual-energy_ X-ray_absorptiometry echocardiography blood
P-1161	-0.7522 -0.1083 -6.1884 -0.2046 -0.3687 -0.6075 -0.0995 -0.0081 -0.0618 -0.0104 -0.0062 -0.0010 -0.0001 -0.6839 -1.4985 -0.0101 -0.0147 -0.2592 -0.7330 -0.3653 -0.0219 -0.1874 -0.0415 -0.1055 -0.0234 -0.5391 -0.1084 -0.1684 -0.0422 -0.4747 -0.0729
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare centers_for_medicare_and_medicaid_services clinics propensity-score
H-1621	-0.5070695281028748	▁high - co st ▁Medica re ▁fee - for - service _ ▁beneficiar ies ▁Center s ▁Medica re ▁Medica id _ service s ▁pro pens ity - s core
D-1621	-0.5070695281028748	high-cost Medicare fee-for-service_ beneficiaries Centers Medicare Medicaid_services propensity-score
P-1621	-2.5026 -0.0422 -0.0107 -0.1228 -0.0263 -0.0078 -0.1194 -0.0132 -0.0014 -0.0068 -0.0007 -1.1496 -0.2177 -0.1105 -2.4175 -0.2678 -0.0919 -0.0018 -0.3533 -2.2217 -1.1858 -0.6869 -1.6993 -0.0917 -0.0048 -0.0047 -0.1620 -0.0276 -0.0299 -2.0126 -0.1282
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals patients hospitalized heart_failure hf conditions acute_myocardial_infarction pneumonia conditions
H-1032	-0.860591471195221	▁hospital s ▁heart _ ▁failure _ HF ▁a cute ▁my o card ial _ in far ction ▁pneu monia
D-1032	-0.860591471195221	hospitals heart_ failure_HF acute myocardial_infarction pneumonia
P-1032	-3.2468 -0.9558 -3.4485 -0.6677 -1.1184 -2.5097 -0.1694 -0.2141 -0.0008 -2.9258 -0.2989 -0.8882 -0.0343 -0.1694 -0.6446 -0.0013 -0.0949 -0.0002 -0.1561 -0.3421 -0.1854
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients heart_failure
H-1744	-1.1018460988998413	▁Patient s ▁en roll ment _ ▁period s ▁heart _ ▁failure _ ▁treatment
D-1744	-1.1018460988998413	Patients enrollment_ periods heart_ failure_ treatment
P-1744	-3.5701 -0.3055 -0.5372 -0.0037 -0.0111 -2.0335 -0.9058 -0.2117 -0.1621 -0.6867 -2.8546 -1.8825 -1.8297 -1.3730 -0.1604
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq new_york_heart_association_class patients hfpef hf_with_reduced_ef
H-788	-0.7694672346115112	▁k cc q _ ▁summary _ ▁score s ▁New ▁York _ heart _ association ▁ HF p EF ▁ HF
D-788	-0.7694672346115112	kccq_ summary_ scores New York_heart_association HFpEF HF
P-788	-0.9010 -0.1526 -1.0078 -2.2102 -2.1813 -0.8136 -0.7792 -0.0152 -0.4123 -0.2209 -0.1493 -1.5216 -0.2197 -1.0643 -0.4791 -0.0121 -0.0572 -0.0592 -0.1135 -0.0224 -4.3480 -0.1877
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp red_blood_cell_transfusion hemoglobin hemoglobin hospitalized patients coronary_heart_disease
H-36	-1.1700836420059204	▁a CP ▁restrict ive ▁red _ cell _ trans fusion _ strate s tri gger _ ▁hem o glob in _ ▁thre s hold ▁higher _ ▁hem o glob in _ ▁levels ▁corona ry _ مرض
D-36	-1.1700836420059204	aCP restrictive red_cell_transfusion_stratestrigger_ hemoglobin_ threshold higher_ hemoglobin_ levels coronary_مرض
P-36	-1.9541 -0.2595 -0.0322 -0.0007 -0.3082 -1.2630 -3.8100 -0.3535 -0.4045 -0.0684 -2.2593 -1.0943 -2.0547 -4.1988 -0.0003 -0.3264 -2.4469 -0.2276 -1.8270 -0.8075 -2.6042 -0.4088 -0.2402 -0.2450 -1.7574 -0.6292 -3.8090 -0.0541 -2.0160 -0.2723 -2.0963 -0.9601 -0.1727 -0.1498 -0.4270 -3.9729 -0.8236 -0.1276
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted interatrial_shunt clinical haemodynamic outcomes patients heart_failure_with_reduced_ejection_fraction
H-1962	-0.7807350158691406	▁implant ed ▁left - to - right ▁inter at rial _ ▁shu nt ▁ha emo dynamic ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction
D-1962	-0.7807350158691406	implanted left-to-right interatrial_ shunt haemodynamic heart_ failure reduced ejection_fraction
P-1962	-5.4281 -0.0300 -0.5402 -0.0149 -0.1110 -0.0499 -0.0050 -0.1905 -0.0831 -0.1043 -0.4631 -0.1779 -0.2745 -0.2090 -1.6903 -0.0331 -3.3606 -1.6188 -2.7435 -2.6262 -0.0421 -0.6864 -0.1526 -0.2043 -0.8437 -0.0062 -0.0833 -0.0879
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise training peak_oxygen_consumption quality_of_life obese patients heart_failure_with_preserved_ejection_fraction randomized clinical
H-1973	-0.5486591458320618	▁Cal o ric _ re stri ction ▁aero bic _ training ▁Peak ▁o xy gen _ ▁Consum p tion ▁Quality _ of _ life ▁Ob ese ▁Old er ▁Patient s ▁Heart _ ▁Fail ure ▁Pres er ved _ e je ction _ Fra ction
D-1973	-0.5486591458320618	Caloric_restriction aerobic_training Peak oxygen_ Consumption Quality_of_life Obese Older Patients Heart_ Failure Preserved_ejection_Fraction
P-1973	-0.5634 -0.2039 -3.4425 -0.4986 -0.0330 -0.0048 -0.0036 -0.0922 -0.0431 -0.1810 -2.1427 -0.0035 -1.6366 -0.0254 -0.0745 -0.6063 -0.0767 -0.0086 -0.0224 -2.3570 -1.5961 -0.0471 -0.3146 -0.6518 -3.1779 -0.0557 -0.4096 -0.0532 -0.7759 -1.0578 -0.2505 -0.2371 -1.0353 -0.0304 -0.0162 -0.0486 -0.0168 -0.2606 -1.0767 -0.6428 -0.0115 -0.2295 -0.6005 -0.0091 -0.5545 -0.0589
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left_ventricular_assist_devices lvads chronic_end-stage_heart_failure bridge_to_transplantation btt patients destination_therapy dt
H-308	-0.745368480682373	▁le ft _ ▁vent ri cular _ assist ▁devices ▁l VAD s ▁chronic ▁end - s tage _ heart _ ▁failure bridge ▁to ▁transplant ation ▁b TT ▁transplant - ine ligi ble ▁patients
D-308	-0.745368480682373	left_ ventricular_assist devices lVADs chronic end-stage_heart_ failurebridge to transplantation bTT transplant-ineligible patients
P-308	-0.8833 -0.0005 -0.2721 -4.6726 -0.2569 -0.1459 -0.0845 -0.0233 -2.1740 -1.4765 -0.0117 -0.0372 -0.3643 -0.4728 -0.0264 -0.0877 -0.0007 -0.1459 -1.3360 -0.3471 -2.6089 -1.7538 -0.4140 -0.4677 -0.0296 -2.6820 -0.1745 -0.3272 -0.2266 -0.0178 -0.0078 -0.0272 -2.3901 -2.0866 -0.0546
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1_time correlated right_ventricular-pulmonary_arterial_coupling pulmonary_vascular_resistance right_ventricular_ejection_fraction
H-742	-0.6266267895698547	▁right ▁vent ri cular - pul mon ary _ ▁arterial _ ▁coup ling pul mon ary _ vas cular _ ▁resist ance ▁right _ ▁vent ri cular _ e je ction _ fraction
D-742	-0.6266267895698547	right ventricular-pulmonary_ arterial_ couplingpulmonary_vascular_ resistance right_ ventricular_ejection_fraction
P-742	-1.0460 -0.8753 -0.2122 -0.0594 -1.1939 -0.9196 -1.0299 -0.0452 -0.5762 -5.8429 -0.2968 -0.2940 -0.7067 -0.4186 -0.0289 -0.0057 -0.2132 -0.6047 -0.0283 -0.9449 -0.5862 -0.0028 -0.1892 -0.5292 -1.3036 -0.0518 -0.1384 -0.2518 -1.6312 -0.0724 -0.0860 -1.0147 -0.0506 -0.5756 -0.1060
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol metoprolol implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-855	-0.4684760868549347	▁car vedi lol ▁met o pro lol ▁implant able ▁cardio ver ter - de fi br illa tor _ therapy ▁MAD IT - C RT _ ▁trial
D-855	-0.4684760868549347	carvedilol metoprolol implantable cardioverter-defibrillator_therapy MADIT-CRT_ trial
P-855	-0.0195 -0.0046 -0.0209 -0.3802 -0.0126 -0.0054 -0.0415 -0.0938 -0.0029 -0.3826 -0.0857 -0.4670 -0.2070 -0.0122 -0.2550 -1.9619 -0.2411 -0.1012 -0.5158 -0.5634 -0.0429 -0.4401 -0.0301 -0.2953 -0.1231 -2.4605 -0.2965 -4.4588 -0.0641
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral glucocorticoids hf
H-610	-1.1143630743026733	▁oral _ ▁gluco cor tico ids ▁dose - related ▁gradi ent ▁ HF _ risk
D-610	-1.1143630743026733	oral_ glucocorticoids dose-related gradient HF_risk
P-610	-1.5816 -1.8695 -2.8956 -1.3325 -1.0277 -0.5633 -2.4065 -0.0320 -0.2767 -2.6960 -0.0261 -0.3687 -0.0038 -1.3950 -0.3140 -2.0030 -0.1521
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ea tac placebo
H-523	-0.7071033120155334	▁HR ▁i va bra dine _ ▁group ▁ea ▁ TAC
D-523	-0.7071033120155334	HR ivabradine_ group ea TAC
P-523	-2.0919 -0.0951 -0.0906 -0.0409 -0.0015 -1.3770 -1.3139 -2.3782 -0.6677 -0.0049 -0.2957 -0.1278
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi death medical hospitalization hf clinic outpatients hf health
H-385	-0.6638428568840027	▁ HF PSI ▁risk _ of _ ▁death ▁medical _ hospital ization ▁ HF ▁clinic ▁out patient s ▁ HF ▁resources
D-385	-0.6638428568840027	HFPSI risk_of_ death medical_hospitalization HF clinic outpatients HF resources
P-385	-0.1387 -0.1104 -0.3947 -2.3726 -2.2201 -0.0508 -0.1037 -1.4225 -0.8501 -0.5367 -0.0169 -0.0822 -0.0515 -0.0026 -1.8692 -0.9529 -0.0017 -0.0237 -1.2136 -0.1134 -1.3107 -1.3027 -0.1270
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up systemic adverse_events patients dcm heart_failure
H-1265	-1.2255905866622925	▁system ic _ ▁advers e _ ▁events ▁et h nic _ group
D-1265	-1.2255905866622925	systemic_ adverse_ events ethnic_group
P-1265	-3.2028 -0.1261 -0.7100 -2.9911 -0.0972 -1.6404 -0.5630 -1.4059 -0.0086 -0.0306 -0.5996 -1.2417 -4.4683 -0.0731
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol therapy metoprolol hazard_ratio confidence_interval
H-862	-0.6151596307754517	▁car vedi lol ▁in appropria te _ therapy ▁met o pro lol haz ard _ rati o
D-862	-0.6151596307754517	carvedilol inappropriate_therapy metoprololhazard_ratio
P-862	-0.5220 -0.0334 -0.0609 -3.1533 -0.0019 -0.1483 -1.6558 -0.2928 -0.1671 -0.1380 -0.0518 -0.0746 -1.0117 -0.0281 -0.7344 -0.4229 -0.0219 -2.7935 -0.3755
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone_supplementation exercise_rehabilitation health outcomes patients chf testosterone
H-1325	-0.8398579955101013	▁testosteron e _ ▁supplement ation ▁exercise _ ▁rehabilita tion ▁CHF ▁low ▁testosteron e _ status
D-1325	-0.8398579955101013	testosterone_ supplementation exercise_ rehabilitation CHF low testosterone_status
P-1325	-1.1566 -0.0467 -1.6707 -1.0226 -0.0269 -1.0420 -0.3464 -1.0396 -0.0129 -3.1848 -1.5101 -1.4342 -0.0276 -1.5508 -0.0476 -0.0952 -0.0630
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change peak_vo2 correlated change lean_body_mass change thigh muscle
H-1987	-0.7477114796638489	▁pe ak _ vo 2 ▁percent ▁lean _ ▁body _ ▁mass ▁th igh _ ▁мышц _ inter mus cular _ rati o
D-1987	-0.7477114796638489	peak_vo2 percent lean_ body_ mass thigh_ мышц_intermuscular_ratio
P-1987	-0.0550 -0.0200 -0.2497 -0.4381 -0.0393 -2.7163 -0.5773 -0.1216 -0.1527 -0.7298 -0.7940 -0.4252 -0.0535 -1.9386 -4.0430 -3.3526 -0.1768 -0.2738 -0.0756 -0.1287 -0.8879 -0.0163 -0.4396 -0.2395
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals get_with_the_guidelines-heart_failure hf patients ef ef ef ef
H-189	-0.6306402683258057	▁guide lines - he art _ fail ure ▁ HF ▁border line ▁EF
D-189	-0.6306402683258057	guidelines-heart_failure HF borderline EF
P-189	-1.0823 -0.0157 -0.1986 -1.7711 -0.2451 -0.1427 -0.0860 -0.0496 -0.3681 -0.0576 -3.9635 -0.0033 -1.2776 -0.1053 -0.0932
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate_cox_model pasp exercise peak_o2 prognostic hazard_ratio peak_o2 pasp
H-830	-1.4984440803527832	▁co x _ model s ▁PAS P ▁exercise ▁pe ak ▁o 2 ▁per ▁kilogram
D-830	-1.4984440803527832	cox_models PASP exercise peak o2 per kilogram
P-830	-0.1439 -0.0144 -2.2386 -0.4474 -4.1767 -5.3656 -1.0381 -3.2238 -0.9585 -0.0637 -0.0519 -0.0969 -2.1641 -0.4641 -3.1304 -0.3971
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac insulin-resistance mitochondrial_oxidative_metabolism metabolic cardiac_hypertrophy hypertrophy heart_failure
H-1787	-0.624153733253479	▁cardiac ▁insulin - re stance ▁decrease d ▁mito cho ndri al ▁oxid ative ▁metabolism ▁metabol ic ▁cardiac ▁hyper trop hy ▁energy
D-1787	-0.624153733253479	cardiac insulin-restance decreased mitochondrial oxidative metabolism metabolic cardiac hypertrophy energy
P-1787	-0.0246 -0.3975 -0.0741 -0.0124 -0.7166 -1.1958 -0.0363 -0.0366 -1.3207 -0.2672 -0.0139 -0.7961 -0.0302 -0.7327 -1.7117 -0.0070 -1.5866 -1.5535 -0.0044 -0.3581 -0.0466 -3.2722 -0.1608
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad rgk rem rem2 rad monomeric_g_proteins ventricular_action_potential gain cardiac l-type_channel activity
H-1672	-0.648223340511322	▁r GK ▁re m ▁Rem 2 ▁Rad ▁Gem / Kir ▁mono me ric _ G _ ▁protein s ▁vent ri cular _ action ▁potential _ ▁du ration ▁EC _ ▁coup ling ▁cardiac _ type _ activ ity
D-1672	-0.648223340511322	rGK rem Rem2 Rad Gem/Kir monomeric_G_ proteins ventricular_action potential_ duration EC_ coupling cardiac_type_activity
P-1672	-1.8298 -0.5214 -0.3277 -0.0048 -0.2494 -0.0012 -0.2568 -0.3768 -1.0748 -0.0029 -1.2115 -0.0100 -0.0721 -0.5340 -1.9348 -0.8003 -1.0799 -0.0365 -0.2266 -0.1441 -0.0983 -1.6100 -0.0367 -2.1590 -0.8166 -0.4436 -0.0187 -0.0346 -0.8856 -1.5055 -0.0085 -1.4266 -0.3543 -1.6509 -0.7697 -2.1683 -0.0460 -0.3170 -0.2353
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular dilatation
H-338	-0.6440374255180359	▁ann ular _ ▁size ▁re duction ▁surgery ▁dia sto lic _ ▁mit ral _ ▁val ve ▁te ther ing ▁anterior ▁le a flet ▁opening ▁posterior ly ▁dis place d _ ▁papil lar y _ ▁muscle ▁left _ vent ri cular _ LV ▁di la tation
D-338	-0.6440374255180359	annular_ size reduction surgery diastolic_ mitral_ valve tethering anterior leaflet opening posteriorly displaced_ papillary_ muscle left_ventricular_LV dilatation
P-338	-0.0044 -0.0001 -1.4377 -1.3448 -0.3460 -0.0000 -0.5014 -0.0044 -0.0077 -0.2340 -0.2267 -1.5878 -0.0062 -0.1441 -4.8590 -0.0474 -0.3900 -0.0043 -0.0052 -0.0287 -0.9207 -0.0274 -0.0004 -0.1524 -0.3740 -0.7057 -0.1232 -0.0011 -0.0458 -0.6676 -1.0961 -0.4200 -0.2874 -0.6017 -0.6817 -0.4118 -0.2283 -5.3768 -0.7707 -0.0121 -0.6726 -2.5642 -2.6385 -0.0454 -0.0010 -0.0869 -0.1766
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology heart_failure_with_preserved_ejection_fraction hfpef myocardial_extracellular_matrix
H-734	-0.43508729338645935	▁pat ho phy si ology ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁H FP EF ▁my o card ial _ extra cel lular _ ▁matri x
D-734	-0.43508729338645935	pathophysiology heart_ failure preserved_ejection_fraction HFPEF myocardial_extracellular_ matrix
P-734	-2.1689 -0.1876 -0.0560 -0.9791 -0.0027 -0.8335 -0.2973 -0.6550 -0.0037 -0.0420 -0.0454 -0.2936 -0.6633 -0.6828 -0.1060 -0.2080 -0.0428 -2.3838 -0.0398 -0.0643 -0.1622 -0.0144 -0.7867 -0.0371 -0.3410 -0.5357 -0.1174 -0.0979 -0.3675 -0.4536 -0.4503 -1.1717 -0.0665
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing cardiac_arrest advantage pulseless_ventricular_fibrillation pvf implanted cardioverter-defibrillator_device
H-1346	-0.3818379044532776	▁breath ing _ control ▁cardiac ▁arrest ▁puls e less _ ▁vent ri cular _ fi bril lation PV F ▁cardio ver ter - de fi br illa tor _ ▁device
D-1346	-0.3818379044532776	breathing_control cardiac arrest pulseless_ ventricular_fibrillationPVF cardioverter-defibrillator_ device
P-1346	-1.3451 -0.0303 -0.5720 -0.0066 -0.2420 -0.5551 -0.2183 -0.0377 -0.0725 -0.1825 -2.4691 -0.3101 -0.1505 -0.0886 -1.5557 -0.1495 -0.0062 -0.2662 -0.1831 -1.0381 -0.0363 -0.2656 -0.2049 -0.0063 -0.0675 -0.5299 -0.1364 -0.0281 -0.5323 -0.8092 -0.0678 -0.0553
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal_probnp nt-probnp midregional_proanp mr-proanp adiponectin elevated chf correlated bmi
H-14	-0.5141561031341553	▁N - termin al ▁pro B NP NT - pro B NP ▁mid region al ▁pro AN P MR - pro AN P ▁adi pon ect in ▁b MI ▁FM
D-14	-0.5141561031341553	N-terminal proBNPNT-proBNP midregional proANPMR-proANP adiponectin bMI FM
P-14	-1.1047 -0.0326 -0.0424 -0.0008 -0.3534 -0.7299 -0.0383 -2.8263 -0.0034 -0.0290 -0.7093 -0.0157 -0.0326 -0.0015 -0.0103 -0.1671 -0.9133 -0.9135 -0.0763 -0.0106 -0.0007 -0.9692 -0.2669 -2.2156 -0.0028 -0.0611 -0.3642 -2.7253 -0.9553 -0.7645 -0.0714 -0.0450
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase_inhibitor pyridostigmine sympathovagal_balance cardiac_remodeling cardiac_function hf myocardial_infarction
H-1136	-0.8702789545059204	▁a ce tyl cho line _ ▁inhibi tor _ ▁py rido stig mine ▁sympa t hova gal _ ▁balance ▁cardiac _ function ▁ HF ▁my o card ial _ in far ction
D-1136	-0.8702789545059204	acetylcholine_ inhibitor_ pyridostigmine sympathovagal_ balance cardiac_function HF myocardial_infarction
P-1136	-0.1574 -1.2205 -0.3082 -3.6129 -0.7935 -4.0978 -0.6763 -0.0089 -0.2951 -2.2628 -0.0141 -0.0028 -0.0335 -0.0189 -0.1016 -0.2409 -0.0566 -0.7977 -0.0325 -0.0003 -1.4270 -3.6059 -1.1821 -0.0114 -3.0945 -0.9832 -3.0515 -0.3883 -0.3346 -0.3902 -0.0045 -0.2403 -0.0469 -0.0968
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac_sympathetic_activity β-blocker
H-1112	-0.620336651802063	▁cardiac _ ▁sympa the tic ▁activity ▁i - meta - i odob enz yl guan i dine ▁i - MI BG ▁β - block er
D-1112	-0.620336651802063	cardiac_ sympathetic activity i-meta-iodobenzylguanidine i-MIBG β-blocker
P-1112	-1.0690 -0.9067 -2.9042 -0.0950 -0.1484 -1.6178 -2.0284 -0.5603 -0.0799 -0.0321 -0.4170 -0.0985 -0.4424 -4.2850 -0.8867 -0.1968 -0.0056 -0.4437 -0.0075 -0.0960 -0.0148 -0.0308 -0.0036 -0.0532 -0.2008 -0.0280 -0.0970
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based heart_disease therapies patients cabg sweden
H-971	-0.7009738683700562	▁Swedish _ web - system ▁en han ce ment ▁e viden ce - based _ care ▁Heart _ مرض ▁Reco mmende d _ therapie s _ ▁registr y
D-971	-0.7009738683700562	Swedish_web-system enhancement evidence-based_care Heart_مرض Recommended_therapies_ registry
P-971	-0.4089 -1.1715 -1.9542 -0.0639 -0.0018 -3.6512 -0.0117 -0.1896 -0.0116 -1.1214 -0.0059 -0.0061 -0.0217 -0.0049 -0.1680 -0.2914 -0.8376 -0.6736 -2.8906 -0.3948 -0.0003 -0.0051 -0.2335 -0.5744 -0.0092 -2.7816 -1.7391 -0.0038 -1.6170 -0.1848
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef clinical reverse_remodeling death hf hospitalization hazard_ratio
H-756	-0.44170328974723816	▁LV EF ▁clinic al ▁com posit e _ ▁response ▁rever se ▁remodel ing _ ▁parameter s ▁ HF _ hospital ization haz ard _ rati o
D-756	-0.44170328974723816	LVEF clinical composite_ response reverse remodeling_ parameters HF_hospitalizationhazard_ratio
P-756	-0.1431 -0.0391 -0.3840 -0.0042 -0.5714 -0.0003 -0.0102 -0.7930 -0.4922 -0.0012 -0.0011 -0.8854 -0.0160 -1.3394 -0.2169 -0.0131 -2.2057 -0.2222 -2.0364 -0.0461 -0.7444 -1.2345 -0.0922 -0.3834 -0.2425 -0.0510 -0.1360 -0.0629
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients brain_natriuretic_peptide bnp bnp patients bnp bnp
H-1569	-0.6400038599967957	▁brain ▁na tri ure tic _ pe pti de ▁b NP
D-1569	-0.6400038599967957	brain natriuretic_peptide bNP
P-1569	-0.3568 -0.0843 -0.0268 -0.0895 -1.1788 -0.3226 -0.1253 -0.2736 -1.3908 -1.0334 -0.1378 -3.1932 -0.1071
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde pde2 cgmp leading camp_hydrolysis cross_talk cgmp camp_signaling
H-1210	-0.740715503692627	▁p de 2 ▁c g mp ▁c AMP _ hydro lys is ▁negative ▁cross _ talk ▁c G MP ▁c AMP _ signal ing
D-1210	-0.740715503692627	pde2 cgmp cAMP_hydrolysis negative cross_talk cGMP cAMP_signaling
P-1210	-0.5781 -0.2012 -0.7833 -0.0408 -3.5364 -1.3689 -0.2044 -1.6543 -0.9625 -0.9224 -0.1253 -0.4844 -0.5156 -0.8677 -0.1506 -0.6060 -0.0093 -4.2503 -0.3448 -0.0269 -0.1024 -0.7680 -0.5385 -0.1256 -0.0329 -0.0581
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse longitudinal_rv_fiber_shortening pasp rv in_vivo rv prognosis
H-493	-1.0363667011260986	▁t AP se long itud in al ▁ RV _ ▁fiber _ short en ing ▁PAS P force _ genera tion ▁in ▁vivo ▁ RV ▁length - force ▁disc los ing
D-493	-1.0363667011260986	tAPselongitudinal RV_ fiber_shortening PASPforce_generation in vivo RV length-force disclosing
P-493	-2.1199 -2.8100 -2.5350 -2.2553 -0.5158 -0.3155 -0.0887 -1.0997 -0.5115 -1.4402 -1.7645 -0.8871 -0.7482 -0.5351 -0.1303 -0.6302 -0.5250 -0.3779 -2.7212 -1.3077 -1.3822 -0.6554 -0.0011 -0.3923 -0.0601 -3.3024 -0.0953 -0.0013 -2.0795 -0.0029 -0.0085 -2.6467 -0.2537
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides szeto-schiller ss ss20 cardiac_function proteomic_remodeling signaling_pathways
H-870	-0.4211316406726837	▁mito cho ndri al - tar get ed ▁antioxidant ▁protect ive _ pe pti des ▁Sze to - Sch iller ▁SS 20 ▁prote om ic _ ▁remodel ing ▁signal ing _ path ways
D-870	-0.4211316406726837	mitochondrial-targeted antioxidant protective_peptides Szeto-Schiller SS20 proteomic_ remodeling signaling_pathways
P-870	-0.4405 -0.7910 -0.4025 -0.0058 -0.0737 -0.0023 -0.0092 -0.0011 -0.5855 -3.1868 -0.0026 -0.5649 -0.1637 -0.0458 -0.2457 -0.0093 -0.0013 -0.0086 -0.0155 -0.0044 -0.3036 -0.4043 -3.7945 -0.0761 -0.6729 -0.7242 -0.3304 -0.0254 -0.2902 -0.3043 -1.0893 -0.0681 -0.0404 -0.0308 -0.0249
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2017	-0.7961102724075317	▁economic _ analys is ▁Patient _ management _ ▁Interven tions ▁Heart _ fail ure ▁cost - E ff ective ness _ model
D-2017	-0.7961102724075317	economic_analysis Patient_management_ Interventions Heart_failure cost-Effectiveness_model
P-2017	-0.5229 -0.7345 -0.4268 -0.1247 -4.4121 -0.4112 -0.3754 -0.2289 -1.2449 -0.0037 -0.0521 -0.0739 -0.9833 -0.0342 -0.5154 -0.0888 -1.2086 -0.8156 -0.0987 -0.5715 -2.1876 -0.2501 -3.4778 -0.2640
2021-01-17 13:35:22 | INFO | fairseq.logging.progress_bar | :    101 / 145 wps=165
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization admissions patient
H-900	-0.5241174697875977	▁re - hospital ization ▁ad missions
D-900	-0.5241174697875977	re-hospitalization admissions
P-900	-0.0134 -0.1038 -0.0056 -0.1879 -0.0135 -0.0121 -3.6392 -0.2174
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes coprimary_end_points end_point change serum_cystatin_c renal_function end_point
H-79	-0.6594147086143494	▁co prima ry _ ▁end ▁points ▁cum ul ative _ ▁urin e _ ▁volume ▁de con gestion _ ▁end ▁point ▁se rum ▁cyst atin _ C
D-79	-0.6594147086143494	coprimary_ end points cumulative_ urine_ volume decongestion_ end point serum cystatin_C
P-79	-0.2270 -0.0407 -0.0885 -1.8116 -1.3227 -0.9243 -0.3233 -0.0384 -0.0107 -0.2302 -1.3114 -0.1057 -1.3762 -0.1089 -0.8865 -0.0001 -0.0041 -1.0573 -0.3062 -0.3219 -0.0237 -0.0011 -0.0357 -1.1596 -1.1091 -1.3320 -4.2005 -0.1061
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical cardiac_arrest cardiopulmonary_resuscitation cpr diagnosis posterior_wall_infarction hospitalized cardiac
H-1291	-0.29282549023628235	▁cardiac _ ▁arrest ▁cardio pul mon ary _ ▁res uscita tion ▁c PR ▁posterior _ wall _ in far ction ▁cardiac _ centre
D-1291	-0.29282549023628235	cardiac_ arrest cardiopulmonary_ resuscitation cPR posterior_wall_infarction cardiac_centre
P-1291	-0.8755 -0.4388 -0.0708 -0.1596 -0.0337 -0.5612 -0.0250 -0.2401 -0.1472 -0.0003 -0.0450 -1.7236 -0.0290 -0.0581 -0.2471 -0.3922 -0.8093 -0.5311 -0.0032 -0.0713 -0.0300 -0.2914 -0.4583 -0.0324 -0.0465
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients patients type_2_diabetes therapy saxagliptin sitagliptin pioglitazone second-generation_sulfonylureas insulin
H-1831	-0.6531786918640137	▁diabetes ▁sax ag lip tin ▁pi og lita zone ▁sul fon yl ure as ▁long - ac ting ▁insulin
D-1831	-0.6531786918640137	diabetes saxagliptin pioglitazone sulfonylureas long-acting insulin
P-1831	-5.3031 -1.1997 -0.0181 -0.7439 -1.5658 -0.4827 -0.0994 -0.0380 -0.1658 -0.9765 -0.0667 -0.1730 -0.0367 -0.0968 -1.5620 -0.0035 -0.0026 -0.0052 -0.3248 -0.8091 -0.0434
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence hyperkalemia mineralocorticoid_receptor_antagonists mineralocorticoid_receptor_antagonists heart_failure hf
H-1702	-0.6054086089134216	▁hyper kal emia ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁heart _ fail
D-1702	-0.6054086089134216	hyperkalemia mineralocorticoid_ receptor_ antagonists heart_fail
P-1702	-0.7024 -0.1410 -0.0260 -0.1495 -0.0935 -0.5219 -1.6161 -2.4782 -0.3185 -0.0655 -0.4575 -0.1795 -0.0528 -0.5812 -0.9208 -0.2108 -2.3813 -0.5448 -0.0616
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade evidence acp erythropoiesis-stimulating_agents patients anemia congestive_heart_failure coronary_heart_disease
H-37	-1.0615880489349365	▁er y thro po ies is - stimul ating _ agent s ▁con ges tive _ heart _ مرض
D-37	-1.0615880489349365	erythropoiesis-stimulating_agents congestive_heart_مرض
P-37	-2.3359 -0.1981 -2.0973 -0.4016 -3.4149 -0.7895 -0.4463 -0.0680 -0.0454 -0.3696 -0.3687 -1.1482 -1.8860 -0.1232 -0.1474 -0.4088 -0.6380 -0.9397 -4.0777 -2.3165 -0.0725
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory patients heart_failure hf reduced_ejection_fraction renin-angiotensin_system ras β-blockers all-cause_mortality readmissions
H-175	-0.6396402716636658	▁ambula tory ▁patients ▁heart _ ▁failure _ HF ▁reduce d ▁e je ction _ fraction r EF ▁re nin - angi oten sin _ system ▁ RAS ▁β - block ers
D-175	-0.6396402716636658	ambulatory patients heart_ failure_HF reduced ejection_fractionrEF renin-angiotensin_system RAS β-blockers
P-175	-0.6937 -0.0016 -2.0243 -0.5962 -0.8110 -0.6941 -4.6276 -0.1572 -0.5370 -0.0081 -0.0187 -0.0465 -0.0333 -0.6515 -0.0719 -0.5133 -0.0068 -0.0004 -0.3322 -0.0606 -0.0991 -0.5782 -1.4314 -1.3657 -0.0972 -2.1086 -0.0017 -0.1436 -0.0021 -0.0230 -0.0188 -3.0657 -0.2868
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr scn5a ventricular_systolic_hf human_induced_pluripotent_stem_cell-derived_cardiomyocytes hipsc-cms
H-1082	-0.723622739315033	▁u PR ▁s cn 5 a ▁human ▁vent ri cular _ ▁sy sto lic ▁ HF _ ▁tissu e ▁human ▁induc ed ▁pluri potent _ ▁stem _ cell - der i ved _ ▁cardio my o cy tes hi PS c - CM s
D-1082	-0.723622739315033	uPR scn5a human ventricular_ systolic HF_ tissue human induced pluripotent_ stem_cell-derived_ cardiomyocyteshiPSc-CMs
P-1082	-0.3095 -0.0541 -2.6133 -1.4689 -0.2565 -0.1330 -0.6699 -0.0487 -0.4768 -0.1232 -0.9545 -2.7590 -0.0404 -0.1926 -0.2927 -0.0033 -1.2532 -3.0340 -0.1625 -4.5540 -0.0182 -0.0023 -0.2110 -0.0051 -0.7733 -0.5089 -0.6743 -0.3077 -0.7123 -0.0125 -0.0475 -0.0121 -0.5983 -0.7247 -2.3884 -1.9553 -0.6152 -0.5931 -2.2757 -0.1911 -1.1162 -0.0300 -0.0046 -0.0053 -0.0485 -0.0549
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd chf crf icc kappa_coefficients
H-802	-0.8084075450897217	▁co PD ▁CHF ▁c RF ▁ICC ▁ka ppa _ co ef fici ents
D-802	-0.8084075450897217	coPD CHF cRF ICC kappa_coefficients
P-802	-3.2417 -1.8845 -0.3458 -2.5789 -0.0501 -1.2235 -0.3363 -0.0110 -1.8201 -0.0385 -0.0090 -0.0056 -0.0215 -0.4896 -0.0700
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient implantable_cardioverter-defibrillator implant change clinical
H-1865	-0.5457774996757507	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion ▁implant ▁clinic al _ status ▁end - of - life
D-1865	-0.5457774996757507	implantable cardioverter-defibrillator_deactivation implant clinical_status end-of-life
P-1865	-3.4445 -0.0110 -0.7268 -0.0355 -0.9113 -0.2974 -0.0124 -0.4538 -2.0500 -0.3176 -0.0353 -0.4149 -0.1160 -0.1482 -0.0269 -0.6527 -1.7439 -0.0662 -1.0262 -0.0810 -0.0820 -0.0280 -0.0052 -0.0159 -0.0032 -1.9599 -0.0703
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients stable_heart_failure left_ventricular_ejection_fraction training training
H-1913	-1.432297945022583	▁stable _ heart _ ▁failure ▁left ▁vent ri cular _ e je ction ▁ fraction ▁aero bic _ training ▁lower _ ▁lim bs
D-1913	-1.432297945022583	stable_heart_ failure left ventricular_ejection fraction aerobic_training lower_ limbs
P-1913	-3.7899 -1.8894 -0.8499 -0.8203 -0.7922 -0.0115 -3.5715 -1.0389 -0.9237 -0.4045 -1.0756 -0.1726 -0.0781 -5.0301 -0.0194 -3.6200 -0.2129 -2.4001 -0.2068 -6.1629 -0.5737 -1.7627 -0.1108 -0.1833 -0.1066
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients heart_failure myocardial_function dilated contracting ventricles aetiologies
H-987	-0.939527690410614	▁heart _ ▁failure ▁poor ▁my o card ial _ function ▁dil ated ▁contract ing _ ▁vent ric les ▁a eti ologie s
D-987	-0.939527690410614	heart_ failure poor myocardial_function dilated contracting_ ventricles aetiologies
P-987	-1.9531 -0.9641 -1.7873 -1.0307 -2.4588 -0.1276 -0.4656 -0.0996 -0.6258 -0.6327 -2.3074 -0.0438 -5.4761 -0.0395 -0.7965 -1.1039 -0.9288 -0.0137 -1.1101 -0.0008 -0.2144 -0.0589 -0.1754 -0.1340
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial cochrane_effective_practice_and_organisation_of_care_taxonomy
H-1847	-0.46401575207710266	▁co ch rane _ effect _ prac tice ▁organisation _ of _ care _ tax ono my
D-1847	-0.46401575207710266	cochrane_effect_practice organisation_of_care_taxonomy
P-1847	-1.1336 -0.0239 -0.0047 -1.8052 -1.7071 -0.7794 -0.7425 -0.1048 -0.6417 -0.4914 -0.0039 -0.0599 -0.1471 -0.5244 -0.2997 -0.0684 -0.0436 -0.1995 -0.0354
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad q65p murine rad q66p l-type_currents cav1.2 cav1.3 wild-type_rad
H-1675	-0.9057134389877319	▁mouse _ Rad _ Q 65 p ▁mur ine ▁human _ ▁Rad ▁Q 66 p ▁l - type _ ▁current s ▁ca V 1.3 _ chan s ▁wild - type _ Rad
D-1675	-0.9057134389877319	mouse_Rad_Q65p murine human_ Rad Q66p l-type_ currents caV1.3_chans wild-type_Rad
P-1675	-0.1473 -1.1357 -6.3451 -2.0336 -1.1856 -0.0856 -0.7249 -0.1426 -0.0021 -3.7719 -0.5395 -0.6922 -0.4544 -0.0458 -0.9143 -2.9326 -0.0750 -0.0058 -0.4617 -0.6484 -0.2078 -0.7404 -0.9019 -0.9471 -1.9577 -1.4630 -0.6871 -0.0611 -0.0179 -0.0075 -0.0665 -0.8688 -0.4355 -0.0878
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients implantable_cardioverter-defibrillator patients implantable_cardioverter-defibrillator
H-1866	-0.4606276750564575	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion _ ▁preference s ▁di stress ing ▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁shock s
D-1866	-0.4606276750564575	implantable cardioverter-defibrillator_deactivation_ preferences distressing implantable_ cardioverter-defibrillator_ shocks
P-1866	-1.0869 -0.0082 -1.3631 -0.0333 -0.7904 -0.3080 -0.0077 -0.8692 -2.3358 -0.5412 -0.1376 -0.2056 -0.3424 -0.3944 -0.1100 -0.6953 -1.4372 -0.0177 -0.2483 -0.0148 -0.1698 -0.1383 -0.0205 -0.2873 -2.1847 -0.0279 -0.4791 -0.1859 -0.0030 -0.3045 -0.8628 -0.2828 -0.0526 -0.1515 -0.8868 -0.0678 -0.3624 -0.0887
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart_failure hf hypertensive_heart_disease hhd pathophysiology therapeutic hhd stable phenotypes
H-274	-0.6422383785247803	▁mouse _ heart _ ▁failure _ HF ▁model ▁hyper tensi ve _ heart _ مرض h HD ▁pat ho phy si ology ▁ therapeut ic _ ▁target s ▁H HD
D-274	-0.6422383785247803	mouse_heart_ failure_HF model hypertensive_heart_مرضhHD pathophysiology therapeutic_ targets HHD
P-274	-0.0079 -0.6915 -1.1435 -0.3673 -0.5404 -1.6255 -0.1451 -2.1995 -0.1180 -0.2478 -0.0337 -0.0379 -0.7860 -0.0637 -3.2758 -1.5718 -0.5311 -0.5707 -0.0261 -0.0627 -1.7419 -0.0015 -2.4602 -0.0212 -0.0117 -0.3569 -0.1803 -0.0491 -1.2352 -0.0290 -0.3528 -0.0659
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient mi hazard_ratios hf
H-1108	-1.1958075761795044	▁MI _ ▁character istic s ▁yi eld ed _ ▁hazard _ ▁ratio s
D-1108	-1.1958075761795044	MI_ characteristics yielded_ hazard_ ratios
P-1108	-3.8247 -2.4577 -4.3987 -0.2764 -0.0791 -0.8824 -0.0003 -0.0488 -0.4558 -0.6529 -0.4267 -0.3414 -0.0362 -3.5950 -0.4611
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare patients acute hospital hf ami pna
H-1693	-0.7635520696640015	▁national ▁Medica re ▁patients ▁a cute _ hospital ▁ HF ▁ AMI ▁p NA
D-1693	-0.7635520696640015	national Medicare patients acute_hospital HF AMI pNA
P-1693	-3.0095 -0.3202 -0.0026 -4.2080 -0.3440 -0.0196 -0.2908 -1.2318 -0.2001 -0.3883 -0.1199 -0.0144 -0.8702 -1.0194 -0.1007 -0.0774
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt nt-probnp aric hf aucs nris
H-289	-0.6566178202629089	▁c t n t ▁NT - pro b NP ▁a RIC _ HF _ model
D-289	-0.6566178202629089	ctnt NT-probNP aRIC_HF_model
P-289	-0.0777 -0.9828 -0.1987 -0.7233 -0.0946 -0.0104 -0.0013 -1.0938 -0.0448 -0.2110 -0.0245 -0.9121 -0.2095 -1.5353 -0.7726 -4.1208 -0.1494
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular_events baseline sst2 metoprolol_succinate
H-404	-1.4033485651016235	▁base line ▁s ST 2 _ status ▁base line ▁s st 2 _ status ▁high ▁ng / m L
D-404	-1.4033485651016235	baseline sST2_status baseline sst2_status high ng/mL
P-404	-1.4326 -0.0115 -0.0204 -0.5699 -0.0489 -3.9506 -0.0105 -4.6781 -0.0168 -1.3231 -1.5993 -0.6086 -4.1827 -0.0788 -2.2315 -4.7523 -1.2453 -0.0208 -0.1513 -2.4870 -0.0501
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl nyha-iiib phosphorylation phosphorylation hdl healthy
H-255	-0.7553157806396484	▁in cuba tion ▁EC ▁HD L NY HA - III b ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - Th r ▁HD L
D-255	-0.7553157806396484	incubation EC HDLNYHA-IIIb phosphorylation eNOS-Ser eNOS-Thr HDL
P-255	-1.2006 -0.0002 -0.0039 -1.9022 -2.7899 -0.4404 -4.0157 -0.0732 -0.1322 -0.0113 -0.0067 -0.6909 -0.1065 -0.6771 -1.4493 -0.0396 -0.0129 -0.0072 -0.0736 -0.0136 -4.4331 -0.0424 -0.1891 -0.2952 -0.0036 -0.9371 -0.4905 -1.4257 -0.4405
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients hospitalized hf preserved_lvef mortality patients lvef lvef mortality
H-117	-0.8732629418373108	▁patients ▁hospital ized ▁ HF ▁LV EF ▁long - term _ ▁mortal ity
D-117	-0.8732629418373108	patients hospitalized HF LVEF long-term_ mortality
P-117	-2.4339 -2.8383 -0.1012 -0.5140 -0.0014 -3.1478 -0.0788 -1.4992 -0.0198 -0.0107 -0.1074 -0.2685 -0.0069 -1.9174 -0.1536
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic_reticular protein phospholamban infarcted hearts metoprolol
H-1551	-0.4464680850505829	▁sar co plas mic _ ▁reti cular SR _ ca (2 +) - up take ▁SR _ ca (2 +) - pump ▁ phos pho lam ban ▁in far cted _ heart s ▁met o pro lol
D-1551	-0.4464680850505829	sarcoplasmic_ reticularSR_ca(2+)-uptake SR_ca(2+)-pump phospholamban infarcted_hearts metoprolol
P-1551	-0.0028 -0.0084 -0.2534 -2.1735 -0.3270 -0.0241 -0.0168 -1.5635 -1.5998 -0.2412 -1.0530 -0.0065 -0.1149 -0.2465 -0.0425 -1.6709 -1.2829 -0.0735 -0.9693 -0.0030 -0.0215 -0.0018 -0.1421 -0.0035 -0.2232 -1.3531 -1.0576 -0.0250 -0.0007 -0.6881 -0.5268 -0.4597 -0.1186 -0.9762 -0.0177 -0.0139 -0.0192 -0.0310 -0.0589
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global_left_ventricular_longitudinal_systolic_strain gls left_ventricular cardiovascular atrial_fibrillation
H-809	-0.6732540130615234	▁global ▁left _ wind ri cular _ ▁longitud in al _ ▁sy sto lic _ ▁strain ▁g LS ▁left _ ▁vent ri cular _ ▁mechanic s ▁advers e _ ▁cardiovascular _ CV ▁at rial _ fi bril lation AF
D-809	-0.6732540130615234	global left_windricular_ longitudinal_ systolic_ strain gLS left_ ventricular_ mechanics adverse_ cardiovascular_CV atrial_fibrillationAF
P-809	-0.0258 -0.3899 -0.2708 -4.8733 -2.1215 -0.0774 -0.5721 -0.3118 -0.0141 -0.0169 -0.0868 -5.0352 -0.1760 -0.1076 -0.1423 -0.0692 -0.5469 -0.1253 -0.0761 -0.0980 -3.3565 -0.0515 -0.1015 -0.1786 -0.0129 -0.0096 -0.2165 -0.0088 -1.3171 -0.2949 -0.9913 -2.2625 -0.8116 -0.0034 -0.2635 -1.1609 -0.0048 -0.0010 -1.3247 -0.0497 -0.0450
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf hf_with_reduced_ef hf_with_preserved_ef change hf mi
H-1109	-1.0837427377700806	▁early - ons et ▁ HF ▁ HF ▁ HF ▁pres er ved _ ▁EF
D-1109	-1.0837427377700806	early-onset HF HF HF preserved_ EF
P-1109	-2.7144 -0.0379 -0.0628 -0.1417 -0.1773 -0.0287 -1.6136 -0.0244 -3.4861 -0.0682 -5.5165 -0.0706 -0.0428 -1.2776 -0.0501 -2.9581 -0.1529
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol von_willebrand_factor metoprolol β2-adrenergic_receptor_haplotype
H-1118	-0.5201398730278015	▁car vedi lol ▁von ▁Will e brand _ factor ▁met o pro lol ▁β 2- ad r energi c _ ▁receptor ▁ha plo type
D-1118	-0.5201398730278015	carvedilol von Willebrand_factor metoprolol β2-adrenergic_ receptor haplotype
P-1118	-2.6905 -0.1969 -0.3527 -0.4907 -1.7583 -0.1820 -0.1292 -1.0434 -0.0827 -0.0824 -0.0090 -0.0082 -0.0537 -1.0201 -0.8092 -0.0190 -0.2632 -1.6401 -0.3246 -0.5087 -0.2126 -0.4617 -0.0024 -1.0577 -0.0970 -0.0277
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise intramuscular_testosterone_supplementation patients chronic_heart_failure chf testosterone collected health outcomes
H-1317	-0.9329394698143005	▁exercise ▁intra mus cular _ ▁testosteron e _ ▁supplement ation ▁chronic _ heart _ ▁failure _ CH F ▁low _ ▁testosteron e
D-1317	-0.9329394698143005	exercise intramuscular_ testosterone_ supplementation chronic_heart_ failure_CHF low_ testosterone
P-1317	-4.5952 -2.4804 -0.0045 -0.0047 -0.4976 -0.5212 -0.0078 -1.5602 -0.1037 -0.0171 -2.1071 -0.2239 -1.6604 -0.5366 -1.2034 -2.3863 -0.6054 -0.2661 -0.0245 -0.3436 -1.4539 -0.0079 -1.7216 -0.0575
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart_failure hf plasma_b-type_natriuretic_peptide bnp preserved_ejection_fraction ef hf
H-187	-1.0043238401412964	▁heart _ ▁failure _ HF ▁plasma b - type ▁na tri ure tic _ pe pti de ▁b NP ▁e je ction _ fraction ▁sex
D-187	-1.0043238401412964	heart_ failure_HF plasmab-type natriuretic_peptide bNP ejection_fraction sex
P-187	-0.2148 -0.6960 -1.0084 -3.0316 -0.0443 -2.2264 -1.6970 -0.7328 -0.2569 -0.0213 -0.1415 -1.1835 -2.4012 -0.6245 -0.1022 -0.2883 -1.6779 -1.7401 -0.2193 -4.6251 -0.9573 -0.1101 -0.9438 -0.4079 -1.1624 -0.5077 -0.0947
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls left_ventricular_ejection_fraction lvef systolic_mitral_annulus_velocity multivariate_models
H-818	-0.7341193556785583	▁g LS ▁out per form ed ▁left _ wind ri cular _ e je ction _ fraction LV EF ▁sy sto lic _ ▁mit ral _ ▁ann ulus _ velo city ▁sa
D-818	-0.7341193556785583	gLS outperformed left_windricular_ejection_fractionLVEF systolic_ mitral_ annulus_velocity sa
P-818	-0.7120 -1.7476 -0.1746 -0.0069 -0.0006 -0.0170 -0.0212 -0.4267 -6.5388 -3.2982 -0.2862 -0.2684 -0.9109 -0.3315 -0.4138 -0.5236 -0.2646 -1.5379 -0.0072 -0.0047 -0.0379 -0.1530 -0.2668 -2.4924 -0.0248 -0.2451 -0.6876 -0.0764 -0.2005 -0.0311 -0.0191 -0.2329 -2.7608 -0.2395
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm telemonitoring implanted medical structured_telephone_support sts human-to-human_contact hh human-to-machine_interface
H-153	-0.8006688952445984	▁home ▁tele monitor ing ▁implant ed _ monitor ing _ ▁devices ▁medical _ support ▁office ▁hours ▁structure d ▁telephone _ support s ▁human - to - human ▁contact ▁human - to - machine ▁interface ▁ HM
D-153	-0.8006688952445984	home telemonitoring implanted_monitoring_ devices medical_support office hours structured telephone_supports human-to-human contact human-to-machine interface HM
P-153	-0.3737 -0.1705 -0.0003 -0.0078 -1.6366 -0.0150 -1.1568 -0.2213 -1.4116 -1.9597 -0.8238 -0.5324 -1.7224 -0.2226 -4.1633 -3.0324 -0.1146 -0.0042 -0.9989 -0.9693 -0.1965 -3.1113 -1.1705 -0.0122 -0.0033 -0.0289 -0.0382 -0.6789 -2.7793 -0.0080 -0.0022 -0.0043 -0.0003 -0.2909 -2.3557 -0.0013 -0.1696 -0.0367
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug patients chronic_obstructive_pulmonary_disease copd chronic_heart_failure chf chronic_renal_failure crf
H-794	-1.202923059463501	▁test - re test _ re test _ re test _ re test ▁Time d ▁up _ go ▁t g _ test ▁patients ▁advanced ▁chronic _ ▁ob struct ive _ ▁pulmonar y _ ရောဂါ _ co PD ▁chronic _ heart _ ▁failure _ CH F ▁chronic _ ▁renal _ ▁failure
D-794	-1.202923059463501	test-retest_retest_retest_retest Timed up_go tg_test patients advanced chronic_ obstructive_ pulmonary_ရောဂါ_coPD chronic_heart_ failure_CHF chronic_ renal_ failure
P-794	-3.3926 -0.2055 -0.0064 -0.0032 -2.2341 -1.3428 -0.0094 -2.0135 -1.7418 -0.0228 -2.5304 -2.0272 -0.0482 -1.8312 -0.0163 -0.6499 -1.5664 -2.6902 -1.7135 -1.5199 -2.4375 -1.0615 -3.6340 -1.4173 -0.2210 -0.2532 -1.0332 -0.0095 -0.1327 -0.1704 -1.2450 -0.0337 -0.5137 -3.7784 -3.3626 -0.9089 -0.1400 -0.1633 -0.0258 -4.3102 -0.2050 -1.3752 -2.0454 -1.0577 -0.4036 -0.9952 -0.3631 -1.4293 -0.3240 -2.6677 -1.1362 -0.1323
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox_regression_analysis patients beta-blockers beta-blockers primary_endpoint therapy antitachycardia_pacing atp shock_therapy
H-859	-0.6584028005599976	▁co x ▁re gression ▁beta - block ers ▁beta - block ers ▁in appropria te _ therapy ▁anti ta chy car dia _ pa cing ▁a TP ▁shock _ therapy
D-859	-0.6584028005599976	cox regression beta-blockers beta-blockers inappropriate_therapy antitachycardia_pacing aTP shock_therapy
P-859	-0.2377 -0.0102 -1.4287 -0.0048 -4.3467 -0.0580 -0.0954 -0.0122 -4.4333 -0.0526 -0.2579 -0.0307 -0.4801 -0.0004 -0.0971 -1.1374 -0.2297 -0.0043 -0.5398 -0.6983 -1.4219 -0.1156 -1.3330 -0.7832 -0.0192 -1.8938 -0.0152 -0.0612 -0.9782 -0.1719 -0.0318 -0.0885
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically legal decisions
H-1680	-0.5243793725967407	▁pediatr ics ▁religious _ ▁belief s ▁life - s usta ining _ ▁treatment
D-1680	-0.5243793725967407	pediatrics religious_ beliefs life-sustaining_ treatment
P-1680	-1.2825 -0.0146 -0.8179 -0.5749 -0.4515 -0.1240 -0.3846 -0.0256 -0.2019 -0.0527 -0.0187 -1.2148 -2.1189 -0.5041 -0.0790
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient prescribing medications medical
H-1122	-0.8245251178741455	▁patient _ ▁preference s ▁priorit ies ▁guide line - re com mend ed _ ▁medication s
D-1122	-0.8245251178741455	patient_ preferences priorities guideline-recommended_ medications
P-1122	-5.0267 -1.4014 -0.1735 -0.0270 -3.5613 -0.4305 -0.8022 -0.0038 -0.0732 -0.0007 -0.0031 -0.0012 -0.0055 -1.0682 -0.5794 -0.1145 -1.5102 -0.0591
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost patient rhythm-control rate-control
H-1241	-0.591770589351654	▁cost ▁ rhythm - control ▁rate - control
D-1241	-0.591770589351654	cost rhythm-control rate-control
P-1241	-0.2305 -0.6768 -0.8614 -0.1766 -0.0041 -1.1436 -0.3785 -0.0069 -1.8557 -0.5836
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left_ventricular_ejection_fraction egfr
H-393	-1.0373280048370361	▁media n _ âge ▁женщин ▁media n ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁media n ▁e G FR
D-393	-1.0373280048370361	median_âge женщин median left_ ventricular_ejection fraction median eGFR
P-393	-0.1800 -0.0180 -1.1279 -1.2365 -6.1554 -0.4856 -0.0158 -0.6284 -0.2291 -4.4945 -0.3946 -0.7617 -1.0177 -0.6291 -0.3067 -0.2435 -2.7748 -0.0047 -0.4763 -0.0130 -0.5203 -1.7427 -0.7292 -1.5335 -0.2145
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells functional_capacity cells peak_vo2
H-127	-1.2272611856460571	▁CD 34 _ ve g _ 2 _ cell s ▁functional _ capaci ty ▁CD 34 _ ve g _ 2 _ cell s ▁pe ak _ vo 2
D-127	-1.2272611856460571	CD34_veg_2_cells functional_capacity CD34_veg_2_cells peak_vo2
P-127	-0.6392 -0.5799 -3.1291 -0.5311 -1.9649 -3.0163 -1.0163 -2.5399 -0.6447 -0.0307 -2.2634 -1.2461 -0.5208 -1.1430 -1.3727 -0.2133 -2.0923 -2.8588 -1.5224 -2.1122 -1.2725 -1.9527 -3.9569 -0.0308 -0.0941 -0.1067 -0.0884 -0.4078 -0.5098 -0.0642 -0.1239
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf hazard_ratios body_mass_index obese
H-1773	-1.233059287071228	▁fit ▁un fit ▁c RF _ ▁distribution ▁hazard _ rati o ▁un fit _ men ▁over weight ▁obes e _ men
D-1773	-1.233059287071228	fit unfit cRF_ distribution hazard_ratio unfit_men overweight obese_men
P-1773	-0.8744 -1.0042 -0.0006 -6.4339 -0.1166 -3.2421 -0.9986 -1.6716 -1.2337 -0.4257 -0.3168 -0.3474 -0.0008 -2.4562 -1.7057 -0.3403 -0.0081 -4.2552 -0.0759 -0.9269 -1.7627 -0.0764 -0.0865
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare_patient_safety_monitoring_system mpsms adverse_event patients hospitalized acute_myocardial_infarction congestive_heart_failure pneumonia conditions surgery
H-2	-0.6670365333557129	▁Medica re _ ▁Patient _ ▁Safety _ monitor ing _ system _ MP SMS ▁advers e _ ▁event _ rate ▁patients ▁hospital ized ▁a cute ▁my o card ial _ in far ction ▁con ges tive _ heart _ ▁failure ▁pneu monia ▁surgery
D-2	-0.6670365333557129	Medicare_ Patient_ Safety_monitoring_system_MPSMS adverse_ event_rate patients hospitalized acute myocardial_infarction congestive_heart_ failure pneumonia surgery
P-2	-0.0625 -0.0007 -1.5527 -1.2762 -0.0840 -1.2344 -0.1509 -0.1686 -0.0303 -0.2751 -0.0765 -2.0754 -0.4325 -0.0240 -2.5273 -0.0211 -0.2307 -1.6073 -0.8059 -0.8247 -3.2231 -1.6533 -0.3913 -0.0967 -0.0007 -4.2060 -0.3285 -0.6958 -0.0320 -0.1267 -0.7861 -0.0058 -0.0356 -0.0065 -0.0102 -0.0137 -0.1459 -1.0104 -0.5966 -1.1811 -0.0071 -0.0892 -1.7750 -0.0392 -0.0990
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi blood_urea_nitrogen b-type_natriuretic_peptide new_york_heart_association_class diabetes atrial_fibrillation all-cause_hospitalization
H-382	-0.5117090344429016	▁ HF PSI ▁model ▁blood ▁u rea ▁nit rogen ▁b - type ▁na tri ure tic _ pe pti de ▁New ▁York _ ▁Heart _ association ▁diabetes _ status ▁at rial _ fi bril lation _ flu tter
D-382	-0.5117090344429016	HFPSI model blood urea nitrogen b-type natriuretic_peptide New York_ Heart_association diabetes_status atrial_fibrillation_flutter
P-382	-0.4889 -1.2831 -2.3607 -3.5769 -0.2052 -0.0312 -0.2191 -0.1262 -0.0156 -1.1269 -0.0234 -0.0365 -0.0129 -0.0331 -0.1203 -0.5698 -0.1055 -0.2062 -0.2355 -0.3820 -0.1267 -0.1578 -0.5214 -0.7772 -0.3927 -1.3024 -0.5208 -2.2476 -0.0225 -0.3383 -0.0027 -0.2890 -0.7813 -0.0203 -0.0076 -0.4370 -0.0025 -0.0070 -1.2799 -0.0747
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary_outcome patients crt hazard_ratio confidence_interval
H-852	-0.9364376068115234	▁c RT _ group ▁control _ group ▁hazard _ rati o
D-852	-0.9364376068115234	cRT_group control_group hazard_ratio
P-852	-2.0645 -0.6185 -1.5280 -1.2009 -0.6390 -1.4039 -1.0625 -0.0173 -0.4711 -1.2128 -0.0417 -1.8129 -0.1007
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality_rate patients hf hf case-fatality_rate
H-1311	-0.5595525503158569	▁cru de ▁28- day ▁case - fat ality _ ▁rate ▁concurrent ▁ HF ▁case - fat ality _ ▁rate
D-1311	-0.5595525503158569	crude 28-day case-fatality_ rate concurrent HF case-fatality_ rate
P-1311	-0.8366 -0.0263 -2.1675 -0.0852 -0.1621 -0.0276 -0.0171 -0.0108 -0.8302 -1.2024 -1.3487 -1.1529 -0.0011 -1.1940 -0.0230 -0.0155 -0.0095 -0.8000 -0.5840 -1.1504 -0.1057
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients heart_failure_and_reduced_ejection_fraction patient
H-659	-0.5177686214447021	▁practice - level ▁guide line - re com mend ed _ ▁treatment ▁out patient s ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction ▁practice
D-659	-0.5177686214447021	practice-level guideline-recommended_ treatment outpatients heart_ failure reduced ejection_fraction practice
P-659	-1.1693 -0.6038 -0.0372 -3.6011 -0.0037 -0.0787 -0.0009 -0.0075 -0.0036 -0.0164 -1.4371 -0.7845 -0.8780 -0.0007 -0.0125 -0.7051 -0.7435 -0.5286 -0.0288 -0.0014 -0.7833 -0.0497 -0.0536 -0.5414 -0.0233 -0.5772 -1.7223 -0.1043
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame chf anthracycline stem_cell allogeneic autologous follow-up
H-1453	-0.6644147634506226	▁sa mp ling _ frame s ▁CHF ▁race / eth nici ty ▁cum ul ative ▁an thra cycli ne _ ▁exposure ▁stem _ cell ▁auto logo us
D-1453	-0.6644147634506226	sampling_frames CHF race/ethnicity cumulative anthracycline_ exposure stem_cell autologous
P-1453	-2.6112 -0.0265 -0.0103 -0.4737 -0.3121 -1.9104 -1.8054 -0.3760 -1.2126 -0.0003 -0.0229 -0.0076 -0.0161 -0.0408 -0.0026 -0.0347 -0.0065 -0.6714 -1.3452 -3.1622 -0.1227 -0.0037 -1.4415 -2.5148 -0.9824 -0.0012 -0.0148 -0.0939 -0.0447
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting_tension fpassive muscle kcl-ki titin titin extracellular_matrix fpassive
H-765	-1.1012113094329834	▁rest ing _ ▁tension _ of _ sar com ere _ leng ▁relations ▁k c l - KI ▁treatment ▁titi n ▁extra cel lular _ ▁matri x ▁F pass ive
D-765	-1.1012113094329834	resting_ tension_of_sarcomere_leng relations kcl-KI treatment titin extracellular_ matrix Fpassive
P-765	-5.1980 -0.0433 -1.3195 -2.0780 -2.6438 -6.3595 -0.3833 -1.3468 -0.0370 -1.2626 -2.1668 -0.3699 -0.4568 -1.5742 -0.6091 -0.0102 -0.0312 -0.2194 -5.6162 -0.8730 -0.0366 -0.5075 -0.0427 -0.0180 -0.3167 -0.0527 -0.1048 -1.1827 -0.1136 -0.0026 -0.2239 -0.0387
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training exercise_capacity muscle quality_of_life cardiac nt-probnp inflammatory il6 hscrp biomarkers
H-1922	-1.273450493812561	▁aero bic ▁resist ance _ training ▁exercise _ capaci ty ▁muscle _ streng th ▁cardiac _ prot b NP ▁infla mma tory ▁h s CR P
D-1922	-1.273450493812561	aerobic resistance_training exercise_capacity muscle_strength cardiac_protbNP inflammatory hsCRP
P-1922	-0.0021 -0.0503 -0.9915 -0.0017 -1.9531 -0.9612 -4.3097 -1.0644 -0.9636 -0.7197 -4.1419 -1.3229 -1.4022 -0.6799 -4.7686 -3.5713 -2.9058 -1.2686 -0.1345 -0.9017 -0.8502 -0.0567 -0.8399 -0.0346 -0.1065 -1.0460 -0.4781 -0.1298
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital readmission all-cause_readmission acr potential_preventable_readmission ppr medicare medicaid readmission cms
H-135	-0.7021917700767517	▁differenti al _ impact ▁hospital _ ▁performance ▁read mission _ ▁metri cs ▁all - ca use _ ▁read mission ▁a CR ▁potential _ ▁Prev en table _ ▁Read mission ▁p PR ▁Center s ▁Medica re ▁Medica id ▁30- day _ ▁read mission ▁c MS
D-135	-0.7021917700767517	differential_impact hospital_ performance readmission_ metrics all-cause_ readmission aCR potential_ Preventable_ Readmission pPR Centers Medicare Medicaid 30-day_ readmission cMS
P-135	-5.2346 -0.0083 -0.6389 -0.2043 -3.8391 -0.6414 -1.4566 -0.5876 -0.0370 -0.8064 -0.7399 -0.0053 -1.5747 -0.0133 -0.0002 -0.0162 -0.1926 -1.4192 -0.0066 -1.4783 -0.0424 -2.5280 -0.3577 -0.7274 -0.0040 -0.0517 -0.0230 -1.2005 -0.0113 -1.0852 -0.0149 -1.4151 -0.0450 -0.1428 -0.0054 -0.4671 -0.0431 -2.6840 -0.0211 -0.1953 -1.0150 -0.0217 -0.6782 -0.4972 -0.0810 -0.0424
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart_failure myocardial_infarction mi β-adrenoceptor_blockade infarcted metoprolol
H-1547	-0.6862966418266296	▁rever si bility _ of _ heart _ ▁failure ▁my o card ial _ in far ction ▁β - ad re no cept or _ block ade ▁in far cted _ ▁rat s ▁met o pro lol
D-1547	-0.6862966418266296	reversibility_of_heart_ failure myocardial_infarction β-adrenoceptor_blockade infarcted_ rats metoprolol
P-1547	-0.4538 -0.1428 -0.0102 -3.9050 -0.5873 -0.7621 -0.7331 -0.8985 -1.0264 -0.2894 -0.0767 -1.1315 -0.0135 -0.1309 -0.6937 -0.0026 -0.0676 -3.7983 -0.0107 -0.0049 -0.5222 -0.7291 -5.2841 -1.2513 -0.2140 -1.2177 -0.0565 -0.5481 -0.0065 -0.3482 -0.8126 -0.3000 -0.0242 -0.3027 -0.0247 -0.0085 -0.0380 -0.2553 -0.0823
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise rehabilitation walking minnesota_quality_of_life exercise
H-1882	-1.070957899093628	▁exercise _ du ration
D-1882	-1.070957899093628	exercise_duration
P-1882	-0.2071 -1.1655 -0.5695 -0.0074 -4.3391 -0.1371
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive_heart_failure correlation_coefficient
H-218	-1.3164658546447754	▁con ges tive _ heart _ ▁failure _ ▁visit s
D-218	-1.3164658546447754	congestive_heart_ failure_ visits
P-218	-0.1764 -0.0065 -0.0273 -0.3233 -3.2807 -0.4735 -4.8550 -2.1835 -0.7257 -0.0128 -3.5983 -0.1347
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine_vasopressin avp physiologic chf avp vasopressin_receptor_antagonist therapy therapeutic chf
H-637	-0.49164852499961853	▁Exc es sive _ ▁secret ion ▁argi nine _ ▁vaso press in ▁a VP ▁physio logic _ process es ▁CHF ▁in hib i tion ▁a VP ▁vaso press in _ ▁receptor _ ▁anta gon ist _ therapy ▁CHF
D-637	-0.49164852499961853	Excessive_ secretion arginine_ vasopressin aVP physiologic_processes CHF inhibition aVP vasopressin_ receptor_ antagonist_therapy CHF
P-637	-3.6473 -0.0289 -0.0231 -1.0870 -1.5364 -0.0208 -0.2471 -0.0312 -1.2270 -0.0526 -0.0491 -0.2678 -0.7959 -0.0096 -1.8863 -0.6626 -0.5981 -0.5649 -0.2574 -0.0761 -1.1827 -0.0007 -0.0356 -0.0093 -1.3828 -0.0059 -0.0969 -0.0181 -0.1064 -0.8581 -0.0862 -0.5581 -0.8046 -0.0372 -0.1025 -0.3283 -0.3026 -0.3370 -0.2251 -0.1186
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies medication physical_therapy implantable_defibrillators circulatory_support transplantation risk_stratification patient heart_failure therapies disease
H-1205	-0.6853660941123962	▁physical _ therapy ▁implant able ▁de fi br illa tors ▁circula tory _ ▁support ▁transplant ation ▁risk _ ▁strat ification ▁heart _ ▁failure ▁ therapie s ▁disease
D-1205	-0.6853660941123962	physical_therapy implantable defibrillators circulatory_ support transplantation risk_ stratification heart_ failure therapies disease
P-1205	-1.1947 -1.5058 -0.0389 -0.0449 -0.0038 -0.5412 -0.0714 -1.3451 -0.2347 -0.0272 -0.0913 -0.0017 -0.8146 -1.1307 -0.4898 -0.0241 -1.2157 -1.5395 -1.0622 -0.1833 -2.4283 -0.7610 -1.3470 -1.5783 -0.0171 -0.0382 -1.1036 -0.8796 -0.1618
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts caspase-3 activity phosphocreatine adenine_nucleotides cytochrome_c bcl2 bax caspase_3 expression
H-961	-0.5800420045852661	▁rat s ▁heart s ▁cas pas e -3 ▁activity ▁ phos pho creati ne ▁a den ine _ ▁nucleo ti des ▁cy to ch rom e ▁b cl 2 ▁Bax ▁cas pas e ▁3 ▁expression
D-961	-0.5800420045852661	rats hearts caspase-3 activity phosphocreatine adenine_ nucleotides cytochrome bcl2 Bax caspase 3 expression
P-961	-0.2357 -0.1308 -5.3953 -0.0271 -1.1550 -0.9793 -0.2555 -1.3223 -0.6275 -0.1221 -0.0010 -1.0010 -3.0594 -0.6383 -0.0338 -0.0028 -0.0027 -1.1751 -0.0323 -0.0245 -0.2369 -0.0189 -0.0152 -0.0306 -0.0226 -0.0513 -1.0292 -0.0109 -0.0605 -0.0333 -0.1434 -0.2642 -0.0449 -2.0553 -0.9049 -0.1546 -0.1633
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right_ventricular_pacing gene_expressions bax bcl-2 caspase-3 rtq-pcr interventricular_septum biopsies heart_failure
H-166	-0.6280622482299805	▁rapid ▁right _ ▁vent ri cular _ pa cing ▁Bax ▁b cl -2 ▁Cas pas e -3 ▁RT q - PC r ▁interven tri cular _ ▁sept um _ ▁bio psi es ▁beag le _ dog s
D-166	-0.6280622482299805	rapid right_ ventricular_pacing Bax bcl-2 Caspase-3 RTq-PCr interventricular_ septum_ biopsies beagle_dogs
P-166	-0.2940 -0.6664 -0.1904 -5.4188 -0.0656 -0.0135 -0.1296 -0.2952 -0.0036 -1.0845 -0.8742 -0.0086 -1.1003 -0.0306 -0.1422 -0.0200 -0.8459 -1.9692 -1.2011 -0.1747 -0.0955 -1.4148 -0.0226 -0.0053 -0.0497 -0.3082 -0.5342 -0.0104 -2.1797 -0.6980 -0.0126 -0.0084 -0.0083 -0.0274 -1.2770 -0.4325 -0.0448 -2.7376 -0.0991
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers β-blockers patients heart_failure_and_reduced_ejection_fraction
H-661	-0.47810810804367065	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors _ angi oten sin _ ▁receptor _ block ers ▁β - block ers
D-661	-0.47810810804367065	angiotensin-converting_ enzyme inhibitors_angiotensin_ receptor_blockers β-blockers
P-661	-1.7654 -0.5335 -1.0258 -0.6306 -1.6690 -0.0021 -0.0770 -0.1304 -0.5644 -0.2664 -0.0448 -0.5917 -0.0837 -1.5017 -0.2203 -0.0538 -0.1756 -0.3071 -0.1673 -0.4931 -1.0653 -0.0439 -0.0259 -0.0064 -0.0582 -0.0152 -1.7680 -0.1005
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary_approaches_to_stop_hypertension dash left_ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling hypertensive_hfpef
H-918	-0.5852910876274109	▁so dium - re strict ed _ ▁dieta ry ▁stop ▁hyper tension _ Die t DAS H / S RD ▁left ▁vent ri cular _ dia sto lic ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve ▁H FP EF
D-918	-0.5852910876274109	sodium-restricted_ dietary stop hypertension_DietDASH/SRD left ventricular_diastolic arterial_ elastance ventricular-arterial_ coupling hypertensive HFPEF
P-918	-0.2976 -0.3151 -0.0517 -0.0023 -0.0014 -0.0105 -0.9819 -4.5449 -0.1688 -3.8920 -0.8051 -0.0054 -0.7911 -3.5074 -0.0524 -0.5050 -1.0560 -1.2165 -0.2403 -0.2227 -0.8399 -0.6865 -0.1738 -0.0840 -0.9729 -0.2580 -0.0583 -0.8496 -1.4532 -0.7693 -0.4911 -0.2012 -0.0288 -0.1497 -0.0243 -0.3860 -0.0458 -0.0413 -0.6345 -0.0520 -0.1631 -0.2088 -0.6188 -0.0339 -0.6372 -0.0005 -0.0242 -0.0318 -0.0928
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute_hf relax-ahf astronaut pronto patient patients end_points
H-1017	-0.36544618010520935	▁a cute _ HF _ ▁trial s ▁RELA X - a HF ▁ AST RON AUT ▁PR ONTO
D-1017	-0.36544618010520935	acute_HF_ trials RELAX-aHF ASTRONAUT PRONTO
P-1017	-0.1256 -0.0024 -0.5888 -0.2980 -2.0323 -0.0978 -0.0167 -0.5126 -0.0950 -0.0130 -0.7999 -0.0241 -0.1121 -0.0105 -0.1419 -0.0119 -0.1232 -0.0011 -2.1976 -0.1044
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol carvedilol sympathetic_activity von_willebrand_factor
H-1119	-0.5915484428405762	▁met o pro lol ▁car vedi lol ▁sympa the tic _ activ ity ▁von _ Will e brand _ factor ▁Ar g 16 / G l n 27 ▁g ly 16 / G lu 27
D-1119	-0.5915484428405762	metoprolol carvedilol sympathetic_activity von_Willebrand_factor Arg16/Gln27 gly16/Glu27
P-1119	-0.8523 -0.0920 -0.0819 -0.0236 -0.0328 -0.0189 -0.0492 -0.0774 -0.0521 -0.1086 -1.4494 -0.1333 -0.0711 -2.9310 -0.2360 -0.9131 -0.6222 -0.4111 -0.7750 -0.0186 -1.9458 -0.0039 -0.2110 -3.2385 -1.6811 -0.3213 -0.4518 -0.1210 -1.0501 -0.9669 -0.1362 -1.0111 -1.7032 -0.0042 -0.0137 -0.0485 -0.0294
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized hf international_classification_of_diseases clinical principal discharge diagnosis
H-1832	-0.4918414354324341	▁Hospital ized _ HF ▁International _ ▁Classifica tion _ of _ ▁Disease s ▁Nin th _ re vision ▁Clinic al _ ▁Modifica tion ▁code s
D-1832	-0.4918414354324341	Hospitalized_HF International_ Classification_of_ Diseases Ninth_revision Clinical_ Modification codes
P-1832	-1.5985 -0.0309 -0.9160 -0.0304 -4.1883 -0.1973 -0.7192 -0.0070 -0.3116 -0.0175 -0.1121 -0.2753 -0.0075 -0.0070 -0.0012 -0.2031 -0.5239 -0.0004 -0.2180 -0.0026 -0.1033 -1.2241 -0.0383 -0.7669 -0.0113 -1.6923 -0.0758
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad q65p movement wild-type_rad q65p l-type_channel rgk_proteins
H-1676	-1.0632575750350952	▁Rad ▁Q 65 p ▁ga ting _ ▁movement ▁wild - type _ ▁Rad ▁Q 65 p _ substitu ion ▁r GK _ ▁protein s
D-1676	-1.0632575750350952	Rad Q65p gating_ movement wild-type_ Rad Q65p_substituion rGK_ proteins
P-1676	-1.1434 -1.9853 -0.1603 -0.8955 -0.6458 -0.0072 -0.4641 -0.0671 -0.6115 -0.0087 -0.0043 -0.5904 -1.1345 -2.4843 -0.0455 -1.2062 -4.7271 -4.0234 -0.5471 -4.6901 -0.3446 -0.6531 -0.9401 -0.0914 -0.0837 -0.0901
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 heart_failure proteomics actin_cytoskeleton ss20 mitochondrial metabolic_pathways
H-876	-0.5678053498268127	▁heart _ ▁failure ▁global _ prote o mics ▁act in _ ▁cy tos kelet on _ path ways ▁mito cho ndri al ▁metabol ic _ path ways
D-876	-0.5678053498268127	heart_ failure global_proteomics actin_ cytoskeleton_pathways mitochondrial metabolic_pathways
P-876	-4.4845 -1.3781 -2.3543 -0.4950 -0.5141 -1.4023 -0.2691 -0.1122 -0.3177 -0.0183 -0.7689 -0.0717 -0.4021 -0.0147 -0.0823 -0.3739 -0.0452 -0.0174 -1.3546 -0.5702 -0.0860 -0.0024 -0.0453 -0.0224 -0.9550 -0.0801 -0.0104 -0.1280 -0.0904
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms left_ventricular_base midpapillary apex baseline ivc_occlusion bivp ste rs
H-324	-0.3061375916004181	▁e cho card i ogram s ▁left ▁vent ri cular ▁base ▁mid pap illa ry ▁ap ex ▁base line ▁IV C ▁oc clusi on ▁bi VP ▁twist ▁bas al ▁rota tions ▁RS
D-324	-0.3061375916004181	echocardiograms left ventricular base midpapillary apex baseline IVC occlusion biVP twist basal rotations RS
P-324	-0.8204 -0.0088 -0.1578 -0.3742 -0.0269 -0.3754 -0.0515 -1.0047 -0.2001 -0.0086 -0.5718 -0.2419 -0.0285 -0.1573 -0.0747 -0.4776 -0.0076 -0.2046 -0.0117 -0.0128 -0.4583 -0.1137 -0.0013 -0.0180 -1.0948 -0.0191 -0.6896 -0.3122 -0.0004 -1.4196 -0.0039 -0.8196 -0.4896 -0.1517
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration pyridostigmine coronary_artery_ligation cardiac sympathetic_tone cardiac_remodeling left_ventricular_dysfunction hf
H-1145	-0.6866532564163208	▁py rido stig mine ▁corona ry _ ▁arter y _ ▁liga tion ▁cardiac ▁va gal ▁sympa the tic _ ▁tone ▁cardiac _ ▁remodel ing ▁ HF
D-1145	-0.6866532564163208	pyridostigmine coronary_ artery_ ligation cardiac vagal sympathetic_ tone cardiac_ remodeling HF
P-1145	-3.8269 -0.0562 -0.0020 -0.0279 -0.0851 -0.0541 -1.7500 -0.8710 -0.0621 -1.7213 -0.0691 -0.6142 -0.4735 -0.3795 -0.0008 -0.2434 -0.0227 -0.0890 -0.5151 -0.3593 -0.2225 -1.1801 -3.0939 -0.0604 -2.5855 -0.3276 -0.4814 -0.0515
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes patients new_york_heart_association nyha heart_failure eplerenone placebo heart_failure medicines emphasis-hf
H-1229	-1.162248969078064	▁joint _ of _ out com es ▁New ▁York _ heart _ association ▁class ▁II _ of _ heart _ fail ure ▁e pler en one ▁place bo ▁standard _ heart _ fail ure _ ▁Medicine s
D-1229	-1.162248969078064	joint_of_outcomes New York_heart_association class II_of_heart_failure eplerenone placebo standard_heart_failure_ Medicines
P-1229	-4.8709 -0.6308 -5.3917 -0.2227 -1.4009 -0.0591 -0.3015 -3.0369 -1.4347 -0.1871 -3.3538 -0.3440 -0.6384 -2.9851 -0.5820 -0.9201 -1.7536 -0.0247 -2.4202 -0.1491 -0.3535 -0.0316 -1.4181 -0.0105 -0.4311 -0.0821 -1.2331 -0.0028 -0.2355 -0.3421 -3.1852 -0.3756 -0.5637 -0.4188 -1.2310 -2.3468 -0.1087 -1.9980 -0.2522
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge patients follow-up physician physician
H-1418	-0.8202374577522278	▁dis charge
D-1418	-0.8202374577522278	discharge
P-1418	-0.7532 -0.0315 -2.4523 -0.0439
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life_expectancy heart_failure patients disease terminal_heart_failure
H-1665	-1.3927339315414429	▁life _ ▁expect an cy ▁treatment _ of _ heart _ ▁failure
D-1665	-1.3927339315414429	life_ expectancy treatment_of_heart_ failure
P-1665	-3.1339 -1.8222 -0.2829 -0.0257 -0.0242 -4.5698 -3.1449 -0.2103 -0.6848 -0.7034 -0.4136 -1.7819 -2.5378 -0.1631
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart_failure discharges university_of_connecticut_health_center patients follow-up
H-723	-0.9835932850837708	▁heart _ dis charge s ▁university _ of _ connect i cut _ health _ center
D-723	-0.9835932850837708	heart_discharges university_of_connecticut_health_center
P-723	-6.2213 -0.5276 -2.9010 -0.0149 -0.0265 -1.9763 -1.1222 -0.0614 -0.1411 -0.8960 -0.0575 -0.0348 -0.2775 -0.8295 -1.0541 -0.4738 -1.0399 -0.0491
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary_capillary_wedge_pressure baseline right_atrial_pressure pulmonary_arterial_pressure pulmonary_resistance
H-1959	-1.1205424070358276	▁Pul mon ary _ ▁cap illa ry _ we dge _ ▁pressure ▁right _ at rial _ ▁pressure ▁pulmonar y _ ▁resist ance
D-1959	-1.1205424070358276	Pulmonary_ capillary_wedge_ pressure right_atrial_ pressure pulmonary_ resistance
P-1959	-0.2462 -0.9479 -0.0733 -0.4318 -6.2650 -1.0726 -0.0161 -0.4919 -2.0425 -0.0016 -0.4963 -0.2621 -7.0540 -0.3380 -0.2414 -0.0144 -0.1474 -1.4406 -0.0006 -0.0058 -0.0946 -6.1340 -0.0007 -0.1211 -0.0734
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute_heart_failure hf pharmacologic therapeutics calcium-sensitizing_agents antagonists endothelin vasopressin adenosine
H-1015	-0.8411697745323181	▁a cute _ heart _ ▁failure _ HF ▁ pharma c ologic _ studie s ▁calci um - sensi t izing ▁agents ▁en do the lin ▁vaso press in ▁ad enos ine
D-1015	-0.8411697745323181	acute_heart_ failure_HF pharmacologic_studies calcium-sensitizing agents endothelin vasopressin adenosine
P-1015	-0.1436 -0.0098 -0.2648 -2.3910 -0.3465 -4.6783 -2.6831 -0.7326 -3.1175 -0.2840 -0.1569 -0.2416 -3.3351 -1.5109 -0.2982 -0.1354 -0.0078 -0.1648 -0.0067 -1.8258 -0.0584 -0.8548 -0.3116 -0.0982 -0.4629 -3.6230 -0.0345 -0.0062 -0.4364 -0.0019 -0.0009 -0.0033 -0.1719 -0.2019
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic_insufficiency mechanical_circulatory_support continuous_flow left_ventricular_assist_devices lvads pulsatile_devices
H-542	-0.6086421012878418	▁a or tic _ insu ffi cie ncy ▁mechanic al _ ▁circula tory _ ▁support ▁continuo us ▁flow ▁left _ vent ri cular _ assist ▁devices ▁pulsa tile _ ▁devices
D-542	-0.6086421012878418	aortic_insufficiency mechanical_ circulatory_ support continuous flow left_ventricular_assist devices pulsatile_ devices
P-542	-0.5369 -0.4122 -0.5967 -0.1155 -0.5144 -0.5678 -1.6798 -0.0208 -0.0530 -0.0035 -0.1027 -1.4728 -0.0099 -0.6946 -0.9422 -0.0349 -0.0194 -0.8217 -1.4889 -0.1367 -5.3652 -0.5284 -0.0488 -0.1304 -0.0277 -1.6620 -0.4480 -0.0059 -0.4371 -0.4962 -0.0280 -0.0746
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in_vivo hf phenylephrine haemodynamic surgical transverse_aortic_constriction tac jq1 pathological cardiac_hypertrophy
H-1047	-0.5175765156745911	▁ HF ▁induc ed ▁mi ce ▁ phen yle ph rine ▁ha emo dynamic _ ▁stress ▁sur g ical ▁trans verse ▁a or tic _ con stri ction ▁j Q 1 ▁cardiac _ ▁hyper trop hy
D-1047	-0.5175765156745911	HF induced mice phenylephrine haemodynamic_ stress surgical transverse aortic_constriction jQ1 cardiac_ hypertrophy
P-1047	-0.3265 -0.0108 -1.3617 -0.0071 -2.9968 -0.0030 -1.1478 -0.0012 -0.1008 -0.0700 -0.0031 -0.0005 -0.0259 -0.0051 -1.0862 -0.2031 -0.2761 -0.0216 -0.0062 -0.4132 -0.0029 -0.8080 -0.3030 -0.0915 -0.1737 -0.1277 -0.0091 -0.0090 -3.0616 -0.8842 -0.7823 -0.4569 -0.5925 -3.2942 -0.0143 -0.8470 -0.0939 -0.0491
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence drugs drugs raas renin_inhibitors endopeptidase_inhibitors vasopeptidase_inhibitors angiotensin_receptor_blockers
H-1490	-0.38555896282196045	▁direct ▁re nin _ ▁inhibi tors ▁neutral ▁en dop ep tida se _ ▁inhibi tors ▁vaso pe pti das e _ ▁inhibi tors ▁ang io ten sin _ ▁receptor _ block ers
D-1490	-0.38555896282196045	direct renin_ inhibitors neutral endopeptidase_ inhibitors vasopeptidase_ inhibitors angiotensin_ receptor_blockers
P-1490	-1.4886 -0.8941 -0.2410 -0.9366 -0.0090 -0.0052 -0.7962 -0.1624 -0.0148 -1.3070 -0.1524 -0.1351 -0.5595 -0.0129 -0.0101 -0.0315 -0.0847 -0.2602 -0.8461 -0.1166 -1.0048 -0.0490 -0.0096 -0.0040 -0.0576 -0.2449 -0.2924 -0.8495 -0.0088 -1.2684 -1.1176 -0.0050 -0.0760 -0.0573
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 healthy cardiomyocytes camp inotropic_effect acute β-ar contractility
H-1216	-0.5661455392837524	▁p de 2 ▁over expression ▁healthy ▁cardio my o cy tes ▁c AMP _ level ▁L - type _ ca 2 ▁current _ ▁amplitud e ▁in o tropi c ▁a cute ▁β - AR _ stimul ation ▁bas al _ contract ility
D-1216	-0.5661455392837524	pde2 overexpression healthy cardiomyocytes cAMP_level L-type_ca2 current_ amplitude inotropic acute β-AR_stimulation basal_contractility
P-1216	-0.8479 -0.5294 -0.0685 -0.5141 -0.1651 -1.2607 -0.5473 -0.2093 -1.1723 -0.6832 -0.0651 -0.0006 -0.0115 -1.7540 -0.6897 -0.6496 -0.0195 -0.0048 -1.6491 -0.0140 -0.0177 -5.2550 -0.8260 -0.1803 -0.0761 -0.2552 -0.2556 -0.0330 -0.4260 -2.7902 -0.0041 -0.8264 -0.0040 -0.1670 -1.7076 -0.2051 -0.1117 -0.0003 -0.0012 -0.1194 -0.5090 -0.1318 -0.0521 -0.0997
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck_stent implanted lad circumflex_artery lcx lcx lad
H-505	-0.5046677589416504	▁bottle ne ck _ ▁sten t ▁proxima l ▁left _ ▁anterior _ ▁descend ing ▁ LAD ▁proxima l ▁circum flex _ ▁arter y ▁proxima l ▁ LC X ▁mid ▁ LAD
D-505	-0.5046677589416504	bottleneck_ stent proximal left_ anterior_ descending LAD proximal circumflex_ artery proximal LCX mid LAD
P-505	-0.0027 -0.0126 -0.0023 -0.6603 -0.3571 -0.0478 -0.1160 -0.0023 -2.6900 -0.4551 -2.2485 -0.4996 -0.0077 -0.0081 -2.2419 -0.0013 -0.0361 -0.0030 -0.8986 -0.0564 -1.6171 -0.1314 -0.1476 -0.2047 -0.0021 -0.4315 -0.0142 -0.2423 -0.7441 -0.8467 -0.1845 -1.3487 -0.3918
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute_myocardial_infarction ami incidence deaths heart_failure hf ami
H-1306	-0.9694821834564209	▁a cute _ me o card ial _ in far ction ▁a cute _ me o card ial _ in far ction ▁ AMI
D-1306	-0.9694821834564209	acute_meocardial_infarction acute_meocardial_infarction AMI
P-1306	-0.5128 -0.0353 -0.3714 -5.1245 -0.3521 -1.4056 -0.0628 -0.0636 -0.3919 -0.0099 -0.0460 -1.6787 -0.3672 -0.1157 -3.8755 -0.1247 -3.2895 -0.2130 -0.0726 -0.2039 -0.0035 -0.0420 -3.0985 -0.4024 -3.2723 -0.0713
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac_washout carvedilol metoprolol β2-adrenergic_receptor_haplotype
H-1117	-0.7289964556694031	▁i - MI BG ▁cardiac _ ▁was hout ▁car vedi lol ▁met o pro lol _ ▁treatment ▁β 2- ad r energi c _ ▁receptor ▁ha plo type
D-1117	-0.7289964556694031	i-MIBG cardiac_ washout carvedilol metoprolol_ treatment β2-adrenergic_ receptor haplotype
P-1117	-0.2455 -0.8346 -1.1482 -0.8643 -1.6079 -1.3135 -3.6177 -0.0067 -0.1281 -0.0066 -0.0191 -0.2954 -0.0308 -0.0079 -0.1512 -3.7838 -2.2303 -0.2323 -0.5369 -0.0343 -0.2246 -1.9055 -0.2221 -0.4562 -0.3790 -0.6352 -0.0109 -0.8242 -0.0726 -0.0446
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle_aerobic_capacity postexercise_phosphocreatine_resynthesis fontan
H-1502	-0.7887126803398132	▁Mus cle ▁aero bic _ capaci ty ▁poste xer ci se ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁Font an
D-1502	-0.7887126803398132	Muscle aerobic_capacity postexercise postexercise phosphocreatine resynthesis Fontan
P-1502	-0.6506 -0.0446 -0.1699 -0.0501 -0.7942 -1.2074 -0.9044 -1.9759 -0.0276 -0.0038 -0.3199 -3.4267 -0.0543 -0.0037 -0.1000 -1.1824 -0.0030 -0.9067 -4.0607 -1.6904 -0.9458 -0.0025 -0.1367 -0.5752 -0.0594 -0.0177 -2.7069 -0.0636
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac_resynchronization_therapy crt patients heart_failure hf outcomes crt dialysis reported
H-904	-0.7445444464683533	▁Card iac _ re syn chron ization _ therapy ▁c RT ▁di al ysis _ dependent ▁heart _ ▁failure
D-904	-0.7445444464683533	Cardiac_resynchronization_therapy cRT dialysis_dependent heart_ failure
P-904	-0.8966 -0.1729 -0.3045 -0.4331 -0.0101 -0.0005 -0.1890 -0.6300 -0.6371 -2.8120 -0.0393 -0.1504 -0.0265 -0.1116 -2.0207 -0.3454 -1.9861 -0.5306 -2.0876 -2.1599 -0.0916
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone patients hyperkalemia renal_function emphasis-hf eplerenone patients hospitalization heart_failure
H-1221	-0.5529299974441528	▁e pler en one ▁hyper kal emia ▁renal _ function ▁EM PHA SIS - HF
D-1221	-0.5529299974441528	eplerenone hyperkalemia renal_function EMPHASIS-HF
P-1221	-0.4154 -0.1046 -0.8088 -0.2318 -1.6533 -0.2060 -0.0159 -0.4623 -0.6524 -0.6673 -0.0332 -0.0065 -0.0820 -0.0352 -0.0002 -3.8460 -0.1788
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ventricular_mass cardiac_apoptosis fibrosis cardiac_metabolic_gene_expression atp
H-655	-0.9061418175697327	▁H - D KO _ mi ce ▁reduce d ▁vent ri cular _ ▁mass ▁cardiac _ ▁apo pto sis ▁fibro sis
D-655	-0.9061418175697327	H-DKO_mice reduced ventricular_ mass cardiac_ apoptosis fibrosis
P-655	-2.3886 -0.2871 -1.2772 -0.3189 -2.3054 -0.2909 -0.0210 -4.2739 -0.0283 -0.1253 -0.4369 -0.0598 -0.4852 -0.5807 -0.0064 -0.4000 -0.4763 -0.0234 -0.8435 -0.0113 -0.0714 -5.8582 -0.2717
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp shock_therapy
H-863	-0.7085328102111816	▁re duction ▁in appropria te _ ▁ATP ▁in appropria te _ ▁shock _ therapy
D-863	-0.7085328102111816	reduction inappropriate_ ATP inappropriate_ shock_therapy
P-863	-1.1432 -0.0005 -1.1641 -0.4240 -0.0839 -1.5012 -0.4590 -1.3473 -0.0058 -0.0457 -0.1710 -3.0861 -0.5550 -0.2403 -0.9841 -0.1252
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint cardiorespiratory_fitness crf body_mass_index heart_failure hf mortality cardiovascular hf mortality
H-1766	-0.777767539024353	▁cardio re spira tory _ fit ▁cardio re spira tory _ fit ▁body ▁mass ▁index ▁heart _ ▁failure ▁un fit _ ▁men
D-1766	-0.777767539024353	cardiorespiratory_fit cardiorespiratory_fit body mass index heart_ failure unfit_ men
P-1766	-1.3099 -0.0443 -0.0493 -0.0028 -0.5832 -0.7911 -3.8275 -0.0522 -0.0345 -0.0013 -0.2024 -0.6517 -0.7528 -1.5922 -0.1250 -0.4210 -0.4052 -2.0164 -2.4239 -0.0012 -0.6043 -2.2766 -0.4375 -0.0603
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized heart_failure dipeptidyl_peptidase-4 dpp-4 antihyperglycemic_agents
H-1827	-0.9734116196632385	▁post marketing _ ▁trial s ▁risk ▁hospital ized _ h HF ▁di pe pti dy l _ ▁pep tida se -4 ▁d PP -4 ▁anti hy per gly ce mic _ agent
D-1827	-0.9734116196632385	postmarketing_ trials risk hospitalized_hHF dipeptidyl_ peptidase-4 dPP-4 antihyperglycemic_agent
P-1827	-0.4798 -0.0206 -3.8073 -0.5922 -0.0393 -2.3017 -0.1285 -0.0451 -0.9079 -6.1082 -0.0745 -0.2151 -0.0095 -0.0364 -2.0066 -2.4083 -0.4579 -0.0814 -0.5398 -1.2399 -0.4672 -0.7177 -0.0934 -0.4821 -0.0714 -3.1722 -0.0499 -3.3352 -0.0465 -1.8494 -0.5911 -0.1414 -0.5198 -0.0587
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox_modeling heart_failure_patient_severity_index hfpsi university_of_michigan hf clinic primary_outcome
H-380	-0.853411853313446	▁quality _ ▁improvement _ ▁database ▁multi vari able ▁co x _ model ing ▁Heart _ fail ure _ ▁Patient _ ▁Sever ity _ index ▁ HF _ ▁clinic
D-380	-0.853411853313446	quality_ improvement_ database multivariable cox_modeling Heart_failure_ Patient_ Severity_index HF_ clinic
P-380	-1.2268 -1.8597 -3.0864 -1.0962 -1.1237 -0.4177 -0.0053 -0.0051 -1.0981 -0.0297 -0.6820 -0.3601 -0.0532 -0.3879 -0.1159 -1.2150 -0.1405 -0.4626 -3.2685 -0.3472 -0.3673 -0.0111 -0.2700 -0.3818 -1.6620 -0.0095 -1.9410 -2.3942 -1.4869 -0.0969
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart_rate cardiac patients patients acute_myocardial_infarction ami patients congestive_heart_failure chf left_ventricular dysfunction
H-1585	-0.8972411155700684	▁Heart _ rati o ▁cardiac ▁patients ▁a cute ▁my o card ial _ in far ction ▁ AMI ▁con ges tive _ heart _ ▁failure ▁left _ ▁vent ri cular _ LV
D-1585	-0.8972411155700684	Heart_ratio cardiac patients acute myocardial_infarction AMI congestive_heart_ failure left_ ventricular_LV
P-1585	-0.7636 -0.6562 -3.0358 -0.1417 -4.7070 -1.4996 -0.1356 -0.0045 -2.7986 -0.2925 -0.6558 -0.1039 -0.3259 -0.5176 -0.0085 -0.0899 -2.3292 -0.0012 -0.1149 -0.0221 -0.0325 -0.2942 -1.2200 -0.3017 -0.6722 -0.9042 -0.1342 -6.2148 -0.3643 -0.0278 -0.9354 -0.8406 -0.2347 -0.1255
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular_cardiomyocytes chronic insulin irs1 irs2 proteins insulin p38 cardiac_dysfunction insulin_resistance type_2_diabetes
H-657	-0.536875307559967	▁ne ona tal _ ▁rat _ ▁vent ri cular _ ▁cardio my o cy tes ▁chronic ▁insulin _ ▁exposure ▁I RS 2 ▁protein s ▁insulin _ action ▁p 38
D-657	-0.536875307559967	neonatal_ rat_ ventricular_ cardiomyocytes chronic insulin_ exposure IRS2 proteins insulin_action p38
P-657	-0.0483 -0.0018 -0.0008 -1.0973 -0.7035 -0.6862 -0.8758 -0.1430 -0.1167 -0.0960 -0.2271 -0.6182 -0.4593 -0.3018 -0.0519 -0.0672 -0.3739 -1.9534 -0.0413 -1.2026 -0.0029 -0.6421 -2.4204 -0.2639 -0.8650 -0.8513 -0.3273 -0.1618 -0.0686 -1.7908 -0.1827
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms left_ventricular midpapillary atrioventricular_delay avd interventricular_delay vvd ste circumferential_strain radial_strain rs
H-323	-0.4535520672798157	▁e cho card i ogram s ▁left ▁vent ri cular _ ▁mid pap illa ry _ level ▁at rio ven tri cular _ de lay ▁interven tri cular _ de lay ▁ VV d ▁regional ▁circum fer ential _ ▁strain ▁radi al _ ▁strain
D-323	-0.4535520672798157	echocardiograms left ventricular_ midpapillary_level atrioventricular_delay interventricular_delay VVd regional circumferential_ strain radial_ strain
P-323	-1.4282 -0.0116 -0.0884 -0.6250 -0.3030 -0.6654 -0.0129 -1.6653 -0.1562 -0.0149 -0.4685 -1.9450 -0.0735 -0.3508 -0.0415 -2.9096 -0.1694 -0.2575 -0.0937 -0.0411 -0.1017 -0.0308 -0.1304 -0.3853 -0.0007 -0.4324 -0.1678 -0.0601 -0.1227 -0.0827 -0.0028 -2.4080 -0.2744 -0.4178 -0.6780 -0.6377 -0.0075 -0.0040 -0.5369 -0.0492 -0.0209 -0.0035 -0.2972 -1.4851 -1.1427 -0.0613
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients new_york_heart_association nyha functional_class hf ejection_fractions chronic stable guideline-directed_medical_therapy gdmt united_states canada europe
H-1870	-1.117684006690979	▁New ▁York _ heart _ association ▁ HF ▁e je ction _ fraction s ▁chronic _ ▁guide line - direct ed _ ▁medical _ therapy
D-1870	-1.117684006690979	New York_heart_association HF ejection_fractions chronic_ guideline-directed_ medical_therapy
P-1870	-1.2391 -1.8601 -0.4085 -5.0020 -0.4268 -1.0348 -2.9761 -4.7480 -0.0952 -0.0198 -0.0150 -1.2062 -0.0004 -0.0357 -0.2337 -0.6088 -5.6011 -0.0009 -0.0748 -0.0005 -0.0262 -0.5035 -0.3720 -0.6842 -0.4376 -2.4984 -0.0681
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients qrs hazard_ratio primary_outcome patients qrs hazard_ratio
H-889	-0.6571419835090637	▁non - LB BB ▁QR S ▁hazard _ rati o
D-889	-0.6571419835090637	non-LBBB QRS hazard_ratio
P-889	-0.7632 -0.0081 -0.0219 -0.2068 -0.1254 -1.0078 -1.9093 -0.6420 -1.0178 -0.1051 -1.7394 -0.3390
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka change riiα cα expression riiα ser96 cα thr197 phosphorylation hf
H-1428	-0.9593009948730469	▁p KA _ ▁sub un its ▁type ▁II ▁regulator y ▁r II α ▁cata ly tic ▁c α ▁ phos phor y lation ▁ HF
D-1428	-0.9593009948730469	pKA_ subunits type II regulatory rIIα catalytic cα phosphorylation HF
P-1428	-0.6997 -1.0694 -3.0591 -0.7022 -0.0667 -0.0015 -1.3598 -1.5002 -0.0430 -0.1672 -5.2521 -1.5896 -2.3977 -0.5270 -0.7265 -0.1516 -2.3419 -0.6821 -0.8352 -0.3417 -1.1113 -0.7418 -0.0778 -0.2118 -0.0023 -0.0864 -0.1555
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous_hf myofiber_shortening septum myofiber_shortening stretch wall
H-1155	-0.43120306730270386	▁ab normal _ ca (2 +) ▁handling ▁dys syn chron ous ▁ HF ▁my o fi ber ▁short en ing _ velo city ▁early - activa ted ▁sept um ▁my o fi ber ▁short en ing ▁stretch _ rati o ▁late - activa ted ▁lateral _ wall
D-1155	-0.43120306730270386	abnormal_ca(2+) handling dyssynchronous HF myofiber shortening_velocity early-activated septum myofiber shortening stretch_ratio late-activated lateral_wall
P-1155	-0.6859 -0.0073 -2.2457 -0.0296 -0.6177 -0.0343 -0.0798 -0.0013 -0.0003 -0.0002 -0.1712 -0.6937 -0.0048 -3.2362 -0.0649 -0.1681 -0.0102 -0.5684 -0.2788 -0.1721 -0.9236 -0.0731 -0.0491 -2.3641 -0.0144 -0.0213 -0.0114 -0.5545 -0.0030 -0.8419 -0.0054 -0.0270 -0.0033 -0.6950 -0.0714 -0.0529 -2.5053 -0.5654 -1.2323 -0.1253 -1.0052 -0.0041 -0.0138 -0.0035 -0.3100 -0.1334 -0.2694 -0.0677 -0.1112
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells transforming_growth_factor-β tgf-β epithelial mesenchymal transition expression pluripotency_markers
H-1342	-0.46862339973449707	▁CHF - der i ved ▁c - K it _ cell s ▁transform ing ▁growth _ factor - β ▁t GF - β ▁epi the li al ▁mes en chy mal _ ▁transition _ ▁marker s ▁pluri pote ncy _ ▁marker s ▁sham s
D-1342	-0.46862339973449707	CHF-derived c-Kit_cells transforming growth_factor-β tGF-β epithelial mesenchymal_ transition_ markers pluripotency_ markers shams
P-1342	-0.2263 -1.0657 -5.6861 -0.0213 -0.0448 -0.0063 -0.0714 -1.1799 -0.1242 -0.8353 -0.4595 -0.0639 -0.8817 -0.0209 -2.1010 -0.7161 -0.0093 -0.7765 -0.1212 -0.5076 -0.0525 -0.1222 -0.0369 -0.8973 -0.0264 -0.1007 -0.0248 -0.0029 -0.4039 -0.0376 -0.1884 -0.3077 -1.6221 -0.2599 -0.6209 -0.0126 -0.7956 -0.0976 -0.0207 -0.4159 -0.3504 -0.0143 -0.0675 -0.0292 -0.0283 -0.1016
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics proteomics transverse_aortic_constriction tac heart_failure signaling_pathway ingenuity_pathway_analysis
H-871	-0.5182780623435974	▁label - free _ shot gun _ prote o mics ▁global _ prote o mics ▁trans verse ▁a or tic _ con stri ction ▁ TAC ▁signal ing _ path way
D-871	-0.5182780623435974	label-free_shotgun_proteomics global_proteomics transverse aortic_constriction TAC signaling_pathway
P-871	-1.3945 -0.0124 -0.0053 -1.3094 -0.7432 -0.0096 -0.3776 -1.1601 -0.1149 -0.0081 -0.3356 -0.6438 -1.4944 -0.0613 -0.0405 -0.0227 -0.0016 -0.7660 -0.6005 -0.1438 -0.1191 -0.1800 -1.3503 -0.0405 -2.0888 -0.0068 -2.4668 -0.0716 -0.1101 -0.0266 -0.1136 -1.2018 -0.0815
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients hfref left_ventricular_ejection_fraction hfpef left_ventricular_ejection_fraction β-blocker hf hospitalization
H-178	-0.827206552028656	▁h Fr EF ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁ HF p EF ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁ RAS - ▁β - block er ▁index ▁ HF
D-178	-0.827206552028656	hFrEF left_ ventricular_ejection fraction HFpEF left_ ventricular_ejection fraction RAS- β-blocker index HF
P-178	-1.1912 -1.0253 -0.5827 -0.0405 -0.8567 -5.2520 -1.0284 -1.5092 -0.3061 -0.8109 -0.6359 -1.0751 -0.7136 -0.0457 -0.5549 -0.2190 -0.3042 -0.0663 -0.2055 -0.3191 -4.3721 -0.8298 -1.0899 -0.2582 -0.3901 -0.4155 -0.6123 -0.8490 -0.0748 -0.2651 -3.1653 -0.2247 -1.0552 -0.0224 -0.2302 -0.2205 -1.4037 -0.1100 -0.0006 -1.2340 -0.3495
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated p70s6k pkc-βii hdl nyha-iiib malondialdehyde bound hdl nyha-iiib hdl healthy
H-257	-0.8588022589683533	▁p 70 s 6 k ▁PK C - β II ▁HD L NY HA - III b ▁malo ndi alde hy de ▁ bound _ HD L
D-257	-0.8588022589683533	p70s6k PKC-βII HDLNYHA-IIIb malondialdehyde bound_HDL
P-257	-0.3058 -0.2242 -0.8723 -0.1663 -1.6282 -0.0057 -1.8235 -0.0782 -0.5477 -0.1450 -1.3164 -0.9575 -2.7293 -0.0734 -0.2513 -0.0447 -0.0295 -0.0046 -0.0100 -0.0690 -3.5331 -0.2998 -1.1817 -0.0035 -1.9283 -1.9656 -0.4603 -4.0269 -0.2232
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross_talk g-protein-coupled_receptors physiological significance regulation hearts chronic β-adrenergic_receptor postischemic_heart_failure
H-1410	-0.777594268321991	▁g - prote in - co up led _ ▁receptor s ▁reciproc al _ ▁regula tion ▁chronic ▁β - ad r energi c _ ▁receptor _ stimul ation ▁post ische mic _ heart _ ▁failure
D-1410	-0.777594268321991	g-protein-coupled_ receptors reciprocal_ regulation chronic β-adrenergic_ receptor_stimulation postischemic_heart_ failure
P-1410	-0.5695 -0.2659 -0.7067 -0.0897 -0.0724 -0.0010 -0.1041 -0.0094 -0.6770 -0.0215 -0.1444 -4.8522 -0.0015 -1.0213 -1.0306 -0.0034 -4.3920 -1.0799 -0.0244 -0.0218 -0.9655 -2.3404 -0.3295 -0.5505 -0.1427 -1.8999 -0.3971 -0.0261 -0.6592 -1.7757 -0.0657 -0.1022 -1.3689 -0.5453 -2.0968 -0.2698 -0.1472
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise exercise
H-1989	-1.0716875791549683	▁weight ▁exercise _ group ▁exercise _ group
D-1989	-1.0716875791549683	weight exercise_group exercise_group
P-1989	-1.7174 -2.1212 -1.1380 -0.5067 -1.0294 -1.5607 -0.3168 -1.0865 -0.1684
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp inflammatory biomarkers hscrp il6 patients hscrp
H-1920	-0.4418620467185974	▁NT - pro B NP ▁infla mma tory _ bio mark ers ▁h s CR p ▁IL 6
D-1920	-0.4418620467185974	NT-proBNP inflammatory_biomarkers hsCRp IL6
P-1920	-0.0168 -0.0492 -0.4402 -1.1020 -0.0258 -0.4651 -0.4487 -0.0223 -0.3526 -0.9354 -0.0228 -0.0488 -0.5473 -0.0308 -0.1011 -1.2114 -0.2047 -0.3001 -2.0741 -0.4382
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection_fraction patients frail biological_phenotype death frailty deficit_index death
H-1010	-0.4619010090827942	▁sex ▁e je ction _ fraction ▁fra il ▁bi ological _ ▁ph eno type ▁risk _ of _ ▁death
D-1010	-0.4619010090827942	sex ejection_fraction frail biological_ phenotype risk_of_ death
P-1010	-2.7007 -0.1660 -0.0316 -0.0171 -0.9313 -0.0019 -0.7746 -0.0273 -0.0649 -0.1304 -0.3920 -0.7291 -0.0130 -0.0111 -1.6173 -0.7883 -0.0527 -0.1977 -0.7168 -0.2453 -0.0909
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients resting_hr follow-up baseline vo2max patients resting_hr p_value
H-1945	-1.0159194469451904	▁rest ing _ HR ▁base line ▁VO 2 max
D-1945	-1.0159194469451904	resting_HR baseline VO2max
P-1945	-2.0649 -0.1779 -0.3432 -0.2650 -2.3741 -0.0047 -1.9756 -0.0824 -0.0018 -3.2972 -0.5883
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β cell phenotype in_vitro cardiac_progenitor_function cell clinical
H-1344	-0.46084800362586975	▁T GF - β ▁inhibi tion ▁c - K it _ cell _ ▁ph eno type ▁function ▁in ▁vi tro ▁cardiac _ pro gen itor _ function ▁cell ▁exp an sion
D-1344	-0.46084800362586975	TGF-β inhibition c-Kit_cell_ phenotype function in vitro cardiac_progenitor_function cell expansion
P-1344	-2.1534 -0.1381 -0.1341 -0.0533 -0.7936 -0.0599 -0.0070 -0.1432 -2.0801 -0.2328 -0.3003 -0.5440 -0.5670 -0.6657 -0.0071 -0.0227 -1.0924 -1.3153 -0.0692 -0.0063 -0.1274 -0.3469 -0.3352 -0.2748 -0.0847 -0.9560 -0.6950 -0.0998 -0.3149 -0.0119 -0.0474 -1.4675 -0.0609
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets in_vitro neurohormonally heart_disease nanomolar jq1 phenylephrine-mediated_hypertrophy cardiomyocytes pathological gene_induction
H-1044	-0.41128772497177124	▁ BET s ▁neuro hormon ally _ ▁induc ed _ heart _ ▁disease ▁na nomo lar _ ▁dos es ▁J Q 1 ▁ phen yle ph rine - media ted _ ▁hyper trop hy ▁cardio my o cy tes ▁path ological _ ▁gene ▁in duction
D-1044	-0.41128772497177124	BETs neurohormonally_ induced_heart_ disease nanomolar_ doses JQ1 phenylephrine-mediated_ hypertrophy cardiomyocytes pathological_ gene induction
P-1044	-0.4263 -0.0284 -0.2469 -0.0879 -0.0952 -0.0768 -1.7273 -0.1181 -0.0085 -0.2302 -1.7397 -0.5743 -3.3035 -0.0128 -0.0016 -0.1420 -1.5454 -0.1295 -0.0005 -0.9205 -0.6329 -0.3470 -0.7427 -0.0042 -0.1172 -0.1622 -0.0123 -0.2195 -0.0463 -0.0106 -0.4614 -1.0845 -0.0058 -0.8612 -0.0366 -0.1030 -1.5333 -0.4788 -0.1600 -0.0025 -0.0555 -0.2947 -0.1798 -0.0828 -0.0010 -0.1727 -0.1063
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric_remodeling concentric_hypertrophy left_ventricular remodeling heart_failure_with_preserved_ejection_fraction hfpef eccentric_hypertrophy patients
H-1524	-0.7241467833518982	▁concentr ic _ ▁remodel ing _ CR ▁concentr ic _ ▁hyper trop hy _ CH ▁left _ ▁vent ri cular _ LV ▁heart _ ▁failure ▁pres er ved _ e je ction ▁ fraction ▁ecce n tric _ ▁hyper trop hy EH
D-1524	-0.7241467833518982	concentric_ remodeling_CR concentric_ hypertrophy_CH left_ ventricular_LV heart_ failure preserved_ejection fraction eccentric_ hypertrophyEH
P-1524	-0.0352 -0.0042 -0.5525 -0.7226 -0.0219 -4.0173 -0.6152 -1.0495 -0.0016 -0.1079 -1.6978 -0.0090 -0.3954 -2.9570 -0.4580 -0.5027 -0.4331 -2.2672 -0.1334 -0.0177 -1.9050 -0.1628 -5.4317 -0.8627 -0.4560 -0.1609 -0.0368 -0.0183 -0.4989 -0.6951 -0.5290 -0.0910 -1.3033 -0.2857 -1.3860 -0.0141 -0.0076 -0.2914 -0.8256 -0.0014 -0.0722 -0.6307 -0.0644 -0.1328
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat functional_status quality_of_life exercise_capacity n-terminal_pro-brain_natriuretic_peptide heart_failure hospitalizations patients nyha_functional_class_iii hf
H-1878	-0.6675176024436951	▁BAT ▁exercise _ capaci ty ▁N - termin al ▁pro - bra in ▁na tri ure tic _ pe pti de ▁burde n _ of _ heart _ ▁failure ▁GD MT - tre ated _ ▁NY HA
D-1878	-0.6675176024436951	BAT exercise_capacity N-terminal pro-brain natriuretic_peptide burden_of_heart_ failure GDMT-treated_ NYHA
P-1878	-2.1318 -4.5210 -1.4612 -0.5780 -0.5653 -1.1422 -0.0183 -0.0119 -0.0006 -0.6197 -0.0384 -0.6504 -0.0166 -0.0224 -0.0157 -0.0623 -0.1865 -0.2623 -0.2863 -0.0446 -0.0885 -0.2293 -0.0058 -2.4247 -0.1170 -0.2073 -0.2125 -1.0574 -3.2864 -1.4496 -0.4512 -0.1618 -0.0006 -0.0920 -0.5348 -1.7959 -0.0114 -1.1878 -0.0838
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change exercise exercise
H-1986	-0.9258974194526672	▁ ML HF ▁ ML HF _ ▁total _ ▁score ▁exercise
D-1986	-0.9258974194526672	MLHF MLHF_ total_ score exercise
P-1986	-0.1332 -0.0774 -0.0547 -2.8138 -0.2619 -0.0366 -2.4182 -1.5574 -0.1842 -0.6470 -0.1277 -3.5197 -0.2049
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx dnx
H-1374	-1.0814589262008667	▁non pa ce ▁non - DN x ▁s ham - I nner vat ed ▁s ham - in v ▁non pa ce ▁DN x ▁s ham - DN x ▁pace _ in v
D-1374	-1.0814589262008667	nonpace non-DNx sham-Innervated sham-inv nonpace DNx sham-DNx pace_inv
P-1374	-0.6561 -3.4840 -0.0175 -0.9638 -0.0916 -0.7455 -0.8239 -1.6682 -0.1065 -0.0282 -1.4146 -0.0001 -0.0814 -0.0135 -2.1041 -0.1070 -0.0278 -0.8459 -0.6758 -1.5412 -0.3610 -0.0071 -1.6372 -0.0386 -1.7690 -0.0434 -0.0292 -3.7103 -0.1210 -4.5150 -1.3906 -3.9774 -0.7710 -3.8492 -0.2342
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise correlated psss btes exercise psss btes
H-1929	-1.285029649734497	▁exercise _ ▁time ▁PS SS
D-1929	-1.285029649734497	exercise_ time PSSS
P-1929	-0.3533 -2.0570 -0.9916 -2.1806 -0.1608 -3.1506 -0.1012
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin hgb hrqol hrqol patients heart_failure outcomes exercise training hf-action
H-836	-0.5762835741043091	▁hem o glob in ▁h gb ▁HR Qo L ▁training - indu ced ▁HR Qo L ▁co hor t _ of ▁patients ▁Heart _ ▁Fail ure ▁ HF - AC TION
D-836	-0.5762835741043091	hemoglobin hgb HRQoL training-induced HRQoL cohort_of patients Heart_ Failure HF-ACTION
P-836	-2.0188 -0.0376 -0.1107 -0.0991 -2.3544 -0.0138 -0.1244 -0.1179 -0.2732 -0.0600 -0.1379 -0.0009 -0.0075 -1.5951 -0.2211 -0.0494 -2.6495 -0.0002 -0.0344 -2.0572 -0.0516 -1.1983 -0.1745 -0.1288 -0.6302 -0.0114 -3.3643 -0.8643 -0.0875 -0.0987 -0.1641 -0.2094 -0.0711
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv_dysfunction hazard_ratio confidence_interval cachexia hazard_ratio multivariate_analyses
H-1166	-1.1270253658294678	▁risk _ of _ ▁event ▁ RV _ ▁dys function ▁ha ard _ rati o
D-1166	-1.1270253658294678	risk_of_ event RV_ dysfunction haard_ratio
P-1166	-0.2141 -2.2708 -0.2195 -0.5488 -0.3278 -0.8147 -0.0401 -1.0840 -1.0391 -0.1341 -4.3768 -0.3425 -0.4571 -0.1008 -0.0089 -6.4157 -0.7647
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial_fibrillation congestive_heart_failure health_care expenditures patients québec randomized rhythm rate-control
H-1234	-0.660912036895752	▁at rial _ fi bril lation ▁con ges tive _ ▁Heart _ ▁Fail ure _ ▁trial ▁health ▁care ▁ex pendi tures ▁ rhythm ▁rate - control ▁treatment
D-1234	-0.660912036895752	atrial_fibrillation congestive_ Heart_ Failure_ trial health care expenditures rhythm rate-control treatment
P-1234	-1.0966 -0.0187 -0.2229 -0.3057 -0.0502 -0.0062 -0.4937 -0.0577 -0.0593 -0.0567 -0.7933 -0.0948 -0.5468 -0.0514 -2.8385 -1.6688 -1.2976 -1.7039 -0.0156 -0.0000 -0.0058 -0.5335 -0.2679 -0.1359 -0.2709 -0.0164 -3.8832 -2.4464 -0.2282
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report calcineurin nfat mir-25 expression basic_helix-loop-helix bhlh transcription_factor dhand hand2 diseased myocardium
H-640	-0.7315321564674377	▁calci ne uri n _ n fat _ signal ling ▁mi R -25 ▁expression ▁basic ▁heli x - loop - heli x ▁tran scription _ factor ▁d HAND ▁disease d ▁human ▁mouse _ my o car dium
D-640	-0.7315321564674377	calcineurin_nfat_signalling miR-25 expression basic helix-loop-helix transcription_factor dHAND diseased human mouse_myocardium
P-640	-0.0035 -1.4199 -0.1808 -0.1590 -3.4752 -1.6484 -0.6241 -0.9651 -0.9606 -0.2900 -0.0262 -0.1831 -0.1436 -0.3471 -2.7398 -0.3951 -0.3202 -0.0845 -0.0033 -0.3420 -0.0197 -0.1289 -3.3877 -0.1149 -0.8275 -0.0271 -1.3354 -0.0645 -2.1816 -0.0846 -0.8357 -0.0313 -0.6826 -3.1683 -0.0750 -0.0719 -0.9251 -0.1236 -0.1327
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart_failure patient compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_dysfunction
H-1668	-0.6238722205162048	▁heart _ ▁failure ▁my o card ial _ ▁is cha emia ▁ta chy - ▁bra dy ar rhythm ias ▁val vu lar _ re gur gi tation ▁pulmonar y _ e mbol ism ▁renal _ ▁dys function
D-1668	-0.6238722205162048	heart_ failure myocardial_ ischaemia tachy- bradyarrhythmias valvular_regurgitation pulmonary_embolism renal_ dysfunction
P-1668	-6.3050 -1.5761 -0.9712 -0.9649 -0.0267 -1.6499 -0.0223 -0.6147 -4.1510 -0.0017 -0.0075 -0.0253 -0.0119 -0.0174 -1.8571 -0.1591 -0.0269 -0.1051 -0.1903 -0.1653 -0.1501 -0.1248 -0.2449 -0.7512 -0.0028 -0.0225 -0.0042 -0.0011 -0.0062 -0.4820 -1.2965 -0.0009 -0.0222 -0.0041 -1.2809 -0.9009 -0.0181 -0.0939 -0.0743
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc_battery hf health_abc_hf_model death
H-629	-0.816944420337677	▁H ABC _ bat tery _ ▁score ▁ HF _ risk ▁health ▁ABC ▁ HF _ model ▁SD _ risk ▁competi ng _ risk
D-629	-0.816944420337677	HABC_battery_ score HF_risk health ABC HF_model SD_risk competing_risk
P-629	-3.4094 -0.0977 -1.0305 -1.3539 -0.0033 -0.5619 -2.2823 -0.0647 -0.0015 -0.7835 -0.7309 -1.2096 -0.2059 -0.2573 -0.0023 -0.4892 -0.2564 -0.5582 -1.3340 -3.5486 -1.8298 -0.0944 -0.1342 -0.6422 -0.2166 -0.1421
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp admission sensitivity specificity confidence_interval area_under_the_curve
H-269	-0.692467987537384	▁NT - pro b NP ▁cut off _ point ▁ad mission ▁p g / m L
D-269	-0.692467987537384	NT-probNP cutoff_point admission pg/mL
P-269	-0.1728 -0.0142 -0.0077 -0.6997 -0.2745 -1.0215 -0.0079 -0.4611 -0.1345 -4.5562 -0.0596 -1.5985 -0.0360 -0.6097 -0.0119 -0.2918 -2.3819 -0.1251
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic r-r_interval hr_variability short-term_fractal_scaling_exponent prognostic
H-1588	-0.48338624835014343	▁prognos tic _ power ▁rapid ▁R - R ▁interval _ os cilla tions ▁non - line ar ▁HR _ ▁variabil ity ▁short - term ▁fra c tal _ ▁scal ing _ ex ponent
D-1588	-0.48338624835014343	prognostic_power rapid R-R interval_oscillations non-linear HR_ variability short-term fractal_ scaling_exponent
P-1588	-0.5221 -0.1017 -0.7459 -0.1691 -2.5833 -1.8210 -0.0340 -0.1049 -0.4611 -0.3789 -0.2177 -0.0095 -0.0074 -1.0757 -0.0062 -0.0016 -0.0044 -0.6279 -0.9509 -0.1912 -0.0087 -0.9453 -0.0206 -0.0122 -3.0378 -0.0756 -0.0476 -0.6540 -0.1469 -0.0499 -0.5280 -0.4271 -0.0176 -0.7845 -0.1481
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart_failure hf patients spontaneous_ventricular_tachycardia hf patients spontaneous_vt hearts
H-1437	-0.9485834836959839	▁heart _ she ▁patients ▁spontane ous _ ▁vent ri cular _ ta chy car dia ▁ HF VT
D-1437	-0.9485834836959839	heart_she patients spontaneous_ ventricular_tachycardia HFVT
P-1437	-1.0983 -1.0796 -4.3500 -1.0364 -0.0472 -0.0030 -0.7598 -1.8469 -0.2858 -0.1617 -0.0956 -1.1109 -0.2559 -0.9006 -0.0305 -0.4226 -0.0077 -1.4743 -3.8167 -0.1882
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls cox_model chronic_heart_failure hypertension diabetes stroke estimated_glomerular_filtration_rate lvef
H-819	-0.7068986296653748	▁g LS ▁co x _ model ▁chronic _ heart _ ▁failure ▁hyper tension ▁diabetes ▁prior _ ▁stroke _ ▁score ▁glo mer ular _ ▁filtr ation _ ▁rate ▁LV EF ▁advers e ▁CV
D-819	-0.7068986296653748	gLS cox_model chronic_heart_ failure hypertension diabetes prior_ stroke_ score glomerular_ filtration_ rate LVEF adverse CV
P-819	-0.7700 -1.7979 -0.5652 -0.0123 -1.9319 -0.3762 -0.3029 -0.6090 -2.2767 -0.4541 -2.3393 -0.6999 -0.0051 -0.0602 -0.7186 -0.3396 -0.5865 -1.2429 -0.4557 -0.0683 -0.0508 -0.0422 -0.3098 -0.8815 -0.1538 -0.8330 -1.0255 -0.0642 -0.0068 -2.1165 -0.0175 -1.1897 -1.5902 -0.1408
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic_function diastolic_filling_formalism relaxation doppler_mitral_inflow_velocity e-wave
H-921	-0.5141074061393738	▁dia sto lic _ ▁fill ing _ ▁formal ism ▁relax ation ▁vis co ela stic ▁passiv e _ sti ff ness ▁do pp ler _ ▁mit ral _ in flow _ velo city ▁e - wa ve
D-921	-0.5141074061393738	diastolic_ filling_ formalism relaxation viscoelastic passive_stiffness doppler_ mitral_inflow_velocity e-wave
P-921	-0.6642 -0.0160 -0.0963 -1.3010 -3.8858 -0.0252 -1.0855 -0.9949 -0.0112 -0.2195 -0.0095 -2.3637 -0.0020 -0.0005 -0.0004 -0.0000 -0.0390 -1.7724 -0.6025 -0.0838 -0.0557 -0.9738 -0.0009 -0.2052 -0.3988 -1.4060 -0.0167 -0.8877 -0.5877 -0.0013 -0.8558 -0.0672 -0.0469 -0.7312 -0.0253 -0.0018 -0.0208 -0.3842 -0.2096
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient vad patients ventricular_assist_device ecmo patients extracorporeal_membrane_oxygenation ecmo vad patients ecmo vad
H-1387	-1.046860933303833	▁ VAD ▁vent ri cular _ assist _ ▁device _ support ▁EC mo _ group ▁extra corp o real _ ▁membran e ▁oxygen ation _ ▁membran e _ support ▁EC mo ▁ VAD
D-1387	-1.046860933303833	VAD ventricular_assist_ device_support ECmo_group extracorporeal_ membrane oxygenation_ membrane_support ECmo VAD
P-1387	-1.2429 -0.2576 -1.4060 -0.1719 -0.0344 -0.3812 -0.0138 -1.3248 -1.4835 -1.6378 -0.5901 -1.0171 -0.8310 -3.1646 -4.3538 -1.6964 -0.0556 -0.3748 -1.0856 -0.3948 -1.9640 -0.0322 -2.9052 -0.3426 -0.4184 -0.2778 -0.0138 -1.9123 -0.9985 -0.4424 -1.0166 -3.1431 -0.3079 -0.8970 -0.4506
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional_status 6-mwt nyha_class patients hfpef hfref prescribed therapy patients hfpef death hf hospitalization
H-244	-0.6590991020202637	▁functional ▁status ▁NY HA ▁ HF p EF ▁H Fr EF ▁ HF p EF ▁ HF _ hospital ization
D-244	-0.6590991020202637	functional status NYHA HFpEF HFrEF HFpEF HF_hospitalization
P-244	-1.1481 -1.3154 -3.8636 -0.2283 -0.9326 -0.0313 -0.1063 -0.0554 -0.9928 -0.0568 -0.0946 -1.6354 -0.0361 -0.5660 -0.4358 -0.7452 -0.0505 -1.7007 -0.0972 -0.1747 -0.1489 -0.0843
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart_failure disease evidence-based health_care
H-2016	-0.8428583145141602	▁cost - effect ive ness ▁heart _ ▁failure _ management _ program s ▁evidence - based _ therapie s ▁health _ system
D-2016	-0.8428583145141602	cost-effectiveness heart_ failure_management_programs evidence-based_therapies health_system
P-2016	-0.0557 -0.2601 -0.0534 -0.0455 -1.0339 -1.0976 -0.3402 -2.9291 -0.3445 -3.0237 -1.3593 -1.0947 -1.2653 -0.4628 -0.0147 -0.0086 -0.5754 -2.6319 -0.0353 -0.8222 -1.3611 -1.0537 -0.0813 -0.2786
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin heart_failure murine resistin transgenic retn gene resistin
H-930	-0.5973294377326965	▁human ized ▁mouse ▁mur ine _ ▁resist in ▁human ▁Ret n _ ▁gene ▁h um - Re t n _ mi ce ▁bas al ▁ inflammation - stimul ated _ ▁resist in
D-930	-0.5973294377326965	humanized mouse murine_ resistin human Retn_ gene hum-Retn_mice basal inflammation-stimulated_ resistin
P-930	-0.1565 -1.6058 -2.0810 -2.4223 -0.0108 -1.4640 -0.0641 -0.0848 -1.0774 -2.6597 -0.0026 -0.2030 -0.1694 -2.6019 -0.0173 -0.0258 -0.5217 -0.0082 -0.0006 -0.2578 -0.5320 -0.0266 -0.1045 -0.0003 -0.6027 -0.0020 -0.1280 -0.0132 -0.5422 -0.6893 -0.7540 -0.0391 -1.2631 -0.1775
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients angiotensin-converting_enzyme_inhibitors angiotensin_receptors_blockers β-blockers
H-1745	-0.4775703251361847	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors _ angi oten sin _ ▁receptor s _ block ers ▁β - block ers
D-1745	-0.4775703251361847	angiotensin-converting_ enzyme inhibitors_angiotensin_ receptors_blockers β-blockers
P-1745	-0.1001 -0.3813 -1.1664 -0.4223 -1.4607 -0.0016 -0.0797 -0.1941 -0.4994 -0.4891 -0.0568 -0.9301 -0.0877 -1.1639 -0.7111 -0.1222 -0.3296 -0.3327 -0.3541 -0.4893 -1.0676 -1.2895 -0.2962 -0.2759 -0.0047 -0.0501 -0.0865 -1.1814 -0.2255
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac_injury ejection_fraction fractional_shortening heart_dilatation hypertrophy transverse_aortic_constriction tac
H-1815	-0.6679053902626038	▁ TTA ▁t g t et Men a _ mi ce ▁cardiac _ ▁injury ▁e je ction _ fraction ▁ fraction al _ ▁short en ing ▁heart _ di la tation ▁trans verse ▁a or tic _ con stri ction TAC
D-1815	-0.6679053902626038	TTA tgtetMena_mice cardiac_ injury ejection_fraction fractional_ shortening heart_dilatation transverse aortic_constrictionTAC
P-1815	-1.7982 -0.5015 -1.0609 -0.4324 -0.4680 -2.2287 -0.4013 -0.0490 -0.9553 -0.2767 -0.0435 -0.0132 -0.5211 -0.8012 -0.7979 -0.0594 -0.0281 -1.4806 -0.0124 -0.6928 -0.0004 -1.2827 -0.6309 -1.3322 -0.1412 -0.1428 -0.1573 -0.9299 -2.6752 -0.2552 -0.0031 -1.2932 -0.0621 -2.1664 -1.5449 -0.5853 -0.2617 -0.1690 -0.1471 -0.0834 -2.0057 -0.0868 -0.1415
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart_failure patients italy confirmatory_factor_analysis cfa schfi_v.6.2 self-care_maintenance self-care_management self-care_confidence
H-1505	-0.7641890645027161	▁heart _ ▁failure _ patient s ▁confirma tory _ factor _ analyse ▁c fa ▁ SCH fi ▁self - Car e _ management ▁Self - Car e _ ▁Confi den ce
D-1505	-0.7641890645027161	heart_ failure_patients confirmatory_factor_analyse cfa SCHfi self-Care_management Self-Care_ Confidence
P-1505	-1.9862 -0.4453 -2.4409 -1.9937 -2.3415 -0.4430 -0.4089 -0.0004 -0.5572 -0.0591 -1.6136 -1.6615 -1.7978 -0.5791 -1.5127 -0.3634 -1.7838 -1.0408 -0.0250 -0.3300 -0.0419 -0.3379 -0.2085 -1.2305 -0.0086 -0.0953 -0.0153 -0.5331 -1.1324 -0.0149 -0.0153 -0.1016 -0.0989
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation_for_ambulatory_heart_failure_trial implantable primary_end_point all-cause_mortality heart_failure hospitalization
H-882	-0.3655109405517578	▁re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart _ ▁Fail ure _ Tri al ▁implant able ▁cardio ver ter _ de fi br illa tor _ de fi br illa tor - C RT
D-882	-0.3655109405517578	resynchronization-Defibrillation Ambulatory_ Heart_ Failure_Trial implantable cardioverter_defibrillator_defibrillator-CRT
P-882	-0.1521 -0.0002 -0.0006 -0.1016 -0.1993 -0.6166 -0.6926 -0.3755 -0.0042 -0.0974 -0.0024 -0.0047 -0.2831 -0.3377 -0.2874 -0.1490 -0.0223 -0.3749 -0.6964 -0.0096 -0.0200 -0.0046 -0.4005 -0.0572 -0.2054 -0.4724 -0.1998 -0.0064 -0.3728 -0.1412 -0.0180 -1.9266 -1.0707 -0.0069 -0.3687 -0.3036 -0.0220 -0.3643 -0.5544 -0.1844 -4.1675 -0.0764
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic_events ies patients ischemic_cardiomyopathy ic cardiac_resynchronization_therapy defibrillator crt-d
H-102	-0.634885847568512	▁ ische mic _ evento s ▁ ische mic _ ▁cardio my o pathy ▁cardiac _ ▁re syn chron ization _ therapy ▁de fi br illa tor ▁c RT - D ▁device
D-102	-0.634885847568512	ischemic_eventos ischemic_ cardiomyopathy cardiac_ resynchronization_therapy defibrillator cRT-D device
P-102	-1.6644 -0.4337 -0.1576 -0.4954 -3.2477 -0.1140 -0.6029 -0.4439 -0.0438 -0.1101 -2.6745 -1.8669 -0.6877 -0.0960 -0.1092 -0.8014 -0.8630 -0.0003 -0.0004 -0.0885 -1.1573 -0.1943 -0.4933 -0.0043 -0.1761 -0.1383 -0.0114 -2.8720 -0.0439 -0.0478 -0.2280 -1.5673 -0.0838 -0.0670
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal_dysfunction chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks follow-up mortality ischemic_cardiomyopathy
H-69	-0.6220468878746033	▁renal _ ▁dys function ▁chronic _ ▁ob struct ive ▁pulmonar y ▁diabetes ▁per i pher al _ vas cular _ dia ▁diabet ic ▁left _ ▁vent ri cular _ e je ction _ fraction ▁I CD _ ▁shock s ▁ ische mic _ ▁cardio my o pathy ▁male ▁sex
D-69	-0.6220468878746033	renal_ dysfunction chronic_ obstructive pulmonary diabetes peripheral_vascular_dia diabetic left_ ventricular_ejection_fraction ICD_ shocks ischemic_ cardiomyopathy male sex
P-69	-0.0201 -0.7376 -1.1903 -0.0103 -0.0139 -1.6090 -0.5660 -0.0023 -0.0156 -0.6418 -0.0046 -1.6295 -0.0120 -0.0422 -0.0002 -0.0065 -0.0989 -1.0082 -0.0125 -0.3753 -3.2976 -2.8472 -1.9629 -0.2597 -0.1927 -4.2247 -0.1570 -0.1836 -0.0730 -0.6738 -0.1682 -0.1044 -0.9211 -0.1374 -0.8337 -0.0115 -0.2838 -0.1071 -0.1510 -0.9626 -0.1065 -0.0622 -0.0809 -1.9338 -1.6729 -0.2898 -0.6455 -0.2081 -1.0993 -0.0272 -0.0488
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients chf testosterone exercise testosterone placebo
H-1318	-1.6696590185165405	▁CHF ▁CHF
D-1318	-1.6696590185165405	CHF CHF
P-1318	-0.3337 -1.7870 -4.4820 -0.0760
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold_proteins cardiac_remodelling field therapeutic
H-996	-0.32816705107688904	▁Raf - MEK 1/2 - ER k 1/2 ▁sc af fold _ ▁protein s ▁adapt ive ▁mal adapt ive _ ▁cardiac _ ▁remodel ling
D-996	-0.32816705107688904	Raf-MEK1/2-ERk1/2 scaffold_ proteins adaptive maladaptive_ cardiac_ remodelling
P-996	-0.2195 -0.0663 -0.0202 -0.7151 -0.0415 -0.5183 -0.0998 -1.0474 -0.5982 -0.1043 -0.0658 -0.2643 -0.5959 -0.0393 -0.2901 -0.0012 -0.3463 -0.0277 -0.0006 -0.8308 -0.0648 -0.3215 -0.0977 -0.0139 -2.1022 -0.0395
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional_ms lv_dilatation heart_failure hf functional_ms hf prolapse degenerative_mitral_valve
H-341	-0.7996673583984375	▁functional _ ▁MS ▁LV ▁di la tation ▁heart _ ▁failure ▁ HF ▁LV ▁pro lapse ▁de genera tive _ ▁mit ral _ val ve
D-341	-0.7996673583984375	functional_ MS LV dilatation heart_ failure HF LV prolapse degenerative_ mitral_valve
P-341	-0.9505 -1.1988 -0.1973 -1.9625 -0.8180 -0.0206 -0.0005 -3.3193 -0.3285 -0.6175 -2.7753 -0.0051 -1.2313 -2.7819 -0.0167 -1.2730 -0.0001 -0.0142 -0.1233 -1.9707 -0.0190 -0.1082 -0.8298 -0.0724 -0.1044 -0.0525
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blockers β-blockers patients heart_failure medications medical
H-1130	-0.7013866305351257	▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin _ recept or _ block ers ▁β - block ers ▁heart _ ▁failure
D-1130	-0.7013866305351257	angiotensin_ converting_ enzyme_ inhibitor angiotensin_receptor_blockers β-blockers heart_ failure
P-1130	-0.6334 -0.9164 -1.1427 -0.0973 -1.2984 -0.3707 -0.1280 -0.1647 -0.5766 -0.0366 -0.6717 -1.0732 -0.0689 -0.0319 -0.3562 -0.3638 -0.1231 -1.2388 -0.9270 -0.4571 -0.3402 -1.8010 -0.1544 -0.0384 -0.0148 -0.1042 -0.0356 -2.4362 -1.0703 -5.0870 -0.6045 -0.0812
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new_york_heart_association_class kccq symptom spearman_correlations 2-way_anova patients hf_with_reduced_ef hfpef
H-783	-0.8481377363204956	▁New ▁York _ heart _ association ▁k cc q ▁over all _ ▁Summa ry ▁Total _ dis tribution s ▁Spe ar man _ ▁corre lation s ▁ HF p EF ▁interaction _ ▁terms
D-783	-0.8481377363204956	New York_heart_association kccq overall_ Summary Total_distributions Spearman_ correlations HFpEF interaction_ terms
P-783	-2.4787 -0.9624 -0.2598 -4.6175 -0.5087 -1.4076 -0.8709 -0.0921 -0.6536 -1.4418 -0.0041 -0.0712 -2.0879 -0.0146 -1.6762 -0.0753 -4.6172 -0.4957 -0.7151 -0.0542 -0.0005 -0.0006 -0.6901 -0.2236 -0.0001 -0.0214 -0.6615 -0.1155 -1.5796 -0.1056 -0.3341 -1.5479 -1.0794 -0.1269 -0.0933
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic lv_ejection_fraction lv_strain strain systole diastolic lv_strain_rate diastole transmitral_flow patients sinus_rhythm follow-up
H-951	-0.8418993353843689	▁LV ▁e je ction _ fraction ▁LV _ ▁strain _ rati o ▁sy stol e ▁dia sto lic _ ▁indice s ▁LV _ ▁strain _ rati o ▁dia stol e ▁early _ trans ral _ ▁flow ▁sinus ▁ rhythm
D-951	-0.8418993353843689	LV ejection_fraction LV_ strain_ratio systole diastolic_ indices LV_ strain_ratio diastole early_transral_ flow sinus rhythm
P-951	-0.1112 -1.6238 -0.0853 -0.0451 -0.4105 -0.8595 -0.0890 -0.3786 -4.1742 -0.3033 -0.3866 -0.0655 -3.0982 -0.1997 -0.4342 -2.1672 -0.7306 -0.1682 -0.3660 -0.0568 -0.0033 -2.4034 -0.3165 -1.8649 -0.1144 -0.3067 -0.0186 -3.3597 -0.0929 -1.1895 -1.1746 -0.1296 -4.3118 -0.2900 -0.9887 -0.4437 -0.5891 -0.5717 -0.0633 -0.2421 -0.2900
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang_ii_infusion ang_ii_infusion uninephrectomy ang_ii_infusion salt_loading ang_ii_infusion uninephrectomy salt_loading
H-276	-0.7844781279563904	▁c 57 b ▁figure ▁ANG ▁II ▁in fusion ▁un ine ph r ecto my ▁ang ▁II ▁in fusion ▁salt ▁load ing ▁un ine ph r ecto my ▁salt _ load ing
D-276	-0.7844781279563904	c57b figure ANG II infusion uninephrectomy ang II infusion salt loading uninephrectomy salt_loading
P-276	-2.6693 -0.3120 -1.0565 -6.1689 -1.4450 -1.0398 -0.0929 -0.0055 -0.8269 -0.0042 -0.2180 -0.0347 -0.0659 -0.2988 -2.0689 -1.4704 -0.7319 -0.0486 -0.0642 -0.5421 -0.0067 -2.6503 -0.0028 -0.1299 -0.0309 -0.2229 -0.7525 -0.5608 -0.9786 -0.2517 -0.0069 -1.0111 -0.1182
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral_blood_flow_velocity tissue_doppler diastolic_mitral_annulus_velocity pulmonary_capillary_wedge_pressure pcwp patients decompensated_systolic_heart_failure hf
H-480	-0.5682527422904968	▁early ▁transmit ral _ ▁blood _ ▁flow _ velo city ▁do pp ler ▁early _ dia sto lic _ mit ral _ ▁ann ulus _ velo city ▁pulmonar y _ ▁cap illa ry _ we dge _ ▁pressure ▁de com pensa ted _ ▁sy sto lic _ heart _ ▁failure HF
D-480	-0.5682527422904968	early transmitral_ blood_ flow_velocity doppler early_diastolic_mitral_ annulus_velocity pulmonary_ capillary_wedge_ pressure decompensated_ systolic_heart_ failureHF
P-480	-1.1135 -2.2620 -0.0275 -0.4064 -4.2273 -1.1540 -0.3484 -0.6510 -0.0589 -0.0162 -1.5797 -0.0002 -0.0643 -1.3559 -0.2242 -0.0889 -0.3640 -0.3195 -0.1468 -2.6377 -0.0285 -0.0891 -1.6133 -0.1222 -0.3822 -0.0337 -0.0077 -0.2753 -0.0030 -0.1510 -0.5876 -0.0813 -0.0268 -0.1853 -1.8151 -0.0011 -0.2440 -0.8913 -1.2719 -0.0017 -0.0018 -0.0124 -0.5223 -1.5635 -0.1964 -0.2702 -0.0516 -0.4736 -0.3095 -1.3817 -0.3217 -0.1323 -0.0219
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak_vo2 exercise
H-1984	-0.8825350403785706	▁pe ak _ vo 2 ▁exercise
D-1984	-0.8825350403785706	peak_vo2 exercise
P-1984	-0.0335 -0.0246 -0.1831 -0.4128 -0.0831 -2.2953 -3.7007 -0.3270
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami patient hospital hospital_compare p-value
H-1698	-1.3412151336669922	▁ AMI ▁hospital
D-1698	-1.3412151336669922	AMI hospital
P-1698	-0.1622 -0.0074 -2.4897 -3.8331 -0.2137
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq patients hfpef log_rank ef
H-789	-1.1593828201293945	▁k cc q ▁ HF p EF
D-789	-1.1593828201293945	kccq HFpEF
P-789	-1.4569 -0.0599 -1.2306 -3.0325 -0.5933 -0.0243 -0.5509 -3.2480 -0.2381
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt nt-probnp report ctnt nt-probnp clinical hf
H-292	-0.7397456169128418	▁c t n T ▁NT - pro b NP ▁laborator y _ report
D-292	-0.7397456169128418	ctnT NT-probNP laboratory_report
P-292	-2.4812 -0.8101 -0.2810 -0.9579 -0.4939 -0.0217 -0.0026 -1.1992 -0.0744 -1.4368 -0.0062 -0.6784 -0.4145 -1.9656 -0.2727
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass_spectrometry c-terminally nt-probnp physiological proteolysis
H-1517	-0.5876249074935913	▁Mass ▁spec tro met ry ▁N - ▁c - termin ally _ process ed _ form s ▁circula ting ▁NT - pro B NP ▁physio logic al _ ▁prote ol ysis ▁pro 2- Le u 3 ▁le u 3- G ly 4 ▁pro 6 - G ly 7 ▁pro 75 - Ar g 76
D-1517	-0.5876249074935913	Mass spectrometry N- c-terminally_processed_forms circulating NT-proBNP physiological_ proteolysis pro2-Leu3 leu3-Gly4 pro6-Gly7 pro75-Arg76
P-1517	-1.7525 -1.6091 -0.1103 -0.0687 -0.0661 -1.6221 -0.0415 -5.9353 -0.0464 -0.0354 -0.0085 -2.5287 -0.6329 -0.0487 -2.3721 -0.4478 -0.1017 -0.0149 -0.0166 -0.0196 -0.0086 -0.0038 -1.4336 -0.0341 -0.0035 -0.2690 -0.0215 -0.4822 -0.7834 -3.2821 -0.7739 -1.2953 -1.1088 -0.5096 -0.0023 -0.2535 -0.7038 -0.0029 -0.0298 -0.8126 -0.0696 -0.7047 -0.3685 -0.2636 -0.0291 -0.8887 -0.0955 -0.2395 -0.2366 -0.0797 -0.0097 -0.2231 -0.0031 -0.2064 -0.1327 -0.0635
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef patients new_york_heart_association_class_ii ejection_fraction fes placebo
H-1329	-1.1984728574752808	▁ HF p EF ▁patients ▁New ▁York _ ▁Heart _ association ▁class _ II
D-1329	-1.1984728574752808	HFpEF patients New York_ Heart_association class_II
P-1329	-0.1318 -0.1453 -0.0994 -0.2223 -2.0678 -3.3014 -0.2863 -0.8104 -0.9873 -0.4900 -1.4863 -1.4926 -1.9574 -0.9811 -4.5909 -0.1253
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left_ventricular systolic_pressure ejection_fraction fractional_shortening cardiac_output lv_end-diastolic_pressure mi metoprolol
H-1548	-0.683082640171051	▁de press ed ▁left _ ▁vent ri cular _ LV _ ▁sy sto lic _ ▁pressure ▁pressure ▁e je ction ▁ fraction _ ▁short en ing ▁cardiac _ ▁output
D-1548	-0.683082640171051	depressed left_ ventricular_LV_ systolic_ pressure pressure ejection fraction_ shortening cardiac_ output
P-1548	-0.0548 -0.0019 -0.0207 -0.1345 -0.1881 -3.1993 -0.1337 -0.0106 -0.9887 -0.3030 -0.8784 -1.6264 -0.1596 -0.4716 -0.4056 -0.2700 -0.2802 -0.9780 -0.0182 -0.0127 -0.6313 -0.0002 -3.5249 -0.3710 -0.0481 -0.0918 -0.0249 -0.9399 -1.5160 -3.6997 -0.1915
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex_activation_therapy_for_the_treatment_of_heart_failure_with_a_reduced_ejection_fraction clinical carotid baroreflex_activation_therapy bat heart_failure hf
H-1867	-0.5904822945594788	▁bar ore flex _ activ ation _ therapy ▁Heart _ fail ure ▁Red u ced _ e je ction _ Fra ction
D-1867	-0.5904822945594788	baroreflex_activation_therapy Heart_failure Reduced_ejection_Fraction
P-1867	-1.9356 -2.0639 -1.2600 -0.1161 -0.2020 -0.2709 -0.2868 -0.2288 -1.2954 -0.1224 -1.0125 -0.0097 -0.5808 -0.0030 -0.0219 -0.1167 -1.1430 -0.1101 -0.0324 -0.0301 -0.7830 -0.0034 -2.4725 -0.0705
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome hazard_ratio
H-1748	-1.5583425760269165	▁en roll ment
D-1748	-1.5583425760269165	enrollment
P-1748	-0.4208 -0.0012 -0.0215 -6.9199 -0.4283
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf blood_glucose obesity systemic_hypertension rheumatic_fever disease
H-1793	-0.6939103603363037	▁ HF ▁risk _ factor s ▁raised _ ▁blood ▁gluco se _ ▁levels ▁obes ity ▁to ba cco ▁system ic _ ▁hyper tension _ SH ▁rhe u matic _ ▁fe ver ▁Cha gas _ مرض
D-1793	-0.6939103603363037	HF risk_factors raised_ blood glucose_ levels obesity tobacco systemic_ hypertension_SH rheumatic_ fever Chagas_مرض
P-1793	-0.6624 -0.0084 -2.5925 -1.4303 -0.0704 -1.2365 -1.5686 -0.4795 -1.1678 -0.5337 -0.0830 -1.9854 -0.5064 -1.4981 -0.0141 -0.0042 -0.0014 -0.0011 -0.0912 -0.0084 -0.5385 -0.3411 -0.0005 -3.8669 -0.2988 -0.0980 -0.0099 -0.0293 -0.3624 -0.0795 -0.0239 -0.8900 -0.0005 -0.9880 -2.3289 -1.6846 -0.1904
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard_ratios confidence_interval hf hf
H-1107	-0.964580774307251	▁age - ▁sex - ad just ed _ risk ▁early - ons et _ HF
D-1107	-0.964580774307251	age- sex-adjusted_risk early-onset_HF
P-1107	-0.4307 -0.4888 -6.7786 -0.0489 -0.0035 -0.0104 -0.0171 -1.3921 -0.7448 -4.2177 -0.0427 -0.0808 -0.3980 -0.9506 -0.0587 -0.5524 -0.1821
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard_ratios crf obese body_mass_index
H-1772	-1.3803772926330566	▁ad just ed ▁hazard _ rati o s ▁low _ C RF _ categorie s ▁obes e ▁body _ index ▁categorie s
D-1772	-1.3803772926330566	adjusted hazard_ratios low_CRF_categories obese body_index categories
P-1772	-0.9212 -0.0057 -0.0299 -4.8078 -1.0048 -0.6810 -0.5576 -2.3329 -0.9552 -1.7263 -2.8438 -0.0702 -3.8961 -1.2498 -0.0125 -4.2258 -0.1034 -1.5223 -0.3166 -1.1411 -2.7609 -0.0253 -1.5925 -0.3464
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline egfr egfr egfr hypertension diuretics esrd
H-395	-0.602398693561554	▁base line ▁e G FR ▁e G FR ▁group ▁un control led _ ▁hyper tension ▁di ure tics
D-395	-0.602398693561554	baseline eGFR eGFR group uncontrolled_ hypertension diuretics
P-395	-0.5803 -0.0024 -0.0047 -0.3968 -0.3051 -2.1152 -0.2690 -0.4928 -1.9270 -1.2249 -0.0016 -0.0056 -0.7413 -0.3098 -0.0030 -0.4674 -0.0266 -0.4957 -2.5388 -0.1398
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial phosphodiesterase-2 pde2 heart_failure hf beta-adrenergic_receptor β-ar healthy diseased cardiomyocytes
H-1208	-1.0056414604187012	▁my o card ial _ phos pho dies tera se -2 ▁p de 2 ▁heart ▁failure ▁ HF ▁p de 2- media ted ▁beta - ad r energi c _ ▁receptor β - AR ▁disease d _ ▁cardio my o cy tes
D-1208	-1.0056414604187012	myocardial_phosphodiesterase-2 pde2 heart failure HF pde2-mediated beta-adrenergic_ receptorβ-AR diseased_ cardiomyocytes
P-1208	-0.2910 -0.2456 -0.9853 -0.2528 -1.3748 -0.3263 -6.2545 -5.0628 -0.5817 -2.0868 -1.6823 -0.4859 -1.6686 -0.9903 -0.4001 -1.1266 -1.6703 -0.0002 -0.5993 -1.0638 -0.3297 -2.0296 -0.0153 -0.6629 -0.0399 -0.0547 -0.6189 -4.5555 -0.7611 -1.0524 -0.0558 -1.7247 -0.0091 -0.2886 -2.2735 -0.0887 -0.4480 -1.0872 -0.2427 -0.2612 -0.2377 -0.1167 -0.0763 -0.0689
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart_failure patients cardiac_resynchronization_therapy defibrillator implantable_cardioverter-defibrillator carvedilol atp shock_therapy metoprolol
H-866	-0.3857131004333496	▁cardiac _ re syn chron ization _ therapy ▁de fi br illa tor ▁implant able ▁cardio ver ter - de fi br illa tor _ ▁device ▁car vedi lol ▁in appropria te ▁ATP _ therapy ▁met o pro lol
D-866	-0.3857131004333496	cardiac_resynchronization_therapy defibrillator implantable cardioverter-defibrillator_ device carvedilol inappropriate ATP_therapy metoprolol
P-866	-0.8250 -0.7283 -0.5985 -0.0021 -0.0020 -0.1708 -1.8691 -0.1191 -0.2549 -0.0199 -1.2211 -0.1081 -0.0167 -0.1340 -0.0020 -0.0727 -0.0439 -0.2096 -0.1110 -0.0062 -0.0347 -0.4609 -0.2753 -0.0407 -0.4630 -1.5380 -0.0507 -0.0041 -0.0041 -1.6011 -0.0004 -0.1207 -0.6539 -2.6933 -0.4126 -0.7717 -0.0227 -0.0040 -0.0087 -0.0932 -0.0455
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich_cocoa skm mitochondrial_structure taub ramirez-sanchez ciaraldi perkins murphy naviaux hogan ceballos maisel henry
H-1245	-0.6225175261497498	▁e pica tech in - rich ▁coco a ▁Sk m ▁mito cho ndri al _ ▁structure
D-1245	-0.6225175261497498	epicatechin-rich cocoa Skm mitochondrial_ structure
P-1245	-2.1783 -0.0017 -0.0313 -0.4611 -0.0479 -0.0027 -0.1734 -0.0066 -1.2069 -0.7110 -0.5604 -1.4040 -0.1025 -0.0029 -0.4241 -0.8148 -2.8804 -0.1955
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up death readmission patients physician physicians
H-1420	-0.8715861439704895	▁follow - up _ ▁visit s ▁risk _ of _ ▁death ▁urgent _ ▁read mission
D-1420	-0.8715861439704895	follow-up_ visits risk_of_ death urgent_ readmission
P-1420	-1.3702 -0.0213 -0.0131 -2.0080 -0.9754 -0.0133 -1.6403 -1.6555 -0.1028 -0.1105 -2.1457 -1.4297 -0.0205 -0.9678 -0.0192 -2.1135 -0.2103
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena_overexpression tac surgery mena cardiac_hypertrophy cardiac
H-1816	-0.903235137462616	▁Men a ▁over expression ▁ TTA / t g t t t t t t t t t _ Men a _ mi ce ▁ TAC
D-1816	-0.903235137462616	Mena overexpression TTA/tgttttttttt_Mena_mice TAC
P-1816	-1.7827 -0.1145 -3.1000 -0.1404 -0.1735 -0.0101 -0.7301 -1.2350 -0.2134 -0.4080 -0.8891 -0.6683 -0.6509 -0.7210 -0.7948 -0.8822 -0.9506 -1.0065 -3.0443 -0.0201 -0.0171 -2.2915 -0.2783 -0.0143 -0.2804 -0.0069 -4.5501 -0.3167
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd diuretic hf outcomes clinical hospitalizations pdrelated complications
H-901	-0.5387861132621765	▁institution ▁di ure tic _ re frac tory ▁severe - end - s tage ▁ HF
D-901	-0.5387861132621765	institution diuretic_refractory severe-end-stage HF
P-901	-3.8065 -0.3181 -0.0357 -0.2158 -0.2278 -0.3363 -0.0008 -0.0160 -1.1443 -0.1657 -0.6978 -0.0237 -0.0602 -0.0002 -0.5249 -0.0010 -2.0607 -0.0628
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp mitochondrial_oxidation glucose lactate fatty_acids myocardial glycolysis
H-1785	-0.5433489084243774	▁ATP _ product ion ▁mito cho ndri al _ ▁oxid ation ▁gluco se ▁lac tate ▁fa tty _ ▁acid s ▁my o card ial _ ▁gly col ysis
D-1785	-0.5433489084243774	ATP_production mitochondrial_ oxidation glucose lactate fatty_ acids myocardial_ glycolysis
P-1785	-0.6011 -2.9343 -0.2451 -0.0927 -3.2368 -0.4407 -0.1026 -0.0011 -1.1847 -0.1579 -0.0153 -0.0920 -0.4143 -0.0042 -0.0050 -0.0048 -0.0575 -0.5017 -3.6308 -0.2249 -0.1848 -0.0316 -0.5610 -0.0818 -0.5660 -0.1984 -0.0139 -0.3632 -0.2323 -0.1200
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic vegf_pathway intravenously injected adenoviral vegf_receptor adenovirus
H-456	-0.5792995691299438	▁pro angi ogen ic _ effect s ▁B ▁activa tion ▁ve GF _ path way ▁a den ovi ral _ ▁ve ctor ▁de co y _ ve GF _ ▁receptor ▁control _ a den ovi ral _ virus ▁ad - C
D-456	-0.5792995691299438	proangiogenic_effects B activation veGF_pathway adenoviral_ vector decoy_veGF_ receptor control_adenoviral_virus ad-C
P-456	-0.0150 -0.0099 -0.1325 -0.1426 -2.2609 -1.1875 -0.9150 -2.1999 -3.2827 -0.0041 -0.9325 -0.1222 -0.3378 -0.3523 -0.0235 -0.0857 -0.0033 -0.1894 -0.0109 -0.6476 -0.7677 -0.0015 -0.0415 -0.0003 -0.0351 -0.6361 -1.1309 -1.7558 -0.6411 -0.0281 -0.4969 -0.4884 -2.5977 -0.4099 -0.5303 -0.4498 -0.2301 -0.3376 -0.2216 -0.0147 -0.4590 -0.6928 -0.0879
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients eplerenone potassium potassium hospitalization hyperkalemia medication adverse_events
H-1226	-0.7084696292877197	▁e pler en one ▁po tas s ium ▁po tas s ium ▁hyper kal emia
D-1226	-0.7084696292877197	eplerenone potassium potassium hyperkalemia
P-1226	-0.9707 -0.0239 -0.9883 -0.2896 -0.0524 -0.1381 -0.2914 -0.6354 -2.2551 -0.2335 -0.0729 -1.3214 -2.1858 -0.1370 -0.0219 -2.2788 -0.1475
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation bottleneck_stent lad lcx myocardial_ischemia stent ischemic_heart_failure stent therapeutic
H-514	-0.5053718686103821	▁bottle ne ck _ ▁sten t ▁proxima l ▁ LAD ▁ LC X ▁rever sible _ ▁my o card ial _ ische mia ▁open _ ▁sten t ▁ ische mic _ heart _ ▁failure
D-514	-0.5053718686103821	bottleneck_ stent proximal LAD LCX reversible_ myocardial_ischemia open_ stent ischemic_heart_ failure
P-514	-0.4061 -0.0177 -0.0018 -0.6059 -0.2769 -0.0302 -0.0024 -0.0004 -0.1075 -0.0002 -1.6760 -0.0022 -0.3384 -0.8326 -0.0002 -0.7432 -2.6545 -0.0749 -0.2825 -0.0090 -0.1889 -3.1976 -0.0552 -0.2981 -0.2667 -0.1249 -0.0324 -0.6252 -0.0942 -0.0159 -0.1395 -1.1449 -0.4694 -1.6985 -1.6653 -0.1142
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient new_york_heart_association_class_iii heart_failure hf left_ventricular_ejection_fraction periodic_breathing pb report
H-1347	-1.301735520362854	▁New ▁York _ heart _ association _ class ▁III _ of _ heart _ fail ▁ HF ▁le ft _ wind ri cular _ e je ction ▁p b
D-1347	-1.301735520362854	New York_heart_association_class III_of_heart_fail HF left_windricular_ejection pb
P-1347	-4.5892 -1.3835 -0.4009 -1.6526 -0.1786 -0.5878 -1.9770 -0.2396 -0.4053 -0.3275 -2.5615 -0.0432 -1.5414 -0.2511 -5.3018 -3.7077 -0.2516 -0.4760 -0.0085 -0.1107 -5.5972 -2.5328 -0.7583 -0.2261 -0.4267 -0.0547 -0.0198 -2.7193 -1.4532 -0.4506 -0.1199
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium spironolactone aas
H-1705	-0.6174108982086182	▁po tas s ium ▁spi rono lac tone ▁non - AA s
D-1705	-0.6174108982086182	potassium spironolactone non-AAs
P-1705	-0.7775 -0.3679 -0.1242 -0.6411 -0.0286 -0.0030 -0.0451 -0.0101 -0.9878 -0.0033 -0.0003 -0.0100 -5.4575 -0.1873
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom cpet patients chf patients exercise exercise patients exercise rehabilitation
H-1880	-1.3576313257217407	▁symptom _ limit ▁maximal _ C PET ▁CHF ▁control ▁exercise
D-1880	-1.3576313257217407	symptom_limit maximal_CPET CHF control exercise
P-1880	-0.4745 -2.1640 -1.3512 -2.6827 -0.4880 -2.3390 -0.0005 -0.7790 -2.2529 -0.1719 -3.5423 -0.0455
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography lv_end-diastolic_volume mitral_valve_opening mva
H-357	-0.6132619380950928	▁e cho card i ography ▁re duction ▁LV ▁end - dia sto lic ▁volume ▁disappear ance ▁MR ▁mit ral _ ▁val ve _ ▁opening ▁mean ▁pressure _ ▁gradi ent
D-357	-0.6132619380950928	echocardiography reduction LV end-diastolic volume disappearance MR mitral_ valve_ opening mean pressure_ gradient
P-357	-0.3610 -0.2303 -1.0587 -0.2752 -0.2914 -2.0948 -0.0001 -0.3508 -0.3203 -0.0202 -0.0075 -0.9841 -0.1482 -0.8651 -1.1422 -0.0009 -0.0869 -0.0393 -0.0065 -0.5370 -1.0233 -0.0103 -3.4826 -0.2966 -0.4372 -1.6280 -1.3996 -0.9367 -0.0281 -0.8550 -0.0929
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical post-lvad_ai aortic_valve leaflet bioprosthetic_aortic_valve_replacement functional_capacity lvad patients symptomatic
H-552	-0.5332987904548645	▁post - L VAD ▁a or tic _ val ve ▁over se wing ▁le a flet ▁repair ▁bio pro sthetic ▁a or tic _ val ve _ ▁replace ment ▁CF _ L VAD
D-552	-0.5332987904548645	post-LVAD aortic_valve oversewing leaflet repair bioprosthetic aortic_valve_ replacement CF_LVAD
P-552	-0.4405 -0.0177 -1.6477 -0.0038 -1.0656 -0.3091 -0.0622 -0.1625 -1.9912 -0.2608 -1.2597 -0.0070 -0.0032 -0.0025 -0.0039 -0.0003 -1.4010 -0.0254 -0.0009 -0.0003 -0.1644 -0.0561 -0.0132 -0.0360 -1.0819 -0.0834 -0.5368 -0.2161 -0.0075 -1.6284 -0.6412 -1.5142 -0.0196 -3.9324 -0.0691
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods_study health_care systolic_heart_failure prescribed β-blocker angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blocker
H-1123	-1.0030251741409302	▁veteran s ▁va ▁health _ care ▁systems ▁sy sto lic _ heart _ ▁failure ▁β - block er ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block er
D-1123	-1.0030251741409302	veterans va health_care systems systolic_heart_ failure β-blocker angiotensin_ converting_ enzyme_ inhibitor angiotensin-receptor_blocker
P-1123	-5.9909 -0.0445 -4.7611 -0.6477 -3.0985 -0.6484 -0.5991 -0.2060 -0.0202 -0.2184 -0.3292 -0.7048 -0.8512 -1.2370 -1.1036 -0.0232 -0.0823 -0.5026 -0.0234 -0.7493 -2.9642 -0.9231 -3.1439 -5.8230 -0.2194 -0.4404 -0.6252 -0.0710 -1.6228 -0.3425 -0.0169 -0.0594 -0.4182 -0.8123 -0.2576 -1.2498 -0.2086 -0.2886 -0.2501 -1.0435 -0.0613 -0.3136 -0.1332
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced_pulmonary_artery_systolic_pressure pasp stress_doppler_echocardiography right_ventricular_contractile_reserve patients pulmonary_hypertension right_heart_failure
H-822	-0.8513531684875488	▁exercise - indu ced ▁pulmonar y _ ▁arter y _ ▁sy sto lic _ ▁pressure ▁stress _ do pp ler _ e cho card i ography ▁right _ vent ri cular _ contract ile _ ▁reserve ▁pulmonar y _ ▁hyper tension ▁right _ heart _ ▁failure
D-822	-0.8513531684875488	exercise-induced pulmonary_ artery_ systolic_ pressure stress_doppler_echocardiography right_ventricular_contractile_ reserve pulmonary_ hypertension right_heart_ failure
P-822	-0.1539 -0.1646 -0.0088 -0.0177 -0.1158 -0.0385 -0.3972 -3.3209 -0.0474 -0.2924 -5.5142 -0.2371 -1.2631 -0.2129 -0.6520 -1.0921 -0.8775 -0.8945 -0.0046 -0.0483 -0.5701 -1.0138 -0.3881 -1.4512 -0.0684 -0.3462 -0.0098 -0.3356 -6.1506 -1.1574 -0.2595 -0.1191 -2.8307 -2.7060 -0.9327 -1.0258 -1.3261 -0.0038 -0.3035 -1.7994 -0.0018 -0.0344 -0.1558 -0.7728 -0.7979 -0.8553 -0.0428 -0.0529
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline embase healthstar cinahl cochrane_library campbell_collaboration joanna_briggs_institute_evidence_based_practice centre_for_reviews_and_dissemination evidence_based_practice_centres
H-1844	-0.5939838290214539	▁literature _ search ▁MED LINE ▁ EMBA SE ▁HE al th STAR ▁c INA HL ▁co ch rane _ ▁Library ▁Campbell _ col labora tion ▁Joan na ▁Brig gs ▁Institute ▁e viden ce _ base d _ prac tice _ centre s
D-1844	-0.5939838290214539	literature_search MEDLINE EMBASE HEalthSTAR cINAHL cochrane_ Library Campbell_collaboration Joanna Briggs Institute evidence_based_practice_centres
P-1844	-2.0959 -2.0667 -0.4863 -0.3932 -1.0636 -0.2335 -0.0006 -0.5018 -1.7105 -0.8888 -0.7547 -1.1277 -1.5229 -0.2808 -0.9593 -1.2319 -0.0053 -0.0004 -0.5330 -0.0537 -0.3614 -1.0123 -0.4864 -0.0097 -0.0079 -0.0045 -0.0041 -0.0188 -0.0046 -0.6989 -2.3974 -0.0007 -0.0008 -0.7891 -0.6053 -0.0535 -0.1436 -0.5550 -0.0142 -2.1579 -0.3591 -0.0967 -0.2933 -0.1497
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart_failure neuro-hormonal_system angiotensin_converting_enzyme_inhibitors angiotensin_receptor_blockers angiotensin_converting_enzyme_inhibitors beta_receptor_blockers mineralocorticoid_receptor_antagonists
H-647	-0.7868111729621887	▁heart _ ▁failure ▁block ade ▁neuro - hormon al _ system ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor _ ▁block ers ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tors _ in tolerance ▁mineral o cor tico id _ ▁receptor ▁anta gon ists
D-647	-0.7868111729621887	heart_ failure blockade neuro-hormonal_system angiotensin_ converting_ enzyme_ inhibitorsangiotensin_ receptor_ blockers angiotensin_ converting_ enzyme_ inhibitors_intolerance mineralocorticoid_ receptor antagonists
P-647	-5.1312 -1.2846 -3.2265 -0.1563 -0.0060 -0.0429 -0.0862 -0.0036 -0.0030 -0.9351 -0.0285 -0.0015 -0.0463 -0.8227 -0.4263 -2.4464 -0.4083 -0.1178 -0.6027 -0.3509 -0.0469 -1.6961 -0.1758 -0.0467 -2.7221 -0.0455 -0.1053 -0.3435 -0.7148 -0.8911 -2.2837 -0.0678 -0.1142 -0.0352 -0.1355 -0.1391 -0.8304 -0.8533 -0.1107 -0.1554 -1.0316 -0.0414 -1.0075 -0.2733 -0.0630 -2.2730 -3.2854 -0.0077 -0.2020 -0.1296 -1.9419 -3.7445 -2.1903 -0.7975 -0.0586 -0.8269 -0.0157 -1.3528 -0.2562 -0.0700
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest rs rs_synchrony ste noninvasive rvpo rs_synchrony strain bivp
H-330	-0.8921517133712769	▁open _ ▁che st ▁twist ▁twist ▁RS ▁RS ▁synchron y ▁ STE ▁regional _ ▁strain ▁bi VP
D-330	-0.8921517133712769	open_ chest twist twist RS RS synchrony STE regional_ strain biVP
P-330	-0.1826 -0.3934 -1.5814 -0.0018 -0.2152 -0.5149 -0.0256 -0.7344 -0.0116 -0.0521 -0.5241 -0.4902 -6.3590 -0.4720 -1.5982 -1.4268 -0.0312 -2.1469 -0.1896
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse pasp tapse pasp cox_regression kaplan-meier_analyses tapse pasp
H-498	-0.8536167740821838	▁T AP se - to - PAS p _ rati o ▁co x ▁re gression ▁Ka plan - me ier
D-498	-0.8536167740821838	TAPse-to-PASp_ratio cox regression Kaplan-meier
P-498	-1.9057 -0.3633 -1.2917 -2.9472 -0.1557 -0.0094 -0.3542 -1.2569 -1.3631 -0.5796 -0.0358 -3.0826 -0.1503 -0.7473 -0.0029 -0.2623 -0.0464 -0.0240 -0.5895 -0.2701 -3.2035 -0.1380
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese body_mass_index chronic stable hfpef
H-1978	-1.5627108812332153	▁obes e _ ▁participants ▁body ▁mass ▁index ▁chronic _ ▁stable _ h FP EF
D-1978	-1.5627108812332153	obese_ participants body mass index chronic_ stable_hFPEF
P-1978	-4.7741 -0.1300 -2.9433 -3.4094 -1.0528 -2.3670 -0.6756 -0.7351 -1.7133 -1.9810 -0.7394 -2.1185 -0.1879 -0.6373 -1.4573 -0.0813
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart_failure hf mrna_splicing cardiac scn5a endoplasmic_reticulum
H-1080	-0.5845803022384644	▁human _ heart _ ▁failure ▁m RNA ▁s plic ing ▁volta ge - ga ted _ ▁cardiac _ na + ▁channel ▁α - sub un it ▁en co ding ▁tru nca ted ▁en do plas mic _ ▁reti culum
D-1080	-0.5845803022384644	human_heart_ failure mRNA splicing voltage-gated_ cardiac_na+ channel α-subunit encoding truncated endoplasmic_ reticulum
P-1080	-0.9094 -0.9847 -0.8712 -0.3973 -0.6601 -1.7373 -0.0043 -1.6015 -0.0001 -0.0079 -0.0604 -0.0008 -0.0459 -0.0066 -0.0076 -0.9106 -0.6283 -0.5478 -1.1379 -5.3070 -0.9127 -1.9985 -0.0036 -0.0026 -0.0193 -0.0830 -0.3028 -0.0208 -0.1124 -0.0644 -0.0058 -0.0043 -1.3054 -0.3543 -0.5330 -1.9218 -0.2633 -0.0360 -0.0006 -0.1349 -0.0614
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart_failure diagnosis myocarditis dilated_cardiomyopathy heart_failure heart_failure anthracycline disease
H-988	-0.9170105457305908	▁pa e dia tric _ heart _ ▁failure ▁my o card itis ▁dil ated _ ▁cardio my o pathy ▁new ▁ons et _ ▁heart _ ▁failure ▁an thra cycli ne ▁child hood _ cancer _ therapie s
D-988	-0.9170105457305908	paediatric_heart_ failure myocarditis dilated_ cardiomyopathy new onset_ heart_ failure anthracycline childhood_cancer_therapies
P-988	-0.8348 -0.0408 -0.1166 -0.4848 -0.9005 -1.1937 -0.9494 -0.7405 -2.4729 -0.0953 -2.4007 -0.1096 -0.1601 -0.0367 -0.1532 -0.2219 -1.4406 -0.0771 -0.0738 -2.9933 -0.7963 -0.0284 -1.2263 -1.5875 -0.3443 -0.9442 -0.9586 -0.0051 -1.3254 -0.6235 -4.6008 -0.2889 -0.5626 -1.7358 -1.9687 -2.1793 -0.5592 -0.4091 -0.1229
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model clinical evidence-based medications costs outcomes
H-2010	-0.5740538239479065	▁economic _ analys is ▁Patient _ management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁cost - E ff ective ness _ model
D-2010	-0.5740538239479065	economic_analysis Patient_management_ Interventions Heart_ Failure cost-Effectiveness_model
P-2010	-0.4421 -0.4600 -0.4193 -0.1504 -3.0329 -0.5476 -0.4028 -0.1446 -0.8250 -0.0036 -0.0380 -0.0457 -0.9712 -0.0209 -0.8546 -0.0660 -0.9300 -0.9113 -0.1911 -0.3747 -0.8296 -0.1505 -1.8806 -0.0848
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic_peptides nps b-type_np n-terminal_pro-b-type_np diagnosis acute_heart_failure patients emergency_department acute_dyspnea
H-1020	-0.6072913408279419	▁na tri ure tic _ pe pti des ▁b - type ▁ NP ▁N - termin al ▁pro - B - type ▁ NP ▁a cute _ dis pne a
D-1020	-0.6072913408279419	natriuretic_peptides b-type NP N-terminal pro-B-type NP acute_dispnea
P-1020	-0.0014 -0.1074 -0.2649 -1.3347 -0.5889 -0.1357 -0.1573 -0.7906 -3.1745 -0.0303 -0.0294 -0.5430 -0.0010 -0.7839 -0.0355 -0.0246 -0.0004 -0.2721 -0.0207 -0.3008 -0.0225 -0.0121 -0.5465 -0.0009 -0.1708 -0.0101 -0.1751 -6.8798 -1.9077 -0.0950 -0.7590 -0.2566
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak_oxygen_consumption peak_vo2 exercise exercise_oscillatory_ventilation eov partial_pressure_of_end-tidal_co2 petco2 gain cardiopulmonary_exercise_testing
H-1275	-0.7794150710105896	▁pe ak _ velo 2 ▁ ven / v co 2 ▁s lope ▁exercise ▁os cilla tory _ ▁ventilation ▁e OV ▁parti al _ press ed _ co 2 PET co 2 ▁cardio pul mon ary _ test
D-1275	-0.7794150710105896	peak_velo2 ven/vco2 slope exercise oscillatory_ ventilation eOV partial_pressed_co2PETco2 cardiopulmonary_test
P-1275	-0.0038 -0.0015 -0.2180 -2.3491 -1.9148 -1.0018 -0.6893 -0.9603 -0.9835 -0.3811 -0.0299 -0.2161 -0.0051 -0.0194 -0.5592 -0.0021 -0.0027 -0.9120 -0.1962 -1.1826 -0.0312 -0.1312 -0.0012 -0.5117 -4.8146 -2.9743 -0.8997 -3.9801 -0.3452 -0.3564 -0.8525 -0.2505 -0.8076 -0.0236 -0.0488 -0.0362 -0.5516 -2.5467 -0.2734 -0.1115
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective_cohort_study denmark bisphosphonates raloxifene
H-1536	-1.1630297899246216	▁national _ ▁retro spec tive _ co hor t _ ▁study ▁bis phos phon ates ▁ra lo xi fen e ▁general _ ▁population
D-1536	-1.1630297899246216	national_ retrospective_cohort_ study bisphosphonates raloxifene general_ population
P-1536	-7.2719 -3.8271 -2.6508 -0.0010 -0.0059 -0.5771 -0.3201 -0.0396 -0.1698 -2.1833 -2.0217 -3.7821 -0.0214 -1.4084 -0.1470 -0.3158 -0.0450 -0.0825 -1.1674 -0.1831 -0.7117 -0.5792 -0.1515 -1.2204 -0.1921
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal strain left_ventricle echocardiographic patients baseline echocardiography crt follow-up echocardiograms
H-429	-0.5769164562225342	▁longitud in al _ ▁strain ▁left _ ▁vent ric le ▁e cho car dio graphic _ ▁measure ments ▁base line ▁e cho card i ography ▁follow - up ▁e cho card i ogram s
D-429	-0.5769164562225342	longitudinal_ strain left_ ventricle echocardiographic_ measurements baseline echocardiography follow-up echocardiograms
P-429	-1.1160 -0.0284 -0.0208 -0.3636 -2.3012 -1.4206 -0.1143 -3.5779 -1.4074 -0.4695 -0.3001 -0.0271 -0.1784 -0.5687 -0.4868 -1.6830 -0.5722 -0.0222 -2.0072 -0.0032 -0.3519 -0.0830 -0.4125 -0.4819 -0.1525 -0.7452 -0.0130 -0.0102 -0.6331 -0.0628 -0.4663 -0.1370 -0.1042 -0.3019 -0.0923 -0.0526
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension lv_dilatation lv_dysfunction mitral_valve organic lesion systolic diastolic_tethering etiology
H-365	-0.7547969222068787	▁severe ▁hyper tension ▁LV ▁di la tation ▁LV ▁dys function ▁mild ▁MR ▁mit ral _ ▁val ve ▁restrict ed _ closure ▁organic _ les ion ▁sy sto lic ▁dia sto lic _ ▁te ther ing
D-365	-0.7547969222068787	severe hypertension LV dilatation LV dysfunction mild MR mitral_ valve restricted_closure organic_lesion systolic diastolic_ tethering
P-365	-2.2301 -0.7522 -0.0026 -0.0971 -0.6964 -0.0184 -0.0022 -0.1867 -0.5851 -0.0158 -1.4265 -0.2097 -3.6424 -0.0131 -0.3613 -2.0071 -0.0196 -3.6130 -0.0003 -0.7318 -0.1154 -3.0329 -0.5470 -1.9430 -0.3525 -0.0882 -0.0083 -0.0514 -1.3318 -0.2440 -0.2876 -0.5473 -0.2258 -0.0084 -0.0068 -2.4429 -0.0828
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl healthy hdl healthy patients chf-nyha-iii hdl nyha-iiib patients chf-nyha-ii hdl nyha-ii
H-250	-1.1741660833358765	▁HD L _ control s ▁CHF - NY HA - III HD L _ NY HA - II
D-250	-1.1741660833358765	HDL_controls CHF-NYHA-IIIHDL_NYHA-II
P-250	-1.8117 -1.3220 -4.4045 -1.5086 -0.0833 -0.8275 -0.0440 -0.0278 -0.0233 -0.3311 -0.0569 -4.8280 -0.5371 -2.7131 -1.9513 -0.0350 -0.2410 -1.6139 -1.0529 -0.0701
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating_factor paf metabolic enzymes follow-up patients diagnosed heart_failure hf healthy
H-1267	-0.9277637600898743	▁plate let - activa ting _ factor _ PA F ▁metabol ic _ ▁enzym es
D-1267	-0.9277637600898743	platelet-activating_factor_PAF metabolic_ enzymes
P-1267	-1.2444 -2.8403 -0.1311 -0.0343 -0.1854 -0.5125 -0.0373 -3.2751 -1.5341 -0.2788 -0.0016 -0.0224 -0.7568 -0.0335 -0.0101 -4.7801 -0.0942
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute_care_surgery acs consultations oht transplantation medical_therapy intravenous inotropes ventricular_assist_devices vads
H-1281	-0.7058654427528381	▁a cute _ care ▁surgery ▁o HT ▁transplant ation ▁medical _ therapy ▁intra ven ous ▁in o trop es ▁vent ri cular _ assist ▁devices VAD s
D-1281	-0.7058654427528381	acute_care surgery oHT transplantation medical_therapy intravenous inotropes ventricular_assist devicesVADs
P-1281	-0.0406 -0.0094 -0.9232 -4.2654 -2.4725 -2.8876 -1.3249 -2.2193 -0.0424 -0.1217 -0.9921 -0.0420 -0.0136 -0.0023 -0.2889 -0.3765 -0.2408 -0.0526 -0.6113 -0.0325 -0.1118 -0.0898 -0.5382 -0.0343 -1.1649 -1.0526 -0.2575 -0.1481 -0.1133
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone_system raas hfref angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers aldosterone_blockade evidence hfpef
H-1489	-0.46362677216529846	▁re nin - angi oten sin - al do ster one _ system ▁re nin - angi oten sin - al do ster one _ system ▁RA AS ▁ang io ten sin _ con ver ting _ ▁enzym e ▁inhibi tors ▁ang io ten sin _ ▁receptor _ block ers ▁al do ster one _ block ade ▁ HF p EF
D-1489	-0.46362677216529846	renin-angiotensin-aldosterone_system renin-angiotensin-aldosterone_system RAAS angiotensin_converting_ enzyme inhibitors angiotensin_ receptor_blockers aldosterone_blockade HFpEF
P-1489	-0.0015 -0.0151 -0.0292 -0.0085 -0.0359 -0.4741 -0.1075 -0.0268 -3.4653 -1.2571 -0.1385 -1.3305 -0.0915 -1.3416 -0.0396 -0.0091 -0.0289 -0.0950 -0.2688 -0.1636 -0.1028 -1.1990 -0.5962 -0.0802 -0.8507 -0.0641 -3.4161 -0.2393 -0.0914 -0.3843 -0.6550 -0.2393 -1.2728 -0.0094 -0.0740 -0.0477 -0.7400 -0.0755 -0.0259 -0.9601 -0.0366 -0.1365 -0.2871 -0.4156 -0.2061 -0.3945 -0.4644 -0.8638 -2.2234 -0.8283 -0.0441 -0.0195 -0.0793 -0.0765 -0.9969 -1.0631 -0.5334 -0.3045 -0.0007 -0.0169 -0.0968 -0.0205 -0.0481
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients hfpef ivabradine exercise_capacity left_ventricular_filling_pressure exercise peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1178	-0.7346779704093933	▁ HF p EF ▁i va bra dine ▁exercise _ capaci ty ▁left ▁vent ri cular ▁fill ing _ ▁pressure ▁exercise ▁pe ak ▁early _ dia sto lic _ mit ral _ velo city
D-1178	-0.7346779704093933	HFpEF ivabradine exercise_capacity left ventricular filling_ pressure exercise peak early_diastolic_mitral_velocity
P-1178	-0.8946 -0.1548 -0.8435 -0.6585 -0.0589 -0.2452 -0.0909 -0.0043 -2.2394 -3.2024 -0.4822 -0.5490 -0.1290 -0.9459 -0.1906 -0.0646 -1.3036 -0.0122 -0.3045 -1.3043 -0.8779 -1.1268 -0.0033 -1.0113 -0.5848 -0.0872 -0.4299 -1.0234 -0.2007 -4.5253 -0.2488 -0.2446 -1.3539 -0.0206 -0.9409 -0.0907
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission lvet patients outcome tonometric
H-583	-0.7701208591461182	▁ad mission ▁l VET ▁un favor able ▁outcome
D-583	-0.7701208591461182	admission lVET unfavorable outcome
P-583	-0.8729 -0.0169 -2.4817 -0.2599 -0.5342 -0.0118 -0.0102 -1.0168 -2.2349 -0.2619
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart_rate blood_pressure renal_function spironolactone ras_blockers β-blockers
H-182	-0.618968665599823	▁heart ▁rate ▁blood ▁pressure ▁renal _ function ▁spi rono lac tone ▁ RAS _ block ers ▁β - block ers
D-182	-0.618968665599823	heart rate blood pressure renal_function spironolactone RAS_blockers β-blockers
P-182	-3.1057 -0.1231 -2.2888 -1.2190 -0.4671 -1.4173 -0.4529 -0.0065 -0.0013 -0.0147 -0.0132 -1.2048 -0.1671 -1.1264 -0.4580 -0.0325 -0.6702 -0.0188 -0.2542 -0.0530 -0.4180 -0.1044
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac β-adrenoceptor_blockade heart_failure reverse cardiac_remodeling elevated plasma_catecholamines
H-1553	-0.8133810758590698	▁cardiac _ ▁performance ▁β - ad re no cept or _ block ade ▁heart _ ▁failure ▁SR _ ca (2 +) - pump ▁rever se ▁cardiac _ ▁remodel ing ▁plasma ▁cate chol amine s
D-1553	-0.8133810758590698	cardiac_ performance β-adrenoceptor_blockade heart_ failure SR_ca(2+)-pump reverse cardiac_ remodeling plasma catecholamines
P-1553	-2.0246 -1.4910 -1.4728 -0.1852 -0.0277 -0.0078 -0.6577 -2.2135 -4.6331 -2.1192 -0.4774 -0.9447 -0.2940 -1.3357 -0.3004 -1.4710 -1.1787 -0.9658 -0.0394 -1.5511 -0.0020 -0.0865 -0.0029 -1.3121 -0.0047 -1.1262 -0.8614 -0.0749 -0.0842 -1.1228 -0.6632 -0.0031 -0.1556 -0.0741 -0.2155 -0.1018
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 congestive_heart_failure phenotypes mitochondrial tac mitochondrial_proteome mitochondrial nonmitochondrial_protein
H-874	-0.9454911351203918	▁con ges tive _ heart _ ▁failure _ ▁ph eno type s ▁mito cho ndri al ▁ TAC
D-874	-0.9454911351203918	congestive_heart_ failure_ phenotypes mitochondrial TAC
P-874	-0.3507 -0.0505 -0.0431 -0.2884 -3.4742 -0.3558 -4.6173 -0.9315 -0.5546 -0.0209 -0.0050 -0.0200 -0.0034 -1.6008 -0.1300 -0.0027 -2.3624 -0.0017 -3.8899 -0.2069
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action randomized exercise training patients hf left_ventricular_ejection_fractions hrqol kansas_city_cardiomyopathy_questionnaire kccq baseline
H-837	-0.8295235633850098	▁ HF - AC TION ▁exercise _ ▁training ▁ HF ▁low _ wind ri cular _ e je ction _ fraction s ▁HR Qo L ▁Kansas _ city ▁Card i om yo pathy _ ▁Question naire ▁k cc q
D-837	-0.8295235633850098	HF-ACTION exercise_ training HF low_windricular_ejection_fractions HRQoL Kansas_city Cardiomyopathy_ Questionnaire kccq
P-837	-0.1319 -0.0261 -0.0873 -0.4347 -0.6758 -0.9462 -2.1148 -0.8102 -0.7392 -0.0109 -0.9311 -0.5624 -4.3492 -1.8744 -0.4934 -0.1505 -0.5625 -0.2075 -0.2729 -0.7148 -0.0118 -0.0872 -0.0952 -0.0373 -0.2136 -0.0226 -1.4531 -0.3459 -1.6192 -0.0729 -0.2479 -4.8852 -3.3270 -1.6516 -0.4254 -0.0237 -1.9348 -0.8889 -0.4329 -0.0347 -0.1040
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan hyponatremia united_states japan congestive_heart_failure patients diuretic therapy serum_sodium systolic_function
H-1196	-0.9096349477767944	▁to lv ap tan ▁con ges tive _ heart _ ▁failure ▁di ure tic _ therapy ▁se rum ▁so dium _ level ▁sy sto lic
D-1196	-0.9096349477767944	tolvaptan congestive_heart_ failure diuretic_therapy serum sodium_level systolic
P-1196	-0.2538 -0.8097 -0.2778 -0.1467 -3.7626 -0.2554 -0.0287 -0.5185 -1.4336 -0.9346 -1.3243 -4.2173 -0.3337 -0.4695 -1.6248 -2.2025 -0.2746 -0.0009 -0.7964 -0.0574 -2.0170 -0.6941 -0.0143 -0.0433 -0.5121 -1.4607 -0.0958
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar atpase activity mrna phospholamban α-myosin_heavy_chain mrna β-myosin_heavy_chain metoprolol
H-1552	-0.5477123260498047	▁de press ed ▁my o fi bril lar _ ca (2 +) - stimul ated _ ▁ATP _ activ ity ▁m RNA _ level ▁SR _ ca (2 +) - pump ▁ phos pho lam ban ▁α - my os in _ ▁heavy _ ▁chain ▁met o pro lol
D-1552	-0.5477123260498047	depressed myofibrillar_ca(2+)-stimulated_ ATP_activity mRNA_level SR_ca(2+)-pump phospholamban α-myosin_ heavy_ chain metoprolol
P-1552	-2.6421 -0.0277 -0.1345 -0.5005 -0.0656 -0.0986 -0.0247 -0.2244 -1.2968 -0.1025 -1.6267 -0.0807 -0.0469 -0.2483 -0.0750 -0.4989 -2.6062 -5.6153 -0.5544 -0.2957 -0.2108 -0.0106 -3.5131 -0.3524 -0.8016 -0.8928 -0.0205 -0.3239 -0.0013 -0.0191 -0.0029 -0.0367 -0.0009 -0.0876 -0.2165 -0.0256 -0.0363 -0.0078 -0.2209 -0.1074 -0.5638 -0.2700 -0.5481 -1.0902 -0.1397 -1.4342 -0.0463 -0.0135 -0.0202 -0.0831 -0.0699
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized coronary_microembolization-induced_hf cxl-1020 left_ventricular_end-diastolic_pressure myocardial_oxygen_consumption ejection_fraction maximal_ventricular_power_index
H-420	-0.5949059724807739	▁corona ry _ micro e mbol ization - indu ced ▁ HF ▁left ▁vent ri cular _ ▁end - dia sto lic _ ▁pressure ▁my o card ial _ ▁oxygen ▁e je ction _ fraction ▁vent ri cular _ power _ index
D-420	-0.5949059724807739	coronary_microembolization-induced HF left ventricular_ end-diastolic_ pressure myocardial_ oxygen ejection_fraction ventricular_power_index
P-420	-0.8437 -0.0429 -0.7544 -1.6621 -0.5996 -0.0010 -0.2626 -0.5391 -0.0041 -0.0034 -0.0925 -0.0016 -2.4610 -2.0886 -0.6081 -0.1202 -0.7716 -1.4682 -0.0228 -0.0074 -0.4205 -0.7012 -0.6348 -1.3441 -0.1131 -0.0417 -1.0111 -0.0503 -0.0815 -3.3448 -0.4552 -0.0083 -0.0039 -1.1156 -0.4072 -1.4132 -0.1226 -0.0937 -0.1482 -0.3260 -1.3109 -0.3816 -0.1830 -0.1082
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline heart_failure t1-mapping administration administration
H-1061	-1.1355245113372803	▁base line ▁heart _ ▁failure ▁t 1- ma pping _ ▁values ▁administration ▁contrast _ agent
D-1061	-1.1355245113372803	baseline heart_ failure t1-mapping_ values administration contrast_agent
P-1061	-0.2976 -0.0058 -1.9396 -0.7090 -3.9327 -2.5946 -0.0825 -0.0247 -0.0051 -2.4859 -3.7189 -0.0670 -0.8279 -0.5213 -0.0498 -1.9071 -0.1347
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard_error_of_measurement mdc mdc
H-805	-0.8397218585014343	▁standard _ error _ of _ ▁measure ment _ ▁value ▁M DC ▁95% ▁confidence _ level
D-805	-0.8397218585014343	standard_error_of_ measurement_ value MDC 95% confidence_level
P-805	-0.2315 -1.1012 -2.6197 -0.9415 -0.4085 -0.5405 -0.0990 -0.0091 -0.3560 -0.7200 -0.9672 -0.0130 -2.3736 -0.4033 -1.3099 -0.5643 -2.2415 -0.2154
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies hf idiopathic_dilated_cardiomyopathy ischemic valvular
H-1794	-0.5787862539291382	▁ HF ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy ▁c ' d ▁ ische mic ▁SH ▁val vu lar ▁alcohol
D-1794	-0.5787862539291382	HF idiopathic dilated_ cardiomyopathy c'd ischemic SH valvular alcohol
P-1794	-0.5673 -0.4044 -1.6161 -3.3912 -0.0580 -0.4621 -0.1201 -0.1831 -0.0753 -2.3760 -1.8147 -0.8904 -0.0274 -0.5294 -0.7092 -0.3796 -0.0228 -0.0646 -0.0086 -0.5511 -0.1534 -0.0110 -0.0788 -0.0527 -0.4355 -0.0654
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 functional_capacity clinical outcomes ambulatory patients hf heart_failure outcomes exercise training hf-action randomized exercise training hf
H-697	-0.5336723327636719	▁ST 2 _ level ▁functional _ capaci ty ▁ambula tory ▁patients ▁ HF ▁Heart _ ▁Fail ure ▁control led _ Tri al _ ▁Investiga ting _ out com es ▁exercise _ training ▁ HF - AC TION
D-697	-0.5336723327636719	ST2_level functional_capacity ambulatory patients HF Heart_ Failure controlled_Trial_ Investigating_outcomes exercise_training HF-ACTION
P-697	-0.2541 -0.0734 -4.1638 -0.7769 -1.5051 -0.4660 -0.3659 -0.3176 -0.3252 -0.0043 -1.3129 -0.3089 -0.0008 -1.4591 -0.0948 -0.6813 -0.0030 -2.2885 -0.0051 -0.2153 -1.9312 -0.0028 -0.3054 -0.1165 -0.0620 -0.1883 -0.4487 -0.0488 -0.0628 -0.7727 -0.2082 -0.4726 -0.3166 -0.0012 -0.4416 -0.0701 -0.1204 -0.5142 -0.1074
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol metoprolol endpoint implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-856	-0.4378177225589752	▁car vedi lol ▁met o pro lol ▁in appropria te ▁implant able ▁cardio ver ter - de fi br illa tor _ therapy ▁MAD IT - C RT ▁multi center _ automat ic _ de ib rilla tor _ ▁Implant ation ▁Card iac _ re syn chron ization _ therapy
D-856	-0.4378177225589752	carvedilol metoprolol inappropriate implantable cardioverter-defibrillator_therapy MADIT-CRT multicenter_automatic_deibrillator_ Implantation Cardiac_resynchronization_therapy
P-856	-1.7081 -0.0281 -0.0302 -0.8062 -0.0148 -0.0068 -0.0533 -0.1513 -0.0002 -0.0566 -0.1016 -0.0015 -0.5123 -0.0929 -0.2646 -0.1682 -0.0195 -0.1122 -1.0717 -0.4026 -0.0504 -0.5171 -0.6024 -0.1054 -2.2434 -0.0379 -0.4271 -0.3221 -4.1291 -0.0128 -0.5952 -0.4733 -0.0038 -0.0287 -1.6049 -0.9102 -0.2185 -0.0232 -0.3478 -0.0666 -0.0302 -2.3567 -0.0110 -0.0359 -0.1823 -0.0025 -0.0004 -0.1651 -0.4578 -0.8105 -0.3510 -0.0403
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate_ratio confidence_interval angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers therapy confidence_interval β-blockers therapy
H-666	-0.5287970304489136	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor _ block ers _ therapy ▁β - block ers
D-666	-0.5287970304489136	angiotensin-converting_ enzyme inhibitorsangiotensin_ receptor_blockers_therapy β-blockers
P-666	-2.1192 -0.7827 -0.5887 -0.4130 -1.2480 -0.0011 -0.1475 -0.0506 -0.5131 -0.0749 -0.0218 -0.3880 -0.0362 -2.3007 -0.0252 -0.0627 -0.2885 -0.1134 -0.3033 -1.0592 -0.0227 -1.9364 -0.3635 -0.1745 -0.0093 -0.0466 -0.0058 -2.0883 -0.1502
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ischemic_hf pathogenesis nyha_functional_class_iv estimated_glomerular_filtration_rate heart_rate hypertension diabetes_mellitus myocardial_infarction
H-1704	-0.6691200733184814	▁ ische mic ▁ HF _ path ogen es is ▁NY HA _ function _ class ▁IV ▁glo mer ular _ ▁filtr ation _ rate ▁heart _ rate ▁diabetes _ ▁mell itus ▁my o card ial _ in far ction
D-1704	-0.6691200733184814	ischemic HF_pathogenesis NYHA_function_class IV glomerular_ filtration_rate heart_rate diabetes_ mellitus myocardial_infarction
P-1704	-1.7779 -0.3618 -0.0235 -0.5363 -0.1117 -1.3162 -0.2424 -0.2815 -0.0226 -2.2247 -0.0107 -0.0186 -3.5469 -0.5192 -2.4468 -0.1957 -0.5159 -0.3625 -0.0932 -0.0053 -0.2110 -0.2737 -0.0310 -0.6531 -0.7823 -2.4045 -0.6063 -0.7021 -0.5399 -1.7311 -2.4660 -0.0392 -1.1832 -0.2769 -0.2768 -0.0174 -0.1332 -0.6513 -0.0004 -0.0229 -0.2795 -0.2079
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt systolic_dysfunction outcomes resynchronization_reverses_remodeling_in_systolic_left_ventricular_dysfunction reverse patients left_ventricular ejection_fraction lvef
H-752	-0.7943025231361389	▁c RT ▁re syn chron ization ▁re VE rse s ▁re syn chron ization _ re ve rse s ▁Sy sto lic ▁left _ ▁v _ En tri cular _ dis function ▁re VERS e ▁left _ ▁vent ri cular _ e je ction _ fraction LV EF
D-752	-0.7943025231361389	cRT resynchronization reVErses resynchronization_reverses Systolic left_ v_Entricular_disfunction reVERSe left_ ventricular_ejection_fractionLVEF
P-752	-1.2608 -1.2995 -1.8704 -0.0025 -0.0005 -0.1524 -0.0500 -0.6335 -0.0098 -0.0137 -0.5746 -2.5974 -0.0061 -0.6482 -1.5419 -0.1193 -3.8833 -0.0511 -0.0526 -1.2233 -0.0136 -0.1420 -0.4020 -0.8626 -1.4594 -1.7299 -3.1461 -0.1061 -0.1742 -0.1586 -0.8994 -0.3959 -1.6362 -0.7262 -0.1902 -3.2849 -0.3126 -4.2958 -0.0922 -0.0569 -1.0564 -1.3187 -0.0877 -0.0663 -0.6684 -0.1667 -0.0270 -0.0071 -0.0451 -0.1959
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars s1pr1s myocyte camp report receptors g-protein-coupled_receptor kinase-2
H-1408	-0.6564383506774902	▁signal ing _ ▁paradigm s ▁activa tion ▁β 1 AR s ▁s 1 PR 1 s ▁my o cy te ▁c AMP ▁receptor s ▁regulator y _ activ ity ▁g - prote in - co up led _ ▁receptor _ ▁kina se -2
D-1408	-0.6564383506774902	signaling_ paradigms activation β1ARs s1PR1s myocyte cAMP receptors regulatory_activity g-protein-coupled_ receptor_ kinase-2
P-1408	-1.7735 -0.1439 -1.9615 -0.4127 -0.1373 -4.4542 -0.0043 -0.5533 -0.2976 -0.1737 -1.2912 -0.9708 -0.0515 -0.0062 -0.8713 -0.1044 -0.2618 -0.0607 -0.1592 -0.1945 -0.0965 -0.3062 -3.8413 -1.0089 -0.7485 -0.0018 -2.4664 -2.4391 -0.4199 -0.5928 -0.1484 -0.4889 -0.0669 -0.0853 -0.0030 -0.0226 -0.0078 -0.3009 -0.2145 -0.9487 -0.1966 -0.0162 -0.9586 -0.2254 -0.0510
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up paf-cpt paf lyso-paf-at downregulated paf-ah lp-pla2 elevated
H-1270	-0.6544061303138733	▁PA F - C PT ▁lys o - PA F - AT ▁l p - PLA 2
D-1270	-0.6544061303138733	PAF-CPT lyso-PAF-AT lp-PLA2
P-1270	-0.9922 -0.9859 -0.2669 -1.6355 -0.5522 -0.8662 -0.0152 -0.0395 -0.4385 -0.7764 -0.3594 -0.2117 -3.6564 -0.0021 -0.0274 -0.0008 -0.0722 -1.3242 -0.2110
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic patients auc auc
H-488	-1.6542084217071533	▁e lateral ▁s ' lateral ▁a UC
D-488	-1.6542084217071533	elateral s'lateral aUC
P-488	-1.2909 -3.7551 -2.2265 -1.7243 -0.0267 -2.5881 -0.4722 -1.9963 -0.8079
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control patients cardiac driven cardioversions costs antiarrhythmic_drugs cad patient confidence_interval patient
H-1239	-0.6180863976478577	▁rate - control ▁cardiac _ procedure s ▁cardio version s ▁cost ▁anti ar rhythm ic _ ▁drugs
D-1239	-0.6180863976478577	rate-control cardiac_procedures cardioversions cost antiarrhythmic_ drugs
P-1239	-0.1783 -0.1647 -0.0012 -3.7469 -0.4334 -0.2096 -0.0020 -2.1317 -0.0309 -0.1911 -0.8841 -0.0562 -0.0695 -0.4573 -0.0800 -0.6993 -0.9768 -1.3154 -0.1153
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients follow-up patients spironolactone hospitalization hazard_ratio confidence_interval death hazard_ratio confidence_interval
H-443	-0.9283824563026428	▁spi rono lac tone ▁risk _ of _ hospital ization
D-443	-0.9283824563026428	spironolactone risk_of_hospitalization
P-443	-7.0907 -0.0335 -0.5525 -0.1150 -0.1995 -0.9857 -0.3382 -0.2472 -0.0093 -0.4602 -0.9515 -0.1574
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients bundle_branch_morphology diabetes_mellitus cardiomyopathy β-blocker angiotensin-converting_enzyme_inhibitor angiotensin_ii_receptor_blocker
H-906	-0.4983612895011902	▁de script ive _ ▁assessment ▁diabetes _ ▁mell itus ▁cardio my o pathy ▁β - block er ▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin _ II ▁receptor _ block er
D-906	-0.4983612895011902	descriptive_ assessment diabetes_ mellitus cardiomyopathy β-blocker angiotensin-converting_ enzyme_ inhibitor angiotensin_II receptor_blocker
P-906	-1.5381 -0.0025 -0.0022 -1.4247 -1.2103 -2.6100 -0.8485 -0.1532 -0.0290 -0.0420 -0.2049 -0.2680 -0.1070 -2.4712 -0.0116 -0.0465 -0.2226 -0.0116 -0.0681 -1.5128 -0.2906 -1.4895 -0.0430 -0.1837 -0.0827 -0.2185 -0.1759 -0.0199 -1.1979 -0.1318 -0.0273 -0.0228 -0.0489 -0.1866 -0.0422 -1.1508 -0.8703 -0.3250 -0.6010 -0.7410 -0.1031 -0.6453 -0.0471
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone_post_myocardial_infarction_heart_failure_efficacy_and_survival_study ephesus post-myocardial_infarction patients heart_failure mortality hospitalizations patients randomized aldosterone_antagonist eplerenone
H-1737	-0.7838013172149658	▁e pler en one ▁post _ my o card ial _ in far ction _ heart _ ▁failure ▁su rvi val _ studie s ▁post - my o card ial _ in far ction _ hospital ization s ▁al do ster one _ ▁anta gon ist ▁e pler en one
D-1737	-0.7838013172149658	eplerenone post_myocardial_infarction_heart_ failure survival_studies post-myocardial_infarction_hospitalizations aldosterone_ antagonist eplerenone
P-1737	-0.7346 -0.0029 -0.9438 -0.0707 -0.0461 -1.9095 -1.8779 -0.2685 -2.3453 -0.0893 -0.1546 -0.5130 -0.0627 -0.1181 -1.2326 -2.2587 -0.5460 -1.0229 -1.4727 -0.0542 -0.0081 -1.1331 -2.2187 -0.8108 -2.6102 -0.0110 -0.6465 -0.1524 -3.8076 -0.0505 -0.3898 -0.2399 -0.0206 -0.1820 -1.9148 -3.6194 -1.8910 -0.3747 -0.5703 -0.5040 -0.8774 -0.0845 -1.3428 -0.8020 -0.0264 -0.0349 -0.0681 -0.0024 -0.0510 -0.1907 -0.1558 -0.2421
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report cardiopulmonary_exercise_testing exercise_rehabilitation patients chronic_heart_failure exercise_rehabilitation patient chronic_heart_failure chf clinical cardiopulmonary_exercise_testing cpet exercise_rehabilitation china
H-1879	-0.891150712966919	▁cardio pul mon ary _ ▁exercise _ test ing _ guide ▁exercise _ ▁rehabilita tion ▁patients ▁chronic _ heart _ ▁failure
D-1879	-0.891150712966919	cardiopulmonary_ exercise_testing_guide exercise_ rehabilitation patients chronic_heart_ failure
P-1879	-0.0633 -0.1171 -0.3734 -0.0612 -0.6395 -1.6998 -0.4375 -1.2141 -0.4895 -1.9435 -3.0598 -0.4424 -0.2736 -0.6336 -0.0076 -2.1428 -0.1769 -0.1218 -0.7554 -0.4742 -1.8975 -3.3085 -0.1634
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence_interval heart mortality death
H-1749	-0.7781927585601807	▁risk _ re duction ▁heart _ related _ ▁mortal ity ▁sud den _ ▁death
D-1749	-0.7781927585601807	risk_reduction heart_related_ mortality sudden_ death
P-1749	-0.1987 -1.7646 -0.4197 -0.0000 -2.7966 -0.3383 -2.6027 -0.1018 -1.5108 -0.0092 -0.0175 -0.0124 -0.8945 -1.5512 -0.1785 -0.0545
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash clinic brachial_systolic_pressure central_end-systolic_pressure
H-924	-0.7406785488128662	▁DAS h / s RD ▁24- ho ur ▁bra chi al _ ▁sy sto lic _ ▁pressure ▁central _ ▁end - sy sto lic _ ▁pressure
D-924	-0.7406785488128662	DASh/sRD 24-hour brachial_ systolic_ pressure central_ end-systolic_ pressure
P-924	-0.0154 -0.5710 -2.2857 -0.8612 -0.7354 -2.5373 -0.0088 -0.2928 -0.4582 -0.1582 -0.0243 -0.3470 -1.1982 -0.0854 -0.5573 -0.8211 -0.0645 -0.2020 -0.4327 -5.0535 -0.0704 -0.8262 -0.1414 -0.3229 -0.3594 -0.3301 -1.7946 -0.1840
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause_mortality hospitalization hf lvef patients heart_failure_survey israel
H-113	-1.034567952156067	▁all - ca use ▁mortal ity ▁hospital ization ▁ HF ▁LV EF
D-113	-1.034567952156067	all-cause mortality hospitalization HF LVEF
P-113	-5.1647 -0.0763 -0.0192 -0.0935 -2.2872 -0.0285 -2.5846 -0.1281 -0.2026 -0.0032 -0.8320 -0.0316 -2.9309 -0.1016
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients hf obese body_mass_index idiopathic-dilated_cardiomyopathy
H-558	-0.6448251008987427	▁ HF ▁obes e ▁body _ index ▁ ≥ 35 ▁kg / m 2 ▁black _ ▁et hni city ▁ idio pathi c - dila ted _ ▁cardio my o pathy
D-558	-0.6448251008987427	HF obese body_index ≥35 kg/m2 black_ ethnicity idiopathic-dilated_ cardiomyopathy
P-558	-0.6488 -0.0598 -5.0767 -0.2022 -0.5550 -0.8688 -0.6057 -1.1247 -1.5510 -0.1568 -0.1835 -0.4896 -0.2188 -2.6554 -0.1419 -1.4103 -0.2905 -0.0544 -0.0198 -0.0828 -0.0048 -0.0796 -2.3508 -0.3091 -0.0029 -0.0482 -0.2155 -0.1461 -1.0330 -0.1166 -0.0482 -0.4839 -0.0442
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients left_ventricular_ejection_fraction world_health_organization idiopathic_dilated_cardiomyopathy coronary_angiography followed_up
H-1743	-1.1076260805130005	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁negative _ ▁ang i ography
D-1743	-1.1076260805130005	idiopathic_ dilated_ cardiomyopathy negative_ angiography
P-1743	-1.6906 -6.7838 -0.2782 -1.1188 -0.1564 -4.6690 -0.2422 -0.0330 -0.9075 -1.1852 -0.4451 -0.1939 -0.1830 -0.1200 -2.0491 -0.4680 -0.2468 -0.2290 -0.0454
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european_society_of_cardiology hfpef symptoms heart_failure preserved_lv_ejection_fraction non-dilated_left_ventricle evidence diastolic_dysfunction lv_relaxation lv_diastolic_stiffness elevated lv_filling_pressures
H-27	-0.8527560830116272	▁european _ soci ety _ of _ card i ology ▁guidelines ▁H FP EF ▁heart _ ▁failure ▁pres er ved ▁LV _ ▁e je ction ▁non - dila ted ▁left _ ▁vent ric le ▁dia sto lic _ dis function
D-27	-0.8527560830116272	european_society_of_cardiology guidelines HFPEF heart_ failure preserved LV_ ejection non-dilated left_ ventricle diastolic_disfunction
P-27	-0.6321 -0.3148 -0.9327 -1.6868 -0.4577 -0.0693 -0.0123 -0.8381 -0.3468 -0.0209 -1.6674 -2.6478 -0.0680 -0.1789 -4.6248 -0.4653 -1.3237 -1.1785 -0.0121 -0.0054 -0.0261 -1.9515 -0.7693 -0.0068 -0.0027 -2.5021 -0.0285 -0.0001 -0.0005 -0.6521 -0.1955 -1.6888 -0.4802 -0.1764 -0.5456 -0.1107 -0.6646 -0.4218 -2.7878 -0.0999 -5.0681 -0.1534
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated_glomerular_filtration_rate egfr type_2_diabetes cholesterol ldl-cholesterol clcnka genotype
H-1803	-0.6388369798660278	▁glo mer ular _ ▁filtr ation _ ▁rate ▁e G FR ▁type ▁2 ▁diabetes ▁total _ ch olesterol ▁CL CN KA ▁ GG ▁geno type
D-1803	-0.6388369798660278	glomerular_ filtration_ rate eGFR type 2 diabetes total_cholesterol CLCNKA GG genotype
P-1803	-0.0757 -1.0193 -0.0115 -0.5714 -0.9452 -0.0511 -0.5551 -0.6207 -0.6400 -0.2924 -0.0609 -5.3713 -0.4990 -0.0569 -2.4060 -0.6359 -0.3900 -0.0000 -0.3227 -0.0701 -0.0772 -0.8042 -0.0033 -1.6404 -0.0218 -0.0580 -0.0487
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography lv_end-diastolic_dimension lv_end-diastolic_pressure wall_stress lung acf
H-474	-0.6304314136505127	▁e cho card i ography ▁LV ▁end - dia sto lic _ dimension ▁LV ▁end - dia sto lic _ ▁pressure wall _ ▁stress ▁lung _ weight ▁un tre ated ▁A CF
D-474	-0.6304314136505127	echocardiography LV end-diastolic_dimension LV end-diastolic_ pressurewall_ stress lung_weight untreated ACF
P-474	-0.5014 -0.0328 -0.6717 -0.3663 -0.1713 -0.4507 -0.1326 -0.0214 -0.0053 -0.6790 -1.1485 -0.2708 -0.8888 -1.3944 -0.4456 -0.0114 -0.0106 -0.1820 -0.7861 -0.1681 -2.3322 -0.5242 -0.4966 -0.4874 -1.3930 -1.4151 -1.6333 -1.0515 -0.0010 -0.0132 -1.5372 -0.0017 -2.0864 -0.1229
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients heart_failure ejection_fraction cardiac_rehabilitation walking exercise
H-570	-0.7001868486404419	▁heart _ ▁failure me an ▁e je ction ▁ fraction ▁standard _ ▁cardiac _ ▁rehabilita tion _ care ▁Nordic _ ▁walking
D-570	-0.7001868486404419	heart_ failuremean ejection fraction standard_ cardiac_ rehabilitation_care Nordic_ walking
P-570	-2.2256 -0.7028 -1.4353 -1.0286 -0.0154 -0.3763 -0.0226 -0.0116 -2.1055 -0.0002 -2.0635 -0.8236 -0.2705 -0.1194 -1.1490 -0.0329 -1.0111 -0.3824 -0.0329 -0.3282 -1.7630 -0.1403 -0.0638
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
H-1836	-0.6258550882339478	▁d RS - stra t ified _ ▁hazard _ ▁ratio s ▁pi og lita zone ▁si tag lip tin ▁sul fon yl ure as ▁insulin
D-1836	-0.6258550882339478	dRS-stratified_ hazard_ ratios pioglitazone sitagliptin sulfonylureas insulin
P-1836	-0.3965 -0.1044 -0.1432 -0.0148 -0.0323 -0.0127 -1.2835 -0.4062 -0.8253 -1.2575 -0.0150 -2.3609 -2.5591 -0.1152 -0.7528 -0.2742 -0.0600 -0.4932 -3.6800 -0.5600 -0.1945 -0.2287 -0.0460 -0.1477 -0.6109 -0.1742 -0.1496
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal_muscle t-score fontan sarcopenic_range_muscle_wasting t-score clinically t-score
H-1501	-0.9841915965080261	▁skelet al _ ▁muscle _ massa ▁t - s core
D-1501	-0.9841915965080261	skeletal_ muscle_massa t-score
P-1501	-0.1059 -0.0077 -0.1386 -3.8916 -0.2067 -1.6644 -0.7296 -0.0328 -0.0442 -0.0223 -4.9178 -0.0487
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker uptitrations composite_end-point all-cause_mortality hf readmissions hfref hazard_ratio confidence_interval
H-181	-0.6586501002311707	▁ RAS - ▁β - block er _ ▁up ti tra tions ▁com posit e _ ▁end - point _ of _ all - ca use _ ▁mortal ity ▁ HF _ ▁read missions ▁H Fr EF haz ard _ rati o
D-181	-0.6586501002311707	RAS- β-blocker_ uptitrations composite_ end-point_of_all-cause_ mortality HF_ readmissions HFrEFhazard_ratio
P-181	-0.2640 -0.0523 -0.3984 -2.8030 -0.0115 -0.3705 -0.3785 -1.5932 -0.3257 -0.0277 -0.0035 -0.0057 -1.7453 -0.0001 -0.0057 -1.4055 -0.0682 -0.0384 -0.0660 -1.4315 -0.4418 -0.2408 -2.0180 -0.0169 -0.0002 -0.0264 -0.1232 -0.3159 -0.0091 -0.1218 -0.0019 -1.0681 -2.7409 -0.0271 -1.7275 -0.4311 -2.9634 -1.6114 -0.0384 -0.1403 -0.1743 -0.0175 -3.4118 -0.3179
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise testosterone baseline peak_oxygen_uptake beck_depression_inventory leg medical_outcomes_study_short-form quality_of_life exercise placebo
H-1323	-0.5653177499771118	▁testosteron e ▁base line ▁pe ak _ ▁oxygen _ ▁up take ▁Beck _ de pression _ in ven tory ▁leg _ streng th
D-1323	-0.5653177499771118	testosterone baseline peak_ oxygen_ uptake Beck_depression_inventory leg_strength
P-1323	-1.5214 -0.0413 -1.1022 -0.0008 -0.0255 -0.0019 -0.2421 -0.4872 -0.7905 -0.7021 -0.0011 -0.0015 -0.8541 -0.3594 -0.0030 -0.2848 -0.6509 -0.0404 -0.0004 -0.0014 -0.8279 -2.4152 -0.3688 -3.3637 -0.0455
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients heart_failure outcomes exercise training hf-action exercise perceived_social_support_score psss barriers_to_exercise_score btes
H-1927	-0.8185802102088928	▁patients ▁en roll ed ▁Heart _ fail ure ▁control led _ Tri al _ ▁Investiga ting _ out com es _ of _ ▁Exerci se _ ▁Training HF - AC TION
D-1927	-0.8185802102088928	patients enrolled Heart_failure controlled_Trial_ Investigating_outcomes_of_ Exercise_ TrainingHF-ACTION
P-1927	-5.5307 -1.4787 -0.0013 -0.1039 -1.0890 -0.1681 -0.8552 -0.0052 -1.4493 -0.0075 -0.1551 -2.1102 -0.0054 -0.2054 -0.0869 -0.0500 -0.4885 -0.4481 -0.0265 -0.0385 -1.1489 -0.2825 -0.0306 -2.7324 -0.0374 -0.2648 -0.6350 -0.4374 -0.0147 -0.0594 -0.1088 -6.8596 -0.0981
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable_analysis st2 death hospitalization hazard_ratio cardiovascular_death hf hospitalization hazard_ratio all-cause_mortality hazard_ratio hazard_ratios
H-703	-1.0042248964309692	▁ST 2 ▁cardiovascular _ ▁death ▁ HF _ hospital ization haz ard _ rati o ▁log 2 _ rati o
D-703	-1.0042248964309692	ST2 cardiovascular_ death HF_hospitalizationhazard_ratio log2_ratio
P-703	-2.4040 -0.2283 -4.6828 -0.6804 -2.0756 -1.0235 -0.0025 -1.4039 -0.1148 -0.6013 -2.5474 -0.0309 -0.1410 -0.6385 -0.0553 -1.4923 -0.1963 -0.7642 -1.8878 -0.0400 -0.9499 -0.1322
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients new_york_heart_association_class_i fontan cardiopulmonary_exercise_testing lean_mass_quantification dual_x-ray_absorptiometry dxa calf muscle magnetic_resonance_spectroscopy healthy
H-1495	-0.6994212865829468	▁New _ heart _ association ▁cardio pul mon ary _ ▁exercise ▁lean _ ▁mass _ ▁quant ification ▁dual ▁x - ray _ ab sor pti ometr y ▁cal f _ ▁muscle ▁magnetic _ ▁res on ance _ spec tros copy
D-1495	-0.6994212865829468	New_heart_association cardiopulmonary_ exercise lean_ mass_ quantification dual x-ray_absorptiometry calf_ muscle magnetic_ resonance_spectroscopy
P-1495	-3.6530 -1.0535 -3.3118 -0.3979 -1.1728 -1.9419 -0.3101 -0.7260 -0.2236 -1.4231 -0.8586 -0.4518 -0.1611 -0.6871 -2.2014 -0.1961 -0.0179 -0.0530 -0.0627 -0.0272 -0.1132 -0.2535 -0.6059 -1.0810 -0.1798 -0.2382 -0.0454 -0.4987 -0.0068 -0.6414 -0.8070 -0.1638 -0.2340 -0.4159 -0.2181 -0.0021 -0.4032 -0.5776 -0.0235 -2.0813 -1.7524 -0.1020
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo dopamine nesiritide bolus diuretic therapy renal_function patients acute_heart_failure renal_dysfunction
H-73	-0.4953255355358124	▁place bo ▁low - dos e ▁dop amine ▁low - dos e ▁nesi riti de ▁di ure tic _ therapy ▁renal _ function
D-73	-0.4953255355358124	placebo low-dose dopamine low-dose nesiritide diuretic_therapy renal_function
P-73	-3.8626 -0.2451 -0.0063 -0.0076 -0.1548 -0.0575 -2.0018 -0.1016 -0.0704 -0.0022 -0.0403 -0.0078 -0.1232 -0.0014 -0.1955 -0.6722 -0.0282 -0.2150 -1.1709 -0.2187 -0.1315 -0.8512 -1.6892 -0.4759 -0.0521
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized crt patients new_york_heart_association_class_iii heart_failure left_ventricular_ejection_fraction qrs_duration echocardiographic evidence left_ventricular_dyssynchrony
H-847	-1.1574629545211792	▁random ized _ ▁trial s ▁c RT ▁New ▁York _ ▁Heart _ association ▁class ▁III ▁IV _ heart _ ▁failure ▁left _ ▁vent ri cular _ e je ction ▁QR S _ ▁du ration ▁e cho car dio graphic _ dis syn chron y
D-847	-1.1574629545211792	randomized_ trials cRT New York_ Heart_association class III IV_heart_ failure left_ ventricular_ejection QRS_ duration echocardiographic_dissynchrony
P-847	-4.7878 -0.0845 -1.0235 -1.3180 -1.6852 -1.8774 -1.5564 -6.5136 -0.8390 -0.6690 -1.1415 -0.3953 -1.3723 -1.0200 -0.3327 -1.3122 -0.7438 -1.7957 -0.6209 -2.3947 -0.0239 -0.2486 -5.3060 -0.4025 -0.3244 -0.2595 -0.8255 -0.1080 -0.0608 -0.0079 -0.3993 -2.1198 -0.8482 -0.0350 -0.2549 -0.0754 -1.3157 -0.5062 -0.8853 -0.7200 -4.0926 -0.9499 -0.0012 -0.9244 -0.9654 -0.0997
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients left_ventricular ejection_fraction stable_hf right-sided_cardiac_catheterization transthoracic_echocardiography transmitral_flow mitral_annulus_velocities systole diastole
H-482	-0.46441346406936646	▁left _ ▁vent ri cular _ LV ▁e je ction ▁ fraction ▁ HF ▁right - side d ▁cardiac _ ▁cat heter ization ▁trans t hora cic _ ▁e cho card i ography ▁transmit ral _ ▁flow _ velo city ▁mit ral _ ▁ann ulus _ velo city ▁dia stol e
D-482	-0.46441346406936646	left_ ventricular_LV ejection fraction HF right-sided cardiac_ catheterization transthoracic_ echocardiography transmitral_ flow_velocity mitral_ annulus_velocity diastole
P-482	-0.2724 -1.2932 -4.2048 -0.2439 -0.0213 -1.5405 -2.6652 -2.6744 -0.0071 -0.0160 -0.3968 -0.0730 -0.2389 -0.1070 -1.8003 -0.0058 -0.0251 -0.0455 -1.2478 -0.4211 -0.0719 -0.0007 -0.0712 -0.0006 -0.1158 -0.0136 -0.0483 -0.3278 -0.8599 -0.0884 -0.2518 -0.0560 -0.1634 -0.0151 -0.0468 -0.3664 -0.1543 -0.8252 -0.2152 -0.5799 -0.1986 -0.0060 -0.3059 -0.3884 -0.0240 -1.0962 -0.1729 -0.5211 -0.0976 -0.0002 -0.0575 -0.1210 -0.0520
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients acute_coronary_syndromes patients stable cad bnp nt-probnp cad prognostic clinical outcome
H-1367	-0.7131648063659668	▁a cute ▁corona ry ▁syndrome s
D-1367	-0.7131648063659668	acute coronary syndromes
P-1367	-0.0819 -0.0012 -1.6059 -0.0474 -0.5652 -0.0378 -3.2790 -0.0867
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline patients hf lyso-paf-at paf-cpt paf paf-ah lp-pla2
H-1269	-0.5619625449180603	▁ HF ▁lys o - PA F - AT ▁PA F - C PT ▁PA F - AH ▁l p - PLA 2
D-1269	-0.5619625449180603	HF lyso-PAF-AT PAF-CPT PAF-AH lp-PLA2
P-1269	-0.2788 -0.0061 -3.4258 -0.0137 -0.0388 -0.5732 -1.0171 -0.2880 -0.2230 -0.3637 -0.2610 -0.0654 -1.3581 -0.4198 -0.5419 -0.4592 -0.1390 -2.0408 -0.9877 -0.0012 -0.0342 -0.0002 -0.0331 -1.2079 -0.2715
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical_therapy patients redo_sternotomy aortic_valve bioprosthetic_valve_replacement dacron_patch_closure aortic_valve patients transcatheter_aortic_valve_procedure surgery aortic_valve
H-549	-0.5373519659042358	▁medical ▁ therapy ▁redo ▁ster no to my ▁a or tic _ val ve _ procedure s ▁bio pro sthetic _ val ve _ ▁replace ment ▁da cro n ▁patch _ closure ▁a or tic _ ▁val ve _ ▁repair s ▁trans cat heter ▁a or tic _ val ve _ procedure ▁open _ chirurgi an ▁a or tic _ ▁val ve _ ▁replace ment
D-549	-0.5373519659042358	medical therapy redo sternotomy aortic_valve_procedures bioprosthetic_valve_ replacement dacron patch_closure aortic_ valve_ repairs transcatheter aortic_valve_procedure open_chirurgian aortic_ valve_ replacement
P-549	-0.1785 -2.2318 -0.0364 -0.2813 -0.3296 -0.0054 -0.1231 -0.6482 -0.0129 -0.0060 -0.0204 -0.1270 -1.1332 -0.3458 -2.1908 -0.0447 -0.1896 -0.1359 -0.0081 -0.0015 -0.5943 -1.6358 -0.2077 -2.0633 -1.3263 -0.0074 -0.5297 -0.0071 -0.0045 -0.4833 -1.1666 -0.0434 -0.0239 -0.0040 -0.0078 -0.0414 -1.3710 -0.0127 -1.1928 -0.7350 -0.3007 -0.0106 -0.0151 -0.0004 -0.0825 -0.0175 -0.0305 -0.0868 -1.7094 -0.0876 -1.6927 -0.0523 -0.6145 -0.3885 -1.5882 -2.7248 -1.1170 -0.0158 -0.0431 -0.0390 -3.0661 -0.0196 -0.7383 -1.7195 -0.0079 -0.2743 -0.0517
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma_n-terminal_pro-b-type_natriuretic_peptide nt-probnp patients acute_heart_failure hf admission emergency_department
H-263	-0.5731961131095886	▁plasma ▁N - termin al _ pro - B - type ▁na tri ure tic _ pe pti de NT - pro B NP
D-263	-0.5731961131095886	plasma N-terminal_pro-B-type natriuretic_peptideNT-proBNP
P-263	-4.8355 -1.2851 -0.0214 -0.0397 -0.0012 -1.4176 -0.5814 -0.0338 -0.6228 -0.0762 -0.0319 -0.0454 -0.0910 -0.2864 -0.1363 -0.1715 -0.2044 -0.0515 -0.1899 -1.2705 -0.0062 -0.0032 -0.9588 -0.0242 -2.4482 -0.0689
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac_troponin_t ctnt n-terminal_pro-b-type_natriuretic_peptide nt-probnp biomarkers hf hf atherosclerosis_risk_in_communities aric
H-286	-0.49664053320884705	▁cardiac ▁trop onin ▁t ▁t ▁t n T ▁high - sensitiv ity _ as say ▁N - termin al ▁pro - B - type ▁na tri ure tic _ pe pti de NT - pro b NP ▁incident _ HF ▁ HF _ risk _ in _ com muni ties ▁Ath eros cle rosi s _ risk _ in _ com muni ties
D-286	-0.49664053320884705	cardiac troponin t t tnT high-sensitivity_assay N-terminal pro-B-type natriuretic_peptideNT-probNP incident_HF HF_risk_in_communities Atherosclerosis_risk_in_communities
P-286	-0.0021 -0.2393 -0.0227 -1.0114 -2.0450 -1.4025 -1.9277 -0.7742 -0.4915 -0.0042 -0.0001 -0.0034 -1.2403 -0.2188 -0.0005 -0.2045 -0.0263 -0.2134 -0.0005 -0.3055 -0.0496 -0.8669 -0.2020 -0.0664 -0.0260 -0.1425 -0.2321 -0.5603 -0.4597 -0.2341 -0.3465 -0.6588 -0.7943 -0.0097 -0.0043 -0.9417 -0.0637 -0.0313 -0.3435 -0.0136 -1.6595 -0.0429 -1.0825 -0.3530 -0.5637 -2.9222 -0.8743 -0.7330 -0.2036 -0.0052 -0.4097 -0.0280 -0.8637 -1.0332 -0.0303 -0.1519 -0.8024 -0.2084 -1.1025 -0.2557 -1.3352 -0.0287 -0.0035 -1.3345 -0.0728
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body_mass_index fat_mass fat-free_mass
H-1167	-1.596560001373291	▁body _ index ▁lower ▁event _ rati o HR _ per ▁kg / m
D-1167	-1.596560001373291	body_index lower event_ratioHR_per kg/m
P-1167	-1.5459 -0.9734 -0.8581 -6.7017 -0.7641 -0.6226 -2.5575 -0.1710 -3.6796 -1.4029 -0.2572 -0.2444 -0.8977 -0.0665 -4.6422 -0.1601
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile_range body_mass_index interquartile_range copd chf crf
H-797	-1.8353112936019897	▁parti ci pant s ▁media n ▁age ▁70 y ▁media n ▁body _ ▁mass ▁index
D-797	-1.8353112936019897	participants median age 70y median body_ mass index
P-797	-5.5289 -0.9393 -3.9463 -0.0703 -1.7768 -0.0171 -2.0369 -3.4072 -0.2109 -1.4847 -0.0151 -1.2560 -1.0823 -3.6095 -0.8462 -4.5950 -0.3778
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse_remodeling ejection_fraction mortality all-cause_hospitalizations hf hospitalizations dialysis patients
H-911	-0.5217829942703247	▁rever se _ ▁remodel ing ▁e je ction _ fraction s ▁ HF _ hospital ization s ▁di al ysis
D-911	-0.5217829942703247	reverse_ remodeling ejection_fractions HF_hospitalizations dialysis
P-911	-0.1328 -0.0054 -0.6465 -0.3485 -0.0164 -0.0030 -0.0131 -0.0171 -0.4238 -0.0027 -4.4163 -1.0770 -0.1160 -2.4177 -0.0381 -0.3448 -0.1286 -0.2412 -0.0068 -0.1725 -0.8654 -0.0456
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates lv_contractility lvef β_coefficient confidence_interval systolic_blood_pressure end-systolic_volume β_coefficient
H-1530	-1.6117563247680664	▁co varia tes ▁reduce d ▁LV _ ▁contract ility ▁lower _ velo city _ velo city _ rati o ▁sy sto lic _ ▁blood _ ▁pressure ▁end - sy sto lic _ ▁volume
D-1530	-1.6117563247680664	covariates reduced LV_ contractility lower_velocity_velocity_ratio systolic_ blood_ pressure end-systolic_ volume
P-1530	-3.4372 -0.0698 -0.0037 -6.0734 -0.0119 -0.3563 -0.9153 -0.1859 -0.0024 -5.8122 -0.5655 -1.1607 -3.0165 -5.2919 -1.8672 -0.6109 -5.7863 -3.1169 -0.0257 -2.9075 -0.1707 -1.6621 -0.4391 -5.1619 -1.5953 -2.6944 -0.8510 -0.0241 -0.3176 -0.4835 -0.2836 -0.2672 -0.0534 -0.8802 -0.3102
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography dilated_lv end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mva
H-348	-0.8193168044090271	▁e cho card i ography ▁end - dia sto lic _ ▁volume _ ▁index ▁LV ▁e je ction ▁ fraction ▁mild _ ▁MR ▁mit ral _ val ve _ ▁opening ▁M VA ▁pressure _ ▁gradi ent
D-348	-0.8193168044090271	echocardiography end-diastolic_ volume_ index LV ejection fraction mild_ MR mitral_valve_ opening MVA pressure_ gradient
P-348	-1.3141 -0.0258 -2.5170 -0.3936 -0.1603 -3.5694 -0.0236 -0.0192 -1.0054 -0.2228 -0.6254 -0.0654 -0.9165 -1.7552 -3.6438 -0.0975 -0.0131 -0.0058 -1.6448 -0.0010 -0.1037 -0.3194 -0.8369 -0.1863 -0.0077 -0.2314 -0.8589 -0.1436 -4.5692 -0.9113 -1.8927 -0.0159 -0.2552 -1.0444 -0.7461 -0.0156 -0.9140 -0.0624
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind clinical renal_optimization_strategies_evaluation rose hospitalized patients acute_heart_failure renal_dysfunction estimated_glomerular_filtration_rate randomized admission
H-74	-0.6592563986778259	▁double - blind ▁place bo - control led ▁clinic al _ ▁trial ▁re nal _ optim ization _ strategi s _ evalua tion ▁ro e ▁patients ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁glo mer ular _ ▁filtr ation ▁rate
D-74	-0.6592563986778259	double-blind placebo-controlled clinical_ trial renal_optimization_strategis_evaluation roe patients acute_heart_ failure renal_ dysfunction glomerular_ filtration rate
P-74	-2.7441 -0.0104 -0.2005 -1.6007 -0.0107 -0.0079 -0.0024 -0.4852 -0.3331 -0.0267 -1.2159 -0.2406 -0.3932 -0.0022 -0.6320 -0.2179 -0.0732 -0.7248 -0.1732 -0.9104 -1.6260 -0.1883 -0.0293 -1.8490 -0.5181 -3.5593 -0.1950 -0.0016 -0.6375 -1.1022 -0.8869 -0.7763 -0.0627 -1.2587 -2.0426 -0.1134 -0.0493 -0.1834 -0.0056 -0.9311 -0.4906 -0.0506 -1.3385 -1.6314 -0.1341
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets signal_transduction pol_ii transcription_factor hf pathogenesis nuclear_factor_of_activated_t_cells nfat nuclear_factor-κb nf-κb transcription_factor gata4
H-1051	-0.5309125185012817	▁ BET s ▁chr omat in - media ted ▁signal ▁trans duction ▁pol ▁II ▁co - activa ting ▁tran scription _ factor _ net work s ▁ HF _ path ogen es is ▁nuclear _ factor _ of _ activa ted _ ▁T _ cell s ▁nuclear _ factor - κ b NF - κ b ▁tran scription _ factor ▁G ATA 4
D-1051	-0.5309125185012817	BETs chromatin-mediated signal transduction pol II co-activating transcription_factor_networks HF_pathogenesis nuclear_factor_of_activated_ T_cells nuclear_factor-κbNF-κb transcription_factor GATA4
P-1051	-0.7806 -0.0765 -0.7333 -0.0127 -0.0031 -0.1959 -0.0383 -0.0119 -0.0237 -0.3794 -0.0300 -0.0153 -0.3937 -0.2375 -0.2309 -0.0145 -0.0107 -0.1221 -0.0360 -0.3245 -0.9489 -0.0573 -1.3868 -0.2896 -0.1670 -0.2881 -0.0633 -0.0648 -1.3120 -0.5131 -0.1419 -0.0298 -2.2118 -0.0034 -0.8384 -0.1877 -2.9855 -0.8328 -1.6324 -0.4855 -0.0105 -0.4551 -2.6292 -1.4899 -0.2991 -0.1124 -0.9884 -0.4613 -0.0617 -0.4942 -1.9574 -0.7498 -1.2720 -0.0584 -0.3560 -0.3732 -1.0294 -0.8442 -0.3523 -0.0670 -1.8009 -0.0011 -0.0053 -0.2776 -0.2524
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes mortality hospitalization exercise_tolerance quality_of_life cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_death hypertension venous_thromboembolic_events ischemic_cerebrovascular_events
H-33	-0.851509153842926	▁mortal ity ▁exercise ▁ tolerance ▁cardiovascular _ ▁events ▁my o card ial _ in far ction ▁con ges tive _ heart _ ▁failure ▁ar rhythm ia ▁cardiac _ event
D-33	-0.851509153842926	mortality exercise tolerance cardiovascular_ events myocardial_infarction congestive_heart_ failure arrhythmia cardiac_event
P-33	-2.8528 -0.0368 -1.8450 -0.6730 -0.0004 -1.3805 -0.9016 -0.7692 -0.8991 -0.0439 -0.4837 -0.0142 -0.3751 -1.1319 -0.0135 -0.0468 -0.0059 -0.0232 -0.0166 -0.7545 -0.9502 -0.5477 -2.2156 -0.2136 -0.0612 -0.5927 -3.1865 -1.0798 -2.6796 -2.5563 -0.0461
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus diabetes patients diabetes peak_vo2 patients diabetes eo-cfus peak_vo2
H-128	-1.2276551723480225	▁ EO - C FU ▁diabetes ▁ EO - C FU ▁pe ak _ vo 2
D-128	-1.2276551723480225	EO-CFU diabetes EO-CFU peak_vo2
P-128	-0.8971 -0.2816 -0.0789 -2.6161 -0.7082 -1.1411 -3.5247 -0.2573 -0.0724 -3.1308 -0.4926 -5.6687 -0.0576 -0.1452 -0.1542 -0.2542 -2.0725 -0.5448
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular_mortality multivariable_adjustment hazard_ratio confidence_interval hazard_ratio confidence_interval
H-562	-1.2198407649993896	▁all - ca use ▁cardiovascular _ ▁mortal ity
D-562	-1.2198407649993896	all-cause cardiovascular_ mortality
P-562	-6.4605 -0.1063 -0.0611 -0.0830 -0.4229 -0.6704 -0.3734 -0.0203 -3.8398 -0.1607
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting video_edge_detection epifluorescence_microscopy myocardial_tissues cardiomyocytes hf
H-1212	-0.4583541750907898	▁immun o blo tting ▁radio en zy matic - ▁fluor esc ence _ ▁res on ance _ ener gy _ transfer - based _ as say s ▁video ▁edge _ ▁det ection ▁epi flu o resc ence _ micro s copy ▁l - type _ ca 2
D-1212	-0.4583541750907898	immunoblotting radioenzymatic- fluorescence_ resonance_energy_transfer-based_assays video edge_ detection epifluorescence_microscopy l-type_ca2
P-1212	-0.8338 -0.0287 -0.0057 -0.0303 -0.2450 -0.3439 -0.0124 -0.0070 -2.3495 -0.0861 -0.2537 -0.0247 -0.5706 -1.2677 -0.1672 -0.0122 -0.8689 -0.3047 -0.0955 -1.4030 -0.3054 -0.9183 -0.2765 -0.9315 -0.3759 -0.0003 -0.0193 -0.2301 -0.4846 -0.7236 -0.0860 -0.0002 -0.0120 -0.0033 -0.6314 -0.3109 -0.0274 -0.1128 -0.3799 -0.0878 -0.1038 -1.8267 -0.0644 -0.0023 -0.2234 -0.1489 -0.0672 -5.1540 -0.0409
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes exercise_capacity peak_oxygen_consumption vo2 co-primary_outcome qol minnesota heart_failure heart qol co-primary_outcome
H-1980	-0.7534869313240051	▁exercise _ capaci ▁pe ak _ ▁oxygen _ ▁consum p tion ▁m L / kg / min ▁co - prima ry _ ▁outcome
D-1980	-0.7534869313240051	exercise_capaci peak_ oxygen_ consumption mL/kg/min co-primary_ outcome
P-1980	-1.0549 -0.7221 -0.8676 -1.5644 -0.0029 -0.1270 -1.4883 -0.4438 -0.0389 -0.0032 -0.0523 -1.5718 -0.8148 -1.0194 -0.1861 -0.3451 -0.0942 -4.5399 -0.0147 -0.0125 -0.0186 -0.6677 -0.3634 -2.6784 -0.1453
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial randomize patients stroke rhythm_control_therapy prospective randomized outcome
H-1649	-0.7649998664855957	▁e ast ▁at rial _ fi bril lation _ for _ ▁Stro ke _ ▁pre vention _ Tri al
D-1649	-0.7649998664855957	east atrial_fibrillation_for_ Stroke_ prevention_Trial
P-1649	-1.8005 -0.1373 -3.0590 -0.0672 -0.1182 -0.9091 -0.0151 -0.0003 -0.7474 -1.7973 -0.2247 -0.1198 -0.0007 -0.6404 -0.7387 -0.0001 -0.5352 -0.7436 -0.0077 -4.2873 -0.1154
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients left_ventricular_ejection_fraction patients hf preserved_left_ventricular_ejection_fraction hospital physicians acute outpatient epidemic medical financial_costs
H-55	-1.156239628791809	▁low _ wind _ e je ction _ fraction ▁patients ▁ HF ▁pres er ved ▁left _ ▁vent ri cular _ e je ction _ fraction ▁hospital ▁a cute _ out patient _ setting s ▁financial
D-55	-1.156239628791809	low_wind_ejection_fraction patients HF preserved left_ ventricular_ejection_fraction hospital acute_outpatient_settings financial
P-55	-1.7780 -0.9524 -6.0550 -1.3556 -3.0364 -1.2341 -0.4249 -1.1022 -0.0462 -2.5993 -1.0026 -0.0048 -1.8586 -0.0543 -0.0424 -0.4174 -0.1315 -6.0950 -0.9863 -0.8783 -0.2371 -0.6713 -0.6910 -0.1487 -1.0844 -0.0288 -2.2710 -0.6878 -0.0012 -2.8710 -0.8328 -0.1446 -2.2019 -0.1071 -0.0176 -1.0590 -0.5562 -0.2704
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic mitochondrial-targeted_peptide ss31 mitochondrial_function tac clinical mitochondrial-targeted_peptide drugs heart_failure
H-878	-0.6222261190414429	▁ TAC - indu ced _ ▁prote om ic _ ▁altera tions ▁mito cho ndri al - tar get ed _ pe pti de _ ▁SS 31 ▁per tur bed _ ▁mito cho ndri al - tar get ed _ pe pti de _ drug
D-878	-0.6222261190414429	TAC-induced_ proteomic_ alterations mitochondrial-targeted_peptide_ SS31 perturbed_ mitochondrial-targeted_peptide_drug
P-878	-0.3674 -0.0098 -0.1453 -0.0443 -0.0332 -0.3216 -2.1926 -0.3935 -0.5409 -1.8132 -3.0054 -0.0074 -0.0383 -1.5085 -2.2013 -0.0129 -0.1523 -0.0049 -0.0138 -0.0046 -0.1066 -0.2423 -0.1641 -0.4443 -1.2687 -1.1209 -0.2494 -0.3847 -0.0008 -0.0043 -0.5276 -0.6099 -0.9852 -0.3411 -0.0033 -2.8251 -0.2080 -0.0264 -0.0066 -0.0690 -0.4535 -0.1138 -0.3106 -0.5144 -2.4425 -2.6567 -0.3538
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf patients hfref left_ventricular ejection_fraction hfpef echo-doppler n-terminal_pro-brain-type_natriuretic_peptide adverse_events
H-494	-0.6968176364898682	▁ HF ▁patients ▁pres er ved ▁left _ ▁vent ri cular LV ▁e je ction ▁ fraction HF p EF ▁e cho - D opp ler _ ▁studies ▁N - termin al _ pro - bra in - type ▁na tri ure tic _ pe pti de
D-494	-0.6968176364898682	HF patients preserved left_ ventricularLV ejection fractionHFpEF echo-Doppler_ studies N-terminal_pro-brain-type natriuretic_peptide
P-494	-0.4301 -0.0049 -5.9814 -2.4362 -0.0284 -0.0220 -0.0378 -0.5810 -3.0060 -0.2833 -0.1140 -1.1338 -1.6640 -0.0608 -0.0349 -0.5330 -0.0175 -1.6859 -0.6780 -0.3781 -0.0160 -0.1103 -0.0256 -0.2971 -0.0046 -0.1108 -2.8957 -0.2589 -0.3757 -0.0157 -0.1312 -0.0008 -1.2199 -0.8909 -0.1003 -2.3064 -0.0444 -0.1245 -0.0087 -0.0412 -0.0208 -0.0837 -1.8214 -0.3862 -0.1792 -0.5534 -0.5477 -2.3465 -0.1154
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds comorbidities hospitalized adjusted_odds_ratio aor confidence_interval eds aor
H-464	-0.8649396300315857	▁low - volu me _ ▁ED s
D-464	-0.8649396300315857	low-volume_ EDs
P-464	-0.2827 -0.0177 -0.0407 -0.0009 -0.5438 -1.3998 -0.0797 -5.2068 -0.2123
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc_battery health_abc_hf_risk_model change c-index net-reclassification-improvement hf
H-631	-0.6515365242958069	▁H ABC _ bat tery _ ▁score s ▁health ▁ABC ▁ HF _ risk _ model ▁discrimina tion net - re class ification - improv ement ▁ HF
D-631	-0.6515365242958069	HABC_battery_ scores health ABC HF_risk_model discriminationnet-reclassification-improvement HF
P-631	-1.3533 -0.1196 -0.7221 -0.4313 -0.0011 -1.0032 -2.9667 -0.0185 -0.6006 -0.2353 -0.2289 -0.0006 -0.4848 -2.1629 -0.0873 -0.1238 -3.0454 -0.0478 -3.4989 -0.0179 -0.0036 -0.0004 -0.0817 -0.1999 -0.0019 -0.0071 -1.0225 -0.6407 -0.3329 -0.1054
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients cardiac_transplant ecct patients diabetes_mellitus chronic_kidney_disease estimated_glomerular_filtration_rate
H-715	-0.7270280122756958	▁cardiac _ ▁transplant ▁EC CT ▁patients ▁diabetes ▁mell itus ▁chronic ▁ki dne y _ مرض ▁glo mer ular _ ▁filtr ation _ rate
D-715	-0.7270280122756958	cardiac_ transplant ECCT patients diabetes mellitus chronic kidney_مرض glomerular_ filtration_rate
P-715	-1.4391 -1.1480 -0.5072 -0.9911 -0.0649 -2.4329 -1.2897 -0.8394 -0.0264 -0.2657 -0.4360 -0.0566 -0.0392 -1.7256 -1.6561 -0.2575 -0.4734 -0.0051 -0.1852 -1.6592 -0.1095 -1.0708 -0.7419 -0.6176 -0.1374
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi rmsea self-care_maintenance cfi rmsea self-care_management cfi rmsea self-care_confidence
H-1507	-0.7084842920303345	▁con struct _ ▁valid ity ▁self - Car e _ Main ten ance _ ▁Scal e ▁RM SE a ▁self - Car e _ management _ ▁Scal e
D-1507	-0.7084842920303345	construct_ validity self-Care_Maintenance_ Scale RMSEa self-Care_management_ Scale
P-1507	-1.5340 -0.0003 -1.4433 -2.7745 -0.0225 -4.6299 -0.0268 -0.3520 -0.1733 -0.2304 -1.6634 -0.6048 -0.0025 -0.2022 -0.0241 -0.0072 -2.5490 -0.6160 -0.7676 -1.0496 -0.0161 -0.1635 -0.0986 -0.2405 -0.7780 -0.2944 -0.2427 -0.0030 -0.5603 -0.1841
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients bat patients quality-of-life nyha_functional_class change
H-1876	-2.205650806427002	▁BAT ▁distance _ ▁walked _ distan ce
D-1876	-2.205650806427002	BAT distance_ walked_distance
P-1876	-1.5515 -5.1278 -2.4294 -1.4007 -3.7519 -0.6260 -0.2055 -4.6730 -0.0852
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients preoperative hypoalbuminemia postoperative albumin hypoalbuminemia albumin lvad
H-537	-0.6420301198959351	▁pre operativ e ▁hypo album in emia ▁post operativ e _ normal ization ▁album in _ ▁levels ▁l VAD
D-537	-0.6420301198959351	preoperative hypoalbuminemia postoperative_normalization albumin_ levels lVAD
P-537	-0.0942 -0.0276 -0.3761 -0.1426 -2.2419 -0.3087 -0.0282 -0.0246 -0.0200 -0.2586 -1.2494 -1.0887 -0.5293 -0.8691 -0.2639 -2.1322 -0.2107 -2.3008 -0.0218 -1.2196 -0.0746
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization confidence_interval acute_myocardial_infarction ami complications kidney_infection urinary_tract_infection uti complications
H-1717	-0.9850996136665344	▁re hospital ization ▁a cute _ my o card ial _ in far ction ▁a cute _ mi o card ial _ in far ction ▁ AMI
D-1717	-0.9850996136665344	rehospitalization acute_myocardial_infarction acute_miocardial_infarction AMI
P-1717	-6.0034 -0.0050 -0.1964 -0.1875 -0.0149 -0.3448 -4.0255 -0.2713 -0.7251 -0.0189 -0.0456 -0.4142 -0.0014 -0.1230 -2.4676 -1.3349 -0.0920 -4.3072 -0.2505 -1.9169 -0.0934 -0.0521 -0.1385 -0.0006 -0.1146 -2.6079 -0.2809 -2.3840 -0.1498
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients heart_failure hf ischemic nonischemic_cardiomyopathies pharmacological implantable_cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_transplantation right_ventricular_assist_devices
H-54	-0.6275519728660583	▁heart _ ▁failure ▁ ische mic ▁non ische mic _ ▁cardio my o pathi es ▁ pharma c ological _ arma ment arium ▁implant able ▁cardio ver ter _ de fi br illa tors ▁cardiac ▁re syn chron ization _ therapy ▁cardiac _ ▁transplant ation ▁left _ assist _ ▁devices
D-54	-0.6275519728660583	heart_ failure ischemic nonischemic_ cardiomyopathies pharmacological_armamentarium implantable cardioverter_defibrillators cardiac resynchronization_therapy cardiac_ transplantation left_assist_ devices
P-54	-5.4886 -0.8379 -0.7760 -0.2752 -0.8100 -0.0229 -0.8629 -0.2495 -0.0368 -0.4657 -0.6248 -0.8624 -0.7069 -0.0419 -0.2252 -3.0046 -0.5337 -0.0462 -0.3936 -0.9798 -0.3913 -0.0419 -0.6510 -0.1415 -0.0107 -0.1385 -0.0296 -0.2380 -0.3120 -0.1871 -0.0391 -0.4925 -0.1360 -0.0188 -0.0043 -0.2821 -0.0002 -0.0002 -0.1294 -1.5667 -0.4114 -0.3495 -1.0168 -0.7769 -0.0393 -0.4783 -1.6704 -1.6105 -2.5433 -1.4919 -0.1547 -0.0345
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf catheterization central_venous_pressure svr cardiac_index
H-230	-2.3123369216918945	▁ SAF ▁ PF _ per form ance ▁central _ ▁ve nous _ ▁pressure ▁s VR _ index
D-230	-2.3123369216918945	SAF PF_performance central_ venous_ pressure sVR_index
P-230	-1.6026 -1.5017 -3.2514 -0.4504 -4.2923 -5.0198 -3.4525 -2.1432 -3.0595 -1.1754 -1.1109 -0.8963 -0.4123 -0.7473 -4.2163 -1.4551 -2.1245 -0.5349 -7.8025 -0.9978
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission bnp reduced_ef preserved_ef bnp ef
H-193	-1.0558249950408936	▁ad mission _ media n _ b NP _ level s ▁reduce d ▁EF
D-193	-1.0558249950408936	admission_median_bNP_levels reduced EF
P-193	-0.0481 -0.0115 -1.2662 -0.6324 -0.0212 -0.6484 -1.3182 -0.8484 -3.9907 -1.1320 -0.8384 -1.7474 -0.0073 -0.1579 -3.7857 -0.4393
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart_failure admission heart_transplantation lv_assist_device death hazard_ratio confidence_interval death hazard_ratio confidence_interval ischemic functional_class
H-435	-1.616532802581787	▁heart _ fail _ ▁ad mission ▁heart _ ▁трансплант ation LV _ assist _ ▁device ▁death
D-435	-1.616532802581787	heart_fail_ admission heart_ трансплантationLV_assist_ device death
P-435	-0.5974 -1.1745 -4.7416 -2.4909 -1.0588 -0.0035 -3.2598 -0.5545 -2.3583 -0.9733 -3.0079 -0.3903 -0.0247 -1.1714 -0.8188 -3.1628 -3.1074 -0.2018
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv_ejection_fraction shortening systolic_elastance contractile_efficiency acf acf allopurinol cardiomyocytes extracellular_flux_analyzer
H-475	-0.44717109203338623	▁LV ▁e je ction _ fraction ▁veloci ty ▁circum fer ential _ ▁short en ing ▁maximal ▁sy sto lic _ ▁elastan ce ▁contract ile _ ▁efficiency ▁a CF ▁allo puri nol _ ▁rat s ▁maximum ▁o 2 _ ▁consum p tion _ ▁rate ▁isola ted _ ▁cardio my o cy tes ▁extra cel lular _ ▁flux ▁anal y zer
D-475	-0.44717109203338623	LV ejection_fraction velocity circumferential_ shortening maximal systolic_ elastance contractile_ efficiency aCF allopurinol_ rats maximum o2_ consumption_ rate isolated_ cardiomyocytes extracellular_ flux analyzer
P-475	-0.0964 -0.0863 -0.0180 -0.0076 -0.5308 -0.0586 -0.7433 -0.0106 -1.0703 -0.0300 -0.0022 -0.8547 -0.7815 -0.1243 -0.0224 -1.0070 -0.0325 -0.0409 -0.0925 -0.3795 -0.2931 -0.0625 -0.0005 -0.5469 -0.2025 -0.7125 -0.8110 -0.0202 -5.4266 -0.0911 -0.0493 -0.3911 -0.1661 -0.0144 -0.5395 -0.6904 -0.0306 -1.8110 -1.8618 -0.0318 -0.1194 -0.3131 -0.5476 -0.2859 -0.0003 -0.7020 -0.0691 -1.0505 -1.1812 -1.2312 -0.3566 -0.0990 -0.0279 -0.0040 -0.0829 -0.4174 -0.8157 -0.0275 -0.0158 -0.1284 -0.0597
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively patients hfpef lv_hypertrophy lvh relative_wall_thickness rwt lvh rwt lvh rwt lvh rwt
H-1526	-0.9865283966064453	▁ HF p EF ▁LV _ ge ometr y ▁normal _ ge ometr y ▁LV _ ▁hyper trop hy ▁relative _ wall _ ▁thi ck ness _ RW t ▁LV H ▁R WT
D-1526	-0.9865283966064453	HFpEF LV_geometry normal_geometry LV_ hypertrophy relative_wall_ thickness_RWt LVH RWT
P-1526	-0.4410 -0.3628 -0.0295 -0.1599 -1.3375 -2.9676 -3.5381 -0.1266 -0.0304 -4.1218 -0.6000 -0.4061 -0.7260 -0.0262 -1.3947 -2.6982 -0.7471 -0.0058 -0.1071 -2.7827 -0.0508 -0.5102 -0.2352 -0.0665 -0.0046 -0.2649 -2.7627 -0.7748 -0.7765 -1.4737 -0.8955 -2.5702 -0.0532 -1.3001 -0.1806
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 angiotensin_receptor_neprilysin_inhibitor neprilysin_inhibitor prodrug angiotensin_receptor_antagonist valsartan hypertension heart_failure_with_preserved_ejection_fraction outcomes heart_failure_with_reduced_ejection_fraction
H-1463	-0.6416175365447998	▁ang io ten sin _ ▁receptor ▁nepri ly sin _ ▁inhibi tor ▁nepri ly sin _ ▁inhibi tor _ pro drug ▁ang io ten sin _ ▁receptor _ ▁anta gon ist _ ▁val sar tan ▁hyper tension
D-1463	-0.6416175365447998	angiotensin_ receptor neprilysin_ inhibitor neprilysin_ inhibitor_prodrug angiotensin_ receptor_ antagonist_ valsartan hypertension
P-1463	-0.0320 -1.3610 -2.3012 -0.4873 -1.3155 -0.0855 -0.2688 -0.8852 -1.0488 -0.1529 -0.6273 -0.0134 -1.4232 -0.2554 -0.6060 -0.1735 -1.6256 -0.0161 -1.0653 -0.4723 -0.0022 -0.0060 -0.1768 -0.4958 -0.3188 -0.9817 -0.0318 -0.6545 -2.2121 -0.0284 -0.1359 -0.0546 -1.1024 -0.0254 -0.0111 -0.9595 -0.1723 -3.3072 -0.1304
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood_pressure mitral_valve_plasty degenerative_mr p3_prolapse chordal_ruptures triangular_resection edge-to-edge_anastomosis ring_annuloplasty physio_ring_30 edwards_lifesciences irvine
H-343	-0.45960259437561035	▁blood ▁pressure ▁mit ral _ plast y ▁de genera tive _ ▁MR ▁p 3 ▁chor dal _ ▁rup tures ▁tri ang ular _ re ection ▁edge - to - ed ge _ an asto mos is ▁ring _ ▁ann ulo plast y ▁Ph y sio _ ▁Ring
D-343	-0.45960259437561035	blood pressure mitral_plasty degenerative_ MR p3 chordal_ ruptures triangular_reection edge-to-edge_anastomosis ring_ annuloplasty Physio_ Ring
P-343	-0.1501 -1.7692 -0.1326 -0.0013 -0.1240 -0.1562 -0.0108 -0.0149 -0.0000 -0.0078 -1.1533 -0.0532 -1.0849 -0.0244 -0.6783 -0.0138 -0.0898 -0.0306 -0.0362 -0.4581 -0.0028 -0.0002 -0.5109 -2.1658 -0.0853 -0.1480 -0.0111 -0.0135 -0.1127 -0.0224 -0.0147 -0.4196 -0.7749 -0.1650 -0.6503 -0.6969 -0.0861 -0.1024 -4.1690 -0.8079 -0.1005 -0.0085 -1.4618 -0.0039 -0.0595 -1.6273 -0.1156 -2.1482 -0.0461
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes incremental_shuttle_walk_test peak_oxygen_uptake muscular echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory beck_depression_inventory health-related_quality_of_life minnesota_living_with_heart_failure_questionnaire medical_outcomes_study_short-form
H-1320	-0.3577536940574646	▁shu ttle _ ▁walk _ test ▁pe ak _ ▁oxygen _ ▁up take ▁e cho car dio graphic ▁N - termin al ▁pro - bra in ▁na tri ure tic _ pe pti de ▁infla mma tory _ ▁marker s ▁be ck _ de pression _ in ven tory
D-1320	-0.3577536940574646	shuttle_ walk_test peak_ oxygen_ uptake echocardiographic N-terminal pro-brain natriuretic_peptide inflammatory_ markers beck_depression_inventory
P-1320	-0.0523 -0.0002 -0.4510 -0.7946 -0.5356 -0.2405 -0.0045 -0.0005 -0.9682 -0.2614 -0.3692 -0.4176 -0.0005 -0.8544 -0.0203 -0.0889 -0.2710 -0.4226 -2.1866 -0.0156 -0.0639 -0.0006 -0.9629 -0.0179 -0.2549 -0.0172 -0.1225 -0.0088 -0.0403 -0.3559 -0.1662 -0.3966 -0.1110 -0.5565 -0.4586 -0.3845 -0.0080 -0.2109 -0.8885 -0.0161 -1.9193 -0.0009 -0.4812 -0.3571 -0.0126 -0.2748 -0.2537 -0.1496 -0.0068 -1.6618 -0.1302
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction_term_analysis lvef patients patients mortality lvef p_value
H-116	-1.1579006910324097	▁inter action _ term _ analyse s ▁severe ly ▁reduce d ▁LV EF ▁long - term _ ▁mortal ity
D-116	-1.1579006910324097	interaction_term_analyses severely reduced LVEF long-term_ mortality
P-116	-3.5380 -0.0015 -1.5235 -0.7353 -1.0273 -2.2983 -2.0195 -2.4914 -0.1172 -0.8203 -0.0266 -0.7555 -0.0196 -4.1709 -0.0452 -0.0134 -0.2946 -0.7096 -0.0103 -3.3595 -0.3383
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto zsf1 obese zsf1 obese zsf1 followed_up metabolic renal echocardiographic hemodynamically euthanization
H-763	-0.7339901924133301	▁w star - K yo to ▁lean _ ▁Z SF 1 ▁obes e _ ▁Z SF 1 ▁high - fat _ Die t ▁eu than ization
D-763	-0.7339901924133301	wstar-Kyoto lean_ ZSF1 obese_ ZSF1 high-fat_Diet euthanization
P-763	-2.5260 -0.9405 -0.0383 -3.6783 -0.0534 -0.0159 -0.0257 -0.8335 -2.0654 -0.0185 -1.3488 -0.0140 -0.0100 -1.1336 -1.1539 -0.0172 -0.2666 -0.0168 -0.0033 -0.0248 -0.5507 -2.4939 -0.0359 -2.4061 -0.0997 -0.2962 -0.4385 -0.0464
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier_curves log-rank_testing risk_stratification patients patients
H-384	-0.6479426026344299	▁Ka plan - Me ier _ ▁cur ves ▁log - rank _ test ▁risk _ ▁strat ification ▁UM / VA / VA - RT _ co hor ts
D-384	-0.6479426026344299	Kaplan-Meier_ curves log-rank_test risk_ stratification UM/VA/VA-RT_cohorts
P-384	-0.3035 -0.0143 -0.0210 -0.9164 -0.0970 -0.5320 -0.4564 -0.0970 -0.0338 -0.0104 -0.0010 -2.0474 -1.3017 -2.7184 -1.2282 -0.4758 -0.3520 -2.2863 -0.1788 -0.0204 -1.5468 -1.1878 -0.4786 -0.3219 -1.5000 -0.1208 -0.0016 -0.0136 -0.8364 -0.3390
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate_cox_regression_analyses hypertension sinus_rhythm hazard_ratio confidence_interval
H-950	-1.2438275814056396	▁multi varia te ▁co x _ re gression _ analyse s ▁long - standing _ ▁persist ent _ ▁AF _ type ▁lack _ of _ ▁hyper tension ▁maintenance _ of _ ▁sinus ▁ rhythm haz ard _ rati o
D-950	-1.2438275814056396	multivariate cox_regression_analyses long-standing_ persistent_ AF_type lack_of_ hypertension maintenance_of_ sinus rhythmhazard_ratio
P-950	-4.5974 -0.1344 -0.2051 -0.5379 -0.0624 -1.6834 -1.0836 -0.0003 -4.9371 -1.5753 -0.0158 -4.0944 -0.0189 -0.0002 -2.5426 -0.2685 -0.0286 -0.4837 -2.4757 -4.8762 -0.4768 -1.9841 -1.6120 -0.9584 -1.5120 -0.6962 -0.0027 -0.2215 -2.7731 -1.0281 -0.4808 -2.0752 -2.5412 -0.1172 -0.5278 -0.0399 -0.3598 -0.4441 -0.0330 -2.9190 -0.5724
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients chronic hf-ref nyha_functional_class_ii egfr potassium eplerenone hyperkalemia
H-1228	-0.7445459961891174	▁chronic ▁ HF - RE F ▁NY HA _ function _ class ▁II ▁e G FR ▁po tas s ium ▁e pler en one ▁w RF
D-1228	-0.7445459961891174	chronic HF-REF NYHA_function_class II eGFR potassium eplerenone wRF
P-1228	-0.3756 -0.2561 -0.0733 -0.1018 -1.3158 -0.2016 -0.0735 -0.0200 -3.3380 -0.1878 -1.9817 -0.1062 -1.7387 -3.0424 -3.3790 -0.5892 -0.0580 -0.4852 -0.1945 -0.3322 -0.0156 -0.0128 -0.2050 -0.0950 -1.7618 -0.6686 -0.1458 -0.0923
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm dual_energy_x-ray_absorptiometry dxa patients chronic_heart_failure chf non-cachectic_chf myocardial
H-12	-0.9173814058303833	▁f f ▁f f ▁f f ▁f f ▁f f ▁dual ▁energy _ ▁X - ray _ ▁ab sor pti ometr y ▁d XA ▁non - dia be tic _ ▁patients ▁chronic _ heart _ ▁failure ▁CC ▁non - ca che ctic ▁CHF ▁my o card ial _ in far ction - bo th
D-12	-0.9173814058303833	ff ff ff ff ff dual energy_ X-ray_ absorptiometry dXA non-diabetic_ patients chronic_heart_ failure CC non-cachectic CHF myocardial_infarction-both
P-12	-0.9222 -0.8189 -1.6356 -0.2253 -1.5175 -0.0904 -2.0994 -0.0990 -3.4778 -0.1622 -4.1048 -0.4685 -1.6806 -2.2615 -0.0866 -0.3915 -0.7605 -1.9402 -1.3424 -0.3333 -0.5445 -0.1511 -0.8157 -0.0297 -2.0445 -0.0146 -0.0016 -0.1467 -0.0120 -3.7869 -0.7782 -1.4005 -0.5300 -2.6746 -1.4904 -1.4336 -4.3448 -0.9154 -0.0160 -0.0005 -0.2547 -0.0167 -0.7604 -2.0400 -0.0600 -0.4194 -0.2043 -0.1870 -0.4010 -0.0037 -0.5169 -0.5326 -0.0048 -0.0076 -0.3274 -0.0872
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline drug spironolactone combined_end_point death hospitalization hf hazard_ratio confidence_interval aas hazard_ratio confidence_interval p_value
H-1707	-0.6101391911506653	▁base line ▁drug _ ▁dose ▁spi rono lac tone ▁end ▁point _ of _ ▁death ▁hospital ization ▁ HF haz ard _ rati o ▁AA s
D-1707	-0.6101391911506653	baseline drug_ dose spironolactone end point_of_ death hospitalization HFhazard_ratio AAs
P-1707	-0.5019 -0.0126 -3.0416 -2.1910 -0.1415 -0.2456 -0.0042 -0.0499 -0.0397 -0.5651 -0.8386 -1.0976 -0.1758 -0.0788 -0.9759 -0.5747 -0.1799 -1.0765 -0.0006 -1.9208 -0.0228 -0.3120 -0.4059 -0.0343 -1.5942 -0.4223 -0.4883 -0.0920
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective_study patients invasively diagnosed pulmonary_arterial_hypertension inoperable chronic_thromboembolic_pulmonary_hypertension right_ventricular pump stable pulmonary_arterial_hypertension medication noninvasive stress_echocardiography cardiopulmonary_exercise_testing
H-823	-0.8997505307197571	▁invasi ve ly ▁pulmonar y ▁arterial _ ▁hyper tension ▁in opera ble ▁chronic ▁ thro mbo e mbol ic _ ▁pulmonar y _ thrombophlebitis ▁im pair ed ▁right _ vent ri cular _ pump s ▁cardio pul mon ary _ test
D-823	-0.8997505307197571	invasively pulmonary arterial_ hypertension inoperable chronic thromboembolic_ pulmonary_thrombophlebitis impaired right_ventricular_pumps cardiopulmonary_test
P-823	-2.8614 -0.0879 -1.1207 -0.5214 -0.0033 -0.7921 -0.3632 -3.8102 -0.0022 -2.4330 -0.0023 -0.0113 -0.0382 -0.7814 -0.0093 -0.6997 -0.1520 -0.0091 -0.0722 -0.6621 -2.3124 -0.0110 -0.1768 -3.5920 -0.5619 -0.0018 -0.0031 -0.3299 -0.0829 -4.4392 -0.5535 -0.0179 -0.2027 -0.5732 -3.4470 -3.6837 -0.2825 -0.2300 -0.0743 -1.5258 -1.5745 -0.5197 -0.0604
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular_death hf hospitalization randomization btes btes cardiovascular_death hf hospitalization exercise hazard_ratio confidence_interval hazard_ratio confidence_interval
H-1930	-1.1104774475097656	▁cardiovascular _ ▁смерти ▁ HF _ hospital ization
D-1930	-1.1104774475097656	cardiovascular_ смерти HF_hospitalization
P-1930	-0.6290 -0.6248 -2.8591 -1.7503 -0.0060 -1.6300 -0.0223 -0.3236 -3.1724 -0.0872
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients hospitalized death all-cause_readmission aor eds aor
H-466	-1.2875313758850098	▁index _ dis tribution ▁low - volu me _ ed _ case s ▁30- day _ ▁өлім _ all - ca use _ ▁read mission ▁high - volu me _ ED s
D-466	-1.2875313758850098	index_distribution low-volume_ed_cases 30-day_ өлім_all-cause_ readmission high-volume_EDs
P-466	-0.5453 -0.8065 -7.1527 -1.2961 -1.3547 -0.0067 -0.0156 -0.0007 -0.9661 -4.4921 -2.1750 -1.0040 -1.2521 -4.6475 -0.1350 -0.8978 -6.3450 -2.4170 -0.4403 -0.0475 -0.0006 -0.0101 -0.2455 -0.9066 -0.0393 -2.2695 -0.0114 -0.0788 -0.0004 -0.3154 -2.1274 -0.2299 -1.1627 -0.3807
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients implantable_cardioverter-defibrillator implantation engage patients decisions implantable_cardioverter-defibrillator
H-1863	-0.5910565853118896	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1863	-0.5910565853118896	implantable cardioverter-defibrillator_deactivation
P-1863	-0.3730 -0.0065 -1.7785 -0.0322 -0.8186 -0.2466 -0.0097 -1.8096 -2.1974 -0.3986 -0.0523 -0.4449 -0.0710 -0.1793 -0.0378 -1.5479 -0.0442
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac_magnetic_resonance t1_time hazard_ratio confidence_interval left_atrial_area hazard_ratio confidence_interval pulmonary_vascular_resistance hazard_ratio confidence_interval cardiac_events
H-739	-0.8493239879608154	▁Card iac _ ▁magnetic _ ▁res on ance ▁left _ at rial _ area ▁pulmonar y _ vas cular _ ▁resist ance
D-739	-0.8493239879608154	Cardiac_ magnetic_ resonance left_atrial_area pulmonary_vascular_ resistance
P-739	-1.2576 -0.0911 -0.3893 -1.3559 -0.1672 -0.6740 -0.1716 -0.0610 -5.4728 -1.0352 -0.4139 -0.0032 -0.8254 -1.2306 -0.5224 -0.0148 -0.1230 -0.9471 -0.1884 -0.5785 -2.2645 -0.0020 -2.4971 -0.0973
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively followed_up hf patients systolic left_ventricular_ejection_fraction hf stable clinical conditions new_york_heart_association_class_i clinical echocardiographic cardiopulmonary_exercise_test
H-1755	-0.97535640001297	▁ HF _ ▁unit s ▁sy sto lic ▁le ft _ ▁vent ri cular _ e je ction ▁ fraction ▁ HF ▁ HF ▁New ▁York _ ▁Heart _ association
D-1755	-0.97535640001297	HF_ units systolic left_ ventricular_ejection fraction HF HF New York_ Heart_association
P-1755	-0.8672 -0.7978 -4.1720 -0.0456 -0.0084 -0.1323 -0.0203 -0.0110 -2.3703 -0.0023 -0.1643 -4.1502 -0.1462 -0.1790 -0.1560 -0.7311 -0.1002 -0.4729 -0.8043 -0.0266 -1.1456 -0.0332 -3.6280 -1.1452 -2.8407 -0.1989 -1.0905 -0.7023 -0.4165 -0.9125 -3.6745 -0.0655
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients end_stage_heart_failure abcd_classification american_college_of_cardiology acc american_heart_association aha new_york_heart_association nyha heart_disease symptoms heart_failure physical medical_treatment
H-1666	-1.2120869159698486	▁ab d _ ▁classifica tion ▁American _ ▁College _ of _ ▁Card i ology ▁a cc _ American _ ▁Heart ▁Association ▁ AHA
D-1666	-1.2120869159698486	abd_ classification American_ College_of_ Cardiology acc_American_ Heart Association AHA
P-1666	-6.5277 -0.0920 -2.2919 -1.1331 -0.0131 -1.1768 -0.4821 -1.6513 -0.3201 -0.0360 -0.0274 -0.7656 -0.2608 -0.0013 -2.7107 -0.1329 -2.6247 -0.3508 -0.0997 -1.2491 -0.6100 -2.9591 -0.0531 -4.4385 -0.2943
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva continuity_equation lv_end-diastolic_volume lv_end-systolic_volume mitral_filling_flow mva mitral_filling_flow continuous_wave_doppler_echocardiography mitral_valve_plasty
H-345	-0.6495801210403442	▁continu ity _ e qu ation LV ▁end - dia sto lic _ ▁volume ▁LV ▁end - sy sto lic _ ▁volume ▁mit ral ▁fill ing ▁flow _ flow ▁veloci ty _ ▁time ▁wa ve _ do pp ler ▁e cho card i ography ▁MR ▁mit ral _ val ve ▁plast y
D-345	-0.6495801210403442	continuity_equationLV end-diastolic_ volume LV end-systolic_ volume mitral filling flow_flow velocity_ time wave_doppler echocardiography MR mitral_valve plasty
P-345	-5.3972 -0.0021 -1.3114 -1.0110 -0.0017 -0.0458 -1.1919 -0.1370 -0.0098 -1.5321 -1.0170 -0.1627 -1.1586 -0.0951 -2.0800 -0.2873 -0.0090 -1.2619 -0.2790 -0.0656 -1.6329 -0.1992 -0.0085 -0.0030 -0.2213 -0.0039 -0.1112 -2.0674 -1.2436 -0.5773 -0.0005 -0.6157 -0.3476 -4.9142 -0.0156 -0.8830 -0.8174 -0.0166 -0.0566 -0.3451 -0.0080 -0.1514 -0.0258 -0.1469 -0.0807 -0.6986 -0.0020 -0.0824 -1.7286 -0.0508 -0.4153 -0.1160 -0.2783 -0.1557
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance rm all-cause_mortality sts hh cri cri cri
H-157	-1.092368483543396	▁stati tis tical _ rati o ▁all - ca use _ ▁mortal ity ▁s TS ▁ HH
D-157	-1.092368483543396	statitistical_ratio all-cause_ mortality sTS HH
P-157	-3.3280 -0.2230 -1.8447 -1.1756 -2.3668 -0.3261 -5.1421 -0.0054 -0.0010 -0.0203 -0.2881 -0.1790 -0.0099 -0.4290 -0.8068 -0.8618 -0.0050 -3.6186 -0.1237
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi hf clinic outcomes hfpsi outcomes tracking patients hfpsi
H-381	-0.6706529855728149	▁ HF PSI ▁Ann ▁Ar bor ▁Veteran s _ ▁Affairs ▁ HF _ ▁clinic VA - RT _ co hor t
D-381	-0.6706529855728149	HFPSI Ann Arbor Veterans_ Affairs HF_ clinicVA-RT_cohort
P-381	-0.2642 -0.2207 -1.0859 -3.3641 -0.4146 -0.0014 -0.1962 -0.0416 -0.3496 -1.8776 -0.2688 -0.0346 -0.3784 -1.0480 -0.2278 -0.1534 -0.0515 -1.0590 -0.0878 -0.0040 -0.0816 -4.0414 -0.1726
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas spironolactone hyperkalemia potassium hypokalemia potassium
H-1706	-0.9640318751335144	▁non - AA s ▁spi rono lac tone _ ▁dose
D-1706	-0.9640318751335144	non-AAs spironolactone_ dose
P-1706	-3.6932 -0.0103 -0.0039 -0.0428 -0.4404 -0.0072 -0.1791 -0.0263 -2.1498 -0.0348 -4.8326 -0.1481
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate_analysis patients preserved_lvef mortality patients lvef hazard_ratio lvef preserved_lvef
H-115	-1.214902400970459	▁pres er ved _ ▁LV EF ▁ha ard _ rati o ▁pres er ved _ ▁LV EF
D-115	-1.214902400970459	preserved_ LVEF haard_ratio preserved_ LVEF
P-115	-5.1428 -0.1869 -0.0147 -0.3276 -2.7161 -0.0588 -3.7675 -2.5229 -0.1682 -0.3304 -0.0178 -3.8561 -0.0312 -0.0371 -0.0917 -1.4685 -0.0276 -1.9304 -0.3867
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients hfpef primary_outcome odds_ratio nyha_class_iii 6-minute_walk_test 6-mwt feet prescribed medications
H-242	-1.4434036016464233	▁ HF p EF ▁ HF p EF ▁
D-242	-1.4434036016464233	HFpEF HFpEF
P-242	-0.3048 -0.0442 -0.0150 -0.3439 -3.0814 -0.2629 -0.0418 -0.6534 -3.8165 -5.8703
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived_pulmonary_arterial_systolic_pressure pasp right_ventricular rv tricuspid_annular_plane_systolic_excursion tapse diastole end-systole clinical follow-up heart_failure hf patients cardiac
H-492	-0.8539659380912781	▁e cho - der i ved ▁pulmonar y _ ▁arterial _ s sto lic _ ▁pressure _ PAS P ▁right _ ▁vent ri cular ▁tri cus pid _ ▁ann ular _ ▁plane ▁sy sto lic _ excursion TA PS e ▁end - sy stol e
D-492	-0.8539659380912781	echo-derived pulmonary_ arterial_sstolic_ pressure_PASP right_ ventricular tricuspid_ annular_ plane systolic_excursionTAPSe end-systole
P-492	-1.8308 -0.0088 -0.0424 -0.0529 -0.0202 -0.0089 -0.0024 -0.0068 -0.6393 -1.4695 -0.0804 -5.8016 -1.4370 -2.3643 -0.1151 -0.5452 -4.9828 -0.6916 -0.2831 -0.1876 -0.3966 -1.8482 -0.0995 -0.0150 -1.8045 -0.0357 -0.0384 -0.7415 -0.4901 -0.0007 -0.2165 -0.9922 -1.3536 -0.2449 -0.8033 -1.1137 -0.0096 -3.3297 -0.1453 -1.8628 -1.4206 -0.0172 -0.7757 -0.0107 -0.2688 -1.4017 -0.1293
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad diabetes odds_ratio electrocardiographic_q_waves left_bundle_branch_block odds_ratio nondiabetes dyslipidemia hypertension odds_ratio
H-1190	-0.48739752173423767	▁severe _ CAD ▁electro car dio graphic _ Q ▁wa ves ▁left ▁bund le _ ▁bran ch _ ▁block ▁non dia bete s ▁dys li pide mia ▁hyper tension ▁to ba cco
D-1190	-0.48739752173423767	severe_CAD electrocardiographic_Q waves left bundle_ branch_ block nondiabetes dyslipidemia hypertension tobacco
P-1190	-1.6041 -1.1433 -1.1032 -0.2586 -0.0185 -0.0467 -0.0486 -1.1980 -0.7259 -0.0621 -0.0168 -0.0385 -0.5243 -0.0341 -0.9444 -0.0769 -0.0034 -0.5849 -0.1964 -0.6813 -0.0594 -0.0318 -0.0105 -3.9269 -0.0085 -0.0173 -0.1844 -0.3678 -0.0060 -0.0113 -0.0394 -0.1462 -2.2965 -0.1558
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area_under_the_receiver_operating_characteristic_curve auc pcwp confidence_interval septal p_values
H-485	-1.550907850265503	▁receive r _ ▁operating _ ▁character istic _ cur ve _ cur ve ▁e / e _ ▁ratio s ▁PC p
D-485	-1.550907850265503	receiver_ operating_ characteristic_curve_curve e/e_ ratios PCp
P-485	-1.3431 -0.0780 -2.0127 -3.1684 -0.2768 -4.4753 -1.3303 -0.4013 -0.3414 -0.0223 -3.5252 -0.9672 -0.0198 -1.8442 -1.0720 -0.0609 -3.5330 -2.5535 -0.0294 -0.6321 -3.6969 -3.6472 -0.6400
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients coronary_artery_disease hypertension trastuzumab administration chf
H-680	-1.0122008323669434	▁tras tuz um ab - tre ated ▁patients ▁corona ry _ ▁arter y _ dia meter
D-680	-1.0122008323669434	trastuzumab-treated patients coronary_ artery_diameter
P-680	-0.0644 -0.0036 -0.0380 -0.1310 -1.3414 -0.0273 -0.0515 -2.5045 -1.0366 -0.0230 -1.6549 -0.0153 -0.0257 -1.3388 -2.1102 -2.3074 -5.4327 -0.1134
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef clinical crt crt systolic_volume_index lv_mass
H-754	-0.7258110046386719	▁LV EF ▁clinic al _ com posit e _ ▁response ▁c RT _ on ▁c RT _ ▁OFF ▁LV _ ▁end _ ▁sy sto lic _ ▁volume _ index
D-754	-0.7258110046386719	LVEF clinical_composite_ response cRT_on cRT_ OFF LV_ end_ systolic_ volume_index
P-754	-0.6702 -0.1119 -0.5696 -0.0036 -0.8423 -0.3090 -0.0006 -0.0039 -0.9743 -1.4240 -0.7199 -0.0179 -1.0013 -1.0389 -0.9370 -0.0545 -0.4045 -0.9380 -0.7457 -0.8737 -4.8551 -0.1890 -1.3912 -0.0680 -0.9069 -0.3197 -0.2132 -1.0982 -0.3085 -1.3254 -0.1844
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β_signaling tgf-β_receptor_type_i cell yield epithelial mesenchymal transition pluripotency_marker nanog cell cells in_vitro
H-1343	-0.607865571975708	▁T GF - β ▁signal ing ▁t GF - β _ ▁receptor ▁s mad ▁small - mo le cule _ ▁inhibi tors ▁c - K it _ cell ▁yi eld ▁epi the li al ▁mes en chy mal _ ▁transition _ ▁marker s ▁pluri pote ncy _ ▁marker ▁c - K it _ cell ▁differenti ation ▁cardio my o cy te - like _ cell s
D-1343	-0.607865571975708	TGF-β signaling tGF-β_ receptor smad small-molecule_ inhibitors c-Kit_cell yield epithelial mesenchymal_ transition_ markers pluripotency_ marker c-Kit_cell differentiation cardiomyocyte-like_cells
P-1343	-0.8445 -0.0437 -0.1809 -0.5735 -0.7503 -0.0959 -1.2811 -0.3190 -0.2552 -2.1964 -2.6065 -2.7952 -1.9536 -0.0015 -2.8803 -0.0063 -0.0020 -0.1660 -0.1656 -1.2201 -0.0266 -0.0186 -0.0197 -0.1056 -1.6501 -0.1044 -0.6839 -2.2987 -1.8013 -0.0001 -0.0625 -0.0097 -0.0359 -0.0132 -0.0073 -0.3325 -0.0555 -0.0399 -0.2462 -0.2219 -0.5763 -0.4927 -0.7381 -0.1056 -0.0828 -0.0061 -0.2201 -0.4402 -0.5955 -0.0765 -2.5543 -0.1600 -0.3185 -2.0125 -0.4487 -0.0220 -0.0490 -0.4553 -0.6602 -0.8636 -1.0544 -0.7545 -0.9419 -0.9036 -0.0740 -0.0045 -0.5838 -0.0688
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients hfref diuretics co-morbidities 6-mwt feet nyha_class_iii
H-243	-0.7049100399017334	▁H Fr EF ▁di ure tics ▁co - mor bid ities ▁NY HA
D-243	-0.7049100399017334	HFrEF diuretics co-morbidities NYHA
P-243	-1.5847 -0.1628 -0.5744 -0.3796 -0.7359 -0.8268 -0.2670 -0.0330 -0.0252 -0.0084 -0.0202 -2.0581 -0.0817 -3.7191 -0.0968
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery hf postoperative echocardiography end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mitral_valve_area mva
H-344	-0.7255449295043945	▁ HF ▁post operativ e _ e cho card i ography ▁end - dia sto lic _ ▁volume _ ▁index ▁LV ▁e je ction _ fraction ▁MR ▁pres er ved ▁mit ral _ val ve _ ▁opening ▁mit ral _ val ve _ area ▁mean ▁pressure _ ▁gradi ent
D-344	-0.7255449295043945	HF postoperative_echocardiography end-diastolic_ volume_ index LV ejection_fraction MR preserved mitral_valve_ opening mitral_valve_area mean pressure_ gradient
P-344	-0.7710 -0.0098 -2.1682 -0.0842 -0.0467 -1.7993 -0.8383 -0.1952 -1.4272 -0.1600 -0.0874 -1.6733 -0.0251 -0.0193 -0.3583 -0.4369 -0.7822 -0.0526 -1.0519 -1.2599 -3.2678 -0.3383 -0.0157 -0.0070 -2.4638 -0.0525 -0.3291 -1.4410 -0.0161 -0.0080 -0.0260 -0.0116 -0.2594 -0.7770 -0.1183 -2.8309 -1.2655 -0.1101 -0.1110 -0.1932 -0.9788 -0.0277 -0.9032 -1.7778 -1.9104 -1.0250 -1.2035 -1.0972 -0.0101 -1.1037 -0.0759
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients systolic_heart_failure ejection_fraction randomized placebo ivabradine shift systolic_heart_failure_treatment_with_the_if_inhibitor_ivabradine_trial patients placebo ivabradine echocardiographic
H-519	-0.7887075543403625	▁sy sto lic _ heart _ fail ure ▁if ▁in hib itor ▁i va bra dine _ Tri al ▁i va bra dine ▁e cho car dio graphic
D-519	-0.7887075543403625	systolic_heart_failure if inhibitor ivabradine_Trial ivabradine echocardiographic
P-519	-0.4804 -0.1566 -0.1165 -0.2412 -0.8663 -0.3885 -2.4491 -0.0900 -6.9712 -1.0760 -0.0350 -0.0169 -0.3700 -0.1401 -0.0611 -0.0111 -0.5117 -1.6639 -0.0096 -1.3461 -1.1844 -0.0673 -0.0086 -1.8452 -0.0319 -0.2079 -0.6138 -2.3589 -0.2897 -0.0525
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard_ratios multivariate_regression tapse pasp hazard_ratio tapse new_york_heart_association_functional_class
H-499	-2.3049755096435547	▁hazard _ rati o ▁t p se _ rati o ▁t p se _ rati o
D-499	-2.3049755096435547	hazard_ratio tpse_ratio tpse_ratio
P-499	-5.4852 -1.6074 -0.1406 -0.5612 -3.3205 -2.3629 -1.3989 -3.0920 -3.0093 -0.0280 -3.3999 -1.5155 -3.1182 -2.8345 -2.9332 -0.0158 -6.3419 -0.3246
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal_function the_chronic_kidney_disease_epidemiology_collaboration patients estimated_glomerular_filtration_rate egfr
H-390	-0.7640146017074585	▁Chro nic _ ▁Kid ney _ ▁Epidemi ology _ col labora tion ▁e qu ation ▁glo mer ular _ ▁filtr ation _ ▁rate ▁e G FR
D-390	-0.7640146017074585	Chronic_ Kidney_ Epidemiology_collaboration equation glomerular_ filtration_ rate eGFR
P-390	-0.4208 -0.1178 -0.3078 -1.5659 -0.0292 -1.5404 -0.1578 -0.0220 -2.4694 -0.9922 -0.0029 -0.0237 -2.3392 -0.0016 -0.3732 -0.6054 -1.5889 -0.0646 -0.4151 -1.6135 -0.1064 -1.1615 -1.0371 -0.5357 -0.1640 -0.7039 -2.0227 -1.0096
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective randomized paradigm-hf chronic_heart_failure systolic_dysfunction lv_ef functional_class nyha elevated bnp nt-pro_bnp primary_endpoint cardiovascular_death hospitalization heart_failure arni lcz696 sacubiltril valsartan
H-1968	-1.2806397676467896	▁para DIG m - HF ▁stabil ized ▁chronic _ heart _ ▁failure ▁sy sto lic _ ▁dys function LV _ EF ▁functional ▁class ▁NY HA _ II - III ▁b NP / NT - pro ▁B NP ▁kar dio vas cular _ ▁смерть _ hospital ization _ for _ heart _ ▁failure ▁sa cubi lt ril ▁sa cubi lt ril
D-1968	-1.2806397676467896	paraDIGm-HF stabilized chronic_heart_ failure systolic_ dysfunctionLV_EF functional class NYHA_II-III bNP/NT-pro BNP kardiovascular_ смерть_hospitalization_for_heart_ failure sacubiltril sacubiltril
P-1968	-6.4452 -1.7949 -0.5372 -0.1042 -0.0103 -4.3978 -0.0229 -0.2111 -0.6987 -1.7235 -1.1293 -2.2262 -1.7793 -0.0742 -1.2908 -0.4725 -0.6633 -0.0112 -2.8229 -1.4388 -1.1689 -3.9110 -0.9199 -0.0332 -0.0089 -2.2416 -0.6439 -0.0356 -0.0084 -3.7786 -0.6308 -2.7003 -0.5990 -0.0041 -0.0048 -1.0450 -0.0257 -4.6900 -0.0454 -0.6842 -0.0785 -0.6189 -3.1789 -4.9966 -0.0789 -0.4148 -2.8531 -1.7233 -0.2739 -0.3625 -0.4510 -3.5246 -1.8104 -0.4420 -0.1510 -0.2661 -1.4472 -0.9967 -0.1360 -0.3200 -4.1311 -0.1111
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia outcomes african_americans aas new_york_heart_association nyha hf left_ventricular_dysfunction randomized spironolactone titrated placebo randomized_aldactone_evaluation_study rales
H-1703	-1.1265462636947632	▁hyper kal emia ▁African _ American s ▁non - AA s ▁New ▁York _ ▁Heart _ association ▁IV ▁ HF ▁left _ ▁vent ri cular _ dis function ▁spi rono lac tone
D-1703	-1.1265462636947632	hyperkalemia African_Americans non-AAs New York_ Heart_association IV HF left_ ventricular_disfunction spironolactone
P-1703	-1.1286 -0.1309 -0.0348 -2.3516 -2.5572 -0.8423 -0.0389 -0.0516 -0.0067 -0.0004 -0.0021 -2.6892 -0.2599 -0.9059 -1.3580 -1.1733 -1.3424 -0.0553 -0.8509 -0.2658 -0.6606 -1.0999 -8.3449 -2.2562 -0.8615 -1.1489 -1.0177 -1.0546 -1.9091 -0.0017 -0.0144 -0.0060 -3.7459 -0.1352
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv_reverse_remodeling lv_end-diastolic_dimension longitudinal strain left_ventricle left_atrial_area right_ventricular_end-diastolic_area_index right_atrial right_ventricular_fractional_area change
H-432	-1.0750162601470947	▁rever se _ ▁remodel ing ▁pre - C RT ▁LV ▁end - dia sto lic _ dimension _ index ▁global ▁longitud in al _ ▁strain ▁left _ ▁vent ric le ▁left _ at rial _ area ▁right _ ▁vent ri cular _ velo city
D-432	-1.0750162601470947	reverse_ remodeling pre-CRT LV end-diastolic_dimension_index global longitudinal_ strain left_ ventricle left_atrial_area right_ ventricular_velocity
P-432	-0.0880 -0.0054 -0.9803 -0.1754 -0.0037 -0.0363 -0.0012 -0.1178 -0.0274 -1.0141 -1.4645 -0.0180 -0.0018 -2.7715 -0.3177 -1.8641 -0.1300 -3.6932 -0.5354 -0.3282 -0.1275 -0.0043 -0.0083 -0.2659 -1.0918 -0.2424 -0.2028 -5.1092 -1.2016 -0.5729 -1.1787 -0.5409 -1.5593 -0.0017 -1.6744 -2.3136 -0.5235 -0.3676 -5.1170 -0.1002 -0.0597 -1.5942 -6.2646 -0.8402 -4.6028 -0.3115
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide diagnostic stable coronary_artery_disease b-type_natriuretic_peptide bnp nt-probnp ventricular_cardiomyocytes ventricular wall_stress myocardial_ischemia
H-1364	-0.8799729347229004	▁na tri ure tic _ pe pti de ▁N - termin al ▁pro - B - type ▁na tri ure tic _ pe pti de ▁N - termin al _ pro - b - type _ na tri ure tic _ pe pti de ▁corona ry _ ▁arter y _ ▁disease ▁b - type ▁na tri ure tic _ pe pti de ▁na tri ure tic _ pe pti de ▁N - termin al _ ▁fragment ▁t - pro B NP ▁vent ri cular _ ▁cardio my o cy tes ▁vent ri cular _ wall ▁stress ▁my o card ial ▁ ische mia
D-1364	-0.8799729347229004	natriuretic_peptide N-terminal pro-B-type natriuretic_peptide N-terminal_pro-b-type_natriuretic_peptide coronary_ artery_ disease b-type natriuretic_peptide natriuretic_peptide N-terminal_ fragment t-proBNP ventricular_ cardiomyocytes ventricular_wall stress myocardial ischemia
P-1364	-2.7059 -0.3538 -0.1895 -0.8301 -0.7562 -0.1747 -0.0503 -0.4177 -1.6200 -0.0130 -0.0380 -0.0005 -0.7493 -0.0164 -0.6370 -0.1335 -0.1527 -0.0736 -0.1855 -0.1535 -1.2758 -0.3096 -0.3037 -0.1314 -0.3437 -4.4171 -0.0076 -0.2016 -0.0006 -0.8138 -0.7951 -0.4725 -4.5678 -1.1374 -0.5061 -1.2240 -1.2578 -0.7324 -0.2735 -1.3947 -0.3282 -0.2757 -0.1336 -0.3811 -4.0571 -0.0431 -0.5382 -0.2083 -0.0346 -2.0124 -4.1277 -2.1972 -0.3223 -0.0203 -0.1023 -0.2648 -0.1016 -1.3257 -0.3103 -1.3666 -0.2489 -0.7357 -3.1152 -1.0456 -0.2628 -1.8112 -0.5653 -1.0190 -0.2890 -0.8877 -3.3129 -0.0123 -0.2562 -0.0003 -0.5344 -0.7514 -4.6243 -0.0065 -0.0127 -1.5373 -0.4222 -0.7995 -0.3459 -0.5258 -0.2385 -6.6729 -0.3305 -0.7447 -0.6326 -0.1148 -0.2314 -1.1752 -0.3812 -0.4794 -2.0809 -2.1348 -0.8779 -0.0589 -0.7711 -0.1362 -3.3294 -0.7500 -0.0876 -0.1157 -0.3629
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 irs2 heart hyperinsulinemia myocardial_insulin_resistance cellular_dysfunction irs1 irs2 heart-specific_irs1_and_irs2_gene_double-knockout h-dko liver-specific_irs1_and_irs2_double-knockout l-dko
H-654	-1.0822492837905884	▁i RS 1 ▁i RS 2 ▁hyper insu line mia ▁my o card ial _ ▁insulin _ ▁resist ance ▁cel lular _ ▁dys function ▁ liver - specific ▁I RS 2 ▁double - k no ckou t ▁l - d KO
D-654	-1.0822492837905884	iRS1 iRS2 hyperinsulinemia myocardial_ insulin_ resistance cellular_ dysfunction liver-specific IRS2 double-knockout l-dKO
P-654	-1.3393 -0.1028 -3.6681 -2.5178 -0.2252 -0.5569 -5.2135 -0.1421 -0.1782 -7.7253 -1.4530 -0.1201 -2.0982 -0.0372 -1.0411 -0.7852 -0.7494 -0.2563 -0.0014 -2.1909 -0.0030 -0.6599 -0.3021 -0.0132 -3.7149 -1.1905 -0.0692 -0.5328 -0.3356 -0.0137 -1.0027 -0.2485 -0.0153 -0.6310 -0.1298 -0.0864 -0.0100 -4.4052 -0.0858 -1.1805 -0.1640 -0.9178 -0.4227
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers interquartile_range β-blockers interquartile_range interquartile_range
H-665	-0.6015352010726929	▁practice - level ▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors _ angi oten sin _ ▁receptor _ block ers ▁inter quart ile
D-665	-0.6015352010726929	practice-level angiotensin-converting_ enzyme inhibitors_angiotensin_ receptor_blockers interquartile
P-665	-1.7691 -0.1969 -0.1112 -3.2798 -0.4450 -0.4495 -0.2950 -1.1097 -0.0013 -0.1218 -0.1095 -0.5527 -0.0634 -0.0314 -0.5668 -0.0535 -1.4804 -1.8224 -0.0983 -0.0625 -0.5522 -0.0804 -0.4883 -0.7140 -0.0297 -1.0026 -0.0006 -0.0480 -2.3922 -0.1176
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ivabradine change peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity correlates exercise_capacity therapy ivabradine correlated peak_oxygen_uptake
H-1177	-0.6323609948158264	▁i va bra dine ▁pe ak ▁early _ dia sto lic _ mit ral _ ▁flow _ velo city ▁pe ak _ ▁early _ dia sto lic _ mit ral _ ▁ann ular _ velo city ▁pe ak _ ▁oxygen _ up take
D-1177	-0.6323609948158264	ivabradine peak early_diastolic_mitral_ flow_velocity peak_ early_diastolic_mitral_ annular_velocity peak_ oxygen_uptake
P-1177	-0.1497 -0.1646 -0.0212 -0.0042 -0.9653 -0.0032 -0.5637 -0.8283 -0.0825 -0.1836 -0.4246 -0.3326 -3.3807 -0.1072 -0.3169 -3.0465 -1.3643 -0.1908 -0.0172 -0.8504 -0.0035 -0.6125 -1.0124 -0.1285 -0.0274 -0.1804 -0.3612 -0.2145 -2.9016 -0.1753 -0.1620 -1.7907 -0.0002 -0.2284 -0.0453 -0.0089 -0.4420 -0.0043 -0.1211 -4.9454 -1.0281 -0.4909 -0.0026 -0.1316 -0.4399
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence transfusion mortality relative_risk mortality patients acute_coronary_syndrome
H-45	-0.8388370275497437	▁low - streng th ▁evidence ▁liberal _ trans fusion _ ▁protocol s ▁short - term _ ▁mortal ity _ rate s ▁aggressiv e _ ▁protocol s ▁a cute _ ▁corona ry ▁syndrome
D-45	-0.8388370275497437	low-strength evidence liberal_transfusion_ protocols short-term_ mortality_rates aggressive_ protocols acute_ coronary syndrome
P-45	-5.0390 -0.0376 -0.0042 -0.0097 -2.0253 -0.9867 -0.5832 -0.1975 -0.1340 -1.2868 -1.2479 -0.0151 -3.5908 -0.0190 -0.0136 -0.3083 -1.0509 -0.0136 -2.6208 -1.1967 -0.4867 -2.1210 -0.0876 -0.7509 -0.2798 -0.0115 -0.9447 -0.0411 -0.1044 -1.9794 -0.0282 -0.5682 -0.5835 -0.1527
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death readmission patients physician hazard_ratio confidence_interval physician follow-up patients follow-up
H-1419	-1.122101902961731	▁risk _ of _ ▁death ▁un plan ned _ ▁read mission
D-1419	-1.122101902961731	risk_of_ death unplanned_ readmission
P-1419	-0.3831 -2.7164 -0.6001 -0.0834 -3.9226 -0.3399 -0.0013 -0.0143 -0.0104 -1.8521 -0.0159 -4.4656 -0.1822
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek human_embryonic_kidney cells β1ar s1pr1 β1ar downregulation sphingosine-1-phosphate s1pr1_agonist s1pr1 downregulation isoproterenol β-adrenergic_receptor_agonist
H-1409	-0.7882270216941833	▁ha ek ▁human ▁em bry o nic _ ▁ki dne y ▁β 1 AR ▁down regul ation ▁sp hing os ine -1 - phos pha te ▁s 1 PR 1 _ ▁ago nist ▁iso prot eren ol ▁β - ad r energi c _ ▁receptor _ ▁ago nist
D-1409	-0.7882270216941833	haek human embryonic_ kidney β1AR downregulation sphingosine-1-phosphate s1PR1_ agonist isoproterenol β-adrenergic_ receptor_ agonist
P-1409	-2.6926 -0.4742 -3.8679 -0.2554 -0.0029 -0.0220 -0.0615 -0.5182 -0.1838 -0.0188 -0.0041 -2.2303 -0.1869 -1.7291 -4.1552 -0.3134 -0.0248 -1.6327 -0.5330 -0.2352 -0.1527 -2.2489 -0.2456 -0.0136 -0.2170 -0.0513 -1.0931 -0.0271 -0.0205 -0.6953 -1.4296 -0.1492 -0.0649 -0.3249 -0.2889 -3.9699 -0.3654 -0.2667 -0.0445 -0.0293 -0.5771 -4.2105 -0.4906 -0.4896 -0.7538 -0.8597 -0.3296 -0.0181 -0.7897 -0.0524
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline training 6-minute_walked_distance quality_of_life kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire symptoms beck_depression_inventory zung_self-rated_depression_scores b-type_natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
H-1330	-1.0323617458343506	kan sas _ city _ card i om _ ▁Question naire ▁Minnesota ▁ depressiv e _ ▁symptoms ▁be ck _ de pression _ in ven tory ▁z ung _ ▁self - rat ed _ dia sto lic _ function
D-1330	-1.0323617458343506	kansas_city_cardiom_ Questionnaire Minnesota depressive_ symptoms beck_depression_inventory zung_ self-rated_diastolic_function
P-1330	-5.1074 -0.0032 -1.8565 -0.1132 -0.4897 -0.7158 -0.0316 -0.0906 -2.2085 -4.0702 -0.0359 -0.0278 -2.7014 -0.2102 -0.0167 -0.8762 -4.4607 -1.4938 -0.0017 -0.3640 -0.0655 -0.0138 -1.4084 -0.1534 -0.5191 -0.0007 -1.4923 -0.1086 -1.4862 -1.7740 -0.0014 -0.0847 -0.0003 -0.3835 -4.4533 -2.2812 -0.3258 -1.2957 -1.0050 -0.5034 -0.0956
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds_ratios confidence_intervals cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_mellitus peripheral_vascular_disease myocardial_infarction heart_failure stroke patients estimated_glomerular_filtration_rate nonsignificant acute_kidney_injury
H-976	-0.5192009806632996	▁cardiovascular _ ▁events ▁at rial _ ▁fi bril lation ▁left _ ▁vent ri cular _ e je ction _ fraction ▁diabetes ▁mell itus ▁per i pher al _ ▁vas cular _ ▁disease ▁my o card ial _ in far ction ▁heart _ ▁failure
D-976	-0.5192009806632996	cardiovascular_ events atrial_ fibrillation left_ ventricular_ejection_fraction diabetes mellitus peripheral_ vascular_ disease myocardial_infarction heart_ failure
P-976	-3.5304 -0.7750 -0.9556 -0.2871 -0.0013 -0.4815 -0.5547 -0.0010 -0.0002 -0.0282 -0.2196 -3.3540 -0.1202 -0.3140 -0.2321 -1.1464 -0.0462 -0.1019 -0.9498 -0.0385 -0.1665 -0.7960 -0.0271 -0.0378 -0.0375 -0.0007 -0.0033 -0.0429 -1.1668 -0.0111 -0.4610 -2.8716 -0.1118 -0.0191 -0.3076 -0.0148 -0.0997 -1.0289 -0.0014 -0.0275 -0.1961 -0.5599 -0.8084 -1.3251 -0.1039
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic_function ea ventricular-arterial_coupling ees ea
H-925	-1.0925859212875366	▁in ▁con jun ction ▁dia sto lic _ function
D-925	-1.0925859212875366	in conjunction diastolic_function
P-925	-0.6527 -0.5605 -0.0029 -0.0050 -0.1566 -0.0542 -0.2991 -1.5275 -0.6982 -7.5174 -0.5446
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard_ratios disease_risk_score drs saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
H-1835	-1.162846326828003	▁disease _ risk _ ▁score ▁d RS - stra t ified _ analyse s ▁sax ag lip tin ▁si tag lip tin ▁sax ag lip tin ▁pi og lita zone ▁insulin
D-1835	-1.162846326828003	disease_risk_ score dRS-stratified_analyses saxagliptin sitagliptin saxagliptin pioglitazone insulin
P-1835	-1.2404 -1.2769 -1.8110 -0.7687 -0.7910 -2.1413 -0.0150 -4.7286 -0.3463 -0.0145 -0.0070 -1.5444 -0.4175 -0.0011 -2.3263 -0.0450 -1.8268 -1.8549 -3.9688 -0.1913 -2.0960 -1.8146 -2.1556 -0.0273 -1.2476 -2.5552 -0.6758 -0.3378 -0.0343 -0.1957 -1.5281 -0.2654 -0.1237
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients revascularization coronary_artery_bypass_surgery hazard_ratio percutaneous_coronary_intervention systolic_blood_pressure left_bundle_branch_block_pattern baseline electrocardiogram
H-106	-0.888927161693573	▁re vas cular ization ▁co ron ary _ ▁arter y _ ▁by pass _ chirurgi ▁hazard ▁ratio ▁per cuta ne ous _ ▁corona ry _ intervention ▁base line _ ▁electro card i ogram
D-106	-0.888927161693573	revascularization coronary_ artery_ bypass_chirurgi hazard ratio percutaneous_ coronary_intervention baseline_ electrocardiogram
P-106	-2.5700 -0.0076 -0.0196 -0.3805 -1.0036 -0.0201 -0.0130 -0.5867 -3.0608 -0.0163 -0.3477 -1.0906 -0.2423 -1.1464 -2.8727 -1.2551 -0.2208 -0.0631 -0.0001 -0.0308 -0.0034 -0.6884 -0.1631 -0.0481 -2.0192 -0.7382 -4.0202 -0.0020 -0.3143 -0.8568 -1.8037 -0.0799 -1.2446 -3.8836 -0.2990
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical biomedical relative_risk confidence_interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1262	-1.2524142265319824	▁bio medic al _ ▁treatment ▁CH m ▁left ▁vent ri cular _ e je ction _ fraction
D-1262	-1.2524142265319824	biomedical_ treatment CHm left ventricular_ejection_fraction
P-1262	-0.0244 -0.0093 -0.0021 -3.7210 -2.0517 -3.9223 -0.5307 -3.9599 -2.5023 -0.1213 -0.1800 -0.2489 -1.2886 -0.1269 -0.0537 -1.2117 -0.2136 -3.4803 -0.1474
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective randomized crossover_study outcome stable_heart_failure patients left_ventricular_ejection_fraction homozygous haplotype β2-receptor randomized carvedilol metoprolol
H-1114	-0.8269113898277283	▁open - label _ ▁cross over _ studie s ▁stable ▁heart _ ▁failure ▁patients ▁le ft _ ▁vent ri cular _ ▁e je ction _ fraction ▁ar g 16 / G l n 27 ▁g ly 16 / G lu 27 ▁β 2- recept or ▁car vedi lol ▁met o pro lol
D-1114	-0.8269113898277283	open-label_ crossover_studies stable heart_ failure patients left_ ventricular_ ejection_fraction arg16/Gln27 gly16/Glu27 β2-receptor carvedilol metoprolol
P-1114	-2.2383 -0.0487 -0.0523 -2.9827 -0.7490 -0.0348 -3.2466 -3.1534 -0.1898 -0.4559 -0.8430 -0.6273 -0.3796 -2.5520 -2.7395 -0.0120 -0.5049 -4.0886 -0.2154 -0.1693 -0.5401 -0.8451 -0.0518 -0.1001 -2.5134 -0.0395 -2.0462 -0.0064 -0.2502 -0.8674 -0.4724 -0.0370 -0.0762 -0.0212 -0.7424 -0.9949 -0.1170 -0.4872 -0.8533 -0.0965 -0.0303 -1.4084 -0.3275 -0.0544 -0.3684 -3.0899 -0.0788 -0.0714 -1.9390 -0.0487 -0.0450 -0.0563 -0.6578 -0.0360
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients death hospitalization aor aor aor aor
H-465	-1.2516893148422241	▁low - volu me _ ed _ case s ▁high - volu me _ ED _ case s
D-465	-1.2516893148422241	low-volume_ed_cases high-volume_ED_cases
P-465	-0.6326 -0.0261 -0.1117 -0.0009 -1.1567 -3.7584 -2.1837 -0.5880 -1.3621 -4.0635 -0.0373 -0.3858 -0.0006 -0.6815 -3.3989 -2.4548 -0.8961 -0.3661 -2.3781 -0.5510
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health_buddy_program all-cause_mortality hazard_ratio confidence_interval inpatient admissions baseline
H-1625	-0.7117071747779846	▁health _ ▁Budd y _ program ▁risk - ad just ed ▁all - ca use _ ▁mortal ity haz ard _ rati o
D-1625	-0.7117071747779846	health_ Buddy_program risk-adjusted all-cause_ mortalityhazard_ratio
P-1625	-1.3692 -1.0460 -1.6520 -0.0153 -1.8042 -0.3985 -0.9458 -0.0699 -0.0013 -0.0003 -0.0329 -1.4766 -0.0172 -0.0017 -0.1765 -0.5754 -1.9412 -0.0526 -1.2104 -0.0234 -0.1410 -0.5608 -0.0231 -4.0692 -0.1882
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted_hazard_ratios dash
H-691	-0.8837860822677612	▁multi vari able - ad just ed _ ▁hazard _ ▁ratio s
D-691	-0.8837860822677612	multivariable-adjusted_ hazard_ ratios
P-691	-1.1821 -0.0082 -0.0209 -0.2386 -0.0078 -0.0120 -0.0247 -0.4151 -2.0472 -0.5364 -0.4080 -0.0181 -6.9753 -0.4786
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt nt-probnp report aric hf systolic_blood_pressure antihypertensive_medication diabetes body_mass_index coronary_heart_disease heart_rate hf area_under_the_receiver_operating_characteristic_curve auc integrated_discrimination_improvement net_reclassification_improvement nri
H-287	-1.0362560749053955	▁c t n t ▁NT - pro b NP ▁a RIC _ HF ▁sy sto lic _ ▁blood _ ▁pressure ▁anti hy per tensi ve _ ▁medication ▁diabetes ▁pre valent ▁corona ry _ heart _ dia meter s
D-287	-1.0362560749053955	ctnt NT-probNP aRIC_HF systolic_ blood_ pressure antihypertensive_ medication diabetes prevalent coronary_heart_diameters
P-287	-0.3402 -1.1086 -0.9955 -0.4058 -0.7801 -0.0088 -0.0039 -0.4219 -0.1276 -3.6453 -0.7240 -0.4979 -1.1431 -5.5483 -0.1733 -0.1616 -0.3807 -0.5759 -1.1845 -1.0401 -0.0089 -1.5673 -0.0272 -0.9313 -0.0295 -0.6499 -1.5126 -2.5462 -1.1591 -0.0001 -1.6746 -0.0188 -0.0371 -0.3742 -0.2098 -3.1972 -1.7480 -1.5468 -4.8904 -0.0542
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone patients hyperkalemia renal_function emphasis-hf patients heart_failure_and_reduced_ejection_fraction hf-ref new_york_heart_association nyha functional_class estimated_glomerular_filtration_rate egfr serum_potassium
H-1222	-0.8437833189964294	▁e pler en one ▁hyper kal emia ▁renal _ function ▁EM PHA SIS - HF
D-1222	-0.8437833189964294	eplerenone hyperkalemia renal_function EMPHASIS-HF
P-1222	-0.6642 -0.1120 -1.2192 -0.1682 -0.8672 -0.1371 -0.0026 -2.1633 -0.5783 -0.3565 -1.9640 -0.0108 -0.1480 -0.0190 -0.0003 -5.8276 -0.1061
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide nesiritide placebo change cystatin_c nesiritide placebo
H-81	-1.4912465810775757	▁low - dos e ▁nesi riti de ▁72 - ho ur ▁cum ul ative _ ▁urin e _ ▁volume
D-81	-1.4912465810775757	low-dose nesiritide 72-hour cumulative_ urine_ volume
P-81	-0.2286 -0.1229 -2.0516 -1.3477 -5.2586 -0.0109 -0.2801 -3.4033 -0.0503 -0.0412 -0.6243 -0.1322 -0.0373 -0.0057 -1.4952 -3.5157 -0.2541 -3.9162 -0.0267 -7.8492 -0.6647
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking functional_capacity 6mwt physical activity symptoms hospital_anxiety_and_depression_scale
H-572	-2.127883195877075	▁standard _ care ▁Nordic _ ▁walking _ ▁led ▁to ▁functional _ capaci ty
D-572	-2.127883195877075	standard_care Nordic_ walking_ led to functional_capacity
P-572	-1.5253 -1.7461 -3.4587 -0.0945 -0.6947 -2.0200 -3.7284 -4.0767 -3.2161 -1.2023 -1.1111 -1.7719 -0.6911 -6.4015 -0.1800
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients hyperkalemia patients diabetes egfr systolic_blood_pressure potassium hyperkalemia leading hospitalization hospitalization primary_outcome hospitalization hf cardiovascular_mortality
H-1225	-0.8797599673271179	▁hyper kal emia ▁w RF ▁diabetes ▁e G FR ▁sy sto lic _ ▁blood _ ▁pressure
D-1225	-0.8797599673271179	hyperkalemia wRF diabetes eGFR systolic_ blood_ pressure
P-1225	-3.0451 -0.5183 -0.0627 -2.4811 -0.6607 -1.1351 -0.3817 -0.6405 -0.9203 -0.0829 -0.0608 -0.3890 -0.3286 -0.7363 -0.6079 -0.4858 -3.2514 -0.0473
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf biosynthetic_enzymes lyso-paf_acetyltransferase lyso-paf-at 1-alkyl-2-acetyl-sn-glycerol_cholinephosphotransferase paf-cpt catabolic_isoenzymes paf-acetylhydrolase paf-ah lipoprotein-associated_phospholipase_a2 lp-pla2 leukocytes
H-1268	-1.4611668586730957	▁PA f ▁bio syn the tic _ ▁enzym es lys o - pa f ▁a ce tyl - pa f _ transfer ase ▁di thi oth rei tol ▁d TT - in sensitiv e ▁CD p _ ▁cho line ▁1- al kyl -2 - ace tyl - s n - gly ce tyl - s n - s n - gly ce tyl - s n - s n - s n - gly ce tyl _ ▁cho line _ phos pho _ transfer ase ▁p f - c pt ▁lipo prote in - as soci ated ▁ phos pho lipa _ a 2 ▁leuk o cy tes
D-1268	-1.4611668586730957	PAf biosynthetic_ enzymeslyso-paf acetyl-paf_transferase dithiothreitol dTT-insensitive CDp_ choline 1-alkyl-2-acetyl-sn-glycetyl-sn-sn-glycetyl-sn-sn-sn-glycetyl_ choline_phospho_transferase pf-cpt lipoprotein-associated phospholipa_a2 leukocytes
P-1268	-2.0665 -1.4535 -3.9391 -0.0185 -0.2170 -0.6708 -2.5856 -0.0053 -0.0531 -1.7646 -0.0062 -0.1697 -1.2913 -2.2435 -0.5379 -0.5019 -0.8389 -1.9299 -1.6475 -2.4337 -2.5070 -0.5305 -3.3673 -0.7550 -0.2690 -1.0588 -0.2418 -0.2270 -2.5161 -1.3373 -2.8717 -0.1347 -0.0006 -0.0324 -0.3145 -0.5139 -2.7050 -1.7450 -0.0392 -7.0559 -0.0297 -0.2166 -0.6536 -0.2786 -4.0724 -0.0873 -0.0321 -0.3082 -0.0216 -0.1286 -1.8703 -2.6317 -2.8246 -0.1820 -1.1323 -0.0081 -0.0622 -5.7464 -0.0089 -0.0605 -1.5177 -0.8396 -4.3602 -1.4154 -3.6922 -0.0177 -0.0596 -5.9668 -0.0136 -0.0564 -6.3023 -0.0127 -0.0539 -2.0526 -0.5087 -5.4130 -1.0845 -2.6595 -0.0106 -3.9206 -1.9384 -1.7997 -6.6204 -0.2018 -1.5824 -2.9580 -1.3305 -0.0583 -2.9476 -0.5480 -1.3470 -3.0659 -0.0951 -0.2041 -0.2765 -0.0003 -0.0810 -0.6442 -0.8139 -1.1183 -6.2353 -7.1059 -0.9673 -0.0490 -4.0272 -0.0251 -0.6901 -0.2869 -0.7044 -0.0952
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine baseline follow-up exercise_capacity mets mets peak_oxygen_uptake peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1175	-0.7089136242866516	▁i va bra dine ▁base line ▁follow - up ▁exercise _ capaci ty ▁pe ak _ ener gy _ up take ▁pe ak _ ▁early _ dia sto lic _ mit ral _ velo city
D-1175	-0.7089136242866516	ivabradine baseline follow-up exercise_capacity peak_energy_uptake peak_ early_diastolic_mitral_velocity
P-1175	-0.0135 -0.2826 -0.0204 -0.0032 -0.0914 -0.0011 -0.2696 -0.0057 -0.0023 -0.6064 -0.5791 -0.2660 -1.0971 -0.0137 -0.0032 -0.2974 -5.2062 -0.0280 -2.0975 -1.4137 -0.3032 -0.3057 -0.0080 -0.7942 -1.4997 -0.4559 -0.0773 -0.4481 -0.3221 -0.1206 -4.9073 -0.1382 -0.1580 -2.4195 -0.0109 -1.8742 -0.0891
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate_analysis chf odds_ratio chest hypertension genes rac2 doxorubicin_efflux_transporter abcc2
H-1455	-1.1298296451568604	▁odds _ of _ ▁CHF ▁o ds _ rati o ▁pre - H CT _ ▁che st _ ▁radi ation ▁hyper tension
D-1455	-1.1298296451568604	odds_of_ CHF ods_ratio pre-HCT_ chest_ radiation hypertension
P-1455	-4.9693 -3.1946 -0.7391 -0.8783 -1.2215 -4.2177 -0.0989 -0.2668 -0.9230 -0.0046 -1.5656 -0.0022 -0.6066 -0.1008 -0.3571 -2.1114 -0.0049 -0.5874 -1.2195 -0.0836 -1.1477 -0.0399 -2.5458 -0.2295
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline follow-up nyha_classification patients patient change patient quality_of_life duke_activity_status_index kansas_city_cardiomyopathy_questionnaire 6_min_walk_test
H-1958	-1.3792012929916382	▁base line ▁NY HA ▁classifica tion
D-1958	-1.3792012929916382	baseline NYHA classification
P-1958	-2.7422 -0.0242 -2.0845 -0.2455 -0.7313 -0.0318 -5.0356 -0.1386
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo dopamine dopamine placebo change cystatin_c dopamine placebo
H-80	-1.247352957725525	▁low - dos e _ ▁dop amine ▁72 - ho ur ▁cum ul ative _ ▁urin e ▁volume ▁dop amine
D-80	-1.247352957725525	low-dose_ dopamine 72-hour cumulative_ urine volume dopamine
P-80	-0.2120 -0.0499 -1.0998 -0.4196 -3.2558 -2.2464 -0.1979 -2.6824 -0.0389 -0.0219 -0.6484 -0.2315 -0.0676 -0.0096 -0.8475 -3.5147 -0.3190 -1.7102 -3.2531 -0.0418 -6.3115 -0.2623
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard_ratio confidence_interval baseline glomerular_filtration_rate chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks new_york_heart_association_class atrial_fibrillation congestive_hf mortality
H-66	-1.077595591545105	▁ha ard _ ▁ratio ▁base line _ ▁glo mer ular _ ▁filtr ation _ rate ▁diabetes
D-66	-1.077595591545105	haard_ ratio baseline_ glomerular_ filtration_rate diabetes
P-66	-3.0139 -0.2827 -0.4630 -0.6711 -3.6746 -0.0064 -0.4411 -0.9140 -0.2408 -0.0077 -0.1402 -0.4743 -0.0391 -0.8750 -1.2394 -2.6473 -4.1439 -0.1221
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable_analysis end_point peak_oxygen_uptake hazard_ratio confidence_interval ventilatory_efficiency_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_disease sodium
H-1761	-1.3429099321365356	▁pe ak _ ▁oxygen _ ▁up take ▁hazard _ rati o ▁confidence _ ▁interval s _ s lope ▁left _ ▁vent ri cular _ e je ction _ fraction ▁so dium
D-1761	-1.3429099321365356	peak_ oxygen_ uptake hazard_ratio confidence_ intervals_slope left_ ventricular_ejection_fraction sodium
P-1761	-0.6822 -0.0100 -0.3959 -3.6423 -0.6605 -0.5668 -0.0087 -0.1310 -0.7783 -0.6300 -0.0334 -5.3014 -1.7921 -0.4085 -1.8308 -6.5453 -2.8943 -0.3239 -4.2386 -0.4753 -1.4387 -0.2431 -0.2009 -0.3068 -0.8605 -0.0939 -0.0649 -0.8083 -0.2139 -2.7957 -1.2260 -4.4751 -0.2390
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute_walked_distance kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire beck_depression_inventory flow-mediated_dilatation fes placebo b-type_natriuretic_peptide mitral
H-1331	-0.8948025107383728	▁Kansas ▁City _ city _ card i om yo pathy _ ▁Question naire ▁Beck _ de pression _ in ven tory ▁z ung ▁flow - media ted _ di la tation _ dia meter
D-1331	-0.8948025107383728	Kansas City_city_cardiomyopathy_ Questionnaire Beck_depression_inventory zung flow-mediated_dilatation_diameter
P-1331	-1.0155 -0.7991 -0.5479 -2.2038 -0.3388 -2.3207 -0.0252 -0.1857 -2.4451 -1.1420 -1.6569 -4.8245 -0.0126 -3.6672 -0.4515 -0.0516 -0.0137 -0.2234 -0.2754 -0.6754 -0.0004 -0.9718 -0.1506 -0.1586 -0.1825 -0.2077 -0.0681 -0.1055 -1.8331 -0.1509 -0.0042 -0.3512 -1.1651 -0.2469 -3.6823 -0.0578
2021-01-17 13:37:06 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-17 13:37:06 | INFO | fairseq_cli.generate | Translated 2,024 sentences (36,145 tokens) in 239.2s (8.46 sentences/s, 151.12 tokens/s)
2021-01-17 13:37:06 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 27.83, 54.4/34.8/24.5/17.6 (BP=0.926, ratio=0.928, syslen=36145, reflen=38932)
